Chrom,Pos,Ref,Alt,AF,RefCount,AltCount,GT,PS,VariantType,VariantInfo,DNAChange,ProteinChange,HugoSymbol,HgncName,HgncFamily,Transcript,TranscriptExon,TranscriptStrand,UniprotID,Str,DbsnpID,DbsnpFilter,Issues,GcContent,LineageAssociation,CancerMolecularGenetics,CCLEDeleterious,StructuralRelation,CosmicHotspot,CosmicOverlappingMutations,AssociatedWith,LoF,Driver,LikelyDriver,TranscriptLikelyLoF,CivicID,CivicDescription,CivicScore,Popaf,LikelyGoF,LikelyLoF,HessDriver,HessSignature,CscapeScore,DannScore,RevelScore,Funseq2Score,PharmgkbID,DidaID,DidaName,GwasDisease,GwasPmID,GTexGene,ModelID,EntrezGeneID
chr17,7676040,C,A,0.962,0,24,1|1,,SNP,MISSENSE,c.329G>T,p.R110L,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs11540654,,as_specific,0.5536159600997507,"""L, E, M, O""",Rec,False,NTRK1,True,p.R110P(13) p.0(9) p.R110C(15) p.R110L(25) p.G59fs*23(3) p.R110fs*13(7) p.R110fs*18(1) p.Y103_G112>C(1) p.R110S(1) p.R110H(4) p.F109_R110insXX(1) p.F109_R110delFR(2) p.M1_T125del(1) p.R110fs*?(1) p.G105_T125del21(1) p.Y107fs*38(1) p.R110fs*39(1) p.Y107fs*44(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:4,Misc:2",0.730165,,0.632,2.0,,,,,,,ACH-000839,7157.0
chr11,55572530,A,C,0.433,17,12,0/1,,SNP,MISSENSE,c.403A>C,p.S135R,OR4C16,olfactory receptor family 4 subfamily C member 16 (gene/pseudogene),"Olfactory receptors, family 4",ENST00000623907.1,1.0,+,Q8NGL9,False,rs1404669415,,as_specific,0.4713216957605985,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:5,0.254053,0.4390371032032782,0.135,2.0,,,,,,,ACH-001111,219428.0
chr17,7674220,C,T,0.958,0,24,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001111,7157.0
chr17,7673781,C,G,0.375,28,14,0/1,,SNP,MISSENSE,c.839G>C,p.R280T,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912660,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R280T(73) p.R280fs*65(9) p.R280I(15) p.R280K(54) p.R280S(17) p.R280G(33) p.R280_R283>S(1) p.R280*(14) p.D281fs*24(1) p.S269fs*21(1) p.F270_D281del12(1) p.R280fs*?(1) p.V272_K292del21(1) p.D281_R282delDR(2) p.R280R(3) p.A276fs*64(1) p.R280fs*64(1) p.G279_R280delGR(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:19,0.96317,0.7002446792674034,0.94,3.0,,,,,,,ACH-001691,7157.0
chr17,7675208,C,A,0.96,0,23,1|1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-002922,7157.0
chr3,179234297,A,G,0.342,24,14,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000943,5290.0
chr7,140753336,A,T,0.691,7,17,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000943,673.0
chr21,33027124,T,G,0.486,18,18,0/1,,SNP,MISSENSE,c.262T>G,p.S88A,OLIG2,oligodendrocyte transcription factor 2,Basic helix-loop-helix proteins,ENST00000333337.3,1.0,+,Q13516,False,rs768519339,,as_specific,0.655860349127182,L,Dom,False,TRA@,False,,cancer;structural_relation;,False,False,True,,,,,7.3,False,False,True,MSI:2,0.652462,,0.094,2.0,,,,,,,ACH-000943,10215.0
chr9,130878466,C,T,0.463,37,31,0/1,,SNP,MISSENSE,c.1379C>T,p.P460L,ABL1,"ABL proto-oncogene 1, non-receptor tyrosine kinase",SH2 domain containing Abl family tyrosine kinases,ENST00000372348.7,8.0,+,P00519,False,rs764105054,,as_specific,0.4763092269326683,L,Dom,False,"""BCR, ETV6, NUP214""",False,p.P441L(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000372348;ENST00000318560;,1616.0,,0.0,7.3,True,False,False,,0.757898,0.7520907195792146,0.858,4.0,,,,,,,ACH-000832,25.0
chr17,7674953,T,A,0.975,0,38,1|1,,SNP,MISSENSE,c.578A>T,p.H193L,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs786201838,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193L(40) p.H193_I195delHLI(1) p.H193R(78) p.H193Y(29) p.?(2) p.H193D(10) p.H193P(15) p.H193N(7) p.P191fs*53(2) p.A189_V197delAPPQHLIRV(4) p.H193H(2) p.H193fs*16(3) p.A189fs*53(1) p.P191fs*6(1) p.K164_P219del(1) p.H193_I195>AP(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:3",0.899081,,0.864,3.0,,,,,,,ACH-000832,7157.0
chr9,5073770,G,T,0.995,0,201,1|1,,SNP,MISSENSE,c.1849G>T,p.V617F,JAK2,Janus kinase 2,Jak family tyrosine kinases SH2 domain containing FERM domain containing,ENST00000381652.4,14.0,+,O60674,False,rs77375493,,as_specific,0.3341645885286783,L,Dom,False,"""ETV6, PCM1, BCR""",True,p.V617F(46751) p.V617I(89) p.V617V(1) p.V617_C618>FR(2),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,True,True,ENST00000636127;ENST00000381652;,64.0,"JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.",83.0,3.4,True,True,False,,0.951124,0.9953201091762558,0.881,4.0,,,,,,,ACH-000005,3717.0
chr17,7674220,C,T,0.952,0,26,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000001,7157.0
chr3,179234297,A,G,0.633,18,33,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000811,5290.0
chr4,152326136,C,A,0.525,20,20,0/1,,SNP,MISSENSE,c.1274G>T,p.R425L,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs1057519896,,as_specific,0.3940149625935162,"""E, L""",Rec,False,,True,p.R505?(14) p.R505H(4) p.R505L(8) p.R505P(1) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"smoking:1,Misc:1",0.868316,,0.601,4.0,,,,,,,ACH-000811,55294.0
chr12,25245350,C,T,0.278,26,9,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000967,3845.0
chr17,7673802,C,T,0.618,12,20,0|1,7673802.0,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000967,7157.0
chr17,39723405,G,A,0.321,19,8,0/1,,SNP,MISSENSE,c.2033G>A,p.R678Q,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,17.0,+,P04626,False,rs1057519862,,as_specific,0.6359102244389028,E,Dom,False,,False,p.R678Q(3) p.R678L(1),cancer;gene_function_gain;,False,False,True,,42.0,"ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.",5.0,7.3,True,False,True,CpG:9,0.905915,0.5881956277268189,0.417,4.0,,,,,,,ACH-000967,2064.0
chr17,7674220,C,T,0.584,9,13,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000473,7157.0
chr17,7675064,G,C,0.24,15,4,0/1,,SNP,NONSENSE,c.548C>G,p.S183*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.S183*(35) p.C182fs*1(1) p.S183L(3) p.?(3) p.V173fs*59(2) p.S183P(3) p.H168fs*23(1) p.E180_S183delERCS(1) p.S183fs*2(1) p.R174fs*24(1) p.E171fs*61(1) p.V173fs*23(1) p.K164_P219del(1) p.S183_D184insPPP*(1) p.S183fs*65(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"APOBEC:7,Misc:1",0.982906,0.1587257172379398,,4.0,,,,,,,ACH-000473,7157.0
chr1,26779863,C,T,0.971,0,36,1|1,,SNP,NONSENSE,c.5314C>T,p.R1772*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,20.0,+,O14497,False,rs879255270,,as_specific,0.5386533665835411,E,Rec,True,1507,True,p.R1989*(19),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:2,POLE:19",0.974353,,,5.0,,,,,,,ACH-000784,8289.0
chr10,8073874,G,A,0.956,0,20,1|1,,SNP,MISSENSE,c.1183G>A,p.A395T,GATA3,GATA binding protein 3,GATA zinc finger domain containing,ENST00000346208.4,6.0,+,P23771,False,rs200935603,,as_specific,0.5261845386533666,E,Rec,False,,False,p.A396T(1) p.A395fs*54(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,,,,,4.31,True,True,True,CpG:1,0.557243,0.5023414627404155,0.556,4.0,,,,,,,ACH-000784,2625.0
chr9,21971029,C,T,0.982,0,55,1|1,,SNP,NONSENSE,c.177G>A,p.W59*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913389,,as_specific,0.6633416458852868,,,True,,True,p.0(1543) p.W110*(37) p.V59fs*61(2) p.?(4) p.W110C(1) p.V59fs*63(1) p.V59fs*60(1) p.V59_G67del(1) p.V59M(1) p.V59fs*58(1) p.V59fs*82(2) p.H83fs*2(2) p.V59fs*45(1) p.D105fs*8(1) p.V59G(1) p.A68fs*3(1),cancer;gene_function_loss;,False,False,True,,1521.0,,0.0,7.3,False,True,False,,0.855169,0.9926462279289228,0.455,5.0,,,,,,,ACH-001696,1029.0
chr17,7675077,G,A,0.971,0,32,1|1,,SNP,MISSENSE,c.535C>T,p.H179Y,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587780070,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,UV:2,Misc:5",0.952817,0.6715806553525823,0.948,3.0,,,,,,,ACH-001696,7157.0
chr17,7674216,C,A,0.983,0,55,1|1,,SNP,MISSENSE,c.747G>T,p.R249S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934571,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.P250fs*14(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:5,Misc:13",0.776711,,0.769,2.0,,,,,,,ACH-000780,7157.0
chr3,179210192,T,C,0.71,8,24,0/1,,SNP,MISSENSE,c.1258T>C,p.C420R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,8.0,+,P42336,False,rs121913272,,as_specific,0.2967581047381546,"""E, O""",Dom,False,,True,p.C420R(82) p.H419_C420delHC(1) p.C420fs*?(1) p.C420_L422>*(1) p.C420C(1),cancer;gene_function_gain;,False,True,True,ENST00000263967;ENST00000643187;,931.0,,12.5,7.3,True,False,True,"MSI:1,Misc:13",0.916819,0.6918433106210673,0.788,3.0,,,,,,,ACH-000117,5290.0
chr3,121993677,G,A,0.648,13,23,0/1,,SNP,MISSENSE,c.940C>T,p.P314S,ILDR1,immunoglobulin like domain containing receptor 1,Deafness associated genes,ENST00000273691.7,6.0,-,Q86SU0,False,,,,0.5935162094763092,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.310223,0.773734276595554,0.056,1.0,,,,,,,ACH-000822,286676.0
chr7,140753336,A,T,0.709,13,35,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000822,673.0
chr17,7675182,G,A,0.981,0,49,1|1,,SNP,NONSENSE,c.430C>T,p.Q144*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs757274881,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.L137_W146del10(1) p.Q144*(35) p.Q144fs*26(5) p.Q144P(5) p.Q144H(6) p.Q144R(4) p.Q144Q(2) p.V143fs*4(1) p.Q144fs*4(1) p.Q144L(8) p.Q144fs*32(1) p.Q144delQ(2) p.V143_P153del(1) p.Q144K(2) p.V143_S149delVQLWVDS(1) p.Q144_G154del11(1) p.P142_Q144delPVQ(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:3,0.991142,0.3246707366533456,,4.0,,,,,,,ACH-000525,7157.0
chr2,201276863,C,T,0.485,16,16,0/1,,SNP,MISSENSE,c.697C>T,p.R233W,CASP8,caspase 8,Caspases Death effector domain containing Ripoptosome Death inducing signaling complex ,ENST00000673742.1,7.0,+,Q14790,False,rs760898260,,as_specific,0.4189526184538653,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:2,POLE:1",0.907555,,0.53,3.0,,,,,,,ACH-000950,841.0
chr4,152326137,G,A,0.464,15,13,0/1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-000950,55294.0
chr5,112838934,C,T,0.333,32,15,0/1,,SNP,NONSENSE,c.3340C>T,p.R1114*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913331,,as_specific,0.3690773067331671,"""E, M, O""",Rec,True,,True,p.R1114*(58) p.?(1) p.R1114G(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:2,POLE:8",0.976874,,,5.0,,,,,,,ACH-000950,324.0
chr12,25245347,C,T,0.728,15,41,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000950,3845.0
chr3,179234297,A,G,0.635,19,36,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-001393,5290.0
chr12,56088823,C,T,0.256,36,13,0/1,,SNP,MISSENSE,c.1064C>T,p.T355I,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,9.0,+,P21860,False,rs993665271,,as_specific,0.5062344139650873,,,False,,False,,cancer;gene_function_gain;,False,False,True,ENST00000267101;ENST00000415288;,,,,7.3,True,False,True,Misc:2,0.853049,0.3473354870029765,0.904,4.0,,,,,,,ACH-001393,2065.0
chr17,7673579,G,A,0.967,0,33,1|1,,SNP,NONSENSE,c.949C>T,p.Q317*,TP53,tumor protein p53,,ENST00000269305.8,9.0,-,P04637,False,,,,0.5062344139650873,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q317*(31) p.Q317fs*28(1) p.Q317R(4) p.Q317K(3) p.Q317fs*20(1) p.P316fs*19(1) p.Q317fs*?(2) p.S315fs*1(1) p.S315fs*22(1) p.S314_K320>*(1) p.Q317fs*19(1) p.Q317fs*45(1) p.S314fs*25(1) p.L308fs*15(1) p.Q317P(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,UV:3,APOBEC:1,Misc:3",0.972477,0.740164595047311,,4.0,,,,,,,ACH-001393,7157.0
chr7,140753336,A,T,0.522,10,12,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000361,673.0
chr2,61492337,C,T,0.546,9,11,0/1,,SNP,MISSENSE,c.1711G>A,p.E571K,XPO1,exportin 1,Exportins,ENST00000401558.7,15.0,-,O14980,False,rs1057520009,,as_specific,0.3067331670822942,L,Dom,False,,True,p.E571K(41) p.E571V(3) p.E571G(5) p.E571I(1) p.E571A(3) p.E571Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"CpG:1,POLE:4",0.979039,0.5942594365771144,0.579,4.0,,,,,,,ACH-000913,7514.0
chr2,197402635,C,A,0.575,18,23,0/1,,SNP,MISSENSE,c.1998G>T,p.K666N,SF3B1,splicing factor 3b subunit 1,SF3b complex,ENST00000335508.11,14.0,-,O75533,False,rs377023736,,as_specific,0.4214463840399002,L,Dom,False,,True,p.K666N(83) p.K666R(33) p.K666T(28) p.K666Q(15) p.K666E(18) p.K666M(11) p.K666?(17),cancer;gene_function_gain;,False,False,True,,114.0,"SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.",2.0,7.3,True,False,False,,0.815723,0.3570206333014795,0.514,4.0,,,,,,,ACH-000913,23451.0
chr3,52609752,G,A,0.481,13,12,0/1,,SNP,NONSENSE,c.2173C>T,p.R725*,PBRM1,polybromo 1,Bromodomain containing,ENST00000409114.7,17.0,-,Q86U86,False,,,,0.4214463840399002,E,Rec,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:4",0.982779,,,5.0,,,,,,,ACH-000913,55193.0
chr3,179218303,G,A,0.676,12,24,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000913,5290.0
chr4,152328233,G,A,0.441,18,14,0/1,,SNP,MISSENSE,c.1153C>T,p.R385C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs867384286,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465C(83) p.R465fs*7(13) p.R465S(1) p.R465Y(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:9,0.934034,0.2550529450691629,0.593,4.0,,,,,,,ACH-000913,55294.0
chr12,132673271,C,G,0.572,17,23,0/1,,SNP,MISSENSE,c.1366G>C,p.A456P,POLE,"DNA polymerase epsilon, catalytic subunit",DNA polymerases,ENST00000320574.10,14.0,-,Q07864,False,,,,0.5660847880299252,,,False,,True,p.A456P(21) p.A456V(2),cancer;gene_function_loss;dna_repair;,False,False,True,,,,,7.3,False,True,True,Misc:1,0.94394,0.5557677881050611,0.62,4.0,,,,,,,ACH-000913,5426.0
chr15,51536240,C,T,0.547,10,12,0/1,,SNP,MISSENSE,c.2240G>A,p.R747Q,DMXL2,Dmx like 2,Deafness associated genes WD repeat domain containing,ENST00000251076.9,12.0,-,Q8TDJ6,False,rs749262883,,as_specific,0.3491271820448878,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.973874,0.2034699033232746,0.475,3.0,,,,,,,ACH-000913,23312.0
chr17,7674894,G,A,0.978,0,42,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000913,7157.0
chr19,11721894,C,A,0.333,21,10,0/1,,SNP,MISSENSE,c.1640G>T,p.R547I,ZNF823,zinc finger protein 823,Zinc fingers C2H2-type,ENST00000341191.11,4.0,-,P16415,False,,,,0.3965087281795511,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.606027,0.5725303625621073,0.086,1.0,,,,,,,ACH-000913,55552.0
chr19,23654274,C,A,0.387,18,11,0/1,,SNP,MISSENSE,c.659G>T,p.R220I,ZNF675,zinc finger protein 675,Zinc fingers C2H2-type,ENST00000359788.9,4.0,-,Q8TD23,False,,,,0.3192019950124688,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.677309,0.3807198003352571,0.062,1.0,,,,,,,ACH-000913,171392.0
chr19,52034921,C,A,0.254,34,11,0/1,,SNP,MISSENSE,c.758G>T,p.R253I,ZNF432,zinc finger protein 432,Zinc fingers C2H2-type,ENST00000221315.10,5.0,-,O94892,False,rs183925976,,as_specific,0.3890274314214463,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:5,0.543116,0.8941856944424009,0.102,2.0,,,,,,,ACH-000913,9668.0
chr1,114713909,G,T,0.456,24,20,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000510,4893.0
chr17,7674887,C,A,0.961,0,24,1|1,,SNP,MISSENSE,c.644G>T,p.S215I,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs587782177,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.S215N(10) p.0(9) p.S215R(22) p.R213_S215>X(1) p.T211fs*28(1) p.R209fs*6(1) p.S215G(12) p.S215_V218>M(1) p.S215I(22) p.H214fs*5(2) p.S215fs*29(1) p.S215T(5) p.S215fs*31(1) p.S215C(5) p.S215fs*32(4) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.D208_V216delDRNTFRHSV(1) p.S215S(2) p.S215fs*?(2) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.H214_S215insX(1) p.?(1) p.K164_P219del(1) p.S215del(1) p.F212_S215del(1) p.S215fs*6(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:4,0.947084,0.4541793437378166,0.913,3.0,,,,,,,ACH-000483,7157.0
chr18,61816181,G,A,0.514,17,14,0/1,,SNP,MISSENSE,c.283C>T,p.P95S,RNF152,ring finger protein 152,Ring finger proteins,ENST00000312828.4,2.0,-,Q8N8N0,False,,,,0.6533665835411472,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.937347,,0.603,3.0,,,,,,,ACH-000483,220441.0
chr7,55165350,G,T,0.474,40,38,0/1,,SNP,MISSENSE,c.1658G>T,p.G553V,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,14.0,+,P00533,False,rs139236063,,as_specific,0.456359102244389,"""E, O""",Dom,False,,True,p.G598V(11),cancer;gene_function_gain;,False,False,True,,997.0,,0.0,7.3,True,False,True,Misc:15,0.888281,0.6519560201016441,0.61,4.0,,,,,,,ACH-000479,1956.0
chr1,114713908,T,C,0.461,71,61,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-000486,4893.0
chr14,104780214,C,T,0.76,12,38,0/1,,SNP,MISSENSE,c.49G>A,p.E17K,AKT1,AKT serine/threonine kinase 1,Pleckstrin homology domain containing,ENST00000554581.5,2.0,-,P31749,False,rs121434592,,as_specific,0.6234413965087282,E,Dom,False,,True,p.E17K(506),cancer;gene_function_gain;,False,True,True,,4.0,"AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.",33.5,7.3,True,False,True,"UV:3,APOBEC:8,Misc:15",0.933449,0.7974696660996897,0.51,4.0,,,,,,,ACH-000486,207.0
chr1,26773456,C,T,0.389,21,13,0/1,,SNP,NONSENSE,c.3826C>T,p.R1276*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,15.0,+,O14497,False,,,,0.57356608478803,E,Rec,True,1507,True,p.R1276*(6) p.M1273fs(1),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:2,0.967435,,,5.0,,,,,,,ACH-000856,8289.0
chr3,179218294,G,A,0.572,18,24,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000856,5290.0
chr11,14294844,T,A,0.972,0,35,1|1,,SNP,MISSENSE,c.215A>T,p.Q72L,RRAS2,RAS related 2,RAS type GTPase family,ENST00000256196.9,3.0,-,P62070,False,rs113954997,,as_specific,0.3566084788029925,,,False,,False,p.Q72L(1),cancer;gene_function_gain;,False,False,True,ENST00000537760;ENST00000256196;ENST00000531807;,,,,7.3,True,False,True,"smoking:3,Misc:7",0.943535,0.304330000116943,0.918,3.0,,,,,,,ACH-000856,22800.0
chr13,32684000,A,T,0.523,20,23,0/1,,SNP,NONSENSE,c.1180A>T,p.R394*,PDS5B,PDS5 cohesin associated factor B,,ENST00000315596.15,11.0,+,Q9NTI5,False,rs750827034,,as_specific,0.256857855361596,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"MSI:1,Misc:1",0.978615,0.5457525180325369,,3.0,,,,,,,ACH-000856,23047.0
chr14,65078029,C,T,0.63,9,17,0/1,,SNP,MISSENSE,c.152G>A,p.R51Q,MAX,MYC associated factor X,Basic helix-loop-helix proteins,ENST00000557746.5,3.0,-,P61244,False,,,,0.4912718204488778,,,False,,True,p.R60Q(11) p.R47_S52del(1),cancer;gene_function_loss;,False,False,True,ENST00000358402;ENST00000618858;ENST00000284165;ENST00000358664;ENST00000555419;ENST00000556979;ENST00000555667;ENST00000557746;ENST00000556443;,,,,7.3,False,True,True,"CpG:5,MSI:2",0.863058,,0.897,3.0,,,,,,,ACH-000856,4149.0
chrX,40062191,T,C,0.587,18,26,0/1,,SNP,MISSENSE,c.4274A>G,p.N1425S,BCOR,BCL6 corepressor,Ankyrin repeat domain containing,ENST00000397354.7,10.0,-,Q6W2J9,False,rs199538037,,as_specific,0.6334164588528678,,Rec,False,RARA,False,p.N1425S(1),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:23,,,0.221,2.0,,,,,,,ACH-000856,54880.0
chr3,41224633,A,G,0.96,0,23,1|1,,SNP,MISSENSE,c.121A>G,p.T41A,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913412,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.T41A(1344) p.A5_A80del(75) p.T41S(7) p.T41I(155) p.A5_Q143del(7) p.T41P(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.T41T(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.T41N(8) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.T40_L46del(1) p.G38_S45del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.A20_R151del(1) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.I35_T41del(1) p.I35_K170del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A39_T42del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.T41_N51del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A39fs*3(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1285.0,,55.0,7.3,True,False,True,Misc:17,0.860853,,0.403,4.0,,,,,,,ACH-000955,1499.0
chr3,179234297,A,G,0.55,8,10,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000955,5290.0
chr4,152328233,G,A,0.534,13,16,0/1,,SNP,MISSENSE,c.1153C>T,p.R385C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs867384286,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465C(83) p.R465fs*7(13) p.R465S(1) p.R465Y(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:9,0.934034,0.2550529450691629,0.593,4.0,,,,,,,ACH-000955,55294.0
chr12,12477384,G,A,0.447,20,15,0/1,,SNP,NONSENSE,c.1447C>T,p.R483*,DUSP16,dual specificity phosphatase 16,MAP kinase phosphatases,ENST00000298573.9,7.0,-,Q9BY84,False,,,,0.5561097256857855,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:1,0.881055,0.8116604069191584,,4.0,,,,,,,ACH-000955,80824.0
chr12,25245350,C,T,0.488,21,20,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000955,3845.0
chr12,56085070,G,A,0.587,13,18,0/1,,SNP,MISSENSE,c.310G>A,p.V104M,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,3.0,+,P21860,False,rs1057519893,,as_specific,0.4937655860349127,,,False,,True,p.V104L(1) p.V104M(6),cancer;gene_function_gain;,False,True,True,,701.0,,15.0,7.3,True,False,True,CpG:12,0.711747,,0.584,4.0,,,,,,,ACH-000955,2065.0
chr12,56088073,C,A,0.39,25,15,0/1,,SNP,MISSENSE,c.785C>A,p.P262H,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,7.0,+,P21860,False,rs1057519817,,as_specific,0.4912718204488778,,,False,,False,,cancer;gene_function_gain;gene_function_loss;,False,False,True,,1218.0,,0.0,7.3,True,True,False,,0.851573,0.9758451424167064,0.376,4.0,,,,,,,ACH-000955,2065.0
chr19,47069155,C,G,0.488,20,20,0/1,,SNP,MISSENSE,c.2335G>C,p.E779Q,ZC3H4,zinc finger CCCH-type containing 4,Zinc fingers CCCH-type,ENST00000253048.10,14.0,-,Q9UPT8,False,rs756950439,,as_specific,0.6783042394014963,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:4,0.890018,0.4849699719102638,0.121,3.0,,,,,,,ACH-000955,23211.0
chr17,7673802,C,T,0.981,0,51,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000232,7157.0
chr2,29209816,C,G,0.238,33,10,0/1,,SNP,MISSENSE,c.3806G>C,p.G1269A,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,25.0,-,Q9UM73,False,rs1057519781,,as_specific,0.4638403990024937,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.G1269A(9),cancer;gene_function_gain;structural_relation;,False,True,True,,308.0,The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.,17.5,7.3,True,False,False,,0.886578,0.6076062063815922,0.662,4.0,,,,,,,ACH-002531,238.0
chr2,29209816,C,G,0.238,33,10,0/1,,SNP,MISSENSE,c.3806G>C,p.G1269A,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,25.0,-,Q9UM73,False,rs1057519781,,as_specific,0.4638403990024937,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.G1269A(9),cancer;gene_function_gain;structural_relation;,False,True,True,,552.0,,10.0,7.3,True,False,False,,0.886578,0.6076062063815922,0.662,4.0,,,,,,,ACH-002531,238.0
chr2,177234232,C,G,0.481,13,13,0/1,,SNP,MISSENSE,c.37G>C,p.D13H,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,rs1057519920,,as_specific,0.3890274314214463,E,Dom,False,,True,p.D29N(3) p.D29H(8) p.I28_D29del(1) p.D29Y(1),cancer;gene_function_gain;,False,False,True,ENST00000397063;ENST00000397062;ENST00000446151;ENST00000464747;ENST00000449627;ENST00000448782;ENST00000586532;ENST00000421929;ENST00000423513;ENST00000588123;,,,,7.3,True,False,True,APOBEC:12,0.939766,0.7123089440446881,0.711,3.0,,,,,,,ACH-002531,4780.0
chr12,25245350,C,A,0.625,29,49,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000669,3845.0
chr17,7675113,G,A,0.989,0,86,1|1,,SNP,NONSENSE,c.499C>T,p.Q167*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.K164fs*3(2) p.Q167fs*13(3) p.S149fs*72(1) p.Q167L(3) p.Y163fs*1(1) p.Q167fs*2(6) p.A159_Q167delAMAIYKQSQ(1) p.Q167fs*4(3) p.Q167Q(3) p.Q165_M169delQSQHM(1) p.Q167H(3) p.Q167*(27) p.Q167K(1) p.Q167fs*12(1) p.A159_M169del(1) p.Q167delQ(1) p.Q167fs*3(3) p.Q167fs*14(4) p.Q167_H168>YL(1) p.P151_V173del23(1) p.Q167_H168>HD(1) p.Q167E(1) p.Q167R(4) p.K164_P219del(1) p.V157_C176del20(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:1,Misc:4",0.993323,0.6915924179262102,,4.0,,,,,,,ACH-000669,7157.0
chr12,25245350,C,G,0.734,8,22,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-000817,3845.0
chr17,7673767,C,T,0.957,0,21,1|1,,SNP,MISSENSE,c.853G>A,p.E285K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs112431538,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E285K(139) p.E285V(15) p.R283fs*16(2) p.E285Q(5) p.E285G(5) p.E285*(19) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.E285A(2) p.R283fs*56(1) p.V272_K292del21(1) p.E285E(5) p.E285fs*20(1) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285fs*60(2) p.E285fs*21(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:20,0.905537,,0.91,3.0,,,,,,,ACH-000817,7157.0
chr3,179218303,G,A,0.61,27,47,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-002669,5290.0
chr7,140753336,A,T,0.534,24,26,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002669,673.0
chr8,87353670,T,G,0.677,10,23,0/1,,SNP,MISSENSE,c.1187T>G,p.L396R,CNBD1,cyclic nucleotide binding domain containing 1,,ENST00000518476.6,10.0,+,Q8NA66,False,,,,0.2668329177057356,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:5,0.541415,,0.584,2.0,,,,,,,ACH-002669,168975.0
chr17,7673704,G,A,0.939,1,30,1|1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-002669,7157.0
chr17,7674947,A,G,0.981,0,50,1|1,,SNP,MISSENSE,c.584T>C,p.I195T,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs760043106,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193_I195delHLI(1) p.I195F(27) p.I195T(83) p.I195N(16) p.I195fs*12(1) p.I195L(1) p.I195S(6) p.I195_G199delIRVEG(1) p.I195fs*52(5) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.I195fs*13(1) p.I195fs*14(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.H193_I195>AP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:13,0.902841,0.76638318620028,0.851,3.0,,,,,,,ACH-000693,7157.0
chr17,7675131,C,T,0.962,0,26,1|1,,SNP,MISSENSE,c.481G>A,p.A161T,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs193920817,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R158fs*8(1) p.S149fs*72(1) p.A161T(54) p.A161S(6) p.A159_Q167delAMAIYKQSQ(1) p.A161D(12) p.V157fs*19(2) p.A161fs*19(1) p.A161fs*20(1) p.A161V(10) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A161A(5) p.R156fs*18(1) p.A161P(1) p.V157_I162delVRAMAI(1) p.M160fs*10(2) p.A161fs*9(3) p.A161G(1) p.M160_A161>IS(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.A161F(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A161fs*8(1) p.A161N(1) p.V157_C176del20(1) p.A161fs*7(1) p.A161fs*10(1) p.V157fs*9(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1114.0,,3.0,7.3,False,True,True,"MSI:1,Misc:2",0.858308,,0.79,3.0,,,,,,,ACH-000420,7157.0
chr12,25245347,C,T,0.632,13,23,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000403,3845.0
chr12,85804944,C,A,0.667,15,32,0/1,,SNP,NONSENSE,c.1066G>T,p.E356*,RASSF9,Ras association domain family member 9,Ras association domain family,ENST00000361228.5,2.0,-,O75901,False,,,,0.4014962593516209,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:5,0.917268,,,3.0,,,,,,,ACH-000403,9182.0
chr17,7675139,C,A,0.965,0,26,1|1,,SNP,MISSENSE,c.473G>T,p.R158L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1699.0,,4.0,7.3,False,True,True,"smoking:22,Misc:1",0.921338,,0.891,3.0,,,,,,,ACH-000403,7157.0
chr10,87957915,C,T,0.958,0,23,1|1,,SNP,NONSENSE,c.697C>T,p.R233*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,7.0,+,P60484,False,rs121909219,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R233*(101) p.0(28) p.G165_K342del(1) p.T232_R233insTQGGAGS(2) p.R233fs*10(14) p.R55fs*1(1) p.R233fs*3(1) p.R234fs*9(1) p.R233fs*24(1) p.R233fs*?(2) p.T232_R233insK*(1) p.N228fs*10(1) p.R233fs*25(2) p.R233fs*13(1) p.R233fs*19(1) p.R233fs*26(1) p.R233fs*20(1) p.R233R(1) p.R233fs*12(1) p.P231fs*2(1) p.K221fs*6(1) p.R233fs*23(1) p.T232_R233insPQGGAGT(1) p.G165_*404del(1) p.R233Q(1),cancer;gene_function_loss;,False,True,True,,110.0,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.",19.0,7.3,False,True,False,,0.971128,0.6883155413500054,,3.0,,,,,,,ACH-000376,5728.0
chr17,7674220,C,T,0.971,0,34,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000376,7157.0
chr3,10142088,C,T,0.974,0,36,1|1,,SNP,MISSENSE,c.241C>T,p.P81S,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs104893829,,as_specific,0.7107231920199502,"""E, M, O""",Rec,False,,True,p.P81S(20) p.S80fs*73(1) p.S72_V87>L(1) p.P81fs*49(2) p.P81L(1) p.C77fs*50(1) p.P81fs*78(2) p.S80_P81>T(1) p.E70fs*50(1) p.P81fs*50(2) p.S80fs*77(1) p.I75_V84>M(1) p.R60fs*35(1) p.V74fs*77(1) p.N78fs*50(1) p.P81T(1) p.F76fs*24(1),cancer;gene_function_loss;,False,True,True,,1837.0,,20.0,3.46,False,True,False,,0.516529,0.5523726074718058,0.678,4.0,,,,,,,ACH-002687,7428.0
chr9,77794572,T,G,0.503,15,15,0/1,,SNP,MISSENSE,c.626A>C,p.Q209P,GNAQ,G protein subunit alpha q,"G protein subunits alpha, group q",ENST00000286548.9,5.0,-,P50148,False,rs121913492,,as_specific,0.3266832917705736,E,Dom,False,,True,p.Q209L(323) p.Q209P(256) p.Q209R(8) p.Q209H(17) p.Q209?(6) p.Q209Y(1) p.Q209K(1),cancer;gene_function_gain;,False,True,True,ENST00000286548;,604.0,,8.0,7.3,True,False,True,Misc:29,0.957692,0.7503423451666995,0.956,4.0,,,,,,,ACH-002687,2776.0
chr12,25245351,C,T,0.972,0,34,1|1,,SNP,MISSENSE,c.34G>A,p.G12S,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,913.0,,38.0,7.3,True,False,True,"smoking:2,Eso:1,Misc:10",0.902584,,0.79,4.0,,,,,,,ACH-000681,3845.0
chr3,179234297,A,T,0.674,15,31,0/1,,SNP,MISSENSE,c.3140A>T,p.H1047L,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,1151.0,,12.5,7.3,True,False,True,"APOBEC:1,Misc:27",0.829278,,0.359,3.0,,,,,,,ACH-000704,5290.0
chr9,5073770,G,T,0.726,28,74,0/1,,SNP,MISSENSE,c.1849G>T,p.V617F,JAK2,Janus kinase 2,Jak family tyrosine kinases SH2 domain containing FERM domain containing,ENST00000381652.4,14.0,+,O60674,False,rs77375493,,as_specific,0.3341645885286783,L,Dom,False,"""ETV6, PCM1, BCR""",True,p.V617F(46751) p.V617I(89) p.V617V(1) p.V617_C618>FR(2),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,True,True,ENST00000636127;ENST00000381652;,64.0,"JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.",83.0,3.4,True,True,False,,0.951124,0.9953201091762558,0.881,4.0,,,,,,,ACH-000195,3717.0
chr17,7674221,G,A,0.692,14,33,0/1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000195,7157.0
chr7,140753336,A,T,0.769,7,23,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000985,673.0
chr8,103885941,T,G,0.467,24,21,0/1,,SNP,MISSENSE,c.676T>G,p.L226V,RIMS2,regulating synaptic membrane exocytosis 2,Regulating synaptic membrane exocytosis family PDZ domain containing,ENST00000436393.6,2.0,+,Q9UQ26,False,,,,0.4538653366583541,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:4,0.304401,0.3848296409933994,0.033,1.0,,,,,,,ACH-000985,9699.0
chr17,7674894,G,A,0.973,0,35,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000530,7157.0
chr12,25245351,C,A,0.983,0,60,1|1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000601,3845.0
chr17,7674221,G,A,0.972,0,35,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000601,7157.0
chr1,235806698,C,T,0.837,10,46,0/1,,SNP,MISSENSE,c.2438G>A,p.R813Q,LYST,lysosomal trafficking regulator,BEACH domain containing  WD repeat domain containing,ENST00000389793.7,6.0,-,Q99698,False,rs558162561,,as_specific,0.3341645885286783,,,False,,False,,cancer;,False,False,True,,,,,3.71,False,False,True,POLE:6,0.93888,0.3128580368010094,0.37,3.0,,,,,,,ACH-002291,1130.0
chr1,114713908,T,C,0.622,16,27,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-000776,4893.0
chr17,7673788,G,A,0.975,0,38,1|1,,SNP,MISSENSE,c.832C>T,p.P278S,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs17849781,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.C275fs*67(1) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:2,APOBEC:1,Misc:2",0.949089,0.8832556364693654,0.963,3.0,,,,,,,ACH-000678,7157.0
chr12,25245350,C,A,0.998,0,586,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000662,3845.0
chr17,7673787,G,C,0.948,0,16,1|1,,SNP,MISSENSE,c.833C>G,p.P278R,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs876659802,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:2,0.892025,,0.951,3.0,,,,,,,ACH-000659,7157.0
chr1,114713909,G,T,0.783,10,39,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000632,4893.0
chr2,124504443,T,G,0.221,20,5,0/1,,SNP,MISSENSE,c.1211T>G,p.L404R,CNTNAP5,contactin associated protein like 5,,ENST00000431078.1,8.0,+,Q8WYK1,False,,,,0.4788029925187032,,,False,,False,,cancer;,False,False,True,ENST00000431078;,,,,7.3,False,False,True,"Eso:1,Misc:1",0.695688,0.6064077545552017,0.921,2.0,,,,,,,ACH-000632,129684.0
chr4,152326214,C,T,0.74,11,33,0/1,,SNP,MISSENSE,c.1196G>A,p.R399Q,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs866987936,,as_specific,0.3665835411471321,"""E, L""",Rec,False,,True,p.R479Q(43) p.R479L(7) p.R479fs*6(3) p.R479P(3) p.D480fs*5(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:1,POLE:1",0.971548,,0.479,4.0,,,,,,,ACH-000632,55294.0
chr9,21971112,G,A,0.966,0,27,1|1,,SNP,MISSENSE,c.94C>T,p.H32Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913385,,as_specific,0.6982543640897756,,,False,,True,p.0(1543) p.P81fs*35(1) p.V82_E88del(1) p.H83Y(39) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.H83N(2) p.P81_A85del(1) p.R80fs*63(1) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1) p.V82fs*62(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;,,,,7.3,False,True,True,Misc:4,0.884844,0.9724149636314106,0.804,4.0,,,,,,,ACH-000632,1029.0
chr11,48325201,C,T,0.966,0,27,1|1,,SNP,SILENT,c.180C>T,p.F60F,OR4C3,olfactory receptor family 4 subfamily C member 3,"Olfactory receptors, family 4",ENST00000319856.5,1.0,+,Q8NH37,False,rs771083268,,as_specific,0.456359102244389,,,False,,False,,cancer;,False,False,True,,,,,3.91,False,False,True,UV:8,0.305394,0.5987220244873074,,0.0,,,,,,,ACH-000632,256144.0
chr17,7674890,T,C,0.489,23,23,0/1,,SNP,MISSENSE,c.641A>G,p.H214R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs1057519992,,as_specific,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H214Y(6) p.H214R(65) p.H214fs*7(2) p.R213_S215>X(1) p.L201_H214del(1) p.T211fs*28(1) p.R209fs*6(1) p.H214fs*5(2) p.H214Q(4) p.H214fs*33(3) p.H214H(1) p.H214Cfs*29(1) p.R213fs*32(1) p.H214fs*2(1) p.D208_V216delDRNTFRHSV(1) p.H214D(4) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.H214A(1) p.H214_S215insX(1) p.?(1) p.K164_P219del(1) p.H214P(1) p.F212_S215del(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:10,0.888834,,0.885,3.0,,,,,,,ACH-000729,7157.0
chr7,140753336,A,T,0.227,20,4,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000552,673.0
chr17,7673802,C,T,0.948,0,18,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000552,7157.0
chr17,7675143,C,A,0.962,0,24,1|1,,SNP,MISSENSE,c.469G>T,p.V157F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs121912654,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.V157F(176) p.0(9) p.V157A(2) p.V157L(7) p.S149fs*72(1) p.V157D(13) p.V157_R158insV(1) p.V157_R158delVR(3) p.V157I(11) p.G154fs*22(1) p.V157fs*13(3) p.V157fs*24(2) p.V157fs*22(2) p.V157fs*19(2) p.T155fs*23(2) p.V157V(5) p.V157G(12) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156fs*18(1) p.V157fs*23(3) p.R156fs*12(1) p.V157delV(2) p.T155_V157>I(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.R156fs*14(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.V157fs*25(1) p.V157_C176del20(1) p.V157>AL(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1092.0,,4.0,7.3,False,True,True,"smoking:20,Misc:8",0.788392,0.832221967405611,0.708,3.0,,,,,,,ACH-000399,7157.0
chr3,179234297,A,G,0.466,24,23,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000207,5290.0
chr17,7675088,C,T,0.979,0,49,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000207,7157.0
chr5,112838934,C,T,0.487,19,17,0/1,,SNP,NONSENSE,c.3340C>T,p.R1114*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913331,,as_specific,0.3690773067331671,"""E, M, O""",Rec,True,,True,p.R1114*(58) p.?(1) p.R1114G(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:2,POLE:8",0.976874,,,5.0,,,,,,,ACH-002654,324.0
chr12,25245351,C,A,0.818,7,36,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-002654,3845.0
chr17,7673704,G,A,0.96,0,23,1|1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-002654,7157.0
chr3,41224610,C,A,0.444,20,17,0/1,,SNP,MISSENSE,c.98C>A,p.S33Y,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913400,,as_specific,0.3940149625935162,"""E, M, O""",Dom,False,PLAG1,True,p.S33C(256) p.A5_A80del(75) p.S33Y(71) p.S33A(24) p.S33P(70) p.S33F(133) p.S33N(3) p.A5_Q143del(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.S33L(4) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.S33T(10) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32_S47del(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_I35del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(2) p.S23_S33del(3) p.A20_R151del(1) p.D32_S33insS(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.S33S(3) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.T3_A126del(2) p.D32fs*9(1) p.S33K(1) p.S23_S33>T(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.S33_G34insS(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_S33del(1) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.S33_G34insGTS(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.S33_G34insGI(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.V22_S33del(2) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.S33del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.Y30_S33del(2) p.A5_I35del(1) p.A5_T59del(1) p.A5_Q72del(1) p.S33_G34del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"POLE:1,Misc:4",0.94112,0.6783982772670947,0.495,4.0,,,,,,,ACH-000958,1499.0
chr7,55174014,G,A,0.37,34,20,0/1,,SNP,MISSENSE,c.2020G>A,p.G674S,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,17.0,+,P00533,False,rs28929495,,as_specific,0.5361596009975063,"""E, O""",Dom,False,,True,p.G719C(39) p.G719S(50) p.V674F(1),cancer;gene_function_gain;,False,True,True,ENST00000455089;ENST00000454757;ENST00000275493;,134.0,"While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.",23.0,7.3,True,False,False,,0.920046,,0.853,4.0,,,,,,,ACH-000958,1956.0
chr12,51991931,C,T,0.382,21,12,0/1,,SNP,NONSENSE,c.1174C>T,p.R392*,ACVR1B,activin A receptor type 1B,Type 1 receptor serine/threonine kinases,ENST00000542485.1,8.0,+,P36896,False,,,,0.4588528678304239,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:1,0.961399,,,5.0,,,,,,,ACH-000958,91.0
chr15,66435113,A,C,0.444,15,12,0/1,,SNP,MISSENSE,c.167A>C,p.Q56P,MAP2K1,mitogen-activated protein kinase kinase 1,Mitogen-activated protein kinase kinases,ENST00000307102.10,2.0,+,Q02750,False,rs1057519729,,as_specific,0.5087281795511222,,,False,,True,p.Q56P(12) p.Q56_G61>R(1) p.F53_Q58>L(1),cancer;gene_function_gain;,False,False,True,ENST00000307102;,83.0,MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.,3.0,7.3,True,False,False,,0.889501,,0.841,4.0,,,,,,,ACH-000958,5604.0
chr17,7675206,G,A,0.946,0,17,1|1,,SNP,NONSENSE,c.406C>T,p.Q136*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5586034912718204,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.N131fs*27(3) p.Q136E(7) p.Q136*(39) p.Q136_C141delQLAKTC(1) p.Q136Q(4) p.Q136P(4) p.Q136_K139delQLAK(1) p.Q136fs*?(1) p.Q136fs*13(2) p.Q136H(6) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.Q136R(2) p.S127_Q136del10(1) p.Q136fs*34(4) p.F134_T140>S(1) p.Q136K(1) p.Y126fs*11(1) p.V73fs*9(1) p.Q136L(1) p.C135_A138delCQLA(1) p.Q136fs*33(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"APOBEC:1,Misc:4",0.992162,0.5859850262275378,,4.0,,,,,,,ACH-000713,7157.0
chr17,39723967,T,C,0.665,11,22,0/1,,SNP,MISSENSE,c.2264T>C,p.L755S,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,19.0,+,P04626,False,rs121913470,,as_specific,0.543640897755611,E,Dom,False,,True,p.L755S(37) p.L755L(1) p.L755P(3) p.L755_S760>A(1) p.L755_T759delLRENT(1) p.L755F(1),cancer;gene_function_gain;,False,True,True,ENST00000584601;ENST00000406381;ENST00000541774;ENST00000445658;ENST00000584450;ENST00000269571;,39.0,"ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.",21.5,7.3,True,False,True,"MSI:1,Misc:3",0.880266,,0.86,4.0,,,,,,,ACH-000595,2064.0
chr17,7674221,G,A,0.954,0,19,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000464,7157.0
chr3,54503539,G,A,0.492,33,29,0/1,,SNP,SILENT,c.429G>A,p.G143G,CACNA2D3,calcium voltage-gated channel auxiliary subunit alpha2delta 3,Calcium voltage-gated channel auxiliary alpha2delta subunits,ENST00000474759.6,5.0,+,Q8IZS8,False,rs267599904,,as_specific,0.4389027431421446,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.29998,0.3298721411859698,,0.0,,,,,,,ACH-000644,55799.0
chr6,31972346,G,A,0.574,25,34,0/1,,SNP,MISSENSE,c.265G>A,p.D89N,STK19,serine/threonine kinase 19,,ENST00000375333.2,2.0,+,P49842,False,rs267600971,,as_specific,0.6433915211970075,,,False,,False,,cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,UV:8,0.461176,0.92198331243146,0.043,4.0,,,,,,,ACH-000644,8859.0
chr6,113943504,G,A,0.345,17,9,0/1,,SNP,NONSENSE,c.1225C>T,p.R409*,HDAC2,histone deacetylase 2,"NuRD complex Histone deacetylases, class I EMSY complex SIN3 histone deacetylase complex",ENST00000519065.6,12.0,-,Q92769,False,rs267600769,,as_specific,0.3167082294264339,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:5,0.992839,0.7103967586921622,,4.0,,,,,,,ACH-000644,3066.0
chr7,140753336,A,T,0.644,23,41,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000644,673.0
chr17,7675184,A,G,0.985,0,62,1|1,,SNP,MISSENSE,c.428T>C,p.V143A,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V143E(9) p.L137_W146del10(1) p.V143A(15) p.K139fs*4(1) p.V143fs*28(2) p.V143V(2) p.V143M(27) p.V143L(4) p.V143fs*4(1) p.V143_P153del(1) p.A138_V143delAKTCPV(1) p.V143G(1) p.C141fs*5(1) p.V143_S149delVQLWVDS(1) p.P142_Q144delPVQ(1) p.V143fs*27(2) p.V143fs*29(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,1254.0,,0.0,7.3,False,True,False,,0.763811,,0.574,2.0,,,,,,,ACH-000843,7157.0
chr17,7675139,C,T,0.979,0,45,1|1,,SNP,MISSENSE,c.473G>A,p.R158H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782144,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1695.0,,3.0,7.3,False,True,True,"CpG:6,MSI:1",0.916199,0.785313106525997,0.844,3.0,,,,,,,ACH-001400,7157.0
chr2,47429812,C,T,0.441,18,14,0/1,,SNP,NONSENSE,c.1147C>T,p.R383*,MSH2,mutS homolog 2,MutS homologs,ENST00000233146.7,7.0,+,P43246,False,rs63749849,,as_specific,0.3316708229426434,E,Rec,True,,False,p.R383*(4),cancer;gene_function_loss;dna_repair;,False,False,True,,727.0,,0.5,7.3,False,True,False,,0.988838,,,5.0,,,,,,,ACH-000982,4436.0
chr3,179234297,A,T,0.585,16,26,0/1,,SNP,MISSENSE,c.3140A>T,p.H1047L,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,1151.0,,12.5,7.3,True,False,True,"APOBEC:1,Misc:27",0.829278,,0.359,3.0,,,,,,,ACH-000982,5290.0
chr12,25245350,C,T,0.375,20,11,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000982,3845.0
chr3,38141150,T,C,0.945,0,16,1|1,,SNP,NONSTOP,c.439T>C,p.*147R,MYD88,myeloid differentiation primary response 88,TIR domain containing,ENST00000495303.6,3.0,+,Q99836,False,rs387907272,,as_specific,0.5511221945137157,L,Dom,True,,True,p.L265P(1704) p.L265>RPP(1) p.L265S(1),cancer;gene_function_gain;gene_function_loss;,False,True,True,ENST00000417037;ENST00000396334;ENST00000424893;ENST00000421516;ENST00000648963;,424.0,,31.0,4.61,True,True,True,Misc:5,0.863097,0.8970450162732663,0.735,4.0,,,,,,,ACH-001533,4615.0
chr17,7673802,C,T,0.941,0,15,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001533,7157.0
chr1,244054357,C,T,0.492,24,23,0/1,,SNP,NONSENSE,c.583C>T,p.R195*,ZBTB18,zinc finger and BTB domain containing 18,BTB domain containing Zinc fingers C2H2-type,ENST00000358704.4,2.0,+,Q99592,False,rs1064792999,,as_specific,0.5486284289276808,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,,0.921162,0.8462985727565925,,3.0,,,,,,,ACH-000971,10472.0
chr3,25627236,C,T,0.559,15,18,0/1,,SNP,MISSENSE,c.1952G>A,p.R651H,TOP2B,DNA topoisomerase II beta,Topoisomerases,ENST00000435706.6,16.0,-,Q02880,False,rs757502615,,as_specific,0.3615960099750623,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,MSI:1,0.920317,,0.514,3.0,,,,,,,ACH-000971,7155.0
chr3,136568813,C,T,0.5,15,14,0/1,,SNP,MISSENSE,c.346G>A,p.A116T,STAG1,stromal antigen 1,Cohesin complex,ENST00000236698.9,5.0,-,Q8WVM7,False,rs757393709,,as_specific,0.314214463840399,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:1,0.796336,0.3712059823763634,0.51,3.0,,,,,,,ACH-000971,10274.0
chr3,179234297,A,G,0.371,21,12,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000971,5290.0
chr12,25245347,C,T,0.546,19,24,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000971,3845.0
chr17,7673579,G,A,0.5,19,20,0/1,,SNP,NONSENSE,c.949C>T,p.Q317*,TP53,tumor protein p53,,ENST00000269305.8,9.0,-,P04637,False,,,,0.5062344139650873,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q317*(31) p.Q317fs*28(1) p.Q317R(4) p.Q317K(3) p.Q317fs*20(1) p.P316fs*19(1) p.Q317fs*?(2) p.S315fs*1(1) p.S315fs*22(1) p.S314_K320>*(1) p.Q317fs*19(1) p.Q317fs*45(1) p.S314fs*25(1) p.L308fs*15(1) p.Q317P(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,UV:3,APOBEC:1,Misc:3",0.972477,0.740164595047311,,4.0,,,,,,,ACH-000068,7157.0
chr17,7674229,C,T,0.532,22,24,0/1,,SNP,MISSENSE,c.734G>A,p.G245D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912656,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:9,0.965383,0.9964714944038346,0.974,3.0,,,,,,,ACH-000068,7157.0
chr7,140753336,A,T,0.721,20,49,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000582,673.0
chr1,241098711,G,A,0.677,10,22,0/1,,SNP,MISSENSE,c.130C>T,p.R44C,RGS7,regulator of G protein signaling 7,Regulators of G-protein signaling,ENST00000366563.5,3.0,-,P49802,False,rs755007339,,as_specific,0.3391521197007481,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:10,POLE:1",0.960396,,0.492,3.0,,,,,,,ACH-000750,6000.0
chr7,140753336,A,T,0.793,5,22,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000750,673.0
chr12,117524896,G,A,0.455,29,24,0/1,,SNP,SILENT,c.2175C>T,p.F725F,KSR2,kinase suppressor of ras 2,RAF family,ENST00000339824.7,14.0,-,Q6VAB6,False,rs887069309,,as_specific,0.5361596009975063,,,False,,False,,cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"UV:4,APOBEC:1",0.787268,0.562508186236627,,0.0,,,,,,,ACH-000750,283455.0
chr19,53109454,G,A,0.973,0,35,1|1,,SNP,SILENT,c.591C>T,p.F197F,ZNF415,zinc finger protein 415,Zinc fingers C2H2-type,ENST00000243643.8,4.0,-,Q09FC8,False,,,,0.3915211970074813,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:4,APOBEC:1",0.173821,0.2937308253866853,,0.0,,,,,,,ACH-000750,55786.0
chr22,35082544,C,T,0.951,0,18,1|1,,SNP,MISSENSE,c.256C>T,p.R86C,ISX,intestine specific homeobox,PRD class homeoboxes and pseudogenes,ENST00000308700.6,2.0,+,Q2M1V0,False,rs372031013,,as_specific,0.5635910224438903,,,False,,False,,cancer;,False,False,True,ENST00000404699;ENST00000308700;,,,,7.3,False,False,True,UV:9,0.724863,0.4238665325866041,0.861,2.0,,,,,,,ACH-000750,91464.0
chr1,162775707,A,T,0.589,13,19,0/1,,SNP,MISSENSE,c.1912A>T,p.I638F,DDR2,discoidin domain receptor tyrosine kinase 2,Receptor Tyrosine Kinases,ENST00000367922.7,16.0,+,Q16832,False,rs1057519789,,as_specific,0.4389027431421446,,,False,,False,p.I638F(1),cancer;gene_function_gain;,False,False,True,ENST00000446985;ENST00000367922;ENST00000367921;,143.0,"DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.",4.0,7.3,True,False,False,,0.806962,0.5469501474668303,0.859,4.0,,,,,,,ACH-000912,4921.0
chr9,21974731,C,A,0.967,0,28,1|1,,SNP,NONSENSE,c.97G>T,p.E33*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000304494.9,1.0,-,"P42771, Q8N726",False,,,,0.6783042394014963,,,True,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V28_V51del(1) p.V28_E33del(2) p.L32_L37del(6) p.R29_A34del(2) p.E33D(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,smoking:2,0.928062,0.8590761602013964,,4.0,,,,,,,ACH-000912,1029.0
chr15,66435113,A,C,0.837,16,89,0/1,,SNP,MISSENSE,c.167A>C,p.Q56P,MAP2K1,mitogen-activated protein kinase kinase 1,Mitogen-activated protein kinase kinases,ENST00000307102.10,2.0,+,Q02750,False,rs1057519729,,as_specific,0.5087281795511222,,,False,,True,p.Q56P(12) p.Q56_G61>R(1) p.F53_Q58>L(1),cancer;gene_function_gain;,False,False,True,ENST00000307102;,83.0,MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.,3.0,7.3,True,False,False,,0.889501,,0.841,4.0,,,,,,,ACH-000247,5604.0
chr21,33027124,T,G,0.619,10,17,0/1,,SNP,MISSENSE,c.262T>G,p.S88A,OLIG2,oligodendrocyte transcription factor 2,Basic helix-loop-helix proteins,ENST00000333337.3,1.0,+,Q13516,False,rs768519339,,as_specific,0.655860349127182,L,Dom,False,TRA@,False,,cancer;structural_relation;,False,False,True,,,,,7.3,False,False,True,MSI:2,0.652462,,0.094,2.0,,,,,,,ACH-000247,10215.0
chr12,25245350,C,A,0.521,22,29,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-002835,3845.0
chr17,7675148,G,T,0.878,3,30,0/1,,SNP,MISSENSE,c.464C>A,p.T155N,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202752,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T155P(16) p.S149fs*72(1) p.T155N(22) p.G154fs*22(1) p.T155I(15) p.P152fs*14(4) p.G154_R156delGTR(1) p.T155fs*23(2) p.T155L(1) p.T155T(5) p.T155S(2) p.D148fs*23(1) p.G154fs*14(2) p.T155A(7) p.T155_V157>I(1) p.T155fs*25(1) p.P153fs*22(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.T155fs*26(2) p.D148_T155delDSTPPPGT(1) p.R156fs*25(1) p.T155fs*15(1) p.T155_R156delTR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:4,0.656667,0.8526069402886141,0.548,2.0,,,,,,,ACH-002835,7157.0
chr17,7673781,C,G,0.96,0,23,1|1,,SNP,MISSENSE,c.839G>C,p.R280T,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912660,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R280T(73) p.R280fs*65(9) p.R280I(15) p.R280K(54) p.R280S(17) p.R280G(33) p.R280_R283>S(1) p.R280*(14) p.D281fs*24(1) p.S269fs*21(1) p.F270_D281del12(1) p.R280fs*?(1) p.V272_K292del21(1) p.D281_R282delDR(2) p.R280R(3) p.A276fs*64(1) p.R280fs*64(1) p.G279_R280delGR(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:19,0.96317,0.7002446792674034,0.94,3.0,,,,,,,ACH-000783,7157.0
chr17,7673802,C,T,0.368,24,13,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000888,7157.0
chr2,177234082,C,T,0.977,0,57,1|1,,SNP,MISSENSE,c.187G>A,p.E63K,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,rs1057519922,,as_specific,0.4064837905236907,E,Dom,False,,True,p.E79K(14) p.E79Q(11),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,APOBEC:7,0.922105,0.4993498434368417,0.363,3.0,,,,,,,ACH-000769,4780.0
chr9,21971109,C,A,0.933,0,14,1|1,,SNP,MISSENSE,c.97G>T,p.D33Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552822,,as_specific,0.6957605985037406,,,False,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V82_E88del(1) p.D84H(2) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.D84Y(9) p.P81_A85del(1) p.D84N(4) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.D84fs*63(2) p.E61_L94del(1) p.R80fs*34(1) p.D84_F90del(1) p.E33D(1) p.A68fs*3(1) p.D84fs*1(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;ENST00000579755;ENST00000530628;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.933446,0.9973373924118374,0.803,4.0,,,,,,,ACH-000769,1029.0
chr17,7673806,C,T,0.929,0,19,1|1,,SNP,MISSENSE,c.814G>A,p.V272M,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912657,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.V272M(88) p.0(9) p.F270fs*72(2) p.V272fs*73(2) p.V272A(7) p.V272L(39) p.V272V(4) p.V272E(9) p.G266_E271delGRNSFE(1) p.E271_R273delEVR(1) p.V272G(7) p.E258fs*71(1) p.V272fs*74(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.V272delV(1) p.R267fs*65(1) p.L265_K305del41(1) p.V272fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:10",0.911253,0.5298191979535021,0.907,3.0,,,,,,,ACH-000769,7157.0
chr17,7674888,T,C,0.286,14,5,0/1,,SNP,MISSENSE,c.643A>G,p.S215G,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs886039484,,as_specific,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.S215N(10) p.0(9) p.S215R(22) p.H214fs*7(2) p.R213_S215>X(1) p.T211fs*28(1) p.R209fs*6(1) p.S215G(12) p.S215_V218>M(1) p.S215I(22) p.H214fs*5(2) p.S215fs*29(1) p.S215T(5) p.S215fs*31(1) p.S215C(5) p.S215fs*32(4) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.R213fs*32(1) p.D208_V216delDRNTFRHSV(1) p.S215S(2) p.S215fs*?(2) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.H214_S215insX(1) p.?(1) p.K164_P219del(1) p.S215del(1) p.F212_S215del(1) p.S215fs*6(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:2,0.923814,0.4185958601831754,0.896,3.0,,,,,,,ACH-001132,7157.0
chr3,179198937,C,T,0.581,14,17,0/1,,SNP,MISSENSE,c.112C>T,p.R38C,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs749415085,,as_specific,0.3690773067331671,"""E, O""",Dom,False,,True,p.R38C(12) p.R38H(23) p.R38S(2) p.R38G(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,,,,7.3,True,False,True,"CpG:1,MSI:1,POLE:2",0.635522,0.8092041904693834,0.737,3.0,,,,,,,ACH-000966,5290.0
chr17,7675235,T,C,0.544,21,23,0/1,,SNP,SPLICE_SITE,c.377A>G,p.Y126C,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y126N(8) p.0(9) p.Y126*(8) p.Y126C(11) p.Y126S(2) p.Y126D(4) p.Y126fs*44(3) p.Y126fs*24(1) p.Y126_K132delYSPALNK(6) p.Y126Y(1) p.?(1) p.Y126_N131delYSPALN(3) p.Y126_S127insQPHH(1) p.Y126fs*?(1) p.Y126fs*11(1) p.V73fs*9(1) p.Y126H(1) p.Y126fs*18(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;ENST00000503591;,,,,7.3,False,True,True,Misc:3,0.955264,0.66576535760223,0.981,3.0,,,,,,,ACH-000966,7157.0
chr19,48499143,C,T,0.535,20,24,0/1,,SNP,SILENT,c.1926G>A,p.E642E,LMTK3,lemur tyrosine kinase 3,Protein phosphatase 1 regulatory subunits Receptor Tyrosine Kinases,ENST00000600059.5,11.0,-,Q96Q04,False,rs769591534,,as_specific,0.7381546134663342,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.145211,,,0.0,,,,,,,ACH-000966,114783.0
chr7,140753336,A,T,0.47,9,7,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000579,673.0
chr9,21971117,G,A,0.953,0,20,1|1,,SNP,MISSENSE,c.89C>T,p.P30L,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552823,,as_specific,0.7007481296758105,,,False,,True,p.0(1543) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A30fs*18(1) p.P81_A85del(1) p.P81H(2) p.A30P(1) p.A30E(1) p.A76fs*64(2) p.P81L(17) p.R80fs*63(1) p.T79fs*37(1) p.A30V(3) p.A30A(2) p.R29_A34del(2) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;,,,,7.3,False,True,True,UV:3,0.6432,0.998490066843982,0.862,4.0,,,,,,,ACH-000579,1029.0
chr17,7674216,C,A,0.972,0,34,1|1,,SNP,MISSENSE,c.747G>T,p.R249S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934571,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.P250fs*14(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:5,Misc:13",0.776711,,0.769,2.0,,,,,,,ACH-001318,7157.0
chr3,179218303,G,A,0.554,24,31,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000408,5290.0
chr12,25245351,C,A,0.771,18,66,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000900,3845.0
chr17,7673820,C,G,0.976,0,39,1|1,,SNP,MISSENSE,c.800G>C,p.R267P,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs587780075,,as_specific,0.5261845386533666,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R267W(34) p.G262_S269delGNLLGRNS(2) p.R267P(19) p.R267L(4) p.R267Q(11) p.R267R(5) p.G266_E271delGRNSFE(2) p.R267G(2) p.E258fs*71(1) p.N268fs*77(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.R267fs*65(1) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:3,Misc:2",0.917211,,0.927,3.0,,,,,,,ACH-000848,7157.0
chr3,10141997,C,G,0.968,0,30,1|1,,SNP,SILENT,c.150C>G,p.A50A,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs61751580,,as_specific,0.7281795511221946,"""E, M, O""",Rec,False,,False,p.A50G(1) p.A50T(2) p.A50P(1) p.A50V(1),cancer;gene_function_loss;,False,False,True,,3173.0,Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.150C>A (p.Ala50=; A50=)(https://www.ncbi.nlm.nih.gov/clinvar/variation/238101/),0.0,3.1,False,True,False,,0.13214,0.5867498393322315,,0.0,,,,,,,ACH-002742,7428.0
chr8,87353670,T,G,0.22,48,12,0/1,,SNP,MISSENSE,c.1187T>G,p.L396R,CNBD1,cyclic nucleotide binding domain containing 1,,ENST00000518476.6,10.0,+,Q8NA66,False,,,,0.2668329177057356,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:5,0.541415,,0.584,2.0,,,,,,,ACH-002742,168975.0
chr12,25245350,C,T,0.723,23,59,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002742,3845.0
chr17,7675088,C,T,0.969,0,31,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002742,7157.0
chr13,102735639,C,A,0.314,76,33,0/1,,SNP,MISSENSE,c.15058G>T,p.D5020Y,CCDC168,coiled-coil domain containing 168,,ENST00000322527.4,4.0,-,Q8NDH2,False,rs1475415081,,as_specific,0.3665835411471321,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:3,0.275423,0.744640615404546,0.088,2.0,,,,,,,ACH-001709,643677.0
chr17,7674220,C,T,0.977,0,41,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001709,7157.0
chr12,25245350,C,T,0.525,34,37,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000270,3845.0
chr4,152326137,G,A,0.431,19,17,0/1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-001119,55294.0
chr3,49375472,C,G,0.63,10,16,0/1,,SNP,MISSENSE,c.118G>C,p.E40Q,RHOA,ras homolog family member A,Rho family GTPases,ENST00000422781.5,2.0,-,P61586,False,rs1057519951,,as_specific,0.4164588528678304,,,False,,False,p.E40V(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,APOBEC:5,0.953878,0.2905929774946746,0.633,3.0,,,,,,,ACH-001543,387.0
chr1,147908084,C,T,0.444,19,14,0/1,,SNP,SILENT,c.129C>T,p.F43F,GJA8,gap junction protein alpha 8,Gap junction proteins,ENST00000369235.1,1.0,+,P48165,False,rs267598000,,as_specific,0.5860349127182045,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:2,UV:6,POLE:2",0.679718,0.8520121336634799,,0.0,,,,,,,ACH-000986,2703.0
chr1,155378509,G,A,0.465,17,12,0/1,,SNP,MISSENSE,c.6217C>T,p.R2073C,ASH1L,ASH1 like histone lysine methyltransferase,PHD finger proteins SET domain containing Lysine methyltransferases Bromodomain containing,ENST00000392403.8,9.0,-,Q9NR48,False,rs772388982,,as_specific,0.3665835411471321,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:4,POLE:2",0.933782,0.6762997319535147,0.429,3.0,,,,,,,ACH-000986,55870.0
chr2,8958590,C,T,0.441,15,12,0/1,,SNP,MISSENSE,c.128G>A,p.R43Q,MBOAT2,membrane bound O-acyltransferase domain containing 2,Membrane bound O-acyltransferases,ENST00000305997.8,2.0,-,Q6ZWT7,False,rs1471364240,,as_specific,0.3192019950124688,,,False,PRKCE,False,,cancer;structural_relation;,False,False,True,,,,,7.3,False,False,True,POLE:8,0.956186,0.6042387472934528,0.534,2.0,,,,,,,ACH-000986,129642.0
chr2,33519957,G,A,0.444,21,16,0/1,,SNP,MISSENSE,c.179G>A,p.R60Q,RASGRP3,RAS guanyl releasing protein 3,EF-hand domain containing,ENST00000402538.7,6.0,+,Q8IV61,False,rs369611073,,as_specific,0.4014962593516209,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"CpG:1,UV:1,POLE:11",0.887942,0.8184020156821371,0.122,2.0,,,,,,,ACH-000986,25780.0
chr2,47806614,G,T,0.448,16,14,0/1,,SNP,NONSENSE,c.3964G>T,p.E1322*,MSH6,mutS homolog 6,MutS homologs PWWP domain containing,ENST00000234420.11,9.0,+,P52701,False,,,,0.3491271820448878,E,Rec,True,,False,p.E1322*(1),cancer;gene_function_loss;dna_repair;,False,False,True,,,,,7.3,False,True,True,POLE:3,0.98704,0.6764572854120865,,4.0,,,,,,,ACH-000986,2956.0
chr2,61492337,C,T,0.464,22,19,0/1,,SNP,MISSENSE,c.1711G>A,p.E571K,XPO1,exportin 1,Exportins,ENST00000401558.7,15.0,-,O14980,False,rs1057520009,,as_specific,0.3067331670822942,L,Dom,False,,True,p.E571K(41) p.E571V(3) p.E571G(5) p.E571I(1) p.E571A(3) p.E571Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"CpG:1,POLE:4",0.979039,0.5942594365771144,0.579,4.0,,,,,,,ACH-000986,7514.0
chr2,201266689,G,A,0.556,9,13,0/1,,SNP,MISSENSE,c.203G>A,p.R68Q,CASP8,caspase 8,Caspases Death effector domain containing Ripoptosome Death inducing signaling complex ,ENST00000673742.1,2.0,+,Q14790,False,rs1339962485,,as_specific,0.4837905236907731,,,False,,False,p.R68*(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:8,0.71862,0.6222062166043786,0.434,2.0,,,,,,,ACH-000986,841.0
chr3,52576679,G,A,0.625,22,36,0/1,,SNP,NONSENSE,c.3598C>T,p.R1200*,PBRM1,polybromo 1,Bromodomain containing,ENST00000409114.7,23.0,-,Q86U86,False,,,,0.3391521197007481,E,Rec,True,,False,p.R1185*(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:2,UV:1,POLE:3",0.990201,,,5.0,,,,,,,ACH-000986,55193.0
chr3,52609752,G,A,0.433,19,13,0/1,,SNP,NONSENSE,c.2173C>T,p.R725*,PBRM1,polybromo 1,Bromodomain containing,ENST00000409114.7,17.0,-,Q86U86,False,,,,0.4214463840399002,E,Rec,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:4",0.982779,,,5.0,,,,,,,ACH-000986,55193.0
chr3,179199088,G,A,0.487,19,19,0/1,,SNP,MISSENSE,c.263G>A,p.R88Q,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs121913287,,as_specific,0.3391521197007481,"""E, O""",Dom,False,,True,p.R88Q(147) p.R88L(1) p.R88?(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,929.0,,0.0,7.3,True,False,True,"CpG:11,MSI:1,POLE:17",0.947755,0.4551598659740948,0.806,3.0,,,,,,,ACH-000986,5290.0
chr4,134200086,C,T,0.621,13,21,0/1,,SNP,MISSENSE,c.934G>A,p.E312K,PABPC4L,poly(A) binding protein cytoplasmic 4 like,RNA binding motif containing,ENST00000421491.4,2.0,-,P0CB38,False,rs868469335,,as_specific,0.4488778054862843,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.762636,0.5238843491955472,,2.0,,,,,,,ACH-000986,132430.0
chr4,152328233,G,A,0.465,15,12,0/1,,SNP,MISSENSE,c.1153C>T,p.R385C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs867384286,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465C(83) p.R465fs*7(13) p.R465S(1) p.R465Y(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:9,0.934034,0.2550529450691629,0.593,4.0,,,,,,,ACH-000986,55294.0
chr5,36051919,C,A,0.679,19,41,0/1,,SNP,NONSENSE,c.160G>T,p.E54*,UGT3A2,UDP glycosyltransferase family 3 member A2,UDP glucuronosyltransferases,ENST00000513300.5,2.0,-,Q3SY77,False,rs1261848267,,as_specific,0.3117206982543641,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:5,0.931947,0.619230364472891,,3.0,,,,,,,ACH-000986,167127.0
chr5,141331561,C,T,0.537,13,19,0/1,,SNP,MISSENSE,c.877C>T,p.R293C,PCDHGA1,"protocadherin gamma subfamily A, 1",Clustered protocadherins,ENST00000517417.2,1.0,+,Q9Y5H4,False,rs898742572,,as_specific,0.4339152119700748,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:8,0.569451,,0.136,2.0,,,,,,,ACH-000986,56114.0
chr6,22294409,G,A,0.566,11,14,0/1,,SNP,SPLICE_SITE,c.204C>T,p.F68F,PRL,prolactin,Growth hormone family,ENST00000306482.2,2.0,-,P01236,False,rs1328141274,,as_specific,0.513715710723192,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:2,POLE:7",0.805713,0.2553283409794127,,0.0,,,,,,,ACH-000986,5617.0
chr6,56603983,C,A,0.416,16,12,0/1,,SNP,NONSENSE,c.10012G>T,p.E3338*,DST,dystonin,Plakins EF-hand domain containing,ENST00000361203.7,36.0,-,Q03001,False,,,,0.3665835411471321,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:5,0.93955,,,5.0,,,,,,,ACH-000986,667.0
chr6,73133449,C,T,0.592,8,14,0/1,,SNP,MISSENSE,c.1276C>T,p.R426C,KCNQ5,potassium voltage-gated channel subfamily Q member 5,Potassium voltage-gated channels,ENST00000370398.5,10.0,+,Q9NR82,False,rs920140431,,as_specific,0.4713216957605985,,,False,,False,,cancer;,False,False,True,ENST00000342056;ENST00000403813;ENST00000355194;ENST00000402622;ENST00000355635;ENST00000370398;ENST00000629977;,,,,7.3,False,False,True,,0.874775,,0.706,2.0,,,,,,,ACH-000986,56479.0
chr6,138843011,C,T,0.679,10,22,0/1,,SNP,SILENT,c.375C>T,p.F125F,ECT2L,epithelial cell transforming 2 like,Rho guanine nucleotide exchange factors F-boxes other,ENST00000541398.6,6.0,+,Q008S8,False,rs772296643,,as_specific,0.3940149625935162,L,Rec,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:6,0.840033,,,0.0,,,,,,,ACH-000986,345930.0
chr6,152376497,G,A,0.526,19,20,0/1,,SNP,NONSENSE,c.9208C>T,p.R3070*,SYNE1,spectrin repeat containing nuclear envelope protein 1,Spectrin repeat containing nuclear envelope family,ENST00000367255.10,58.0,-,Q8NF91,False,rs549779256,,as_specific,0.3615960099750623,,,True,,False,p.R3070*(1),cancer;gene_function_loss;,False,False,True,,,,,4.61,False,True,True,"UV:1,POLE:6",0.990774,0.7745245064613034,,5.0,,,,,,,ACH-000986,23345.0
chr7,94910184,G,A,0.442,26,21,0/1,,SNP,MISSENSE,c.71G>A,p.R24Q,PPP1R9A,protein phosphatase 1 regulatory subunit 9A,Sterile alpha motif domain containing Protein phosphatase 1 regulatory subunits PDZ domain containing,ENST00000433360.6,2.0,+,Q9ULJ8,False,,,,0.428927680798005,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.932198,,0.204,2.0,,,,,,,ACH-000986,55607.0
chr7,95299095,C,T,0.432,27,20,0/1,,SNP,MISSENSE,c.917G>A,p.R306Q,PON1,paraoxonase 1,Paraoxonases,ENST00000222381.8,9.0,-,P27169,False,rs749649413,,as_specific,0.3890274314214463,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:10,0.68897,0.7807916363368471,0.135,2.0,,,,,,,ACH-000986,5444.0
chr10,60088161,G,A,0.964,0,27,1|1,,SNP,NONSENSE,c.3526C>T,p.R1176*,ANK3,ankyrin 3,Ankyrin repeat domain containing,ENST00000280772.7,29.0,-,Q12955,False,rs142673853,,as_specific,0.428927680798005,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:6",0.994636,0.1753566424350816,,4.0,,,,,,,ACH-000986,288.0
chr12,118029791,C,T,0.686,16,40,0/1,,SNP,NONSENSE,c.892C>T,p.R298*,RFC5,replication factor C subunit 5,AAA ATPases,ENST00000454402.7,10.0,+,P40937,False,rs141299152,,as_specific,0.3940149625935162,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:9,0.981015,0.5309457166501192,,4.0,,,,,,,ACH-000986,5985.0
chr12,132673703,C,A,0.192,26,4,0/1,,SNP,MISSENSE,c.1231G>T,p.V411L,POLE,"DNA polymerase epsilon, catalytic subunit",DNA polymerases,ENST00000320574.10,13.0,-,Q07864,False,rs1057519945,,as_specific,0.5810473815461347,,,False,,True,p.V411L(104) p.V411M(1),cancer;gene_function_loss;dna_repair;,False,False,True,,,,,7.3,False,True,True,,0.907765,0.520500289313063,0.457,4.0,,,,,,,ACH-000986,5426.0
chr14,60720206,G,T,0.462,6,5,0/1,,SNP,MISSENSE,c.1103C>A,p.S368Y,SIX4,SIX homeobox 4,SINE class homeoboxes,ENST00000216513.5,2.0,-,Q9UIU6,False,rs369624724,,as_specific,0.4339152119700748,,,False,,False,,cancer;,False,False,True,ENST00000216513;ENST00000556952;,,,,7.3,False,False,True,POLE:4,0.811413,0.7712694842308909,0.814,2.0,,,,,,,ACH-000986,51804.0
chr14,90302832,C,T,0.408,19,10,0/1,,SNP,SILENT,c.1299G>A,p.S433S,NRDE2,"NRDE-2, necessary for RNA interference, domain containing",,ENST00000354366.8,6.0,-,Q9H7Z3,False,rs937745011,,as_specific,0.4463840399002494,,,False,,False,,cancer;,False,False,True,,,,,4.13,False,False,True,POLE:6,0.47157,0.6242118313774039,,0.0,,,,,,,ACH-000986,55051.0
chr15,100648364,C,T,0.438,17,13,0/1,,SNP,NONSENSE,c.859C>T,p.R287*,ASB7,ankyrin repeat and SOCS box containing 7,Ankyrin repeat domain containing,ENST00000332783.12,6.0,+,Q9H672,False,,,,0.3790523690773067,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:6",0.983089,,,4.0,,,,,,,ACH-000986,140460.0
chr17,7674894,G,A,0.528,10,11,0/1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000986,7157.0
chr20,46501480,C,A,0.251,22,7,0/1,,SNP,MISSENSE,c.1859G>T,p.R620I,ZNF334,zinc finger protein 334,Zinc fingers C2H2-type,ENST00000347606.8,5.0,-,Q9HCZ1,False,rs1283478256,,as_specific,0.4139650872817955,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.573305,0.3784578311898174,0.127,3.0,,,,,,,ACH-000986,55713.0
chr21,28986161,C,A,0.395,25,17,0/1,,SNP,MISSENSE,c.323G>T,p.R108I,LTN1,listerin E3 ubiquitin protein ligase 1,Ring finger proteins,ENST00000389195.7,3.0,-,O94822,False,,,,0.3167082294264339,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.867562,,0.312,2.0,,,,,,,ACH-000986,26046.0
chrX,73447385,C,T,0.9,0,11,0/1,,SNP,SILENT,c.132C>T,p.F44F,CDX4,caudal type homeobox 4,HOXL subclass homeoboxes,ENST00000373514.2,1.0,+,O14627,False,,,,0.6084788029925187,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:3,POLE:7",,0.6380293339556065,,0.0,,,,,,,ACH-000986,1046.0
chr12,25245351,C,A,0.907,1,18,1|1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000521,3845.0
chr17,7673835,C,A,0.972,0,36,1|1,,SNP,MISSENSE,c.785G>T,p.G262V,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1131691025,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G262delG(3) p.G262_S269delGNLLGRNS(2) p.G262V(14) p.G262fs*83(5) p.G262H(1) p.G262S(2) p.E258fs*71(1) p.S261_L264>R(1) p.G262D(7) p.S261_G262insX(1) p.G262G(1) p.G262R(1) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:4,Misc:1",0.951072,0.4986101440760339,0.929,3.0,,,,,,,ACH-000521,7157.0
chr3,179199088,G,A,0.59,10,17,0/1,,SNP,MISSENSE,c.263G>A,p.R88Q,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs121913287,,as_specific,0.3391521197007481,"""E, O""",Dom,False,,True,p.R88Q(147) p.R88L(1) p.R88?(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,929.0,,0.0,7.3,True,False,True,"CpG:11,MSI:1,POLE:17",0.947755,0.4551598659740948,0.806,3.0,,,,,,,ACH-000939,5290.0
chr10,11948444,T,A,0.55,8,11,0/1,,SNP,MISSENSE,c.3099A>T,p.E1033D,UPF2,"UPF2, regulator of nonsense mediated mRNA decay",,ENST00000356352.6,15.0,-,Q9HAU5,False,rs1367060563,,as_specific,0.314214463840399,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.697602,,0.02,3.0,,,,,,,ACH-000939,26019.0
chr17,7674220,C,T,0.575,16,23,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000939,7157.0
chr17,7675088,C,T,0.705,12,31,0/1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000939,7157.0
chr12,25245350,C,T,0.366,27,15,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002745,3845.0
chr17,7674872,T,C,0.958,0,24,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-002745,7157.0
chr17,7674945,G,A,0.978,0,42,1|1,,SNP,NONSENSE,c.586C>T,p.R196*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516435,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R196*(221) p.R196P(18) p.R196Q(5) p.R196R(6) p.I195fs*12(1) p.R196_R202del(1) p.R196fs*51(4) p.I195_G199delIRVEG(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.R196L(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.R196fs*13(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.986209,0.7393785927987923,,4.0,,,,,,,ACH-002979,7157.0
chr12,25245350,C,T,0.548,41,49,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002744,3845.0
chr17,7675077,G,A,0.944,1,36,1|1,,SNP,MISSENSE,c.535C>T,p.H179Y,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587780070,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,UV:2,Misc:5",0.952817,0.6715806553525823,0.948,3.0,,,,,,,ACH-002744,7157.0
chr7,140753336,A,T,0.375,15,8,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000550,673.0
chr19,57135184,G,A,0.322,40,17,0/1,,SNP,MISSENSE,c.1153C>T,p.H385Y,ZIM3,zinc finger imprinted 3,Zinc fingers C2H2-type,ENST00000269834.1,5.0,-,Q96PE6,False,rs150510557,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.419835,0.5507929749384455,0.288,2.0,,,,,,,ACH-000550,114026.0
chr3,179218303,G,A,0.484,31,26,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000725,5290.0
chr8,87353670,T,G,0.526,9,9,0/1,,SNP,MISSENSE,c.1187T>G,p.L396R,CNBD1,cyclic nucleotide binding domain containing 1,,ENST00000518476.6,10.0,+,Q8NA66,False,,,,0.2668329177057356,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:5,0.541415,,0.584,2.0,,,,,,,ACH-000427,168975.0
chr17,7674220,C,T,0.962,0,24,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000427,7157.0
chr6,133462352,T,G,0.273,32,12,0/1,,SNP,MISSENSE,c.293T>G,p.L98R,EYA4,EYA transcriptional coactivator and phosphatase 4,Deafness associated genes EYA transcriptional coactivator and phosphatases,ENST00000452339.6,7.0,+,O95677,False,,,,0.42643391521197,,,False,,False,p.L152R(1),cancer;,False,False,True,,,,,7.3,False,False,True,Eso:1,0.921487,0.5323340899918068,0.602,2.0,,,,,,,ACH-002839,2070.0
chr4,1806162,A,G,0.528,26,29,0|1,1806162.0,SNP,MISSENSE,c.1951A>G,p.K651E,FGFR3,fibroblast growth factor receptor 3,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000481110.6,14.0,+,P22607,False,rs78311289,,as_specific,0.6533665835411472,"""L, E""",Dom,False,"""IGH@, ETV6""",True,p.K650E(48) p.K650Q(5) p.T651M(1),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,ENST00000440486;ENST00000481110;ENST00000340107;ENST00000412135;ENST00000352904;,1400.0,,0.0,7.3,True,True,True,Misc:3,0.919131,0.965456918024718,0.837,3.0,,,,,,,ACH-000024,2261.0
chr9,21971112,G,A,0.294,24,9,0/1,,SNP,MISSENSE,c.94C>T,p.H32Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913385,,as_specific,0.6982543640897756,,,False,,True,p.0(1543) p.P81fs*35(1) p.V82_E88del(1) p.H83Y(39) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.H83N(2) p.P81_A85del(1) p.R80fs*63(1) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1) p.V82fs*62(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;,,,,7.3,False,True,True,Misc:4,0.884844,0.9724149636314106,0.804,4.0,,,,,,,ACH-000024,1029.0
chr17,7675088,C,T,0.959,0,23,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000024,7157.0
chr22,27798957,C,T,0.395,20,17,0/1,,SNP,SILENT,c.1587G>A,p.Q529Q,MN1,"MN1 proto-oncogene, transcriptional regulator",,ENST00000302326.5,1.0,-,Q10571,False,rs1211453471,,as_specific,0.6807980049875312,"""L, O""",Dom,False,ETV6,False,,cancer;structural_relation;,False,False,True,,,,,7.3,False,False,True,MSI:2,0.106828,0.6258915196524149,,0.0,,,,,,,ACH-000024,4330.0
chr17,7674220,C,T,0.979,0,46,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000030,7157.0
chr3,41224622,C,T,0.512,20,20,0/1,,SNP,MISSENSE,c.110C>T,p.S37F,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913403,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.S37F(236) p.S37C(174) p.S37A(70) p.A5_Q143del(7) p.S37P(30) p.S37Y(49) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.S37T(2) p.Y30_T40del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.S37L(2) p.S37S(2) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(4) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.I35_S37>T(1) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.S37_G38>W(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.I35_T41del(1) p.D32fs*9(1) p.I35_K170del(1) p.S37V(1) p.H36_S37del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.S37_A39>S(1) p.I35_G38del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"UV:2,POLE:1,APOBEC:6,Misc:2",0.946363,,0.586,4.0,,,,,,,ACH-000538,1499.0
chr7,140753336,A,T,0.432,22,15,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001350,673.0
chr17,7675157,G,A,0.979,0,44,1|1,,SNP,MISSENSE,c.455C>T,p.P152L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782705,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.P152fs*18(21) p.P152P(6) p.0(9) p.P152S(29) p.S149fs*72(1) p.P152L(75) p.P153fs*28(7) p.P152_P153insXXX(1) p.P152T(9) p.P152fs*14(6) p.P152A(2) p.P153fs*16(2) p.P152Q(4) p.P152R(7) p.P152fs*28(3) p.D148fs*23(1) p.T150fs*16(4) p.P152fs*27(1) p.P152fs*29(6) p.V143_P153del(1) p.P151_V173del23(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"CpG:2,UV:1",0.952593,0.8618240470838262,0.878,3.0,,,,,,,ACH-001350,7157.0
chr7,140753336,A,T,0.62,19,31,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000572,673.0
chr3,192798931,G,C,0.577,11,14,0/1,,SNP,MISSENSE,c.931C>G,p.Q311E,MB21D2,Mab-21 domain containing 2,,ENST00000392452.3,2.0,-,Q8IYB1,False,rs988241015,,as_specific,0.5361596009975063,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:19,0.760565,,0.374,3.0,,,,,,,ACH-000945,151963.0
chr12,25227342,T,A,0.981,0,50,1|1,,SNP,MISSENSE,c.182A>T,p.Q61L,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs121913240,,as_specific,0.3491271820448878,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,908.0,,7.5,7.3,True,False,True,"smoking:2,UV:1,Misc:3",0.912028,0.63424462401125,0.885,4.0,,,,,,,ACH-000945,3845.0
chr3,179218294,G,A,0.539,17,20,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000545,5290.0
chr17,7675088,C,T,0.977,0,42,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000545,7157.0
chr3,179218303,G,A,0.502,24,23,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-001675,5290.0
chr9,21971121,G,A,0.981,1,55,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-001675,1029.0
chr17,7674220,C,T,0.969,0,33,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001675,7157.0
chr12,25245350,C,A,0.924,14,183,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000764,3845.0
chr17,7673803,G,A,0.977,0,43,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000764,7157.0
chr17,7673787,G,A,0.981,0,50,1|1,,SNP,MISSENSE,c.833C>T,p.P278L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs876659802,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:1,Misc:2",0.909152,0.7609434722182151,0.94,3.0,,,,,,,ACH-002051,7157.0
chr7,6387261,C,T,0.25,35,11,0/1,,SNP,MISSENSE,c.85C>T,p.P29S,RAC1,Rac family small GTPase 1,Rho family GTPases Endogenous ligands,ENST00000356142.4,2.0,+,P63000,False,rs1057519874,,as_specific,0.3117206982543641,,,False,,True,p.P29S(58) p.P29L(3),cancer;gene_function_gain;,False,False,True,,367.0,,4.0,7.3,True,False,True,"UV:19,APOBEC:1",0.898956,0.7595241052535948,0.585,3.0,,,,,,,ACH-000621,5879.0
chr17,7674227,T,C,0.451,18,15,0/1,,SNP,MISSENSE,c.736A>G,p.M246V,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs483352695,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G244_M246del(1) p.M246T(14) p.M246I(29) p.M246V(42) p.M246R(13) p.M246L(5) p.C242fs*98(1) p.M246_P250delMNRRP(4) p.M246K(13) p.M246fs*19(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.M246fs*1(2) p.G245fs*16(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:3,0.914229,0.7801251233587941,0.924,3.0,,,,,,,ACH-000961,7157.0
chr11,101051562,C,T,0.541,22,27,0/1,,SNP,MISSENSE,c.2219G>A,p.R740Q,PGR,progesterone receptor,Nuclear hormone receptors,ENST00000325455.10,5.0,-,P06401,False,rs149186732,,as_specific,0.3017456359102244,,,False,,False,,cancer;gene_function_gain;,False,False,True,ENST00000325455;ENST00000534013;ENST00000263463;ENST00000617858;ENST00000619228;,,,,7.3,True,False,True,"CpG:1,POLE:5",0.981043,0.5890141148230612,0.779,3.0,,,,,,,ACH-001636,5241.0
chr12,25245351,C,A,0.362,31,16,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000809,3845.0
chr17,7670700,G,A,0.96,0,23,1|1,,SNP,MISSENSE,c.1009C>T,p.R337C,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs587782529,,as_specific,0.4812967581047381,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R337C(43) p.R337H(73) p.R337L(10) p.R337S(1) p.R337P(1) p.R337G(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000504937;ENST00000619186;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000445888;ENST00000619485;ENST00000615910;,,,,7.3,False,True,True,"CpG:3,MSI:1",0.648253,0.5401534229107201,0.715,3.0,,,,,,,ACH-000809,7157.0
chr17,7673704,G,A,0.973,0,36,1|1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-000223,7157.0
chr17,7674872,T,C,0.971,0,33,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000911,7157.0
chr1,114713909,G,T,0.436,17,13,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-001986,4893.0
chr4,152323033,G,A,0.742,7,22,0/1,,SNP,NONSENSE,c.1732C>T,p.R578*,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,11.0,-,Q969H0,False,,,,0.4189526184538653,"""E, L""",Rec,True,,False,p.R658*(3),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:4,POLE:6",0.985892,0.3354639856325636,,5.0,,,,,,,ACH-001986,55294.0
chr8,58815669,G,A,0.717,10,27,0/1,,SNP,MISSENSE,c.1061C>T,p.S354L,TOX,thymocyte selection associated high mobility group box,,ENST00000361421.2,7.0,-,O94900,False,rs200969018,,as_specific,0.4987531172069825,,,False,,False,,cancer;,False,False,True,,,,,3.91,False,False,True,"UV:1,POLE:6",0.936795,,0.167,4.0,,,,,,,ACH-001986,9760.0
chr8,76852088,C,T,0.679,9,19,0/1,,SNP,MISSENSE,c.5167C>T,p.P1723S,ZFHX4,zinc finger homeobox 4,ZF class homeoboxes and pseudogenes,ENST00000651372.2,10.0,+,Q86UP3,False,rs866599341,,as_specific,0.4663341645885286,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.774546,0.3978937415298598,0.347,2.0,,,,,,,ACH-001986,79776.0
chr19,11033437,G,A,0.583,9,16,0/1,,SNP,MISSENSE,c.3694G>A,p.G1232S,SMARCA4,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4",Bromodomain containing,ENST00000344626.9,26.0,+,P51532,False,,,,0.5835411471321695,E,Rec,False,,False,p.G1232D(1) p.D1183_M1317del(1),cancer;gene_function_loss;,False,False,True,ENST00000344626;ENST00000643549;ENST00000646693;ENST00000642726;ENST00000646484;ENST00000644737;ENST00000642628;ENST00000643296;ENST00000647230;ENST00000646510;ENST00000429416;ENST00000645460;ENST00000541122;ENST00000589677;ENST00000444061;ENST00000590574;ENST00000413806;ENST00000450717;ENST00000643208;ENST00000642350;ENST00000647268;,,,,7.3,False,True,True,CpG:1,0.931439,,0.906,4.0,,,,,,,ACH-000457,6597.0
chr3,179218294,G,A,0.959,0,22,1|1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000680,5290.0
chr5,112838934,C,T,0.37,18,10,0/1,,SNP,NONSENSE,c.3340C>T,p.R1114*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913331,,as_specific,0.3690773067331671,"""E, M, O""",Rec,True,,True,p.R1114*(58) p.?(1) p.R1114G(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:2,POLE:8",0.976874,,,5.0,,,,,,,ACH-000680,324.0
chr5,112839879,C,T,0.5,12,11,0/1,,SNP,NONSENSE,c.4285C>T,p.Q1429*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs74535574,,as_specific,0.4638403990024937,"""E, M, O""",Rec,True,,True,p.Q1429*(58) p.Q1429H(1) p.Q1429fs*8(4) p.Y1376fs*41(1) p.P1424fs*19(1) p.Q1429fs*44(1) p.S1411fs*41(1) p.?(1) p.K1192fs*3(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,Misc:5,0.988299,0.2425819783561997,,5.0,,,,,,,ACH-000680,324.0
chr12,25227342,T,A,0.667,9,20,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs121913240,,as_specific,0.3491271820448878,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,908.0,,7.5,7.3,True,False,True,"smoking:2,UV:1,Misc:3",0.912028,0.63424462401125,0.885,4.0,,,,,,,ACH-000680,3845.0
chr15,66435113,A,C,0.407,38,25,0/1,,SNP,MISSENSE,c.167A>C,p.Q56P,MAP2K1,mitogen-activated protein kinase kinase 1,Mitogen-activated protein kinase kinases,ENST00000307102.10,2.0,+,Q02750,False,rs1057519729,,as_specific,0.5087281795511222,,,False,,True,p.Q56P(12) p.Q56_G61>R(1) p.F53_Q58>L(1),cancer;gene_function_gain;,False,False,True,ENST00000307102;,83.0,MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.,3.0,7.3,True,False,False,,0.889501,,0.841,4.0,,,,,,,ACH-000589,5604.0
chr17,7673820,C,G,0.974,0,36,1|1,,SNP,MISSENSE,c.800G>C,p.R267P,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs587780075,,as_specific,0.5261845386533666,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R267W(34) p.G262_S269delGNLLGRNS(2) p.R267P(19) p.R267L(4) p.R267Q(11) p.R267R(5) p.G266_E271delGRNSFE(2) p.R267G(2) p.E258fs*71(1) p.N268fs*77(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.R267fs*65(1) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:3,Misc:2",0.917211,,0.927,3.0,,,,,,,ACH-000589,7157.0
chr17,7675088,C,T,0.983,0,62,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000248,7157.0
chr7,55181312,G,T,0.255,81,27,0/1,,SNP,MISSENSE,c.2168G>T,p.S723I,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,19.0,+,P00533,False,rs121913465,,as_specific,0.571072319201995,"""E, O""",Dom,False,,True,p.A767_S768insTLA(2) p.S768I(41) p.S768_V769>IL(1) p.V769_D770insANV(1) p.F723F(2) p.S768N(1) p.V769_D770insASV(1) p.F723S(1) p.F723L(1),cancer;gene_function_gain;,False,True,True,ENST00000455089;ENST00000454757;ENST00000275493;,562.0,,20.5,7.3,True,False,True,"smoking:1,Misc:1",0.853807,0.4997915506246814,0.765,4.0,,,,,,,ACH-000865,1956.0
chr17,7670694,C,A,0.209,36,8,0/1,,SNP,NONSENSE,c.1015G>T,p.E339*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,,,,0.4738154613466334,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E339Q(1) p.E339*(20) p.E339K(2) p.E339fs*6(1) p.E339fs*8(3) p.E339fs*13(1) p.E339_M340>V(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,Misc:2",0.989639,,,4.0,,,,,,,ACH-000865,7157.0
chr17,7675076,T,C,0.603,20,31,0/1,,SNP,MISSENSE,c.536A>G,p.H179R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519991,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:27,0.941824,,0.935,3.0,,,,,,,ACH-000865,7157.0
chr12,25245350,C,T,0.724,12,34,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002486,3845.0
chr17,7673776,G,A,0.976,0,41,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-002486,7157.0
chr17,7673802,C,T,0.937,0,15,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-002066,7157.0
chr3,179218286,C,G,0.333,26,12,0/1,,SNP,MISSENSE,c.1616C>G,p.P539R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913285,,as_specific,0.3017456359102244,"""E, O""",Dom,False,,True,p.P539L(1) p.P539R(27) p.P539S(6) p.P539T(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;,,,,7.3,True,False,True,Misc:4,0.88552,,0.893,3.0,,,,,,,ACH-000536,5290.0
chr3,179234297,A,G,0.337,32,15,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000536,5290.0
chr12,25245350,C,T,0.976,0,39,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000155,3845.0
chr10,87957915,C,T,0.976,0,41,1|1,,SNP,NONSENSE,c.697C>T,p.R233*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,7.0,+,P60484,False,rs121909219,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R233*(101) p.0(28) p.G165_K342del(1) p.T232_R233insTQGGAGS(2) p.R233fs*10(14) p.R55fs*1(1) p.R233fs*3(1) p.R234fs*9(1) p.R233fs*24(1) p.R233fs*?(2) p.T232_R233insK*(1) p.N228fs*10(1) p.R233fs*25(2) p.R233fs*13(1) p.R233fs*19(1) p.R233fs*26(1) p.R233fs*20(1) p.R233R(1) p.R233fs*12(1) p.P231fs*2(1) p.K221fs*6(1) p.R233fs*23(1) p.T232_R233insPQGGAGT(1) p.G165_*404del(1) p.R233Q(1),cancer;gene_function_loss;,False,True,True,,110.0,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.",19.0,7.3,False,True,False,,0.971128,0.6883155413500054,,3.0,,,,,,,ACH-000883,5728.0
chr17,7673802,C,T,0.609,18,29,0|1,7673802.0,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000883,7157.0
chr14,91785354,G,A,0.548,18,21,0/1,,SNP,SILENT,c.1170C>T,p.F390F,TC2N,"tandem C2 domains, nuclear",Synaptotagmin like tandem C2 proteins,ENST00000435962.7,11.0,-,Q8N9U0,False,rs776984565,,as_specific,0.3167082294264339,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:9,0.835346,,,0.0,,,,,,,ACH-002885,123036.0
chr17,7673802,C,T,0.951,0,18,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-002885,7157.0
chr8,24914431,C,T,0.4,20,13,0/1,,SNP,MISSENSE,c.638C>T,p.A213V,NEFM,neurofilament medium,Intermediate filaments Type IV,ENST00000518131.5,1.0,+,P07197,False,,,,0.6384039900249376,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.673945,0.3618281763558523,0.587,3.0,,,,,,,ACH-000940,4741.0
chr17,7674893,C,T,0.368,23,13,0/1,,SNP,MISSENSE,c.638G>A,p.R213Q,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs587778720,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"CpG:2,UV:1,POLE:2",0.920288,0.776972471915739,0.92,3.0,,,,,,,ACH-000940,7157.0
chr10,87933147,C,T,0.964,0,26,1|1,,SNP,NONSENSE,c.388C>T,p.R130*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,5.0,+,P60484,False,rs121909224,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R130G(140) p.R130Q(108) p.R130fs*4(13) p.R130fs*2(1) p.K128_R130del(4) p.0(28) p.R130L(19) p.R130*(83) p.R130P(7) p.R55fs*1(1) p.R130?(1) p.R130fs*?(5) p.R130R(1) p.R130_T131>P(4) p.R130fs*50(1) p.G129fs*50(1) p.Y27_N212>Y(2) p.G129fs*51(1) p.F56fs*2(1) p.?(1) p.K125fs*46(1) p.A121_F145del(1) p.K128fs*47(1) p.R130Xfs*?(1),cancer;gene_function_loss;,False,False,True,,636.0,,2.0,7.3,False,True,False,,0.97629,0.898071104088428,,4.0,,,,,,,ACH-000231,5728.0
chr17,7674241,G,A,0.965,0,26,1|1,,SNP,MISSENSE,c.722C>T,p.S241F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:4,APOBEC:7,Misc:1",0.912713,0.9893558821746748,0.958,3.0,,,,,,,ACH-000231,7157.0
chr3,179218303,G,A,0.5,26,27,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-002883,5290.0
chr17,7673767,C,T,0.963,0,28,1|1,,SNP,MISSENSE,c.853G>A,p.E285K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs112431538,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E285K(139) p.E285V(15) p.R283fs*16(2) p.E285Q(5) p.E285G(5) p.E285*(19) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.E285A(2) p.R283fs*56(1) p.V272_K292del21(1) p.E285E(5) p.E285fs*20(1) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285fs*60(2) p.E285fs*21(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:20,0.905537,,0.91,3.0,,,,,,,ACH-002883,7157.0
chr17,7675149,T,G,0.963,0,26,1|1,,SNP,MISSENSE,c.463A>C,p.T155P,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T155P(16) p.S149fs*72(1) p.T155N(22) p.G154fs*22(1) p.T155I(15) p.P152fs*14(5) p.G154_R156delGTR(1) p.T155fs*23(2) p.T155L(1) p.T155T(5) p.T155S(2) p.D148fs*23(1) p.G154fs*14(2) p.T155A(7) p.T155_V157>I(1) p.T155fs*25(1) p.P153fs*22(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.T155fs*26(2) p.D148_T155delDSTPPPGT(1) p.T155fs*15(1) p.T155_R156delTR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:1,0.904506,0.8516826607141765,0.581,2.0,,,,,,,ACH-000594,7157.0
chr2,177234225,C,G,0.578,19,25,0/1,,SNP,MISSENSE,c.44G>C,p.G15A,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.3890274314214463,E,Dom,False,,False,p.G31A(3) p.G31V(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,APOBEC:2,0.927893,0.6355940721378454,0.425,3.0,,,,,,,ACH-000447,4780.0
chr17,7673537,G,A,0.947,0,18,1|1,,SNP,NONSENSE,c.991C>T,p.Q331*,TP53,tumor protein p53,,ENST00000269305.8,9.0,-,P04637,False,,,,0.4713216957605985,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q331*(36) p.Q331P(3) p.Q331Q(2) p.Q331H(5) p.Q331fs*6(1) p.Q331fs*14(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"UV:2,APOBEC:14",0.991875,0.4912909886354796,,4.0,,,,,,,ACH-000447,7157.0
chr8,103885868,T,G,0.41,22,15,0/1,,SNP,SILENT,c.603T>G,p.S201S,RIMS2,regulating synaptic membrane exocytosis 2,Regulating synaptic membrane exocytosis family PDZ domain containing,ENST00000436393.6,2.0,+,Q9UQ26,False,,,,0.456359102244389,,,False,,False,p.S231S(1),cancer;,False,False,True,,,,,7.3,False,False,True,"Eso:5,Misc:3",0.098697,0.8196511821522737,,0.0,,,,,,,ACH-000842,9699.0
chr12,25245350,C,A,0.988,1,91,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000842,3845.0
chr15,54014540,T,G,0.968,0,30,1|1,,SNP,MISSENSE,c.1637T>G,p.L546R,UNC13C,unc-13 homolog C,UNC13 homologs,ENST00000260323.15,1.0,+,Q8NB66,False,rs768743988,,as_specific,0.4114713216957606,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.578572,0.4991649834086551,0.54,2.0,,,,,,,ACH-000842,440279.0
chr17,7673802,C,T,0.982,1,60,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000842,7157.0
chr2,177234231,T,C,0.985,0,67,1|1,,SNP,MISSENSE,c.38A>G,p.D13G,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,rs1057519921,,as_specific,0.3865336658354115,E,Dom,False,,True,p.D29G(5) p.I28_D29del(1),cancer;gene_function_gain;,False,False,True,ENST00000397063;ENST00000397062;ENST00000446151;ENST00000464747;ENST00000449627;ENST00000448782;ENST00000586532;ENST00000421929;ENST00000423513;ENST00000588123;,,,,7.3,True,False,True,Misc:1,0.915079,0.8080626400525819,0.747,3.0,,,,,,,ACH-000488,4780.0
chr17,7676040,C,A,0.955,0,20,1|1,,SNP,MISSENSE,c.329G>T,p.R110L,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs11540654,,as_specific,0.5536159600997507,"""L, E, M, O""",Rec,False,NTRK1,True,p.R110P(13) p.0(9) p.R110C(15) p.R110L(25) p.G59fs*23(3) p.R110fs*13(7) p.R110fs*18(1) p.Y103_G112>C(1) p.R110S(1) p.R110H(4) p.F109_R110insXX(1) p.F109_R110delFR(2) p.M1_T125del(1) p.R110fs*?(1) p.G105_T125del21(1) p.Y107fs*38(1) p.R110fs*39(1) p.Y107fs*44(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:4,Misc:2",0.730165,,0.632,2.0,,,,,,,ACH-000488,7157.0
chr7,140753336,A,T,0.5,15,16,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001306,673.0
chr17,7673803,G,A,0.965,0,29,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001306,7157.0
chr17,7674214,G,A,0.963,0,28,1|1,,SNP,MISSENSE,c.749C>T,p.P250L,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs1064794311,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.P250S(14) p.P250L(45) p.P250P(4) p.P250_L252delPIL(1) p.I251fs*94(1) p.P250Q(2) p.M246_P250delMNRRP(4) p.L252_I254delLTI(1) p.P250H(2) p.R249_T256delRPILTIIT(1) p.P250_I251insXXXXXX(1) p.R249_I251delRPI(1) p.P250_I251insXXXXXXX(1) p.P250fs*14(1) p.P250_T253delPILT(1) p.R249_P250>SS(1) p.P250T(1) p.R248_P250delRRP(1) p.P250F(3) p.?(1) p.N247_P250delNRRP(1) p.P250N(2) p.P250_I251insX(1) p.P250A(2) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:6",0.955548,0.8788840738650362,0.962,3.0,,,,,,,ACH-000724,7157.0
chr17,7673802,C,T,0.579,16,22,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001694,7157.0
chr17,7675216,C,A,0.697,12,30,0/1,,SNP,MISSENSE,c.396G>T,p.K132N,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs866775781,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.K132Q(17) p.K132E(20) p.M133fs*37(1) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1) p.M133fs*16(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:2,0.935195,0.5705763221732115,0.895,3.0,,,,,,,ACH-001694,7157.0
chr17,7675140,G,C,0.962,0,25,1|1,,SNP,MISSENSE,c.472C>G,p.R158G,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.R156fs*12(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:2,0.832892,0.7785254108979192,0.862,3.0,,,,,,,ACH-000481,7157.0
chr17,7675161,G,C,0.955,0,20,1|1,,SNP,MISSENSE,c.451C>G,p.P151A,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934874,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.P152fs*18(9) p.0(9) p.P151A(10) p.P151S(78) p.P151P(15) p.S149fs*72(1) p.P151H(29) p.P151T(16) p.P151fs*30(8) p.P151L(8) p.T150_P151del(1) p.P151R(9) p.D148fs*23(1) p.T150fs*16(4) p.P153delP(1) p.T150_P151delTP(1) p.P152fs*28(1) p.V143_P153del(1) p.P151_V173del23(1) p.P152fs*14(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:3,0.904839,0.7313745701714766,0.889,3.0,,,,,,,ACH-000635,7157.0
chr9,21971109,C,A,0.889,2,20,0/1,,SNP,MISSENSE,c.97G>T,p.D33Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552822,,as_specific,0.6957605985037406,,,False,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V82_E88del(1) p.D84H(2) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.D84Y(9) p.P81_A85del(1) p.D84N(4) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.D84fs*63(2) p.E61_L94del(1) p.R80fs*34(1) p.D84_F90del(1) p.E33D(1) p.A68fs*3(1) p.D84fs*1(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;ENST00000579755;ENST00000530628;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.933446,0.9973373924118374,0.803,4.0,,,,,,,ACH-002465,1029.0
chr17,7673803,G,A,0.937,0,14,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000053,7157.0
chr11,114247318,A,C,0.258,22,7,0/1,,SNP,MISSENSE,c.1745A>C,p.K582T,ZBTB16,zinc finger and BTB domain containing 16,BTB domain containing Zinc fingers C2H2-type,ENST00000335953.9,6.0,+,Q05516,False,,,,0.571072319201995,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:3,0.875141,0.6811253666552484,0.377,4.0,,,,,,,ACH-000664,7704.0
chr17,7673802,C,T,0.639,12,23,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000664,7157.0
chr3,179218303,G,A,0.423,62,45,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000360,5290.0
chr7,140753349,C,G,0.302,47,18,0/1,,SNP,MISSENSE,c.1786G>C,p.G596R,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs121913361,,as_specific,0.341645885286783,E,Dom,False,"""AKAP9, KIAA1549""",True,p.G596C(2) p.G596D(5) p.G596R(9) p.G596S(1) p.D594_T599del(1) p.G596fs*2(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,1627.0,,5.0,7.3,True,False,False,,0.925144,0.7114496350172248,0.945,4.0,,,,,,,ACH-000360,673.0
chr12,6591493,G,A,0.403,37,25,0/1,,SNP,MISSENSE,c.3313C>T,p.R1105W,CHD4,chromodomain helicase DNA binding protein 4,NuRD complex PHD finger proteins,ENST00000544040.7,22.0,-,Q14839,False,,,,0.4214463840399002,,,False,,False,p.R1105W(1),cancer;,False,False,True,ENST00000357008;ENST00000544484;ENST00000645022;ENST00000544040;ENST00000643335;ENST00000646806;ENST00000642879;ENST00000645645;ENST00000645095;ENST00000644352;ENST00000645005;ENST00000644289;,,,,7.3,False,False,True,CpG:1,0.865761,0.9329487759798832,0.855,4.0,,,,,,,ACH-000360,1108.0
chr17,7673802,C,T,0.979,0,44,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000360,7157.0
chr17,7673728,C,A,0.975,0,38,1|1,,SNP,NONSENSE,c.892G>T,p.E298*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs201744589,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E298*(55) p.E298D(2) p.H296_S303delHHELPPGS(1) p.E298Q(1) p.E298K(3) p.E298G(1) p.E298_P301delELPP(1) p.E298V(2) p.L299fs*2(1) p.G293fs*1(1) p.E298A(1) p.L265_K305del41(1) p.E298fs*43(1) p.E298E(1) p.E298fs*53(1) p.E298fs*48(1) p.E298fs*47(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:11,Misc:2",0.975532,0.9950158138511048,,3.0,,,,,,,ACH-000665,7157.0
chr3,41224606,G,A,0.225,23,6,0/1,,SNP,MISSENSE,c.94G>A,p.D32N,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs28931588,,as_specific,0.3965087281795511,"""E, M, O""",Dom,False,PLAG1,True,p.D32H(66) p.D32Y(177) p.A5_A80del(75) p.D32N(123) p.D32V(66) p.D32G(92) p.A5_Q143del(7) p.Q28_D32>H(2) p.D32A(22) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32E(11) p.D32_S47del(2) p.Y30_T40del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_D32del(6) p.W25_I35del(1) p.Q28_I140del(1) p.Q28fs*20(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.WQQQSYLD25?(5) p.E9_I140del(1) p.H24_G38del(1) p.S23_S33del(3) p.A20_R151del(1) p.D32_S33insS(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.D32D(1) p.T3_A126del(2) p.D32fs*9(1) p.S23_S33>T(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.W25_S33del(1) p.W25_H36del(2) p.A5_D144>D(1) p.D32F(3) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.V22_S33del(2) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D32del(1) p.D6_A43del(1) p.S23_A39del(1) p.Y30_S33del(2) p.A5_I35del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"POLE:2,Misc:5",0.958143,,0.348,4.0,,,,,,,ACH-000507,1499.0
chr12,25245350,C,T,0.983,0,57,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002647,3845.0
chr17,7673781,C,G,0.967,0,28,1|1,,SNP,MISSENSE,c.839G>C,p.R280T,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912660,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R280T(73) p.R280fs*65(9) p.R280I(15) p.R280K(54) p.R280S(17) p.R280G(33) p.R280_R283>S(1) p.R280*(14) p.D281fs*24(1) p.S269fs*21(1) p.F270_D281del12(1) p.R280fs*?(1) p.V272_K292del21(1) p.D281_R282delDR(2) p.R280R(3) p.A276fs*64(1) p.R280fs*64(1) p.G279_R280delGR(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:19,0.96317,0.7002446792674034,0.94,3.0,,,,,,,ACH-000905,7157.0
chr17,39711955,C,T,0.603,30,47,0/1,,SNP,MISSENSE,c.929C>T,p.S310F,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,8.0,+,P04626,False,rs1057519816,,as_specific,0.5685785536159601,E,Dom,False,,True,p.S310F(27) p.S310Y(11),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"APOBEC:22,Misc:3",0.922658,,0.533,4.0,,,,,,,ACH-000905,2064.0
chr14,39350159,C,T,0.304,16,7,0/1,,SNP,SILENT,c.3915C>T,p.F1305F,MIA2,melanoma inhibitory activity 2,MIA family,ENST00000553728.1,28.0,+,Q96PC5,False,rs529369922,,as_specific,0.3665835411471321,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:3,0.314119,0.7016692960625165,,0.0,,,,,,,ACH-000930,4253.0
chr17,7673740,C,A,0.622,12,23,0/1,,SNP,NONSENSE,c.880G>T,p.E294*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1057520607,,as_specific,0.5261845386533666,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E294*(57) p.E294E(4) p.E294K(5) p.K291fs*48(8) p.E294fs*11(1) p.E294fs*51(19) p.E294D(2) p.K291fs*49(1) p.E294fs*12(3) p.R290fs*50(1) p.E294Q(2) p.E294fs*52(2) p.E294fs*?(1) p.E294V(1) p.R290_P295>X(1) p.G293fs*1(1) p.L265_K305del41(1) p.E294G(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:3,APOBEC:1,Misc:5",0.973947,0.4390645778956161,,4.0,,,,,,,ACH-000930,7157.0
chr17,7674221,G,A,0.968,0,30,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000691,7157.0
chr3,179218294,G,A,0.465,24,20,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000818,5290.0
chr2,232845773,A,T,0.511,21,22,0/1,,SNP,MISSENSE,c.3347A>T,p.E1116V,GIGYF2,GRB10 interacting GYF protein 2,Trinucleotide repeat containing,ENST00000373563.9,26.0,+,Q6Y7W6,False,rs200196994,,as_specific,0.3965087281795511,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.96634,0.4150211375788842,0.502,3.0,,,,,,,ACH-000936,26058.0
chr10,133391346,G,A,0.479,26,22,0/1,,SNP,MISSENSE,c.1427G>A,p.R476H,PAOX,polyamine oxidase,,ENST00000278060.10,7.0,+,Q6QHF9,False,rs1472318687,,as_specific,0.5810473815461347,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.345895,,0.619,2.0,,,,,,,ACH-000936,196743.0
chr17,39725079,G,A,0.472,28,24,0/1,,SNP,MISSENSE,c.2524G>A,p.V842I,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,21.0,+,P04626,False,rs1057519738,,as_specific,0.5835411471321695,E,Dom,False,,True,p.V842I(18) p.V842E(1),cancer;gene_function_gain;,False,True,True,,45.0,"ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",9.0,7.3,True,False,True,CpG:7,0.925625,0.7707432895054793,0.538,4.0,,,,,,,ACH-000936,2064.0
chr12,25245350,C,T,0.607,21,33,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002743,3845.0
chr17,7675131,C,T,0.97,0,32,1|1,,SNP,MISSENSE,c.481G>A,p.A161T,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs193920817,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R158fs*8(1) p.S149fs*72(1) p.A161T(54) p.A161S(6) p.A159_Q167delAMAIYKQSQ(1) p.A161D(12) p.V157fs*19(2) p.A161fs*19(1) p.A161fs*20(1) p.A161V(10) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A161A(5) p.R156fs*18(1) p.A161P(1) p.V157_I162delVRAMAI(1) p.M160fs*10(2) p.A161fs*9(3) p.A161G(1) p.M160_A161>IS(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.A161F(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A161fs*8(1) p.A161N(1) p.V157_C176del20(1) p.A161fs*7(1) p.A161fs*10(1) p.V157fs*9(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1114.0,,3.0,7.3,False,True,True,"MSI:1,Misc:2",0.858308,,0.79,3.0,,,,,,,ACH-002743,7157.0
chr7,140753336,A,T,0.975,0,40,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000322,673.0
chr12,117258434,C,T,0.217,37,9,0/1,,SNP,MISSENSE,c.2494G>A,p.E832K,NOS1,nitric oxide synthase 1,PDZ domain containing,ENST00000338101.8,15.0,-,P29475,False,,,,0.5211970074812967,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.9399,0.5495956213489199,0.224,3.0,,,,,,,ACH-000322,4842.0
chr12,25245350,C,T,0.411,23,16,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002680,3845.0
chr17,7673788,G,T,0.981,0,52,1|1,,SNP,MISSENSE,c.832C>A,p.P278T,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs17849781,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.C275fs*67(1) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"APOBEC:2,Misc:1",0.94024,,0.954,3.0,,,,,,,ACH-002680,7157.0
chr4,186603847,G,C,0.957,0,21,1|1,,SNP,NONSENSE,c.10679C>G,p.S3560*,FAT1,FAT atypical cadherin 1,Cadherin related,ENST00000441802.7,19.0,-,Q14517,False,,,,0.4438902743142144,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,APOBEC:3,0.981642,0.7467963515870453,,3.0,,,,,,,ACH-000767,2195.0
chr12,25245350,C,A,0.542,22,25,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000139,3845.0
chr13,48381402,C,T,0.967,0,28,1|1,,SNP,NONSENSE,c.1654C>T,p.R552*,RB1,RB transcriptional corepressor 1,Endogenous ligands,ENST00000267163.5,17.0,+,P06400,False,rs121913303,,as_specific,0.3167082294264339,"""L, E, M, O""",Rec,True,,True,p.0(19) p.R552*(4) p.?(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:2,0.971778,0.6552822183013718,,4.0,,,,,,,ACH-000756,5925.0
chr17,7673796,C,T,0.961,0,26,1|1,,SNP,MISSENSE,c.824G>A,p.C275Y,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs863224451,,as_specific,0.5286783042394015,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C275Y(63) p.C275R(16) p.C275fs*70(2) p.C275G(6) p.C275F(41) p.C275C(4) p.C275fs*67(1) p.C275W(10) p.V274_P278delVCACP(1) p.C275S(2) p.C275fs*31(4) p.S269fs*21(1) p.F270_D281del12(1) p.C275_A276ins10(1) p.V272_K292del21(1) p.C275*(2) p.R273_C275delRVC(1) p.A276fs*29(1) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,4.61,False,True,True,Misc:8,0.940206,0.7514021782512973,0.972,3.0,,,,,,,ACH-000756,7157.0
chr19,45364429,T,C,0.77,9,31,0/1,,SNP,MISSENSE,c.713A>G,p.N238S,ERCC2,"ERCC excision repair 2, TFIIH core complex helicase subunit",Xeroderma pigmentosum complementation groups General transcription factors ERCC excision repair associated DNA helicases,ENST00000391945.10,8.0,-,P18074,False,,,,0.6533665835411472,E,Rec,False,,False,,cancer;gene_function_loss;,False,False,True,ENST00000391945;ENST00000391944;ENST00000391941;ENST00000485403;ENST00000586131;,,,,7.3,False,True,True,Misc:9,0.846521,0.7059457509313488,0.853,4.0,,,,,,,ACH-000756,2068.0
chr12,25245350,C,A,0.965,0,28,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000354,3845.0
chr14,94289949,C,T,0.27,37,13,0/1,,SNP,SILENT,c.645G>A,p.G215G,SERPINA10,serpin family A member 10,Serpin peptidase inhibitors,ENST00000261994.9,2.0,-,Q9UK55,False,rs367966236,,as_specific,0.4214463840399002,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.250393,0.9200414317847768,,0.0,,,,,,,ACH-000354,51156.0
chr17,7675136,G,A,0.965,0,29,1|1,,SNP,MISSENSE,c.476C>T,p.A159V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.A159V(42) p.R158fs*8(1) p.A159D(10) p.S149fs*72(1) p.R158_A159insX(4) p.A159fs*11(6) p.A159_Q167delAMAIYKQSQ(1) p.R158_A159delRA(2) p.A159P(25) p.V157fs*19(2) p.A159S(5) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A159A(8) p.R156fs*18(1) p.A159T(9) p.V157_I162delVRAMAI(1) p.A159fs*21(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A159fs*19(1) p.R158_A159insXX(1) p.V157_C176del20(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"UV:1,Misc:3",0.890391,,0.774,3.0,,,,,,,ACH-000354,7157.0
chr3,179218303,G,A,0.546,9,14,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000351,5290.0
chr4,152328233,G,A,0.634,10,21,0/1,,SNP,MISSENSE,c.1153C>T,p.R385C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs867384286,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465C(83) p.R465fs*7(13) p.R465S(1) p.R465Y(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:9,0.934034,0.2550529450691629,0.593,4.0,,,,,,,ACH-000351,55294.0
chr17,7675184,A,G,0.965,0,32,1|1,,SNP,MISSENSE,c.428T>C,p.V143A,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V143E(9) p.L137_W146del10(1) p.V143A(15) p.K139fs*4(1) p.V143fs*28(2) p.V143V(2) p.V143M(27) p.V143L(4) p.V143fs*4(1) p.V143_P153del(1) p.A138_V143delAKTCPV(1) p.V143G(1) p.C141fs*5(1) p.V143_S149delVQLWVDS(1) p.P142_Q144delPVQ(1) p.V143fs*27(2) p.V143fs*29(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,1254.0,,0.0,7.3,False,True,False,,0.763811,,0.574,2.0,,,,,,,ACH-000351,7157.0
chr15,66481793,G,A,0.521,22,24,0/1,,SNP,MISSENSE,c.79G>A,p.E27K,MAP2K1,mitogen-activated protein kinase kinase 1,Mitogen-activated protein kinase kinases,ENST00000566326.1,2.0,+,Q02750,False,rs1057519733,,as_specific,0.5536159600997507,,,False,,True,p.E203K(6),cancer;gene_function_gain;,False,False,True,,1626.0,,0.0,7.3,True,False,True,"UV:2,APOBEC:1",0.95851,0.3843929791359048,0.621,4.0,,,,,,,ACH-001642,5604.0
chr3,179234297,A,G,0.6,20,30,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000910,5290.0
chr3,185152807,G,A,0.215,28,8,0/1,,SNP,MISSENSE,c.17C>T,p.S6L,C3orf70,chromosome 3 open reading frame 70,,ENST00000335012.3,1.0,-,A6NLC5,False,rs757159118,,as_specific,0.713216957605985,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,,0.537681,0.2540093356083243,0.084,2.0,,,,,,,ACH-000910,285382.0
chr3,179234297,A,G,0.527,8,10,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000866,5290.0
chr13,48381402,C,T,0.925,0,11,1|1,,SNP,NONSENSE,c.1654C>T,p.R552*,RB1,RB transcriptional corepressor 1,Endogenous ligands,ENST00000267163.5,17.0,+,P06400,False,rs121913303,,as_specific,0.3167082294264339,"""L, E, M, O""",Rec,True,,True,p.0(19) p.R552*(4) p.?(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:2,0.971778,0.6552822183013718,,4.0,,,,,,,ACH-000866,5925.0
chr12,25245350,C,A,0.789,20,77,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000400,3845.0
chr14,103133425,C,T,0.981,0,53,1|1,,SNP,MISSENSE,c.1609C>T,p.R537C,TNFAIP2,TNF alpha induced protein 2,,ENST00000560869.6,10.0,+,Q03169,False,rs200141678,,as_specific,0.6184538653366584,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,POLE_MSI:1,0.509624,0.9511766430137872,0.095,2.0,,,,,,,ACH-000278,7127.0
chr17,7674872,T,C,0.961,0,23,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000278,7157.0
chr17,7670708,C,A,0.966,0,28,1|1,,SNP,MISSENSE,c.1001G>T,p.G334V,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,,,,0.4788029925187032,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G334V(4) p.G334W(2) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000504937;ENST00000619186;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000445888;ENST00000619485;ENST00000615910;,,,,7.3,False,True,True,smoking:4,0.918799,0.3645537172285162,0.951,3.0,,,,,,,ACH-000523,7157.0
chr3,41224646,C,T,0.977,0,42,1|1,,SNP,MISSENSE,c.134C>T,p.S45F,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913409,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.S45F(831) p.A5_A80del(75) p.S45P(400) p.S45S(1) p.A5_Q143del(7) p.S45T(2) p.S45C(34) p.S45del(114) p.T42_K49>Q(1) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.S45Y(35) p.S45A(21) p.A5_E54del(1) p.M8_L132del(1) p.S45_E54del(1) p.S45N(7) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.S45_S47>C(3) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.T40_L46del(1) p.P44_S45insGATTTAP(1) p.G38_S45del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.A20_R151del(1) p.S45_D58del(1) p.E9_S47del(1) p.P44_S45>AP(1) p.A43_E54del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.I35_K170del(1) p.S45E(1) p.S45_G50del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.S45?(1) p.A43_E53del(2) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.P44_S45insAP(1) p.A5_D144>D(1) p.V22_T102del(1) p.P44_N51del(1) p.P44_S45del(2) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.A5_R90del(1) p.Y30_A97del(1) p.S45_G48del(1) p.T41_N51del(1) p.I35_L46del(1) p.V22_A80del(1) p.S45fs*2(1) p.A21_A152del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.S23_I140del(1) p.A39fs*3(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.T42_G48del(1) p.S45_L46del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1286.0,,60.0,7.3,True,False,True,"APOBEC:2,Misc:5",0.910016,0.7837109539631295,0.353,4.0,,,,,,,ACH-000957,1499.0
chr3,179234297,A,G,0.406,19,13,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000957,5290.0
chr11,59650774,T,G,0.567,12,16,0/1,,SNP,MISSENSE,c.1564A>C,p.T522P,PATL1,"PAT1 homolog 1, processing body mRNA decay factor",,ENST00000300146.10,13.0,-,Q86TB9,False,,,,0.3092269326683292,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.914069,0.4062507710916099,0.312,2.0,,,,,,,ACH-000957,219988.0
chr12,25245350,C,T,0.605,17,23,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000957,3845.0
chr17,7674220,C,T,0.955,0,21,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000668,7157.0
chr1,114713909,G,T,0.541,16,19,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000120,4893.0
chr12,25245351,C,A,0.561,20,24,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000091,3845.0
chr9,77794572,T,A,0.48,12,11,0/1,,SNP,MISSENSE,c.626A>T,p.Q209L,GNAQ,G protein subunit alpha q,"G protein subunits alpha, group q",ENST00000286548.9,5.0,-,P50148,False,rs121913492,,as_specific,0.3266832917705736,E,Dom,False,,True,p.Q209L(323) p.Q209P(256) p.Q209R(8) p.Q209H(17) p.Q209?(6) p.Q209Y(1) p.Q209K(1),cancer;gene_function_gain;,False,False,True,ENST00000286548;,,,,7.3,True,False,True,Misc:10,0.923293,,0.936,4.0,,,,,,,ACH-001441,2776.0
chr17,7675077,G,C,0.977,0,44,1|1,,SNP,MISSENSE,c.535C>G,p.H179D,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587780070,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:3",0.951765,,0.916,3.0,,,,,,,ACH-000574,7157.0
chr7,140753336,A,T,0.611,21,34,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000258,673.0
chr4,152326214,C,T,0.559,16,19,0/1,,SNP,MISSENSE,c.1196G>A,p.R399Q,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs866987936,,as_specific,0.3665835411471321,"""E, L""",Rec,False,,True,p.R479Q(43) p.R479L(7) p.R479fs*6(3) p.R479P(3) p.D480fs*5(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:1,POLE:1",0.971548,,0.479,4.0,,,,,,,ACH-000293,55294.0
chr17,7675088,C,T,0.975,0,40,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000293,7157.0
chr12,25245351,C,A,0.976,0,40,1|1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000667,3845.0
chr17,7676088,G,C,0.976,0,40,1|1,,SNP,NONSENSE,c.281C>G,p.S94*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.571072319201995,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.S94*(9) p.G59fs*23(3) p.W91fs*13(1) p.S94fs*29(1) p.M1_T125del(1) p.S94T(2) p.S33fs*23(1) p.S94fs*54(1) p.V73fs*9(1) p.S94L(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,APOBEC:3,0.990972,0.597131788569749,,4.0,,,,,,,ACH-000667,7157.0
chr7,140753336,A,T,0.481,58,54,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001528,673.0
chr14,104780214,C,T,0.445,74,62,0/1,,SNP,MISSENSE,c.49G>A,p.E17K,AKT1,AKT serine/threonine kinase 1,Pleckstrin homology domain containing,ENST00000554581.5,2.0,-,P31749,False,rs121434592,,as_specific,0.6234413965087282,E,Dom,False,,True,p.E17K(506),cancer;gene_function_gain;,False,True,True,,4.0,"AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.",33.5,7.3,True,False,True,"UV:3,APOBEC:8,Misc:15",0.933449,0.7974696660996897,0.51,4.0,,,,,,,ACH-001528,207.0
chr7,140753336,A,T,0.485,34,35,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000906,673.0
chr11,54707643,C,T,0.674,15,31,0/1,,SNP,SILENT,c.759C>T,p.F253F,OR4A5,olfactory receptor family 4 subfamily A member 5,"Olfactory receptors, family 4",ENST00000319760.8,1.0,+,Q8NH83,False,,,,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:7,APOBEC:1",0.411778,,,1.0,,,,,,,ACH-000906,81318.0
chr17,7674241,G,A,0.981,0,51,1|1,,SNP,MISSENSE,c.722C>T,p.S241F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:4,APOBEC:7,Misc:1",0.912713,0.9893558821746748,0.958,3.0,,,,,,,ACH-000906,7157.0
chr3,179218303,G,A,0.556,11,14,0|1,179218303.0,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000997,5290.0
chr8,24914431,C,T,0.564,16,23,0/1,,SNP,MISSENSE,c.638C>T,p.A213V,NEFM,neurofilament medium,Intermediate filaments Type IV,ENST00000518131.5,1.0,+,P07197,False,,,,0.6384039900249376,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.673945,0.3618281763558523,0.587,3.0,,,,,,,ACH-000997,4741.0
chr8,96785205,T,G,0.375,20,11,0/1,,SNP,MISSENSE,c.308T>G,p.V103G,CPQ,carboxypeptidase Q,M14 carboxypeptidases,ENST00000220763.10,2.0,+,Q9Y646,False,,,,0.4413965087281795,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.722579,0.8064408212755596,0.596,2.0,,,,,,,ACH-000997,10404.0
chr12,25245347,C,T,0.384,23,14,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000997,3845.0
chr13,38688746,T,G,0.581,17,25,0/1,,SNP,MISSENSE,c.1402T>G,p.L468V,FREM2,FRAS1 related extracellular matrix protein 2,,ENST00000280481.9,1.0,+,Q5SZK8,False,,,,0.571072319201995,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.267066,0.3287328725445634,0.222,2.0,,,,,,,ACH-000997,341640.0
chr17,7674241,G,A,0.486,18,18,0/1,,SNP,MISSENSE,c.722C>T,p.S241F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:4,APOBEC:7,Misc:1",0.912713,0.9893558821746748,0.958,3.0,,,,,,,ACH-000997,7157.0
chr1,182057190,C,G,0.267,53,18,0/1,,SNP,MISSENSE,c.821G>C,p.G274A,ZNF648,zinc finger protein 648,Zinc fingers C2H2-type,ENST00000339948.3,2.0,-,Q5T619,False,rs754881990,,as_specific,0.7032418952618454,,,False,,False,,cancer;,False,False,True,,,,,4.01,False,False,True,"MSI:2,Misc:1",0.276278,0.7092301016865457,0.049,2.0,,,,,,,ACH-002659,127665.0
chr7,140753336,A,T,0.693,11,27,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002659,673.0
chr11,533874,T,A,0.625,14,24,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,3.0,-,P01112,False,rs121913233,,as_specific,0.6458852867830424,"""E, L, M""",Dom,False,,True,p.Q61R(289) p.Q61K(113) p.Q61L(184) p.Q61H(24) p.Q61?(16) p.Q61P(3) p.Q61*(1) p.Q61Q(1) p.Q61E(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,854.0,,0.0,7.3,True,True,True,"smoking:2,Misc:4",0.786029,0.9921539220757206,0.839,4.0,,,,,,,ACH-000777,3265.0
chr17,7676040,C,A,0.37,17,9,0/1,,SNP,MISSENSE,c.329G>T,p.R110L,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs11540654,,as_specific,0.5536159600997507,"""L, E, M, O""",Rec,False,NTRK1,True,p.R110P(13) p.0(9) p.R110C(15) p.R110L(25) p.G59fs*23(3) p.R110fs*13(7) p.R110fs*18(1) p.Y103_G112>C(1) p.R110S(1) p.R110H(4) p.F109_R110insXX(1) p.F109_R110delFR(2) p.M1_T125del(1) p.R110fs*?(1) p.G105_T125del21(1) p.Y107fs*38(1) p.R110fs*39(1) p.Y107fs*44(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:4,Misc:2",0.730165,,0.632,2.0,,,,,,,ACH-000777,7157.0
chr17,7675088,C,T,0.979,0,45,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000752,7157.0
chr12,25245350,C,A,0.595,20,29,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-002664,3845.0
chr17,7674221,G,A,0.967,0,31,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-002664,7157.0
chr3,179218303,G,A,0.181,29,6,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000934,5290.0
chr17,7676203,C,A,0.876,3,28,0/1,,SNP,NONSENSE,c.166G>T,p.E56*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.6034912718204489,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E56K(4) p.E56*(5) p.E56V(1) p.D48fs*55(1) p.E51fs*59(1) p.Q52fs*67(1) p.M1_T125del(1) p.E56E(1) p.S33fs*23(1) p.E56fs*67(2) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,APOBEC:1,0.981156,0.7537498776341308,,3.0,,,,,,,ACH-000934,7157.0
chr17,7673803,G,A,0.98,0,49,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001670,7157.0
chr17,7674917,T,C,0.967,0,28,1|1,,SNP,MISSENSE,c.614A>G,p.Y205C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs1057520007,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y205D(20) p.Y205S(11) p.Y205C(70) p.L201_H214del(1) p.Y205H(9) p.E204_N210delEYLDDRN(1) p.Y205F(8) p.Y205N(3) p.Y205fs*42(1) p.Y205fs*43(1) p.Y205*(8) p.?(1) p.K164_P219del(1) p.E204fs*39(1) p.Y205fs*?(1) p.L206fs*42(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:11",0.8532,0.8002667275111726,0.873,3.0,,,,,,,ACH-001992,7157.0
chr1,114713909,G,T,0.49,26,23,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000878,4893.0
chr3,41224646,C,T,0.933,0,14,1|1,,SNP,MISSENSE,c.134C>T,p.S45F,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913409,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.S45F(831) p.A5_A80del(75) p.S45P(400) p.S45S(1) p.A5_Q143del(7) p.S45T(2) p.S45C(34) p.S45del(114) p.T42_K49>Q(1) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.S45Y(35) p.S45A(21) p.A5_E54del(1) p.M8_L132del(1) p.S45_E54del(1) p.S45N(7) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.S45_S47>C(3) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.T40_L46del(1) p.P44_S45insGATTTAP(1) p.G38_S45del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.A20_R151del(1) p.S45_D58del(1) p.E9_S47del(1) p.P44_S45>AP(1) p.A43_E54del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.I35_K170del(1) p.S45E(1) p.S45_G50del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.S45?(1) p.A43_E53del(2) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.P44_S45insAP(1) p.A5_D144>D(1) p.V22_T102del(1) p.P44_N51del(1) p.P44_S45del(2) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.A5_R90del(1) p.Y30_A97del(1) p.S45_G48del(1) p.T41_N51del(1) p.I35_L46del(1) p.V22_A80del(1) p.S45fs*2(1) p.A21_A152del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.S23_I140del(1) p.A39fs*3(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.T42_G48del(1) p.S45_L46del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1286.0,,60.0,7.3,True,False,True,"APOBEC:2,Misc:5",0.910016,0.7837109539631295,0.353,4.0,,,,,,,ACH-000878,1499.0
chr17,7674187,T,A,0.945,1,33,1|1,,SNP,MISSENSE,c.776A>T,p.D259V,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,,,,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.D259Y(25) p.D259G(4) p.E258_S260delEDS(1) p.D259V(16) p.D259A(1) p.E258fs*85(1) p.D259N(6) p.D259E(3) p.D259H(3) p.E258fs*71(1) p.D259fs*86(5) p.D259D(2) p.D259fs*5(3) p.L257fs*85(1) p.E258fs*2(1) p.D259S(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:4,0.899544,0.984493544122167,0.742,3.0,,,,,,,ACH-000878,7157.0
chr17,7673809,C,A,0.526,23,27,0/1,,SNP,NONSENSE,c.811G>T,p.E271*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,,,,0.5311720698254364,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.F270fs*72(2) p.E271K(32) p.E271D(3) p.E271*(18) p.G266_E271delGRNSFE(2) p.E271_R273delEVR(1) p.E271V(7) p.E271G(4) p.E271Q(3) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.E271P(1) p.R267fs*65(1) p.E271fs*35(1) p.L265_K305del41(1) p.S269fs*34(1) p.E271delE(1) p.E271E(2) p.E271fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,smoking:1,0.992462,0.7896914912957856,,4.0,,,,,,,ACH-001641,7157.0
chr17,7676040,C,A,0.625,15,27,0/1,,SNP,MISSENSE,c.329G>T,p.R110L,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs11540654,,as_specific,0.5536159600997507,"""L, E, M, O""",Rec,False,NTRK1,True,p.R110P(13) p.0(9) p.R110C(15) p.R110L(25) p.G59fs*23(3) p.R110fs*13(7) p.R110fs*18(1) p.Y103_G112>C(1) p.R110S(1) p.R110H(4) p.F109_R110insXX(1) p.F109_R110delFR(2) p.M1_T125del(1) p.R110fs*?(1) p.G105_T125del21(1) p.Y107fs*38(1) p.R110fs*39(1) p.Y107fs*44(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:4,Misc:2",0.730165,,0.632,2.0,,,,,,,ACH-001641,7157.0
chr12,25227349,C,T,0.508,31,30,0/1,,SNP,MISSENSE,c.175G>A,p.A59T,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs121913528,,as_specific,0.3566084788029925,"""L, E, M, O""",Dom,False,KRAS,True,p.A59G(6) p.A59T(28) p.A59E(4) p.T58_A59insVA(1) p.A59S(2) p.A59L(1) p.A59del(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,,,,7.3,True,False,True,"MSI:2,Misc:1",0.901617,0.6627303446996679,0.869,4.0,,,,,,,ACH-001001,3845.0
chr17,7675145,C,G,0.976,0,41,1|1,,SNP,MISSENSE,c.467G>C,p.R156P,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S149fs*72(1) p.R156P(22) p.R156fs*14(12) p.G154fs*22(1) p.R156G(4) p.V157_R158delVR(1) p.R156C(6) p.R156R(3) p.G154_R156delGTR(1) p.R156fs*25(7) p.T155fs*23(2) p.R156L(3) p.R156H(10) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156S(3) p.R156fs*18(1) p.R156fs*12(1) p.T155_V157>I(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.T155_R156delTR(1) p.R156fs*?(1) p.R156delR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,Misc:2",0.890792,0.8157253021490875,0.609,3.0,,,,,,,ACH-001001,7157.0
chr17,7674230,C,A,0.965,0,28,1|1,,SNP,MISSENSE,c.733G>T,p.G245C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,smoking:7,0.969132,0.8210775969704124,0.97,3.0,,,,,,,ACH-000628,7157.0
chr17,7674894,G,A,0.966,0,27,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000144,7157.0
chr17,7674887,C,A,0.319,31,14,0/1,,SNP,MISSENSE,c.644G>T,p.S215I,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs587782177,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.S215N(10) p.0(9) p.S215R(22) p.R213_S215>X(1) p.T211fs*28(1) p.R209fs*6(1) p.S215G(12) p.S215_V218>M(1) p.S215I(22) p.H214fs*5(2) p.S215fs*29(1) p.S215T(5) p.S215fs*31(1) p.S215C(5) p.S215fs*32(4) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.D208_V216delDRNTFRHSV(1) p.S215S(2) p.S215fs*?(2) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.H214_S215insX(1) p.?(1) p.K164_P219del(1) p.S215del(1) p.F212_S215del(1) p.S215fs*6(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:4,0.947084,0.4541793437378166,0.913,3.0,,,,,,,ACH-000853,7157.0
chr17,7675139,C,A,0.703,13,33,0/1,,SNP,MISSENSE,c.473G>T,p.R158L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1699.0,,4.0,7.3,False,True,True,"smoking:22,Misc:1",0.921338,,0.891,3.0,,,,,,,ACH-000853,7157.0
chr1,182057190,C,G,0.275,38,14,0/1,,SNP,MISSENSE,c.821G>C,p.G274A,ZNF648,zinc finger protein 648,Zinc fingers C2H2-type,ENST00000339948.3,2.0,-,Q5T619,False,rs754881990,,as_specific,0.7032418952618454,,,False,,False,,cancer;,False,False,True,,,,,4.01,False,False,True,"MSI:2,Misc:1",0.276278,0.7092301016865457,0.049,2.0,,,,,,,ACH-000963,127665.0
chr3,41224633,A,G,0.954,1,41,1|1,,SNP,MISSENSE,c.121A>G,p.T41A,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913412,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.T41A(1344) p.A5_A80del(75) p.T41S(7) p.T41I(155) p.A5_Q143del(7) p.T41P(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.T41T(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.T41N(8) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.T40_L46del(1) p.G38_S45del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.A20_R151del(1) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.I35_T41del(1) p.I35_K170del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A39_T42del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.T41_N51del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A39fs*3(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1285.0,,55.0,7.3,True,False,True,Misc:17,0.860853,,0.403,4.0,,,,,,,ACH-000963,1499.0
chr3,179210192,T,C,0.458,13,12,0/1,,SNP,MISSENSE,c.1258T>C,p.C420R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,8.0,+,P42336,False,rs121913272,,as_specific,0.2967581047381546,"""E, O""",Dom,False,,True,p.C420R(82) p.H419_C420delHC(1) p.C420fs*?(1) p.C420_L422>*(1) p.C420C(1),cancer;gene_function_gain;,False,True,True,ENST00000263967;ENST00000643187;,931.0,,12.5,7.3,True,False,True,"MSI:1,Misc:13",0.916819,0.6918433106210673,0.788,3.0,,,,,,,ACH-000963,5290.0
chr4,152328233,G,A,0.533,14,15,0/1,,SNP,MISSENSE,c.1153C>T,p.R385C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs867384286,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465C(83) p.R465fs*7(13) p.R465S(1) p.R465Y(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:9,0.934034,0.2550529450691629,0.593,4.0,,,,,,,ACH-000963,55294.0
chr10,62813726,G,T,0.194,35,8,0/1,,SNP,SILENT,c.912C>A,p.A304A,EGR2,early growth response 2,Zinc fingers C2H2-type,ENST00000242480.4,2.0,-,P11161,False,rs752399953,,as_specific,0.6608478802992519,,,False,,False,,cancer;,False,False,True,,,,,4.13,False,False,True,"MSI:3,Misc:1",0.081345,0.4941389069847913,,0.0,,,,,,,ACH-000963,1959.0
chr17,7673787,G,T,0.619,17,27,0/1,,SNP,MISSENSE,c.833C>A,p.P278H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs876659802,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,smoking:1,0.891462,0.7226458581020908,0.95,3.0,,,,,,,ACH-000963,7157.0
chr22,20990476,G,A,0.469,32,28,0/1,,SNP,MISSENSE,c.742G>A,p.G248R,LZTR1,leucine zipper like transcription regulator 1,BTB domain containing,ENST00000646124.2,8.0,+,Q8N653,False,rs869320686,,as_specific,0.5536159600997507,,,False,,False,p.G248R(1),cancer;gene_function_loss;,False,False,True,ENST00000215739;ENST00000646124;,,,,7.3,False,True,True,CpG:2,0.944955,,0.839,4.0,,,,,,,ACH-000963,8216.0
chr22,23614162,T,A,0.483,46,44,0/1,,SNP,MISSENSE,c.594A>T,p.E198D,DRICH1,aspartate rich 1,,ENST00000317749.9,9.0,-,Q6PGQ1,False,,,,0.4364089775561097,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.677174,,0.093,1.0,,,,,,,ACH-000963,51233.0
chr7,140753336,A,T,0.945,0,16,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000219,673.0
chr3,179218294,G,A,0.729,2,7,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000847,5290.0
chr17,7674220,C,A,0.968,0,29,1|1,,SNP,MISSENSE,c.743G>T,p.R248L,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:4,Misc:3",0.932907,0.9843307954424446,0.96,3.0,,,,,,,ACH-000670,7157.0
chr17,7675216,C,G,0.372,33,18,0/1,,SNP,MISSENSE,c.396G>C,p.K132N,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs866775781,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.K132Q(17) p.K132E(20) p.M133fs*37(1) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1) p.M133fs*16(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,APOBEC:11,0.933912,,0.895,3.0,,,,,,,ACH-002020,7157.0
chr3,179199158,G,C,0.259,43,14,0/1,,SNP,MISSENSE,c.333G>C,p.K111N,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs1057519934,,as_specific,0.3117206982543641,"""E, O""",Dom,False,,True,p.K111N(19) p.K111E(21) p.K111del(3) p.K111_I112>N(3) p.K111Q(1) p.E110_N114>D(1),cancer;gene_function_gain;,False,True,True,,1234.0,,12.0,7.3,True,False,True,APOBEC:3,0.833086,0.3622488448114973,0.307,3.0,,,,,,,ACH-000927,5290.0
chr3,192798931,G,C,0.295,33,15,0/1,,SNP,MISSENSE,c.931C>G,p.Q311E,MB21D2,Mab-21 domain containing 2,,ENST00000392452.3,2.0,-,Q8IYB1,False,rs988241015,,as_specific,0.5361596009975063,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:19,0.760565,,0.374,3.0,,,,,,,ACH-000927,151963.0
chr17,7673767,C,T,0.969,0,31,1|1,,SNP,MISSENSE,c.853G>A,p.E285K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs112431538,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E285K(139) p.E285V(15) p.R283fs*16(2) p.E285Q(5) p.E285G(5) p.E285*(19) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.E285A(2) p.R283fs*56(1) p.V272_K292del21(1) p.E285E(5) p.E285fs*20(1) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285fs*60(2) p.E285fs*21(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:20,0.905537,,0.91,3.0,,,,,,,ACH-000927,7157.0
chr7,140753336,A,T,0.561,48,54,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000283,673.0
chr1,114713908,T,C,0.667,23,47,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-001190,4893.0
chr17,7674230,C,T,0.957,0,22,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-001190,7157.0
chr17,50699880,A,T,0.298,36,14,0/1,,SNP,MISSENSE,c.297T>A,p.D99E,ANKRD40,ankyrin repeat domain 40,Ankyrin repeat domain containing,ENST00000285243.7,3.0,-,Q6AI12,False,rs145395652,,as_specific,0.4139650872817955,,,False,,False,,cancer;,False,False,True,,,,,3.91,False,False,True,Misc:5,0.499144,0.7255237238178662,0.051,1.0,,,,,,,ACH-001190,91369.0
chr17,7674894,G,A,0.984,0,59,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000643,7157.0
chr3,10142030,C,G,0.956,0,20,1|1,,SNP,SILENT,c.183C>G,p.P61P,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs63650860,,as_specific,0.71571072319202,"""E, M, O""",Rec,False,,True,p.V62fs*5(11) p.P61P(5) p.P61fs*62(1) p.P59_P61del(1) p.G57fs*4(1) p.V62fs*1(1) p.P61fs(1) p.R60fs*70(1) p.G57fs*69(1) p.A56_R69>G(1) p.E52_S65del(2) p.V62fs*12(1) p.E55_R64del(1) p.P61fs*61(1) p.R60fs*35(1) p.M54fs*66(1) p.V62fs*68(2) p.?(1) p.P61fs*70(1),cancer;gene_function_loss;,False,False,True,,1931.0,,0.0,3.03,False,True,False,,0.162049,,,0.0,,,,,,,ACH-000358,7428.0
chr17,7675101,C,A,0.947,0,17,1|1,,SNP,NONSENSE,c.511G>T,p.E171*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.571072319201995,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.S149fs*72(1) p.E171K(11) p.Q167fs*2(6) p.E171A(1) p.E171fs*9(1) p.E171*(14) p.H168fs*23(1) p.E171Q(4) p.T170fs*2(1) p.H168_E171del(1) p.E171fs*3(3) p.E171V(2) p.T170fs*8(1) p.E171D(2) p.E171fs*1(1) p.E171fs*10(3) p.H168fs*3(1) p.P151_V173del23(1) p.E171fs*61(1) p.E171G(4) p.K164_P219del(1) p.H168fs*69(1) p.E171_V172delEV(1) p.V157_C176del20(1) p.T170_E171insXX(1) p.V172_E180delVVRRCPHHE(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,APOBEC:1,Misc:2",0.993507,0.446196160933848,,4.0,,,,,,,ACH-000358,7157.0
chr3,48159442,T,A,0.419,19,12,0/1,,SNP,NONSENSE,c.1336A>T,p.R446*,CDC25A,cell division cycle 25A,Class III Cys-based CDC25 phosphatases,ENST00000302506.8,14.0,-,P30304,False,,,,0.5112219451371571,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,,0.960525,0.7337216270426539,,3.0,,,,,,,ACH-000956,993.0
chr3,179218307,A,G,0.542,10,12,0/1,,SNP,MISSENSE,c.1637A>G,p.Q546R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs397517201,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.Q546E(20) p.Q546K(167) p.Q546R(58) p.Q546P(22) p.Q546L(7) p.Q546H(13) p.Q546Q(2) p.Q546?(2),cancer;gene_function_gain;,False,False,True,,888.0,,0.0,7.3,True,False,True,"MSI:1,Misc:12",0.913286,0.8370601625573337,0.646,3.0,,,,,,,ACH-000956,5290.0
chr7,140753345,A,C,0.374,14,8,0/1,,SNP,MISSENSE,c.1790T>G,p.L597R,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs121913366,,as_specific,0.3441396508728179,E,Dom,False,"""AKAP9, KIAA1549""",True,p.L597S(25) p.L597R(28) p.L597V(11) p.L597Q(24) p.L597_A598insT(2) p.L597P(2) p.D594_T599del(1) p.L597L(5),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,288.0,,12.0,7.3,True,False,False,,0.907837,0.6412624323982704,0.964,4.0,,,,,,,ACH-000956,673.0
chr12,25245350,C,A,0.981,0,52,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000790,3845.0
chr12,25245350,C,T,0.741,32,79,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000688,3845.0
chr17,7674202,A,C,0.966,0,27,1|1,,SNP,MISSENSE,c.761T>G,p.I254S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs1330865474,,as_specific,0.5511221945137157,"""L, E, M, O""",Rec,False,NTRK1,True,p.I254V(5) p.0(9) p.I254T(3) p.L252_I254delLTI(9) p.I254_T256delIIT(2) p.I254F(7) p.I254fs*10(5) p.I254fs*7(1) p.I254S(8) p.I254D(2) p.I254N(7) p.I254fs*91(2) p.I255delI(2) p.R249_T256delRPILTIIT(1) p.I254del(5) p.I254I(1) p.I254fs*8(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"Eso:1,Misc:2",0.956697,0.996781600281312,0.953,3.0,,,,,,,ACH-000688,7157.0
chr9,77794572,T,G,0.94,0,14,1|1,,SNP,MISSENSE,c.626A>C,p.Q209P,GNAQ,G protein subunit alpha q,"G protein subunits alpha, group q",ENST00000286548.9,5.0,-,P50148,False,rs121913492,,as_specific,0.3266832917705736,E,Dom,False,,True,p.Q209L(323) p.Q209P(256) p.Q209R(8) p.Q209H(17) p.Q209?(6) p.Q209Y(1) p.Q209K(1),cancer;gene_function_gain;,False,True,True,ENST00000286548;,604.0,,8.0,7.3,True,False,True,Misc:29,0.957692,0.7503423451666995,0.956,4.0,,,,,,,ACH-002014,2776.0
chr2,208248388,C,T,0.425,19,13,0/1,,SNP,MISSENSE,c.395G>A,p.R132H,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",,ENST00000415913.5,4.0,-,O75874,False,rs121913500,,as_specific,0.3815461346633416,O,Dom,False,,True,p.R132C(1014) p.R132H(6941) p.R132S(229) p.R132?(201) p.R132G(285) p.R132L(126) p.R132P(1) p.R132V(1) p.G131_R132>VL(1),cancer;gene_function_gain;,False,True,True,ENST00000345146;ENST00000446179;ENST00000415913;ENST00000415282;,420.0,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",9.0,7.3,True,False,True,"CpG:293,MSI:2",0.92638,0.6554284709455193,0.852,2.0,,,,,,,ACH-001143,3417.0
chr3,179218294,G,A,0.765,7,27,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000381,5290.0
chr12,25245347,C,T,0.579,24,34,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000381,3845.0
chr1,114713909,G,T,0.542,10,12,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000509,4893.0
chr17,7674945,G,A,0.96,0,23,1|1,,SNP,NONSENSE,c.586C>T,p.R196*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516435,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R196*(221) p.R196P(18) p.R196Q(5) p.R196R(6) p.I195fs*12(1) p.R196_R202del(1) p.R196fs*51(4) p.I195_G199delIRVEG(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.R196L(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.R196fs*13(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.986209,0.7393785927987923,,4.0,,,,,,,ACH-000509,7157.0
chr17,7673802,C,T,0.952,0,20,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001129,7157.0
chr21,43094667,T,G,0.416,6,4,0/1,,SNP,MISSENSE,c.470A>C,p.Q157P,U2AF1,U2 small nuclear RNA auxiliary factor 1,Spliceosomal E complex RNA binding motif containing Spliceosomal A complex,ENST00000291552.8,6.0,-,Q01081,False,rs371246226,,as_specific,0.5211970074812967,L,Dom,False,,True,p.Q157R(59) p.Q157P(115) p.Q157G(1) p.Q157fs*?(1),cancer;gene_function_gain;,False,True,True,,127.0,"U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.",50.0,7.3,True,False,False,,0.939163,,0.555,3.0,,,,,,,ACH-001129,7307.0
chr17,7675161,G,A,0.976,0,43,1|1,,SNP,MISSENSE,c.451C>T,p.P151S,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934874,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.P152fs*18(9) p.0(9) p.P151A(10) p.P151S(78) p.P151P(15) p.S149fs*72(1) p.P151H(29) p.P151T(16) p.P151fs*30(8) p.P151L(8) p.T150_P151del(1) p.P151R(9) p.D148fs*23(1) p.T150fs*16(4) p.P153delP(1) p.T150_P151delTP(1) p.P152fs*28(1) p.V143_P153del(1) p.P151_V173del23(1) p.P152fs*14(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"UV:1,Misc:7",0.908193,,0.898,3.0,,,,,,,ACH-000238,7157.0
chr1,114716123,C,T,0.549,14,15,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121434596,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G13D(361) p.G13V(89) p.G13R(150) p.G13G(4) p.G13A(16) p.G13C(39) p.G13Y(1) p.G13S(16) p.G13N(3),cancer;gene_function_gain;,False,False,True,,93.0,"While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.",5.0,7.3,True,False,False,,0.857833,0.4966910708773087,0.699,4.0,,,,,,,ACH-000050,4893.0
chr17,7670700,G,A,0.975,0,41,1|1,,SNP,MISSENSE,c.1009C>T,p.R337C,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs587782529,,as_specific,0.4812967581047381,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R337C(43) p.R337H(73) p.R337L(10) p.R337S(1) p.R337P(1) p.R337G(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000504937;ENST00000619186;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000445888;ENST00000619485;ENST00000615910;,,,,7.3,False,True,True,"CpG:3,MSI:1",0.648253,0.5401534229107201,0.715,3.0,,,,,,,ACH-002757,7157.0
chr17,7675143,C,A,0.96,0,24,1|1,,SNP,MISSENSE,c.469G>T,p.V157F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs121912654,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.V157F(176) p.0(9) p.V157A(2) p.V157L(7) p.S149fs*72(1) p.V157D(13) p.V157_R158insV(1) p.V157_R158delVR(3) p.V157I(11) p.G154fs*22(1) p.V157fs*13(3) p.V157fs*24(2) p.V157fs*22(2) p.V157fs*19(2) p.T155fs*23(2) p.V157V(5) p.V157G(12) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156fs*18(1) p.V157fs*23(3) p.R156fs*12(1) p.V157delV(2) p.T155_V157>I(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.R156fs*14(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.V157fs*25(1) p.V157_C176del20(1) p.V157>AL(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1092.0,,4.0,7.3,False,True,True,"smoking:20,Misc:8",0.788392,0.832221967405611,0.708,3.0,,,,,,,ACH-000508,7157.0
chr17,7674230,C,A,0.964,0,25,1|1,,SNP,MISSENSE,c.733G>T,p.G245C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,smoking:7,0.969132,0.8210775969704124,0.97,3.0,,,,,,,ACH-000749,7157.0
chr12,25245350,C,A,0.617,19,30,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-002672,3845.0
chr12,25245350,C,A,0.892,16,124,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000243,3845.0
chr17,7673826,A,G,0.973,0,38,1|1,,SNP,MISSENSE,c.794T>C,p.L265P,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs879253942,,as_specific,0.5236907730673317,"""L, E, M, O""",Rec,False,NTRK1,True,p.L265P(22) p.0(9) p.G262_S269delGNLLGRNS(2) p.L265delL(6) p.N263fs*5(1) p.L265Q(1) p.L265L(4) p.L265M(4) p.E258fs*71(1) p.L265R(3) p.L265fs*80(3) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.L265_K305del41(1) p.L265fs*7(2) p.L265_R267delLGR(1) p.L265fs*81(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:2,0.963093,0.7116267074453874,0.948,3.0,,,,,,,ACH-000098,7157.0
chr17,7674262,T,C,0.512,19,20,0/1,,SNP,MISSENSE,c.701A>G,p.Y234C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587780073,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y234C(87) p.Y234N(13) p.T230_Y234delTTIHY(1) p.H233_C242del10(1) p.Y234S(8) p.Y234fs*6(1) p.Y234D(7) p.Y234fs*4(1) p.D228fs*12(1) p.H233fs*6(1) p.Y234*(15) p.Y234delY(4) p.Y234fs*11(1) p.Y234H(23) p.I232fs*5(1) p.Y234fs*15(1) p.Y234F(1) p.Y234fs*1(1) p.V225fs*23(1) p.Y234fs*5(1) p.I232_Y236delIHYNY(1) p.?(1) p.Y234del(2) p.Y234R(1) p.Y234Y(1) p.Y234_N235insX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1068.0,,0.0,7.3,False,True,True,Misc:7,0.865205,0.7361252184832682,0.945,3.0,,,,,,,ACH-000382,7157.0
chr12,25245350,C,G,0.794,21,81,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-002967,3845.0
chr19,3118944,A,T,0.725,14,36,0/1,,SNP,MISSENSE,c.626A>T,p.Q209L,GNA11,G protein subunit alpha 11,"G protein subunits alpha, group q",ENST00000078429.9,5.0,+,P29992,False,rs1057519742,,as_specific,0.655860349127182,E,Dom,False,,True,p.Q209L(384) p.Q209P(8) p.Q209R(6) p.Q209A(1) p.Q209?(2),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000078429;,,,,7.3,True,True,True,Misc:36,0.752569,0.9807448018376348,0.833,4.0,,,,,,,ACH-002926,2767.0
chr12,25245351,C,G,0.539,39,47,0/1,,SNP,MISSENSE,c.34G>C,p.G12R,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,530.0,,32.5,7.3,True,False,True,"smoking:1,Misc:32",0.915109,0.6459561688690294,0.821,4.0,,,,,,,ACH-000921,3845.0
chr17,7673728,C,A,0.417,20,15,0/1,,SNP,NONSENSE,c.892G>T,p.E298*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs201744589,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E298*(55) p.E298D(2) p.H296_S303delHHELPPGS(1) p.E298Q(1) p.E298K(3) p.E298G(1) p.E298_P301delELPP(1) p.E298V(2) p.L299fs*2(1) p.G293fs*1(1) p.E298A(1) p.L265_K305del41(1) p.E298fs*43(1) p.E298E(1) p.E298fs*53(1) p.E298fs*48(1) p.E298fs*47(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:11,Misc:2",0.975532,0.9950158138511048,,3.0,,,,,,,ACH-000921,7157.0
chr16,3738617,G,A,0.673,17,38,0/1,,SNP,MISSENSE,c.4336C>T,p.R1446C,CREBBP,CREB binding protein,Zinc fingers ZZ-type Lysine acetyltransferases Bromodomain containing,ENST00000262367.10,26.0,-,Q92793,False,rs398124146,,as_specific,0.3965087281795511,L,Dom/Rec,False,"""MLL, MORF, RUNXBP2""",True,p.R1446H(4) p.R1446C(5) p.R1446L(2) p.R1446G(1),cancer;gene_function_loss;structural_relation;,False,False,True,ENST00000262367;ENST00000382070;ENST00000570939;,,,,7.3,False,True,True,CpG:3,0.796118,0.3112722326765591,0.952,3.0,,,,,,,ACH-000395,1387.0
chr17,7675174,C,T,0.969,0,32,1|1,,SNP,NONSENSE,c.438G>A,p.W146*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1131691026,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.L137_W146del10(1) p.W146*(77) p.W146C(2) p.W146fs*23(1) p.Q144fs*32(1) p.W146R(5) p.W146fs*1(1) p.W146fs*22(1) p.V143_P153del(1) p.W146_V147insXXXXXXX(1) p.W146S(1) p.V143_S149delVQLWVDS(1) p.Q144_G154del11(1) p.W146fs*25(1) p.W146G(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:1,Misc:4",0.979855,0.7887579526713587,,4.0,,,,,,,ACH-000395,7157.0
chr17,7674241,G,A,0.919,3,44,1|1,,SNP,MISSENSE,c.722C>T,p.S241F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:4,APOBEC:7,Misc:1",0.912713,0.9893558821746748,0.958,3.0,,,,,,,ACH-000698,7157.0
chr17,7676203,C,A,0.24,59,18,0/1,,SNP,NONSENSE,c.166G>T,p.E56*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.6034912718204489,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E56K(4) p.E56*(5) p.E56V(1) p.D48fs*55(1) p.E51fs*59(1) p.Q52fs*67(1) p.M1_T125del(1) p.E56E(1) p.S33fs*23(1) p.E56fs*67(2) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,APOBEC:1,0.981156,0.7537498776341308,,3.0,,,,,,,ACH-000698,7157.0
chr10,121520163,G,C,0.553,18,20,0/1,,SNP,MISSENSE,c.71C>G,p.S24W,FGFR2,fibroblast growth factor receptor 2,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000478859.5,6.0,-,P21802,False,rs79184941,,as_specific,0.5486284289276808,E,Dom,False,,True,p.S252W(40) p.S24F(1) p.S252L(1),cancer;gene_function_gain;,False,False,True,ENST00000357555;ENST00000613048;ENST00000358487;ENST00000478859;ENST00000356226;ENST00000369060;ENST00000369059;ENST00000346997;ENST00000351936;ENST00000457416;ENST00000360144;ENST00000369056;ENST00000369058;ENST00000336553;,,,,7.3,True,False,True,Misc:13,0.975776,0.3740753510818667,0.796,4.0,,,,,,,ACH-000988,2263.0
chr17,7674872,T,C,0.376,25,15,0/1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000988,7157.0
chr12,25245350,C,A,0.653,33,64,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000347,3845.0
chr12,21801129,C,T,0.286,36,14,0/1,,SNP,MISSENSE,c.4565G>A,p.G1522E,ABCC9,ATP binding cassette subfamily C member 9,ATP binding cassette subfamily C,ENST00000261200.8,38.0,-,O60706,False,,,,0.3740648379052369,,,False,,False,,cancer;,False,False,True,ENST00000261200;,,,,7.3,False,False,True,UV:5,0.925845,,0.804,3.0,,,,,,,ACH-000738,10060.0
chr17,7673802,C,T,0.404,38,24,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000810,7157.0
chr21,10598078,C,T,0.323,60,30,0/1,,SNP,MISSENSE,c.1340C>T,p.S447L,TPTE,transmembrane phosphatase with tensin homology,PTEN protein phosphatases C2 tensin-type domain containing,ENST00000618007.4,21.0,+,P56180,False,rs759301774,,as_specific,0.3366583541147132,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.960969,0.8168519472261235,,2.0,,,,,,,ACH-000810,7179.0
chr5,112839942,C,T,0.971,0,32,1|1,,SNP,NONSENSE,c.4348C>T,p.R1450*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913332,,as_specific,0.456359102244389,"""E, M, O""",Rec,True,,True,p.R1450*(222) p.R1450fs*5(1) p.P1424fs*19(1) p.R1450fs*20(1) p.R1450fs*22(1) p.R1435fs*23(1) p.?(1) p.K1192fs*3(1) p.S1436fs*22(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:15,POLE:2",0.916986,0.7909056506666835,,5.0,,,,,,,ACH-000758,324.0
chr17,7673796,C,A,0.529,16,19,0/1,,SNP,MISSENSE,c.824G>T,p.C275F,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs863224451,,as_specific,0.5286783042394015,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C275Y(63) p.C275R(16) p.C275fs*70(2) p.C275G(6) p.C275F(41) p.C275C(4) p.C275fs*67(1) p.C275W(10) p.V274_P278delVCACP(1) p.C275S(2) p.C275fs*31(4) p.S269fs*21(1) p.F270_D281del12(1) p.C275_A276ins10(1) p.V272_K292del21(1) p.C275*(2) p.R273_C275delRVC(1) p.A276fs*29(1) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:3,Misc:7",0.948115,,0.981,3.0,,,,,,,ACH-000867,7157.0
chr17,7674230,C,T,0.932,2,40,1|1,7674230.0,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-000145,7157.0
chr12,25245351,C,A,0.784,6,23,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000496,3845.0
chr3,179218294,G,A,0.766,3,12,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000129,5290.0
chr12,25245350,C,T,0.567,14,17,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000007,3845.0
chr17,7673806,C,T,0.979,0,48,1|1,,SNP,MISSENSE,c.814G>A,p.V272M,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912657,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.V272M(88) p.0(9) p.F270fs*72(2) p.V272fs*73(2) p.V272A(7) p.V272L(39) p.V272V(4) p.V272E(9) p.G266_E271delGRNSFE(1) p.E271_R273delEVR(1) p.V272G(7) p.E258fs*71(1) p.V272fs*74(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.V272delV(1) p.R267fs*65(1) p.L265_K305del41(1) p.V272fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:10",0.911253,0.5298191979535021,0.907,3.0,,,,,,,ACH-000647,7157.0
chrX,126164924,G,A,0.953,0,20,1|1,,SNP,MISSENSE,c.1001C>T,p.P334L,DCAF12L2,DDB1 and CUL4 associated factor 12 like 2,WD repeat domain containing,ENST00000360028.4,1.0,-,Q5VW00,False,rs1229366218,,as_specific,0.628428927680798,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:3,,0.7605194133261891,0.174,2.0,,,,,,,ACH-000647,340578.0
chr1,196280873,A,C,0.723,9,25,0/1,,SNP,MISSENSE,c.2897T>G,p.L966R,KCNT2,potassium sodium-activated channel subfamily T member 2,Potassium sodium-activated channel subfamily T ,ENST00000294725.13,25.0,-,Q6UVM3,False,,,,0.3017456359102244,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.785299,0.604557166113562,0.315,3.0,,,,,,,ACH-000880,343450.0
chr3,41224613,G,A,0.604,12,21,0/1,,SNP,MISSENSE,c.101G>A,p.G34E,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs28931589,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.A5_Q143del(7) p.G34V(103) p.G34R(123) p.G34E(112) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32_S47del(2) p.G34A(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_I35del(1) p.G34D(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.G34I(1) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(2) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.D32fs*9(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.S33_G34insS(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.S33_G34insGTS(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.S33_G34insGI(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_I35del(1) p.A5_T59del(1) p.G34C(1) p.A5_Q72del(1) p.S33_G34del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"MSI:1,UV:1,POLE:1,Misc:2",0.963821,0.7939394540558168,0.593,4.0,,,,,,,ACH-000880,1499.0
chr3,179210291,G,A,0.448,15,12,0/1,,SNP,MISSENSE,c.1357G>A,p.E453K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,8.0,+,P42336,False,rs1057519925,,as_specific,0.3341645885286783,"""E, O""",Dom,False,,True,p.H450_P458delHGLEDLLNP(1) p.E453_P458>D(1) p.E453K(23) p.P449_L455del(1) p.E453delE(1) p.E453Q(1) p.H450fs*9(1) p.P447_L455del(1) p.E453G(1) p.E453_L455delEDL(1) p.E453A(1) p.E453del(1) p.G451_L456>V(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"Eso:1,APOBEC:11",0.966176,0.6378698336955063,0.544,3.0,,,,,,,ACH-000880,5290.0
chr3,179218304,A,C,0.545,9,12,0/1,,SNP,MISSENSE,c.1634A>C,p.E545A,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913274,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;,,,,7.3,True,False,True,Misc:14,0.929104,0.8384288221013635,0.715,3.0,,,,,,,ACH-000880,5290.0
chr12,25245350,C,T,0.432,23,16,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000880,3845.0
chr1,26761012,C,T,0.614,19,28,0/1,,SNP,NONSENSE,c.2077C>T,p.R693*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,5.0,+,O14497,False,,,,0.5311720698254364,E,Rec,True,1507,True,p.R693Q(1) p.R693*(5),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:2,UV:1",0.971312,0.8787078769488789,,5.0,,,,,,,ACH-000965,8289.0
chr17,7674220,C,T,0.963,0,25,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000639,7157.0
chr12,25245350,C,A,0.971,0,33,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000803,3845.0
chr17,7674230,C,A,0.668,7,15,0/1,,SNP,MISSENSE,c.733G>T,p.G245C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,smoking:7,0.969132,0.8210775969704124,0.97,3.0,,,,,,,ACH-000803,7157.0
chr3,179218303,G,A,0.634,11,19,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000463,5290.0
chr12,25227341,T,A,0.968,0,31,1|1,,SNP,MISSENSE,c.183A>T,p.Q61H,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs17851045,,as_specific,0.3466334164588528,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"smoking:2,Misc:3",0.812146,0.6464448787056057,0.647,4.0,,,,,,,ACH-000463,3845.0
chr17,7674872,T,C,0.533,14,18,0/1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000277,7157.0
chr3,179218303,G,A,0.517,23,25,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-002884,5290.0
chr17,7673767,C,T,0.958,0,23,1|1,,SNP,MISSENSE,c.853G>A,p.E285K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs112431538,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E285K(139) p.E285V(15) p.R283fs*16(2) p.E285Q(5) p.E285G(5) p.E285*(19) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.E285A(2) p.R283fs*56(1) p.V272_K292del21(1) p.E285E(5) p.E285fs*20(1) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285fs*60(2) p.E285fs*21(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:20,0.905537,,0.91,3.0,,,,,,,ACH-002884,7157.0
chr3,179234230,A,G,0.319,35,16,0/1,,SNP,MISSENSE,c.3073A>G,p.T1025A,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs397517202,,as_specific,0.3840399002493765,"""E, O""",Dom,False,,True,p.T1025A(34) p.T1025T(22) p.T1025I(5) p.T1025N(4) p.T1025?(13) p.T1025S(4) p.T1025P(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"POLE:3,Misc:2",0.92038,0.3510097656726454,0.587,3.0,,,,,,,ACH-000444,5290.0
chr12,25245351,C,A,0.602,44,67,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000444,3845.0
chr17,7675143,C,A,0.977,0,47,1|1,,SNP,MISSENSE,c.469G>T,p.V157F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs121912654,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.V157F(176) p.0(9) p.V157A(2) p.V157L(7) p.S149fs*72(1) p.V157D(13) p.V157_R158insV(1) p.V157_R158delVR(3) p.V157I(11) p.G154fs*22(1) p.V157fs*13(3) p.V157fs*24(2) p.V157fs*22(2) p.V157fs*19(2) p.T155fs*23(2) p.V157V(5) p.V157G(12) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156fs*18(1) p.V157fs*23(3) p.R156fs*12(1) p.V157delV(2) p.T155_V157>I(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.R156fs*14(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.V157fs*25(1) p.V157_C176del20(1) p.V157>AL(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1092.0,,4.0,7.3,False,True,True,"smoking:20,Misc:8",0.788392,0.832221967405611,0.708,3.0,,,,,,,ACH-002052,7157.0
chr5,112839942,C,T,0.941,0,16,1|1,,SNP,NONSENSE,c.4348C>T,p.R1450*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913332,,as_specific,0.456359102244389,"""E, M, O""",Rec,True,,True,p.R1450*(222) p.R1450fs*5(1) p.P1424fs*19(1) p.R1450fs*20(1) p.R1450fs*22(1) p.R1435fs*23(1) p.?(1) p.K1192fs*3(1) p.S1436fs*22(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:15,POLE:2",0.916986,0.7909056506666835,,5.0,,,,,,,ACH-000532,324.0
chr12,25245350,C,T,0.628,15,26,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000532,3845.0
chr17,7675088,C,T,0.974,0,38,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000532,7157.0
chr17,7675151,C,A,0.95,0,20,1|1,,SNP,MISSENSE,c.461G>T,p.G154V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs762846821,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S149fs*72(1) p.G154R(1) p.G154V(44) p.G154fs*22(1) p.P152fs*14(5) p.G154_R156delGTR(1) p.G154I(3) p.G154D(7) p.G154S(9) p.D148fs*23(1) p.P153fs*26(2) p.G154fs*?(1) p.G154G(12) p.G154fs*14(2) p.G154A(1) p.G154fs*27(3) p.P153fs*22(2) p.P151_V173del23(1) p.G154fs*16(4) p.Q144_G154del11(1) p.D148_T155delDSTPPPGT(1) p.P153_G154insX(1) p.G154C(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,smoking:6,0.82126,0.8527250621892793,0.754,3.0,,,,,,,ACH-002526,7157.0
chr1,147908084,C,T,0.348,36,20,0/1,,SNP,SILENT,c.129C>T,p.F43F,GJA8,gap junction protein alpha 8,Gap junction proteins,ENST00000369235.1,1.0,+,P48165,False,rs267598000,,as_specific,0.5860349127182045,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:2,UV:6,POLE:2",0.679718,0.8520121336634799,,0.0,,,,,,,ACH-001982,2703.0
chr7,140753336,A,T,0.765,12,41,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001982,673.0
chr10,133168288,C,T,0.256,28,9,0/1,,SNP,SILENT,c.336C>T,p.F112F,KNDC1,kinase non-catalytic C-lobe domain containing 1,,ENST00000304613.8,3.0,+,Q76NI1,False,rs570488032,,as_specific,0.6109725685785536,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"CpG:1,POLE:5",0.777036,0.62828040447614,,0.0,,,,,,,ACH-001982,85442.0
chr11,124309847,C,T,0.964,0,26,1|1,,SNP,MISSENSE,c.920G>A,p.G307E,OR8D1,olfactory receptor family 8 subfamily D member 1,"Olfactory receptors, family 8",ENST00000641015.1,3.0,-,Q8WZ84,False,,,,0.3665835411471321,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.397431,0.5996429978944064,0.019,1.0,,,,,,,ACH-001982,283159.0
chr1,59674073,C,G,0.493,28,28,0/1,,SNP,SILENT,c.1524C>G,p.S508S,FGGY,FGGY carbohydrate kinase domain containing,,ENST00000371218.8,15.0,+,Q96C11,False,,,,0.5536159600997507,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"smoking:3,Misc:2",0.224542,0.5941869175221429,,0.0,,,,,,,ACH-000846,55277.0
chr17,7674220,C,A,0.353,33,17,0/1,,SNP,MISSENSE,c.743G>T,p.R248L,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:4,Misc:3",0.932907,0.9843307954424446,0.96,3.0,,,,,,,ACH-000846,7157.0
chr3,179218303,G,A,0.621,12,17,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000019,5290.0
chr12,4518087,C,T,0.53,8,9,0/1,,SNP,MISSENSE,c.1004G>A,p.R335Q,C12orf4,chromosome 12 open reading frame 4,,ENST00000261250.8,8.0,-,Q9NQ89,False,rs532268400,,as_specific,0.3591022443890274,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.977517,0.5996129798173001,0.258,3.0,,,,,,,ACH-000019,57102.0
chr17,7675143,C,A,0.965,0,26,1|1,,SNP,MISSENSE,c.469G>T,p.V157F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs121912654,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.V157F(176) p.0(9) p.V157A(2) p.V157L(7) p.S149fs*72(1) p.V157D(13) p.V157_R158insV(1) p.V157_R158delVR(3) p.V157I(11) p.G154fs*22(1) p.V157fs*13(3) p.V157fs*24(2) p.V157fs*22(2) p.V157fs*19(2) p.T155fs*23(2) p.V157V(5) p.V157G(12) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156fs*18(1) p.V157fs*23(3) p.R156fs*12(1) p.V157delV(2) p.T155_V157>I(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.R156fs*14(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.V157fs*25(1) p.V157_C176del20(1) p.V157>AL(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1092.0,,4.0,7.3,False,True,True,"smoking:20,Misc:8",0.788392,0.832221967405611,0.708,3.0,,,,,,,ACH-000844,7157.0
chr17,7674252,C,T,0.947,0,25,1|1,,SNP,MISSENSE,c.711G>A,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:9",0.902715,0.9958849948114716,0.923,3.0,,,,,,,ACH-000894,7157.0
chr17,7675994,C,A,0.957,0,22,1|1,,SNP,SPLICE_SITE,c.375G>T,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:12,MSI:1,Misc:4",0.468898,0.7805428798268306,,0.0,,,,,,,ACH-001489,7157.0
chr5,112839693,C,T,0.983,0,57,1|1,,SNP,NONSENSE,c.4099C>T,p.Q1367*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913328,,as_specific,0.4638403990024937,"""E, M, O""",Rec,True,,True,p.Q1367*(39) p.Q1367H(2) p.K1363fs*7(1) p.?(1) p.K1192fs*3(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"APOBEC:2,Misc:1",0.963926,0.5902091700563789,,5.0,,,,,,,ACH-000009,324.0
chr17,7674921,C,A,0.966,0,27,1|1,,SNP,NONSENSE,c.610G>T,p.E204*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,,,,0.5610972568578554,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E204*(35) p.L201_H214del(1) p.E204fs*43(3) p.E204G(3) p.E204_N210delEYLDDRN(1) p.E204K(2) p.E204D(1) p.V203_E204>LV(1) p.E204fs*4(1) p.E204fs*5(3) p.E204V(2) p.E204E(2) p.?(1) p.K164_P219del(1) p.G199fs*42(1) p.E204fs*39(1) p.E204A(1) p.E204Q(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:3,Misc:2",0.978031,,,3.0,,,,,,,ACH-000009,7157.0
chr3,189869329,C,T,0.448,15,13,0/1,,SNP,MISSENSE,c.1135C>T,p.R379C,TP63,tumor protein p63,,ENST00000264731.8,9.0,+,Q9H3D4,False,rs761885185,,as_specific,0.3665835411471321,,,False,TP63,False,p.R379C(2),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,True,True,True,UV:9,0.978306,0.4008252000510195,0.654,3.0,,,,,,,ACH-000788,8626.0
chr7,140753336,A,T,0.37,34,22,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000788,673.0
chr15,66436824,C,T,0.428,25,17,0/1,,SNP,MISSENSE,c.370C>T,p.P124S,MAP2K1,mitogen-activated protein kinase kinase 1,Mitogen-activated protein kinase kinases,ENST00000307102.10,3.0,+,Q02750,False,rs1057519732,,as_specific,0.4887780548628428,,,False,,True,p.P124L(12) p.P124S(22) p.P124Q(3),cancer;gene_function_gain;,False,False,True,ENST00000307102;,82.0,"MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.",3.0,7.3,True,False,True,"UV:13,Misc:1",0.931772,0.6090424855436817,0.855,4.0,,,,,,,ACH-000788,5604.0
chr17,7673800,C,A,0.974,0,37,1|1,,SNP,MISSENSE,c.820G>T,p.V274F,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1057520005,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V274A(21) p.V274F(26) p.V274D(9) p.V274G(5) p.V274L(11) p.V274_P278delVCACP(1) p.R273fs*71(1) p.S269fs*21(1) p.V274fs*71(1) p.F270_D281del12(1) p.V274I(5) p.V272_K292del21(1) p.R273_C275delRVC(1) p.R267fs*65(1) p.L265_K305del41(1) p.V274V(3) p.V274fs*32(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:3",0.759652,0.6981666958941316,0.773,2.0,,,,,,,ACH-000788,7157.0
chr2,29220829,G,T,0.531,24,27,0/1,,SNP,MISSENSE,c.3522C>A,p.F1174L,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,23.0,-,Q9UM73,False,rs863225281,,as_specific,0.5361596009975063,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.F1174L(136) p.F1174S(3) p.F1174V(8) p.F1174?(5) p.F1174C(12) p.F1174I(6),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000642122;ENST00000389048;ENST00000618119;,8.0,"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.",33.5,7.3,True,False,False,,0.936591,0.5618789444624813,0.752,4.0,,,,,,,ACH-001188,238.0
chr7,140753336,A,T,0.75,13,42,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000253,673.0
chr17,7674248,T,C,0.628,15,26,0/1,,SNP,MISSENSE,c.715A>G,p.N239D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs876660807,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N239D(42) p.N239fs*22(1) p.H233_C242del10(1) p.N239_C242delNSSC(3) p.N239T(8) p.N239S(26) p.N239fs*25(12) p.C238_N239insX(1) p.N239fs*4(1) p.H233fs*6(1) p.N239K(7) p.M237_N239delMCN(1) p.N239fs*8(3) p.N239I(1) p.N239_S240insN(1) p.N239Y(6) p.V225fs*23(1) p.N239fs*1(2) p.N239_S240insX(2) p.N239N(1) p.C238_M246delCNSSCMGGM(1) p.N239fs*26(1) p.N239_S240delNS(2) p.N239fs*6(1) p.N239fs*?(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.N239*(1) p.N239_S241>T(1) p.N239fs*24(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:8,0.936288,0.9973610804975211,0.948,3.0,,,,,,,ACH-000422,7157.0
chr7,140753336,A,T,0.4,19,12,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000348,673.0
chr17,7674233,C,A,0.98,0,48,1|1,,SNP,MISSENSE,c.730G>T,p.G244C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs1057519989,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,MSI:1",0.967868,0.7256135967181565,0.94,3.0,,,,,,,ACH-000559,7157.0
chr3,179218303,G,A,0.579,15,23,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000792,5290.0
chr17,7674241,G,C,0.576,14,18,0/1,,SNP,MISSENSE,c.722C>G,p.S241C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"APOBEC:1,Misc:2",0.900614,0.9732631616330862,0.952,3.0,,,,,,,ACH-000792,7157.0
chr17,7675151,C,A,0.965,0,27,1|1,,SNP,MISSENSE,c.461G>T,p.G154V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs762846821,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S149fs*72(1) p.G154R(1) p.G154V(44) p.G154fs*22(1) p.P152fs*14(5) p.G154_R156delGTR(1) p.G154I(3) p.G154D(7) p.G154S(9) p.D148fs*23(1) p.P153fs*26(2) p.G154fs*?(1) p.G154G(12) p.G154fs*14(2) p.G154A(1) p.G154fs*27(3) p.P153fs*22(2) p.P151_V173del23(1) p.G154fs*16(4) p.Q144_G154del11(1) p.D148_T155delDSTPPPGT(1) p.P153_G154insX(1) p.G154C(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,smoking:6,0.82126,0.8527250621892793,0.754,3.0,,,,,,,ACH-000800,7157.0
chr5,140843246,C,G,0.977,0,43,1|1,,SNP,MISSENSE,c.1925C>G,p.S642C,PCDHA8,protocadherin alpha 8,Clustered protocadherins,ENST00000531613.2,1.0,+,Q9Y5H6,False,,,,0.655860349127182,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:4,0.364475,0.6352371337245045,0.023,1.0,,,,,,,ACH-002215,56140.0
chr7,55143387,G,A,0.342,56,28,0/1,,SNP,MISSENSE,c.323G>A,p.R108K,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,3.0,+,P00533,False,rs1057519828,,as_specific,0.4788029925187032,"""E, O""",Dom,False,,True,p.R108K(17) p.V30_R297>G(5),cancer;gene_function_gain;,False,False,True,ENST00000455089;ENST00000342916;ENST00000454757;ENST00000344576;ENST00000420316;ENST00000275493;ENST00000450046;,994.0,,3.0,7.3,True,False,True,APOBEC:2,0.906526,,0.854,4.0,,,,,,,ACH-002215,1956.0
chr17,7674221,G,A,0.262,13,4,0/1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000649,7157.0
chr2,29213994,A,C,0.678,14,31,0/1,,SNP,MISSENSE,c.3733T>G,p.F1245V,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,24.0,-,Q9UM73,False,rs281864720,,as_specific,0.5311720698254364,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.F1245C(10) p.F1245I(5) p.F1245V(11) p.F1245L(5),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000642122;ENST00000389048;ENST00000618119;,1295.0,,7.5,7.3,True,False,False,,0.916148,,0.929,4.0,,,,,,,ACH-001481,238.0
chr17,7673764,C,T,0.944,0,15,1|1,,SNP,MISSENSE,c.856G>A,p.E286K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs786201059,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E286G(17) p.E286K(94) p.E286fs*59(2) p.R283fs*16(2) p.E286*(17) p.E286V(9) p.E286fs*17(2) p.E286Q(7) p.E286D(2) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.R283fs*56(1) p.V272_K292del21(1) p.E286A(2) p.E286E(2) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:3,Misc:1",0.93585,0.6532670016064752,0.949,3.0,,,,,,,ACH-001481,7157.0
chr12,25245350,C,A,0.994,0,158,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000505,3845.0
chr17,7675088,C,T,0.961,0,23,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000505,7157.0
chr17,7674238,C,T,0.956,0,20,1|1,,SNP,MISSENSE,c.725G>A,p.C242Y,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912655,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C242fs*20(2) p.C242F(85) p.C242Y(54) p.C242S(35) p.C242*(5) p.H233_C242del10(1) p.N239_C242delNSSC(3) p.C242fs*5(21) p.C242W(6) p.C242G(4) p.C242R(13) p.N239fs*4(1) p.C242C(4) p.C242fs*98(1) p.C242fs*?(3) p.S241_G245delSCMGG(1) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.C242fs*23(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1064.0,,0.0,7.3,False,True,True,Misc:3,0.964036,0.9882502870966408,0.973,3.0,,,,,,,ACH-000515,7157.0
chr17,7673806,C,T,0.963,0,26,1|1,,SNP,MISSENSE,c.814G>A,p.V272M,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912657,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.V272M(88) p.0(9) p.F270fs*72(2) p.V272fs*73(2) p.V272A(7) p.V272L(39) p.V272V(4) p.V272E(9) p.G266_E271delGRNSFE(1) p.E271_R273delEVR(1) p.V272G(7) p.E258fs*71(1) p.V272fs*74(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.V272delV(1) p.R267fs*65(1) p.L265_K305del41(1) p.V272fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:10",0.911253,0.5298191979535021,0.907,3.0,,,,,,,ACH-002345,7157.0
chr8,21987235,C,T,0.697,9,25,0/1,,SNP,MISSENSE,c.1672C>T,p.R558C,XPO7,exportin 7,Exportins,ENST00000252512.14,14.0,+,Q9UIA9,False,rs1486570253,,as_specific,0.456359102244389,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:1,POLE:4",0.929422,0.8355317362585007,0.518,2.0,,,,,,,ACH-001578,23039.0
chr3,179199088,G,A,0.414,16,11,0/1,,SNP,MISSENSE,c.263G>A,p.R88Q,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs121913287,,as_specific,0.3391521197007481,"""E, O""",Dom,False,,True,p.R88Q(147) p.R88L(1) p.R88?(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,929.0,,0.0,7.3,True,False,True,"CpG:11,MSI:1,POLE:17",0.947755,0.4551598659740948,0.806,3.0,,,,,,,ACH-000974,5290.0
chr6,54941280,A,G,0.261,33,11,0/1,,SNP,MISSENSE,c.2309A>G,p.K770R,FAM83B,family with sequence similarity 83 member B,,ENST00000306858.8,5.0,+,Q5T0W9,False,,,,0.3790523690773067,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.473904,0.3260530961855065,0.059,3.0,,,,,,,ACH-000974,222584.0
chr12,25245350,C,A,0.486,18,17,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000974,3845.0
chr22,36312189,C,T,0.325,24,11,0/1,,SNP,MISSENSE,c.1588G>A,p.E530K,MYH9,myosin heavy chain 9,Deafness associated genes Myosin heavy chains,ENST00000216181.11,14.0,-,P35579,False,,,,0.5910224438902744,L,Dom,False,ALK,False,,cancer;structural_relation;,False,False,True,ENST00000216181;,,,,7.3,False,False,True,APOBEC:1,0.972154,0.4807432056641652,0.945,4.0,,,,,,,ACH-000974,4627.0
chr11,533874,T,A,0.63,20,34,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,3.0,-,P01112,False,rs121913233,,as_specific,0.6458852867830424,"""E, L, M""",Dom,False,,True,p.Q61R(289) p.Q61K(113) p.Q61L(184) p.Q61H(24) p.Q61?(16) p.Q61P(3) p.Q61*(1) p.Q61Q(1) p.Q61E(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,854.0,,0.0,7.3,True,True,True,"smoking:2,Misc:4",0.786029,0.9921539220757206,0.839,4.0,,,,,,,ACH-000858,3265.0
chr17,7674216,C,A,0.974,0,36,1|1,,SNP,MISSENSE,c.747G>T,p.R249S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934571,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.P250fs*14(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:5,Misc:13",0.776711,,0.769,2.0,,,,,,,ACH-000858,7157.0
chr12,25245351,C,A,0.819,9,44,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000511,3845.0
chr1,114713908,T,A,0.483,14,13,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000739,4893.0
chrX,40062191,T,C,0.961,0,24,1|1,,SNP,MISSENSE,c.4274A>G,p.N1425S,BCOR,BCL6 corepressor,Ankyrin repeat domain containing,ENST00000397354.7,10.0,-,Q6W2J9,False,rs199538037,,as_specific,0.6334164588528678,,Rec,False,RARA,False,p.N1425S(1),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:23,,,0.221,2.0,,,,,,,ACH-000739,54880.0
chr1,155322078,G,C,0.499,18,20,0/1,,SNP,MISSENSE,c.305G>C,p.C102S,RUSC1,RUN and SH3 domain containing 1,,ENST00000368352.10,2.0,+,Q9BVN2,False,,,,0.6508728179551122,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:3,0.387191,0.6895776785066173,0.088,3.0,,,,,,,ACH-000954,23623.0
chr3,44651139,A,G,0.273,49,18,0/1,,SNP,SILENT,c.72A>G,p.E24E,ZNF35,zinc finger protein 35,Zinc fingers C2H2-type,ENST00000453164.1,2.0,+,P13682,False,rs753622014,,as_specific,0.5261845386533666,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.290013,0.6196210973327331,,0.0,,,,,,,ACH-000954,7584.0
chr3,179234302,G,C,0.65,20,41,0/1,,SNP,MISSENSE,c.3145G>C,p.G1049R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913277,,as_specific,0.3840399002493765,"""E, O""",Dom,False,,True,p.G1049R(78) p.G1049S(34) p.G1049A(6) p.G1049D(3) p.G1049G(9) p.G1049C(1),cancer;gene_function_gain;,False,False,True,,940.0,,0.0,7.3,True,False,True,"APOBEC:1,Misc:7",0.830715,0.3903762856806781,0.391,3.0,,,,,,,ACH-000954,5290.0
chr12,25245350,C,T,0.474,23,19,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000954,3845.0
chr17,7674220,C,T,0.98,0,50,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000954,7157.0
chr17,39724811,C,T,0.75,16,52,0/1,,SNP,MISSENSE,c.2393C>T,p.T798I,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,20.0,+,P04626,False,,,,0.5960099750623441,E,Dom,False,,False,,cancer;gene_function_gain;,False,False,True,ENST00000584601;ENST00000406381;ENST00000541774;ENST00000445658;ENST00000584450;ENST00000269571;,2331.0,,0.0,7.3,True,False,False,,0.908715,0.5110437939199052,0.783,4.0,,,,,,,ACH-000954,2064.0
chr17,39725079,G,A,0.708,18,45,0/1,,SNP,MISSENSE,c.2524G>A,p.V842I,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,21.0,+,P04626,False,rs1057519738,,as_specific,0.5835411471321695,E,Dom,False,,True,p.V842I(18) p.V842E(1),cancer;gene_function_gain;,False,True,True,,45.0,"ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",9.0,7.3,True,False,True,CpG:7,0.925625,0.7707432895054793,0.538,4.0,,,,,,,ACH-000954,2064.0
chr22,41169525,G,A,0.391,29,17,0/1,,SNP,MISSENSE,c.4195G>A,p.D1399N,EP300,E1A binding protein p300,Zinc fingers ZZ-type Lysine acetyltransferases Bromodomain containing,ENST00000263253.9,26.0,+,Q09472,False,rs1057519889,,as_specific,0.3765586034912718,"""L, E""",Rec,False,"""MLL, RUNXBP2""",True,p.D1399Y(3) p.D1399N(3),cancer;gene_function_loss;structural_relation;,False,False,True,ENST00000263253;,,,,7.3,False,True,True,"CpG:5,POLE:1",0.923848,0.3793505958908378,0.881,4.0,,,,,,,ACH-000954,2033.0
chr12,25245348,C,A,0.405,21,17,0/1,,SNP,MISSENSE,c.37G>T,p.G13C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913535,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,911.0,,0.0,7.3,True,False,True,"smoking:7,MSI:1,Misc:4",0.929283,,0.868,4.0,,,,,,,ACH-000666,3845.0
chr17,7673767,C,T,0.977,0,43,1|1,,SNP,MISSENSE,c.853G>A,p.E285K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs112431538,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E285K(139) p.E285V(15) p.R283fs*16(2) p.E285Q(5) p.E285G(5) p.E285*(19) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.E285A(2) p.R283fs*56(1) p.V272_K292del21(1) p.E285E(5) p.E285fs*20(1) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285fs*60(2) p.E285fs*21(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:20,0.905537,,0.91,3.0,,,,,,,ACH-000666,7157.0
chr17,7675143,C,A,0.987,0,78,1|1,,SNP,MISSENSE,c.469G>T,p.V157F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs121912654,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.V157F(176) p.0(9) p.V157A(2) p.V157L(7) p.S149fs*72(1) p.V157D(13) p.V157_R158insV(1) p.V157_R158delVR(3) p.V157I(11) p.G154fs*22(1) p.V157fs*13(3) p.V157fs*24(2) p.V157fs*22(2) p.V157fs*19(2) p.T155fs*23(2) p.V157V(5) p.V157G(12) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156fs*18(1) p.V157fs*23(3) p.R156fs*12(1) p.V157delV(2) p.T155_V157>I(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.R156fs*14(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.V157fs*25(1) p.V157_C176del20(1) p.V157>AL(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1092.0,,4.0,7.3,False,True,True,"smoking:20,Misc:8",0.788392,0.832221967405611,0.708,3.0,,,,,,,ACH-000727,7157.0
chr12,25245350,C,T,0.811,11,47,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000652,3845.0
chr17,7673802,C,T,0.973,0,36,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000652,7157.0
chr3,179234297,A,G,0.85,7,45,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000859,5290.0
chr17,7675124,T,C,0.966,0,28,1|1,,SNP,MISSENSE,c.488A>G,p.Y163C,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs148924904,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y163C(136) p.0(9) p.S149fs*72(1) p.Y163fs*1(2) p.Y163H(19) p.Y163N(20) p.A159_Q167delAMAIYKQSQ(1) p.Y163S(5) p.Y163*(8) p.Y163fs*14(1) p.A159_M169del(1) p.Y163_Q165delYKQ(1) p.Y163D(4) p.Y163del(1) p.Y163Y(3) p.P151_V173del23(1) p.I162_Y163delIY(1) p.Y163fs*7(2) p.V157_C176del20(1) p.Y163fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:11,0.897865,0.7273008533507418,0.872,3.0,,,,,,,ACH-000859,7157.0
chr3,179234297,A,T,0.981,0,53,1|1,,SNP,MISSENSE,c.3140A>T,p.H1047L,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,1151.0,,12.5,7.3,True,False,True,"APOBEC:1,Misc:27",0.829278,,0.359,3.0,,,,,,,ACH-000330,5290.0
chr17,7674953,T,C,0.96,0,25,1|1,,SNP,MISSENSE,c.578A>G,p.H193R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs786201838,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193L(40) p.H193_I195delHLI(1) p.H193R(78) p.H193Y(29) p.?(2) p.H193D(10) p.H193P(15) p.H193N(7) p.P191fs*53(2) p.A189_V197delAPPQHLIRV(4) p.H193H(2) p.H193fs*16(3) p.A189fs*53(1) p.P191fs*6(1) p.K164_P219del(1) p.H193_I195>AP(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:16,0.888726,0.7365336169861475,0.884,3.0,,,,,,,ACH-000330,7157.0
chr3,179218294,G,A,0.37,16,9,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000919,5290.0
chr4,152326137,G,A,0.606,14,23,0/1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-000919,55294.0
chr10,62092489,C,G,0.639,16,27,0/1,,SNP,MISSENSE,c.3026C>G,p.A1009G,ARID5B,AT-rich interaction domain 5B,AT-rich interaction domain containing,ENST00000279873.12,10.0,+,Q14865,False,,,,0.571072319201995,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,Misc:3,0.639587,0.4020160309416056,0.146,3.0,,,,,,,ACH-000919,84159.0
chr7,140753336,A,T,0.412,29,22,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000730,673.0
chr15,40382906,C,T,0.444,25,20,0/1,,SNP,MISSENSE,c.71C>T,p.S24F,KNSTRN,kinetochore localized astrin/SPAG5 binding protein,,ENST00000249776.12,1.0,+,Q9Y448,False,rs868438023,,as_specific,0.5960099750623441,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:9,0.504041,,0.061,1.0,,,,,,,ACH-000730,90417.0
chr7,140781611,C,A,0.645,10,19,0/1,,SNP,MISSENSE,c.1397G>T,p.G466V,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,11.0,-,P15056,False,rs121913351,,as_specific,0.3591022443890274,E,Dom,False,"""AKAP9, KIAA1549""",True,p.G466V(34) p.G466E(17) p.G466A(5) p.G466R(13) p.G466?(2),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,2222.0,,14.0,7.3,True,False,True,"smoking:5,Misc:1",0.903772,,0.962,4.0,,,,,,,ACH-000448,673.0
chr17,7674221,G,A,0.971,0,35,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-002043,7157.0
chr1,18482884,G,A,0.386,26,17,0/1,,SNP,MISSENSE,c.1903G>A,p.E635K,KLHDC7A,kelch domain containing 7A,,ENST00000400664.2,1.0,+,Q5VTJ3,False,,,,0.6957605985037406,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:12,0.519318,0.610893992681146,0.341,2.0,,,,,,,ACH-001990,127707.0
chr7,140753336,A,T,0.314,25,10,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001990,673.0
chr11,100061367,C,T,0.947,0,17,1|1,,SNP,MISSENSE,c.1136C>T,p.S379F,CNTN5,contactin 5,I-set domain containing Immunoglobulin like domain containing Ig-like cell adhesion molecule family Fibronectin type III domain containing,ENST00000524871.6,10.0,+,O94779,False,rs866845091,,as_specific,0.3690773067331671,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:9,0.853193,,0.164,2.0,,,,,,,ACH-001990,53942.0
chr14,19781125,C,T,0.154,68,11,0/1,,SNP,MISSENSE,c.803C>T,p.S268F,OR4M1,olfactory receptor family 4 subfamily M member 1,"Olfactory receptors, family 4",ENST00000641200.1,2.0,+,Q8NGD0,False,,,,0.4039900249376558,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.407885,,0.191,2.0,,,,,,,ACH-001990,441670.0
chr14,62987180,C,T,0.379,17,10,0/1,,SNP,SILENT,c.441G>A,p.T147T,KCNH5,potassium voltage-gated channel subfamily H member 5,Potassium voltage-gated channels,ENST00000322893.12,5.0,-,Q8NCM2,False,rs753750382,,as_specific,0.3516209476309227,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:13,0.518467,0.7718770094283447,,0.0,,,,,,,ACH-001990,27133.0
chr17,7675088,C,T,0.977,0,42,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002968,7157.0
chr12,25245350,C,G,0.486,20,17,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-000763,3845.0
chr12,25245350,C,G,0.526,14,17,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-001100,3845.0
chr17,7674221,G,A,0.971,0,34,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-001100,7157.0
chr17,7675148,G,T,0.947,0,16,1|1,,SNP,MISSENSE,c.464C>A,p.T155N,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202752,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T155P(16) p.S149fs*72(1) p.T155N(22) p.G154fs*22(1) p.T155I(15) p.P152fs*14(4) p.G154_R156delGTR(1) p.T155fs*23(2) p.T155L(1) p.T155T(5) p.T155S(2) p.D148fs*23(1) p.G154fs*14(2) p.T155A(7) p.T155_V157>I(1) p.T155fs*25(1) p.P153fs*22(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.T155fs*26(2) p.D148_T155delDSTPPPGT(1) p.R156fs*25(1) p.T155fs*15(1) p.T155_R156delTR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:4,0.656667,0.8526069402886141,0.548,2.0,,,,,,,ACH-000816,7157.0
chr17,7675994,C,A,0.983,0,56,1|1,,SNP,SPLICE_SITE,c.375G>T,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:12,MSI:1,Misc:4",0.468898,0.7805428798268306,,0.0,,,,,,,ACH-000355,7157.0
chr17,7674252,C,A,0.964,0,26,1|1,,SNP,MISSENSE,c.711G>T,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1066.0,,7.0,7.3,False,True,True,"smoking:1,Misc:3",0.91752,0.995844327753855,0.923,3.0,,,,,,,ACH-000705,7157.0
chr7,140753336,A,T,0.435,25,19,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002084,673.0
chr17,7676059,G,A,0.953,0,19,1|1,,SNP,NONSENSE,c.310C>T,p.Q104*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5561097256857855,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.G59fs*23(3) p.S95_G108del(1) p.W91fs*13(1) p.Q104fs*19(2) p.Y103_G112>C(1) p.Q104*(15) p.Y103_Q104>*(1) p.Y103fs*15(1) p.M1_T125del(1) p.Q104L(1) p.Q104H(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:1,0.976972,0.3103062833861155,,4.0,,,,,,,ACH-001863,7157.0
chr17,7675157,G,A,0.952,0,19,1|1,,SNP,MISSENSE,c.455C>T,p.P152L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782705,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.P152fs*18(21) p.P152P(6) p.0(9) p.P152S(29) p.S149fs*72(1) p.P152L(75) p.P153fs*28(7) p.P152_P153insXXX(1) p.P152T(9) p.P152fs*14(6) p.P152A(2) p.P153fs*16(2) p.P152Q(4) p.P152R(7) p.P152fs*28(3) p.D148fs*23(1) p.T150fs*16(4) p.P152fs*27(1) p.P152fs*29(6) p.V143_P153del(1) p.P151_V173del23(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"CpG:2,UV:1",0.952593,0.8618240470838262,0.878,3.0,,,,,,,ACH-000338,7157.0
chr3,10149862,T,A,0.957,0,23,1|1,,SNP,MISSENSE,c.539T>A,p.I180N,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,3.0,+,P40337,False,,,,0.4588528678304239,"""E, M, O""",Rec,False,,True,p.I180V(2) p.I180fs*36(1) p.I180N(5) p.L178_V181del(1) p.I180fs*14(1) p.I180fs*21(1) p.D179_I180del(1) p.I180fs*22(3) p.I180fs*>34(1),cancer;gene_function_loss;,False,False,True,ENST00000256474;ENST00000345392;,2246.0,,0.0,7.3,False,True,False,,0.628697,0.7497780012218718,0.924,4.0,,,,,,,ACH-000411,7428.0
chr17,7675076,T,C,0.667,10,23,0/1,,SNP,MISSENSE,c.536A>G,p.H179R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519991,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:27,0.941824,,0.935,3.0,,,,,,,ACH-000969,7157.0
chr20,58909366,G,A,0.354,31,16,0/1,,SNP,MISSENSE,c.602G>A,p.R201H,GNAS,GNAS complex locus,"G protein subunits alpha, group s Granins",ENST00000371085.7,8.0,+,"O95467, P63092, P84996, Q5JWF2",False,rs121913495,,as_specific,0.4987531172069825,E,Dom,False,,True,p.R201H(703) p.R201C(858) p.R201?(16) p.R201L(4) p.R201S(32) p.R201G(2) p.R201R(1) p.R201P(1),cancer;gene_function_gain;,False,False,True,ENST00000371100;ENST00000371102;ENST00000604005;ENST00000371095;ENST00000371085;ENST00000354359;ENST00000265620;,,,,7.3,True,False,True,CpG:10,0.822809,0.7272591405043412,0.969,4.0,,,,,,,ACH-000969,2778.0
chr17,7674945,G,A,0.982,0,56,1|1,,SNP,NONSENSE,c.586C>T,p.R196*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516435,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R196*(221) p.R196P(18) p.R196Q(5) p.R196R(6) p.I195fs*12(1) p.R196_R202del(1) p.R196fs*51(4) p.I195_G199delIRVEG(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.R196L(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.R196fs*13(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.986209,0.7393785927987923,,4.0,,,,,,,ACH-000264,7157.0
chr12,25245350,C,T,0.667,20,44,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000164,3845.0
chr17,7673802,C,T,0.966,0,29,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000164,7157.0
chr17,7674220,C,T,0.5,16,16,0|1,7674220.0,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000334,7157.0
chr17,7674221,G,A,0.472,18,16,1|0,7674220.0,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000334,7157.0
chr17,7673704,G,A,0.559,17,21,0/1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-002871,7157.0
chr17,7674241,G,A,0.361,22,12,0/1,,SNP,MISSENSE,c.722C>T,p.S241F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:4,APOBEC:7,Misc:1",0.912713,0.9893558821746748,0.958,3.0,,,,,,,ACH-002871,7157.0
chr4,1804372,A,G,0.438,14,11,0/1,,SNP,MISSENSE,c.1118A>G,p.Y373C,FGFR3,fibroblast growth factor receptor 3,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000481110.6,9.0,+,P22607,False,rs121913485,,as_specific,0.6633416458852868,"""L, E""",Dom,False,"""IGH@, ETV6""",True,p.Y373C(651),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000440486;ENST00000481110;ENST00000340107;,196.0,,15.0,7.3,True,False,True,Misc:9,0.418651,0.2884393883555972,0.8,2.0,,,,,,,ACH-000714,2261.0
chr4,1804372,A,G,0.438,14,11,0/1,,SNP,MISSENSE,c.1118A>G,p.Y373C,FGFR3,fibroblast growth factor receptor 3,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000481110.6,9.0,+,P22607,False,rs121913485,,as_specific,0.6633416458852868,"""L, E""",Dom,False,"""IGH@, ETV6""",True,p.Y373C(651),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000440486;ENST00000481110;ENST00000340107;,2404.0,,0.0,7.3,True,False,True,Misc:9,0.418651,0.2884393883555972,0.8,2.0,,,,,,,ACH-000714,2261.0
chr12,25245350,C,A,0.96,0,23,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000023,3845.0
chr17,7673776,G,A,0.955,0,22,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-000023,7157.0
chr12,25227341,T,G,0.541,38,44,0/1,,SNP,MISSENSE,c.183A>C,p.Q61H,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs17851045,,as_specific,0.3466334164588528,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,True,True,,907.0,,10.5,7.3,True,False,True,"POLE:1,Eso:2,Misc:7",0.798711,,0.644,4.0,,,,,,,ACH-002738,3845.0
chr17,7675235,T,C,0.982,0,57,1|1,,SNP,SPLICE_SITE,c.377A>G,p.Y126C,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y126N(8) p.0(9) p.Y126*(8) p.Y126C(11) p.Y126S(2) p.Y126D(4) p.Y126fs*44(3) p.Y126fs*24(1) p.Y126_K132delYSPALNK(6) p.Y126Y(1) p.?(1) p.Y126_N131delYSPALN(3) p.Y126_S127insQPHH(1) p.Y126fs*?(1) p.Y126fs*11(1) p.V73fs*9(1) p.Y126H(1) p.Y126fs*18(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;ENST00000503591;,,,,7.3,False,True,True,Misc:3,0.955264,0.66576535760223,0.981,3.0,,,,,,,ACH-002738,7157.0
chr4,109816202,G,C,0.572,8,11,0/1,,SNP,MISSENSE,c.38G>C,p.R13P,GAR1,GAR1 ribonucleoprotein,H/ACA ribonucleoprotein complex,ENST00000226796.7,2.0,+,Q9NY12,False,,,,0.5635910224438903,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:2,0.747259,0.4780282849612072,0.321,3.0,,,,,,,ACH-000857,54433.0
chr17,7675218,T,C,0.972,0,36,1|1,,SNP,MISSENSE,c.394A>G,p.K132E,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs747342068,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.N131delN(4) p.K132Q(17) p.K132E(20) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1) p.L130fs*16(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:1,0.958388,0.6452318251866822,0.968,3.0,,,,,,,ACH-000857,7157.0
chr12,25079261,C,T,0.976,0,40,1|1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-000528,Unknown
chr17,7673788,G,A,0.977,0,44,1|1,,SNP,MISSENSE,c.832C>T,p.P278S,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs17849781,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.C275fs*67(1) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:2,APOBEC:1,Misc:2",0.949089,0.8832556364693654,0.963,3.0,,,,,,,ACH-000528,7157.0
chr12,25245350,C,T,0.548,18,23,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000932,3845.0
chr18,51065549,G,A,0.515,16,17,0/1,,SNP,MISSENSE,c.794G>A,p.R265H,SMAD4,SMAD family member 4,SMAD family,ENST00000588745.5,5.0,+,Q13485,False,rs377767347,,as_specific,0.3740648379052369,,,False,,True,p.R361H(38) p.0(28) p.T265I(1),cancer;gene_function_loss;,False,False,True,ENST00000398417;ENST00000342988;ENST00000588745;,,,,7.3,False,True,True,"CpG:5,POLE:1",0.950582,,0.955,3.0,,,,,,,ACH-000932,4089.0
chr3,179199690,G,A,0.621,10,17,0/1,,SNP,SPLICE_SITE,c.353G>A,p.G118D,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,3.0,+,P42336,False,rs587777790,,as_specific,0.3092269326683292,"""E, O""",Dom,False,,True,p.G118D(17),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:10,0.895712,0.1837857299103737,0.484,3.0,,,,,,,ACH-000587,5290.0
chr7,55181378,C,T,0.798,9,35,0|1,55181370.0,SNP,MISSENSE,c.2234C>T,p.T745M,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,19.0,+,P00533,False,rs121434569,,as_specific,0.5760598503740648,"""E, O""",Dom,False,,True,p.T790M(302) p.K745_E749del(8) p.K745_L747del(1) p.K745_E746insIPVAIK(17) p.K745_A750del(21) p.K745T(1) p.K745_A750delKELREA(1) p.I744_K745insKIPVAI(5) p.K745_E746insVPVAIK(4) p.K745R(1) p.K745_E746insTPVAIK(2) p.I744_E749>LKR(1) p.K745_E749delKELRE(6) p.K745_E746>PVAIK(1) p.I744_A750>VK(1),cancer;gene_function_gain;,False,True,True,,34.0,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",386.25,4.13,True,False,False,,0.885883,,0.529,4.0,,,,,,,ACH-000587,1956.0
chr7,55191822,T,G,0.746,17,50,0/1,,SNP,MISSENSE,c.2438T>G,p.L813R,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,20.0,+,P00533,False,rs121434568,,as_specific,0.5486284289276808,"""E, O""",Dom,False,,True,p.L858R(2311) p.L858Q(1) p.Y813C(1) p.L858K(1),cancer;gene_function_gain;,False,True,True,ENST00000455089;ENST00000454757;ENST00000275493;,33.0,"EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.",375.0,7.3,True,False,True,"smoking:5,Misc:5",0.914202,0.7052349118740907,0.961,4.0,PA166157527,,,,,,ACH-000587,1956.0
chr17,7673802,C,T,0.978,0,45,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000587,7157.0
chr12,25245347,C,T,0.656,10,21,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000768,3845.0
chr17,7673781,C,T,0.976,0,40,1|1,,SNP,MISSENSE,c.839G>A,p.R280K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912660,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R280T(73) p.R280fs*65(9) p.R280I(15) p.R280K(54) p.R280S(17) p.R280G(33) p.R280_R283>S(1) p.R280*(14) p.D281fs*24(1) p.S269fs*21(1) p.F270_D281del12(1) p.R280fs*?(1) p.V272_K292del21(1) p.D281_R282delDR(2) p.R280R(3) p.A276fs*64(1) p.R280fs*64(1) p.G279_R280delGR(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:3,APOBEC:9,Misc:1",0.967416,0.760916428914671,0.935,3.0,,,,,,,ACH-000768,7157.0
chr4,152328358,C,A,0.53,18,21,0/1,,SNP,MISSENSE,c.1028G>T,p.G343V,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs1157879635,,as_specific,0.3466334164588528,"""E, L""",Rec,False,,True,p.G423V(7) p.V424fs*13(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,Misc:3,0.921189,,0.603,4.0,,,,,,,ACH-000830,55294.0
chr3,10149862,T,A,0.958,0,22,1|1,,SNP,MISSENSE,c.539T>A,p.I180N,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,3.0,+,P40337,False,,,,0.4588528678304239,"""E, M, O""",Rec,False,,True,p.I180V(2) p.I180fs*36(1) p.I180N(5) p.L178_V181del(1) p.I180fs*14(1) p.I180fs*21(1) p.D179_I180del(1) p.I180fs*22(3) p.I180fs*>34(1),cancer;gene_function_loss;,False,False,True,ENST00000256474;ENST00000345392;,2246.0,,0.0,7.3,False,True,False,,0.628697,0.7497780012218718,0.924,4.0,,,,,,,ACH-000429,7428.0
chr21,10596079,C,T,0.213,74,19,0/1,,SNP,MISSENSE,c.1268C>T,p.S423L,TPTE,transmembrane phosphatase with tensin homology,PTEN protein phosphatases C2 tensin-type domain containing,ENST00000618007.4,20.0,+,P56180,False,rs570468666,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,3.4,False,False,True,"UV:6,POLE:10",0.988995,0.3421619570457261,,2.0,,,,,,,ACH-000793,7179.0
chr1,155378509,G,A,0.189,76,16,0/1,,SNP,MISSENSE,c.6217C>T,p.R2073C,ASH1L,ASH1 like histone lysine methyltransferase,PHD finger proteins SET domain containing Lysine methyltransferases Bromodomain containing,ENST00000392403.8,9.0,-,Q9NR48,False,rs772388982,,as_specific,0.3665835411471321,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:4,POLE:2",0.933782,0.6762997319535147,0.429,3.0,,,,,,,ACH-000586,55870.0
chr17,7673802,C,A,0.974,0,35,1|1,,SNP,MISSENSE,c.818G>T,p.R273L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,918.0,,0.0,7.3,False,True,True,"smoking:15,Misc:9",0.887493,0.7009283873752175,0.921,3.0,,,,,,,ACH-000586,7157.0
chr17,7674220,C,A,0.98,0,49,1|1,,SNP,MISSENSE,c.743G>T,p.R248L,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:4,Misc:3",0.932907,0.9843307954424446,0.96,3.0,,,,,,,ACH-000179,7157.0
chr1,114716126,C,T,0.737,14,41,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-000146,4893.0
chr3,179234296,C,T,0.529,33,37,0/1,,SNP,MISSENSE,c.3139C>T,p.H1047Y,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913281,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"MSI:4,Misc:2",0.841311,0.4540869654537645,0.401,3.0,,,,,,,ACH-000192,5290.0
chr10,21727928,G,T,0.706,4,12,0/1,,SNP,SPLICE_SITE,c.2111G>T,p.R704L,MLLT10,"MLLT10, histone lysine methyltransferase DOT1L cofactor",PHD finger proteins,ENST00000377072.8,17.0,+,P55197,False,,,,0.3541147132169576,L,Dom,False,"""MLL, PICALM, CDK6""",False,,cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,,0.916214,,0.693,3.0,,,,,,,ACH-000192,8028.0
chr10,121520163,G,C,0.834,4,26,0/1,,SNP,MISSENSE,c.71C>G,p.S24W,FGFR2,fibroblast growth factor receptor 2,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000478859.5,6.0,-,P21802,False,rs79184941,,as_specific,0.5486284289276808,E,Dom,False,,True,p.S252W(40) p.S24F(1) p.S252L(1),cancer;gene_function_gain;,False,False,True,ENST00000357555;ENST00000613048;ENST00000358487;ENST00000478859;ENST00000356226;ENST00000369060;ENST00000369059;ENST00000346997;ENST00000351936;ENST00000457416;ENST00000360144;ENST00000369056;ENST00000369058;ENST00000336553;,,,,7.3,True,False,True,Misc:13,0.975776,0.3740753510818667,0.796,4.0,,,,,,,ACH-000192,2263.0
chr17,7674894,G,A,0.96,0,23,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-002730,7157.0
chr1,114713909,G,T,0.423,17,12,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000260,4893.0
chr17,7673777,G,C,0.941,0,17,1|1,,SNP,MISSENSE,c.843C>G,p.D281E,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1057519984,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.D281Y(11) p.D281N(31) p.R282W(10) p.D281E(35) p.D281D(8) p.D281H(27) p.R280_R283>S(1) p.D281V(6) p.D281>AGPY(1) p.D281fs*24(1) p.D281_R282>EW(2) p.D281fs*63(2) p.D281G(11) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*24(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.D281R(1) p.R280fs*62(1) p.D281A(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:3,0.774718,,0.909,2.0,,,,,,,ACH-002485,7157.0
chr3,179204536,G,A,0.55,18,21,0/1,,SNP,MISSENSE,c.1093G>A,p.E365K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,6.0,+,P42336,False,rs1064793732,,as_specific,0.3391521197007481,"""E, O""",Dom,False,,True,p.E365K(9),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"APOBEC:2,Misc:1",0.947437,,0.485,3.0,,,,,,,ACH-000657,5290.0
chr11,14294844,T,A,0.979,0,45,1|1,,SNP,MISSENSE,c.215A>T,p.Q72L,RRAS2,RAS related 2,RAS type GTPase family,ENST00000256196.9,3.0,-,P62070,False,rs113954997,,as_specific,0.3566084788029925,,,False,,False,p.Q72L(1),cancer;gene_function_gain;,False,False,True,ENST00000537760;ENST00000256196;ENST00000531807;,,,,7.3,True,False,True,"smoking:3,Misc:7",0.943535,0.304330000116943,0.918,3.0,,,,,,,ACH-000657,22800.0
chr14,65093796,T,C,0.488,26,25,0/1,,SNP,MISSENSE,c.56A>G,p.H19R,MAX,MYC associated factor X,Basic helix-loop-helix proteins,ENST00000557746.5,2.0,-,P61244,False,,,,0.4962593516209476,,,False,,False,,cancer;gene_function_loss;,False,False,True,ENST00000341653;ENST00000358402;ENST00000618858;ENST00000284165;ENST00000358664;ENST00000556979;ENST00000555667;ENST00000557746;ENST00000556443;ENST00000246163;,,,,7.3,False,True,True,,0.87741,0.7219757037771258,0.944,3.0,,,,,,,ACH-000657,4149.0
chr19,11021837,C,T,0.508,29,30,0/1,,SNP,MISSENSE,c.2729C>T,p.T910M,SMARCA4,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4",Bromodomain containing,ENST00000344626.9,19.0,+,P51532,False,rs1238758086,,as_specific,0.6159600997506235,E,Rec,False,,False,p.T910M(4),cancer;gene_function_loss;,False,False,True,ENST00000344626;ENST00000643549;ENST00000646693;ENST00000642726;ENST00000646484;ENST00000644737;ENST00000642628;ENST00000643296;ENST00000647230;ENST00000646510;ENST00000429416;ENST00000645460;ENST00000541122;ENST00000589677;ENST00000444061;ENST00000590574;ENST00000413806;ENST00000450717;ENST00000643208;ENST00000642350;ENST00000647268;ENST00000646513;,,,,7.3,False,True,True,CpG:5,0.835176,0.70580160552957,0.906,4.0,,,,,,,ACH-000657,6597.0
chrX,71118821,G,T,0.679,8,19,0/1,,SNP,MISSENSE,c.67G>T,p.D23Y,MED12,mediator complex subunit 12,Trinucleotide repeat containing Mediator complex,ENST00000374080.8,1.0,+,Q93074,False,,,,0.6807980049875312,M,Dom,False,,False,p.D23G(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000374102;ENST00000374080;,,,,7.3,True,True,True,Misc:4,,0.2663150667441342,0.773,3.0,,,,,,,ACH-000657,9968.0
chr7,140753336,A,T,0.564,22,26,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001704,673.0
chr9,21968243,C,T,0.964,0,25,1|1,,SNP,SPLICE_SITE,c.e3+1G>A,,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000304494.9,,-,"P42771, Q8N726",False,,,,0.5211970074812967,,,False,,True,p.0(1543) p.?(5),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:2,APOBEC:3",0.96591,,,1.60078017050623,,,,,,,ACH-001704,1029.0
chr3,179218286,C,G,0.42,10,8,0/1,,SNP,MISSENSE,c.1616C>G,p.P539R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913285,,as_specific,0.3017456359102244,"""E, O""",Dom,False,,True,p.P539L(1) p.P539R(27) p.P539S(6) p.P539T(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;,,,,7.3,True,False,True,Misc:4,0.88552,,0.893,3.0,,,,,,,ACH-000879,5290.0
chr17,7673704,G,A,0.404,34,22,0/1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-000879,7157.0
chr17,7674872,T,C,0.613,11,19,0/1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000879,7157.0
chr1,114713909,G,T,0.455,12,9,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-001097,4893.0
chr17,7675085,C,A,0.967,0,29,1|1,,SNP,MISSENSE,c.527G>T,p.C176F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202962,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C176F(140) p.0(9) p.C176S(27) p.C176Y(67) p.C176W(15) p.C176fs*71(7) p.C176R(21) p.C176fs*5(3) p.R174fs*1(2) p.C176*(10) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(7) p.C176G(5) p.H168fs*23(1) p.H178fs*3(1) p.R174_H178>S(1) p.V173fs*69(1) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R174_E180>K(1) p.C176_P177delCP(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.C176delC(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*72(1) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,Misc:11",0.941923,,0.951,3.0,,,,,,,ACH-001060,7157.0
chr1,114713909,G,T,0.275,29,10,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000478,4893.0
chr17,7675189,G,C,0.941,0,17,1|1,,SNP,MISSENSE,c.423C>G,p.C141W,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519977,,as_specific,0.5835411471321695,"""L, E, M, O""",Rec,False,NTRK1,True,p.C141Y(78) p.C141fs*29(2) p.0(9) p.N131fs*27(3) p.L137_W146del10(1) p.K139fs*4(1) p.C141W(12) p.Q136_C141delQLAKTC(1) p.C141G(4) p.C141C(4) p.C141_P142insXX(1) p.C141*(14) p.C141R(17) p.A138_P142delAKTCP(1) p.C141fs*34(1) p.C141fs*30(1) p.C141S(2) p.C141fs*8(2) p.C141F(4) p.A138_V143delAKTCPV(1) p.C141A(1) p.C141fs*5(1) p.A138_C141delAKTC(1) p.P142delP(1) p.K139_C141>N(1) p.P142fs*7(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:1,Misc:1",0.867415,0.4043806300494801,0.808,3.0,,,,,,,ACH-000852,7157.0
chr17,7673802,C,A,0.923,0,12,1|1,,SNP,MISSENSE,c.818G>T,p.R273L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,918.0,,0.0,7.3,False,True,True,"smoking:15,Misc:9",0.887493,0.7009283873752175,0.921,3.0,,,,,,,ACH-000276,7157.0
chr17,7675224,G,C,0.95,0,18,1|1,,SNP,MISSENSE,c.388C>G,p.L130V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs863224683,,as_specific,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.L130V(15) p.A129_K132delALNK(1) p.L130P(5) p.L130R(6) p.L130L(4) p.L130fs*19(3) p.L130H(7) p.L130F(6) p.L130Sfs*?(1) p.L130fs*41(1) p.L130_M133delLNKM(1) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.L130fs*40(2) p.S127fs*36(1) p.?(1) p.A129_N131delALN(1) p.L130delL(1) p.P128fs*17(1) p.Y126_N131delYSPALN(3) p.A129_L130insXX(1) p.Y126fs*11(1) p.L130fs*39(1) p.N131fs*27(1) p.V73fs*9(1) p.L130fs*16(1) p.Y126fs*18(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:4,0.87451,0.3245416644848618,0.887,3.0,,,,,,,ACH-000617,7157.0
chr3,179199088,G,A,0.516,16,20,0/1,,SNP,MISSENSE,c.263G>A,p.R88Q,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs121913287,,as_specific,0.3391521197007481,"""E, O""",Dom,False,,True,p.R88Q(147) p.R88L(1) p.R88?(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,929.0,,0.0,7.3,True,False,True,"CpG:11,MSI:1,POLE:17",0.947755,0.4551598659740948,0.806,3.0,,,,,,,ACH-000928,5290.0
chr4,152326137,G,A,0.424,19,14,0/1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-000928,55294.0
chr10,87957915,C,T,0.387,30,17,0/1,,SNP,NONSENSE,c.697C>T,p.R233*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,7.0,+,P60484,False,rs121909219,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R233*(101) p.0(28) p.G165_K342del(1) p.T232_R233insTQGGAGS(2) p.R233fs*10(14) p.R55fs*1(1) p.R233fs*3(1) p.R234fs*9(1) p.R233fs*24(1) p.R233fs*?(2) p.T232_R233insK*(1) p.N228fs*10(1) p.R233fs*25(2) p.R233fs*13(1) p.R233fs*19(1) p.R233fs*26(1) p.R233fs*20(1) p.R233R(1) p.R233fs*12(1) p.P231fs*2(1) p.K221fs*6(1) p.R233fs*23(1) p.T232_R233insPQGGAGT(1) p.G165_*404del(1) p.R233Q(1),cancer;gene_function_loss;,False,True,True,,110.0,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.",19.0,7.3,False,True,False,,0.971128,0.6883155413500054,,3.0,,,,,,,ACH-000928,5728.0
chr19,52212729,C,T,0.61,11,17,0/1,,SNP,MISSENSE,c.10C>T,p.R4W,PPP2R1A,protein phosphatase 2 scaffold subunit Aalpha,STRIPAK complex Protein phosphatase 2 scaffold subunits,ENST00000462990.5,5.0,+,P30153,False,rs1057519946,,as_specific,0.5885286783042394,E,Dom?,False,,True,p.R183W(26) p.R183G(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,MSI:1,POLE_MSI:1",0.872264,0.6395465794564451,0.294,4.0,,,,,,,ACH-000928,5518.0
chr7,140753336,A,T,0.905,4,38,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000614,673.0
chr7,140753336,A,T,0.586,26,40,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000008,673.0
chr12,25245351,C,A,0.952,0,20,1|1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000311,3845.0
chr17,7675085,C,A,0.2,44,10,0/1,,SNP,MISSENSE,c.527G>T,p.C176F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202962,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C176F(140) p.0(9) p.C176S(27) p.C176Y(67) p.C176W(15) p.C176fs*71(7) p.C176R(21) p.C176fs*5(3) p.R174fs*1(2) p.C176*(10) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(7) p.C176G(5) p.H168fs*23(1) p.H178fs*3(1) p.R174_H178>S(1) p.V173fs*69(1) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R174_E180>K(1) p.C176_P177delCP(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.C176delC(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*72(1) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,Misc:11",0.941923,,0.951,3.0,,,,,,,ACH-000311,7157.0
chr3,179234297,A,G,0.428,21,18,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000554,5290.0
chr17,7670685,G,A,0.952,0,20,1|1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-000554,7157.0
chr1,26766318,C,T,0.972,0,36,1|1,,SNP,NONSENSE,c.2830C>T,p.Q944*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,9.0,+,O14497,False,,,,0.4588528678304239,E,Rec,True,1507,False,p.Q944*(2),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,APOBEC:4,0.983171,0.8947234672431982,,5.0,,,,,,,ACH-000147,8289.0
chr3,179234297,A,G,0.782,18,66,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000147,5290.0
chr17,7674238,C,A,0.981,0,50,1|1,,SNP,MISSENSE,c.725G>T,p.C242F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912655,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C242fs*20(2) p.C242F(85) p.C242Y(54) p.C242S(35) p.C242*(5) p.H233_C242del10(1) p.N239_C242delNSSC(3) p.C242fs*5(21) p.C242W(6) p.C242G(4) p.C242R(13) p.N239fs*4(1) p.C242C(4) p.C242fs*98(1) p.C242fs*?(3) p.S241_G245delSCMGG(1) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.C242fs*23(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1062.0,,0.0,7.3,False,True,True,"smoking:9,Misc:1",0.969422,0.995194520180769,0.977,3.0,,,,,,,ACH-000211,7157.0
chr17,7674886,A,C,0.969,0,31,1|1,,SNP,MISSENSE,c.645T>G,p.S215R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs1057520001,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.S215N(10) p.0(9) p.S215R(22) p.R213_S215>X(1) p.T211fs*28(1) p.S215G(12) p.S215_V218>M(1) p.S215I(22) p.H214fs*5(2) p.S215fs*29(1) p.S215T(5) p.S215fs*31(1) p.V216fs*33(1) p.S215C(5) p.S215fs*32(4) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.D208_V216delDRNTFRHSV(1) p.S215S(2) p.S215fs*?(2) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.V216fs*6(1) p.H214_S215insX(1) p.?(1) p.K164_P219del(1) p.S215del(1) p.V216fs*32(1) p.F212_S215del(1) p.S215fs*6(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:1,Misc:2",0.885902,0.4736268999129067,0.812,2.0,,,,,,,ACH-002523,7157.0
chr9,21971109,C,A,0.974,0,36,1|1,,SNP,MISSENSE,c.97G>T,p.D33Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552822,,as_specific,0.6957605985037406,,,False,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V82_E88del(1) p.D84H(2) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.D84Y(9) p.P81_A85del(1) p.D84N(4) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.D84fs*63(2) p.E61_L94del(1) p.R80fs*34(1) p.D84_F90del(1) p.E33D(1) p.A68fs*3(1) p.D84fs*1(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;ENST00000579755;ENST00000530628;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.933446,0.9973373924118374,0.803,4.0,,,,,,,ACH-000979,1029.0
chr17,7673800,C,A,0.724,15,42,0/1,,SNP,MISSENSE,c.820G>T,p.V274F,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1057520005,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V274A(21) p.V274F(26) p.V274D(9) p.V274G(5) p.V274L(11) p.V274_P278delVCACP(1) p.R273fs*71(1) p.S269fs*21(1) p.V274fs*71(1) p.F270_D281del12(1) p.V274I(5) p.V272_K292del21(1) p.R273_C275delRVC(1) p.R267fs*65(1) p.L265_K305del41(1) p.V274V(3) p.V274fs*32(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:3",0.759652,0.6981666958941316,0.773,2.0,,,,,,,ACH-000979,7157.0
chr17,7670685,G,A,0.96,0,25,1|1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-000409,7157.0
chr2,48709012,C,T,0.642,11,20,0/1,,SNP,MISSENSE,c.616G>A,p.E206K,LHCGR,luteinizing hormone/choriogonadotropin receptor,Glycoprotein hormone receptors,ENST00000294954.12,8.0,-,P22888,False,rs776172758,,as_specific,0.4763092269326683,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.845786,0.5344319733109912,0.369,3.0,,,,,,,ACH-001239,3973.0
chr7,140753335,CA,AT,0.614,21,35,0/1,,DNP,MISSENSE,c.1799_1800TG>AT,p.V600D,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs121913377,,as_specific,0.3358208955223881,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,,11.0,"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.",47.0,7.3,True,False,False,,,,,,,,,,,,ACH-001239,673.0
chr15,54014540,T,G,0.559,17,24,0/1,,SNP,MISSENSE,c.1637T>G,p.L546R,UNC13C,unc-13 homolog C,UNC13 homologs,ENST00000260323.15,1.0,+,Q8NB66,False,rs768743988,,as_specific,0.4114713216957606,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.578572,0.4991649834086551,0.54,2.0,,,,,,,ACH-002954,440279.0
chr12,25245350,C,T,0.994,0,163,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002070,3845.0
chr3,10146631,T,C,0.973,3,154,1|1,,SNP,MISSENSE,c.458T>C,p.L153P,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,2.0,+,P40337,False,,,,0.42643391521197,"""E, M, O""",Rec,False,,True,p.L153P(7) p.?fs(1) p.L153fs*20(2) p.L153fs*6(3) p.T152fs*5(1) p.G144fs*19(1) p.L153fs*21(2) p.L153fs*4(2) p.L153Q(1) p.?(2) p.L153R(1) p.P154fs*2(1),cancer;gene_function_loss;,False,False,True,ENST00000256474;,1923.0,,7.5,7.3,False,True,False,,0.854456,0.342845851150866,0.956,4.0,,,,,,,ACH-000317,7428.0
chr12,25245350,C,T,0.781,93,343,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001494,3845.0
chr17,7673802,C,T,0.997,1,406,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001494,7157.0
chr12,25245351,C,A,0.889,4,44,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000522,3845.0
chr17,7676031,A,C,0.933,6,90,1|1,7676031.0,SNP,MISSENSE,c.338T>G,p.F113C,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.F113S(5) p.G59fs*23(3) p.F113C(8) p.F113fs*37(1) p.F113delF(3) p.F113L(9) p.F113_G117delFLHSG(1) p.M1_T125del(1) p.G105_T125del21(1) p.F113V(3) p.Y107fs*44(1) p.S33fs*23(1) p.V73fs*9(1) p.G112fs*9(1) p.P13fs*18(1) p.G112fs*7(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000508793;ENST00000604348;ENST00000503591;,,,,7.3,False,True,True,Misc:2,0.916379,0.3595884184044838,0.952,3.0,,,,,,,ACH-000522,7157.0
chr1,114713907,T,G,0.515,80,82,0/1,,SNP,MISSENSE,c.183A>C,p.Q61H,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913255,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.E62fs*6(3) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,893.0,,0.0,7.3,True,False,True,"Eso:1,Misc:1",0.749252,0.6040398297406732,0.742,4.0,,,,,,,ACH-000183,4893.0
chr3,179218303,G,A,0.5,74,72,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000183,5290.0
chr6,114057325,G,A,0.543,31,38,0/1,,SNP,MISSENSE,c.973C>T,p.R325C,HS3ST5,heparan sulfate-glucosamine 3-sulfotransferase 5,"Sulfotransferases, membrane bound",ENST00000312719.9,5.0,-,Q8IZT8,False,rs374141405,,as_specific,0.4114713216957606,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:2,Misc:1",0.767604,,0.569,3.0,,,,,,,ACH-000273,222537.0
chr17,7674232,C,T,0.994,0,171,1|1,,SNP,MISSENSE,c.731G>A,p.G244D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs985033810,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"MSI:1,Misc:1",0.965383,0.9978215722974868,0.953,3.0,,,,,,,ACH-001632,7157.0
chr17,7675088,C,T,0.997,0,407,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-001698,7157.0
chr12,25245347,C,T,0.997,1,377,1|1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000378,3845.0
chr12,25245347,C,T,0.447,116,91,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000872,3845.0
chr3,111593733,C,T,0.169,56,10,0/1,,SNP,MISSENSE,c.469G>A,p.E157K,ZBED2,zinc finger BED-type containing 2,Zinc fingers BED-type,ENST00000317012.5,2.0,-,Q9BTP6,False,rs372487455,,as_specific,0.5935162094763092,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,UV:8,0.417165,0.2763064726899049,0.059,2.0,,,,,,,ACH-001002,79413.0
chr7,140753336,A,T,0.63,56,92,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001002,673.0
chr17,7674872,T,C,0.972,0,34,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-001002,7157.0
chr7,15612396,C,T,0.877,11,84,0/1,,SNP,SILENT,c.906G>A,p.A302A,MEOX2,mesenchyme homeobox 2,HOXL subclass homeoboxes,ENST00000262041.6,3.0,-,P50222,False,rs777058351,,as_specific,0.4513715710723192,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:1,0.151979,0.443010527327373,,0.0,,,,,,,ACH-001735,4223.0
chr9,21971112,G,A,0.492,298,293,0/1,,SNP,MISSENSE,c.94C>T,p.H32Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913385,,as_specific,0.6982543640897756,,,False,,True,p.0(1543) p.P81fs*35(1) p.V82_E88del(1) p.H83Y(39) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.H83N(2) p.P81_A85del(1) p.R80fs*63(1) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1) p.V82fs*62(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;,,,,7.3,False,True,True,Misc:4,0.884844,0.9724149636314106,0.804,4.0,,,,,,,ACH-001735,1029.0
chr17,7674220,C,T,0.492,232,212,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001735,7157.0
chr17,7675994,C,T,0.43,166,125,0/1,,SNP,SPLICE_SITE,c.375G>A,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:5,0.392984,0.6099495421221454,,0.0,,,,,,,ACH-001735,7157.0
chr17,7674230,C,T,0.977,0,44,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-002230,7157.0
chr17,7674872,T,C,0.982,0,54,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000480,7157.0
chr17,7674238,C,A,0.997,0,395,1|1,,SNP,MISSENSE,c.725G>T,p.C242F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912655,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C242fs*20(2) p.C242F(85) p.C242Y(54) p.C242S(35) p.C242*(5) p.H233_C242del10(1) p.N239_C242delNSSC(3) p.C242fs*5(21) p.C242W(6) p.C242G(4) p.C242R(13) p.N239fs*4(1) p.C242C(4) p.C242fs*98(1) p.C242fs*?(3) p.S241_G245delSCMGG(1) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.C242fs*23(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1062.0,,0.0,7.3,False,True,True,"smoking:9,Misc:1",0.969422,0.995194520180769,0.977,3.0,,,,,,,ACH-001655,7157.0
chr7,98912179,C,T,0.53,108,125,0/1,,SNP,MISSENSE,c.2162C>T,p.S721F,TRRAP,transformation/transcription domain associated protein,SAGA complex,ENST00000446306.7,17.0,+,Q9Y4A5,False,rs147405090,,as_specific,0.4688279301745636,,,False,,False,p.S722F(3),cancer;,False,False,True,,,,,7.3,False,False,True,"UV:8,POLE_MSI:1",0.926675,,0.603,4.0,,,,,,,ACH-002004,8295.0
chr7,140753336,A,T,0.997,0,377,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002004,673.0
chr17,7674220,C,T,0.986,0,76,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000374,7157.0
chr12,25225628,C,T,0.328,135,66,0/1,,SNP,MISSENSE,c.436G>A,p.A146T,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,906.0,,21.0,7.3,True,False,True,"MSI:3,Misc:4",0.951882,0.7493523432445548,0.909,4.0,,,,,,,ACH-000838,3845.0
chr7,140753336,A,T,0.752,45,137,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000477,673.0
chr3,179218294,G,A,0.33,91,42,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-001654,5290.0
chr12,25245350,C,G,0.51,216,224,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-001654,3845.0
chr17,7676071,G,A,0.987,1,146,1|1,,SNP,NONSENSE,c.298C>T,p.Q100*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5685785536159601,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q100*(21) p.G59fs*23(3) p.S95_G108del(1) p.W91fs*13(1) p.Q100Rfs*?(4) p.M1_T125del(1) p.Q100fs*?(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:2,0.971696,0.7830969093579188,,4.0,,,,,,,ACH-001654,7157.0
chr7,140753336,A,T,0.75,21,64,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000052,673.0
chr2,208248388,C,A,0.594,81,117,0/1,,SNP,MISSENSE,c.395G>T,p.R132L,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",,ENST00000415913.5,4.0,-,O75874,False,rs121913500,,as_specific,0.3815461346633416,O,Dom,False,,True,p.R132C(1014) p.R132H(6941) p.R132S(229) p.R132?(201) p.R132G(285) p.R132L(126) p.R132P(1) p.R132V(1) p.G131_R132>VL(1),cancer;gene_function_gain;,False,True,True,ENST00000345146;ENST00000446179;ENST00000415913;ENST00000415282;,880.0,,10.0,7.3,True,False,True,"smoking:1,Misc:2",0.940233,0.5706276054536243,0.835,2.0,,,,,,,ACH-001380,3417.0
chr3,179234297,A,G,0.737,21,60,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000142,5290.0
chr17,7673776,G,A,0.964,0,26,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-000142,7157.0
chr17,7674894,G,A,0.302,364,162,0/1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000237,7157.0
chr4,152326214,C,T,0.981,0,60,1|1,,SNP,MISSENSE,c.1196G>A,p.R399Q,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs866987936,,as_specific,0.3665835411471321,"""E, L""",Rec,False,,True,p.R479Q(43) p.R479L(7) p.R479fs*6(3) p.R479P(3) p.D480fs*5(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:1,POLE:1",0.971548,,0.479,4.0,,,,,,,ACH-000412,55294.0
chr12,25245350,C,T,0.952,0,24,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000412,3845.0
chr17,7675088,C,T,0.899,3,31,0/1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000412,7157.0
chr17,7675088,C,T,0.973,0,34,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002195,7157.0
chr2,218584683,C,T,0.427,246,179,0/1,,SNP,MISSENSE,c.392C>T,p.P131L,CNOT9,CCR4-NOT transcription complex subunit 9,CCR4-NOT transcription complex,ENST00000295701.9,4.0,+,Q92600,False,rs267599211,,as_specific,0.399002493765586,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:12,0.918335,,0.599,3.0,,,,,,,ACH-002510,9125.0
chr7,140753336,A,T,0.595,223,320,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002510,673.0
chr1,114713909,G,T,0.483,100,94,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000124,4893.0
chr17,7676059,G,A,0.993,0,148,1|1,,SNP,NONSENSE,c.310C>T,p.Q104*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5561097256857855,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.G59fs*23(3) p.S95_G108del(1) p.W91fs*13(1) p.Q104fs*19(2) p.Y103_G112>C(1) p.Q104*(15) p.Y103_Q104>*(1) p.Y103fs*15(1) p.M1_T125del(1) p.Q104L(1) p.Q104H(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:1,0.976972,0.3103062833861155,,4.0,,,,,,,ACH-002122,7157.0
chr1,114713908,T,C,0.42,18,13,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-002041,4893.0
chr17,7674232,C,T,0.995,0,197,1|1,,SNP,MISSENSE,c.731G>A,p.G244D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs985033810,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"MSI:1,Misc:1",0.965383,0.9978215722974868,0.953,3.0,,,,,,,ACH-002041,7157.0
chr9,21971109,C,T,0.921,1,25,1|1,,SNP,MISSENSE,c.97G>A,p.D33N,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552822,,as_specific,0.6957605985037406,,,False,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V82_E88del(1) p.D84H(2) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.D84Y(9) p.P81_A85del(1) p.D84N(4) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.D84fs*63(2) p.E61_L94del(1) p.R80fs*34(1) p.D84_F90del(1) p.E33D(1) p.A68fs*3(1) p.D84fs*1(1),cancer;gene_function_loss;,False,False,True,ENST00000579755;ENST00000530628;,,,,7.3,False,True,True,,0.952808,0.9930000372192356,0.731,4.0,,,,,,,ACH-000746,1029.0
chr17,7674950,A,C,0.983,0,64,1|1,,SNP,MISSENSE,c.581T>G,p.L194R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs1057519998,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.L194P(11) p.H193_I195delHLI(1) p.L194R(49) p.L194L(5) p.L194F(21) p.L194H(6) p.L194delL(2) p.I195fs*52(1) p.P191fs*53(2) p.L194fs*52(1) p.A189_V197delAPPQHLIRV(4) p.L194I(1) p.L194fs*15(2) p.L194V(2) p.A189fs*53(1) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.L194fs*14(1) p.H193_I195>AP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:9,0.901087,,0.933,3.0,,,,,,,ACH-000746,7157.0
chr2,61492337,C,T,0.41,35,27,0/1,,SNP,MISSENSE,c.1711G>A,p.E571K,XPO1,exportin 1,Exportins,ENST00000401558.7,15.0,-,O14980,False,rs1057520009,,as_specific,0.3067331670822942,L,Dom,False,,True,p.E571K(41) p.E571V(3) p.E571G(5) p.E571I(1) p.E571A(3) p.E571Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"CpG:1,POLE:4",0.979039,0.5942594365771144,0.579,4.0,,,,,,,ACH-000874,7514.0
chr17,7675088,C,T,0.603,12,20,0/1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-001490,7157.0
chr17,7675101,C,A,0.432,20,15,0/1,,SNP,NONSENSE,c.511G>T,p.E171*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.571072319201995,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.S149fs*72(1) p.E171K(11) p.Q167fs*2(6) p.E171A(1) p.E171fs*9(1) p.E171*(14) p.H168fs*23(1) p.E171Q(4) p.T170fs*2(1) p.H168_E171del(1) p.E171fs*3(3) p.E171V(2) p.T170fs*8(1) p.E171D(2) p.E171fs*1(1) p.E171fs*10(3) p.H168fs*3(1) p.P151_V173del23(1) p.E171fs*61(1) p.E171G(4) p.K164_P219del(1) p.H168fs*69(1) p.E171_V172delEV(1) p.V157_C176del20(1) p.T170_E171insXX(1) p.V172_E180delVVRRCPHHE(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,APOBEC:1,Misc:2",0.993507,0.446196160933848,,4.0,,,,,,,ACH-001490,7157.0
chr3,10142176,A,C,0.875,0,6,0/1,,SNP,MISSENSE,c.329A>C,p.H110P,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,,,,0.6533665835411472,"""E, M, O""",Rec,False,,True,p.S111fs*22(1) p.H110>RIN(1) p.H110Q(1) p.H110fs*49(4) p.H110_S111del(1) p.I109_R113del(1) p.?(2) p.R107fs*45(1) p.H110Y(3) p.H110fs*22(2) p.G106fs*49(1) p.H110N(1),cancer;gene_function_loss;,False,False,True,ENST00000256474;ENST00000345392;,2463.0,,0.0,7.3,False,True,False,,0.835688,,0.701,4.0,,,,,,,ACH-002139,7428.0
chr4,152326137,G,A,0.487,178,169,0/1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-001495,55294.0
chr17,7675216,C,A,0.994,0,189,1|1,,SNP,MISSENSE,c.396G>T,p.K132N,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs866775781,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.K132Q(17) p.K132E(20) p.M133fs*37(1) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1) p.M133fs*16(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:2,0.935195,0.5705763221732115,0.895,3.0,,,,,,,ACH-001495,7157.0
chr3,179198937,C,T,0.76,32,105,0/1,,SNP,MISSENSE,c.112C>T,p.R38C,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs749415085,,as_specific,0.3690773067331671,"""E, O""",Dom,False,,True,p.R38C(12) p.R38H(23) p.R38S(2) p.R38G(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,,,,7.3,True,False,True,"CpG:1,MSI:1,POLE:2",0.635522,0.8092041904693834,0.737,3.0,,,,,,,ACH-001610,5290.0
chr7,15612396,C,T,0.363,82,47,0/1,,SNP,SILENT,c.906G>A,p.A302A,MEOX2,mesenchyme homeobox 2,HOXL subclass homeoboxes,ENST00000262041.6,3.0,-,P50222,False,rs777058351,,as_specific,0.4513715710723192,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:1,0.151979,0.443010527327373,,0.0,,,,,,,ACH-001610,4223.0
chr7,47803294,G,A,0.181,197,38,0/1,,SNP,SILENT,c.7878C>T,p.C2626C,PKD1L1,"polycystin 1 like 1, transient receptor potential channel interacting",,ENST00000289672.6,53.0,-,Q8TDX9,False,rs371109435,,as_specific,0.456359102244389,,,False,PKD1L1,False,,cancer;structural_relation;,False,False,True,,,,,3.57,False,False,True,,0.145496,0.868349617110768,,0.0,,,,,,,ACH-001610,168507.0
chr7,95299095,C,T,0.362,236,127,0/1,,SNP,MISSENSE,c.917G>A,p.R306Q,PON1,paraoxonase 1,Paraoxonases,ENST00000222381.8,9.0,-,P27169,False,rs749649413,,as_specific,0.3890274314214463,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:10,0.68897,0.7807916363368471,0.135,2.0,,,,,,,ACH-001610,5444.0
chr8,119418083,C,T,0.367,54,31,0/1,,SNP,SILENT,c.336C>T,p.F112F,CCN3,,,ENST00000259526.4,3.0,+,,False,rs201508830,,as_specific,0.4887780548628428,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.68008,,,0.0,,,,,,,ACH-001610,4856.0
chr10,87957915,C,T,0.997,0,305,1|1,,SNP,NONSENSE,c.697C>T,p.R233*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,7.0,+,P60484,False,rs121909219,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R233*(101) p.0(28) p.G165_K342del(1) p.T232_R233insTQGGAGS(2) p.R233fs*10(14) p.R55fs*1(1) p.R233fs*3(1) p.R234fs*9(1) p.R233fs*24(1) p.R233fs*?(2) p.T232_R233insK*(1) p.N228fs*10(1) p.R233fs*25(2) p.R233fs*13(1) p.R233fs*19(1) p.R233fs*26(1) p.R233fs*20(1) p.R233R(1) p.R233fs*12(1) p.P231fs*2(1) p.K221fs*6(1) p.R233fs*23(1) p.T232_R233insPQGGAGT(1) p.G165_*404del(1) p.R233Q(1),cancer;gene_function_loss;,False,True,True,,110.0,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.",19.0,7.3,False,True,False,,0.971128,0.6883155413500054,,3.0,,,,,,,ACH-001610,5728.0
chr17,7673803,G,A,0.598,321,478,0/1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001610,7157.0
chr17,7675088,C,T,0.38,295,183,0/1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-001610,7157.0
chr7,140753336,A,T,0.983,1,124,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002121,673.0
chr2,29220829,G,T,0.513,19,22,0/1,,SNP,MISSENSE,c.3522C>A,p.F1174L,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,23.0,-,Q9UM73,False,rs863225281,,as_specific,0.5361596009975063,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.F1174L(136) p.F1174S(3) p.F1174V(8) p.F1174?(5) p.F1174C(12) p.F1174I(6),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000642122;ENST00000389048;ENST00000618119;,8.0,"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.",33.5,7.3,True,False,False,,0.936591,0.5618789444624813,0.752,4.0,,,,,,,ACH-000345,238.0
chr1,114716124,C,G,0.504,59,60,0/1,,SNP,MISSENSE,c.37G>C,p.G13R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121434595,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G13D(361) p.G13V(89) p.G13R(150) p.G13G(4) p.G13A(16) p.G13C(39) p.G13Y(1) p.G13S(16) p.G13N(3),cancer;gene_function_gain;,False,False,True,ENST00000369535;,896.0,,2.5,7.3,True,False,True,"smoking:1,Misc:5",0.837442,0.2725070107592524,0.763,4.0,,,,,,,ACH-000498,4893.0
chr17,7674221,G,A,0.944,0,17,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000498,7157.0
chr3,179234297,A,G,0.484,66,61,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-002117,5290.0
chr17,7675122,T,C,0.981,0,51,1|1,,SNP,MISSENSE,c.490A>G,p.K164E,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs879254249,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.K164fs*3(2) p.S149fs*72(1) p.K164*(11) p.K164E(16) p.Y163fs*1(1) p.K164K(2) p.K164T(2) p.A159_Q167delAMAIYKQSQ(1) p.K164N(5) p.K164M(4) p.Y163fs*14(1) p.K164Q(2) p.A159_M169del(1) p.Y163_Q165delYKQ(1) p.K164fs*17(1) p.P151_V173del23(1) p.K164_Q165insXXX(1) p.K164R(1) p.K164fs*6(2) p.K164_P219del(1) p.V157_C176del20(1) p.K164fs*5(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.940445,,0.875,3.0,,,,,,,ACH-002117,7157.0
chr1,114713909,G,T,0.527,91,98,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-002040,4893.0
chr7,140781602,C,A,0.217,153,43,0/1,,SNP,MISSENSE,c.1406G>T,p.G469V,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,11.0,-,P15056,False,rs121913355,,as_specific,0.3541147132169576,E,Dom,False,"""AKAP9, KIAA1549""",True,p.G469A(70) p.G469R(28) p.G469V(34) p.G469E(20) p.G469S(7) p.G469del(2) p.G469?(1) p.G469L(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,841.0,,0.0,7.3,True,False,False,,0.904589,0.5516173069766263,0.958,4.0,,,,,,,ACH-002040,673.0
chr17,7675088,C,T,0.976,2,87,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000255,7157.0
chr1,114713909,G,T,0.537,38,43,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000025,4893.0
chr17,7675136,G,A,0.948,0,16,1|1,,SNP,MISSENSE,c.476C>T,p.A159V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.A159V(42) p.R158fs*8(1) p.A159D(10) p.S149fs*72(1) p.R158_A159insX(4) p.A159fs*11(6) p.A159_Q167delAMAIYKQSQ(1) p.R158_A159delRA(2) p.A159P(25) p.V157fs*19(2) p.A159S(5) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A159A(8) p.R156fs*18(1) p.A159T(9) p.V157_I162delVRAMAI(1) p.A159fs*21(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A159fs*19(1) p.R158_A159insXX(1) p.V157_C176del20(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"UV:1,Misc:3",0.890391,,0.774,3.0,,,,,,,ACH-001125,7157.0
chr17,7674252,C,T,0.997,0,399,1|1,,SNP,MISSENSE,c.711G>A,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:9",0.902715,0.9958849948114716,0.923,3.0,,,,,,,ACH-001608,7157.0
chr17,7673776,G,A,0.97,0,31,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-002284,7157.0
chr2,39054637,T,A,0.985,0,67,1|1,,SNP,MISSENSE,c.697A>T,p.N233Y,SOS1,SOS Ras/Rac guanine nucleotide exchange factor 1,Rho guanine nucleotide exchange factors Pleckstrin homology domain containing,ENST00000395038.6,5.0,-,Q07889,False,rs1057519963,,as_specific,0.2967581047381546,,,False,,False,p.N233Y(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"smoking:3,Misc:5",0.884903,,0.58,4.0,,,,,,,ACH-000787,6654.0
chr3,41224633,A,G,0.327,39,18,0/1,,SNP,MISSENSE,c.121A>G,p.T41A,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913412,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.T41A(1344) p.A5_A80del(75) p.T41S(7) p.T41I(155) p.A5_Q143del(7) p.T41P(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.T41T(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.T41N(8) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.T40_L46del(1) p.G38_S45del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.A20_R151del(1) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.I35_T41del(1) p.I35_K170del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A39_T42del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.T41_N51del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A39fs*3(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1285.0,,55.0,7.3,True,False,True,Misc:17,0.860853,,0.403,4.0,,,,,,,ACH-000787,1499.0
chr12,121016393,C,G,0.381,60,37,0/1,,SNP,MISSENSE,c.82G>C,p.E28Q,C12orf43,chromosome 12 open reading frame 43,,ENST00000288757.7,1.0,-,Q96C57,False,,,,0.6109725685785536,,,False,,False,p.E28D(1),cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:3,0.568243,,0.193,3.0,,,,,,,ACH-000787,64897.0
chr17,7674221,G,A,0.918,1,22,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000787,7157.0
chr5,112839942,C,T,0.964,1,55,1|1,,SNP,NONSENSE,c.4348C>T,p.R1450*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913332,,as_specific,0.456359102244389,"""E, M, O""",Rec,True,,True,p.R1450*(222) p.R1450fs*5(1) p.P1424fs*19(1) p.R1450fs*20(1) p.R1450fs*22(1) p.R1435fs*23(1) p.?(1) p.K1192fs*3(1) p.S1436fs*22(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:15,POLE:2",0.916986,0.7909056506666835,,5.0,,,,,,,ACH-000236,324.0
chr7,140753336,A,T,0.421,86,61,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000236,673.0
chr8,103885868,T,C,0.224,97,28,0/1,,SNP,SILENT,c.603T>C,p.S201S,RIMS2,regulating synaptic membrane exocytosis 2,Regulating synaptic membrane exocytosis family PDZ domain containing,ENST00000436393.6,2.0,+,Q9UQ26,False,rs778061023,,as_specific,0.456359102244389,,,False,,False,p.S231S(1),cancer;,False,False,True,,,,,7.3,False,False,True,"Eso:2,Misc:2",0.107839,0.8026226825447922,,0.0,,,,,,,ACH-002141,9699.0
chr17,7674230,C,T,0.971,0,37,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-002141,7157.0
chr18,56614459,G,A,0.375,26,14,0/1,,SNP,MISSENSE,c.700C>T,p.R234C,TXNL1,thioredoxin like 1,,ENST00000217515.11,6.0,-,O43396,False,rs1431809567,,as_specific,0.3067331670822942,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.951588,,0.457,3.0,,,,,,,ACH-002141,9352.0
chr17,7674220,C,T,0.953,1,42,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000245,7157.0
chr6,138773767,C,T,0.472,64,57,0/1,,SNP,SILENT,c.93C>T,p.F31F,CCDC28A,coiled-coil domain containing 28A,,ENST00000332797.10,1.0,+,Q8IWP9,False,,,,0.6059850374064838,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:4,0.356658,,,0.0,,,,,,,ACH-001523,25901.0
chr17,7675095,C,A,0.656,93,180,0/1,,SNP,MISSENSE,c.517G>T,p.V173L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs876660754,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V173V(8) p.V173L(71) p.S149fs*72(1) p.V173fs*7(2) p.V173G(8) p.V173M(56) p.V173fs*59(2) p.V173E(4) p.V173W(1) p.V173fs*1(4) p.H168fs*23(1) p.V173fs*69(1) p.V173A(13) p.E171fs*1(1) p.P151_V173del23(1) p.E171fs*61(1) p.V173fs*8(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.V173*(1) p.V172_R174delVVR(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,Misc:5",0.942797,0.3054701539093767,0.88,3.0,,,,,,,ACH-001523,7157.0
chr17,7675208,C,A,0.211,168,44,0/1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-001523,7157.0
chr3,179210192,T,C,0.603,49,75,0/1,,SNP,MISSENSE,c.1258T>C,p.C420R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,8.0,+,P42336,False,rs121913272,,as_specific,0.2967581047381546,"""E, O""",Dom,False,,True,p.C420R(82) p.H419_C420delHC(1) p.C420fs*?(1) p.C420_L422>*(1) p.C420C(1),cancer;gene_function_gain;,False,True,True,ENST00000263967;ENST00000643187;,931.0,,12.5,7.3,True,False,True,"MSI:1,Misc:13",0.916819,0.6918433106210673,0.788,3.0,,,,,,,ACH-000711,5290.0
chr17,7674221,G,A,0.853,5,30,0/1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000711,7157.0
chr9,21971112,G,A,0.458,14,12,0/1,,SNP,MISSENSE,c.94C>T,p.H32Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913385,,as_specific,0.6982543640897756,,,False,,True,p.0(1543) p.P81fs*35(1) p.V82_E88del(1) p.H83Y(39) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.H83N(2) p.P81_A85del(1) p.R80fs*63(1) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1) p.V82fs*62(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;,,,,7.3,False,True,True,Misc:4,0.884844,0.9724149636314106,0.804,4.0,,,,,,,ACH-000782,1029.0
chr17,7674220,C,T,0.572,42,58,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000782,7157.0
chr17,7675994,C,T,0.421,60,43,0/1,,SNP,SPLICE_SITE,c.375G>A,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:5,0.392984,0.6099495421221454,,0.0,,,,,,,ACH-000782,7157.0
chr9,21971121,G,A,0.388,483,302,0/1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-001740,1029.0
chr17,42322464,T,A,0.656,48,96,0/1,,SNP,MISSENSE,c.1919A>T,p.Y640F,STAT3,signal transducer and activator of transcription 3,SH2 domain containing,ENST00000264657.9,21.0,-,P40763,False,rs769031989,,as_specific,0.4812967581047381,,,False,,True,p.Y640F(99),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:3,0.859332,,0.644,3.0,,,,,,,ACH-002317,6774.0
chr2,177234071,T,A,0.209,1089,292,0/1,,SNP,MISSENSE,c.198A>T,p.E66D,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.4114713216957606,E,Dom,False,,True,p.E82D(6) p.G81_F83delGEF(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:2,0.771414,0.5803762220004356,0.245,3.0,,,,,,,ACH-002045,4780.0
chr9,21971121,G,A,0.912,0,9,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-000303,1029.0
chr17,82442278,A,C,0.53,5,6,0/1,,SNP,MISSENSE,c.1444A>C,p.T482P,HEXD,,,ENST00000337014.10,12.0,+,,False,rs746519705,,as_specific,0.6608478802992519,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.449693,,0.246,2.0,,,,,,,ACH-000303,284004.0
chr9,21974685,G,A,0.99,0,94,1|1,,SNP,MISSENSE,c.143C>T,p.P48L,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000304494.9,1.0,-,"P42771, Q8N726",False,,,,0.6783042394014963,,,False,,True,p.0(1543) p.P48L(15) p.V28_V51del(1) p.P48R(1) p.?(2) p.P48P(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000498124;,,,,7.3,False,True,True,"CpG:2,UV:2",0.643699,0.99687765901035,0.765,4.0,,,,,,,ACH-000251,1029.0
chr12,25245350,C,A,0.822,82,381,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000251,3845.0
chr17,7675232,G,A,0.962,2,79,1|1,,SNP,MISSENSE,c.380C>T,p.S127F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs730881999,,as_specific,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.S127Y(9) p.0(9) p.S127fs*43(1) p.S127F(49) p.S127T(7) p.P128fs*42(3) p.P128fs*18(1) p.S127P(10) p.S127fs*22(1) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126_N131delYSPALN(3) p.Y126_S127insQPHH(1) p.S127S(1) p.Y126fs*11(1) p.S127C(1) p.V73fs*9(1) p.S127fs*42(1) p.Y126fs*18(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;ENST00000503591;,,,,7.3,False,True,True,"UV:1,APOBEC:1,Misc:2",0.950312,,0.925,3.0,,,,,,,ACH-000251,7157.0
chr17,7675088,C,T,0.996,0,263,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000017,7157.0
chr9,21971121,G,A,0.997,0,377,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-001736,1029.0
chr13,28018505,C,G,0.416,93,61,0/1,,SNP,MISSENSE,c.2503G>C,p.D835H,FLT3,fms related tyrosine kinase 3,CD molecules Immunoglobulin like domain containing Receptor Tyrosine Kinases,ENST00000241453.12,20.0,-,P36888,False,rs121913488,,as_specific,0.42643391521197,L,Dom,False,,True,p.D835Y(394) p.D835E(71) p.D835?(716) p.D835delD(25) p.D835F(3) p.D835V(85) p.D835H(85) p.D835N(7) p.D835A(10) p.R834_D835insALG(1) p.D835_M837>VFP(1) p.D835_I836>V(1) p.R834_D835delRD(1) p.D835I(1) p.D835D(1) p.D835G(1) p.D835_S838del(1) p.D835_I836delDI(1),cancer;gene_function_gain;,False,True,True,ENST00000241453;,612.0,,9.5,7.3,True,False,False,,0.916081,0.7230147259414358,0.878,2.0,,,,,,,ACH-001736,2322.0
chr17,7674221,G,A,0.398,159,105,0/1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-001736,7157.0
chr6,87589942,G,A,0.334,35,18,0/1,,SNP,MISSENSE,c.16C>T,p.R6C,RARS2,"arginyl-tRNA synthetase 2, mitochondrial","Aminoacyl tRNA synthetases, Class I",ENST00000369536.10,1.0,-,Q5T160,False,rs201899366,,as_specific,0.655860349127182,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:1,APOBEC:1",0.690019,0.2614908707431299,0.5,3.0,,,,,,,ACH-000873,57038.0
chr7,55191831,T,A,0.251,178,58,0/1,,SNP,MISSENSE,c.2447T>A,p.L816Q,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,20.0,+,P00533,False,rs121913444,,as_specific,0.5486284289276808,"""E, O""",Dom,False,,True,p.L861R(7) p.L861Q(84),cancer;gene_function_gain;,False,True,True,ENST00000455089;ENST00000454757;ENST00000275493;,1020.0,,10.5,7.3,True,False,True,smoking:5,0.920062,0.7240095346289797,0.864,4.0,,,,,,,ACH-000873,1956.0
chr3,179234297,A,G,0.988,0,82,1|1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-001392,5290.0
chr17,7675182,G,A,0.996,0,272,1|1,,SNP,NONSENSE,c.430C>T,p.Q144*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs757274881,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.L137_W146del10(1) p.Q144*(35) p.Q144fs*26(5) p.Q144P(5) p.Q144H(6) p.Q144R(4) p.Q144Q(2) p.V143fs*4(1) p.Q144fs*4(1) p.Q144L(8) p.Q144fs*32(1) p.Q144delQ(2) p.V143_P153del(1) p.Q144K(2) p.V143_S149delVQLWVDS(1) p.Q144_G154del11(1) p.P142_Q144delPVQ(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:3,0.991142,0.3246707366533456,,4.0,,,,,,,ACH-001392,7157.0
chr12,25227341,T,G,0.944,2,53,1|1,,SNP,MISSENSE,c.183A>C,p.Q61H,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs17851045,,as_specific,0.3466334164588528,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,True,True,,907.0,,10.5,7.3,True,False,True,"POLE:1,Eso:2,Misc:7",0.798711,,0.644,4.0,,,,,,,ACH-000178,3845.0
chr11,534288,C,T,0.444,144,113,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,2.0,-,P01112,False,rs104894230,,as_specific,0.6783042394014963,"""E, L, M""",Dom,False,,True,p.G12V(255) p.G12C(33) p.G12S(83) p.G12?(1) p.G12A(11) p.G12D(66) p.G12R(15) p.G12_G13insAG(1) p.G12T(2),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,,,,7.3,True,True,True,Misc:2,0.826996,0.9928105567062409,0.781,4.0,,,,,,,ACH-001552,3265.0
chr11,45252585,G,A,0.989,0,100,1|1,,SNP,MISSENSE,c.682C>T,p.P228S,SYT13,synaptotagmin 13,Synaptotagmins,ENST00000020926.8,4.0,-,Q7L8C5,False,rs868559206,,as_specific,0.6359102244389028,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.811471,0.6513425404758019,0.349,3.0,,,,,,,ACH-001552,57586.0
chr16,71184966,C,T,0.333,94,41,0/1,,SNP,MISSENSE,c.160G>A,p.E54K,HYDIN,"HYDIN, axonemal central pair apparatus protein",Protein phosphatase 1 regulatory subunits,ENST00000393567.7,3.0,-,Q4G0P3,False,rs267604623,,as_specific,0.3790523690773067,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.95297,0.8042631224145012,0.215,2.0,,,,,,,ACH-001552,Unknown
chr1,114713908,T,C,0.485,130,120,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-002397,4893.0
chr17,7674230,C,A,0.959,2,74,1|1,,SNP,MISSENSE,c.733G>T,p.G245C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,smoking:7,0.969132,0.8210775969704124,0.97,3.0,,,,,,,ACH-000500,7157.0
chr12,25227341,T,G,0.539,128,153,0/1,,SNP,MISSENSE,c.183A>C,p.Q61H,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs17851045,,as_specific,0.3466334164588528,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,True,True,,907.0,,10.5,7.3,True,False,True,"POLE:1,Eso:2,Misc:7",0.798711,,0.644,4.0,,,,,,,ACH-001852,3845.0
chr17,7674220,C,T,0.996,0,277,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001852,7157.0
chr17,7673767,C,T,0.998,0,484,1|1,,SNP,MISSENSE,c.853G>A,p.E285K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs112431538,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E285K(139) p.E285V(15) p.R283fs*16(2) p.E285Q(5) p.E285G(5) p.E285*(19) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.E285A(2) p.R283fs*56(1) p.V272_K292del21(1) p.E285E(5) p.E285fs*20(1) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285fs*60(2) p.E285fs*21(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:20,0.905537,,0.91,3.0,,,,,,,ACH-001412,7157.0
chr13,32684000,A,T,0.475,89,74,0/1,,SNP,NONSENSE,c.1180A>T,p.R394*,PDS5B,PDS5 cohesin associated factor B,,ENST00000315596.15,11.0,+,Q9NTI5,False,rs750827034,,as_specific,0.256857855361596,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"MSI:1,Misc:1",0.978615,0.5457525180325369,,3.0,,,,,,,ACH-000933,23047.0
chr17,7675088,C,T,0.904,5,58,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002104,7157.0
chr9,21971029,C,T,0.95,0,18,1|1,,SNP,NONSENSE,c.177G>A,p.W59*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913389,,as_specific,0.6633416458852868,,,True,,True,p.0(1543) p.W110*(37) p.V59fs*61(2) p.?(4) p.W110C(1) p.V59fs*63(1) p.V59fs*60(1) p.V59_G67del(1) p.V59M(1) p.V59fs*58(1) p.V59fs*82(2) p.H83fs*2(2) p.V59fs*45(1) p.D105fs*8(1) p.V59G(1) p.A68fs*3(1),cancer;gene_function_loss;,False,False,True,,1521.0,,0.0,7.3,False,True,False,,0.855169,0.9926462279289228,0.455,5.0,,,,,,,ACH-001024,1029.0
chr17,7674953,T,C,0.979,0,44,1|1,,SNP,MISSENSE,c.578A>G,p.H193R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs786201838,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193L(40) p.H193_I195delHLI(1) p.H193R(78) p.H193Y(29) p.?(2) p.H193D(10) p.H193P(15) p.H193N(7) p.P191fs*53(2) p.A189_V197delAPPQHLIRV(4) p.H193H(2) p.H193fs*16(3) p.A189fs*53(1) p.P191fs*6(1) p.K164_P219del(1) p.H193_I195>AP(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:16,0.888726,0.7365336169861475,0.884,3.0,,,,,,,ACH-001024,7157.0
chr11,533875,G,T,0.847,68,372,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,3.0,-,P01112,False,rs28933406,,as_specific,0.6458852867830424,"""E, L, M""",Dom,False,,True,p.Q61R(289) p.Q61K(113) p.Q61L(184) p.Q61H(24) p.Q61?(16) p.Q61P(3) p.Q61*(1) p.Q61Q(1) p.Q61E(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,,,,7.3,True,True,True,"smoking:1,UV:1,Misc:7",0.895199,0.9848035961304592,0.748,4.0,,,,,,,ACH-001751,3265.0
chr17,7673802,C,T,0.962,1,49,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000630,7157.0
chr7,140753336,A,T,0.995,0,230,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002458,673.0
chr3,41224607,A,T,0.693,11,28,0/1,,SNP,MISSENSE,c.95A>T,p.D32V,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913396,,as_specific,0.3940149625935162,"""E, M, O""",Dom,False,PLAG1,True,p.D32H(66) p.D32Y(177) p.A5_A80del(75) p.D32N(123) p.D32V(66) p.D32G(92) p.A5_Q143del(7) p.Q28_D32>H(2) p.D32A(22) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32E(11) p.D32_S47del(2) p.Y30_T40del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_D32del(6) p.W25_I35del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.WQQQSYLD25?(5) p.E9_I140del(1) p.H24_G38del(1) p.S23_S33del(3) p.A20_R151del(1) p.D32_S33insS(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.D32D(1) p.T3_A126del(2) p.D32fs*9(1) p.S23_S33>T(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.W25_S33del(1) p.W25_H36del(2) p.A5_D144>D(1) p.D32F(3) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.V22_S33del(2) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D32del(1) p.D6_A43del(1) p.S23_A39del(1) p.Y30_S33del(2) p.A5_I35del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,Misc:7,0.949258,0.7771428993677211,0.642,4.0,,,,,,,ACH-000984,1499.0
chr3,179199148,G,A,0.438,66,52,0/1,,SNP,MISSENSE,c.323G>A,p.R108H,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs886042002,,as_specific,0.3092269326683292,"""E, O""",Dom,False,,True,p.R108H(27) p.G106_R108del(3) p.R108P(1) p.R108C(2) p.R108L(1) p.V105_R108del(2) p.G106_R108delGNR(1) p.R108del(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,CpG:6,0.929086,,0.466,3.0,,,,,,,ACH-000984,5290.0
chr5,16694504,C,T,0.381,105,60,1|0,16694502.0,SNP,MISSENSE,c.3667G>A,p.G1223R,MYO10,myosin X,"Myosins, class X Pleckstrin homology domain containing FERM domain containing",ENST00000513610.6,27.0,-,Q9HD67,False,rs1434873123,,as_specific,0.5386533665835411,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,4.61,False,True,True,MSI:2,0.874456,0.9984442399688634,0.448,2.0,,,,,,,ACH-000984,4651.0
chr7,55154129,C,T,0.271,53,19,0/1,,SNP,MISSENSE,c.731C>T,p.A244V,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,6.0,+,P00533,False,rs149840192,,as_specific,0.5985037406483791,"""E, O""",Dom,False,,True,p.A289V(13) p.V30_R297>G(5) p.A289D(2),cancer;gene_function_gain;,False,False,True,,996.0,,3.0,7.3,True,False,True,Misc:15,0.935273,0.7748146050567428,0.647,4.0,,,,,,,ACH-000984,1956.0
chr17,7673802,C,T,0.567,27,34,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000984,7157.0
chr1,235806723,C,T,0.547,39,48,0/1,,SNP,MISSENSE,c.2413G>A,p.E805K,LYST,lysosomal trafficking regulator,BEACH domain containing  WD repeat domain containing,ENST00000389793.7,6.0,-,Q99698,False,rs762160809,,as_specific,0.3291770573566084,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.945424,0.741277648574315,0.199,3.0,,,,,,,ACH-000999,1130.0
chr2,178704933,C,T,0.351,156,86,0/1,,SNP,MISSENSE,c.25906G>A,p.E8636K,TTN,titin,Fibronectin type III domain containing I-set domain containing Immunoglobulin like domain containing,ENST00000342992.10,101.0,-,Q8WZ42,False,rs532933900,,as_specific,0.3266832917705736,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:6,POLE:2",0.929445,0.6903741952482925,0.247,3.0,,,,,,,ACH-000999,7273.0
chr2,201307600,G,A,0.55,78,98,0/1,,SNP,SILENT,c.798C>T,p.F266F,FLACC1,,,ENST00000439709.5,11.0,-,,False,rs766784931,,as_specific,0.4413965087281795,,,False,,False,,cancer;,False,False,True,,,,,4.13,False,False,True,"CpG:1,POLE:7",0.851517,0.747677436287858,,0.0,,,,,,,ACH-000999,130540.0
chr2,224805211,G,A,0.601,86,134,0/1,,SNP,MISSENSE,c.4028C>T,p.S1343L,DOCK10,dedicator of cytokinesis 10,Pleckstrin homology domain containing DOCK C2 domain containing,ENST00000409592.7,36.0,-,Q96BY6,False,rs374472028,,as_specific,0.399002493765586,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:2,POLE:3",0.9399,0.6955300606994255,0.447,2.0,,,,,,,ACH-000999,55619.0
chr5,5486781,C,T,0.379,19,11,0/1,,SNP,MISSENSE,c.6581C>T,p.S2194L,ICE1,interactor of little elongation complex ELL subunit 1,,ENST00000296564.9,18.0,+,Q9Y2F5,False,rs1217550481,,as_specific,0.3615960099750623,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"CpG:1,POLE:4",0.614157,0.7281769916279962,0.182,3.0,,,,,,,ACH-000999,23379.0
chr5,37195921,C,T,0.313,80,38,0/1,,SNP,MISSENSE,c.3748G>A,p.A1250T,CPLANE1,,,ENST00000508244.5,20.0,-,,False,rs752334335,,as_specific,0.3366583541147132,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:1,Misc:1",0.495274,,0.015,1.0,,,,,,,ACH-000999,65250.0
chr6,73440307,C,T,0.219,91,25,0/1,,SNP,MISSENSE,c.1016G>A,p.R339H,CGAS,cyclic GMP-AMP synthase,,ENST00000370315.4,3.0,-,Q8N884,False,rs190867294,,as_specific,0.3690773067331671,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:2,0.439248,,0.08,2.0,,,,,,,ACH-000999,115004.0
chr8,24914431,C,T,0.676,6,13,0/1,,SNP,MISSENSE,c.638C>T,p.A213V,NEFM,neurofilament medium,Intermediate filaments Type IV,ENST00000518131.5,1.0,+,P07197,False,,,,0.6384039900249376,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.673945,0.3618281763558523,0.587,3.0,,,,,,,ACH-000999,4741.0
chr8,119418083,C,T,0.481,41,37,0/1,,SNP,SILENT,c.336C>T,p.F112F,CCN3,,,ENST00000259526.4,3.0,+,,False,rs201508830,,as_specific,0.4887780548628428,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.68008,,,0.0,,,,,,,ACH-000999,4856.0
chr11,124660747,C,T,0.246,111,36,0/1,,SNP,MISSENSE,c.286G>A,p.E96K,SIAE,sialic acid acetylesterase,,ENST00000263593.8,3.0,-,Q9HAT2,False,rs375087861,,as_specific,0.4214463840399002,,,False,,False,,cancer;,False,False,True,,,,,4.01,False,False,True,POLE:8,0.732919,0.2883132437171025,0.445,2.0,,,,,,,ACH-000999,54414.0
chr12,11885968,C,T,0.42,96,70,0/1,,SNP,MISSENSE,c.1195C>T,p.R399C,ETV6,ETS variant 6,ETS transcription factor family,ENST00000396373.9,7.0,+,P41212,False,rs724159945,,as_specific,0.456359102244389,"""L, E, M""",Dom,False,"""NTRK3, RUNX1, PDGFRB, ABL1, MN1, ABL2, FACL6, CHIC2, ARNT, JAK2, EVI1, CDX2, STL, HLXB9, MDS2, PER1, SYK, TTL, FGFR3, PAX5""",False,p.R399S(1) p.R399P(1),cancer;gene_function_loss;structural_relation;,False,False,True,ENST00000396373;,811.0,,0.0,7.3,False,True,False,,0.788245,0.4701281260891469,0.897,3.0,,,,,,,ACH-000999,2120.0
chr12,25079261,C,T,0.406,61,42,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-000999,Unknown
chr16,58578787,C,T,0.44,62,47,0/1,,SNP,MISSENSE,c.1496G>A,p.R499H,CNOT1,CCR4-NOT transcription complex subunit 1,CCR4-NOT transcription complex,ENST00000317147.10,13.0,-,A5YKK6,False,rs763930906,,as_specific,0.4014962593516209,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,,0.929355,0.3826400907176781,0.481,4.0,,,,,,,ACH-000999,23019.0
chr17,7674221,G,A,0.491,24,22,0/1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000999,7157.0
chr17,39724747,G,A,0.582,23,31,0/1,,SNP,MISSENSE,c.2329G>A,p.V777M,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,20.0,+,P04626,False,rs121913471,,as_specific,0.57356608478803,E,Dom,False,,True,p.V777L(25) p.G776_V777insVC(1) p.V777M(2) p.G776_V777insL(2) p.V777_G778insCG(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,MSI:2,0.865881,0.4523294373683869,0.36,4.0,,,,,,,ACH-000999,2064.0
chr21,31703875,G,A,0.244,72,22,0/1,,SNP,NONSENSE,c.211C>T,p.R71*,SCAF4,SR-related CTD associated factor 4,RNA binding motif containing,ENST00000286835.12,4.0,-,O95104,False,rs1439594249,,as_specific,0.3042394014962593,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,Misc:1",0.967411,,,4.0,,,,,,,ACH-000999,57466.0
chr17,7673802,C,T,0.962,0,24,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-002181,7157.0
chr3,10142088,C,T,0.358,411,216,0/1,,SNP,MISSENSE,c.241C>T,p.P81S,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs104893829,,as_specific,0.7107231920199502,"""E, M, O""",Rec,False,,True,p.P81S(20) p.S80fs*73(1) p.S72_V87>L(1) p.P81fs*49(2) p.P81L(1) p.C77fs*50(1) p.P81fs*78(2) p.S80_P81>T(1) p.E70fs*50(1) p.P81fs*50(2) p.S80fs*77(1) p.I75_V84>M(1) p.R60fs*35(1) p.V74fs*77(1) p.N78fs*50(1) p.P81T(1) p.F76fs*24(1),cancer;gene_function_loss;,False,True,True,,1837.0,,20.0,3.46,False,True,False,,0.516529,0.5523726074718058,0.678,4.0,,,,,,,ACH-001843,7428.0
chr3,41224609,T,C,0.556,143,176,0/1,,SNP,MISSENSE,c.97T>C,p.S33P,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs1057519886,,as_specific,0.3940149625935162,"""E, M, O""",Dom,False,PLAG1,True,p.S33C(256) p.A5_A80del(75) p.S33Y(71) p.S33A(24) p.S33P(70) p.S33F(133) p.S33N(3) p.A5_Q143del(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(9) p.H24_Y142del(1) p.A5_E54del(1) p.S33L(4) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.S33T(10) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32_S47del(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_D32del(4) p.W25_I35del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(2) p.S23_S33del(3) p.A20_R151del(1) p.D32_S33insS(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.S33S(3) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.T3_A126del(2) p.D32fs*9(1) p.S33K(1) p.S23_S33>T(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.S33_G34insS(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_S33del(1) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.S33_G34insGTS(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.S33_G34insGI(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.V22_S33del(2) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.S33del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.Y30_S33del(2) p.A5_I35del(1) p.A5_T59del(1) p.A5_Q72del(1) p.S33_G34del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,Misc:7,0.977284,0.5653453896300243,0.464,4.0,,,,,,,ACH-001843,1499.0
chr12,25245350,C,T,0.438,208,160,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001843,3845.0
chr20,58909366,G,A,0.418,394,274,0/1,,SNP,MISSENSE,c.602G>A,p.R201H,GNAS,GNAS complex locus,"G protein subunits alpha, group s Granins",ENST00000371085.7,8.0,+,"O95467, P63092, P84996, Q5JWF2",False,rs121913495,,as_specific,0.4987531172069825,E,Dom,False,,True,p.R201H(703) p.R201C(858) p.R201?(16) p.R201L(4) p.R201S(32) p.R201G(2) p.R201R(1) p.R201P(1),cancer;gene_function_gain;,False,False,True,ENST00000371100;ENST00000371102;ENST00000604005;ENST00000371095;ENST00000371085;ENST00000354359;ENST00000265620;,,,,7.3,True,False,True,CpG:10,0.822809,0.7272591405043412,0.969,4.0,,,,,,,ACH-001843,2778.0
chr17,7675217,T,C,0.953,0,20,1|1,,SNP,MISSENSE,c.395A>G,p.K132R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519996,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.N131delN(4) p.K132Q(17) p.K132E(20) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:4,0.930493,0.6899109988020597,0.908,3.0,,,,,,,ACH-000074,7157.0
chr17,7674247,T,C,0.37,100,58,0/1,,SNP,MISSENSE,c.716A>G,p.N239S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs1057519999,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N239D(42) p.N239fs*22(1) p.H233_C242del10(1) p.N239_C242delNSSC(3) p.N239T(8) p.N239S(26) p.N239fs*25(12) p.C238_N239insX(1) p.N239fs*4(1) p.H233fs*6(1) p.N239K(7) p.M237_N239delMCN(1) p.N239fs*8(3) p.N239I(1) p.N239_S240insN(1) p.N239Y(6) p.V225fs*23(1) p.N239fs*1(2) p.N239_S240insX(2) p.N239N(1) p.C238_M246delCNSSCMGGM(1) p.N239fs*26(1) p.N239_S240delNS(2) p.N239fs*6(1) p.N239fs*?(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.N239*(1) p.N239_S241>T(1) p.N239fs*24(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:4,0.948527,0.99879692764426,0.897,3.0,,,,,,,ACH-001416,7157.0
chr4,1806162,A,G,0.792,6,24,0|1,1806162.0,SNP,MISSENSE,c.1951A>G,p.K651E,FGFR3,fibroblast growth factor receptor 3,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000481110.6,14.0,+,P22607,False,rs78311289,,as_specific,0.6533665835411472,"""L, E""",Dom,False,"""IGH@, ETV6""",True,p.K650E(48) p.K650Q(5) p.T651M(1),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,ENST00000440486;ENST00000481110;ENST00000340107;ENST00000412135;ENST00000352904;,1400.0,,0.0,7.3,True,True,True,Misc:3,0.919131,0.965456918024718,0.837,3.0,,,,,,,ACH-000396,2261.0
chr17,7673809,C,T,0.779,0,6,0/1,,SNP,MISSENSE,c.811G>A,p.E271K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1060501191,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.F270fs*72(2) p.E271K(32) p.E271D(3) p.E271*(18) p.G266_E271delGRNSFE(2) p.E271_R273delEVR(1) p.E271V(7) p.E271G(4) p.E271Q(3) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.E271P(1) p.R267fs*65(1) p.E271fs*35(1) p.L265_K305del41(1) p.S269fs*34(1) p.E271delE(1) p.E271E(2) p.E271fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:12,0.963135,,0.935,3.0,,,,,,,ACH-000396,7157.0
chr17,39723405,G,A,0.253,62,21,0/1,,SNP,MISSENSE,c.2033G>A,p.R678Q,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,17.0,+,P04626,False,rs1057519862,,as_specific,0.6359102244389028,E,Dom,False,,False,p.R678Q(3) p.R678L(1),cancer;gene_function_gain;,False,False,True,,42.0,"ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.",5.0,7.3,True,False,True,CpG:9,0.905915,0.5881956277268189,0.417,4.0,,,,,,,ACH-000396,2064.0
chr12,25245351,C,A,0.352,35,18,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-001355,3845.0
chr17,7675157,G,A,0.332,18,8,0/1,,SNP,MISSENSE,c.455C>T,p.P152L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782705,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.P152fs*18(21) p.P152P(6) p.0(9) p.P152S(29) p.S149fs*72(1) p.P152L(75) p.P153fs*28(7) p.P152_P153insXXX(1) p.P152T(9) p.P152fs*14(6) p.P152A(2) p.P153fs*16(2) p.P152Q(4) p.P152R(7) p.P152fs*28(3) p.D148fs*23(1) p.T150fs*16(4) p.P152fs*27(1) p.P152fs*29(6) p.V143_P153del(1) p.P151_V173del23(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"CpG:2,UV:1",0.952593,0.8618240470838262,0.878,3.0,,,,,,,ACH-001355,7157.0
chr2,201285316,C,T,0.472,50,49,0/1,,SNP,SPLICE_SITE,c.1303C>T,p.R435*,CASP8,caspase 8,Caspases Death effector domain containing Ripoptosome Death inducing signaling complex ,ENST00000673742.1,8.0,+,Q14790,False,rs1368296717,,as_specific,0.4588528678304239,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,POLE:1",0.983275,0.362918514097208,,4.0,,,,,,,ACH-000959,841.0
chr2,232845773,A,T,0.417,58,40,0/1,,SNP,MISSENSE,c.3347A>T,p.E1116V,GIGYF2,GRB10 interacting GYF protein 2,Trinucleotide repeat containing,ENST00000373563.9,26.0,+,Q6Y7W6,False,rs200196994,,as_specific,0.3965087281795511,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.96634,0.4150211375788842,0.502,3.0,,,,,,,ACH-000959,26058.0
chr3,37014545,G,A,0.981,0,52,1|1,,SNP,SPLICE_SITE,c.e10+1G>A,,MLH1,mutL homolog 1,MutL homologs,ENST00000458205.6,,+,P40692,False,rs267607789,,as_specific,0.3690773067331671,"""E, O""",Rec,False,,False,p.?(4),splicing;cancer;gene_function_loss;dna_repair;,False,False,True,,731.0,,2.5,7.3,False,True,False,,0.972304,0.4673546425590275,,1.59129685669006,,,,,,,ACH-000959,4292.0
chr3,179218304,A,G,0.508,36,41,0/1,,SNP,MISSENSE,c.1634A>G,p.E545G,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913274,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;,883.0,,2.0,7.3,True,False,True,Misc:2,0.960085,0.8156814306896972,0.737,3.0,,,,,,,ACH-000959,5290.0
chr12,12477384,G,A,0.514,58,59,0/1,,SNP,NONSENSE,c.1447C>T,p.R483*,DUSP16,dual specificity phosphatase 16,MAP kinase phosphatases,ENST00000298573.9,7.0,-,Q9BY84,False,,,,0.5561097256857855,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:1,0.881055,0.8116604069191584,,4.0,,,,,,,ACH-000959,80824.0
chr17,7674230,C,T,0.176,63,14,0/1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-000959,7157.0
chr21,31703875,G,A,0.518,50,59,0/1,,SNP,NONSENSE,c.211C>T,p.R71*,SCAF4,SR-related CTD associated factor 4,RNA binding motif containing,ENST00000286835.12,4.0,-,O95104,False,rs1439594249,,as_specific,0.3042394014962593,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,Misc:1",0.967411,,,4.0,,,,,,,ACH-000959,57466.0
chr1,114716126,C,T,0.486,169,153,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-001374,4893.0
chr17,7674954,G,A,0.997,0,315,1|1,,SNP,MISSENSE,c.577C>T,p.H193Y,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs876658468,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193L(40) p.H193_I195delHLI(1) p.H193R(78) p.H193Y(29) p.?(2) p.H193D(10) p.H193P(15) p.H193N(7) p.P191fs*53(2) p.A189_V197delAPPQHLIRV(4) p.H193H(2) p.H193fs*16(3) p.A189fs*53(1) p.P191fs*6(1) p.K164_P219del(1) p.H193_I195>AP(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:4,0.947843,,0.887,3.0,,,,,,,ACH-001401,7157.0
chr19,11033318,G,A,0.966,1,59,1|1,,SNP,MISSENSE,c.3575G>A,p.R1192H,SMARCA4,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4",Bromodomain containing,ENST00000344626.9,26.0,+,P51532,False,,,,0.6309226932668329,E,Rec,False,,False,p.R1192G(1) p.D1183_M1317del(1),cancer;gene_function_loss;,False,False,True,ENST00000344626;ENST00000643549;ENST00000646693;ENST00000642726;ENST00000646484;ENST00000644737;ENST00000642628;ENST00000643296;ENST00000647230;ENST00000646510;ENST00000429416;ENST00000645460;ENST00000541122;ENST00000589677;ENST00000444061;ENST00000590574;ENST00000413806;ENST00000450717;ENST00000643208;ENST00000642350;ENST00000647268;,,,,7.3,False,True,True,"CpG:1,MSI:1",0.954787,0.8464081146800616,0.97,4.0,,,,,,,ACH-000086,6597.0
chr17,7674233,C,A,0.997,0,412,1|1,,SNP,MISSENSE,c.730G>T,p.G244C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs1057519989,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,MSI:1",0.967868,0.7256135967181565,0.94,3.0,,,,,,,ACH-001549,7157.0
chr17,7675994,C,A,0.986,0,70,1|1,,SNP,SPLICE_SITE,c.375G>T,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:12,MSI:1,Misc:4",0.468898,0.7805428798268306,,0.0,,,,,,,ACH-002286,7157.0
chr4,54727495,T,C,0.996,0,262,1|1,,SNP,MISSENSE,c.1727T>C,p.L576P,KIT,KIT proto-oncogene receptor tyrosine kinase,CD molecules Immunoglobulin like domain containing Receptor Tyrosine Kinases,ENST00000288135.6,11.0,+,P10721,False,rs121913513,,as_specific,0.3915211970074813,"""L, M, O, E""",Dom,False,,True,p.L576P(231) p.Y570_Y578del(10) p.V569_L576>G(1) p.Y568_L576>CCV(1) p.Y570_L576del(21) p.V560_L576del(25) p.N564_L576del(12) p.L576F(6) p.V569_L576del(25) p.L576_P577insPTQL(2) p.Q575_W582>L(1) p.N567_L576>E(1) p.Q575_D579del(1) p.I563_L576del(4) p.Y568_L576>VN(3) p.Q556_L576del(6) p.N567_L576del(1) p.Y553_L576>NCLHLYSSQ(1) p.E561_D579>P(1) p.L576del(13) p.N567_Y578>ED(1) p.Q575_W582>R(1) p.V560_Y578del(2) p.N564_Y578del(4) p.N567_L576>I(3) p.L576_P577insPT(1) p.Q575_L576ins17(1) p.Q575_P577>T(2) p.L576_P577insQL(4) p.T574_H580del(1) p.P573_D579del(1) p.N567_Y578>SCV(2) p.I571_L576del(3) p.I563_P577>TI(1) p.N567_P577del(1) p.L576_P577del(1) p.L576_G592del(1) p.L576_P577ins15(1) p.E561_P577del(1) p.T574_K581del(1) p.Q575_K581del(1) p.I563_P577>N(2) p.V569_Y578del(3) p.Q575_L576ins15(1) p.K558_L576>N(1) p.V559_L576del(1) p.V559_S590del(1) p.Q556_L576>H(1) p.K558_L576>NV(1) p.V569_P577del(1) p.E554_L576>DNCSHLSPQQP(1) p.L576_P577insTQL(2) p.I563_L576>F(2) p.N567_L576>KV(2) p.G565_D579>V(2) p.I571_N587del(1) p.Y568_L576>CV(1) p.E561_Y578del(1) p.L576_P577insEE(1) p.L576R(1) p.T574_F584del(1) p.N567_L576>KQV(1) p.N567_L576>F(1) p.N567_N576>KE(1) p.Y568_L576del(1) p.N564_P577del(2) p.Y570_L576>R(1) p.E562_Y578>DF(1) p.I563_P577del(1) p.K558_L576del(1),cancer;gene_function_gain;,False,True,True,ENST00000412167;ENST00000288135;,72.0,"KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.",16.0,7.3,True,False,True,,0.938375,0.6662251943763033,0.86,4.0,,,,,,,ACH-002508,3815.0
chr9,21974680,G,A,0.996,0,279,1|1,,SNP,NONSENSE,c.148C>T,p.Q50*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000304494.9,1.0,-,"P42771, Q8N726",False,rs864622636,,as_specific,0.6733167082294265,,,True,,True,p.0(1543) p.Q50*(15) p.V28_V51del(1) p.?(2) p.Q50R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"MSI:1,UV:5,Misc:1",0.976963,0.9323197853333872,,5.0,,,,,,,ACH-002508,1029.0
chr3,179218303,G,A,0.633,25,43,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000720,5290.0
chr17,7670664,C,A,0.984,0,65,1|1,,SNP,NONSENSE,c.1045G>T,p.E349*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,,,,0.5062344139650873,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.A347fs*26(1) p.A347fs*17(1) p.E349fs*21(2) p.E349*(8) p.L348fs*16(1) p.L348_G361>W(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,smoking:2,0.981767,,,4.0,,,,,,,ACH-000720,7157.0
chr7,6387261,C,T,0.301,87,36,0/1,,SNP,MISSENSE,c.85C>T,p.P29S,RAC1,Rac family small GTPase 1,Rho family GTPases Endogenous ligands,ENST00000356142.4,2.0,+,P63000,False,rs1057519874,,as_specific,0.3117206982543641,,,False,,True,p.P29S(58) p.P29L(3),cancer;gene_function_gain;,False,False,True,,367.0,,4.0,7.3,True,False,True,"UV:19,APOBEC:1",0.898956,0.7595241052535948,0.585,3.0,,,,,,,ACH-000205,5879.0
chr12,25245350,C,T,0.691,17,43,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000205,3845.0
chr17,7675143,C,A,0.977,0,42,1|1,,SNP,MISSENSE,c.469G>T,p.V157F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs121912654,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.V157F(176) p.0(9) p.V157A(2) p.V157L(7) p.S149fs*72(1) p.V157D(13) p.V157_R158insV(1) p.V157_R158delVR(3) p.V157I(11) p.G154fs*22(1) p.V157fs*13(3) p.V157fs*24(2) p.V157fs*22(2) p.V157fs*19(2) p.T155fs*23(2) p.V157V(5) p.V157G(12) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156fs*18(1) p.V157fs*23(3) p.R156fs*12(1) p.V157delV(2) p.T155_V157>I(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.R156fs*14(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.V157fs*25(1) p.V157_C176del20(1) p.V157>AL(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1092.0,,4.0,7.3,False,True,True,"smoking:20,Misc:8",0.788392,0.832221967405611,0.708,3.0,,,,,,,ACH-000379,7157.0
chr17,7674890,T,C,0.196,50,10,0/1,,SNP,MISSENSE,c.641A>G,p.H214R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs1057519992,,as_specific,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H214Y(6) p.H214R(65) p.H214fs*7(2) p.R213_S215>X(1) p.L201_H214del(1) p.T211fs*28(1) p.R209fs*6(1) p.H214fs*5(2) p.H214Q(4) p.H214fs*33(3) p.H214H(1) p.H214Cfs*29(1) p.R213fs*32(1) p.H214fs*2(1) p.D208_V216delDRNTFRHSV(1) p.H214D(4) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.H214A(1) p.H214_S215insX(1) p.?(1) p.K164_P219del(1) p.H214P(1) p.F212_S215del(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:10,0.888834,,0.885,3.0,,,,,,,ACH-000561,7157.0
chr7,140753336,A,T,0.685,104,223,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001522,673.0
chr9,21974770,C,G,0.915,1,20,1|1,,SNP,MISSENSE,c.58G>C,p.A20P,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000304494.9,1.0,-,"P42771, Q8N726",False,,,,0.7032418952618454,,,False,,True,p.0(1543) p.A20S(1) p.A20E(1) p.A19_A20insTA(3) p.A20T(2) p.A20P(3) p.A20A(2) p.A20_A21del(1) p.A20fs*6(1) p.(M9_A20delinsT^E10_A20del)(1) p.S12fs*20(1) p.A20fs*26(1) p.A20fs*24(1),cancer;gene_function_loss;,False,False,True,,1522.0,,0.0,7.3,False,True,False,,0.752985,,0.54,4.0,,,,,,,ACH-000266,1029.0
chr12,25245350,C,A,0.768,6,28,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000266,3845.0
chr17,7674887,C,A,0.973,0,37,1|1,,SNP,MISSENSE,c.644G>T,p.S215I,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs587782177,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.S215N(10) p.0(9) p.S215R(22) p.R213_S215>X(1) p.T211fs*28(1) p.R209fs*6(1) p.S215G(12) p.S215_V218>M(1) p.S215I(22) p.H214fs*5(2) p.S215fs*29(1) p.S215T(5) p.S215fs*31(1) p.S215C(5) p.S215fs*32(4) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.D208_V216delDRNTFRHSV(1) p.S215S(2) p.S215fs*?(2) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.H214_S215insX(1) p.?(1) p.K164_P219del(1) p.S215del(1) p.F212_S215del(1) p.S215fs*6(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:4,0.947084,0.4541793437378166,0.913,3.0,,,,,,,ACH-000266,7157.0
chr3,49375472,C,G,0.47,204,187,0/1,,SNP,MISSENSE,c.118G>C,p.E40Q,RHOA,ras homolog family member A,Rho family GTPases,ENST00000422781.5,2.0,-,P61586,False,rs1057519951,,as_specific,0.4164588528678304,,,False,,False,p.E40V(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,APOBEC:5,0.953878,0.2905929774946746,0.633,3.0,,,,,,,ACH-000458,387.0
chr11,533874,T,A,0.483,661,613,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,3.0,-,P01112,False,rs121913233,,as_specific,0.6458852867830424,"""E, L, M""",Dom,False,,True,p.Q61R(289) p.Q61K(113) p.Q61L(184) p.Q61H(24) p.Q61?(16) p.Q61P(3) p.Q61*(1) p.Q61Q(1) p.Q61E(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,854.0,,0.0,7.3,True,True,True,"smoking:2,Misc:4",0.786029,0.9921539220757206,0.839,4.0,,,,,,,ACH-000458,3265.0
chr17,7673782,T,C,0.999,0,1428,1|1,,SNP,MISSENSE,c.838A>G,p.R280G,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs753660142,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R280T(73) p.R280fs*65(9) p.R280I(15) p.R280K(54) p.R280S(17) p.R280G(33) p.R280_R283>S(1) p.R280*(14) p.S269fs*21(1) p.F270_D281del12(1) p.R280fs*?(1) p.V272_K292del21(1) p.D281_R282delDR(2) p.R280R(3) p.A276fs*64(1) p.R280fs*64(1) p.G279fs*65(2) p.G279_R280delGR(1) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:2,0.948566,0.6023677190456652,0.924,3.0,,,,,,,ACH-000458,7157.0
chr12,121016393,C,G,0.218,60,17,0/1,,SNP,MISSENSE,c.82G>C,p.E28Q,C12orf43,chromosome 12 open reading frame 43,,ENST00000288757.7,1.0,-,Q96C57,False,,,,0.6109725685785536,,,False,,False,p.E28D(1),cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:3,0.568243,,0.193,3.0,,,,,,,ACH-002266,64897.0
chr17,7674241,G,T,0.953,1,43,1|1,,SNP,MISSENSE,c.722C>A,p.S241Y,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:5,0.89243,,0.96,3.0,,,,,,,ACH-002266,7157.0
chr9,21971187,G,A,0.923,0,11,1|1,,SNP,NONSENSE,c.19C>T,p.R7*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913387,,as_specific,0.6458852867830424,,,True,,True,p.0(1543) p.R58*(112) p.A4_P11del(12) p.V28_V51del(1) p.?(5) p.M54fs*61(2) p.R58fs*61(2) p.P3_P11del(2) p.R58fs*59(2) p.M53_R58del(3) p.A57fs*85(1) p.A57_R58>V*(1) p.G55fs*86(1) p.G55fs*61(1) p.S7_A19del(1) p.R58fs*62(1) p.R58R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:10,UV:4",0.788085,0.9908618465891524,0.22,5.0,,,,,,,ACH-000562,1029.0
chr17,7674241,G,A,0.962,0,30,1|1,,SNP,MISSENSE,c.722C>T,p.S241F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:4,APOBEC:7,Misc:1",0.912713,0.9893558821746748,0.958,3.0,,,,,,,ACH-000562,7157.0
chr17,7673823,C,T,0.994,3,457,1|1,,SNP,MISSENSE,c.797G>A,p.G266E,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs193920774,,as_specific,0.5236907730673317,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G266V(35) p.G266R(59) p.G266E(59) p.G262_S269delGNLLGRNS(2) p.G266_E271delGRNSFE(2) p.G266fs*79(6) p.G266fs*9(1) p.G266*(14) p.E258fs*71(1) p.G266S(1) p.G266G(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.G266T(1) p.G266A(3) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:1,Misc:1",0.961163,0.7111218214186509,0.973,3.0,,,,,,,ACH-002044,7157.0
chr1,114716126,C,T,0.422,89,67,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-000372,4893.0
chr4,152326137,G,A,0.992,0,120,1|1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-000372,55294.0
chr9,5073770,G,T,0.998,0,627,1|1,,SNP,MISSENSE,c.1849G>T,p.V617F,JAK2,Janus kinase 2,Jak family tyrosine kinases SH2 domain containing FERM domain containing,ENST00000381652.4,14.0,+,O60674,False,rs77375493,,as_specific,0.3341645885286783,L,Dom,False,"""ETV6, PCM1, BCR""",True,p.V617F(46751) p.V617I(89) p.V617V(1) p.V617_C618>FR(2),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,True,True,ENST00000636127;ENST00000381652;,64.0,"JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.",83.0,3.4,True,True,False,,0.951124,0.9953201091762558,0.881,4.0,,,,,,,ACH-000004,3717.0
chr17,7674250,C,A,0.929,0,12,1|1,,SNP,MISSENSE,c.713G>T,p.C238F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs730882005,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C238Y(66) p.0(9) p.C238F(41) p.C238fs*?(1) p.C238S(20) p.H233_C242del10(1) p.C238R(16) p.M237_C238insX(1) p.C238_N239insX(1) p.H233fs*6(1) p.M237_N239delMCN(1) p.C238delC(1) p.C238W(4) p.C238*(5) p.V225fs*23(1) p.C238G(2) p.C238fs*2(1) p.C238del(1) p.C238_M246delCNSSCMGGM(1) p.M237fs*1(1) p.C238C(1) p.?(1) p.C238_M243delCNSSCM(1) p.Y236_M243delYMCNSSCM(1) p.C238fs*1(1) p.C238fs*9(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:2,Misc:10",0.966634,,0.958,3.0,,,,,,,ACH-002293,7157.0
chr5,112839693,C,T,0.928,10,140,1|1,,SNP,NONSENSE,c.4099C>T,p.Q1367*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913328,,as_specific,0.4638403990024937,"""E, M, O""",Rec,True,,True,p.Q1367*(39) p.Q1367H(2) p.K1363fs*7(1) p.?(1) p.K1192fs*3(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"APOBEC:2,Misc:1",0.963926,0.5902091700563789,,5.0,,,,,,,ACH-001456,324.0
chr12,25225713,T,A,0.646,66,124,0/1,,SNP,MISSENSE,c.351A>T,p.K117N,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs770248150,,as_specific,0.3241895261845386,"""L, E, M, O""",Dom,False,KRAS,True,p.K117N(36) p.K117E(3) p.K117R(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,1120.0,,0.0,7.3,True,False,False,,0.689416,,0.764,3.0,,,,,,,ACH-001456,3845.0
chr17,7674230,C,T,0.992,0,138,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-001456,7157.0
chr9,21971109,C,A,0.997,1,323,1|1,,SNP,MISSENSE,c.97G>T,p.D33Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552822,,as_specific,0.6957605985037406,,,False,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V82_E88del(1) p.D84H(2) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.D84Y(9) p.P81_A85del(1) p.D84N(4) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.D84fs*63(2) p.E61_L94del(1) p.R80fs*34(1) p.D84_F90del(1) p.E33D(1) p.A68fs*3(1) p.D84fs*1(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;ENST00000579755;ENST00000530628;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.933446,0.9973373924118374,0.803,4.0,,,,,,,ACH-002464,1029.0
chr12,25225628,C,G,0.434,76,58,0/1,,SNP,MISSENSE,c.436G>C,p.A146P,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,905.0,,7.5,7.3,True,False,False,,0.968872,0.6595086461751286,0.935,4.0,,,,,,,ACH-002464,3845.0
chr4,152328232,C,T,0.437,103,81,0/1,,SNP,MISSENSE,c.1154G>A,p.R385H,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs1057519895,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465H(72) p.R465fs*7(9) p.R465L(3) p.R465Y(2) p.R465P(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:15,0.938974,0.1731430175559941,0.557,4.0,,,,,,,ACH-000173,55294.0
chr17,7675113,G,A,0.883,3,31,0/1,,SNP,NONSENSE,c.499C>T,p.Q167*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.K164fs*3(2) p.Q167fs*13(3) p.S149fs*72(1) p.Q167L(3) p.Y163fs*1(1) p.Q167fs*2(6) p.A159_Q167delAMAIYKQSQ(1) p.Q167fs*4(3) p.Q167Q(3) p.Q165_M169delQSQHM(1) p.Q167H(3) p.Q167*(27) p.Q167K(1) p.Q167fs*12(1) p.A159_M169del(1) p.Q167delQ(1) p.Q167fs*3(3) p.Q167fs*14(4) p.Q167_H168>YL(1) p.P151_V173del23(1) p.Q167_H168>HD(1) p.Q167E(1) p.Q167R(4) p.K164_P219del(1) p.V157_C176del20(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:1,Misc:4",0.993323,0.6915924179262102,,4.0,,,,,,,ACH-000173,7157.0
chr9,136504892,A,G,0.893,0,7,0/1,,SNP,MISSENSE,c.4799T>C,p.L1600P,NOTCH1,notch 1,Ankyrin repeat domain containing,ENST00000651671.1,26.0,-,P46531,False,,,,0.6907730673316709,L,Dom,False,TRB@,True,p.L1600P(66) p.L1600fs*10(10) p.L1600Q(10) p.L1600_H1601insA(1) p.L1600_H1601insL(2) p.L1600H(1),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,ENST00000277541;,1031.0,,0.0,7.3,True,True,False,,0.720263,,0.973,3.0,,,,,,,ACH-002216,4851.0
chr17,7675124,T,C,0.333,36,16,0/1,,SNP,MISSENSE,c.488A>G,p.Y163C,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs148924904,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y163C(136) p.0(9) p.S149fs*72(1) p.Y163fs*1(2) p.Y163H(19) p.Y163N(20) p.A159_Q167delAMAIYKQSQ(1) p.Y163S(5) p.Y163*(8) p.Y163fs*14(1) p.A159_M169del(1) p.Y163_Q165delYKQ(1) p.Y163D(4) p.Y163del(1) p.Y163Y(3) p.P151_V173del23(1) p.I162_Y163delIY(1) p.Y163fs*7(2) p.V157_C176del20(1) p.Y163fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:11,0.897865,0.7273008533507418,0.872,3.0,,,,,,,ACH-002216,7157.0
chr17,7675994,C,T,0.622,54,89,0/1,,SNP,SPLICE_SITE,c.375G>A,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:5,0.392984,0.6099495421221454,,0.0,,,,,,,ACH-002216,7157.0
chr7,140753336,A,T,0.681,53,120,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001274,673.0
chr14,19921503,G,A,0.194,143,34,0/1,,SNP,SILENT,c.897G>A,p.R299R,OR4K5,olfactory receptor family 4 subfamily K member 5,"Olfactory receptors, family 4",ENST00000315915.4,1.0,+,Q8NGD3,False,rs749816085,,as_specific,0.3615960099750623,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:8,0.212404,0.3686502739396499,,0.0,,,,,,,ACH-001274,79317.0
chr17,7673788,G,A,0.204,35,8,0/1,,SNP,MISSENSE,c.832C>T,p.P278S,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs17849781,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.C275fs*67(1) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:2,APOBEC:1,Misc:2",0.949089,0.8832556364693654,0.963,3.0,,,,,,,ACH-000180,7157.0
chr2,109398779,C,T,0.647,179,318,0/1,,SNP,MISSENSE,c.1135C>T,p.R379C,SH3RF3,SH3 domain containing ring finger 3,Ring finger proteins,ENST00000309415.8,4.0,+,Q8TEJ3,False,rs753317886,,as_specific,0.6134663341645885,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:3,MSI:1",0.706856,0.9782492224321296,0.238,2.0,,,,,,,ACH-001960,344558.0
chr17,7673764,C,T,0.999,0,883,1|1,,SNP,MISSENSE,c.856G>A,p.E286K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs786201059,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E286G(17) p.E286K(94) p.E286fs*59(2) p.R283fs*16(2) p.E286*(17) p.E286V(9) p.E286fs*17(2) p.E286Q(7) p.E286D(2) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.R283fs*56(1) p.V272_K292del21(1) p.E286A(2) p.E286E(2) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:3,Misc:1",0.93585,0.6532670016064752,0.949,3.0,,,,,,,ACH-001960,7157.0
chr12,25245351,C,A,0.863,3,26,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000845,3845.0
chr15,78275702,G,A,0.428,16,15,0/1,,SNP,MISSENSE,c.770G>A,p.R257Q,DNAJA4,DnaJ heat shock protein family (Hsp40) member A4,DNAJ (HSP40) heat shock proteins,ENST00000446172.2,5.0,+,Q8WW22,False,rs751859584,,as_specific,0.3815461346633416,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.955019,0.8791568405664497,0.449,3.0,,,,,,,ACH-000845,55466.0
chr17,7670694,C,A,0.921,1,25,1|1,,SNP,NONSENSE,c.1015G>T,p.E339*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,,,,0.4738154613466334,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E339Q(1) p.E339*(20) p.E339K(2) p.E339fs*6(1) p.E339fs*8(3) p.E339fs*13(1) p.E339_M340>V(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,Misc:2",0.989639,,,4.0,,,,,,,ACH-000845,7157.0
chr17,7676059,G,A,0.995,0,213,1|1,,SNP,NONSENSE,c.310C>T,p.Q104*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5561097256857855,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.G59fs*23(3) p.S95_G108del(1) p.W91fs*13(1) p.Q104fs*19(2) p.Y103_G112>C(1) p.Q104*(15) p.Y103_Q104>*(1) p.Y103fs*15(1) p.M1_T125del(1) p.Q104L(1) p.Q104H(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:1,0.976972,0.3103062833861155,,4.0,,,,,,,ACH-001997,7157.0
chr17,7676051,G,C,0.704,35,85,0/1,,SNP,MISSENSE,c.318C>G,p.S106R,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5486284289276808,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S106R(10) p.S106fs*17(1) p.G59fs*23(3) p.S95_G108del(1) p.W91fs*13(1) p.Y103_G112>C(1) p.S106_Y107delSY(1) p.Y103fs*15(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y107fs*16(1) p.Y107fs*44(1) p.S33fs*23(1) p.V73fs*9(1) p.S106fs*15(1) p.S95fs*37(1) p.S106S(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:2,0.721253,0.6184438760423083,0.635,3.0,,,,,,,ACH-002305,7157.0
chr5,112815564,C,T,0.482,57,52,0/1,,SNP,NONSENSE,c.904C>T,p.R302*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,9.0,+,P25054,False,rs137854568,,as_specific,0.42643391521197,"""E, M, O""",Rec,True,,True,p.R302*(20),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:5,POLE:2",0.990411,0.6055737490403407,,5.0,,,,,,,ACH-000998,324.0
chr10,69930525,A,G,0.572,14,19,0/1,,SNP,SILENT,c.1656A>G,p.K552K,COL13A1,collagen type XIII alpha 1 chain,Collagens,ENST00000645393.1,30.0,+,Q5TAT6,False,rs1359228988,,as_specific,0.5610972568578554,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"MSI:1,Misc:2",0.428259,0.7380836328002583,,0.0,,,,,,,ACH-000998,1305.0
chr12,56098849,A,G,0.511,47,48,0/1,,SNP,MISSENSE,c.2783A>G,p.E928G,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,23.0,+,P21860,False,,,,0.4663341645885286,,,False,,False,p.E928G(2),cancer;gene_function_gain;,False,False,True,ENST00000267101;ENST00000415288;ENST00000550070;ENST00000553131;ENST00000549832;,,,,7.3,True,False,True,,0.978165,,0.74,4.0,,,,,,,ACH-000998,2065.0
chr14,64542713,A,G,0.536,32,37,0/1,,SNP,MISSENSE,c.1864A>G,p.S622G,HSPA2,heat shock protein family A (Hsp70) member 2,Heat shock 70kDa proteins,ENST00000394709.2,2.0,+,P54652,False,,,,0.4912718204488778,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,,,0.027,3.0,,,,,,,ACH-000998,3306.0
chr17,35750138,T,G,0.174,38,9,0/1,,SNP,MISSENSE,c.566A>C,p.D189A,GAS2L2,growth arrest specific 2 like 2,,ENST00000604641.6,2.0,-,Q8NHY3,False,rs1192558412,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.610651,0.5095418527025265,0.061,2.0,,,,,,,ACH-000998,246176.0
chr17,39723967,T,C,0.421,25,15,0/1,,SNP,MISSENSE,c.2264T>C,p.L755S,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,19.0,+,P04626,False,rs121913470,,as_specific,0.543640897755611,E,Dom,False,,True,p.L755S(37) p.L755L(1) p.L755P(3) p.L755_S760>A(1) p.L755_T759delLRENT(1) p.L755F(1),cancer;gene_function_gain;,False,True,True,ENST00000584601;ENST00000406381;ENST00000541774;ENST00000445658;ENST00000584450;ENST00000269571;,39.0,"ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.",21.5,7.3,True,False,True,"MSI:1,Misc:3",0.880266,,0.86,4.0,,,,,,,ACH-000998,2064.0
chr3,41224610,C,T,0.5,12,12,0/1,,SNP,MISSENSE,c.98C>T,p.S33F,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913400,,as_specific,0.3940149625935162,"""E, M, O""",Dom,False,PLAG1,True,p.S33C(256) p.A5_A80del(75) p.S33Y(71) p.S33A(24) p.S33P(70) p.S33F(133) p.S33N(3) p.A5_Q143del(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.S33L(4) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.S33T(10) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32_S47del(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_I35del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(2) p.S23_S33del(3) p.A20_R151del(1) p.D32_S33insS(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.S33S(3) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.T3_A126del(2) p.D32fs*9(1) p.S33K(1) p.S23_S33>T(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.S33_G34insS(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_S33del(1) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.S33_G34insGTS(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.S33_G34insGI(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.V22_S33del(2) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.S33del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.Y30_S33del(2) p.A5_I35del(1) p.A5_T59del(1) p.A5_Q72del(1) p.S33_G34del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"APOBEC:3,Misc:2",0.95219,0.6305593185900997,0.534,4.0,,,,,,,ACH-000677,1499.0
chr3,179199156,A,G,0.278,48,18,0/1,,SNP,MISSENSE,c.331A>G,p.K111E,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs1057519933,,as_specific,0.3167082294264339,"""E, O""",Dom,False,,True,p.K111N(19) p.K111E(21) p.K111del(3) p.K111_I112>N(3) p.K111Q(1) p.E110_N114>D(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:6,0.886097,0.3672865370763588,0.506,3.0,,,,,,,ACH-000677,5290.0
chr12,25245351,C,A,0.94,0,18,1|1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000677,3845.0
chr17,7674230,C,A,0.973,0,34,1|1,,SNP,MISSENSE,c.733G>T,p.G245C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,smoking:7,0.969132,0.8210775969704124,0.97,3.0,,,,,,,ACH-000917,7157.0
chr12,25245350,C,G,0.621,10,17,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-000489,3845.0
chr17,7674220,C,T,0.911,4,46,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000944,7157.0
chr7,140753336,A,T,0.691,49,107,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002386,673.0
chr9,21974680,G,A,0.99,0,98,1|1,,SNP,NONSENSE,c.148C>T,p.Q50*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000304494.9,1.0,-,"P42771, Q8N726",False,rs864622636,,as_specific,0.6733167082294265,,,True,,True,p.0(1543) p.Q50*(15) p.V28_V51del(1) p.?(2) p.Q50R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"MSI:1,UV:5,Misc:1",0.976963,0.9323197853333872,,5.0,,,,,,,ACH-002386,1029.0
chr5,146590095,A,C,0.67,67,134,0/1,,SNP,MISSENSE,c.1193T>G,p.V398G,PPP2R2B,protein phosphatase 2 regulatory subunit Bbeta,Protein phosphatase 2 regulatory subunits WD repeat domain containing,ENST00000336640.10,9.0,-,Q00005,False,rs778098894,,as_specific,0.4364089775561097,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,Misc:1,0.930669,0.8565917001618066,0.252,2.0,,,,,,,ACH-000441,5521.0
chr7,140753336,A,T,0.995,0,202,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000441,673.0
chr7,143935997,G,A,0.983,2,180,1|1,,SNP,SILENT,c.765G>A,p.T255T,OR2F2,olfactory receptor family 2 subfamily F member 2,"Olfactory receptors, family 2",ENST00000408955.2,1.0,+,O95006,False,rs866839513,,as_specific,0.4812967581047381,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:8,POLE:2",0.213677,0.7729173493360563,,0.0,,,,,,,ACH-000441,135948.0
chr19,16765052,C,T,0.524,32,34,0/1,,SNP,MISSENSE,c.2270C>T,p.S757F,NWD1,NACHT and WD repeat domain containing 1,WD repeat domain containing,ENST00000552788.1,8.0,+,Q149M9,False,,,,0.5810473815461347,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.688043,0.4955802451240924,0.218,2.0,,,,,,,ACH-000441,284434.0
chr3,179234297,A,G,0.644,25,49,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-001409,5290.0
chr4,1801841,C,G,0.765,40,127,0/1,,SNP,MISSENSE,c.746C>G,p.S249C,FGFR3,fibroblast growth factor receptor 3,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000481110.6,7.0,+,P22607,False,rs121913483,,as_specific,0.685785536159601,"""L, E""",Dom,False,"""IGH@, ETV6""",True,p.S249C(2119) p.R248_S249insC(1) p.R248_S249delRS(1) p.R248_S249insL(1) p.S249T(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000440486;ENST00000481110;ENST00000340107;ENST00000412135;ENST00000613647;ENST00000352904;ENST00000507588;,628.0,,11.0,7.3,True,False,True,"smoking:1,APOBEC:29,Misc:1",0.910414,0.5885492886327983,0.902,3.0,,,,,,,ACH-001409,2261.0
chrX,45063557,C,T,0.992,0,127,1|1,,SNP,NONSENSE,c.1663C>T,p.Q555*,KDM6A,lysine demethylase 6A,Lysine demethylases Tetratricopeptide repeat domain containing,ENST00000377967.8,16.0,+,O15550,False,,,,0.4887780548628428,"""E, L""",Rec,True,,False,p.Q555*(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,APOBEC:9,,0.82235673787134,,3.0,,,,,,,ACH-001409,7403.0
chr1,114713908,T,A,0.643,44,80,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-001569,4893.0
chr12,25245348,C,A,0.998,0,423,1|1,,SNP,MISSENSE,c.37G>T,p.G13C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913535,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,911.0,,0.0,7.3,True,False,True,"smoking:7,MSI:1,Misc:4",0.929283,,0.868,4.0,,,,,,,ACH-000851,3845.0
chr12,25245350,C,G,0.5,12,10,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-000446,3845.0
chr14,65078029,C,T,0.913,5,54,1|1,,SNP,MISSENSE,c.152G>A,p.R51Q,MAX,MYC associated factor X,Basic helix-loop-helix proteins,ENST00000557746.5,3.0,-,P61244,False,,,,0.4912718204488778,,,False,,True,p.R60Q(11) p.R47_S52del(1),cancer;gene_function_loss;,False,False,True,ENST00000358402;ENST00000618858;ENST00000284165;ENST00000358664;ENST00000555419;ENST00000556979;ENST00000555667;ENST00000557746;ENST00000556443;,,,,7.3,False,True,True,"CpG:5,MSI:2",0.863058,,0.897,3.0,,,,,,,ACH-000446,4149.0
chr12,25245350,C,A,0.971,1,67,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-001151,3845.0
chr16,64982231,T,G,0.794,13,52,0/1,,SNP,MISSENSE,c.1070A>C,p.K357T,CDH11,cadherin 11,Type II classical cadherins,ENST00000268603.9,8.0,-,P55287,False,,,,0.456359102244389,M,Dom,False,USP6,False,,cancer;structural_relation;,False,False,True,,,,,7.3,False,False,True,Eso:4,0.449463,0.6011010823797833,0.153,3.0,,,,,,,ACH-001151,1009.0
chr3,179203778,G,A,0.469,53,45,0/1,,SNP,MISSENSE,c.1048G>A,p.D350N,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,5.0,+,P42336,False,rs1064793349,,as_specific,0.3341645885286783,"""E, O""",Dom,False,,False,p.D350G(1) p.D350H(2) p.D350N(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"POLE:1,APOBEC:2",0.942501,0.7475876730683143,0.229,3.0,,,,,,,ACH-000902,5290.0
chr3,179234297,A,G,0.579,32,43,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000902,5290.0
chr15,66481793,G,A,0.465,38,33,0/1,,SNP,MISSENSE,c.79G>A,p.E27K,MAP2K1,mitogen-activated protein kinase kinase 1,Mitogen-activated protein kinase kinases,ENST00000566326.1,2.0,+,Q02750,False,rs1057519733,,as_specific,0.5536159600997507,,,False,,True,p.E203K(6),cancer;gene_function_gain;,False,False,True,,1626.0,,0.0,7.3,True,False,True,"UV:2,APOBEC:1",0.95851,0.3843929791359048,0.621,4.0,,,,,,,ACH-000902,5604.0
chr3,179218306,C,A,0.48,122,110,0/1,,SNP,MISSENSE,c.1636C>A,p.Q546K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913286,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.Q546E(20) p.Q546K(167) p.Q546R(58) p.Q546P(22) p.Q546L(7) p.Q546H(13) p.Q546Q(2) p.Q546?(2),cancer;gene_function_gain;,False,False,True,,885.0,,5.0,7.3,True,False,True,Misc:8,0.948839,,0.338,3.0,,,,,,,ACH-000820,5290.0
chr8,87353670,T,C,0.255,197,68,0/1,,SNP,MISSENSE,c.1187T>C,p.L396P,CNBD1,cyclic nucleotide binding domain containing 1,,ENST00000518476.6,10.0,+,Q8NA66,False,,,,0.2668329177057356,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:4,0.617285,0.6783272684169215,0.633,2.0,,,,,,,ACH-000820,168975.0
chr12,25245350,C,A,0.694,98,243,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000820,3845.0
chr17,7673704,G,A,0.883,10,74,0/1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-002132,7157.0
chr17,7675088,C,T,0.984,0,69,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000268,7157.0
chr2,74415153,T,G,0.667,1,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002223,388963.0
chr7,34811853,C,T,0.325,121,60,0/1,,SNP,SILENT,c.435C>T,p.F145F,NPSR1,neuropeptide S receptor 1,Neuropeptide receptors,ENST00000531252.5,4.0,+,Q6W5P4,False,,,,0.4314214463840399,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:8,0.67834,,,2.0,,,,,,,ACH-002223,387129.0
chr7,140753336,A,T,0.276,142,55,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000423,673.0
chr1,114713908,T,C,0.687,38,83,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-000716,4893.0
chr17,7673803,G,A,0.95,0,18,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000716,7157.0
chr9,21971187,G,A,0.875,0,6,0/1,,SNP,NONSENSE,c.19C>T,p.R7*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913387,,as_specific,0.6458852867830424,,,True,,True,p.0(1543) p.R58*(112) p.A4_P11del(12) p.V28_V51del(1) p.?(5) p.M54fs*61(2) p.R58fs*61(2) p.P3_P11del(2) p.R58fs*59(2) p.M53_R58del(3) p.A57fs*85(1) p.A57_R58>V*(1) p.G55fs*86(1) p.G55fs*61(1) p.S7_A19del(1) p.R58fs*62(1) p.R58R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:10,UV:4",0.788085,0.9908618465891524,0.22,5.0,,,,,,,ACH-000548,1029.0
chr2,112918757,C,T,0.298,105,43,0/1,,SNP,MISSENSE,c.605C>T,p.S202L,IL37,interleukin 37,Interleukins,ENST00000263326.7,5.0,+,Q9NZH6,False,,,,0.4488778054862843,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.489672,0.7542446510973951,0.025,1.0,,,,,,,ACH-000884,27178.0
chr7,140753336,A,T,0.646,123,222,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000884,673.0
chr17,7673823,C,T,0.479,404,362,0/1,,SNP,MISSENSE,c.797G>A,p.G266E,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs193920774,,as_specific,0.5236907730673317,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G266V(35) p.G266R(59) p.G266E(59) p.G262_S269delGNLLGRNS(2) p.G266_E271delGRNSFE(2) p.G266fs*79(6) p.G266fs*9(1) p.G266*(14) p.E258fs*71(1) p.G266S(1) p.G266G(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.G266T(1) p.G266A(3) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:1,Misc:1",0.961163,0.7111218214186509,0.973,3.0,,,,,,,ACH-000884,7157.0
chr7,113879510,C,T,0.275,32,10,0/1,,SNP,MISSENSE,c.1582G>A,p.E528K,PPP1R3A,protein phosphatase 1 regulatory subunit 3A,Protein phosphatase 1 regulatory subunits,ENST00000284601.4,4.0,-,Q16821,False,rs1380388302,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.413804,0.7808996545670526,0.071,2.0,,,,,,,ACH-000899,5506.0
chr7,140753336,A,T,0.61,52,84,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000899,673.0
chr8,87353670,T,G,0.455,20,14,0/1,,SNP,MISSENSE,c.1187T>G,p.L396R,CNBD1,cyclic nucleotide binding domain containing 1,,ENST00000518476.6,10.0,+,Q8NA66,False,,,,0.2668329177057356,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:5,0.541415,,0.584,2.0,,,,,,,ACH-000899,168975.0
chr12,25245350,C,T,0.239,38,14,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000685,3845.0
chr2,74415153,T,G,0.443,4,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002210,388963.0
chr17,7673802,C,T,0.948,0,18,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-002210,7157.0
chr3,10142113,T,A,0.967,0,28,1|1,,SNP,MISSENSE,c.266T>A,p.L89H,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs5030807,,as_specific,0.7032418952618454,"""E, M, O""",Rec,False,,True,p.L89H(20) p.V84_E94>E(1) p.L89fs*67(1) p.L89fs*43(1) p.L89P(7) p.L89R(5) p.W88fs*41(1) p.V84fs*69(1) p.R60fs*35(1) p.P86fs*42(1) p.W88fs*40(1) p.F76fs*24(1),cancer;gene_function_loss;,False,False,True,ENST00000256474;ENST00000345392;,2308.0,,0.0,7.3,False,True,False,,0.745276,,0.719,4.0,,,,,,,ACH-000648,7428.0
chr3,10142113,T,A,0.997,0,423,1|1,,SNP,MISSENSE,c.266T>A,p.L89H,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs5030807,,as_specific,0.7032418952618454,"""E, M, O""",Rec,False,,True,p.L89H(20) p.V84_E94>E(1) p.L89fs*67(1) p.L89fs*43(1) p.L89P(7) p.L89R(5) p.W88fs*41(1) p.V84fs*69(1) p.R60fs*35(1) p.P86fs*42(1) p.W88fs*40(1) p.F76fs*24(1),cancer;gene_function_loss;,False,False,True,ENST00000256474;ENST00000345392;,2308.0,,0.0,7.3,False,True,False,,0.745276,,0.719,4.0,,,,,,,ACH-001687,7428.0
chr8,87353670,T,G,0.498,29,30,0/1,,SNP,MISSENSE,c.1187T>G,p.L396R,CNBD1,cyclic nucleotide binding domain containing 1,,ENST00000518476.6,10.0,+,Q8NA66,False,,,,0.2668329177057356,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:5,0.541415,,0.584,2.0,,,,,,,ACH-000392,168975.0
chr9,21971112,G,A,0.957,0,26,1|1,,SNP,MISSENSE,c.94C>T,p.H32Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913385,,as_specific,0.6982543640897756,,,False,,True,p.0(1543) p.P81fs*35(1) p.V82_E88del(1) p.H83Y(39) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.H83N(2) p.P81_A85del(1) p.R80fs*63(1) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1) p.V82fs*62(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;,,,,7.3,False,True,True,Misc:4,0.884844,0.9724149636314106,0.804,4.0,,,,,,,ACH-000392,1029.0
chr17,7674252,C,A,0.906,5,60,1|1,,SNP,MISSENSE,c.711G>T,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1066.0,,7.0,7.3,False,True,True,"smoking:1,Misc:3",0.91752,0.995844327753855,0.923,3.0,,,,,,,ACH-000392,7157.0
chr17,7674872,T,C,0.993,1,318,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-001542,7157.0
chr2,47429812,C,T,0.432,106,75,0/1,,SNP,NONSENSE,c.1147C>T,p.R383*,MSH2,mutS homolog 2,MutS homologs,ENST00000233146.7,7.0,+,P43246,False,rs63749849,,as_specific,0.3316708229426434,E,Rec,True,,False,p.R383*(4),cancer;gene_function_loss;dna_repair;,False,False,True,,727.0,,0.5,7.3,False,True,False,,0.988838,,,5.0,,,,,,,ACH-001345,4436.0
chr3,179234297,A,T,0.43,67,48,0/1,,SNP,MISSENSE,c.3140A>T,p.H1047L,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,1151.0,,12.5,7.3,True,False,True,"APOBEC:1,Misc:27",0.829278,,0.359,3.0,,,,,,,ACH-001345,5290.0
chr12,25245350,C,T,0.517,107,114,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001345,3845.0
chr2,29209798,C,T,0.452,81,67,0/1,,SNP,MISSENSE,c.3824G>A,p.R1275Q,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,25.0,-,Q9UM73,False,rs113994087,,as_specific,0.4763092269326683,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.R1275Q(87) p.R1275?(10) p.R1275L(5) p.R1275*(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000642122;ENST00000389048;ENST00000618119;,9.0,"ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.",23.0,7.3,True,False,False,,0.970662,0.7515153163777522,0.885,4.0,,,,,,,ACH-001300,238.0
chr2,177234225,C,G,0.376,66,38,0/1,,SNP,MISSENSE,c.44G>C,p.G15A,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.3890274314214463,E,Dom,False,,False,p.G31A(3) p.G31V(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,APOBEC:2,0.927893,0.6355940721378454,0.425,3.0,,,,,,,ACH-002188,4780.0
chr17,7674221,G,A,0.967,0,28,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-002188,7157.0
chr17,7674221,G,A,0.439,240,186,0/1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-001498,7157.0
chr2,61492337,C,T,0.524,25,25,0/1,,SNP,MISSENSE,c.1711G>A,p.E571K,XPO1,exportin 1,Exportins,ENST00000401558.7,15.0,-,O14980,False,rs1057520009,,as_specific,0.3067331670822942,L,Dom,False,,True,p.E571K(41) p.E571V(3) p.E571G(5) p.E571I(1) p.E571A(3) p.E571Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"CpG:1,POLE:4",0.979039,0.5942594365771144,0.579,4.0,,,,,,,ACH-001203,7514.0
chr8,21987235,C,T,0.881,8,62,0/1,,SNP,MISSENSE,c.1672C>T,p.R558C,XPO7,exportin 7,Exportins,ENST00000252512.14,14.0,+,Q9UIA9,False,rs1486570253,,as_specific,0.456359102244389,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:1,POLE:4",0.929422,0.8355317362585007,0.518,2.0,,,,,,,ACH-001203,23039.0
chr17,7674872,T,C,0.971,0,33,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-003071,7157.0
chr3,37014545,G,A,0.976,0,38,1|1,,SNP,SPLICE_SITE,c.e10+1G>A,,MLH1,mutL homolog 1,MutL homologs,ENST00000458205.6,,+,P40692,False,rs267607789,,as_specific,0.3690773067331671,"""E, O""",Rec,False,,False,p.?(4),splicing;cancer;gene_function_loss;dna_repair;,False,False,True,,731.0,,2.5,7.3,False,True,False,,0.972304,0.4673546425590275,,1.59129685669006,,,,,,,ACH-002275,4292.0
chr9,21971121,G,A,0.967,0,30,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-002275,1029.0
chr17,7675208,C,A,0.977,0,45,1|1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-000279,7157.0
chr7,140753336,A,T,0.459,103,87,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002096,673.0
chr3,179199088,G,A,0.514,46,47,0/1,,SNP,MISSENSE,c.263G>A,p.R88Q,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs121913287,,as_specific,0.3391521197007481,"""E, O""",Dom,False,,True,p.R88Q(147) p.R88L(1) p.R88?(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,929.0,,0.0,7.3,True,False,True,"CpG:11,MSI:1,POLE:17",0.947755,0.4551598659740948,0.806,3.0,,,,,,,ACH-002026,5290.0
chr12,25245350,C,A,0.509,126,127,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-002026,3845.0
chr17,7674229,C,T,0.943,3,96,1|1,,SNP,MISSENSE,c.734G>A,p.G245D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912656,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:9,0.965383,0.9964714944038346,0.974,3.0,,,,,,,ACH-000618,7157.0
chr3,10142103,C,T,0.929,0,12,1|1,,SNP,MISSENSE,c.256C>T,p.P86S,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs398123481,,as_specific,0.7032418952618454,"""E, M, O""",Rec,False,,True,p.V84fs*72(1) p.P86fs*72(2) p.P86L(5) p.S72_V87>L(1) p.V84_E94>E(1) p.L85_V87del(2) p.P86H(8) p.P86S(7) p.P86T(3) p.V84_P86del(1) p.P86R(1) p.L85fs*46(1) p.V87fs*72(2) p.L85fs*44(1) p.V84fs*69(1) p.R60fs*35(1) p.P86fs*73(1) p.P86fs*42(1) p.P86A(1) p.F76fs*24(1),cancer;gene_function_loss;,False,True,True,ENST00000256474;ENST00000345392;,1902.0,,42.5,7.3,False,True,False,,0.560478,0.6375405313600008,0.879,4.0,,,,,,,ACH-002192,7428.0
chr17,7673802,C,A,0.971,0,32,1|1,,SNP,MISSENSE,c.818G>T,p.R273L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,918.0,,0.0,7.3,False,True,True,"smoking:15,Misc:9",0.887493,0.7009283873752175,0.921,3.0,,,,,,,ACH-000733,7157.0
chr2,177234076,C,T,0.538,37,41,0/1,,SNP,MISSENSE,c.193G>A,p.G65S,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.4089775561097257,E,Dom,False,,False,p.G81_F83delGEF(2) p.G81S(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:1,0.88056,0.4432380589086047,0.511,3.0,,,,,,,ACH-002213,4780.0
chr11,533874,T,A,0.982,0,56,1|1,,SNP,MISSENSE,c.182A>T,p.Q61L,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,3.0,-,P01112,False,rs121913233,,as_specific,0.6458852867830424,"""E, L, M""",Dom,False,,True,p.Q61R(289) p.Q61K(113) p.Q61L(184) p.Q61H(24) p.Q61?(16) p.Q61P(3) p.Q61*(1) p.Q61Q(1) p.Q61E(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,854.0,,0.0,7.3,True,True,True,"smoking:2,Misc:4",0.786029,0.9921539220757206,0.839,4.0,,,,,,,ACH-002213,3265.0
chr7,140781611,C,A,0.437,46,36,0/1,,SNP,MISSENSE,c.1397G>T,p.G466V,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,11.0,-,P15056,False,rs121913351,,as_specific,0.3591022443890274,E,Dom,False,"""AKAP9, KIAA1549""",True,p.G466V(34) p.G466E(17) p.G466A(5) p.G466R(13) p.G466?(2),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,2222.0,,14.0,7.3,True,False,True,"smoking:5,Misc:1",0.903772,,0.962,4.0,,,,,,,ACH-000826,673.0
chr9,21971187,G,A,0.941,0,15,1|1,,SNP,NONSENSE,c.19C>T,p.R7*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913387,,as_specific,0.6458852867830424,,,True,,True,p.0(1543) p.R58*(112) p.A4_P11del(12) p.V28_V51del(1) p.?(5) p.M54fs*61(2) p.R58fs*61(2) p.P3_P11del(2) p.R58fs*59(2) p.M53_R58del(3) p.A57fs*85(1) p.A57_R58>V*(1) p.G55fs*86(1) p.G55fs*61(1) p.S7_A19del(1) p.R58fs*62(1) p.R58R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:10,UV:4",0.788085,0.9908618465891524,0.22,5.0,,,,,,,ACH-000826,1029.0
chr17,7675208,C,A,0.951,0,19,1|1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-000826,7157.0
chr3,138655402,T,A,0.383,68,44,0/1,,SNP,MISSENSE,c.3200A>T,p.D1067V,PIK3CB,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit beta,Phosphatidylinositol 3-kinase subunits,ENST00000674063.1,24.0,-,P42338,False,,,,0.3965087281795511,,,False,,False,p.D1067V(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:2,0.877675,0.8684901576871266,0.65,4.0,,,,,,,ACH-002189,5291.0
chr17,7674893,C,T,0.49,31,27,0|1,7674893.0,SNP,MISSENSE,c.638G>A,p.R213Q,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs587778720,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"CpG:2,UV:1,POLE:2",0.920288,0.776972471915739,0.92,3.0,,,,,,,ACH-002189,7157.0
chr17,7674894,G,A,0.509,27,31,1|0,7674893.0,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-002189,7157.0
chr1,114713909,G,T,0.468,107,95,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-001618,4893.0
chr12,25245350,C,T,0.469,193,169,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001098,3845.0
chr1,114713908,T,A,0.421,106,77,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000002,4893.0
chr2,74415153,T,G,0.377,4,2,0|1,74415153.0,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000002,388963.0
chr9,21971121,G,A,0.959,0,22,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-000002,1029.0
chr2,74415153,T,G,0.6,1,2,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002361,388963.0
chr17,35750138,T,G,0.182,31,7,0/1,,SNP,MISSENSE,c.566A>C,p.D189A,GAS2L2,growth arrest specific 2 like 2,,ENST00000604641.6,2.0,-,Q8NHY3,False,rs1192558412,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.610651,0.5095418527025265,0.061,2.0,,,,,,,ACH-000482,246176.0
chr1,114713908,T,A,0.48,181,169,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000915,4893.0
chr2,74415153,T,G,0.428,3,2,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000915,388963.0
chr2,137616283,G,A,0.214,324,87,0/1,,SNP,MISSENSE,c.3532G>A,p.E1178K,THSD7B,thrombospondin type 1 domain containing 7B,,ENST00000409968.6,18.0,+,Q9C0I4,False,,,,0.3965087281795511,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:10,0.841992,,0.147,2.0,,,,,,,ACH-000915,80731.0
chr8,24330030,G,A,0.51,77,81,0/1,,SNP,MISSENSE,c.1018G>A,p.E340K,ADAM28,ADAM metallopeptidase domain 28,ADAM metallopeptidase domain containing,ENST00000265769.9,11.0,+,Q9UKQ2,False,rs1303422157,,as_specific,0.4389027431421446,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.941061,0.4816883945654127,0.69,3.0,,,,,,,ACH-000915,10863.0
chr17,7674894,G,A,0.914,1,20,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000915,7157.0
chr19,55810246,G,A,0.417,64,46,0/1,,SNP,MISSENSE,c.364C>T,p.R122C,NLRP11,NLR family pyrin domain containing 11,NLR family Pyrin domain containing,ENST00000589093.5,3.0,-,P59045,False,rs762382161,,as_specific,0.3790523690773067,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:3,POLE:5",0.789354,0.4940730716066587,0.167,1.0,,,,,,,ACH-000915,204801.0
chr4,152326137,G,A,0.505,53,56,0/1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-000565,55294.0
chr5,112792446,C,T,0.326,34,15,0/1,,SNP,SPLICE_SITE,c.646C>T,p.R216*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,7.0,+,P25054,False,rs62619935,,as_specific,0.286783042394015,"""E, M, O""",Rec,False,,True,p.R216*(37),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:8,0.976009,0.6330647374785708,,5.0,,,,,,,ACH-000565,324.0
chr12,25245350,C,A,0.919,1,21,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000565,3845.0
chr17,7673704,G,A,0.984,0,62,1|1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-000565,7157.0
chr18,51065549,G,A,0.978,0,41,1|1,,SNP,MISSENSE,c.794G>A,p.R265H,SMAD4,SMAD family member 4,SMAD family,ENST00000588745.5,5.0,+,Q13485,False,rs377767347,,as_specific,0.3740648379052369,,,False,,True,p.R361H(38) p.0(28) p.T265I(1),cancer;gene_function_loss;,False,False,True,ENST00000398417;ENST00000342988;ENST00000588745;,,,,7.3,False,True,True,"CpG:5,POLE:1",0.950582,,0.955,3.0,,,,,,,ACH-000565,4089.0
chr1,205584907,G,A,0.501,102,105,0/1,,SNP,SILENT,c.891G>A,p.R297R,MFSD4A,major facilitator superfamily domain containing 4A,,ENST00000367147.9,5.0,+,Q8N468,False,,,,0.5835411471321695,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:3,APOBEC:1",0.27733,,,0.0,,,,,,,ACH-000835,148808.0
chr7,140753336,A,T,0.558,42,48,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000835,673.0
chr3,179218303,G,A,0.979,0,49,1|1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-002180,5290.0
chr4,1801841,C,G,0.526,8,10,0/1,,SNP,MISSENSE,c.746C>G,p.S249C,FGFR3,fibroblast growth factor receptor 3,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000481110.6,7.0,+,P22607,False,rs121913483,,as_specific,0.685785536159601,"""L, E""",Dom,False,"""IGH@, ETV6""",True,p.S249C(2119) p.R248_S249insC(1) p.R248_S249delRS(1) p.R248_S249insL(1) p.S249T(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000440486;ENST00000481110;ENST00000340107;ENST00000412135;ENST00000613647;ENST00000352904;ENST00000507588;,628.0,,11.0,7.3,True,False,True,"smoking:1,APOBEC:29,Misc:1",0.910414,0.5885492886327983,0.902,3.0,,,,,,,ACH-002180,2261.0
chr4,152326215,G,C,0.5,33,35,0/1,,SNP,MISSENSE,c.1195C>G,p.R399G,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs747241612,,as_specific,0.3690773067331671,"""E, L""",Rec,False,,True,p.R479G(6) p.R479fs*6(3) p.R479*(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"APOBEC:2,Misc:1",0.95731,0.8017648428317331,0.571,4.0,,,,,,,ACH-002180,55294.0
chr1,114713908,T,C,0.994,0,172,1|1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-000875,4893.0
chr17,7675994,C,T,0.983,0,60,1|1,,SNP,SPLICE_SITE,c.375G>A,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:5,0.392984,0.6099495421221454,,0.0,,,,,,,ACH-000875,7157.0
chr12,25245350,C,T,0.852,63,375,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000339,3845.0
chr10,87933147,C,T,0.987,0,85,1|1,,SNP,NONSENSE,c.388C>T,p.R130*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,5.0,+,P60484,False,rs121909224,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R130G(140) p.R130Q(108) p.R130fs*4(13) p.R130fs*2(1) p.K128_R130del(4) p.0(28) p.R130L(19) p.R130*(83) p.R130P(7) p.R55fs*1(1) p.R130?(1) p.R130fs*?(5) p.R130R(1) p.R130_T131>P(4) p.R130fs*50(1) p.G129fs*50(1) p.Y27_N212>Y(2) p.G129fs*51(1) p.F56fs*2(1) p.?(1) p.K125fs*46(1) p.A121_F145del(1) p.K128fs*47(1) p.R130Xfs*?(1),cancer;gene_function_loss;,False,False,True,,636.0,,2.0,7.3,False,True,False,,0.97629,0.898071104088428,,4.0,,,,,,,ACH-000897,5728.0
chr17,7673802,C,T,0.97,0,31,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000897,7157.0
chr1,18482884,G,A,0.402,11,7,0/1,,SNP,MISSENSE,c.1903G>A,p.E635K,KLHDC7A,kelch domain containing 7A,,ENST00000400664.2,1.0,+,Q5VTJ3,False,,,,0.6957605985037406,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:12,0.519318,0.610893992681146,0.341,2.0,,,,,,,ACH-000935,127707.0
chr4,55090053,C,T,0.373,48,28,0/1,,SNP,MISSENSE,c.3095G>A,p.R1032Q,KDR,kinase insert domain receptor,I-set domain containing CD molecules V-set domain containing Immunoglobulin like domain containing Receptor Tyrosine Kinases,ENST00000263923.5,23.0,-,P35968,False,rs1190050670,,as_specific,0.4139650872817955,E,Dom,False,,False,p.R1032Q(3) p.R1032*(2),cancer;gene_function_gain;,False,False,True,ENST00000645273;ENST00000263923;,,,,7.3,True,False,True,"UV:7,POLE:2",0.936328,0.7230888046184373,0.844,4.0,,,,,,,ACH-000935,3791.0
chr7,134449780,G,A,0.172,376,75,0/1,,SNP,SILENT,c.369C>T,p.F123F,AKR1B1,aldo-keto reductase family 1 member B,Aldo-keto reductases,ENST00000285930.9,4.0,-,P15121,False,,,,0.4413965087281795,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.447737,,,0.0,,,,,,,ACH-000935,231.0
chr7,140753336,AC,TT,0.823,32,144,0/1,,DNP,MISSENSE,c.1798_1799GT>AA,p.V600K,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs121913227,,as_specific,0.3383084577114428,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,,563.0,,107.5,7.3,True,False,False,,,,,,,,,,,,ACH-000935,673.0
chr8,24401924,C,T,0.622,51,81,0/1,,SNP,SILENT,c.1152C>T,p.F384F,ADAMDEC1,ADAM like decysin 1,,ENST00000256412.8,12.0,+,O15204,False,,,,0.3890274314214463,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.389375,0.7660207150085191,,0.0,,,,,,,ACH-000935,27299.0
chr9,21971121,G,A,0.925,0,11,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-000935,1029.0
chr16,20948554,C,T,0.365,40,22,0/1,,SNP,MISSENSE,c.11272G>A,p.E3758K,DNAH3,dynein axonemal heavy chain 3,"Dyneins, axonemal",ENST00000261383.3,57.0,-,Q8TD57,False,rs868191973,,as_specific,0.5336658354114713,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:5,POLE:1",0.842971,0.5833986939601346,0.17,2.0,,,,,,,ACH-000935,55567.0
chr1,38045466,T,G,0.389,6,4,0|1,38045451.0,SNP,SILENT,c.1278A>C,p.P426P,POU3F1,POU class 3 homeobox 1,POU class homeoboxes and pseudogenes,ENST00000373012.5,1.0,-,Q03052,False,rs746275953,,as_specific,0.7007481296758105,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.3252,0.6755287290451399,,0.0,,,,,,,ACH-002182,5453.0
chr1,47302272,G,A,0.337,358,178,0/1,,SNP,MISSENSE,c.227C>T,p.S76L,STIL,"STIL, centriolar assembly protein",,ENST00000360380.7,5.0,-,Q15468,False,rs147160336,,as_specific,0.371571072319202,,,False,insAAAAG,False,,cancer;structural_relation;,False,False,True,,,,,3.43,False,False,True,"UV:1,POLE:5",0.662729,0.9307931768294434,0.073,3.0,,,,,,,ACH-000655,6491.0
chr7,55154129,C,T,0.293,319,128,0/1,,SNP,MISSENSE,c.731C>T,p.A244V,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,6.0,+,P00533,False,rs149840192,,as_specific,0.5985037406483791,"""E, O""",Dom,False,,True,p.A289V(13) p.V30_R297>G(5) p.A289D(2),cancer;gene_function_gain;,False,False,True,,996.0,,3.0,7.3,True,False,True,Misc:15,0.935273,0.7748146050567428,0.647,4.0,,,,,,,ACH-000655,1956.0
chr17,7673802,C,T,0.998,0,668,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000655,7157.0
chr2,177234232,C,G,0.572,17,24,0/1,,SNP,MISSENSE,c.37G>C,p.D13H,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,rs1057519920,,as_specific,0.3890274314214463,E,Dom,False,,True,p.D29N(3) p.D29H(8) p.I28_D29del(1) p.D29Y(1),cancer;gene_function_gain;,False,False,True,ENST00000397063;ENST00000397062;ENST00000446151;ENST00000464747;ENST00000449627;ENST00000448782;ENST00000586532;ENST00000421929;ENST00000423513;ENST00000588123;,,,,7.3,True,False,True,APOBEC:12,0.939766,0.7123089440446881,0.711,3.0,,,,,,,ACH-000726,4780.0
chr17,7674894,G,A,0.901,2,33,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000726,7157.0
chr17,7673803,G,A,0.964,0,26,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000041,7157.0
chr17,7674872,T,C,0.97,0,33,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000499,7157.0
chr4,152326137,G,A,0.467,70,61,0|1,152326117.0,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-000995,55294.0
chr7,55160191,C,T,0.263,48,16,0/1,,SNP,MISSENSE,c.1216C>T,p.R406C,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,11.0,+,P00533,False,rs377567759,,as_specific,0.399002493765586,"""E, O""",Dom,False,,False,p.R451F(1),cancer;gene_function_gain;,False,False,True,ENST00000455089;ENST00000342916;ENST00000454757;ENST00000344576;ENST00000275493;ENST00000638463;,454.0,,2.0,4.61,True,False,False,,0.866565,0.4756760940862369,0.92,4.0,,,,,,,ACH-000995,1956.0
chr7,140734715,G,A,0.409,110,82,0/1,,SNP,MISSENSE,c.2183C>T,p.A728V,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,18.0,-,P15056,False,,,,0.3665835411471321,E,Dom,False,"""AKAP9, KIAA1549""",False,,cancer;gene_function_gain;structural_relation;,False,False,True,,1198.0,,2.0,7.3,True,False,False,,0.932197,0.5112538785945971,0.508,4.0,,,,,,,ACH-000995,673.0
chr16,627527,G,A,0.237,93,27,0/1,,SNP,MISSENSE,c.751G>A,p.G251S,RAB40C,"RAB40C, member RAS oncogene family","RAB, member RAS oncogene GTPases",ENST00000248139.8,6.0,+,Q96S21,False,rs145997805,,as_specific,0.6608478802992519,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,MSI:1,0.382905,,0.051,3.0,,,,,,,ACH-000995,57799.0
chr17,7674945,G,A,0.5,23,22,0/1,,SNP,NONSENSE,c.586C>T,p.R196*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516435,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R196*(221) p.R196P(18) p.R196Q(5) p.R196R(6) p.I195fs*12(1) p.R196_R202del(1) p.R196fs*51(4) p.I195_G199delIRVEG(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.R196L(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.R196fs*13(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.986209,0.7393785927987923,,4.0,,,,,,,ACH-000995,7157.0
chr17,7675994,C,T,0.367,56,32,0/1,,SNP,SPLICE_SITE,c.375G>A,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:5,0.392984,0.6099495421221454,,0.0,,,,,,,ACH-000995,7157.0
chr19,11033318,G,A,0.471,61,56,0/1,,SNP,MISSENSE,c.3575G>A,p.R1192H,SMARCA4,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4",Bromodomain containing,ENST00000344626.9,26.0,+,P51532,False,,,,0.6309226932668329,E,Rec,False,,False,p.R1192G(1) p.D1183_M1317del(1),cancer;gene_function_loss;,False,False,True,ENST00000344626;ENST00000643549;ENST00000646693;ENST00000642726;ENST00000646484;ENST00000644737;ENST00000642628;ENST00000643296;ENST00000647230;ENST00000646510;ENST00000429416;ENST00000645460;ENST00000541122;ENST00000589677;ENST00000444061;ENST00000590574;ENST00000413806;ENST00000450717;ENST00000643208;ENST00000642350;ENST00000647268;,,,,7.3,False,True,True,"CpG:1,MSI:1",0.954787,0.8464081146800616,0.97,4.0,,,,,,,ACH-000995,6597.0
chr19,47069155,C,G,0.31,97,42,0/1,,SNP,MISSENSE,c.2335G>C,p.E779Q,ZC3H4,zinc finger CCCH-type containing 4,Zinc fingers CCCH-type,ENST00000253048.10,14.0,-,Q9UPT8,False,rs756950439,,as_specific,0.6783042394014963,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:4,0.890018,0.4849699719102638,0.121,3.0,,,,,,,ACH-000995,23211.0
chr17,7675140,G,C,0.958,1,46,1|1,,SNP,MISSENSE,c.472C>G,p.R158G,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.R156fs*12(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:2,0.832892,0.7785254108979192,0.862,3.0,,,,,,,ACH-000368,7157.0
chr17,41516933,C,T,0.972,1,72,1|1,,SNP,MISSENSE,c.613G>A,p.V205I,KRT15,keratin 15,"Keratins, type I",ENST00000393976.6,5.0,-,P19012,False,rs138271368,,as_specific,0.5910224438902744,,,False,,False,,cancer;,False,False,True,,,,,4.01,False,False,True,"CpG:12,Misc:1",0.364973,0.8570172175887601,0.586,3.0,,,,,,,ACH-000368,3866.0
chr6,46140105,G,A,0.273,152,57,0/1,,SNP,SILENT,c.522G>A,p.S174S,ENPP4,ectonucleotide pyrophosphatase/phosphodiesterase 4,,ENST00000321037.5,2.0,+,Q9Y6X5,False,rs751766694,,as_specific,0.4014962593516209,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:3,POLE:5",0.180625,0.848781258809006,,0.0,,,,,,,ACH-000401,22875.0
chr7,140753336,A,T,0.65,36,63,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000401,673.0
chr17,7675209,A,G,0.867,3,25,0/1,,SNP,MISSENSE,c.403T>C,p.C135R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519975,,as_specific,0.5536159600997507,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.?(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,Misc:3,0.94193,0.2485372874595451,0.964,3.0,,,,,,,ACH-000401,7157.0
chr17,7673802,C,T,0.941,0,15,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000121,7157.0
chr4,186618797,G,A,0.998,0,428,1|1,,SNP,NONSENSE,c.7789C>T,p.R2597*,FAT1,FAT atypical cadherin 1,Cadherin related,ENST00000441802.7,10.0,-,Q14517,False,rs777631605,,as_specific,0.42643391521197,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:2,POLE:5",0.965983,,,3.0,,,,,,,ACH-002091,2195.0
chr17,7675160,G,T,0.97,0,32,1|1,,SNP,MISSENSE,c.452C>A,p.P151H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057520000,,as_specific,0.5835411471321695,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.P151A(10) p.P151S(78) p.P151P(15) p.S149fs*72(1) p.P151H(29) p.P151T(16) p.P151fs*30(8) p.P151L(8) p.T150_P151del(1) p.P151R(9) p.P153fs*28(1) p.D148fs*23(1) p.T150fs*16(4) p.P153delP(2) p.T150_P151delTP(1) p.P152fs*28(1) p.V143_P153del(1) p.P151_V173del23(1) p.P152fs*14(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"smoking:1,Misc:3",0.897467,0.7204064233224524,0.87,3.0,,,,,,,ACH-002091,7157.0
chr12,25225628,C,T,0.996,0,273,1|1,,SNP,MISSENSE,c.436G>A,p.A146T,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,906.0,,21.0,7.3,True,False,True,"MSI:3,Misc:4",0.951882,0.7493523432445548,0.909,4.0,,,,,,,ACH-000252,3845.0
chr17,7674230,C,T,0.972,0,37,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-000252,7157.0
chr17,7673787,G,C,0.996,0,270,1|1,,SNP,MISSENSE,c.833C>G,p.P278R,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs876659802,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:2,0.892025,,0.951,3.0,,,,,,,ACH-001386,7157.0
chr12,25245350,C,G,0.954,0,22,1|1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-002102,3845.0
chr1,114713908,T,A,0.436,67,53,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000881,4893.0
chr11,534285,C,T,0.947,0,17,1|1,,SNP,MISSENSE,c.38G>A,p.G13D,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,2.0,-,P01112,False,rs104894226,,as_specific,0.6758104738154613,"""E, L, M""",Dom,False,,True,p.G13C(7) p.G13R(341) p.G13D(23) p.G13S(20) p.G13V(23) p.G13N(1) p.G12_G13insAG(1) p.G13I(2) p.G13G(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,274.0,,7.5,7.3,True,True,True,"UV:2,Misc:1",0.863157,0.9915849661786216,0.736,4.0,,,,,,,ACH-000881,3265.0
chr14,19781125,C,T,0.454,45,40,0/1,,SNP,MISSENSE,c.803C>T,p.S268F,OR4M1,olfactory receptor family 4 subfamily M member 1,"Olfactory receptors, family 4",ENST00000641200.1,2.0,+,Q8NGD0,False,,,,0.4039900249376558,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.407885,,0.191,2.0,,,,,,,ACH-000881,441670.0
chr19,58499498,G,A,0.37,18,10,0/1,,SNP,MISSENSE,c.1409C>T,p.T470I,SLC27A5,solute carrier family 27 member 5,Solute carriers Acyl-CoA synthetase family,ENST00000601355.1,7.0,-,Q9Y2P5,False,,,,0.6533665835411472,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:13,0.911109,0.5951441230767975,0.581,2.0,,,,,,,ACH-000881,10998.0
chr3,138946321,G,C,0.502,22,22,0/1,,SNP,MISSENSE,c.402C>G,p.C134W,FOXL2,forkhead box L2,Forkhead boxes,ENST00000648323.1,1.0,-,P58012,False,rs1057519865,,as_specific,0.6733167082294265,O,Dom,False,,True,p.C134W(534) p.C134C(1),cancer;gene_function_gain;gene_function_loss;,False,True,True,ENST00000648323;ENST00000330315;,198.0,"The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.",70.0,7.3,True,True,False,,0.669192,0.9204190217867712,0.884,3.0,,,,,,,ACH-002149,668.0
chr3,185152807,G,A,0.333,40,20,0/1,,SNP,MISSENSE,c.17C>T,p.S6L,C3orf70,chromosome 3 open reading frame 70,,ENST00000335012.3,1.0,-,A6NLC5,False,rs757159118,,as_specific,0.713216957605985,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,,0.537681,0.2540093356083243,0.084,2.0,,,,,,,ACH-001402,285382.0
chr12,25245351,C,A,0.623,120,203,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-001402,3845.0
chr16,69711199,C,T,0.304,57,24,0/1,,SNP,MISSENSE,c.500G>A,p.R167Q,NQO1,NAD(P)H quinone dehydrogenase 1,,ENST00000379047.7,5.0,-,P15559,False,rs766847268,,as_specific,0.4588528678304239,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:4,0.927174,,0.362,2.0,,,,,,,ACH-001402,1728.0
chr19,1220641,C,T,0.72,22,56,0|1,1220630.0,SNP,NONSENSE,c.658C>T,p.Q220*,STK11,serine/threonine kinase 11,,ENST00000326873.12,5.0,+,Q15831,False,rs1131690940,,as_specific,0.7182044887780549,"""E, M, O""",Rec,True,,True,p.Q220*(4) p.0(15),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,smoking:2,0.985752,0.9958392207664156,,4.0,,,,,,,ACH-001402,6794.0
chr17,7674953,T,C,0.998,1,918,1|1,,SNP,MISSENSE,c.578A>G,p.H193R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs786201838,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193L(40) p.H193_I195delHLI(1) p.H193R(78) p.H193Y(29) p.?(2) p.H193D(10) p.H193P(15) p.H193N(7) p.P191fs*53(2) p.A189_V197delAPPQHLIRV(4) p.H193H(2) p.H193fs*16(3) p.A189fs*53(1) p.P191fs*6(1) p.K164_P219del(1) p.H193_I195>AP(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:16,0.888726,0.7365336169861475,0.884,3.0,,,,,,,ACH-000823,7157.0
chr12,25245350,C,T,0.603,33,52,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002186,3845.0
chr17,7673823,C,A,0.956,0,21,1|1,,SNP,MISSENSE,c.797G>T,p.G266V,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs193920774,,as_specific,0.5236907730673317,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G266V(35) p.G266R(59) p.G266E(59) p.G262_S269delGNLLGRNS(2) p.G266_E271delGRNSFE(2) p.G266fs*79(6) p.G266fs*9(1) p.G266*(14) p.E258fs*71(1) p.G266S(1) p.G266G(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.G266T(1) p.G266A(3) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:8",0.944543,0.742718688783359,0.974,3.0,,,,,,,ACH-002186,7157.0
chr17,7674230,C,T,0.972,0,33,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-002308,7157.0
chr19,11033317,C,T,0.487,39,38,0/1,,SNP,MISSENSE,c.3574C>T,p.R1192C,SMARCA4,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4",Bromodomain containing,ENST00000344626.9,26.0,+,P51532,False,,,,0.628428927680798,E,Rec,False,,False,p.R1192G(1) p.D1183_M1317del(1),cancer;gene_function_loss;,False,False,True,ENST00000344626;ENST00000643549;ENST00000646693;ENST00000642726;ENST00000646484;ENST00000644737;ENST00000642628;ENST00000643296;ENST00000647230;ENST00000646510;ENST00000429416;ENST00000645460;ENST00000541122;ENST00000589677;ENST00000444061;ENST00000590574;ENST00000413806;ENST00000450717;ENST00000643208;ENST00000642350;ENST00000647268;,,,,7.3,False,True,True,"CpG:3,UV:2",0.945566,0.8416027746955556,0.939,4.0,,,,,,,ACH-002308,6597.0
chr12,25225628,C,G,0.739,49,137,0/1,,SNP,MISSENSE,c.436G>C,p.A146P,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,905.0,,7.5,7.3,True,False,False,,0.968872,0.6595086461751286,0.935,4.0,,,,,,,ACH-002246,3845.0
chr17,7674894,G,A,0.997,1,541,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-001415,7157.0
chr17,7674252,C,A,0.992,0,150,1|1,,SNP,MISSENSE,c.711G>T,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1066.0,,7.0,7.3,False,True,True,"smoking:1,Misc:3",0.91752,0.995844327753855,0.923,3.0,,,,,,,ACH-001113,7157.0
chr3,179218303,G,A,0.25,86,27,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000824,5290.0
chr12,25079261,C,T,0.423,117,84,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-000824,Unknown
chr17,7670682,C,A,0.338,44,23,0/1,,SNP,NONSENSE,c.1027G>T,p.E343*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,,,,0.4937655860349127,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R342_N345delRELN(1) p.M340fs*2(1) p.E343*(10) p.F341fs*2(1) p.I332fs*5(1) p.E343fs*3(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,smoking:3,0.962923,0.6473102813071807,,3.0,,,,,,,ACH-000824,7157.0
chr17,7674220,C,T,0.48,41,40,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001163,7157.0
chr17,7675175,C,T,0.897,2,26,0/1,,SNP,NONSENSE,c.437G>A,p.W146*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1206165503,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.L137_W146del10(1) p.W146*(77) p.W146C(2) p.W146fs*23(1) p.Q144fs*32(1) p.W146R(5) p.W146fs*1(1) p.W146fs*22(1) p.V143_P153del(1) p.W146_V147insXXXXXXX(1) p.W146S(1) p.V143_S149delVQLWVDS(1) p.Q144_G154del11(1) p.W146fs*25(1) p.W146G(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:2,0.973064,0.4974007156256589,,3.0,,,,,,,ACH-000541,7157.0
chr1,111231257,C,A,0.338,51,27,0/1,,SNP,MISSENSE,c.292C>A,p.L98I,CHI3L2,chitinase 3 like 2,Chitinases,ENST00000445067.6,6.0,+,Q15782,False,rs1039610150,,as_specific,0.3890274314214463,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.789134,0.476784583335317,0.186,4.0,,,,,,,ACH-000191,1117.0
chr7,140753336,A,T,0.716,40,102,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000191,673.0
chr3,37014545,G,A,0.929,1,25,1|1,,SNP,SPLICE_SITE,c.e10+1G>A,,MLH1,mutL homolog 1,MutL homologs,ENST00000458205.6,,+,P40692,False,rs267607789,,as_specific,0.3690773067331671,"""E, O""",Rec,False,,False,p.?(4),splicing;cancer;gene_function_loss;dna_repair;,False,False,True,,731.0,,2.5,7.3,False,True,False,,0.972304,0.4673546425590275,,1.59129685669006,,,,,,,ACH-000960,4292.0
chr10,94358187,T,C,0.538,75,85,0/1,,SNP,SILENT,c.246A>G,p.E82E,NOC3L,NOC3 like DNA replication regulator,,ENST00000371361.3,3.0,-,Q8WTT2,False,rs1484111564,,as_specific,0.3915211970074813,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.202088,,,0.0,,,,,,,ACH-000960,64318.0
chr17,7674252,C,A,0.925,42,510,1|1,,SNP,MISSENSE,c.711G>T,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1066.0,,7.0,7.3,False,True,True,"smoking:1,Misc:3",0.91752,0.995844327753855,0.923,3.0,,,,,,,ACH-000452,7157.0
chr9,21971121,G,A,0.997,0,312,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-001096,1029.0
chr1,114713908,T,A,0.93,17,228,1|1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-002120,4893.0
chr6,161107946,G,A,0.972,0,36,1|1,,SNP,MISSENSE,c.4096G>A,p.G1366R,MAP3K4,mitogen-activated protein kinase kinase kinase 4,Mitogen-activated protein kinase kinase kinases,ENST00000392142.9,21.0,+,Q9Y6R4,False,,,,0.4812967581047381,,,False,,False,p.G1366R(5),cancer;,False,False,True,,,,,7.3,False,False,True,CpG:3,0.903475,,0.564,4.0,,,,,,,ACH-002120,4216.0
chr7,140753336,A,T,0.692,46,97,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000827,673.0
chr17,7674221,G,A,0.971,0,34,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000717,7157.0
chr6,87015770,G,A,0.977,0,44,1|1,,SNP,MISSENSE,c.436G>A,p.V146I,HTR1E,5-hydroxytryptamine receptor 1E,"5-hydroxytryptamine receptors, G protein-coupled",ENST00000305344.7,2.0,+,P28566,False,rs200719637,,as_specific,0.5386533665835411,,,False,,False,,cancer;,False,False,True,,,,,4.01,False,False,True,CpG:5,0.390972,0.4787399617294208,0.504,3.0,,,,,,,ACH-001861,3354.0
chr12,25245351,C,G,0.708,22,54,0/1,,SNP,MISSENSE,c.34G>C,p.G12R,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,530.0,,32.5,7.3,True,False,True,"smoking:1,Misc:32",0.915109,0.6459561688690294,0.821,4.0,,,,,,,ACH-000502,3845.0
chr1,26773456,C,T,0.385,76,49,0/1,,SNP,NONSENSE,c.3826C>T,p.R1276*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,15.0,+,O14497,False,,,,0.57356608478803,E,Rec,True,1507,True,p.R1276*(6) p.M1273fs(1),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:2,0.967435,,,5.0,,,,,,,ACH-001145,8289.0
chr3,179199148,G,A,0.744,20,59,0/1,,SNP,MISSENSE,c.323G>A,p.R108H,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs886042002,,as_specific,0.3092269326683292,"""E, O""",Dom,False,,True,p.R108H(27) p.G106_R108del(3) p.R108P(1) p.R108C(2) p.R108L(1) p.V105_R108del(2) p.G106_R108delGNR(1) p.R108del(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,CpG:6,0.929086,,0.466,3.0,,,,,,,ACH-001145,5290.0
chr12,56085070,G,A,0.691,113,238,0/1,,SNP,MISSENSE,c.310G>A,p.V104M,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,3.0,+,P21860,False,rs1057519893,,as_specific,0.4937655860349127,,,False,,True,p.V104L(1) p.V104M(6),cancer;gene_function_gain;,False,True,True,,701.0,,15.0,7.3,True,False,True,CpG:12,0.711747,,0.584,4.0,,,,,,,ACH-001145,2065.0
chr17,7673802,C,T,0.998,0,589,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001145,7157.0
chr19,47069155,C,G,0.248,204,62,0/1,,SNP,MISSENSE,c.2335G>C,p.E779Q,ZC3H4,zinc finger CCCH-type containing 4,Zinc fingers CCCH-type,ENST00000253048.10,14.0,-,Q9UPT8,False,rs756950439,,as_specific,0.6783042394014963,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:4,0.890018,0.4849699719102638,0.121,3.0,,,,,,,ACH-001145,23211.0
chr2,201285316,C,T,0.703,63,163,0/1,,SNP,SPLICE_SITE,c.1303C>T,p.R435*,CASP8,caspase 8,Caspases Death effector domain containing Ripoptosome Death inducing signaling complex ,ENST00000673742.1,8.0,+,Q14790,False,rs1368296717,,as_specific,0.4588528678304239,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,POLE:1",0.983275,0.362918514097208,,4.0,,,,,,,ACH-001414,841.0
chr3,49375472,C,G,0.495,56,58,0/1,,SNP,MISSENSE,c.118G>C,p.E40Q,RHOA,ras homolog family member A,Rho family GTPases,ENST00000422781.5,2.0,-,P61586,False,rs1057519951,,as_specific,0.4164588528678304,,,False,,False,p.E40V(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,APOBEC:5,0.953878,0.2905929774946746,0.633,3.0,,,,,,,ACH-001414,387.0
chr3,179218303,G,A,0.388,67,43,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-001414,5290.0
chr4,1801837,C,T,0.487,63,60,0/1,,SNP,MISSENSE,c.742C>T,p.R248C,FGFR3,fibroblast growth factor receptor 3,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000481110.6,7.0,+,P22607,False,rs121913482,,as_specific,0.685785536159601,"""L, E""",Dom,False,"""IGH@, ETV6""",True,p.R248C(423) p.R248H(2) p.R248_S249insC(1) p.R248_S249delRS(1) p.R248_S249insL(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000440486;ENST00000481110;ENST00000340107;ENST00000412135;ENST00000613647;ENST00000352904;ENST00000507588;,2403.0,,0.0,7.3,True,False,False,,0.746396,0.5773203331809318,0.855,3.0,,,,,,,ACH-001414,2261.0
chr17,7675088,C,T,0.906,3,43,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000588,7157.0
chr1,114713909,G,T,0.841,86,458,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-001363,4893.0
chr17,7673790,C,A,0.958,2,66,1|1,,SNP,MISSENSE,c.830G>T,p.C277F,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs763098116,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C277Y(17) p.C275fs*67(1) p.C277*(8) p.C277C(4) p.C277G(9) p.C277W(3) p.C277F(26) p.C277S(2) p.C277fs*68(1) p.V274_P278delVCACP(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.C277fs*?(1) p.C277fs*29(2) p.V272_K292del21(1) p.A276fs*64(1) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.A276_C277delAC(1) p.L265_K305del41(1) p.C277R(2) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:2",0.917615,0.8063810398136229,0.932,3.0,,,,,,,ACH-001363,7157.0
chr2,74415153,T,G,0.6,1,2,0|1,74415153.0,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000421,388963.0
chr5,112780895,C,T,0.333,40,19,0/1,,SNP,NONSENSE,c.637C>T,p.R213*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,6.0,+,P25054,False,rs587781392,,as_specific,0.3092269326683292,"""E, M, O""",Rec,True,,True,p.R213*(56) p.R213fs*39(1) p.R213fs*?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:16,0.977364,,,5.0,,,,,,,ACH-000421,324.0
chr5,112839942,C,T,0.661,40,81,0/1,,SNP,NONSENSE,c.4348C>T,p.R1450*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913332,,as_specific,0.456359102244389,"""E, M, O""",Rec,True,,True,p.R1450*(222) p.R1450fs*5(1) p.P1424fs*19(1) p.R1450fs*20(1) p.R1450fs*22(1) p.R1435fs*23(1) p.?(1) p.K1192fs*3(1) p.S1436fs*22(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:15,POLE:2",0.916986,0.7909056506666835,,5.0,,,,,,,ACH-000421,324.0
chr12,25245351,C,A,0.613,12,18,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000421,3845.0
chr17,7674221,G,A,0.925,0,12,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000421,7157.0
chr2,197402110,T,C,0.317,77,36,0/1,,SNP,MISSENSE,c.2098A>G,p.K700E,SF3B1,splicing factor 3b subunit 1,SF3b complex,ENST00000335508.11,15.0,-,O75533,False,rs559063155,,as_specific,0.3740648379052369,L,Dom,False,,True,p.K700E(689) p.K700>RVWEVRE(1) p.Q699_K700del(3),cancer;gene_function_gain;,False,False,True,,565.0,,2.0,4.13,True,False,True,Misc:13,0.96117,,0.619,4.0,,,,,,,ACH-002127,23451.0
chr17,7673803,G,A,0.977,0,43,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-002127,7157.0
chr12,25079261,C,T,0.36,53,28,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-001275,Unknown
chr19,37669823,C,A,0.985,0,64,1|1,,SNP,MISSENSE,c.326G>T,p.R109I,ZNF781,zinc finger protein 781,Zinc fingers C2H2-type,ENST00000590008.5,5.0,-,Q8N8C0,False,rs138038465,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,3.91,False,False,True,POLE:6,0.571441,0.647378901951124,0.083,1.0,,,,,,,ACH-002147,163115.0
chr12,25245350,C,A,0.815,24,115,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000775,3845.0
chr2,74415153,T,G,0.583,2,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000137,388963.0
chr17,7673803,G,A,0.976,0,40,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000137,7157.0
chr3,41224622,C,G,0.593,364,526,0/1,,SNP,MISSENSE,c.110C>G,p.S37C,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913403,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.S37F(236) p.S37C(174) p.S37A(70) p.A5_Q143del(7) p.S37P(30) p.S37Y(49) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.S37T(2) p.Y30_T40del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.S37L(2) p.S37S(2) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(4) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.I35_S37>T(1) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.S37_G38>W(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.I35_T41del(1) p.D32fs*9(1) p.I35_K170del(1) p.S37V(1) p.H36_S37del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.S37_A39>S(1) p.I35_G38del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"APOBEC:7,Misc:2",0.939753,0.7262964133289883,0.489,4.0,,,,,,,ACH-000221,1499.0
chr17,7674859,C,T,0.998,0,564,1|1,,SNP,SPLICE_SITE,c.672G>A,p.E224E,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,,,,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E224D(14) p.V225fs*24(1) p.E224*(5) p.E224E(6) p.E221fs*4(1) p.E224fs*5(1) p.E224G(2) p.?(5) p.E224K(5) p.E224fs*23(1) p.P219_V225delPYEPPEV(1) p.E224fs*24(1) p.E224Q(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:2,0.713932,,,0.0,,,,,,,ACH-000221,7157.0
chr9,21971112,G,A,0.285,188,73,0/1,,SNP,MISSENSE,c.94C>T,p.H32Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913385,,as_specific,0.6982543640897756,,,False,,True,p.0(1543) p.P81fs*35(1) p.V82_E88del(1) p.H83Y(39) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.H83N(2) p.P81_A85del(1) p.R80fs*63(1) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1) p.V82fs*62(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;,,,,7.3,False,True,True,Misc:4,0.884844,0.9724149636314106,0.804,4.0,,,,,,,ACH-000577,1029.0
chr17,7674230,C,T,0.995,0,209,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-001605,7157.0
chr12,25245350,C,G,0.988,1,175,1|1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-001541,3845.0
chr12,25245347,C,T,0.151,67,10,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000285,3845.0
chr1,114713909,G,T,0.482,112,101,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000602,4893.0
chr12,25245350,C,T,0.721,32,84,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000094,3845.0
chr17,7675161,G,A,0.968,0,29,1|1,,SNP,MISSENSE,c.451C>T,p.P151S,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934874,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.P152fs*18(9) p.0(9) p.P151A(10) p.P151S(78) p.P151P(15) p.S149fs*72(1) p.P151H(29) p.P151T(16) p.P151fs*30(8) p.P151L(8) p.T150_P151del(1) p.P151R(9) p.D148fs*23(1) p.T150fs*16(4) p.P153delP(1) p.T150_P151delTP(1) p.P152fs*28(1) p.V143_P153del(1) p.P151_V173del23(1) p.P152fs*14(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"UV:1,Misc:7",0.908193,,0.898,3.0,,,,,,,ACH-000094,7157.0
chr5,112839942,C,T,0.977,0,41,1|1,,SNP,NONSENSE,c.4348C>T,p.R1450*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913332,,as_specific,0.456359102244389,"""E, M, O""",Rec,True,,True,p.R1450*(222) p.R1450fs*5(1) p.P1424fs*19(1) p.R1450fs*20(1) p.R1450fs*22(1) p.R1435fs*23(1) p.?(1) p.K1192fs*3(1) p.S1436fs*22(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:15,POLE:2",0.916986,0.7909056506666835,,5.0,,,,,,,ACH-002161,324.0
chr2,29220829,G,T,0.316,45,20,0/1,,SNP,MISSENSE,c.3522C>A,p.F1174L,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,23.0,-,Q9UM73,False,rs863225281,,as_specific,0.5361596009975063,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.F1174L(136) p.F1174S(3) p.F1174V(8) p.F1174?(5) p.F1174C(12) p.F1174I(6),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000642122;ENST00000389048;ENST00000618119;,8.0,"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.",33.5,7.3,True,False,False,,0.936591,0.5618789444624813,0.752,4.0,,,,,,,ACH-000259,238.0
chr3,44651139,A,G,0.665,124,236,0/1,,SNP,SILENT,c.72A>G,p.E24E,ZNF35,zinc finger protein 35,Zinc fingers C2H2-type,ENST00000453164.1,2.0,+,P13682,False,rs753622014,,as_specific,0.5261845386533666,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.290013,0.6196210973327331,,0.0,,,,,,,ACH-000941,7584.0
chr3,179234302,G,C,0.673,34,71,0/1,,SNP,MISSENSE,c.3145G>C,p.G1049R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913277,,as_specific,0.3840399002493765,"""E, O""",Dom,False,,True,p.G1049R(78) p.G1049S(34) p.G1049A(6) p.G1049D(3) p.G1049G(9) p.G1049C(1),cancer;gene_function_gain;,False,False,True,,940.0,,0.0,7.3,True,False,True,"APOBEC:1,Misc:7",0.830715,0.3903762856806781,0.391,3.0,,,,,,,ACH-000941,5290.0
chr4,152330755,G,A,0.479,25,25,0/1,,SNP,NONSENSE,c.859C>T,p.R287*,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,6.0,-,Q969H0,False,,,,0.3291770573566084,"""E, L""",Rec,True,,False,p.R367*(4),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:4,0.971636,0.509471476416619,,5.0,,,,,,,ACH-000941,55294.0
chr12,25245350,C,T,0.466,152,130,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000941,3845.0
chr17,7674220,C,T,0.996,0,311,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000941,7157.0
chr17,39724811,C,T,0.352,378,199,0/1,,SNP,MISSENSE,c.2393C>T,p.T798I,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,20.0,+,P04626,False,,,,0.5960099750623441,E,Dom,False,,False,,cancer;gene_function_gain;,False,False,True,ENST00000584601;ENST00000406381;ENST00000541774;ENST00000445658;ENST00000584450;ENST00000269571;,2331.0,,0.0,7.3,True,False,False,,0.908715,0.5110437939199052,0.783,4.0,,,,,,,ACH-000941,2064.0
chr17,39725079,G,A,0.392,204,136,0/1,,SNP,MISSENSE,c.2524G>A,p.V842I,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,21.0,+,P04626,False,rs1057519738,,as_specific,0.5835411471321695,E,Dom,False,,True,p.V842I(18) p.V842E(1),cancer;gene_function_gain;,False,True,True,,45.0,"ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",9.0,7.3,True,False,True,CpG:7,0.925625,0.7707432895054793,0.538,4.0,,,,,,,ACH-000941,2064.0
chr11,533875,G,T,0.996,0,229,1|1,,SNP,MISSENSE,c.181C>A,p.Q61K,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,3.0,-,P01112,False,rs28933406,,as_specific,0.6458852867830424,"""E, L, M""",Dom,False,,True,p.Q61R(289) p.Q61K(113) p.Q61L(184) p.Q61H(24) p.Q61?(16) p.Q61P(3) p.Q61*(1) p.Q61Q(1) p.Q61E(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,,,,7.3,True,True,True,"smoking:1,UV:1,Misc:7",0.895199,0.9848035961304592,0.748,4.0,,,,,,,ACH-001196,3265.0
chr2,177234232,C,G,0.686,21,51,0/1,,SNP,MISSENSE,c.37G>C,p.D13H,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,rs1057519920,,as_specific,0.3890274314214463,E,Dom,False,,True,p.D29N(3) p.D29H(8) p.I28_D29del(1) p.D29Y(1),cancer;gene_function_gain;,False,False,True,ENST00000397063;ENST00000397062;ENST00000446151;ENST00000464747;ENST00000449627;ENST00000448782;ENST00000586532;ENST00000421929;ENST00000423513;ENST00000588123;,,,,7.3,True,False,True,APOBEC:12,0.939766,0.7123089440446881,0.711,3.0,,,,,,,ACH-000442,4780.0
chr3,179218303,G,A,0.763,92,292,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000442,5290.0
chr9,21971121,G,A,0.998,0,702,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-001347,1029.0
chr17,7673704,G,A,0.998,0,620,1|1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-001347,7157.0
chr2,39054637,T,A,0.706,24,62,0/1,,SNP,MISSENSE,c.697A>T,p.N233Y,SOS1,SOS Ras/Rac guanine nucleotide exchange factor 1,Rho guanine nucleotide exchange factors Pleckstrin homology domain containing,ENST00000395038.6,5.0,-,Q07889,False,rs1057519963,,as_specific,0.2967581047381546,,,False,,False,p.N233Y(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"smoking:3,Misc:5",0.884903,,0.58,4.0,,,,,,,ACH-000825,6654.0
chr2,74415153,T,G,0.562,2,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002270,388963.0
chr11,533874,T,C,0.455,100,83,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,3.0,-,P01112,False,rs121913233,,as_specific,0.6458852867830424,"""E, L, M""",Dom,False,,True,p.Q61R(289) p.Q61K(113) p.Q61L(184) p.Q61H(24) p.Q61?(16) p.Q61P(3) p.Q61*(1) p.Q61Q(1) p.Q61E(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,,,,7.3,True,True,True,Misc:29,0.796387,0.985128922959183,0.811,4.0,,,,,,,ACH-002270,3265.0
chr5,68295278,A,G,0.525,61,80,0/1,,SNP,MISSENSE,c.610A>G,p.K204E,PIK3R1,phosphoinositide-3-kinase regulatory subunit 1,SH2 domain containing,ENST00000523872.1,6.0,+,P27986,False,,,,0.3740648379052369,"""E, O""",Rec,False,,False,p.K567E(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,,0.885938,0.6249064453763302,0.468,4.0,,,,,,,ACH-000877,5295.0
chr17,7674232,C,T,0.996,0,288,1|1,,SNP,MISSENSE,c.731G>A,p.G244D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs985033810,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"MSI:1,Misc:1",0.965383,0.9978215722974868,0.953,3.0,,,,,,,ACH-000877,7157.0
chr17,7673782,T,C,0.896,1,16,0/1,,SNP,MISSENSE,c.838A>G,p.R280G,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs753660142,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R280T(73) p.R280fs*65(9) p.R280I(15) p.R280K(54) p.R280S(17) p.R280G(33) p.R280_R283>S(1) p.R280*(14) p.S269fs*21(1) p.F270_D281del12(1) p.R280fs*?(1) p.V272_K292del21(1) p.D281_R282delDR(2) p.R280R(3) p.A276fs*64(1) p.R280fs*64(1) p.G279fs*65(2) p.G279_R280delGR(1) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:2,0.948566,0.6023677190456652,0.924,3.0,,,,,,,ACH-002274,7157.0
chr3,41224619,A,C,0.998,1,465,1|1,,SNP,MISSENSE,c.107A>C,p.H36P,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,,,,0.3940149625935162,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.H36P(36) p.A5_Q143del(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H36R(4) p.H24_S47del(9) p.D32_H36>D(1) p.D32_S47del(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(4) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.H36Y(5) p.M5_N141>D(2) p.I35_S37>T(1) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.I35_T41del(1) p.D32fs*9(1) p.I35_K170del(1) p.H36_S37del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.I35_G38del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.H36del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,Misc:5,0.921608,0.6930548131248792,0.421,4.0,,,,,,,ACH-002017,1499.0
chr19,3118944,A,T,0.99,0,106,1|1,,SNP,MISSENSE,c.626A>T,p.Q209L,GNA11,G protein subunit alpha 11,"G protein subunits alpha, group q",ENST00000078429.9,5.0,+,P29992,False,rs1057519742,,as_specific,0.655860349127182,E,Dom,False,,True,p.Q209L(384) p.Q209P(8) p.Q209R(6) p.Q209A(1) p.Q209?(2),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000078429;,,,,7.3,True,True,True,Misc:36,0.752569,0.9807448018376348,0.833,4.0,,,,,,,ACH-002017,2767.0
chr1,11130747,C,T,0.429,7,5,0/1,,SNP,MISSENSE,c.5395G>A,p.E1799K,MTOR,mechanistic target of rapamycin kinase,MTOR complex 1 MTOR complex 2,ENST00000361445.9,39.0,-,P42345,False,rs863225264,,as_specific,0.5760598503740648,,,False,,False,,cancer;gene_function_gain;,False,False,True,,544.0,,2.0,7.3,True,False,True,"CpG:5,UV:1,POLE:5",0.978079,0.534376468210211,0.638,4.0,,,,,,,ACH-000907,2475.0
chr7,140753336,A,T,0.503,87,88,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002143,673.0
chr7,55165350,G,T,0.441,109,90,0/1,,SNP,MISSENSE,c.1658G>T,p.G553V,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,14.0,+,P00533,False,rs139236063,,as_specific,0.456359102244389,"""E, O""",Dom,False,,True,p.G598V(11),cancer;gene_function_gain;,False,False,True,,997.0,,0.0,7.3,True,False,True,Misc:15,0.888281,0.6519560201016441,0.61,4.0,,,,,,,ACH-002259,1956.0
chr3,38141150,T,C,0.976,1,87,1|1,,SNP,NONSTOP,c.439T>C,p.*147R,MYD88,myeloid differentiation primary response 88,TIR domain containing,ENST00000495303.6,3.0,+,Q99836,False,rs387907272,,as_specific,0.5511221945137157,L,Dom,True,,True,p.L265P(1704) p.L265>RPP(1) p.L265S(1),cancer;gene_function_gain;gene_function_loss;,False,True,True,ENST00000417037;ENST00000396334;ENST00000424893;ENST00000421516;ENST00000648963;,424.0,,31.0,4.61,True,True,True,Misc:5,0.863097,0.8970450162732663,0.735,4.0,,,,,,,ACH-000158,4615.0
chr7,140753336,A,T,0.569,66,81,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000799,673.0
chr16,85657534,G,C,0.344,62,30,0/1,,SNP,MISSENSE,c.1570G>C,p.E524Q,GSE1,Gse1 coiled-coil protein,,ENST00000253458.12,8.0,+,Q14687,False,,,,0.6309226932668329,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"APOBEC:1,Misc:1",0.9044,0.4190385836400985,0.296,2.0,,,,,,,ACH-000975,23199.0
chr17,7674217,C,G,0.996,0,277,1|1,,SNP,MISSENSE,c.746G>C,p.R249T,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782329,,as_specific,0.5610972568578554,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,119.0,"This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",30.0,7.3,False,True,False,,0.925053,0.9926141649708672,0.921,3.0,,,,,,,ACH-000975,7157.0
chr2,208248389,G,A,0.381,39,26,0/1,,SNP,MISSENSE,c.394C>T,p.R132C,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",,ENST00000415913.5,4.0,-,O75874,False,rs121913499,,as_specific,0.3790523690773067,O,Dom,False,,True,p.R132C(1014) p.R132H(6941) p.R132S(229) p.R132?(201) p.R132G(285) p.R132L(126) p.R132P(1) p.R132V(1) p.G131_R132>VL(1),splicing;cancer;gene_function_gain;,False,True,True,ENST00000345146;ENST00000446179;ENST00000415913;ENST00000415282;,59.0,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",53.0,7.3,True,False,True,"CpG:19,MSI:1,UV:15",0.961719,0.6398382252727418,0.814,2.0,,,,,,,ACH-000161,3417.0
chr4,122353074,C,T,0.443,48,38,0/1,,SNP,MISSENSE,c.14020C>T,p.R4674C,KIAA1109,KIAA1109,,ENST00000264501.8,81.0,+,Q2LD37,False,rs1278017597,,as_specific,0.3740648379052369,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:6,POLE:2",0.970087,0.945197709844172,0.567,2.0,,,,,,,ACH-000987,84162.0
chr5,140876305,C,T,0.539,167,194,0/1,,SNP,MISSENSE,c.833C>T,p.S278F,PCDHA12,protocadherin alpha 12,Clustered protocadherins,ENST00000398631.3,1.0,+,Q9UN75,False,,,,0.4164588528678304,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.39157,0.7685311463665571,0.061,3.0,,,,,,,ACH-000987,56137.0
chr7,143935997,G,A,0.465,46,39,0/1,,SNP,SILENT,c.765G>A,p.T255T,OR2F2,olfactory receptor family 2 subfamily F member 2,"Olfactory receptors, family 2",ENST00000408955.2,1.0,+,O95006,False,rs866839513,,as_specific,0.4812967581047381,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:8,POLE:2",0.213677,0.7729173493360563,,0.0,,,,,,,ACH-000987,135948.0
chr8,139619073,C,T,0.364,13,7,0/1,,SNP,MISSENSE,c.310G>A,p.D104N,KCNK9,potassium two pore domain channel subfamily K member 9,Potassium two pore domain channel subfamily K ,ENST00000648164.1,2.0,-,Q9NPC2,False,rs1237927464,,as_specific,0.5810473815461347,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:1,UV:4,POLE:1,Eso:1",0.963423,0.7804895268309929,0.112,3.0,,,,,,,ACH-000987,51305.0
chr9,122553806,G,A,0.42,89,65,0/1,,SNP,MISSENSE,c.595G>A,p.E199K,OR1N2,olfactory receptor family 1 subfamily N member 2,"Olfactory receptors, family 1",ENST00000373688.3,1.0,+,Q8NGR9,False,,,,0.513715710723192,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:2,POLE:4",0.4538,0.496271946391159,0.054,1.0,,,,,,,ACH-000987,138882.0
chr11,54707643,C,T,0.471,36,32,0/1,,SNP,SILENT,c.759C>T,p.F253F,OR4A5,olfactory receptor family 4 subfamily A member 5,"Olfactory receptors, family 4",ENST00000319760.8,1.0,+,Q8NH83,False,,,,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:7,APOBEC:1",0.411778,,,1.0,,,,,,,ACH-000987,81318.0
chr11,55367976,G,A,0.487,40,39,0/1,,SNP,START_CODON_SNP,c.3G>A,p.M1I,OR4A15,olfactory receptor family 4 subfamily A member 15,"Olfactory receptors, family 4",ENST00000641526.1,1.0,+,Q8NGL6,False,rs149233751,,as_specific,0.4189526184538653,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.452696,,0.125,2.0,,,,,,,ACH-000987,81328.0
chr11,67418924,G,T,0.333,5,2,0/1,,SNP,MISSENSE,c.164G>T,p.G55V,CARNS1,carnosine synthase 1,,ENST00000307823.7,4.0,+,A5YM72,False,rs780435597,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.300515,,0.112,2.0,,,,,,,ACH-000987,57571.0
chr12,21801129,C,T,0.982,0,56,1|1,,SNP,MISSENSE,c.4565G>A,p.G1522E,ABCC9,ATP binding cassette subfamily C member 9,ATP binding cassette subfamily C,ENST00000261200.8,38.0,-,O60706,False,,,,0.3740648379052369,,,False,,False,,cancer;,False,False,True,ENST00000261200;,,,,7.3,False,False,True,UV:5,0.925845,,0.804,3.0,,,,,,,ACH-000987,10060.0
chr17,7673579,G,A,0.422,37,26,0/1,,SNP,NONSENSE,c.949C>T,p.Q317*,TP53,tumor protein p53,,ENST00000269305.8,9.0,-,P04637,False,,,,0.5062344139650873,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q317*(31) p.Q317fs*28(1) p.Q317R(4) p.Q317K(3) p.Q317fs*20(1) p.P316fs*19(1) p.Q317fs*?(2) p.S315fs*1(1) p.S315fs*22(1) p.S314_K320>*(1) p.Q317fs*19(1) p.Q317fs*45(1) p.S314fs*25(1) p.L308fs*15(1) p.Q317P(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,UV:3,APOBEC:1,Misc:3",0.972477,0.740164595047311,,4.0,,,,,,,ACH-000987,7157.0
chr17,7674229,C,A,0.995,1,206,1|1,,SNP,MISSENSE,c.734G>T,p.G245V,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912656,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:9,Misc:5",0.964727,,0.972,3.0,,,,,,,ACH-001525,7157.0
chr17,7674250,C,T,0.976,0,40,1|1,,SNP,MISSENSE,c.713G>A,p.C238Y,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs730882005,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C238Y(66) p.0(9) p.C238F(41) p.C238fs*?(1) p.C238S(20) p.H233_C242del10(1) p.C238R(16) p.M237_C238insX(1) p.C238_N239insX(1) p.H233fs*6(1) p.M237_N239delMCN(1) p.C238delC(1) p.C238W(4) p.C238*(5) p.V225fs*23(1) p.C238G(2) p.C238fs*2(1) p.C238del(1) p.C238_M246delCNSSCMGGM(1) p.M237fs*1(1) p.C238C(1) p.?(1) p.C238_M243delCNSSCM(1) p.Y236_M243delYMCNSSCM(1) p.C238fs*1(1) p.C238fs*9(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,2648.0,,0.75,7.3,False,True,True,Misc:7,0.960468,0.9929718951229356,0.957,3.0,,,,,,,ACH-000583,7157.0
chr17,7673764,C,T,0.918,1,23,1|1,,SNP,MISSENSE,c.856G>A,p.E286K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs786201059,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E286G(17) p.E286K(94) p.E286fs*59(2) p.R283fs*16(2) p.E286*(17) p.E286V(9) p.E286fs*17(2) p.E286Q(7) p.E286D(2) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.R283fs*56(1) p.V272_K292del21(1) p.E286A(2) p.E286E(2) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:3,Misc:1",0.93585,0.6532670016064752,0.949,3.0,,,,,,,ACH-000204,7157.0
chr2,74415153,T,G,0.438,4,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-001364,388963.0
chr17,7674256,T,C,0.974,0,36,1|1,,SNP,MISSENSE,c.707A>G,p.Y236C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs730882026,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y236delY(4) p.Y236C(58) p.H233_C242del10(1) p.Y236N(21) p.Y236*(13) p.Y236H(13) p.Y236D(6) p.H233fs*6(1) p.Y236_M237>*(1) p.Y236S(4) p.Y236fs*5(1) p.V225fs*23(1) p.Y236Y(2) p.Y236fs*4(2) p.I232_Y236delIHYNY(1) p.?(1) p.Y236_M243delYMCNSSCM(1) p.N235_Y236delNY(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:5,0.844922,0.9351637534056272,0.811,2.0,,,,,,,ACH-001364,7157.0
chr17,7674957,G,A,0.987,0,80,1|1,,SNP,NONSENSE,c.574C>T,p.Q192*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs866380588,,as_specific,0.5885286783042394,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q192*(84) p.Q192fs*16(1) p.Q192fs*17(1) p.Q192K(2) p.Q192delQ(1) p.Q192Q(2) p.?(2) p.G187fs*16(2) p.Q192H(3) p.P191_Q192del(2) p.Q192fs*30(1) p.P191fs*53(2) p.Q192R(5) p.A189_V197delAPPQHLIRV(4) p.Q192fs*56(1) p.A189fs*53(1) p.P191delP(2) p.P191fs*6(1) p.Q192>XXXXXXXXX(1) p.K164_P219del(1) p.P191_Q192delPQ(1) p.A189_Q192>E(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"APOBEC:11,Misc:2",0.991592,,,4.0,,,,,,,ACH-000807,7157.0
chr17,7674221,G,A,0.944,3,58,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000390,7157.0
chr9,5073770,G,T,0.987,0,86,1|1,,SNP,MISSENSE,c.1849G>T,p.V617F,JAK2,Janus kinase 2,Jak family tyrosine kinases SH2 domain containing FERM domain containing,ENST00000381652.4,14.0,+,O60674,False,rs77375493,,as_specific,0.3341645885286783,L,Dom,False,"""ETV6, PCM1, BCR""",True,p.V617F(46751) p.V617I(89) p.V617V(1) p.V617_C618>FR(2),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,True,True,ENST00000636127;ENST00000381652;,64.0,"JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.",83.0,3.4,True,True,False,,0.951124,0.9953201091762558,0.881,4.0,,,,,,,ACH-001577,3717.0
chr12,25227341,T,G,0.519,56,61,0/1,,SNP,MISSENSE,c.183A>C,p.Q61H,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs17851045,,as_specific,0.3466334164588528,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,True,True,,907.0,,10.5,7.3,True,False,True,"POLE:1,Eso:2,Misc:7",0.798711,,0.644,4.0,,,,,,,ACH-000085,3845.0
chr17,7674872,T,C,0.966,0,31,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000085,7157.0
chr7,140753336,A,T,0.434,58,47,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000895,673.0
chrX,77654139,G,A,0.338,135,69,0/1,,SNP,NONSENSE,c.4276C>T,p.R1426*,ATRX,"ATRX, chromatin remodeler",X-linked mental retardation RNA helicases,ENST00000373344.10,14.0,-,P46100,False,rs919106518,,as_specific,0.3067331670822942,E,Rec,True,,False,p.R1426*(5),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:2,,0.9398074430307196,,3.0,,,,,,,ACH-000895,546.0
chr17,7675182,G,A,0.942,0,14,1|1,,SNP,NONSENSE,c.430C>T,p.Q144*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs757274881,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.L137_W146del10(1) p.Q144*(35) p.Q144fs*26(5) p.Q144P(5) p.Q144H(6) p.Q144R(4) p.Q144Q(2) p.V143fs*4(1) p.Q144fs*4(1) p.Q144L(8) p.Q144fs*32(1) p.Q144delQ(2) p.V143_P153del(1) p.Q144K(2) p.V143_S149delVQLWVDS(1) p.Q144_G154del11(1) p.P142_Q144delPVQ(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:3,0.991142,0.3246707366533456,,4.0,,,,,,,ACH-000015,7157.0
chr1,114713908,T,C,0.361,141,77,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-000547,4893.0
chr3,179218303,G,A,0.742,33,91,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000547,5290.0
chr9,134436505,C,T,0.528,58,68,0/1,,SNP,MISSENSE,c.1199C>T,p.S400F,RXRA,retinoid X receptor alpha,Nuclear hormone receptors,ENST00000672570.1,10.0,+,P19793,False,rs1057519958,,as_specific,0.6159600997506235,,,False,,False,,cancer;,False,False,True,ENST00000481739;,,,,7.3,False,False,True,"APOBEC:9,Misc:1",0.936383,,0.951,4.0,,,,,,,ACH-000547,6256.0
chr8,30700128,G,A,0.551,30,37,0/1,,SNP,SILENT,c.648C>T,p.S216S,GSR,glutathione-disulfide reductase,,ENST00000221130.11,6.0,-,P00390,False,,,,0.4139650872817955,,,False,,False,p.S216S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,Misc:2,0.228928,0.985360814836269,,0.0,,,,,,,ACH-002250,2936.0
chr1,114716126,C,T,0.336,94,51,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-000795,4893.0
chr4,152328232,C,T,0.457,88,72,0/1,,SNP,MISSENSE,c.1154G>A,p.R385H,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs1057519895,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465H(72) p.R465fs*7(9) p.R465L(3) p.R465Y(2) p.R465P(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:15,0.938974,0.1731430175559941,0.557,4.0,,,,,,,ACH-000795,55294.0
chr9,136503316,A,G,0.548,20,23,0/1,,SNP,MISSENSE,c.5033T>C,p.L1678P,NOTCH1,notch 1,Ankyrin repeat domain containing,ENST00000651671.1,27.0,-,P46531,False,,,,0.6708229426433915,L,Dom,False,TRB@,True,p.L1678P(60) p.L1678fs*4(8) p.L1678Q(5) p.L1678fs*3(1),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,ENST00000277541;,1034.0,,0.0,7.3,True,True,False,,0.908274,0.7783096917559785,0.78,3.0,,,,,,,ACH-000795,4851.0
chr17,7673802,C,T,0.476,21,20,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000795,7157.0
chr17,7676096,C,T,0.425,56,41,0/1,,SNP,NONSENSE,c.273G>A,p.W91*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs876660548,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.G59fs*23(3) p.W91*(29) p.P92fs*57(1) p.W91fs*13(1) p.W91fs*57(1) p.P87fs*54(1) p.A86fs*55(1) p.D48fs*55(1) p.W91fs*?(1) p.M1_T125del(1) p.S33fs*23(1) p.V73fs*9(1) p.W91fs*32(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"MSI:2,Misc:2",0.978778,,,4.0,,,,,,,ACH-000795,7157.0
chr17,7674893,C,T,0.665,12,25,0/1,,SNP,MISSENSE,c.638G>A,p.R213Q,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs587778720,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"CpG:2,UV:1,POLE:2",0.920288,0.776972471915739,0.92,3.0,,,,,,,ACH-002272,7157.0
chr1,241098711,G,A,0.581,33,46,0/1,,SNP,MISSENSE,c.130C>T,p.R44C,RGS7,regulator of G protein signaling 7,Regulators of G-protein signaling,ENST00000366563.5,3.0,-,P49802,False,rs755007339,,as_specific,0.3391521197007481,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:10,POLE:1",0.960396,,0.492,3.0,,,,,,,ACH-000882,6000.0
chr7,6387261,C,T,0.644,52,87,0/1,,SNP,MISSENSE,c.85C>T,p.P29S,RAC1,Rac family small GTPase 1,Rho family GTPases Endogenous ligands,ENST00000356142.4,2.0,+,P63000,False,rs1057519874,,as_specific,0.3117206982543641,,,False,,True,p.P29S(58) p.P29L(3),cancer;gene_function_gain;,False,False,True,,367.0,,4.0,7.3,True,False,True,"UV:19,APOBEC:1",0.898956,0.7595241052535948,0.585,3.0,,,,,,,ACH-000882,5879.0
chr7,140753336,AC,TT,0.442,119,92,0/1,,DNP,MISSENSE,c.1798_1799GT>AA,p.V600K,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs121913227,,as_specific,0.3383084577114428,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,,563.0,,107.5,7.3,True,False,False,,,,,,,,,,,,ACH-000882,673.0
chr19,49665874,C,T,0.302,54,21,0/1,,SNP,SILENT,c.51C>T,p.F17F,BCL2L12,BCL2 like 12,BCL2 family,ENST00000246785.7,1.0,+,Q9HB09,False,rs267605591,,as_specific,0.5810473815461347,,,False,,False,p.F17F(3),cancer;,False,False,True,,,,,7.3,False,False,True,UV:13,0.317245,0.5554178105170933,,0.0,,,,,,,ACH-000882,83596.0
chr17,7674220,C,T,0.515,198,203,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001745,7157.0
chr17,7675994,C,A,0.401,149,101,0/1,,SNP,SPLICE_SITE,c.375G>T,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:12,MSI:1,Misc:4",0.468898,0.7805428798268306,,0.0,,,,,,,ACH-001745,7157.0
chr17,7673802,C,T,0.995,1,225,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001539,7157.0
chr12,20370109,G,A,0.304,31,14,0/1,,SNP,SILENT,c.825G>A,p.L275L,PDE3A,phosphodiesterase 3A,Phosphodiesterases,ENST00000359062.3,1.0,+,Q14432,False,rs750288734,,as_specific,0.6034912718204489,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,APOBEC:11,0.166036,0.7111934997787612,,0.0,,,,,,,ACH-000694,5139.0
chr3,41224633,A,G,0.988,2,264,1|1,,SNP,MISSENSE,c.121A>G,p.T41A,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913412,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.T41A(1344) p.A5_A80del(75) p.T41S(7) p.T41I(155) p.A5_Q143del(7) p.T41P(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.T41T(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.T41N(8) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.T40_L46del(1) p.G38_S45del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.A20_R151del(1) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.I35_T41del(1) p.I35_K170del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A39_T42del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.T41_N51del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A39fs*3(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1285.0,,55.0,7.3,True,False,True,Misc:17,0.860853,,0.403,4.0,,,,,,,ACH-002023,1499.0
chr12,56088138,G,A,0.619,184,315,0/1,,SNP,MISSENSE,c.850G>A,p.G284R,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,7.0,+,P21860,False,rs1057519803,,as_specific,0.4738154613466334,,,False,,False,p.G284R(3),cancer;gene_function_gain;,False,True,True,,703.0,,15.0,7.3,True,False,False,,0.6915,,0.138,4.0,,,,,,,ACH-002023,2065.0
chr17,7674230,C,T,0.996,0,241,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-002023,7157.0
chr17,39711955,C,T,0.712,391,971,0/1,,SNP,MISSENSE,c.929C>T,p.S310F,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,8.0,+,P04626,False,rs1057519816,,as_specific,0.5685785536159601,E,Dom,False,,True,p.S310F(27) p.S310Y(11),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"APOBEC:22,Misc:3",0.922658,,0.533,4.0,,,,,,,ACH-002023,2064.0
chr17,39723405,G,A,0.717,233,582,0/1,,SNP,MISSENSE,c.2033G>A,p.R678Q,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,17.0,+,P04626,False,rs1057519862,,as_specific,0.6359102244389028,E,Dom,False,,False,p.R678Q(3) p.R678L(1),cancer;gene_function_gain;,False,False,True,,42.0,"ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.",5.0,7.3,True,False,True,CpG:9,0.905915,0.5881956277268189,0.417,4.0,,,,,,,ACH-002023,2064.0
chr12,25245350,C,T,0.5,6,7,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000089,3845.0
chr17,7674230,C,T,0.959,2,59,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-000089,7157.0
chr2,201285307,C,T,0.424,44,33,0/1,,SNP,NONSENSE,c.1294C>T,p.R432*,CASP8,caspase 8,Caspases Death effector domain containing Ripoptosome Death inducing signaling complex ,ENST00000673742.1,8.0,+,Q14790,False,rs931648756,,as_specific,0.4588528678304239,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:1,0.956297,0.6202561045388233,,3.0,,,,,,,ACH-000908,841.0
chrX,100688435,T,C,0.548,18,22,0/1,,SNP,SILENT,c.921A>G,p.E307E,SYTL4,synaptotagmin like 4,Synaptotagmin like tandem C2 proteins,ENST00000372989.5,12.0,-,Q96C24,False,,,,0.4214463840399002,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,,,,0.0,,,,,,,ACH-000908,94121.0
chr17,7675151,C,A,0.996,0,261,1|1,,SNP,MISSENSE,c.461G>T,p.G154V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs762846821,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S149fs*72(1) p.G154R(1) p.G154V(44) p.G154fs*22(1) p.P152fs*14(5) p.G154_R156delGTR(1) p.G154I(3) p.G154D(7) p.G154S(9) p.D148fs*23(1) p.P153fs*26(2) p.G154fs*?(1) p.G154G(12) p.G154fs*14(2) p.G154A(1) p.G154fs*27(3) p.P153fs*22(2) p.P151_V173del23(1) p.G154fs*16(4) p.Q144_G154del11(1) p.D148_T155delDSTPPPGT(1) p.P153_G154insX(1) p.G154C(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,smoking:6,0.82126,0.8527250621892793,0.754,3.0,,,,,,,ACH-000718,7157.0
chr4,54733174,T,A,0.817,42,186,0/1,,SNP,MISSENSE,c.2466T>A,p.N822K,KIT,KIT proto-oncogene receptor tyrosine kinase,CD molecules Immunoglobulin like domain containing Receptor Tyrosine Kinases,ENST00000288135.6,17.0,+,P10721,False,rs121913514,,as_specific,0.3341645885286783,"""L, M, O, E""",Dom,False,,True,p.N822K(186) p.N822H(8) p.N822Y(25) p.N822I(3) p.N822S(3) p.N822T(1) p.N822D(1) p.N822N(1) p.S821_N822>GY(1),cancer;gene_function_gain;,False,True,True,,1263.0,,24.5,7.3,True,False,False,,0.726274,,0.682,4.0,,,,,,,ACH-000263,3815.0
chr17,7674220,C,T,0.959,0,24,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000263,7157.0
chr7,140753336,A,T,0.489,362,350,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000200,673.0
chr10,102011755,G,T,0.424,88,65,0/1,,SNP,MISSENSE,c.799C>A,p.Q267K,ARMH3,,,ENST00000370033.9,11.0,-,,False,rs1301593069,,as_specific,0.3890274314214463,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"MSI:1,Misc:3",0.934421,0.6234100280836133,0.271,2.0,,,,,,,ACH-000200,79591.0
chr12,25245350,C,T,0.78,3,13,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000350,3845.0
chr12,25245350,C,T,0.428,20,15,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000042,3845.0
chr17,7674220,C,T,0.961,1,49,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000042,7157.0
chr17,7674220,C,T,0.462,151,132,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001368,7157.0
chr17,39711955,C,T,0.445,162,126,0/1,,SNP,MISSENSE,c.929C>T,p.S310F,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,8.0,+,P04626,False,rs1057519816,,as_specific,0.5685785536159601,E,Dom,False,,True,p.S310F(27) p.S310Y(11),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"APOBEC:22,Misc:3",0.922658,,0.533,4.0,,,,,,,ACH-001368,2064.0
chr17,7673787,G,A,0.62,24,42,0/1,,SNP,MISSENSE,c.833C>T,p.P278L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs876659802,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:1,Misc:2",0.909152,0.7609434722182151,0.94,3.0,,,,,,,ACH-002285,7157.0
chr3,52609752,G,A,0.978,0,41,1|1,,SNP,NONSENSE,c.2173C>T,p.R725*,PBRM1,polybromo 1,Bromodomain containing,ENST00000409114.7,17.0,-,Q86U86,False,,,,0.4214463840399002,E,Rec,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:4",0.982779,,,5.0,,,,,,,ACH-001839,55193.0
chr1,114713909,G,T,0.64,79,132,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-002240,4893.0
chr17,7674945,G,A,0.984,0,64,1|1,,SNP,NONSENSE,c.586C>T,p.R196*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516435,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R196*(221) p.R196P(18) p.R196Q(5) p.R196R(6) p.I195fs*12(1) p.R196_R202del(1) p.R196fs*51(4) p.I195_G199delIRVEG(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.R196L(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.R196fs*13(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.986209,0.7393785927987923,,4.0,,,,,,,ACH-002240,7157.0
chr3,179218303,G,A,0.447,87,73,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-001411,5290.0
chr17,7675088,C,T,0.969,0,31,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-001233,7157.0
chr3,179234297,A,G,0.485,76,69,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000472,5290.0
chr17,7674229,C,A,0.985,0,65,1|1,,SNP,MISSENSE,c.734G>T,p.G245V,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912656,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:9,Misc:5",0.964727,,0.972,3.0,,,,,,,ACH-002243,7157.0
chr17,7674221,G,A,0.633,18,30,0/1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-002090,7157.0
chr4,22515661,C,A,0.8,0,3,0/1,,SNP,MISSENSE,c.124G>T,p.G42C,ADGRA3,adhesion G protein-coupled receptor A3,"I-set domain containing Adhesion G protein-coupled receptors, subfamily A",ENST00000334304.10,1.0,-,Q8IWK6,False,rs555110508,,as_specific,0.7605985037406484,,,False,,False,,cancer;,False,False,True,,,,,3.21,False,False,True,,0.544299,,0.104,3.0,,,,,,,ACH-000789,166647.0
chr17,82442278,A,C,0.373,4,2,0|1,82442272.0,SNP,MISSENSE,c.1444A>C,p.T482P,HEXD,,,ENST00000337014.10,12.0,+,,False,rs746519705,,as_specific,0.6608478802992519,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.449693,,0.246,2.0,,,,,,,ACH-000789,284004.0
chr5,112839942,C,T,0.342,60,30,0/1,,SNP,NONSENSE,c.4348C>T,p.R1450*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913332,,as_specific,0.456359102244389,"""E, M, O""",Rec,True,,True,p.R1450*(222) p.R1450fs*5(1) p.P1424fs*19(1) p.R1450fs*20(1) p.R1450fs*22(1) p.R1435fs*23(1) p.?(1) p.K1192fs*3(1) p.S1436fs*22(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:15,POLE:2",0.916986,0.7909056506666835,,5.0,,,,,,,ACH-000501,324.0
chr12,25245351,C,T,0.794,5,19,0/1,,SNP,MISSENSE,c.34G>A,p.G12S,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,913.0,,38.0,7.3,True,False,True,"smoking:2,Eso:1,Misc:10",0.902584,,0.79,4.0,,,,,,,ACH-000501,3845.0
chr17,7675088,C,T,0.975,1,43,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000501,7157.0
chr15,51536240,C,T,0.224,180,53,0/1,,SNP,MISSENSE,c.2240G>A,p.R747Q,DMXL2,Dmx like 2,Deafness associated genes WD repeat domain containing,ENST00000251076.9,12.0,-,Q8TDJ6,False,rs749262883,,as_specific,0.3491271820448878,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.973874,0.2034699033232746,0.475,3.0,,,,,,,ACH-002174,23312.0
chr9,21971109,C,A,0.998,0,485,1|1,,SNP,MISSENSE,c.97G>T,p.D33Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552822,,as_specific,0.6957605985037406,,,False,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V82_E88del(1) p.D84H(2) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.D84Y(9) p.P81_A85del(1) p.D84N(4) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.D84fs*63(2) p.E61_L94del(1) p.R80fs*34(1) p.D84_F90del(1) p.E33D(1) p.A68fs*3(1) p.D84fs*1(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;ENST00000579755;ENST00000530628;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.933446,0.9973373924118374,0.803,4.0,,,,,,,ACH-002466,1029.0
chr1,114713908,T,C,0.838,8,41,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-002509,4893.0
chr5,102498735,C,T,0.194,295,69,0/1,,SNP,MISSENSE,c.110G>A,p.G37E,SLCO6A1,solute carrier organic anion transporter family member 6A1,,ENST00000506729.6,1.0,-,Q86UG4,False,,,,0.6134663341645885,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.539342,,0.034,2.0,,,,,,,ACH-002509,133482.0
chr11,45252585,G,A,0.454,165,134,0/1,,SNP,MISSENSE,c.682C>T,p.P228S,SYT13,synaptotagmin 13,Synaptotagmins,ENST00000020926.8,4.0,-,Q7L8C5,False,rs868559206,,as_specific,0.6359102244389028,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.811471,0.6513425404758019,0.349,3.0,,,,,,,ACH-002509,57586.0
chr19,58499498,G,A,0.692,63,149,0/1,,SNP,MISSENSE,c.1409C>T,p.T470I,SLC27A5,solute carrier family 27 member 5,Solute carriers Acyl-CoA synthetase family,ENST00000601355.1,7.0,-,Q9Y2P5,False,,,,0.6533665835411472,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:13,0.911109,0.5951441230767975,0.581,2.0,,,,,,,ACH-002509,10998.0
chr1,114713909,G,T,0.994,0,186,1|1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-002097,4893.0
chr4,69639279,C,T,0.242,48,15,0/1,,SNP,MISSENSE,c.362G>A,p.G121E,UGT2A2,UDP glucuronosyltransferase family 2 member A2,UDP glucuronosyltransferases,ENST00000604629.5,1.0,-,Q9Y4X1,False,,,,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:4,POLE:1,Misc:1",0.510168,0.4438499299774333,0.2,3.0,,,,,,,ACH-002097,574537.0
chr4,186534037,C,T,0.219,126,33,0/1,,SNP,SILENT,c.705G>A,p.R235R,MTNR1A,melatonin receptor 1A,Melatonin receptors,ENST00000307161.5,2.0,-,P48039,False,,,,0.516209476309227,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:4,Misc:1",0.238471,0.6290285008831573,,0.0,,,,,,,ACH-002097,4543.0
chr7,143935997,G,A,0.529,51,55,0/1,,SNP,SILENT,c.765G>A,p.T255T,OR2F2,olfactory receptor family 2 subfamily F member 2,"Olfactory receptors, family 2",ENST00000408955.2,1.0,+,O95006,False,rs866839513,,as_specific,0.4812967581047381,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:8,POLE:2",0.213677,0.7729173493360563,,0.0,,,,,,,ACH-002097,135948.0
chr17,7673772,C,G,0.983,0,57,1|1,,SNP,MISSENSE,c.848G>C,p.R283P,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,,,,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R283C(24) p.R283H(15) p.R283P(26) p.R283fs*16(2) p.R283R(4) p.R280_R283>S(1) p.R283G(2) p.R283S(1) p.R283L(4) p.R283fs*62(5) p.R283fs*59(1) p.S269fs*21(1) p.T284fs*57(1) p.R283delR(1) p.R283fs*56(1) p.V272_K292del21(1) p.R282_E287delRRTEEE(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.R283fs*63(2) p.R283fs*22(1) p.G279fs*59(1) p.R283fs*?(1) p.T284_G293del10(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:6,Misc:2",0.865354,,0.804,3.0,,,,,,,ACH-001599,7157.0
chr2,120286075,G,A,0.5,35,37,0/1,,SNP,MISSENSE,c.316G>A,p.E106K,RALB,RAS like proto-oncogene B,RAS type GTPase family,ENST00000272519.10,3.0,+,P11234,False,rs139389446,,as_specific,0.4214463840399002,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:1,POLE:5",0.962835,0.4210676526317435,0.356,3.0,,,,,,,ACH-000080,5899.0
chr3,10142179,G,A,0.923,0,11,1|1,,SNP,MISSENSE,c.332G>A,p.S111N,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs869025631,,as_specific,0.6508728179551122,"""E, M, O""",Rec,False,,True,p.S111fs*22(2) p.S111fs*47(1) p.S111N(6) p.H110_S111del(1) p.I109_R113del(1) p.S111fs*48(3) p.S111G(3) p.S111R(10) p.S111I(3) p.R107fs*45(1) p.S111S(2) p.S111fs*45(1) p.?(1) p.S111_Y112del(1) p.S111fs*49(1),cancer;gene_function_loss;,False,True,True,,1763.0,,12.5,7.3,False,True,False,,0.669942,0.6352099914181082,0.541,4.0,,,,,,,ACH-002168,7428.0
chr17,7673802,C,T,0.96,0,23,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000006,7157.0
chr8,103885868,T,C,0.193,96,22,0/1,,SNP,SILENT,c.603T>C,p.S201S,RIMS2,regulating synaptic membrane exocytosis 2,Regulating synaptic membrane exocytosis family PDZ domain containing,ENST00000436393.6,2.0,+,Q9UQ26,False,rs778061023,,as_specific,0.456359102244389,,,False,,False,p.S231S(1),cancer;,False,False,True,,,,,7.3,False,False,True,"Eso:2,Misc:2",0.107839,0.8026226825447922,,0.0,,,,,,,ACH-000225,9699.0
chr17,7674885,C,T,0.901,2,28,1|1,,SNP,MISSENSE,c.646G>A,p.V216M,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs730882025,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V216M(79) p.V216L(12) p.V216E(5) p.V216fs*6(2) p.V216fs*31(2) p.V216A(4) p.T211fs*28(1) p.S215_V218>M(1) p.V218delV(8) p.H214fs*5(2) p.S215fs*29(1) p.V216G(6) p.S215fs*31(1) p.V216_Y220delVVVPY(1) p.V216fs*33(1) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.?(1) p.K164_P219del(1) p.V216fs*5(1) p.V216fs*32(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1) p.V216fs*28(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:6,0.94216,0.4523770722957338,0.956,3.0,,,,,,,ACH-000225,7157.0
chr1,114713908,T,C,0.451,87,69,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-002258,4893.0
chr7,140753336,A,T,0.153,96,17,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002258,673.0
chr17,7673806,C,T,0.947,0,17,1|1,,SNP,MISSENSE,c.814G>A,p.V272M,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912657,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.V272M(88) p.0(9) p.F270fs*72(2) p.V272fs*73(2) p.V272A(7) p.V272L(39) p.V272V(4) p.V272E(9) p.G266_E271delGRNSFE(1) p.E271_R273delEVR(1) p.V272G(7) p.E258fs*71(1) p.V272fs*74(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.V272delV(1) p.R267fs*65(1) p.L265_K305del41(1) p.V272fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:10",0.911253,0.5298191979535021,0.907,3.0,,,,,,,ACH-002258,7157.0
chr17,7673802,C,T,0.967,0,27,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000849,7157.0
chr7,140753336,A,T,0.666,42,88,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002389,673.0
chr17,7673766,T,A,0.998,0,573,1|1,,SNP,MISSENSE,c.854A>T,p.E285V,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912667,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E285K(139) p.E285V(15) p.R283fs*16(2) p.E285Q(5) p.E285G(5) p.E285*(19) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.E285A(2) p.R283fs*56(1) p.V272_K292del21(1) p.E285E(5) p.E285fs*20(1) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285fs*60(2) p.E285fs*21(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:3,0.939529,0.7686276362483941,0.936,3.0,,,,,,,ACH-000337,7157.0
chr17,7674220,C,T,0.941,2,51,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000294,7157.0
chr6,155260389,G,A,0.301,341,147,0/1,,SNP,SILENT,c.678C>T,p.G226G,TFB1M,"transcription factor B1, mitochondrial",Seven-beta-strand methyltransferase motif containing,ENST00000367166.5,6.0,-,Q8WVM0,False,rs149796947,,as_specific,0.4364089775561097,,,False,,False,,cancer;,False,False,True,,,,,3.76,False,False,True,,0.302449,,,0.0,,,,,,,ACH-000791,51106.0
chr12,25245350,C,G,0.784,215,767,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-000791,3845.0
chr3,179234297,A,G,0.578,43,61,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000796,5290.0
chr9,21971121,G,A,0.92,1,22,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-000796,1029.0
chr12,25245350,C,T,0.75,11,43,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000796,3845.0
chr1,114713908,T,A,0.504,93,85,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000745,4893.0
chr2,197402110,T,C,0.159,38,6,0/1,,SNP,MISSENSE,c.2098A>G,p.K700E,SF3B1,splicing factor 3b subunit 1,SF3b complex,ENST00000335508.11,15.0,-,O75533,False,rs559063155,,as_specific,0.3740648379052369,L,Dom,False,,True,p.K700E(689) p.K700>RVWEVRE(1) p.Q699_K700del(3),cancer;gene_function_gain;,False,False,True,,565.0,,2.0,4.13,True,False,True,Misc:13,0.96117,,0.619,4.0,,,,,,,ACH-001842,23451.0
chr14,104780214,C,T,0.748,32,95,0/1,,SNP,MISSENSE,c.49G>A,p.E17K,AKT1,AKT serine/threonine kinase 1,Pleckstrin homology domain containing,ENST00000554581.5,2.0,-,P31749,False,rs121434592,,as_specific,0.6234413965087282,E,Dom,False,,True,p.E17K(506),cancer;gene_function_gain;,False,True,True,,4.0,"AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.",33.5,7.3,True,False,True,"UV:3,APOBEC:8,Misc:15",0.933449,0.7974696660996897,0.51,4.0,,,,,,,ACH-001842,207.0
chr17,7674220,C,T,0.992,0,123,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001842,7157.0
chr17,7673802,C,T,0.537,260,291,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001450,7157.0
chr17,7673790,C,A,0.996,0,248,1|1,,SNP,MISSENSE,c.830G>T,p.C277F,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs763098116,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C277Y(17) p.C275fs*67(1) p.C277*(8) p.C277C(4) p.C277G(9) p.C277W(3) p.C277F(26) p.C277S(2) p.C277fs*68(1) p.V274_P278delVCACP(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.C277fs*?(1) p.C277fs*29(2) p.V272_K292del21(1) p.A276fs*64(1) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.A276_C277delAC(1) p.L265_K305del41(1) p.C277R(2) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:2",0.917615,0.8063810398136229,0.932,3.0,,,,,,,ACH-001403,7157.0
chr4,55089802,C,T,0.687,34,73,0/1,,SNP,SPLICE_SITE,c.3193G>A,p.A1065T,KDR,kinase insert domain receptor,I-set domain containing CD molecules V-set domain containing Immunoglobulin like domain containing Receptor Tyrosine Kinases,ENST00000263923.5,24.0,-,P35968,False,rs56302315,,as_specific,0.4089775561097257,E,Dom,False,,True,p.A1065T(6),cancer;gene_function_gain;,False,False,True,,467.0,,3.0,3.71,True,False,False,,0.901202,0.50039802522337,0.592,4.0,,,,,,,ACH-002173,3791.0
chr17,7675124,T,C,0.939,0,14,1|1,,SNP,MISSENSE,c.488A>G,p.Y163C,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs148924904,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y163C(136) p.0(9) p.S149fs*72(1) p.Y163fs*1(2) p.Y163H(19) p.Y163N(20) p.A159_Q167delAMAIYKQSQ(1) p.Y163S(5) p.Y163*(8) p.Y163fs*14(1) p.A159_M169del(1) p.Y163_Q165delYKQ(1) p.Y163D(4) p.Y163del(1) p.Y163Y(3) p.P151_V173del23(1) p.I162_Y163delIY(1) p.Y163fs*7(2) p.V157_C176del20(1) p.Y163fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:11,0.897865,0.7273008533507418,0.872,3.0,,,,,,,ACH-002173,7157.0
chr9,21971121,G,A,0.889,0,7,0/1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-000715,1029.0
chr17,7675137,C,G,0.957,1,49,1|1,,SNP,MISSENSE,c.475G>C,p.A159P,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs730882000,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.A159V(42) p.R158fs*8(1) p.A159D(10) p.S149fs*72(1) p.R158_A159insX(4) p.A159fs*11(6) p.A159_Q167delAMAIYKQSQ(1) p.R158_A159delRA(2) p.A159P(25) p.V157fs*19(2) p.A159S(5) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A159A(8) p.R156fs*18(1) p.A159T(9) p.V157_I162delVRAMAI(1) p.A159fs*21(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A159fs*19(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"smoking:4,Misc:5",0.942569,0.6971257236095824,0.815,3.0,,,,,,,ACH-000715,7157.0
chr17,7675217,T,C,0.951,0,20,1|1,,SNP,MISSENSE,c.395A>G,p.K132R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519996,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.N131delN(4) p.K132Q(17) p.K132E(20) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:4,0.930493,0.6899109988020597,0.908,3.0,,,,,,,ACH-002233,7157.0
chr17,7674252,C,T,0.987,0,80,1|1,,SNP,MISSENSE,c.711G>A,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:9",0.902715,0.9958849948114716,0.923,3.0,,,,,,,ACH-000571,7157.0
chr18,67513723,G,A,0.468,52,45,0/1,,SNP,MISSENSE,c.916C>T,p.R306C,DSEL,dermatan sulfate epimerase-like,,ENST00000310045.8,2.0,-,Q8IZU8,False,rs778536579,,as_specific,0.3940149625935162,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"MSI:1,Misc:1",,0.8051583124128727,0.485,3.0,,,,,,,ACH-000571,92126.0
chr3,10146561,G,T,0.902,10,94,1|1,,SNP,MISSENSE,c.388G>T,p.V130F,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,2.0,+,P40337,False,,,,0.4738154613466334,"""E, M, O""",Rec,False,,True,p.V130L(12) p.V130F(4) p.V130fs*28(1) p.V130D(3) p.V130G(2) p.V130>F(1) p.H125fs*27(1) p.V130fs*29(1) p.V130I(1),cancer;gene_function_loss;,False,False,True,ENST00000256474;,1875.0,,0.0,7.3,False,True,False,,0.806104,0.603848791077047,0.966,4.0,,,,,,,ACH-002167,7428.0
chr17,7675076,T,C,0.993,1,300,1|1,,SNP,MISSENSE,c.536A>G,p.H179R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519991,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:27,0.941824,,0.935,3.0,,,,,,,ACH-000869,7157.0
chr17,7673802,C,A,0.431,33,24,0/1,,SNP,MISSENSE,c.818G>T,p.R273L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,918.0,,0.0,7.3,False,True,True,"smoking:15,Misc:9",0.887493,0.7009283873752175,0.921,3.0,,,,,,,ACH-000305,7157.0
chr17,7674262,T,C,0.577,36,53,0/1,,SNP,MISSENSE,c.701A>G,p.Y234C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587780073,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y234C(87) p.Y234N(13) p.T230_Y234delTTIHY(1) p.H233_C242del10(1) p.Y234S(8) p.Y234fs*6(1) p.Y234D(7) p.Y234fs*4(1) p.D228fs*12(1) p.H233fs*6(1) p.Y234*(15) p.Y234delY(4) p.Y234fs*11(1) p.Y234H(23) p.I232fs*5(1) p.Y234fs*15(1) p.Y234F(1) p.Y234fs*1(1) p.V225fs*23(1) p.Y234fs*5(1) p.I232_Y236delIHYNY(1) p.?(1) p.Y234del(2) p.Y234R(1) p.Y234Y(1) p.Y234_N235insX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1068.0,,0.0,7.3,False,True,True,Misc:7,0.865205,0.7361252184832682,0.945,3.0,,,,,,,ACH-000305,7157.0
chr17,7675088,C,T,0.978,0,52,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-001206,7157.0
chr17,7673790,C,A,0.994,1,347,1|1,,SNP,MISSENSE,c.830G>T,p.C277F,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs763098116,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C277Y(17) p.C275fs*67(1) p.C277*(8) p.C277C(4) p.C277G(9) p.C277W(3) p.C277F(26) p.C277S(2) p.C277fs*68(1) p.V274_P278delVCACP(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.C277fs*?(1) p.C277fs*29(2) p.V272_K292del21(1) p.A276fs*64(1) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.A276_C277delAC(1) p.L265_K305del41(1) p.C277R(2) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:2",0.917615,0.8063810398136229,0.932,3.0,,,,,,,ACH-001500,7157.0
chr7,140753336,A,T,0.744,125,343,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002461,673.0
chr1,38045466,T,G,0.56,2,3,0/1,,SNP,SILENT,c.1278A>C,p.P426P,POU3F1,POU class 3 homeobox 1,POU class homeoboxes and pseudogenes,ENST00000373012.5,1.0,-,Q03052,False,rs746275953,,as_specific,0.7007481296758105,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.3252,0.6755287290451399,,0.0,,,,,,,ACH-002218,5453.0
chr1,114713909,G,T,0.664,52,104,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-002152,4893.0
chr11,54707643,C,T,0.946,3,68,1|1,,SNP,SILENT,c.759C>T,p.F253F,OR4A5,olfactory receptor family 4 subfamily A member 5,"Olfactory receptors, family 4",ENST00000319760.8,1.0,+,Q8NH83,False,,,,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:7,APOBEC:1",0.411778,,,1.0,,,,,,,ACH-002152,81318.0
chr9,136504892,A,G,0.75,0,2,0/1,,SNP,MISSENSE,c.4799T>C,p.L1600P,NOTCH1,notch 1,Ankyrin repeat domain containing,ENST00000651671.1,26.0,-,P46531,False,,,,0.6907730673316709,L,Dom,False,TRB@,True,p.L1600P(66) p.L1600fs*10(10) p.L1600Q(10) p.L1600_H1601insA(1) p.L1600_H1601insL(2) p.L1600H(1),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,ENST00000277541;,1031.0,,0.0,7.3,True,True,False,,0.720263,,0.973,3.0,,,,,,,ACH-000519,4851.0
chr17,7675124,T,C,0.5,25,25,0/1,,SNP,MISSENSE,c.488A>G,p.Y163C,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs148924904,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y163C(136) p.0(9) p.S149fs*72(1) p.Y163fs*1(2) p.Y163H(19) p.Y163N(20) p.A159_Q167delAMAIYKQSQ(1) p.Y163S(5) p.Y163*(8) p.Y163fs*14(1) p.A159_M169del(1) p.Y163_Q165delYKQ(1) p.Y163D(4) p.Y163del(1) p.Y163Y(3) p.P151_V173del23(1) p.I162_Y163delIY(1) p.Y163fs*7(2) p.V157_C176del20(1) p.Y163fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:11,0.897865,0.7273008533507418,0.872,3.0,,,,,,,ACH-000519,7157.0
chr17,7675994,C,T,0.519,30,29,0/1,,SNP,SPLICE_SITE,c.375G>A,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:5,0.392984,0.6099495421221454,,0.0,,,,,,,ACH-000519,7157.0
chr4,122353074,C,T,0.338,50,25,0/1,,SNP,MISSENSE,c.14020C>T,p.R4674C,KIAA1109,KIAA1109,,ENST00000264501.8,81.0,+,Q2LD37,False,rs1278017597,,as_specific,0.3740648379052369,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:6,POLE:2",0.970087,0.945197709844172,0.567,2.0,,,,,,,ACH-000013,84162.0
chr17,7674220,C,T,0.948,1,45,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000013,7157.0
chr17,7674893,C,T,0.91,2,29,1|1,,SNP,MISSENSE,c.638G>A,p.R213Q,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs587778720,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"CpG:2,UV:1,POLE:2",0.920288,0.776972471915739,0.92,3.0,,,,,,,ACH-000040,7157.0
chr3,41224606,G,T,0.432,137,107,0/1,,SNP,MISSENSE,c.94G>T,p.D32Y,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs28931588,,as_specific,0.3965087281795511,"""E, M, O""",Dom,False,PLAG1,True,p.D32H(66) p.D32Y(177) p.A5_A80del(75) p.D32N(123) p.D32V(66) p.D32G(92) p.A5_Q143del(7) p.Q28_D32>H(2) p.D32A(22) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32E(11) p.D32_S47del(2) p.Y30_T40del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_D32del(6) p.W25_I35del(1) p.Q28_I140del(1) p.Q28fs*20(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.WQQQSYLD25?(5) p.E9_I140del(1) p.H24_G38del(1) p.S23_S33del(3) p.A20_R151del(1) p.D32_S33insS(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.D32D(1) p.T3_A126del(2) p.D32fs*9(1) p.S23_S33>T(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.W25_S33del(1) p.W25_H36del(2) p.A5_D144>D(1) p.D32F(3) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.V22_S33del(2) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D32del(1) p.D6_A43del(1) p.S23_A39del(1) p.Y30_S33del(2) p.A5_I35del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,Misc:5,0.950078,0.7611388076560383,0.59,4.0,,,,,,,ACH-001280,1499.0
chr2,74415153,T,G,0.608,1,2,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000976,388963.0
chr12,25245350,C,T,0.723,19,47,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000976,3845.0
chr17,7675088,C,T,0.974,0,39,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000976,7157.0
chr17,7673802,C,T,0.995,1,386,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001038,7157.0
chr17,7675190,C,T,0.996,0,235,1|1,,SNP,MISSENSE,c.422G>A,p.C141Y,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781288,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.C141Y(78) p.C141fs*29(2) p.0(9) p.N131fs*27(3) p.L137_W146del10(1) p.K139fs*4(1) p.C141W(12) p.Q136_C141delQLAKTC(1) p.C141G(4) p.C141C(4) p.C141_P142insXX(1) p.C141*(14) p.C141R(17) p.A138_P142delAKTCP(1) p.C141fs*34(1) p.C141fs*30(1) p.C141S(2) p.C141fs*8(2) p.C141F(4) p.A138_V143delAKTCPV(1) p.C141A(1) p.C141fs*5(1) p.A138_C141delAKTC(1) p.K139_C141>N(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,Misc:3,0.931226,0.2411594683277477,0.897,3.0,,,,,,,ACH-001841,7157.0
chr3,37014545,G,A,0.964,0,26,1|1,,SNP,SPLICE_SITE,c.e10+1G>A,,MLH1,mutL homolog 1,MutL homologs,ENST00000458205.6,,+,P40692,False,rs267607789,,as_specific,0.3690773067331671,"""E, O""",Rec,False,,False,p.?(4),splicing;cancer;gene_function_loss;dna_repair;,False,False,True,,731.0,,2.5,7.3,False,True,False,,0.972304,0.4673546425590275,,1.59129685669006,,,,,,,ACH-002238,4292.0
chr2,74415153,T,G,0.597,3,5,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000815,388963.0
chr17,7674268,A,C,0.949,1,36,1|1,,SNP,MISSENSE,c.695T>G,p.I232S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,,,,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.I232F(10) p.0(9) p.I232V(5) p.T230_Y234delTTIHY(1) p.C229_H233delCTTIH(2) p.I232N(4) p.S227_I232delSDCTTI(1) p.D228fs*12(1) p.I232T(6) p.I232fs*5(1) p.I232S(5) p.Y234fs*15(1) p.V225fs*23(1) p.I232I(1) p.I232L(1) p.I232fs*15(1) p.T230fs*6(2) p.I232_Y236delIHYNY(1) p.I232fs*8(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:2,0.956697,0.3115463556296232,0.935,3.0,,,,,,,ACH-002129,7157.0
chr6,46140105,G,A,0.566,58,76,0/1,,SNP,SILENT,c.522G>A,p.S174S,ENPP4,ectonucleotide pyrophosphatase/phosphodiesterase 4,,ENST00000321037.5,2.0,+,Q9Y6X5,False,rs751766694,,as_specific,0.4014962593516209,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:3,POLE:5",0.180625,0.848781258809006,,0.0,,,,,,,ACH-001339,22875.0
chr7,140753336,A,T,0.649,122,244,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001339,673.0
chr17,7675209,A,G,0.995,0,201,1|1,,SNP,MISSENSE,c.403T>C,p.C135R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519975,,as_specific,0.5536159600997507,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.?(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,Misc:3,0.94193,0.2485372874595451,0.964,3.0,,,,,,,ACH-001339,7157.0
chr1,114713908,T,A,0.743,49,146,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000802,4893.0
chr1,114716127,C,A,0.26,101,35,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913250,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,897.0,,0.0,7.3,True,False,True,"smoking:1,MSI:1,Misc:1",0.849577,,0.773,4.0,,,,,,,ACH-001127,4893.0
chr2,74415153,T,G,0.486,3,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-001127,388963.0
chr9,136504892,A,G,0.539,6,6,0/1,,SNP,MISSENSE,c.4799T>C,p.L1600P,NOTCH1,notch 1,Ankyrin repeat domain containing,ENST00000651671.1,26.0,-,P46531,False,,,,0.6907730673316709,L,Dom,False,TRB@,True,p.L1600P(66) p.L1600fs*10(10) p.L1600Q(10) p.L1600_H1601insA(1) p.L1600_H1601insL(2) p.L1600H(1),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,ENST00000277541;,1031.0,,0.0,7.3,True,True,False,,0.720263,,0.973,3.0,,,,,,,ACH-001127,4851.0
chr17,7673704,G,A,0.343,45,23,0/1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-001127,7157.0
chr17,7674216,C,A,0.992,0,127,1|1,,SNP,MISSENSE,c.747G>T,p.R249S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934571,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.P250fs*14(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:5,Misc:13",0.776711,,0.769,2.0,,,,,,,ACH-001458,7157.0
chr18,47841840,G,C,0.994,0,166,1|1,,SNP,NONSENSE,c.1391C>G,p.S464*,SMAD2,SMAD family member 2,SMAD family,ENST00000262160.11,11.0,-,Q15796,False,,,,0.3840399002493765,,,True,,True,p.S464L(2) p.S464*(4) p.R462fs*>4(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,APOBEC:5,0.982351,0.8311300959289666,,4.0,,,,,,,ACH-001458,4087.0
chr17,7675085,C,T,0.98,0,52,1|1,,SNP,MISSENSE,c.527G>A,p.C176Y,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202962,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C176F(140) p.0(9) p.C176S(27) p.C176Y(67) p.C176W(15) p.C176fs*71(7) p.C176R(21) p.C176fs*5(3) p.R174fs*1(2) p.C176*(10) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(7) p.C176G(5) p.H168fs*23(1) p.H178fs*3(1) p.R174_H178>S(1) p.V173fs*69(1) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R174_E180>K(1) p.C176_P177delCP(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.C176delC(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*72(1) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"MSI:1,Misc:4",0.9259,0.4503884992219147,0.949,3.0,,,,,,,ACH-000893,7157.0
chr4,152326214,C,T,0.5,30,30,0/1,,SNP,MISSENSE,c.1196G>A,p.R399Q,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs866987936,,as_specific,0.3665835411471321,"""E, L""",Rec,False,,True,p.R479Q(43) p.R479L(7) p.R479fs*6(3) p.R479P(3) p.D480fs*5(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:1,POLE:1",0.971548,,0.479,4.0,,,,,,,ACH-000249,55294.0
chr12,25227341,T,G,0.471,30,24,0/1,,SNP,MISSENSE,c.183A>C,p.Q61H,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs17851045,,as_specific,0.3466334164588528,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,True,True,,907.0,,10.5,7.3,True,False,True,"POLE:1,Eso:2,Misc:7",0.798711,,0.644,4.0,,,,,,,ACH-000249,3845.0
chr4,271796,C,A,0.435,40,30,0/1,,SNP,MISSENSE,c.1061G>T,p.R354I,ZNF732,zinc finger protein 732,Zinc fingers C2H2-type,ENST00000419098.6,4.0,-,B4DXR9,False,,,,0.3965087281795511,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.572909,0.3244032311225991,0.097,1.0,,,,,,,ACH-001184,654254.0
chr7,140753336,A,T,0.995,0,199,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002042,673.0
chr17,7674220,C,T,0.981,0,58,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-002209,7157.0
chr8,87353670,T,G,0.541,53,68,0/1,,SNP,MISSENSE,c.1187T>G,p.L396R,CNBD1,cyclic nucleotide binding domain containing 1,,ENST00000518476.6,10.0,+,Q8NA66,False,,,,0.2668329177057356,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:5,0.541415,,0.584,2.0,,,,,,,ACH-002446,168975.0
chr17,7675131,C,T,0.912,10,116,1|1,,SNP,MISSENSE,c.481G>A,p.A161T,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs193920817,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R158fs*8(1) p.S149fs*72(1) p.A161T(54) p.A161S(6) p.A159_Q167delAMAIYKQSQ(1) p.A161D(12) p.V157fs*19(2) p.A161fs*19(1) p.A161fs*20(1) p.A161V(10) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A161A(5) p.R156fs*18(1) p.A161P(1) p.V157_I162delVRAMAI(1) p.M160fs*10(2) p.A161fs*9(3) p.A161G(1) p.M160_A161>IS(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.A161F(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A161fs*8(1) p.A161N(1) p.V157_C176del20(1) p.A161fs*7(1) p.A161fs*10(1) p.V157fs*9(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1114.0,,3.0,7.3,False,True,True,"MSI:1,Misc:2",0.858308,,0.79,3.0,,,,,,,ACH-001201,7157.0
chr7,140781602,C,G,0.991,0,121,1|1,,SNP,MISSENSE,c.1406G>C,p.G469A,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,11.0,-,P15056,False,rs121913355,,as_specific,0.3541147132169576,E,Dom,False,"""AKAP9, KIAA1549""",True,p.G469A(70) p.G469R(28) p.G469V(34) p.G469E(20) p.G469S(7) p.G469del(2) p.G469?(1) p.G469L(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,992.0,,5.0,7.3,True,False,False,,0.908834,,0.9,4.0,,,,,,,ACH-002363,673.0
chr11,108333954,A,G,0.997,0,296,1|1,,SNP,MISSENSE,c.7996A>G,p.T2666A,ATM,ATM serine/threonine kinase,,ENST00000452508.6,55.0,+,Q13315,False,rs745775382,,as_specific,0.3216957605985037,"""L, O""",Rec,False,,False,p.T2666A(1) p.T2666I(1),cancer;gene_function_loss;dna_repair;,False,False,True,ENST00000278616;ENST00000452508;,901.0,,3.0,7.3,False,True,False,,0.915908,0.5561440258583976,0.853,3.0,,,,,,,ACH-002363,472.0
chr17,7674256,T,C,0.915,2,35,1|1,,SNP,MISSENSE,c.707A>G,p.Y236C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs730882026,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y236delY(4) p.Y236C(58) p.H233_C242del10(1) p.Y236N(21) p.Y236*(13) p.Y236H(13) p.Y236D(6) p.H233fs*6(1) p.Y236_M237>*(1) p.Y236S(4) p.Y236fs*5(1) p.V225fs*23(1) p.Y236Y(2) p.Y236fs*4(2) p.I232_Y236delIHYNY(1) p.?(1) p.Y236_M243delYMCNSSCM(1) p.N235_Y236delNY(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:5,0.844922,0.9351637534056272,0.811,2.0,,,,,,,ACH-000876,7157.0
chr19,12681620,G,T,0.523,24,22,0/1,,SNP,MISSENSE,c.147C>A,p.F49L,DHPS,deoxyhypusine synthase,,ENST00000210060.12,1.0,-,P49366,False,,,,0.628428927680798,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"APOBEC:1,Misc:1",0.653494,0.2434374689520425,0.084,3.0,,,,,,,ACH-000876,1725.0
chr17,7674893,C,T,0.359,15,8,0/1,,SNP,MISSENSE,c.638G>A,p.R213Q,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs587778720,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"CpG:2,UV:1,POLE:2",0.920288,0.776972471915739,0.92,3.0,,,,,,,ACH-000654,7157.0
chr17,7673803,G,A,0.976,0,38,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000437,7157.0
chr3,41224613,G,T,0.468,155,132,0/1,,SNP,MISSENSE,c.101G>T,p.G34V,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs28931589,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.A5_Q143del(7) p.G34V(103) p.G34R(123) p.G34E(112) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32_S47del(2) p.G34A(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_I35del(1) p.G34D(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.G34I(1) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(2) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.D32fs*9(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.S33_G34insS(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.S33_G34insGTS(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.S33_G34insGI(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_I35del(1) p.A5_T59del(1) p.G34C(1) p.A5_Q72del(1) p.S33_G34del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"smoking:2,Misc:4",0.950078,,0.532,4.0,,,,,,,ACH-001959,1499.0
chr17,7673704,G,A,0.998,0,562,1|1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-001959,7157.0
chr17,7674221,G,A,0.978,0,47,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-002226,7157.0
chr12,25245350,C,A,0.975,0,41,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000186,3845.0
chr17,7674256,T,C,0.977,0,48,1|1,,SNP,MISSENSE,c.707A>G,p.Y236C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs730882026,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y236delY(4) p.Y236C(58) p.H233_C242del10(1) p.Y236N(21) p.Y236*(13) p.Y236H(13) p.Y236D(6) p.H233fs*6(1) p.Y236_M237>*(1) p.Y236S(4) p.Y236fs*5(1) p.V225fs*23(1) p.Y236Y(2) p.Y236fs*4(2) p.I232_Y236delIHYNY(1) p.?(1) p.Y236_M243delYMCNSSCM(1) p.N235_Y236delNY(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:5,0.844922,0.9351637534056272,0.811,2.0,,,,,,,ACH-000186,7157.0
chr1,114716126,C,T,0.443,106,82,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-000197,4893.0
chr17,7674220,C,T,0.566,23,30,0|1,7674220.0,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000197,7157.0
chr17,7674230,C,T,0.346,33,17,1|0,7674220.0,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-000197,7157.0
chr12,25245350,C,A,0.588,42,57,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000599,3845.0
chr7,98912179,C,T,0.473,76,68,0/1,,SNP,MISSENSE,c.2162C>T,p.S721F,TRRAP,transformation/transcription domain associated protein,SAGA complex,ENST00000446306.7,17.0,+,Q9Y4A5,False,rs147405090,,as_specific,0.4688279301745636,,,False,,False,p.S722F(3),cancer;,False,False,True,,,,,7.3,False,False,True,"UV:8,POLE_MSI:1",0.926675,,0.603,4.0,,,,,,,ACH-002316,8295.0
chr12,25225628,C,T,0.388,99,62,0/1,,SNP,MISSENSE,c.436G>A,p.A146T,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,906.0,,21.0,7.3,True,False,True,"MSI:3,Misc:4",0.951882,0.7493523432445548,0.909,4.0,,,,,,,ACH-002316,3845.0
chr17,7674252,C,T,0.922,2,37,1|1,,SNP,MISSENSE,c.711G>A,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:9",0.902715,0.9958849948114716,0.923,3.0,,,,,,,ACH-002316,7157.0
chr7,140753336,A,T,0.574,50,69,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002207,673.0
chr17,7674218,T,C,0.997,0,368,1|1,,SNP,MISSENSE,c.745A>G,p.R249G,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782082,,as_specific,0.5610972568578554,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.N247_R248delNR(2) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:3,0.96222,0.7229412758792237,0.888,2.0,,,,,,,ACH-000157,7157.0
chr7,79007168,A,C,0.537,27,30,0/1,,SNP,MISSENSE,c.340T>G,p.L114V,MAGI2,"membrane associated guanylate kinase, WW and PDZ domain containing 2",Membrane associated guanylate kinases PDZ domain containing,ENST00000354212.9,2.0,-,Q86UL8,False,,,,0.3341645885286783,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"Eso:1,Misc:1",0.70916,0.5631261489261696,0.074,4.0,,,,,,,ACH-000466,9863.0
chr17,7674885,C,T,0.924,1,28,1|1,,SNP,MISSENSE,c.646G>A,p.V216M,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs730882025,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V216M(79) p.V216L(12) p.V216E(5) p.V216fs*6(2) p.V216fs*31(2) p.V216A(4) p.T211fs*28(1) p.S215_V218>M(1) p.V218delV(8) p.H214fs*5(2) p.S215fs*29(1) p.V216G(6) p.S215fs*31(1) p.V216_Y220delVVVPY(1) p.V216fs*33(1) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.?(1) p.K164_P219del(1) p.V216fs*5(1) p.V216fs*32(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1) p.V216fs*28(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:6,0.94216,0.4523770722957338,0.956,3.0,,,,,,,ACH-000466,7157.0
chr3,65391193,G,T,0.166,35,6,0/1,,SNP,MISSENSE,c.2365C>A,p.P789T,MAGI1,"membrane associated guanylate kinase, WW and PDZ domain containing 1",Trinucleotide repeat containing Membrane associated guanylate kinases PDZ domain containing,ENST00000497477.6,14.0,-,Q96QZ7,False,rs770193154,,as_specific,0.5037406483790524,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:6,0.864519,0.6661910679274031,0.351,4.0,,,,,,,ACH-002255,Unknown
chr12,25245350,C,A,0.693,75,182,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-001353,3845.0
chr2,177234216,C,T,0.764,69,220,0/1,,SNP,MISSENSE,c.53G>A,p.R18Q,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.3940149625935162,E,Dom,False,,True,p.D16_R34del(1) p.R34Q(8) p.R34P(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,POLE:1,0.971853,0.51590549331288,0.412,3.0,,,,,,,ACH-000593,4780.0
chr3,179218303,G,A,0.677,43,100,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000593,5290.0
chr1,114713908,T,A,0.533,45,51,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-001021,4893.0
chrX,40062191,T,C,0.857,0,5,0/1,,SNP,MISSENSE,c.4274A>G,p.N1425S,BCOR,BCL6 corepressor,Ankyrin repeat domain containing,ENST00000397354.7,10.0,-,Q6W2J9,False,rs199538037,,as_specific,0.6334164588528678,,Rec,False,RARA,False,p.N1425S(1),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:23,,,0.221,2.0,,,,,,,ACH-001021,54880.0
chr17,7674230,C,T,0.995,0,210,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-001367,7157.0
chr17,7674220,C,A,0.996,0,287,1|1,,SNP,MISSENSE,c.743G>T,p.R248L,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:4,Misc:3",0.932907,0.9843307954424446,0.96,3.0,,,,,,,ACH-000837,7157.0
chr1,114713909,G,T,0.259,123,43,0|1,114713909.0,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000841,4893.0
chr7,140753346,G,C,0.35,432,227,0/1,,SNP,MISSENSE,c.1789C>G,p.L597V,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs121913369,,as_specific,0.341645885286783,E,Dom,False,"""AKAP9, KIAA1549""",True,p.L597S(25) p.L597R(28) p.L597V(11) p.L597Q(24) p.L597_A598insT(2) p.L597P(2) p.D594_T599del(1) p.L597L(5),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,585.0,,7.5,7.3,True,False,False,,0.850074,0.6272836932606044,0.796,4.0,,,,,,,ACH-000841,673.0
chr17,7675143,C,A,0.998,1,532,1|1,,SNP,MISSENSE,c.469G>T,p.V157F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs121912654,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.V157F(176) p.0(9) p.V157A(2) p.V157L(7) p.S149fs*72(1) p.V157D(13) p.V157_R158insV(1) p.V157_R158delVR(3) p.V157I(11) p.G154fs*22(1) p.V157fs*13(3) p.V157fs*24(2) p.V157fs*22(2) p.V157fs*19(2) p.T155fs*23(2) p.V157V(5) p.V157G(12) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156fs*18(1) p.V157fs*23(3) p.R156fs*12(1) p.V157delV(2) p.T155_V157>I(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.R156fs*14(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.V157fs*25(1) p.V157_C176del20(1) p.V157>AL(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1092.0,,4.0,7.3,False,True,True,"smoking:20,Misc:8",0.788392,0.832221967405611,0.708,3.0,,,,,,,ACH-000841,7157.0
chr17,7674220,C,T,0.975,0,41,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000295,7157.0
chr3,179218303,G,A,0.539,41,48,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-001331,5290.0
chr19,16807664,C,T,0.397,51,32,0/1,,SNP,MISSENSE,c.3815C>T,p.T1272M,NWD1,NACHT and WD repeat domain containing 1,WD repeat domain containing,ENST00000552788.1,16.0,+,Q149M9,False,rs758051323,,as_specific,0.5586034912718204,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:3,MSI:1",0.444756,,0.275,2.0,,,,,,,ACH-001331,284434.0
chr12,25245350,C,T,0.72,99,268,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000460,3845.0
chr12,25245350,C,T,0.556,20,26,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-002140,3845.0
chr5,68295269,A,G,0.375,41,26,0/1,,SNP,MISSENSE,c.601A>G,p.N201D,PIK3R1,phosphoinositide-3-kinase regulatory subunit 1,SH2 domain containing,ENST00000523872.1,6.0,+,P27986,False,rs1057519841,,as_specific,0.371571072319202,"""E, O""",Rec,False,,False,p.N564D(4),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"POLE:1,Misc:5",0.944295,,0.362,4.0,,,,,,,ACH-002171,5295.0
chr17,7673790,C,A,0.976,0,39,1|1,,SNP,MISSENSE,c.830G>T,p.C277F,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs763098116,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C277Y(17) p.C275fs*67(1) p.C277*(8) p.C277C(4) p.C277G(9) p.C277W(3) p.C277F(26) p.C277S(2) p.C277fs*68(1) p.V274_P278delVCACP(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.C277fs*?(1) p.C277fs*29(2) p.V272_K292del21(1) p.A276fs*64(1) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.A276_C277delAC(1) p.L265_K305del41(1) p.C277R(2) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:2",0.917615,0.8063810398136229,0.932,3.0,,,,,,,ACH-002171,7157.0
chr17,7675208,C,A,0.971,0,33,1|1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-002261,7157.0
chr19,1220641,C,T,0.959,0,22,1|1,,SNP,NONSENSE,c.658C>T,p.Q220*,STK11,serine/threonine kinase 11,,ENST00000326873.12,5.0,+,Q15831,False,rs1131690940,,as_specific,0.7182044887780549,"""E, M, O""",Rec,True,,True,p.Q220*(4) p.0(15),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,smoking:2,0.985752,0.9958392207664156,,4.0,,,,,,,ACH-001417,6794.0
chr1,114713909,G,T,0.184,131,27,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000964,4893.0
chr9,136504892,A,G,0.6,8,12,0/1,,SNP,MISSENSE,c.4799T>C,p.L1600P,NOTCH1,notch 1,Ankyrin repeat domain containing,ENST00000651671.1,26.0,-,P46531,False,,,,0.6907730673316709,L,Dom,False,TRB@,True,p.L1600P(66) p.L1600fs*10(10) p.L1600Q(10) p.L1600_H1601insA(1) p.L1600_H1601insL(2) p.L1600H(1),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,ENST00000277541;,1031.0,,0.0,7.3,True,True,False,,0.720263,,0.973,3.0,,,,,,,ACH-000964,4851.0
chr17,7674188,C,A,0.966,0,29,1|1,,SNP,MISSENSE,c.775G>T,p.D259Y,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,,,,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.D259Y(25) p.D259G(4) p.E258_S260delEDS(1) p.D259V(16) p.D259A(1) p.E258fs*85(1) p.D259N(6) p.D259E(3) p.D259H(3) p.E258fs*71(1) p.D259fs*86(5) p.D259D(2) p.D259fs*5(3) p.L257fs*85(1) p.E258fs*2(1) p.D259S(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:1",0.913497,0.8436528385612934,0.737,3.0,,,,,,,ACH-000743,7157.0
chr17,7675148,G,T,0.989,0,91,1|1,,SNP,MISSENSE,c.464C>A,p.T155N,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202752,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T155P(16) p.S149fs*72(1) p.T155N(22) p.G154fs*22(1) p.T155I(15) p.P152fs*14(4) p.G154_R156delGTR(1) p.T155fs*23(2) p.T155L(1) p.T155T(5) p.T155S(2) p.D148fs*23(1) p.G154fs*14(2) p.T155A(7) p.T155_V157>I(1) p.T155fs*25(1) p.P153fs*22(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.T155fs*26(2) p.D148_T155delDSTPPPGT(1) p.R156fs*25(1) p.T155fs*15(1) p.T155_R156delTR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:4,0.656667,0.8526069402886141,0.548,2.0,,,,,,,ACH-001232,7157.0
chr17,7675208,C,T,0.966,0,29,1|1,,SNP,MISSENSE,c.404G>A,p.C135Y,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,Misc:4,0.958746,,0.955,3.0,,,,,,,ACH-000383,7157.0
chr12,25245351,C,G,0.961,0,26,1|1,,SNP,MISSENSE,c.34G>C,p.G12R,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,530.0,,32.5,7.3,True,False,True,"smoking:1,Misc:32",0.915109,0.6459561688690294,0.821,4.0,,,,,,,ACH-000174,3845.0
chr17,7675130,G,T,0.976,0,39,1|1,,SNP,MISSENSE,c.482C>A,p.A161D,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1064795691,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R158fs*8(1) p.S149fs*72(1) p.A161T(54) p.A161S(6) p.A159_Q167delAMAIYKQSQ(1) p.A161D(12) p.A161fs*19(1) p.A161fs*20(1) p.A161V(10) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A161A(5) p.R156fs*18(1) p.A161P(1) p.V157_I162delVRAMAI(1) p.A161fs*9(3) p.A161G(1) p.M160_A161>IS(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.A161F(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A161fs*8(1) p.I162fs*8(1) p.A161N(1) p.V157_C176del20(1) p.A161fs*7(1) p.A161fs*10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"smoking:2,Misc:1",0.946572,0.7293906543769855,0.908,3.0,,,,,,,ACH-000174,7157.0
chr2,209692788,T,G,0.333,59,27,0/1,,SNP,SILENT,c.618T>G,p.T206T,MAP2,microtubule associated protein 2,A-kinase anchoring proteins,ENST00000360351.8,7.0,+,P11137,False,,,,0.4488778054862843,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.18431,0.7057025688061067,,0.0,,,,,,,ACH-000235,4133.0
chr12,25245350,C,T,0.561,20,24,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000235,3845.0
chr17,7674230,C,T,0.963,1,57,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-000235,7157.0
chr17,7674872,T,C,0.971,0,33,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000451,7157.0
chr12,25245350,C,T,0.562,10,9,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001106,3845.0
chr17,7674220,C,T,0.396,33,20,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001106,7157.0
chr12,92145427,G,A,0.432,46,35,0/1,,SNP,SILENT,c.109C>T,p.L37L,BTG1,BTG anti-proliferation factor 1,BTG/Tob family,ENST00000256015.5,1.0,-,P62324,False,rs369374957,,as_specific,0.7456359102244389,L,Dom,False,MYC,False,p.L37M(1) p.R35_L37delRQL(1),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:3,0.198117,0.7013235344455819,,0.0,,,,,,,ACH-002221,694.0
chr17,7675131,C,T,0.956,0,21,1|1,,SNP,MISSENSE,c.481G>A,p.A161T,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs193920817,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R158fs*8(1) p.S149fs*72(1) p.A161T(54) p.A161S(6) p.A159_Q167delAMAIYKQSQ(1) p.A161D(12) p.V157fs*19(2) p.A161fs*19(1) p.A161fs*20(1) p.A161V(10) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A161A(5) p.R156fs*18(1) p.A161P(1) p.V157_I162delVRAMAI(1) p.M160fs*10(2) p.A161fs*9(3) p.A161G(1) p.M160_A161>IS(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.A161F(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A161fs*8(1) p.A161N(1) p.V157_C176del20(1) p.A161fs*7(1) p.A161fs*10(1) p.V157fs*9(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1114.0,,3.0,7.3,False,True,True,"MSI:1,Misc:2",0.858308,,0.79,3.0,,,,,,,ACH-000626,7157.0
chr3,179234296,C,T,0.452,55,46,0/1,,SNP,MISSENSE,c.3139C>T,p.H1047Y,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913281,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"MSI:4,Misc:2",0.841311,0.4540869654537645,0.401,3.0,,,,,,,ACH-000885,5290.0
chr12,25245348,C,A,0.531,15,20,0/1,,SNP,MISSENSE,c.37G>T,p.G13C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913535,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,911.0,,0.0,7.3,True,False,True,"smoking:7,MSI:1,Misc:4",0.929283,,0.868,4.0,,,,,,,ACH-000885,3845.0
chrX,40062191,T,C,0.584,4,6,0/1,,SNP,MISSENSE,c.4274A>G,p.N1425S,BCOR,BCL6 corepressor,Ankyrin repeat domain containing,ENST00000397354.7,10.0,-,Q6W2J9,False,rs199538037,,as_specific,0.6334164588528678,,Rec,False,RARA,False,p.N1425S(1),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:23,,,0.221,2.0,,,,,,,ACH-000885,54880.0
chr7,140753336,A,T,0.225,380,113,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000296,673.0
chr17,7674262,T,C,0.998,0,544,1|1,,SNP,MISSENSE,c.701A>G,p.Y234C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587780073,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y234C(87) p.Y234N(13) p.T230_Y234delTTIHY(1) p.H233_C242del10(1) p.Y234S(8) p.Y234fs*6(1) p.Y234D(7) p.Y234fs*4(1) p.D228fs*12(1) p.H233fs*6(1) p.Y234*(15) p.Y234delY(4) p.Y234fs*11(1) p.Y234H(23) p.I232fs*5(1) p.Y234fs*15(1) p.Y234F(1) p.Y234fs*1(1) p.V225fs*23(1) p.Y234fs*5(1) p.I232_Y236delIHYNY(1) p.?(1) p.Y234del(2) p.Y234R(1) p.Y234Y(1) p.Y234_N235insX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1068.0,,0.0,7.3,False,True,True,Misc:7,0.865205,0.7361252184832682,0.945,3.0,,,,,,,ACH-000296,7157.0
chr3,179234297,A,G,0.244,59,18,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000518,5290.0
chr9,21971097,C,A,0.912,0,10,1|1,,SNP,NONSENSE,c.109G>T,p.E37*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913384,,as_specific,0.6982543640897756,,,True,,True,p.0(1543) p.E88*(15) p.V82_E88del(1) p.V28_V51del(1) p.E88K(3) p.?(4) p.L32_L37del(6) p.H83fs*2(2) p.E88fs*58(1) p.R87fs*30(1) p.E61_L94del(1) p.L37L(2) p.E87K(2) p.D84_F90del(1) p.A68fs*3(1) p.L37fs*6(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,smoking:2,0.92205,0.9909344162016276,0.584,5.0,,,,,,,ACH-000518,1029.0
chr17,7675088,C,T,0.978,0,43,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000518,7157.0
chr19,694935,C,G,0.573,2,4,0/1,,SNP,MISSENSE,c.115G>C,p.E39Q,PRSS57,"protease, serine 57","Proteases, serine",ENST00000613411.4,2.0,-,Q6UWY2,False,,,,0.6708229426433915,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"smoking:1,APOBEC:2",0.60301,0.9952650726363436,0.482,2.0,,,,,,,ACH-000518,400668.0
chr12,25245350,C,A,0.65,37,67,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000332,3845.0
chr17,7675076,T,C,0.969,0,31,1|1,,SNP,MISSENSE,c.536A>G,p.H179R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519991,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:27,0.941824,,0.935,3.0,,,,,,,ACH-000332,7157.0
chr1,114713909,G,T,0.479,49,45,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000206,4893.0
chr3,179218303,G,A,0.219,59,17,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-001336,5290.0
chr1,44941518,T,C,0.23,91,26,0/1,,SNP,MISSENSE,c.442A>G,p.K148E,EIF2B3,eukaryotic translation initiation factor 2B subunit gamma,,ENST00000360403.7,4.0,-,Q9NR50,False,rs151056457,,as_specific,0.371571072319202,,,False,,False,,cancer;,False,False,True,,,,,3.71,False,False,True,Misc:2,0.942131,0.7633554435648935,0.622,4.0,,,,,,,ACH-001848,8891.0
chr7,140753336,A,T,0.523,271,292,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001848,673.0
chr14,104780214,C,T,0.988,1,143,1|1,,SNP,MISSENSE,c.49G>A,p.E17K,AKT1,AKT serine/threonine kinase 1,Pleckstrin homology domain containing,ENST00000554581.5,2.0,-,P31749,False,rs121434592,,as_specific,0.6234413965087282,E,Dom,False,,True,p.E17K(506),cancer;gene_function_gain;,False,True,True,,4.0,"AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.",33.5,7.3,True,False,True,"UV:3,APOBEC:8,Misc:15",0.933449,0.7974696660996897,0.51,4.0,,,,,,,ACH-001848,207.0
chr12,25245350,C,A,0.515,163,167,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-001399,3845.0
chr17,7673835,C,A,0.998,0,465,1|1,,SNP,MISSENSE,c.785G>T,p.G262V,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1131691025,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G262delG(3) p.G262_S269delGNLLGRNS(2) p.G262V(14) p.G262fs*83(5) p.G262H(1) p.G262S(2) p.E258fs*71(1) p.S261_L264>R(1) p.G262D(7) p.S261_G262insX(1) p.G262G(1) p.G262R(1) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:4,Misc:1",0.951072,0.4986101440760339,0.929,3.0,,,,,,,ACH-001399,7157.0
chr1,114716126,C,T,0.413,54,39,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-000101,4893.0
chr17,7675994,C,T,0.506,46,47,0/1,,SNP,SPLICE_SITE,c.375G>A,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:5,0.392984,0.6099495421221454,,0.0,,,,,,,ACH-000101,7157.0
chr3,44651139,A,G,0.361,30,17,0/1,,SNP,SILENT,c.72A>G,p.E24E,ZNF35,zinc finger protein 35,Zinc fingers C2H2-type,ENST00000453164.1,2.0,+,P13682,False,rs753622014,,as_specific,0.5261845386533666,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.290013,0.6196210973327331,,0.0,,,,,,,ACH-000978,7584.0
chr3,179234230,A,G,0.488,20,19,0/1,,SNP,MISSENSE,c.3073A>G,p.T1025A,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs397517202,,as_specific,0.3840399002493765,"""E, O""",Dom,False,,True,p.T1025A(34) p.T1025T(22) p.T1025I(5) p.T1025N(4) p.T1025?(13) p.T1025S(4) p.T1025P(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"POLE:3,Misc:2",0.92038,0.3510097656726454,0.587,3.0,,,,,,,ACH-000978,5290.0
chr7,5992018,G,A,0.944,0,17,1|1,,SNP,NONSENSE,c.943C>T,p.R315*,PMS2,"PMS1 homolog 2, mismatch repair system component",MutL homologs,ENST00000265849.12,9.0,-,P54278,False,rs200640585,,as_specific,0.3765586034912718,E,Rec,True,,False,,cancer;gene_function_loss;dna_repair;,False,False,True,,768.0,,0.0,4.61,False,True,False,,0.988427,,,5.0,,,,,,,ACH-000978,5395.0
chr17,7673802,C,T,0.469,16,14,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000978,7157.0
chr17,7675994,C,A,0.437,48,38,0/1,,SNP,SPLICE_SITE,c.375G>T,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:12,MSI:1,Misc:4",0.468898,0.7805428798268306,,0.0,,,,,,,ACH-000978,7157.0
chr12,25245350,C,T,0.428,25,21,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000265,3845.0
chr12,25245351,C,T,0.958,0,23,1|1,,SNP,MISSENSE,c.34G>A,p.G12S,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,913.0,,38.0,7.3,True,False,True,"smoking:2,Eso:1,Misc:10",0.902584,,0.79,4.0,,,,,,,ACH-000426,3845.0
chr3,179234297,A,G,0.237,76,23,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000549,5290.0
chr3,41224622,C,T,0.482,33,31,0/1,,SNP,MISSENSE,c.110C>T,p.S37F,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913403,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.S37F(236) p.S37C(174) p.S37A(70) p.A5_Q143del(7) p.S37P(30) p.S37Y(49) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.S37T(2) p.Y30_T40del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.S37L(2) p.S37S(2) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(4) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.I35_S37>T(1) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.S37_G38>W(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.I35_T41del(1) p.D32fs*9(1) p.I35_K170del(1) p.S37V(1) p.H36_S37del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.S37_A39>S(1) p.I35_G38del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"UV:2,POLE:1,APOBEC:6,Misc:2",0.946363,,0.586,4.0,,,,,,,ACH-002183,1499.0
chr3,179234297,A,G,0.3,104,46,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-002183,5290.0
chr12,25079261,C,T,0.446,105,84,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-002183,Unknown
chr2,29220829,G,T,0.284,42,17,0/1,,SNP,MISSENSE,c.3522C>A,p.F1174L,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,23.0,-,Q9UM73,False,rs863225281,,as_specific,0.5361596009975063,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.F1174L(136) p.F1174S(3) p.F1174V(8) p.F1174?(5) p.F1174C(12) p.F1174I(6),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000642122;ENST00000389048;ENST00000618119;,8.0,"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.",33.5,7.3,True,False,False,,0.936591,0.5618789444624813,0.752,4.0,,,,,,,ACH-000149,238.0
chr2,74415153,T,G,0.561,2,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000149,388963.0
chr12,25245350,C,T,0.542,11,15,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000193,3845.0
chr17,7675208,C,T,0.975,0,41,1|1,,SNP,MISSENSE,c.404G>A,p.C135Y,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,Misc:4,0.958746,,0.955,3.0,,,,,,,ACH-000193,7157.0
chr1,11124516,G,T,0.436,25,23,0/1,,SNP,MISSENSE,c.6644C>A,p.S2215Y,MTOR,mechanistic target of rapamycin kinase,MTOR complex 1 MTOR complex 2,ENST00000361445.9,47.0,-,P42345,False,rs587777894,,as_specific,0.4738154613466334,,,False,,True,p.S2215F(7) p.S2215P(2) p.S2215Y(4),cancer;gene_function_gain;,False,False,True,ENST00000376838;ENST00000361445;,542.0,,2.0,7.3,True,False,True,"POLE:5,Misc:3",0.939304,0.7640120565895359,0.857,4.0,,,,,,,ACH-000993,2475.0
chr1,26779863,C,T,0.442,30,23,0/1,,SNP,NONSENSE,c.5314C>T,p.R1772*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,20.0,+,O14497,False,rs879255270,,as_specific,0.5386533665835411,E,Rec,True,1507,True,p.R1989*(19),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:2,POLE:19",0.974353,,,5.0,,,,,,,ACH-000993,8289.0
chr2,61488232,C,T,0.334,74,33,0/1,,SNP,MISSENSE,c.2246G>A,p.R749Q,XPO1,exportin 1,Exportins,ENST00000401558.7,19.0,-,O14980,False,,,,0.314214463840399,L,Dom,False,,False,p.R749Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,POLE:6,0.957886,0.4542722343535141,0.555,4.0,,,,,,,ACH-000993,7514.0
chr2,201266689,G,A,0.524,19,22,0/1,,SNP,MISSENSE,c.203G>A,p.R68Q,CASP8,caspase 8,Caspases Death effector domain containing Ripoptosome Death inducing signaling complex ,ENST00000673742.1,2.0,+,Q14790,False,rs1339962485,,as_specific,0.4837905236907731,,,False,,False,p.R68*(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:8,0.71862,0.6222062166043786,0.434,2.0,,,,,,,ACH-000993,841.0
chr3,33825327,A,T,0.413,37,24,0/1,,SNP,MISSENSE,c.603A>T,p.L201F,PDCD6IP,programmed cell death 6 interacting protein,,ENST00000307296.8,5.0,+,Q8WUM4,False,rs760399252,,as_specific,0.3516209476309227,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,Misc:4,0.811316,0.7310520190990235,0.109,3.0,,,,,,,ACH-000993,10015.0
chr3,37326567,G,T,0.469,58,49,0/1,,SNP,NONSENSE,c.4681G>T,p.E1561*,GOLGA4,golgin A4,,ENST00000361924.6,14.0,+,Q13439,False,,,,0.3241895261845386,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:4,0.960188,0.4576086696437853,,4.0,,,,,,,ACH-000993,2803.0
chr3,44571158,G,T,0.505,58,63,0/1,,SNP,MISSENSE,c.2048G>T,p.R683I,ZKSCAN7,zinc finger with KRAB and SCAN domains 7,SCAN domain containing Zinc fingers C2H2-type,ENST00000273320.7,6.0,+,Q9P0L1,False,,,,0.4339152119700748,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,,0.6725349831807684,0.226,2.0,,,,,,,ACH-000993,55888.0
chr4,13600444,G,A,0.625,18,30,0/1,,SNP,SILENT,c.6456C>T,p.F2152F,BOD1L1,biorientation of chromosomes in cell division 1 like 1,,ENST00000040738.10,10.0,-,Q8NFC6,False,rs139854434,,as_specific,0.5062344139650873,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.556372,,,0.0,,,,,,,ACH-000993,259282.0
chr4,174309929,C,T,0.536,12,15,0/1,,SNP,MISSENSE,c.758C>T,p.S253L,CEP44,centrosomal protein 44,,ENST00000503780.6,8.0,+,Q9C0F1,False,rs769157129,,as_specific,0.3117206982543641,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.671898,0.7046283533608756,0.022,1.0,,,,,,,ACH-000993,80817.0
chr5,87353188,G,T,0.594,13,22,0|1,87353183.0,SNP,NONSENSE,c.1285G>T,p.E429*,RASA1,RAS p21 protein activator 1,Pleckstrin homology domain containing SH2 domain containing C2 and RasGAP domain containing,ENST00000274376.11,9.0,+,P20936,False,,,,0.2668329177057356,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:6,0.990548,,,5.0,,,,,,,ACH-000993,5921.0
chr5,112842204,C,T,0.536,33,42,0/1,,SNP,NONSENSE,c.6610C>T,p.R2204*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs752654519,,as_specific,0.399002493765586,"""E, M, O""",Rec,True,,False,p.R2204*(1) p.?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:6,0.968212,,,5.0,,,,,,,ACH-000993,324.0
chr5,178884161,G,T,0.442,24,21,0/1,,SNP,MISSENSE,c.1709G>T,p.R570I,ZNF354B,zinc finger protein 354B,Zinc fingers C2H2-type,ENST00000322434.8,5.0,+,Q96LW1,False,,,,0.3591022443890274,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"POLE:5,POLE_MSI:2",0.524458,0.647320332471674,0.171,3.0,,,,,,,ACH-000993,117608.0
chr6,7886011,G,A,0.563,23,32,0/1,,SNP,SILENT,c.996C>T,p.F332F,TXNDC5,thioredoxin domain containing 5,Protein disulfide isomerases,ENST00000379757.9,8.0,-,Q8NBS9,False,rs1490334573,,as_specific,0.4089775561097257,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.735445,,,0.0,,,,,,,ACH-000993,81567.0
chr7,64521477,C,A,0.529,15,17,0/1,,SNP,MISSENSE,c.1277G>T,p.R426I,ZNF680,zinc finger protein 680,Zinc fingers C2H2-type,ENST00000309683.11,4.0,-,Q8NEM1,False,,,,0.3690773067331671,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.553864,0.224083413426304,0.123,1.0,,,,,,,ACH-000993,340252.0
chr7,112821884,G,A,0.622,13,22,0/1,,SNP,NONSENSE,c.1078C>T,p.R360*,BMT2,base methyltransferase of 25S rRNA 2 homolog,Seven-beta-strand methyltransferase motif containing,ENST00000297145.9,5.0,-,Q1RMZ1,False,,,,0.3865336658354115,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,UV:1,POLE:6",0.989297,0.704523634213334,,3.0,,,,,,,ACH-000993,154743.0
chr8,106683256,G,A,0.528,20,25,0/1,,SNP,MISSENSE,c.340G>A,p.E114K,OXR1,oxidation resistance 1,,ENST00000312046.10,3.0,+,Q8N573,False,rs140427774,,as_specific,0.2768079800498753,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.960079,0.3272973592775082,0.131,2.0,,,,,,,ACH-000993,55074.0
chr8,131970537,C,T,0.569,21,28,0/1,,SNP,SILENT,c.1053C>T,p.F351F,EFR3A,EFR3 homolog A,,ENST00000254624.10,10.0,+,Q14156,False,rs528953018,,as_specific,0.341645885286783,,,False,,False,p.S348fs*15(1),cancer;,False,False,True,,,,,4.61,False,False,True,POLE:9,0.857641,,,0.0,,,,,,,ACH-000993,23167.0
chr9,96759055,C,A,0.491,28,27,0/1,,SNP,MISSENSE,c.1775G>T,p.R592I,ZNF510,zinc finger protein 510,Zinc fingers C2H2-type,ENST00000375231.5,6.0,-,Q9Y2H8,False,,,,0.4064837905236907,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.565791,0.9462341456382224,0.155,3.0,,,,,,,ACH-000993,22869.0
chr10,26751614,C,A,0.408,32,20,0/1,,SNP,MISSENSE,c.1254G>T,p.K418N,ABI1,abl interactor 1,,ENST00000376140.3,10.0,-,Q8IZP0,False,,,,0.4014962593516209,,,False,4218,False,p.P418delP(1),cancer;structural_relation;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.766554,0.6212872973204427,0.069,3.0,,,,,,,ACH-000993,10006.0
chr10,87864488,G,T,0.506,46,45,0/1,,SNP,NONSENSE,c.19G>T,p.E7*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,1.0,+,P60484,False,,,,0.5187032418952618,"""L, E, M, O""",Rec,True,,True,p.E7*(20) p.0(28) p.E7fs*17(3) p.A3fs*14(1) p.E7fs*3(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:11,0.975157,,,4.0,,,,,,,ACH-000993,5728.0
chr10,103091607,C,T,0.513,65,76,0/1,,SNP,MISSENSE,c.1168G>A,p.E390K,NT5C2,"5'-nucleotidase, cytosolic II",5'-nucleotidases,ENST00000404739.7,14.0,-,P49902,False,,,,0.4114713216957606,,,False,,False,,cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,POLE:8,0.95902,,0.287,3.0,,,,,,,ACH-000993,22978.0
chr10,104072062,G,A,0.405,26,20,0/1,,SNP,NONSENSE,c.433C>T,p.R145*,COL17A1,collagen type XVII alpha 1 chain,Collagens,ENST00000648076.2,8.0,-,Q9UMD9,False,rs121912774,,as_specific,0.4812967581047381,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:6",0.988052,,,4.0,,,,,,,ACH-000993,1308.0
chr10,133168288,C,T,0.398,70,43,0/1,,SNP,SILENT,c.336C>T,p.F112F,KNDC1,kinase non-catalytic C-lobe domain containing 1,,ENST00000304613.8,3.0,+,Q76NI1,False,rs570488032,,as_specific,0.6109725685785536,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"CpG:1,POLE:5",0.777036,0.62828040447614,,0.0,,,,,,,ACH-000993,85442.0
chr11,30011821,C,A,0.463,28,24,0/1,,SNP,MISSENSE,c.858G>T,p.E286D,KCNA4,potassium voltage-gated channel subfamily A member 4,Potassium voltage-gated channels,ENST00000328224.7,2.0,-,P22459,False,rs376461903,,as_specific,0.5037406483790524,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.415433,,0.119,3.0,,,,,,,ACH-000993,3739.0
chr11,108244873,C,T,0.404,59,40,0/1,,SNP,NONSENSE,c.748C>T,p.R250*,ATM,ATM serine/threonine kinase,,ENST00000452508.6,8.0,+,Q13315,False,rs772821016,,as_specific,0.341645885286783,"""L, O""",Rec,True,,False,p.R250*(2),cancer;gene_function_loss;dna_repair;,False,False,True,,,,,7.3,False,True,True,POLE:6,0.989323,0.4344006001004029,,4.0,,,,,,,ACH-000993,472.0
chr11,118312838,G,A,0.441,41,31,0/1,,SNP,SILENT,c.324G>A,p.A108A,CD3E,CD3e molecule,CD molecules,ENST00000361763.9,6.0,+,P07766,False,rs1313464574,,as_specific,0.4688279301745636,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:2,POLE:5",0.24591,0.7833280852820209,,0.0,,,,,,,ACH-000993,916.0
chr12,6522850,C,A,0.529,74,81,0/1,,SNP,MISSENSE,c.1977C>A,p.F659L,NCAPD2,non-SMC condensin I complex subunit D2,Condensin I subunits,ENST00000315579.10,16.0,+,Q15021,False,rs1229509033,,as_specific,0.4788029925187032,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.712147,0.6654701648720541,0.248,3.0,,,,,,,ACH-000993,9918.0
chr12,22524531,C,T,0.489,24,26,0/1,,SNP,MISSENSE,c.542G>A,p.R181Q,C2CD5,C2 calcium dependent domain containing 5,C2 domain containing,ENST00000536386.5,6.0,-,Q86YS7,False,,,,0.3441396508728179,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.95068,0.7949617100242056,0.295,2.0,,,,,,,ACH-000993,9847.0
chr12,25079261,C,T,0.479,57,55,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-000993,Unknown
chr12,55320808,C,T,0.391,36,24,0/1,,SNP,MISSENSE,c.209C>T,p.S70L,OR6C1,olfactory receptor family 6 subfamily C member 1,"Olfactory receptors, family 6",ENST00000642104.1,2.0,+,Q96RD1,False,rs867442232,,as_specific,0.4089775561097257,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"CpG:1,UV:6,POLE:4",0.456295,0.6678185587690577,0.082,2.0,,,,,,,ACH-000993,390321.0
chr12,109176163,G,T,0.469,130,113,0/1,,SNP,MISSENSE,c.1337G>T,p.R446I,ACACB,acetyl-CoA carboxylase beta,,ENST00000338432.11,9.0,+,O00763,False,,,,0.4937655860349127,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.666619,0.6832232865751316,0.452,2.0,,,,,,,ACH-000993,32.0
chr12,132676598,G,C,0.294,29,10,0/1,,SNP,MISSENSE,c.857C>G,p.P286R,POLE,"DNA polymerase epsilon, catalytic subunit",DNA polymerases,ENST00000320574.10,9.0,-,Q07864,False,rs1057519943,,as_specific,0.5062344139650873,,,False,,True,p.P286R(174) p.P286(R^S)(4) p.P286L(2) p.P286(R^S297F)(3) p.P286S(1),cancer;gene_function_loss;dna_repair;,False,False,True,ENST00000320574;ENST00000535270;,,,,7.3,False,True,True,Misc:24,0.884997,0.8045687881348066,0.837,4.0,,,,,,,ACH-000993,5426.0
chr13,37104489,G,A,0.49,54,52,0/1,,SNP,SILENT,c.768C>T,p.F256F,CSNK1A1L,casein kinase 1 alpha 1 like,,ENST00000379800.4,1.0,-,Q8N752,False,rs1259640190,,as_specific,0.4613466334164589,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:1,POLE:7",0.702014,0.3957998572715522,,0.0,,,,,,,ACH-000993,122011.0
chr15,101010564,C,T,0.527,27,30,0/1,,SNP,SILENT,c.1104C>T,p.F368F,LRRK1,leucine rich repeat kinase 1,Roco domain containing,ENST00000388948.8,8.0,+,Q38SD2,False,rs375815703,,as_specific,0.3640897755610973,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"UV:1,POLE:8",0.880065,0.70019330654589,,0.0,,,,,,,ACH-000993,79705.0
chr16,20324229,G,A,0.4,21,17,0/1,,SNP,MISSENSE,c.122C>T,p.S41L,GP2,glycoprotein 2,,ENST00000302555.10,3.0,-,P55259,False,rs140222432,,as_specific,0.5112219451371571,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:4,POLE:4",,0.8448349288810331,0.399,3.0,,,,,,,ACH-000993,2813.0
chr16,20987990,G,A,0.589,28,34,0/1,,SNP,MISSENSE,c.6677C>T,p.S2226L,DNAH3,dynein axonemal heavy chain 3,"Dyneins, axonemal",ENST00000261383.3,45.0,-,Q8TD57,False,,,,0.4613466334164589,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:8,0.743573,,0.266,2.0,,,,,,,ACH-000993,55567.0
chr16,81017800,C,T,0.5,18,18,0/1,,SNP,MISSENSE,c.320C>T,p.S107L,CENPN,centromere protein N,Constitutive centromere associated network,ENST00000305850.9,5.0,+,Q96H22,False,rs528102999,,as_specific,0.286783042394015,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:1,POLE:6",0.574041,0.8107043631896932,0.054,3.0,,,,,,,ACH-000993,55839.0
chr17,60066310,G,T,0.546,21,23,0/1,,SNP,MISSENSE,c.1315C>A,p.L439I,HEATR6,HEAT repeat containing 6,,ENST00000184956.11,9.0,-,Q6AI08,False,,,,0.3192019950124688,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.933473,0.7148591497029754,0.18,3.0,,,,,,,ACH-000993,63897.0
chr18,31909676,C,T,0.453,30,30,0/1,,SNP,MISSENSE,c.856G>A,p.E286K,TRAPPC8,trafficking protein particle complex 8,Trafficking protein particle complex,ENST00000283351.9,6.0,-,Q9Y2L5,False,rs550493135,,as_specific,0.2942643391521197,,,False,,False,,cancer;,False,False,True,,,,,4.13,False,False,True,POLE:8,0.907801,0.4006713386371949,0.093,3.0,,,,,,,ACH-000993,22878.0
chr19,23654274,C,A,0.595,15,21,0/1,,SNP,MISSENSE,c.659G>T,p.R220I,ZNF675,zinc finger protein 675,Zinc fingers C2H2-type,ENST00000359788.9,4.0,-,Q8TD23,False,,,,0.3192019950124688,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.677309,0.3807198003352571,0.062,1.0,,,,,,,ACH-000993,171392.0
chr19,44476775,C,A,0.553,37,51,0/1,,SNP,MISSENSE,c.1706G>T,p.R569I,ZNF180,zinc finger protein 180,Zinc fingers C2H2-type,ENST00000221327.8,5.0,-,Q9UJW8,False,,,,0.4089775561097257,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.600042,0.5526935747837397,0.192,2.0,,,,,,,ACH-000993,7733.0
chr19,51993481,C,T,0.442,73,56,0/1,,SNP,MISSENSE,c.1595G>A,p.R532Q,ZNF615,zinc finger protein 615,Zinc fingers C2H2-type,ENST00000602063.5,6.0,-,Q8N8J6,False,rs781201122,,as_specific,0.4413965087281795,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"UV:1,POLE:5",0.525335,0.4098288604168833,0.091,2.0,,,,,,,ACH-000993,284370.0
chr19,56423689,G,T,0.38,50,31,0/1,,SNP,MISSENSE,c.1031G>T,p.R344I,ZNF583,zinc finger protein 583,Zinc fingers C2H2-type,ENST00000333201.13,5.0,+,Q96ND8,False,,,,0.4239401496259352,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.502331,0.9340041829650398,0.252,2.0,,,,,,,ACH-000993,147949.0
chr17,7674262,T,C,0.434,78,57,0/1,,SNP,MISSENSE,c.701A>G,p.Y234C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587780073,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y234C(87) p.Y234N(13) p.T230_Y234delTTIHY(1) p.H233_C242del10(1) p.Y234S(8) p.Y234fs*6(1) p.Y234D(7) p.Y234fs*4(1) p.D228fs*12(1) p.H233fs*6(1) p.Y234*(15) p.Y234delY(4) p.Y234fs*11(1) p.Y234H(23) p.I232fs*5(1) p.Y234fs*15(1) p.Y234F(1) p.Y234fs*1(1) p.V225fs*23(1) p.Y234fs*5(1) p.I232_Y236delIHYNY(1) p.?(1) p.Y234del(2) p.Y234R(1) p.Y234Y(1) p.Y234_N235insX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1068.0,,0.0,7.3,False,True,True,Misc:7,0.865205,0.7361252184832682,0.945,3.0,,,,,,,ACH-000611,7157.0
chr17,7675139,C,A,0.998,0,398,1|1,,SNP,MISSENSE,c.473G>T,p.R158L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1699.0,,4.0,7.3,False,True,True,"smoking:22,Misc:1",0.921338,,0.891,3.0,,,,,,,ACH-000887,7157.0
chr17,7674885,C,A,0.974,0,38,1|1,,SNP,MISSENSE,c.646G>T,p.V216L,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs730882025,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V216M(79) p.V216L(12) p.V216E(5) p.V216fs*6(2) p.V216fs*31(2) p.V216A(4) p.T211fs*28(1) p.S215_V218>M(1) p.V218delV(8) p.H214fs*5(2) p.S215fs*29(1) p.V216G(6) p.S215fs*31(1) p.V216_Y220delVVVPY(1) p.V216fs*33(1) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.?(1) p.K164_P219del(1) p.V216fs*5(1) p.V216fs*32(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1) p.V216fs*28(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:3",0.950879,0.4008923180147776,0.948,3.0,,,,,,,ACH-000627,7157.0
chr2,112918757,C,T,0.337,52,26,0/1,,SNP,MISSENSE,c.605C>T,p.S202L,IL37,interleukin 37,Interleukins,ENST00000263326.7,5.0,+,Q9NZH6,False,,,,0.4488778054862843,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.489672,0.7542446510973951,0.025,1.0,,,,,,,ACH-002159,27178.0
chr7,140753336,A,T,0.804,33,139,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002159,673.0
chr17,7673823,C,T,0.632,13,23,0/1,,SNP,MISSENSE,c.797G>A,p.G266E,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs193920774,,as_specific,0.5236907730673317,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G266V(35) p.G266R(59) p.G266E(59) p.G262_S269delGNLLGRNS(2) p.G266_E271delGRNSFE(2) p.G266fs*79(6) p.G266fs*9(1) p.G266*(14) p.E258fs*71(1) p.G266S(1) p.G266G(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.G266T(1) p.G266A(3) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:1,Misc:1",0.961163,0.7111218214186509,0.973,3.0,,,,,,,ACH-002159,7157.0
chr2,112918757,C,T,0.521,23,25,0/1,,SNP,MISSENSE,c.605C>T,p.S202L,IL37,interleukin 37,Interleukins,ENST00000263326.7,5.0,+,Q9NZH6,False,,,,0.4488778054862843,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.489672,0.7542446510973951,0.025,1.0,,,,,,,ACH-000968,27178.0
chr7,150627766,C,T,0.685,47,105,0/1,,SNP,MISSENSE,c.832G>A,p.E278K,GIMAP6,"GTPase, IMAP family member 6","GTPases, IMAP",ENST00000328902.9,3.0,-,Q6P9H5,False,rs865805939,,as_specific,0.5361596009975063,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.546435,0.714292516827213,0.029,2.0,,,,,,,ACH-000968,474344.0
chr19,53109454,G,A,0.584,38,56,0/1,,SNP,SILENT,c.591C>T,p.F197F,ZNF415,zinc finger protein 415,Zinc fingers C2H2-type,ENST00000243643.8,4.0,-,Q09FC8,False,,,,0.3915211970074813,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:4,APOBEC:1",0.173821,0.2937308253866853,,0.0,,,,,,,ACH-000968,55786.0
chr19,55785681,G,A,0.451,35,28,0/1,,SNP,MISSENSE,c.3046C>T,p.P1016S,NLRP11,NLR family pyrin domain containing 11,NLR family Pyrin domain containing,ENST00000589093.5,10.0,-,P59045,False,,,,0.4014962593516209,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.460994,0.8240174056710319,0.188,1.0,,,,,,,ACH-000968,204801.0
chr17,7675088,C,T,0.347,37,19,0/1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002298,7157.0
chr17,7674220,C,T,0.939,3,48,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000440,7157.0
chr6,27807658,G,A,0.692,74,168,0/1,,SNP,SILENT,c.249C>T,p.H83H,H2BC13,,,ENST00000377401.3,1.0,-,,False,rs147149614,,as_specific,0.5785536159600998,,,False,,False,,cancer;,False,False,True,,,,,3.91,False,False,True,Misc:1,0.134151,0.7535661040960056,,0.0,,,,,,,ACH-000762,8340.0
chr17,7674894,G,A,0.965,0,26,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-002239,7157.0
chr3,179234297,A,G,0.487,81,76,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-001819,5290.0
chr17,7675217,T,C,0.996,0,254,1|1,,SNP,MISSENSE,c.395A>G,p.K132R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519996,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.N131delN(4) p.K132Q(17) p.K132E(20) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:4,0.930493,0.6899109988020597,0.908,3.0,,,,,,,ACH-001819,7157.0
chr17,7670685,G,A,0.491,62,66,0/1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-000353,7157.0
chr1,114713909,G,T,0.5,68,66,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-002165,4893.0
chr3,12604200,G,A,0.554,25,30,0/1,,SNP,MISSENSE,c.770C>T,p.S257L,RAF1,"Raf-1 proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000251849.8,7.0,-,P04049,False,rs80338796,,as_specific,0.4488778054862843,M,Dom,False,SRGAP3,False,,cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"CpG:1,UV:3,POLE:2",0.962209,0.2822015270045693,0.651,3.0,,,,,,,ACH-002165,5894.0
chr12,25227341,T,G,0.497,91,88,0/1,,SNP,MISSENSE,c.183A>C,p.Q61H,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs17851045,,as_specific,0.3466334164588528,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,True,True,,907.0,,10.5,7.3,True,False,True,"POLE:1,Eso:2,Misc:7",0.798711,,0.644,4.0,,,,,,,ACH-001647,3845.0
chr17,7674947,A,G,0.985,2,201,1|1,,SNP,MISSENSE,c.584T>C,p.I195T,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs760043106,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193_I195delHLI(1) p.I195F(27) p.I195T(83) p.I195N(16) p.I195fs*12(1) p.I195L(1) p.I195S(6) p.I195_G199delIRVEG(1) p.I195fs*52(5) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.I195fs*13(1) p.I195fs*14(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.H193_I195>AP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:13,0.902841,0.76638318620028,0.851,3.0,,,,,,,ACH-001647,7157.0
chr17,7674950,A,C,0.998,1,424,1|1,,SNP,MISSENSE,c.581T>G,p.L194R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs1057519998,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.L194P(11) p.H193_I195delHLI(1) p.L194R(49) p.L194L(5) p.L194F(21) p.L194H(6) p.L194delL(2) p.I195fs*52(1) p.P191fs*53(2) p.L194fs*52(1) p.A189_V197delAPPQHLIRV(4) p.L194I(1) p.L194fs*15(2) p.L194V(2) p.A189fs*53(1) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.L194fs*14(1) p.H193_I195>AP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:9,0.901087,,0.933,3.0,,,,,,,ACH-001559,7157.0
chr17,7675088,C,T,0.999,0,727,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-001858,7157.0
chr1,11130747,C,T,0.364,6,3,0/1,,SNP,MISSENSE,c.5395G>A,p.E1799K,MTOR,mechanistic target of rapamycin kinase,MTOR complex 1 MTOR complex 2,ENST00000361445.9,39.0,-,P42345,False,rs863225264,,as_specific,0.5760598503740648,,,False,,False,,cancer;gene_function_gain;,False,False,True,,544.0,,2.0,7.3,True,False,True,"CpG:5,UV:1,POLE:5",0.978079,0.534376468210211,0.638,4.0,,,,,,,ACH-000067,2475.0
chr7,55154129,C,A,0.382,48,29,0/1,,SNP,MISSENSE,c.731C>A,p.A244D,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,6.0,+,P00533,False,rs149840192,,as_specific,0.5985037406483791,"""E, O""",Dom,False,,True,p.A289V(13) p.V30_R297>G(5) p.A289D(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:4,0.934085,,0.59,4.0,,,,,,,ACH-000067,1956.0
chr17,7674220,C,T,0.952,0,22,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000067,7157.0
chrX,73447385,C,T,0.9,0,8,0/1,,SNP,SILENT,c.132C>T,p.F44F,CDX4,caudal type homeobox 4,HOXL subclass homeoboxes,ENST00000373514.2,1.0,+,O14627,False,,,,0.6084788029925187,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:3,POLE:7",,0.6380293339556065,,0.0,,,,,,,ACH-000067,1046.0
chr2,61492337,C,T,0.797,12,50,0/1,,SNP,MISSENSE,c.1711G>A,p.E571K,XPO1,exportin 1,Exportins,ENST00000401558.7,15.0,-,O14980,False,rs1057520009,,as_specific,0.3067331670822942,L,Dom,False,,True,p.E571K(41) p.E571V(3) p.E571G(5) p.E571I(1) p.E571A(3) p.E571Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"CpG:1,POLE:4",0.979039,0.5942594365771144,0.579,4.0,,,,,,,ACH-001685,7514.0
chr17,7675208,C,A,0.76,13,39,0/1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-000055,7157.0
chr17,7675085,C,A,0.98,0,54,1|1,,SNP,MISSENSE,c.527G>T,p.C176F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202962,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C176F(140) p.0(9) p.C176S(27) p.C176Y(67) p.C176W(15) p.C176fs*71(7) p.C176R(21) p.C176fs*5(3) p.R174fs*1(2) p.C176*(10) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(7) p.C176G(5) p.H168fs*23(1) p.H178fs*3(1) p.R174_H178>S(1) p.V173fs*69(1) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R174_E180>K(1) p.C176_P177delCP(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.C176delC(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*72(1) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,Misc:11",0.941923,,0.951,3.0,,,,,,,ACH-002115,7157.0
chr17,7673776,G,A,0.96,0,22,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-000443,7157.0
chr17,7675085,C,A,0.996,0,270,1|1,,SNP,MISSENSE,c.527G>T,p.C176F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202962,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C176F(140) p.0(9) p.C176S(27) p.C176Y(67) p.C176W(15) p.C176fs*71(7) p.C176R(21) p.C176fs*5(3) p.R174fs*1(2) p.C176*(10) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(7) p.C176G(5) p.H168fs*23(1) p.H178fs*3(1) p.R174_H178>S(1) p.V173fs*69(1) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R174_E180>K(1) p.C176_P177delCP(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.C176delC(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*72(1) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,Misc:11",0.941923,,0.951,3.0,,,,,,,ACH-001193,7157.0
chr17,7674220,C,T,0.423,30,22,0|1,7674220.0,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-002257,7157.0
chr1,114716126,C,T,0.49,616,569,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-000512,4893.0
chr16,20987990,G,A,0.412,301,203,0/1,,SNP,MISSENSE,c.6677C>T,p.S2226L,DNAH3,dynein axonemal heavy chain 3,"Dyneins, axonemal",ENST00000261383.3,45.0,-,Q8TD57,False,,,,0.4613466334164589,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:8,0.743573,,0.266,2.0,,,,,,,ACH-000512,55567.0
chr17,7673537,G,A,0.465,327,273,0/1,,SNP,NONSENSE,c.991C>T,p.Q331*,TP53,tumor protein p53,,ENST00000269305.8,9.0,-,P04637,False,,,,0.4713216957605985,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q331*(36) p.Q331P(3) p.Q331Q(2) p.Q331H(5) p.Q331fs*6(1) p.Q331fs*14(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"UV:2,APOBEC:14",0.991875,0.4912909886354796,,4.0,,,,,,,ACH-000512,7157.0
chr1,114713908,T,C,0.806,14,65,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-001613,4893.0
chr17,7675088,C,T,0.942,2,49,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002116,7157.0
chr7,140753336,A,T,0.824,28,133,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000450,673.0
chr6,43435850,C,T,0.254,51,16,0/1,,SNP,MISSENSE,c.1579C>T,p.R527W,ABCC10,ATP binding cassette subfamily C member 10,ATP binding cassette subfamily C,ENST00000244533.7,3.0,+,Q5T3U5,False,rs1376706540,,as_specific,0.5486284289276808,,,False,,False,,cancer;,False,False,True,ENST00000372515;ENST00000372530;ENST00000244533;,,,,7.3,False,False,True,CpG:4,0.763231,0.6501312796962896,0.936,3.0,,,,,,,ACH-000323,89845.0
chr17,7674899,G,A,0.215,44,10,0/1,,SNP,MISSENSE,c.632C>T,p.T211I,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,,,,0.5486284289276808,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T211A(3) p.L201_H214del(1) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.T211I(13) p.T211T(9) p.T211fs*36(3) p.R209fs*35(2) p.T211S(1) p.D208_V216delDRNTFRHSV(1) p.T211fs*4(3) p.T211N(4) p.N210fs*35(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.T211fs*5(2) p.?(1) p.K164_P219del(1) p.T211_F212insX(1) p.D207_R213delDDRNTFR(1) p.T211P(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:3,0.906768,0.7184935624161278,0.944,3.0,,,,,,,ACH-000323,7157.0
chr7,140753336,A,T,0.972,1,69,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000456,673.0
chr17,7674188,C,A,0.949,1,37,1|1,,SNP,MISSENSE,c.775G>T,p.D259Y,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,,,,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.D259Y(25) p.D259G(4) p.E258_S260delEDS(1) p.D259V(16) p.D259A(1) p.E258fs*85(1) p.D259N(6) p.D259E(3) p.D259H(3) p.E258fs*71(1) p.D259fs*86(5) p.D259D(2) p.D259fs*5(3) p.L257fs*85(1) p.E258fs*2(1) p.D259S(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:1",0.913497,0.8436528385612934,0.737,3.0,,,,,,,ACH-000456,7157.0
chr2,218584683,C,T,0.407,119,82,0/1,,SNP,MISSENSE,c.392C>T,p.P131L,CNOT9,CCR4-NOT transcription complex subunit 9,CCR4-NOT transcription complex,ENST00000295701.9,4.0,+,Q92600,False,rs267599211,,as_specific,0.399002493765586,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:12,0.918335,,0.599,3.0,,,,,,,ACH-002338,9125.0
chr7,140753336,A,T,0.807,24,103,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002338,673.0
chr17,35750138,T,G,0.177,27,6,0/1,,SNP,MISSENSE,c.566A>C,p.D189A,GAS2L2,growth arrest specific 2 like 2,,ENST00000604641.6,2.0,-,Q8NHY3,False,rs1192558412,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.610651,0.5095418527025265,0.061,2.0,,,,,,,ACH-002338,246176.0
chr3,10146602,C,T,0.171,237,49,0/1,,SNP,SILENT,c.429C>T,p.D143D,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,2.0,+,P40337,False,rs773556807,,as_specific,0.4488778054862843,"""E, M, O""",Rec,False,,True,p.G144fs*14(7) p.D143fs*16(6) p.V142fs*12(1) p.Q145fs*30(1) p.G144fs*19(1) p.D143E(2) p.D143fs*29(1) p.V142fs*30(1) p.N141fs*30(1) p.S139fs*12(1) p.D143fs*1(1),cancer;gene_function_loss;,False,False,True,,3040.0,,0.0,7.3,False,True,False,,0.201881,,,0.0,,,,,,,ACH-001369,7428.0
chr3,179234230,A,G,0.452,44,38,0/1,,SNP,MISSENSE,c.3073A>G,p.T1025A,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs397517202,,as_specific,0.3840399002493765,"""E, O""",Dom,False,,True,p.T1025A(34) p.T1025T(22) p.T1025I(5) p.T1025N(4) p.T1025?(13) p.T1025S(4) p.T1025P(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"POLE:3,Misc:2",0.92038,0.3510097656726454,0.587,3.0,,,,,,,ACH-001369,5290.0
chr3,179234289,T,A,0.346,40,21,0/1,,SNP,MISSENSE,c.3132T>A,p.N1044K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,,,,0.3890274314214463,"""E, O""",Dom,False,,True,p.N1044S(10) p.N1044K(19) p.N1044D(4) p.N1044Y(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:1,0.532595,0.3978034586592674,0.418,3.0,,,,,,,ACH-001369,5290.0
chr17,7673803,G,A,0.166,343,70,0/1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001369,7157.0
chr7,140753336,A,T,0.71,47,107,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000812,673.0
chr9,21974685,G,A,0.965,5,164,1|1,,SNP,MISSENSE,c.143C>T,p.P48L,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000304494.9,1.0,-,"P42771, Q8N726",False,,,,0.6783042394014963,,,False,,True,p.0(1543) p.P48L(15) p.V28_V51del(1) p.P48R(1) p.?(2) p.P48P(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000498124;,,,,7.3,False,True,True,"CpG:2,UV:2",0.643699,0.99687765901035,0.765,4.0,,,,,,,ACH-000812,1029.0
chr3,179218303,G,A,0.318,251,106,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-001442,5290.0
chr17,7675208,C,A,0.493,251,235,0/1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-001442,7157.0
chr17,7674252,C,T,0.996,0,275,1|1,,SNP,MISSENSE,c.711G>A,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:9",0.902715,0.9958849948114716,0.923,3.0,,,,,,,ACH-001390,7157.0
chr1,114713909,G,T,0.575,16,23,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000436,4893.0
chr4,166734992,C,T,0.433,33,25,0/1,,SNP,MISSENSE,c.1231G>A,p.E411K,SPOCK3,"SPARC/osteonectin, cwcv and kazal like domains proteoglycan 3",SPARC family,ENST00000504953.5,11.0,-,Q9BQ16,False,rs1422436706,,as_specific,0.286783042394015,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:4,APOBEC:1",0.826878,0.5547059656852829,0.274,2.0,,,,,,,ACH-002387,50859.0
chr7,140753336,A,T,0.458,70,61,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002387,673.0
chr12,25245351,C,G,0.995,0,225,1|1,,SNP,MISSENSE,c.34G>C,p.G12R,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,530.0,,32.5,7.3,True,False,True,"smoking:1,Misc:32",0.915109,0.6459561688690294,0.821,4.0,,,,,,,ACH-002039,3845.0
chr17,7675113,G,A,0.995,0,210,1|1,,SNP,NONSENSE,c.499C>T,p.Q167*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.K164fs*3(2) p.Q167fs*13(3) p.S149fs*72(1) p.Q167L(3) p.Y163fs*1(1) p.Q167fs*2(6) p.A159_Q167delAMAIYKQSQ(1) p.Q167fs*4(3) p.Q167Q(3) p.Q165_M169delQSQHM(1) p.Q167H(3) p.Q167*(27) p.Q167K(1) p.Q167fs*12(1) p.A159_M169del(1) p.Q167delQ(1) p.Q167fs*3(3) p.Q167fs*14(4) p.Q167_H168>YL(1) p.P151_V173del23(1) p.Q167_H168>HD(1) p.Q167E(1) p.Q167R(4) p.K164_P219del(1) p.V157_C176del20(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:1,Misc:4",0.993323,0.6915924179262102,,4.0,,,,,,,ACH-002039,7157.0
chr17,7674885,C,T,0.998,0,439,1|1,,SNP,MISSENSE,c.646G>A,p.V216M,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs730882025,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V216M(79) p.V216L(12) p.V216E(5) p.V216fs*6(2) p.V216fs*31(2) p.V216A(4) p.T211fs*28(1) p.S215_V218>M(1) p.V218delV(8) p.H214fs*5(2) p.S215fs*29(1) p.V216G(6) p.S215fs*31(1) p.V216_Y220delVVVPY(1) p.V216fs*33(1) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.?(1) p.K164_P219del(1) p.V216fs*5(1) p.V216fs*32(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1) p.V216fs*28(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:6,0.94216,0.4523770722957338,0.956,3.0,,,,,,,ACH-001373,7157.0
chr19,52213070,C,T,0.98,0,51,1|1,,SNP,MISSENSE,c.230C>T,p.S77F,PPP2R1A,protein phosphatase 2 scaffold subunit Aalpha,STRIPAK complex Protein phosphatase 2 scaffold subunits,ENST00000462990.5,6.0,+,P30153,False,,,,0.5785536159600998,E,Dom?,False,,True,p.S256F(17) p.S256Y(3),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,Misc:1,0.918687,0.8421824510093718,0.383,4.0,,,,,,,ACH-001373,5518.0
chr3,179218303,G,A,0.68,53,119,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-001864,5290.0
chr12,20370109,G,A,0.374,59,36,0/1,,SNP,SILENT,c.825G>A,p.L275L,PDE3A,phosphodiesterase 3A,Phosphodiesterases,ENST00000359062.3,1.0,+,Q14432,False,rs750288734,,as_specific,0.6034912718204489,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,APOBEC:11,0.166036,0.7111934997787612,,0.0,,,,,,,ACH-001864,5139.0
chr17,7673806,C,T,0.997,0,323,1|1,,SNP,MISSENSE,c.814G>A,p.V272M,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912657,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.V272M(88) p.0(9) p.F270fs*72(2) p.V272fs*73(2) p.V272A(7) p.V272L(39) p.V272V(4) p.V272E(9) p.G266_E271delGRNSFE(1) p.E271_R273delEVR(1) p.V272G(7) p.E258fs*71(1) p.V272fs*74(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.V272delV(1) p.R267fs*65(1) p.L265_K305del41(1) p.V272fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:10",0.911253,0.5298191979535021,0.907,3.0,,,,,,,ACH-001864,7157.0
chr17,38552032,C,T,0.255,203,71,0/1,,SNP,MISSENSE,c.2581G>A,p.E861K,SRCIN1,SRC kinase signaling inhibitor 1,,ENST00000617146.5,14.0,-,Q9C0H9,False,rs780941487,,as_specific,0.6159600997506235,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.809394,,0.135,2.0,,,,,,,ACH-001864,80725.0
chr3,179218294,G,A,0.434,88,71,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-001366,5290.0
chr17,7675189,G,C,0.504,244,250,0/1,,SNP,MISSENSE,c.423C>G,p.C141W,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519977,,as_specific,0.5835411471321695,"""L, E, M, O""",Rec,False,NTRK1,True,p.C141Y(78) p.C141fs*29(2) p.0(9) p.N131fs*27(3) p.L137_W146del10(1) p.K139fs*4(1) p.C141W(12) p.Q136_C141delQLAKTC(1) p.C141G(4) p.C141C(4) p.C141_P142insXX(1) p.C141*(14) p.C141R(17) p.A138_P142delAKTCP(1) p.C141fs*34(1) p.C141fs*30(1) p.C141S(2) p.C141fs*8(2) p.C141F(4) p.A138_V143delAKTCPV(1) p.C141A(1) p.C141fs*5(1) p.A138_C141delAKTC(1) p.P142delP(1) p.K139_C141>N(1) p.P142fs*7(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:1,Misc:1",0.867415,0.4043806300494801,0.808,3.0,,,,,,,ACH-001366,7157.0
chr5,168062106,A,C,0.24,43,11,0/1,,SNP,MISSENSE,c.660A>C,p.E220D,TENM2,teneurin transmembrane protein 2,,ENST00000520394.5,4.0,+,Q9NT68,False,,,,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.748591,0.8041055601781425,0.1,1.0,,,,,,,ACH-000475,57451.0
chr17,7676040,C,A,0.99,0,100,1|1,,SNP,MISSENSE,c.329G>T,p.R110L,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs11540654,,as_specific,0.5536159600997507,"""L, E, M, O""",Rec,False,NTRK1,True,p.R110P(13) p.0(9) p.R110C(15) p.R110L(25) p.G59fs*23(3) p.R110fs*13(7) p.R110fs*18(1) p.Y103_G112>C(1) p.R110S(1) p.R110H(4) p.F109_R110insXX(1) p.F109_R110delFR(2) p.M1_T125del(1) p.R110fs*?(1) p.G105_T125del21(1) p.Y107fs*38(1) p.R110fs*39(1) p.Y107fs*44(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:4,Misc:2",0.730165,,0.632,2.0,,,,,,,ACH-000475,7157.0
chr1,114713908,T,A,0.961,5,161,1|1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000898,4893.0
chr3,41224613,G,T,0.542,21,27,0/1,,SNP,MISSENSE,c.101G>T,p.G34V,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs28931589,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.A5_Q143del(7) p.G34V(103) p.G34R(123) p.G34E(112) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32_S47del(2) p.G34A(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_I35del(1) p.G34D(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.G34I(1) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(2) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.D32fs*9(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.S33_G34insS(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.S33_G34insGTS(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.S33_G34insGI(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_I35del(1) p.A5_T59del(1) p.G34C(1) p.A5_Q72del(1) p.S33_G34del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"smoking:2,Misc:4",0.950078,,0.532,4.0,,,,,,,ACH-000898,1499.0
chr7,48272486,A,C,0.278,120,43,0/1,,SNP,MISSENSE,c.2820A>C,p.E940D,ABCA13,ATP binding cassette subfamily A member 13,ATP binding cassette subfamily A,ENST00000435803.6,17.0,+,Q86UQ4,False,,,,0.3466334164588528,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"Eso:2,Misc:1",0.29762,0.6066101677373489,0.122,1.0,,,,,,,ACH-000898,154664.0
chr17,7673704,G,A,0.981,0,59,1|1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-000326,7157.0
chr1,114713908,T,A,0.478,129,112,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000598,4893.0
chr12,92145427,G,A,0.43,50,45,0/1,,SNP,SILENT,c.109C>T,p.L37L,BTG1,BTG anti-proliferation factor 1,BTG/Tob family,ENST00000256015.5,1.0,-,P62324,False,rs369374957,,as_specific,0.7456359102244389,L,Dom,False,MYC,False,p.L37M(1) p.R35_L37delRQL(1),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:3,0.198117,0.7013235344455819,,0.0,,,,,,,ACH-000598,694.0
chr19,17838299,C,T,0.992,0,129,1|1,,SNP,MISSENSE,c.1533G>A,p.M511I,JAK3,Janus kinase 3,Jak family tyrosine kinases,ENST00000527670.5,10.0,-,P52333,False,rs752661478,,as_specific,0.5286783042394015,L,Dom,False,,True,p.M511I(37) p.M511fs*9(16) p.T512fs*8(1),cancer;gene_function_gain;,False,False,True,,1288.0,,0.0,7.3,True,False,False,,0.703737,,0.179,4.0,,,,,,,ACH-002314,3718.0
chr3,179218307,A,G,0.444,24,15,0/1,,SNP,MISSENSE,c.1637A>G,p.Q546R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs397517201,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.Q546E(20) p.Q546K(167) p.Q546R(58) p.Q546P(22) p.Q546L(7) p.Q546H(13) p.Q546Q(2) p.Q546?(2),cancer;gene_function_gain;,False,False,True,,888.0,,0.0,7.3,True,False,True,"MSI:1,Misc:12",0.913286,0.8370601625573337,0.646,3.0,,,,,,,ACH-000397,5290.0
chr17,7670685,G,A,0.935,0,13,1|1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-000397,7157.0
chr3,179234297,A,G,0.523,44,47,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-001277,5290.0
chr17,7673803,G,A,0.995,1,393,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001277,7157.0
chr7,140753336,A,T,0.602,31,47,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000112,673.0
chr3,179218303,G,A,0.327,45,18,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000808,5290.0
chr17,7673809,C,T,0.962,0,25,1|1,,SNP,MISSENSE,c.811G>A,p.E271K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1060501191,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.F270fs*72(2) p.E271K(32) p.E271D(3) p.E271*(18) p.G266_E271delGRNSFE(2) p.E271_R273delEVR(1) p.E271V(7) p.E271G(4) p.E271Q(3) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.E271P(1) p.R267fs*65(1) p.E271fs*35(1) p.L265_K305del41(1) p.S269fs*34(1) p.E271delE(1) p.E271E(2) p.E271fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:12,0.963135,,0.935,3.0,,,,,,,ACH-000808,7157.0
chr2,61492337,C,T,0.472,37,34,0/1,,SNP,MISSENSE,c.1711G>A,p.E571K,XPO1,exportin 1,Exportins,ENST00000401558.7,15.0,-,O14980,False,rs1057520009,,as_specific,0.3067331670822942,L,Dom,False,,True,p.E571K(41) p.E571V(3) p.E571G(5) p.E571I(1) p.E571A(3) p.E571Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"CpG:1,POLE:4",0.979039,0.5942594365771144,0.579,4.0,,,,,,,ACH-002059,7514.0
chr3,37014545,G,A,0.993,0,162,1|1,,SNP,SPLICE_SITE,c.e10+1G>A,,MLH1,mutL homolog 1,MutL homologs,ENST00000458205.6,,+,P40692,False,rs267607789,,as_specific,0.3690773067331671,"""E, O""",Rec,False,,False,p.?(4),splicing;cancer;gene_function_loss;dna_repair;,False,False,True,,731.0,,2.5,7.3,False,True,False,,0.972304,0.4673546425590275,,1.59129685669006,,,,,,,ACH-002059,4292.0
chr6,73440307,C,T,0.485,155,139,0/1,,SNP,MISSENSE,c.1016G>A,p.R339H,CGAS,cyclic GMP-AMP synthase,,ENST00000370315.4,3.0,-,Q8N884,False,rs190867294,,as_specific,0.3690773067331671,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:2,0.439248,,0.08,2.0,,,,,,,ACH-002059,115004.0
chr8,24914431,C,T,0.474,190,176,0/1,,SNP,MISSENSE,c.638C>T,p.A213V,NEFM,neurofilament medium,Intermediate filaments Type IV,ENST00000518131.5,1.0,+,P07197,False,,,,0.6384039900249376,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.673945,0.3618281763558523,0.587,3.0,,,,,,,ACH-002059,4741.0
chr3,10146516,C,T,0.989,0,90,1|1,,SNP,MISSENSE,c.343C>T,p.H115Y,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,2.0,+,P40337,False,rs5030811,,as_specific,0.4812967581047381,"""E, M, O""",Rec,False,,True,p.?(4) p.H115Y(14) p.H115fs*17(3) p.H115N(9) p.H115del(1) p.H115fs*16(1) p.H115fs*15(1) p.H115fs*42(1) p.H115fs*44(3) p.H115Q(2) p.H115R(1) p.H115L(1) p.H115D(1) p.H115P(1) p.H115fs*41(1),cancer;gene_function_loss;,False,True,True,ENST00000256474;,1921.0,,10.0,7.3,False,True,False,,0.869877,0.6366346398958602,0.918,4.0,,,,,,,ACH-002190,7428.0
chr3,10142041,C,G,0.997,0,315,1|1,,SNP,MISSENSE,c.194C>G,p.S65W,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs5030826,,as_specific,0.713216957605985,"""E, M, O""",Rec,False,,True,p.S65L(20) p.S65A(2) p.S65T(4) p.S65*(20) p.S65W(6) p.P61fs*62(1) p.S65fs*92(2) p.S65S(2) p.R64fs*63(2) p.S65>Q(1) p.V62fs*1(1) p.S65fs*2(4) p.A56_R69>G(1) p.E52_S65del(2) p.S65_N67del(2) p.P61fs*61(1) p.R60fs*35(1) p.M54fs*66(1) p.S65P(1),cancer;gene_function_loss;,False,True,True,ENST00000256474;ENST00000345392;,1787.0,,105.0,7.3,False,True,False,,0.497143,0.7508064083452698,0.943,4.0,,,,,,,ACH-000272,7428.0
chr3,179234297,A,G,0.466,41,36,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-001786,5290.0
chr5,112827194,C,T,0.433,200,139,0/1,,SNP,NONSENSE,c.1495C>T,p.R499*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,12.0,+,P25054,False,rs137854580,,as_specific,0.3291770573566084,"""E, M, O""",Rec,True,,True,p.R499*(17) p.?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:9,0.982885,0.869361168564048,,5.0,,,,,,,ACH-001786,324.0
chr7,140753336,A,T,0.79,114,438,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001645,673.0
chr2,15942195,C,T,0.421,32,23,0/1,,SNP,MISSENSE,c.131C>T,p.P44L,MYCN,"MYCN proto-oncogene, bHLH transcription factor",Basic helix-loop-helix proteins,ENST00000281043.4,2.0,+,P04198,False,rs1057519919,,as_specific,0.6683291770573566,O,Dom,False,,True,p.P44L(26) p.P44S(1) p.P44H(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"UV:1,Misc:3",0.515175,0.4174349376723238,0.425,3.0,,,,,,,ACH-000104,4613.0
chr2,74415153,T,G,0.402,6,4,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000104,388963.0
chr17,7673806,C,T,0.974,0,35,1|1,,SNP,MISSENSE,c.814G>A,p.V272M,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912657,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.V272M(88) p.0(9) p.F270fs*72(2) p.V272fs*73(2) p.V272A(7) p.V272L(39) p.V272V(4) p.V272E(9) p.G266_E271delGRNSFE(1) p.E271_R273delEVR(1) p.V272G(7) p.E258fs*71(1) p.V272fs*74(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.V272delV(1) p.R267fs*65(1) p.L265_K305del41(1) p.V272fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:10",0.911253,0.5298191979535021,0.907,3.0,,,,,,,ACH-000104,7157.0
chr12,25245347,C,T,0.587,11,17,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000168,3845.0
chr10,43114502,C,G,0.61,27,37,0/1,,SNP,MISSENSE,c.1902C>G,p.C634W,RET,ret proto-oncogene,Cadherin related Receptor Tyrosine Kinases,ENST00000355710.8,11.0,+,P07949,False,rs77709286,,as_specific,0.6359102244389028,"""E, O""",Dom,False,"""H4, PRKAR1A, NCOA4, PCM1, GOLGA5, TRIM33, KTN1, TRIM27, HOOK3, KIF5B, CCDC6""",True,p.E632_T636del(1) p.C634R(48) p.E632_C634>L(1) p.C634W(25) p.C634_R635insPK(1) p.C634Y(25) p.E632_T636>SS(14) p.C634S(5) p.C634T(1) p.E632_I638del(2) p.C634C(1) p.E632_A640>VRP(1) p.L633_A639del(1) p.C634G(2) p.C634P(1) p.C634F(1) p.E632_V637>AA(1) p.C634A(1) p.D631_I638>A(1) p.E632_A639>HR(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000355710;ENST00000498820;ENST00000340058;,112.0,"RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.",3.0,7.3,True,False,False,,0.769359,0.3351363119086636,0.911,4.0,,,,,,,ACH-001321,5979.0
chr12,25245347,C,T,0.401,20,14,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000414,3845.0
chr17,39723967,T,C,0.5,26,25,0/1,,SNP,MISSENSE,c.2264T>C,p.L755S,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,19.0,+,P04626,False,rs121913470,,as_specific,0.543640897755611,E,Dom,False,,True,p.L755S(37) p.L755L(1) p.L755P(3) p.L755_S760>A(1) p.L755_T759delLRENT(1) p.L755F(1),cancer;gene_function_gain;,False,True,True,ENST00000584601;ENST00000406381;ENST00000541774;ENST00000445658;ENST00000584450;ENST00000269571;,39.0,"ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.",21.5,7.3,True,False,True,"MSI:1,Misc:3",0.880266,,0.86,4.0,,,,,,,ACH-000560,2064.0
chr1,244054357,C,T,0.382,51,31,0/1,,SNP,NONSENSE,c.583C>T,p.R195*,ZBTB18,zinc finger and BTB domain containing 18,BTB domain containing Zinc fingers C2H2-type,ENST00000358704.4,2.0,+,Q99592,False,rs1064792999,,as_specific,0.5486284289276808,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,,0.921162,0.8462985727565925,,3.0,,,,,,,ACH-002287,10472.0
chr5,112839693,C,T,0.961,1,49,1|1,,SNP,NONSENSE,c.4099C>T,p.Q1367*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913328,,as_specific,0.4638403990024937,"""E, M, O""",Rec,True,,True,p.Q1367*(39) p.Q1367H(2) p.K1363fs*7(1) p.?(1) p.K1192fs*3(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"APOBEC:2,Misc:1",0.963926,0.5902091700563789,,5.0,,,,,,,ACH-002287,324.0
chr7,15612396,C,T,0.314,47,20,0/1,,SNP,SILENT,c.906G>A,p.A302A,MEOX2,mesenchyme homeobox 2,HOXL subclass homeoboxes,ENST00000262041.6,3.0,-,P50222,False,rs777058351,,as_specific,0.4513715710723192,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:1,0.151979,0.443010527327373,,0.0,,,,,,,ACH-002287,4223.0
chr16,90032824,G,A,0.233,35,11,0/1,,SNP,MISSENSE,c.395G>A,p.R132H,GAS8,growth arrest specific 8,Dynein regulatory complex,ENST00000268699.9,4.0,+,O95995,False,rs145845004,,as_specific,0.5561097256857855,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.694614,,0.023,3.0,,,,,,,ACH-002287,2622.0
chr17,7670685,G,A,0.984,0,63,1|1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-002287,7157.0
chr17,7675139,C,T,0.94,1,31,1|1,,SNP,MISSENSE,c.473G>A,p.R158H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782144,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1695.0,,3.0,7.3,False,True,True,"CpG:6,MSI:1",0.916199,0.785313106525997,0.844,3.0,,,,,,,ACH-002235,7157.0
chr17,39711955,C,T,0.54,138,158,0/1,,SNP,MISSENSE,c.929C>T,p.S310F,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,8.0,+,P04626,False,rs1057519816,,as_specific,0.5685785536159601,E,Dom,False,,True,p.S310F(27) p.S310Y(11),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"APOBEC:22,Misc:3",0.922658,,0.533,4.0,,,,,,,ACH-002235,2064.0
chr17,7674957,G,A,0.982,0,56,1|1,,SNP,NONSENSE,c.574C>T,p.Q192*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs866380588,,as_specific,0.5885286783042394,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q192*(84) p.Q192fs*16(1) p.Q192fs*17(1) p.Q192K(2) p.Q192delQ(1) p.Q192Q(2) p.?(2) p.G187fs*16(2) p.Q192H(3) p.P191_Q192del(2) p.Q192fs*30(1) p.P191fs*53(2) p.Q192R(5) p.A189_V197delAPPQHLIRV(4) p.Q192fs*56(1) p.A189fs*53(1) p.P191delP(2) p.P191fs*6(1) p.Q192>XXXXXXXXX(1) p.K164_P219del(1) p.P191_Q192delPQ(1) p.A189_Q192>E(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"APOBEC:11,Misc:2",0.991592,,,4.0,,,,,,,ACH-000415,7157.0
chr1,162754625,C,G,0.295,344,146,0/1,,SNP,SPLICE_SITE,c.187C>G,p.L63V,DDR2,discoidin domain receptor tyrosine kinase 2,Receptor Tyrosine Kinases,ENST00000367922.7,6.0,+,Q16832,False,rs144594252,,as_specific,0.5361596009975063,,,False,,False,p.L63V(1),cancer;gene_function_gain;,False,False,True,ENST00000446985;ENST00000415555;ENST00000367922;ENST00000367921;,139.0,"Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.",4.0,4.31,True,False,False,,0.767159,0.6551530537577313,0.859,4.0,,,,,,,ACH-001303,4921.0
chr2,29209798,C,T,0.733,52,150,0/1,,SNP,MISSENSE,c.3824G>A,p.R1275Q,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,25.0,-,Q9UM73,False,rs113994087,,as_specific,0.4763092269326683,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.R1275Q(87) p.R1275?(10) p.R1275L(5) p.R1275*(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000642122;ENST00000389048;ENST00000618119;,9.0,"ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.",23.0,7.3,True,False,False,,0.970662,0.7515153163777522,0.885,4.0,,,,,,,ACH-001303,238.0
chr17,7674220,C,T,0.96,2,53,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000534,7157.0
chr1,26779863,C,T,0.471,217,196,0/1,,SNP,NONSENSE,c.5314C>T,p.R1772*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,20.0,+,O14497,False,rs879255270,,as_specific,0.5386533665835411,E,Rec,True,1507,True,p.R1989*(19),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:2,POLE:19",0.974353,,,5.0,,,,,,,ACH-001518,8289.0
chr2,39054637,T,A,0.993,1,158,1|1,,SNP,MISSENSE,c.697A>T,p.N233Y,SOS1,SOS Ras/Rac guanine nucleotide exchange factor 1,Rho guanine nucleotide exchange factors Pleckstrin homology domain containing,ENST00000395038.6,5.0,-,Q07889,False,rs1057519963,,as_specific,0.2967581047381546,,,False,,False,p.N233Y(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"smoking:3,Misc:5",0.884903,,0.58,4.0,,,,,,,ACH-001518,6654.0
chr2,47798940,G,A,0.445,348,272,0/1,,SNP,SILENT,c.957G>A,p.T319T,MSH6,mutS homolog 6,MutS homologs PWWP domain containing,ENST00000234420.11,4.0,+,P52701,False,rs375210430,,as_specific,0.4688279301745636,E,Rec,False,,False,,cancer;gene_function_loss;dna_repair;,False,False,True,,,,,7.3,False,True,True,CpG:2,0.12227,,,0.0,,,,,,,ACH-001518,2956.0
chr3,179199088,G,A,0.511,49,51,0/1,,SNP,MISSENSE,c.263G>A,p.R88Q,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs121913287,,as_specific,0.3391521197007481,"""E, O""",Dom,False,,True,p.R88Q(147) p.R88L(1) p.R88?(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,929.0,,0.0,7.3,True,False,True,"CpG:11,MSI:1,POLE:17",0.947755,0.4551598659740948,0.806,3.0,,,,,,,ACH-001518,5290.0
chr10,87952142,C,T,0.364,170,93,0/1,,SNP,MISSENSE,c.517C>T,p.R173C,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,6.0,+,P60484,False,rs121913293,,as_specific,0.3266832917705736,"""L, E, M, O""",Rec,False,,True,p.R173C(51) p.0(28) p.R173H(34) p.G165_K342del(1) p.R55fs*1(1) p.V166fs*17(3) p.R173fs*6(1) p.R173fs*10(2) p.Y27_N212>Y(2) p.G165fs*9(3) p.?(1) p.R172fs*5(1) p.R172_Y174>N(1) p.R173S(1) p.R173R(1) p.G165_*404del(1),cancer;gene_function_loss;,False,True,True,ENST00000371953;,838.0,,13.0,7.3,False,True,True,CpG:1,0.941832,0.6442282294657126,0.972,3.0,,,,,,,ACH-001518,5728.0
chr10,87957915,C,T,0.534,152,175,0/1,,SNP,NONSENSE,c.697C>T,p.R233*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,7.0,+,P60484,False,rs121909219,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R233*(101) p.0(28) p.G165_K342del(1) p.T232_R233insTQGGAGS(2) p.R233fs*10(14) p.R55fs*1(1) p.R233fs*3(1) p.R234fs*9(1) p.R233fs*24(1) p.R233fs*?(2) p.T232_R233insK*(1) p.N228fs*10(1) p.R233fs*25(2) p.R233fs*13(1) p.R233fs*19(1) p.R233fs*26(1) p.R233fs*20(1) p.R233R(1) p.R233fs*12(1) p.P231fs*2(1) p.K221fs*6(1) p.R233fs*23(1) p.T232_R233insPQGGAGT(1) p.G165_*404del(1) p.R233Q(1),cancer;gene_function_loss;,False,True,True,,110.0,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.",19.0,7.3,False,True,False,,0.971128,0.6883155413500054,,3.0,,,,,,,ACH-001518,5728.0
chr11,14294851,C,T,0.487,112,111,0/1,,SNP,MISSENSE,c.208G>A,p.A70T,RRAS2,RAS related 2,RAS type GTPase family,ENST00000256196.9,3.0,-,P62070,False,rs782457908,,as_specific,0.3516209476309227,,,False,,False,,cancer;gene_function_gain;,False,False,True,ENST00000537760;ENST00000256196;ENST00000531807;,,,,7.3,True,False,True,MSI:1,0.92714,0.6182533489350014,0.863,3.0,,,,,,,ACH-001518,22800.0
chr17,7674220,C,T,0.487,217,198,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001518,7157.0
chr9,21971109,C,A,0.996,0,291,1|1,,SNP,MISSENSE,c.97G>T,p.D33Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552822,,as_specific,0.6957605985037406,,,False,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V82_E88del(1) p.D84H(2) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.D84Y(9) p.P81_A85del(1) p.D84N(4) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.D84fs*63(2) p.E61_L94del(1) p.R80fs*34(1) p.D84_F90del(1) p.E33D(1) p.A68fs*3(1) p.D84fs*1(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;ENST00000579755;ENST00000530628;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.933446,0.9973373924118374,0.803,4.0,,,,,,,ACH-002463,1029.0
chr17,7674954,G,T,0.455,230,196,0/1,,SNP,MISSENSE,c.577C>A,p.H193N,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs876658468,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193L(40) p.H193_I195delHLI(1) p.H193R(78) p.H193Y(29) p.?(2) p.H193D(10) p.H193P(15) p.H193N(7) p.P191fs*53(2) p.A189_V197delAPPQHLIRV(4) p.H193H(2) p.H193fs*16(3) p.A189fs*53(1) p.P191fs*6(1) p.K164_P219del(1) p.H193_I195>AP(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:2,Misc:1",0.958162,0.6998343217034384,0.875,3.0,,,,,,,ACH-002463,7157.0
chr17,7674220,C,T,0.958,4,74,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000321,7157.0
chr9,134728709,G,A,0.723,40,105,0/1,,SNP,MISSENSE,c.826G>A,p.E276K,COL5A1,collagen type V alpha 1 chain,Collagens,ENST00000371817.8,6.0,+,P20908,False,rs776904091,,as_specific,0.6508728179551122,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"CpG:1,UV:5",0.932935,0.685208390871408,0.549,3.0,,,,,,,ACH-000753,1289.0
chr17,7673781,C,G,0.79,3,14,0/1,,SNP,MISSENSE,c.839G>C,p.R280T,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912660,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R280T(73) p.R280fs*65(9) p.R280I(15) p.R280K(54) p.R280S(17) p.R280G(33) p.R280_R283>S(1) p.R280*(14) p.D281fs*24(1) p.S269fs*21(1) p.F270_D281del12(1) p.R280fs*?(1) p.V272_K292del21(1) p.D281_R282delDR(2) p.R280R(3) p.A276fs*64(1) p.R280fs*64(1) p.G279_R280delGR(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:19,0.96317,0.7002446792674034,0.94,3.0,,,,,,,ACH-000753,7157.0
chr2,211387009,C,A,0.304,436,195,0/1,,SNP,MISSENSE,c.3325G>T,p.G1109C,ERBB4,erb-b2 receptor tyrosine kinase 4,Erb-b2 receptor tyrosine kinases,ENST00000342788.9,27.0,-,Q15303,False,,,,0.486284289276808,,,False,,False,,cancer;gene_function_gain;,False,False,True,,1673.0,,0.0,7.3,True,False,False,,0.695834,0.5809453320496251,0.596,4.0,,,,,,,ACH-002029,2066.0
chr17,7670703,C,A,0.998,0,466,1|1,,SNP,NONSENSE,c.1006G>T,p.E336*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,,,,0.4812967581047381,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E336*(8) p.E336fs*12(1) p.E336K(2) p.E336fs*?(1) p.R335_E336insGV(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,APOBEC:3,0.958201,0.6395889856789665,,3.0,,,,,,,ACH-002029,7157.0
chr2,208248389,G,A,0.468,57,46,0/1,,SNP,MISSENSE,c.394C>T,p.R132C,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",,ENST00000415913.5,4.0,-,O75874,False,rs121913499,,as_specific,0.3790523690773067,O,Dom,False,,True,p.R132C(1014) p.R132H(6941) p.R132S(229) p.R132?(201) p.R132G(285) p.R132L(126) p.R132P(1) p.R132V(1) p.G131_R132>VL(1),splicing;cancer;gene_function_gain;,False,True,True,ENST00000345146;ENST00000446179;ENST00000415913;ENST00000415282;,59.0,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",53.0,7.3,True,False,True,"CpG:19,MSI:1,UV:15",0.961719,0.6398382252727418,0.814,2.0,,,,,,,ACH-000209,3417.0
chr2,177234082,C,T,0.515,49,51,0/1,,SNP,MISSENSE,c.187G>A,p.E63K,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,rs1057519922,,as_specific,0.4064837905236907,E,Dom,False,,True,p.E79K(14) p.E79Q(11),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,APOBEC:7,0.922105,0.4993498434368417,0.363,3.0,,,,,,,ACH-000449,4780.0
chr12,25245350,C,T,0.504,135,142,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001382,3845.0
chr4,152328233,G,A,0.417,110,79,0/1,,SNP,MISSENSE,c.1153C>T,p.R385C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs867384286,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465C(83) p.R465fs*7(13) p.R465S(1) p.R465Y(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:9,0.934034,0.2550529450691629,0.593,4.0,,,,,,,ACH-000989,55294.0
chr5,16694504,C,T,0.435,71,53,0/1,,SNP,MISSENSE,c.3667G>A,p.G1223R,MYO10,myosin X,"Myosins, class X Pleckstrin homology domain containing FERM domain containing",ENST00000513610.6,27.0,-,Q9HD67,False,rs1434873123,,as_specific,0.5386533665835411,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,4.61,False,True,True,MSI:2,0.874456,0.9984442399688634,0.448,2.0,,,,,,,ACH-000989,4651.0
chr8,123787317,G,A,0.604,28,42,0/1,,SNP,MISSENSE,c.1135G>A,p.A379T,FAM91A1,family with sequence similarity 91 member A1,,ENST00000334705.12,13.0,+,Q658Y4,False,rs760648737,,as_specific,0.3291770573566084,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.934124,0.6955841921839186,0.477,2.0,,,,,,,ACH-000989,157769.0
chr12,25227349,C,T,0.473,33,26,0/1,,SNP,MISSENSE,c.175G>A,p.A59T,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs121913528,,as_specific,0.3566084788029925,"""L, E, M, O""",Dom,False,KRAS,True,p.A59G(6) p.A59T(28) p.A59E(4) p.T58_A59insVA(1) p.A59S(2) p.A59L(1) p.A59del(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,,,,7.3,True,False,True,"MSI:2,Misc:1",0.901617,0.6627303446996679,0.869,4.0,,,,,,,ACH-000989,3845.0
chr15,74619299,C,T,0.44,67,51,0/1,,SNP,NONSENSE,c.103C>T,p.R35*,CLK3,CDC like kinase 3,CDC like kinases,ENST00000345005.8,2.0,+,P49761,False,rs1459068786,,as_specific,0.5960099750623441,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,4.31,False,True,True,CpG:1,0.985517,0.4834332357948266,,5.0,,,,,,,ACH-000989,1198.0
chr18,51065548,C,T,0.467,42,37,0/1,,SNP,MISSENSE,c.793C>T,p.R265C,SMAD4,SMAD family member 4,SMAD family,ENST00000588745.5,5.0,+,Q13485,False,rs80338963,,as_specific,0.3765586034912718,,,False,,True,p.R361C(37) p.0(28) p.R361G(6) p.T265I(1) p.R361S(3),cancer;gene_function_loss;,False,False,True,ENST00000398417;ENST00000342988;ENST00000588745;,,,,7.3,False,True,True,"CpG:7,MSI:1",0.953716,,0.945,3.0,,,,,,,ACH-000989,4089.0
chr20,58909365,C,T,0.409,30,20,0/1,,SNP,MISSENSE,c.601C>T,p.R201C,GNAS,GNAS complex locus,"G protein subunits alpha, group s Granins",ENST00000371085.7,8.0,+,"O95467, P63092, P84996, Q5JWF2",False,rs11554273,,as_specific,0.4987531172069825,E,Dom,False,,True,p.R201H(703) p.R201C(858) p.R201?(16) p.R201L(4) p.R201S(32) p.R201G(2) p.R201R(1) p.R201P(1),cancer;gene_function_gain;,False,False,True,ENST00000371100;ENST00000371102;ENST00000604005;ENST00000371095;ENST00000371085;ENST00000354359;ENST00000265620;,826.0,,5.0,7.3,True,False,True,"CpG:6,UV:1",0.649806,0.7035793687008755,0.943,4.0,,,,,,,ACH-000989,2778.0
chr17,7674957,G,A,0.98,0,48,1|1,,SNP,NONSENSE,c.574C>T,p.Q192*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs866380588,,as_specific,0.5885286783042394,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q192*(84) p.Q192fs*16(1) p.Q192fs*17(1) p.Q192K(2) p.Q192delQ(1) p.Q192Q(2) p.?(2) p.G187fs*16(2) p.Q192H(3) p.P191_Q192del(2) p.Q192fs*30(1) p.P191fs*53(2) p.Q192R(5) p.A189_V197delAPPQHLIRV(4) p.Q192fs*56(1) p.A189fs*53(1) p.P191delP(2) p.P191fs*6(1) p.Q192>XXXXXXXXX(1) p.K164_P219del(1) p.P191_Q192delPQ(1) p.A189_Q192>E(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"APOBEC:11,Misc:2",0.991592,,,4.0,,,,,,,ACH-002170,7157.0
chr17,7674241,G,A,0.345,186,92,0/1,,SNP,MISSENSE,c.722C>T,p.S241F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:4,APOBEC:7,Misc:1",0.912713,0.9893558821746748,0.958,3.0,,,,,,,ACH-001407,7157.0
chr17,7675088,C,T,0.957,3,78,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000699,7157.0
chr17,7675136,G,A,0.998,2,573,1|1,,SNP,MISSENSE,c.476C>T,p.A159V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.A159V(42) p.R158fs*8(1) p.A159D(10) p.S149fs*72(1) p.R158_A159insX(4) p.A159fs*11(6) p.A159_Q167delAMAIYKQSQ(1) p.R158_A159delRA(2) p.A159P(25) p.V157fs*19(2) p.A159S(5) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A159A(8) p.R156fs*18(1) p.A159T(9) p.V157_I162delVRAMAI(1) p.A159fs*21(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A159fs*19(1) p.R158_A159insXX(1) p.V157_C176del20(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"UV:1,Misc:3",0.890391,,0.774,3.0,,,,,,,ACH-000606,7157.0
chr9,21971029,C,T,0.728,15,42,0/1,,SNP,NONSENSE,c.177G>A,p.W59*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913389,,as_specific,0.6633416458852868,,,True,,True,p.0(1543) p.W110*(37) p.V59fs*61(2) p.?(4) p.W110C(1) p.V59fs*63(1) p.V59fs*60(1) p.V59_G67del(1) p.V59M(1) p.V59fs*58(1) p.V59fs*82(2) p.H83fs*2(2) p.V59fs*45(1) p.D105fs*8(1) p.V59G(1) p.A68fs*3(1),cancer;gene_function_loss;,False,False,True,,1521.0,,0.0,7.3,False,True,False,,0.855169,0.9926462279289228,0.455,5.0,,,,,,,ACH-000723,1029.0
chr9,21971097,C,A,0.235,31,8,0/1,,SNP,NONSENSE,c.109G>T,p.E37*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913384,,as_specific,0.6982543640897756,,,True,,True,p.0(1543) p.E88*(15) p.V82_E88del(1) p.V28_V51del(1) p.E88K(3) p.?(4) p.L32_L37del(6) p.H83fs*2(2) p.E88fs*58(1) p.R87fs*30(1) p.E61_L94del(1) p.L37L(2) p.E87K(2) p.D84_F90del(1) p.A68fs*3(1) p.L37fs*6(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,smoking:2,0.92205,0.9909344162016276,0.584,5.0,,,,,,,ACH-000723,1029.0
chr12,25079261,C,T,0.611,104,163,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-000723,Unknown
chr12,25225627,G,A,0.441,130,101,0/1,,SNP,MISSENSE,c.437C>T,p.A146V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs1057519725,,as_specific,0.3291770573566084,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1) p.T148fs*6(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,322.0,,8.0,7.3,True,False,False,,0.940928,0.6906510308302181,0.89,4.0,,,,,,,ACH-001459,3845.0
chr17,7676215,G,A,0.991,0,107,1|1,,SNP,NONSENSE,c.154C>T,p.Q52*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5985037406483791,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q52*(9) p.D48fs*55(1) p.E51fs*59(1) p.I50fs*4(1) p.Q52H(1) p.Q52fs*67(1) p.M1_T125del(1) p.Q52fs*71(1) p.Q52fs*6(1) p.S33fs*23(1) p.E51_Q52insX(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:1,0.969339,0.7507677472451469,,3.0,,,,,,,ACH-001459,7157.0
chr17,31350209,C,T,0.994,0,170,1|1,,SNP,NONSENSE,c.7285C>T,p.R2429*,NF1,neurofibromin 1,,ENST00000356175.7,49.0,+,P21359,False,rs786202457,,as_specific,0.341645885286783,O,Rec,True,ASIC2,True,p.R2450*(5) p.0(9),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:2,POLE:10",0.987214,,,5.0,,,,,,,ACH-001459,4763.0
chr11,534286,C,G,0.469,21,14,0/1,,SNP,MISSENSE,c.37G>C,p.G13R,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,2.0,-,P01112,False,rs104894228,,as_specific,0.6758104738154613,"""E, L, M""",Dom,False,,True,p.G13C(7) p.G13R(341) p.G13D(23) p.G13S(20) p.G13V(23) p.G13N(1) p.G12_G13insAG(1) p.G13I(2) p.G13G(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,,,,7.3,True,True,True,"smoking:2,Misc:6",0.900257,0.9989834113290028,0.791,4.0,,,,,,,ACH-000692,3265.0
chr17,7675994,C,A,0.974,1,88,1|1,,SNP,SPLICE_SITE,c.375G>T,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:12,MSI:1,Misc:4",0.468898,0.7805428798268306,,0.0,,,,,,,ACH-000692,7157.0
chr17,7676031,A,C,0.973,2,77,1|1,,SNP,MISSENSE,c.338T>G,p.F113C,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.F113S(5) p.G59fs*23(3) p.F113C(8) p.F113fs*37(1) p.F113delF(3) p.F113L(9) p.F113_G117delFLHSG(1) p.M1_T125del(1) p.G105_T125del21(1) p.F113V(3) p.Y107fs*44(1) p.S33fs*23(1) p.V73fs*9(1) p.G112fs*9(1) p.P13fs*18(1) p.G112fs*7(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000508793;ENST00000604348;ENST00000503591;,,,,7.3,False,True,True,Misc:2,0.916379,0.3595884184044838,0.952,3.0,,,,,,,ACH-002304,7157.0
chr17,7674232,C,T,0.992,0,130,1|1,,SNP,MISSENSE,c.731G>A,p.G244D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs985033810,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"MSI:1,Misc:1",0.965383,0.9978215722974868,0.953,3.0,,,,,,,ACH-001630,7157.0
chr6,161107946,G,A,0.363,29,16,0/1,,SNP,MISSENSE,c.4096G>A,p.G1366R,MAP3K4,mitogen-activated protein kinase kinase kinase 4,Mitogen-activated protein kinase kinase kinases,ENST00000392142.9,21.0,+,Q9Y6R4,False,,,,0.4812967581047381,,,False,,False,p.G1366R(5),cancer;,False,False,True,,,,,7.3,False,False,True,CpG:3,0.903475,,0.564,4.0,,,,,,,ACH-000388,4216.0
chr12,25225628,C,T,0.543,71,84,0/1,,SNP,MISSENSE,c.436G>A,p.A146T,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,906.0,,21.0,7.3,True,False,True,"MSI:3,Misc:4",0.951882,0.7493523432445548,0.909,4.0,,,,,,,ACH-000388,3845.0
chr17,7674220,C,T,0.488,48,47,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000388,7157.0
chr5,112839942,C,T,0.349,94,49,0/1,,SNP,NONSENSE,c.4348C>T,p.R1450*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913332,,as_specific,0.456359102244389,"""E, M, O""",Rec,True,,True,p.R1450*(222) p.R1450fs*5(1) p.P1424fs*19(1) p.R1450fs*20(1) p.R1450fs*22(1) p.R1435fs*23(1) p.?(1) p.K1192fs*3(1) p.S1436fs*22(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:15,POLE:2",0.916986,0.7909056506666835,,5.0,,,,,,,ACH-001460,324.0
chr12,25245350,C,G,0.719,81,203,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-001460,3845.0
chr17,7670685,G,A,0.957,4,123,1|1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-001460,7157.0
chr17,7673803,G,A,0.359,15,8,0/1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000833,7157.0
chr17,7674917,T,C,0.433,18,12,0/1,,SNP,MISSENSE,c.614A>G,p.Y205C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs1057520007,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y205D(20) p.Y205S(11) p.Y205C(70) p.L201_H214del(1) p.Y205H(9) p.E204_N210delEYLDDRN(1) p.Y205F(8) p.Y205N(3) p.Y205fs*42(1) p.Y205fs*43(1) p.Y205*(8) p.?(1) p.K164_P219del(1) p.E204fs*39(1) p.Y205fs*?(1) p.L206fs*42(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:11",0.8532,0.8002667275111726,0.873,3.0,,,,,,,ACH-000833,7157.0
chr4,65601852,G,A,0.378,22,13,0/1,,SNP,SILENT,c.699C>T,p.C233C,EPHA5,EPH receptor A5,Sterile alpha motif domain containing Fibronectin type III domain containing EPH receptors,ENST00000273854.7,3.0,-,P54756,False,rs747700048,,as_specific,0.456359102244389,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"MSI:3,Misc:1",0.11926,,,0.0,,,,,,,ACH-000990,2044.0
chr17,7675160,G,T,0.28,43,16,0/1,,SNP,MISSENSE,c.452C>A,p.P151H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057520000,,as_specific,0.5835411471321695,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.P151A(10) p.P151S(78) p.P151P(15) p.S149fs*72(1) p.P151H(29) p.P151T(16) p.P151fs*30(8) p.P151L(8) p.T150_P151del(1) p.P151R(9) p.P153fs*28(1) p.D148fs*23(1) p.T150fs*16(4) p.P153delP(2) p.T150_P151delTP(1) p.P152fs*28(1) p.V143_P153del(1) p.P151_V173del23(1) p.P152fs*14(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"smoking:1,Misc:3",0.897467,0.7204064233224524,0.87,3.0,,,,,,,ACH-000990,7157.0
chr17,7675157,G,A,0.961,0,24,1|1,,SNP,MISSENSE,c.455C>T,p.P152L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782705,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.P152fs*18(21) p.P152P(6) p.0(9) p.P152S(29) p.S149fs*72(1) p.P152L(75) p.P153fs*28(7) p.P152_P153insXXX(1) p.P152T(9) p.P152fs*14(6) p.P152A(2) p.P153fs*16(2) p.P152Q(4) p.P152R(7) p.P152fs*28(3) p.D148fs*23(1) p.T150fs*16(4) p.P152fs*27(1) p.P152fs*29(6) p.V143_P153del(1) p.P151_V173del23(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"CpG:2,UV:1",0.952593,0.8618240470838262,0.878,3.0,,,,,,,ACH-001544,7157.0
chr9,77794572,T,G,0.981,0,56,1|1,,SNP,MISSENSE,c.626A>C,p.Q209P,GNAQ,G protein subunit alpha q,"G protein subunits alpha, group q",ENST00000286548.9,5.0,-,P50148,False,rs121913492,,as_specific,0.3266832917705736,E,Dom,False,,True,p.Q209L(323) p.Q209P(256) p.Q209R(8) p.Q209H(17) p.Q209?(6) p.Q209Y(1) p.Q209K(1),cancer;gene_function_gain;,False,True,True,ENST00000286548;,604.0,,8.0,7.3,True,False,True,Misc:29,0.957692,0.7503423451666995,0.956,4.0,,,,,,,ACH-002018,2776.0
chr17,7674890,T,C,0.984,2,206,1|1,,SNP,MISSENSE,c.641A>G,p.H214R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs1057519992,,as_specific,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H214Y(6) p.H214R(65) p.H214fs*7(2) p.R213_S215>X(1) p.L201_H214del(1) p.T211fs*28(1) p.R209fs*6(1) p.H214fs*5(2) p.H214Q(4) p.H214fs*33(3) p.H214H(1) p.H214Cfs*29(1) p.R213fs*32(1) p.H214fs*2(1) p.D208_V216delDRNTFRHSV(1) p.H214D(4) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.H214A(1) p.H214_S215insX(1) p.?(1) p.K164_P219del(1) p.H214P(1) p.F212_S215del(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:10,0.888834,,0.885,3.0,,,,,,,ACH-000673,7157.0
chr2,197615926,G,A,0.429,3,3,0/1,,SNP,SILENT,c.1104C>T,p.F368F,RFTN2,raftlin family member 2,,ENST00000295049.9,7.0,-,Q52LD8,False,rs766286621,,as_specific,0.4014962593516209,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:12,0.799516,0.4710389418791714,,0.0,,,,,,,ACH-000462,130132.0
chr10,87952142,C,T,0.992,1,126,1|1,,SNP,MISSENSE,c.517C>T,p.R173C,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,6.0,+,P60484,False,rs121913293,,as_specific,0.3266832917705736,"""L, E, M, O""",Rec,False,,True,p.R173C(51) p.0(28) p.R173H(34) p.G165_K342del(1) p.R55fs*1(1) p.V166fs*17(3) p.R173fs*6(1) p.R173fs*10(2) p.Y27_N212>Y(2) p.G165fs*9(3) p.?(1) p.R172fs*5(1) p.R172_Y174>N(1) p.R173S(1) p.R173R(1) p.G165_*404del(1),cancer;gene_function_loss;,False,True,True,ENST00000371953;,838.0,,13.0,7.3,False,True,True,CpG:1,0.941832,0.6442282294657126,0.972,3.0,,,,,,,ACH-002228,5728.0
chr17,7674230,C,T,0.982,0,55,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-002228,7157.0
chr6,56069053,C,T,0.638,21,39,0/1,,SNP,MISSENSE,c.2084G>A,p.G695E,COL21A1,collagen type XXI alpha 1 chain,Collagens,ENST00000244728.10,22.0,-,Q96P44,False,rs769722166,,as_specific,0.3491271820448878,,,False,,False,,cancer;,False,False,True,ENST00000244728;ENST00000370819;ENST00000535941;,,,,7.3,False,False,True,UV:6,0.793911,0.8745009108264294,0.955,2.0,,,,,,,ACH-000785,81578.0
chr2,74415153,T,G,0.5,3,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-001365,388963.0
chr17,7675139,C,A,0.974,0,38,1|1,,SNP,MISSENSE,c.473G>T,p.R158L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1699.0,,4.0,7.3,False,True,True,"smoking:22,Misc:1",0.921338,,0.891,3.0,,,,,,,ACH-001365,7157.0
chr17,7675157,G,A,0.44,77,64,0/1,,SNP,MISSENSE,c.455C>T,p.P152L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782705,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.P152fs*18(21) p.P152P(6) p.0(9) p.P152S(29) p.S149fs*72(1) p.P152L(75) p.P153fs*28(7) p.P152_P153insXXX(1) p.P152T(9) p.P152fs*14(6) p.P152A(2) p.P153fs*16(2) p.P152Q(4) p.P152R(7) p.P152fs*28(3) p.D148fs*23(1) p.T150fs*16(4) p.P152fs*27(1) p.P152fs*29(6) p.V143_P153del(1) p.P151_V173del23(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"CpG:2,UV:1",0.952593,0.8618240470838262,0.878,3.0,,,,,,,ACH-000162,7157.0
chr12,25245350,C,A,0.514,161,165,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-001376,3845.0
chr11,67418924,G,T,0.275,9,3,0/1,,SNP,MISSENSE,c.164G>T,p.G55V,CARNS1,carnosine synthase 1,,ENST00000307823.7,4.0,+,A5YM72,False,rs780435597,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.300515,,0.112,2.0,,,,,,,ACH-000102,57571.0
chr17,7674256,T,C,0.96,1,50,1|1,,SNP,MISSENSE,c.707A>G,p.Y236C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs730882026,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y236delY(4) p.Y236C(58) p.H233_C242del10(1) p.Y236N(21) p.Y236*(13) p.Y236H(13) p.Y236D(6) p.H233fs*6(1) p.Y236_M237>*(1) p.Y236S(4) p.Y236fs*5(1) p.V225fs*23(1) p.Y236Y(2) p.Y236fs*4(2) p.I232_Y236delIHYNY(1) p.?(1) p.Y236_M243delYMCNSSCM(1) p.N235_Y236delNY(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:5,0.844922,0.9351637534056272,0.811,2.0,,,,,,,ACH-000102,7157.0
chr7,140753336,A,T,0.481,73,69,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002162,673.0
chr12,25079261,C,T,0.591,61,84,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-002162,Unknown
chr3,179234297,A,G,0.442,75,54,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000280,5290.0
chr17,7674216,C,A,0.977,0,45,1|1,,SNP,MISSENSE,c.747G>T,p.R249S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934571,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.P250fs*14(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:5,Misc:13",0.776711,,0.769,2.0,,,,,,,ACH-000476,7157.0
chr12,20370109,G,A,0.782,14,55,0/1,,SNP,SILENT,c.825G>A,p.L275L,PDE3A,phosphodiesterase 3A,Phosphodiesterases,ENST00000359062.3,1.0,+,Q14432,False,rs750288734,,as_specific,0.6034912718204489,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,APOBEC:11,0.166036,0.7111934997787612,,0.0,,,,,,,ACH-000309,5139.0
chr12,25245350,C,T,0.634,15,28,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000309,3845.0
chr17,7674953,T,C,0.973,0,36,1|1,,SNP,MISSENSE,c.578A>G,p.H193R,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs786201838,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193L(40) p.H193_I195delHLI(1) p.H193R(78) p.H193Y(29) p.?(2) p.H193D(10) p.H193P(15) p.H193N(7) p.P191fs*53(2) p.A189_V197delAPPQHLIRV(4) p.H193H(2) p.H193fs*16(3) p.A189fs*53(1) p.P191fs*6(1) p.K164_P219del(1) p.H193_I195>AP(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:16,0.888726,0.7365336169861475,0.884,3.0,,,,,,,ACH-000309,7157.0
chr17,7674230,C,T,0.986,0,77,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-000761,7157.0
chr1,11109318,A,C,0.492,64,60,0/1,,SNP,MISSENSE,c.7500T>G,p.I2500M,MTOR,mechanistic target of rapamycin kinase,MTOR complex 1 MTOR complex 2,ENST00000361445.9,56.0,-,P42345,False,rs1057519915,,as_specific,0.4139650872817955,,,False,,False,,cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"POLE:2,Misc:1",0.489755,0.2036095928105966,0.368,3.0,,,,,,,ACH-001081,2475.0
chr1,26779863,C,T,0.517,70,74,0/1,,SNP,NONSENSE,c.5314C>T,p.R1772*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,20.0,+,O14497,False,rs879255270,,as_specific,0.5386533665835411,E,Rec,True,1507,True,p.R1989*(19),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:2,POLE:19",0.974353,,,5.0,,,,,,,ACH-001081,8289.0
chr1,225411395,C,T,0.481,99,92,0/1,,SNP,MISSENSE,c.1130G>A,p.R377Q,LBR,lamin B receptor,Tudor domain containing,ENST00000272163.9,9.0,-,Q14739,False,rs750036742,,as_specific,0.4214463840399002,,,False,,False,,cancer;,False,False,True,ENST00000272163;ENST00000338179;,,,,7.3,False,False,True,"CpG:1,POLE:6",0.974591,0.4373041680044568,0.921,4.0,,,,,,,ACH-001081,3930.0
chr2,61492337,C,T,0.454,49,39,0/1,,SNP,MISSENSE,c.1711G>A,p.E571K,XPO1,exportin 1,Exportins,ENST00000401558.7,15.0,-,O14980,False,rs1057520009,,as_specific,0.3067331670822942,L,Dom,False,,True,p.E571K(41) p.E571V(3) p.E571G(5) p.E571I(1) p.E571A(3) p.E571Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"CpG:1,POLE:4",0.979039,0.5942594365771144,0.579,4.0,,,,,,,ACH-001081,7514.0
chr2,105242203,G,T,0.487,40,39,0/1,,SNP,MISSENSE,c.345G>T,p.W115C,GPR45,G protein-coupled receptor 45,"G protein-coupled receptors, Class A orphans",ENST00000258456.3,1.0,+,Q9Y5Y3,False,,,,0.6433915211970075,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.469619,0.8577178259192072,0.685,3.0,,,,,,,ACH-001081,11250.0
chr2,201307600,G,A,0.412,135,90,0/1,,SNP,SILENT,c.798C>T,p.F266F,FLACC1,,,ENST00000439709.5,11.0,-,,False,rs766784931,,as_specific,0.4413965087281795,,,False,,False,,cancer;,False,False,True,,,,,4.13,False,False,True,"CpG:1,POLE:7",0.851517,0.747677436287858,,0.0,,,,,,,ACH-001081,130540.0
chr2,216190251,G,A,0.541,35,42,0/1,,SNP,MISSENSE,c.1861G>A,p.E621K,XRCC5,X-ray repair cross complementing 5,,ENST00000392133.7,19.0,+,P13010,False,rs762387474,,as_specific,0.399002493765586,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,POLE:6,0.779999,,0.118,4.0,,,,,,,ACH-001081,7520.0
chr3,3056153,C,T,0.407,61,43,0/1,,SNP,MISSENSE,c.3014C>T,p.S1005L,CNTN4,contactin 4,I-set domain containing Immunoglobulin like domain containing Ig-like cell adhesion molecule family Fibronectin type III domain containing,ENST00000397461.5,24.0,+,Q8IWV2,False,rs753714750,,as_specific,0.399002493765586,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"UV:1,POLE:7",0.90868,0.5574255684262086,0.233,3.0,,,,,,,ACH-001081,152330.0
chr3,12604200,G,A,0.512,38,38,0/1,,SNP,MISSENSE,c.770C>T,p.S257L,RAF1,"Raf-1 proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000251849.8,7.0,-,P04049,False,rs80338796,,as_specific,0.4488778054862843,M,Dom,False,SRGAP3,False,,cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"CpG:1,UV:3,POLE:2",0.962209,0.2822015270045693,0.651,3.0,,,,,,,ACH-001081,5894.0
chr3,52609752,G,A,0.503,90,91,0/1,,SNP,NONSENSE,c.2173C>T,p.R725*,PBRM1,polybromo 1,Bromodomain containing,ENST00000409114.7,17.0,-,Q86U86,False,,,,0.4214463840399002,E,Rec,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:4",0.982779,,,5.0,,,,,,,ACH-001081,55193.0
chr4,271628,C,A,0.541,66,79,0/1,,SNP,MISSENSE,c.1229G>T,p.R410I,ZNF732,zinc finger protein 732,Zinc fingers C2H2-type,ENST00000419098.6,4.0,-,B4DXR9,False,,,,0.399002493765586,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.645598,0.8796910864124182,0.071,1.0,,,,,,,ACH-001081,654254.0
chr4,105275342,C,A,0.448,134,112,0/1,,SNP,MISSENSE,c.4832C>A,p.S1611Y,TET2,tet methylcytosine dioxygenase 2,,ENST00000380013.8,11.0,+,Q6N021,False,rs527895107,,as_specific,0.4638403990024937,L,Rec,False,,False,p.L1609fs*45(1) p.S1611fs*?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:4,0.566194,0.4785680586641168,0.145,3.0,,,,,,,ACH-001081,54790.0
chr4,152322940,G,A,0.458,117,96,0/1,,SNP,MISSENSE,c.1825C>T,p.R609W,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,11.0,-,Q969H0,False,,,,0.4513715710723192,"""E, L""",Rec,False,,True,p.R689W(13) p.R689fs*5(3),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,POLE:1",0.902984,,0.349,4.0,,,,,,,ACH-001081,55294.0
chr4,183253883,C,T,0.531,118,133,0/1,,SNP,SILENT,c.1080C>T,p.F360F,WWC2,WW and C2 domain containing 2,C2 and WW domain containing,ENST00000403733.8,9.0,+,Q6AWC2,False,rs376596593,,as_specific,0.4339152119700748,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:4,0.835239,0.8930160638013765,,0.0,,,,,,,ACH-001081,80014.0
chr5,5486781,C,T,0.36,16,8,0/1,,SNP,MISSENSE,c.6581C>T,p.S2194L,ICE1,interactor of little elongation complex ELL subunit 1,,ENST00000296564.9,18.0,+,Q9Y2F5,False,rs1217550481,,as_specific,0.3615960099750623,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"CpG:1,POLE:4",0.614157,0.7281769916279962,0.182,3.0,,,,,,,ACH-001081,23379.0
chr5,112839942,C,T,0.558,49,62,0/1,,SNP,NONSENSE,c.4348C>T,p.R1450*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913332,,as_specific,0.456359102244389,"""E, M, O""",Rec,True,,True,p.R1450*(222) p.R1450fs*5(1) p.P1424fs*19(1) p.R1450fs*20(1) p.R1450fs*22(1) p.R1435fs*23(1) p.?(1) p.K1192fs*3(1) p.S1436fs*22(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:15,POLE:2",0.916986,0.7909056506666835,,5.0,,,,,,,ACH-001081,324.0
chr6,36800026,G,A,0.415,32,22,0/1,,SNP,SILENT,c.228C>T,p.F76F,CPNE5,copine 5,Copines,ENST00000244751.7,4.0,-,Q9HCH3,False,rs574969645,,as_specific,0.5586034912718204,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:2,POLE:3",0.796244,0.648325619611832,,0.0,,,,,,,ACH-001081,57699.0
chr6,100848542,C,T,0.512,40,44,0/1,,SNP,MISSENSE,c.407G>A,p.R136Q,ASCC3,activating signal cointegrator 1 complex subunit 3,DNA helicases RNA helicases,ENST00000369162.7,4.0,-,Q8N3C0,False,rs919581054,,as_specific,0.3690773067331671,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.861267,0.8833219842277246,0.11,2.0,,,,,,,ACH-001081,10973.0
chr7,122320320,G,A,0.621,221,348,0/1,,SNP,NONSENSE,c.3613C>T,p.R1205*,CADPS2,calcium dependent secretion activator 2,Pleckstrin homology domain containing C2 domain containing,ENST00000412584.6,28.0,-,Q86UW7,False,rs1354028382,,as_specific,0.4239401496259352,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:2,POLE:5",0.982409,,,3.0,,,,,,,ACH-001081,93664.0
chr7,123663082,C,A,0.63,115,196,0/1,,SNP,MISSENSE,c.1496C>A,p.S499Y,LMOD2,leiomodin 2,,ENST00000458573.3,2.0,+,Q6P5Q4,False,rs375211570,,as_specific,0.4463840399002494,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:5,0.822721,0.7669925534427456,0.227,2.0,,,,,,,ACH-001081,442721.0
chr9,19346108,G,A,0.268,97,35,0/1,,SNP,SILENT,c.3192G>A,p.S1064S,DENND4C,DENN domain containing 4C,DENN/MADD domain containing,ENST00000602925.5,22.0,+,Q5VZ89,False,rs772506615,,as_specific,0.4089775561097257,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.307599,,,0.0,,,,,,,ACH-001081,55667.0
chr9,70350138,C,T,0.543,39,45,0/1,,SNP,NONSENSE,c.2914C>T,p.R972*,SMC5,structural maintenance of chromosomes 5,Structural maintenance of chromosomes proteins SMC5-6 protein complex,ENST00000361138.7,23.0,+,Q8IY18,False,,,,0.2892768079800499,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:6,0.987138,0.4846730011874592,,4.0,,,,,,,ACH-001081,23137.0
chr9,123099547,C,T,0.488,64,61,0/1,,SNP,MISSENSE,c.2887C>T,p.R963W,RABGAP1,RAB GTPase activating protein 1,,ENST00000373647.9,24.0,+,Q9Y3P9,False,rs199744049,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:6,0.887003,0.868190973232113,0.098,3.0,,,,,,,ACH-001081,23637.0
chr10,62262785,G,A,0.573,32,43,0/1,,SNP,NONSENSE,c.97C>T,p.R33*,RTKN2,rhotekin 2,Pleckstrin homology domain containing,ENST00000373789.8,2.0,-,Q8IZC4,False,rs772033296,,as_specific,0.3192019950124688,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,4.61,False,True,True,"UV:2,POLE:8",0.98958,0.5182343534520232,,4.0,,,,,,,ACH-001081,219790.0
chr10,89729158,G,T,0.468,65,57,0/1,,SNP,NONSENSE,c.2182G>T,p.E728*,KIF20B,kinesin family member 20B,Kinesins,ENST00000260753.8,18.0,+,Q96Q89,False,,,,0.2468827930174563,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:5,0.981534,0.6047170384126032,,3.0,,,,,,,ACH-001081,9585.0
chr10,127110321,G,A,0.473,152,137,0/1,,SNP,MISSENSE,c.2527G>A,p.E843K,DOCK1,dedicator of cytokinesis 1,DOCK C2 domain containing,ENST00000280333.9,25.0,+,Q14185,False,,,,0.4039900249376558,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.9624,,0.192,3.0,,,,,,,ACH-001081,1793.0
chr11,47326780,C,T,0.513,67,65,0/1,,SNP,NONSENSE,c.4765C>T,p.R1589*,MADD,MAP kinase activating death domain,DENN/MADD domain containing,ENST00000311027.9,34.0,+,Q8WXG6,False,rs267602902,,as_specific,0.516209476309227,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:7,0.985355,0.8462858303024167,,4.0,,,,,,,ACH-001081,8567.0
chr11,108244873,C,T,0.361,117,63,0/1,,SNP,NONSENSE,c.748C>T,p.R250*,ATM,ATM serine/threonine kinase,,ENST00000452508.6,8.0,+,Q13315,False,rs772821016,,as_specific,0.341645885286783,"""L, O""",Rec,True,,False,p.R250*(2),cancer;gene_function_loss;dna_repair;,False,False,True,,,,,7.3,False,True,True,POLE:6,0.989323,0.4344006001004029,,4.0,,,,,,,ACH-001081,472.0
chr11,108247071,C,T,0.334,66,32,0/1,,SNP,MISSENSE,c.1009C>T,p.R337C,ATM,ATM serine/threonine kinase,,ENST00000452508.6,9.0,+,Q13315,False,rs138398778,,as_specific,0.3241895261845386,"""L, O""",Rec,False,,True,p.R337H(5) p.R337C(12) p.R337P(1) p.R337S(2) p.F336_A340delFRNIA(1),cancer;gene_function_loss;dna_repair;,False,False,True,,,,,3.83,False,True,True,"CpG:4,UV:2,POLE:1",0.94575,0.3982998846051833,0.36,3.0,,,,,,,ACH-001081,472.0
chr12,25225628,C,T,0.511,63,68,0/1,,SNP,MISSENSE,c.436G>A,p.A146T,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,906.0,,21.0,7.3,True,False,True,"MSI:3,Misc:4",0.951882,0.7493523432445548,0.909,4.0,,,,,,,ACH-001081,3845.0
chr12,91164646,C,T,0.4,46,31,0/1,,SNP,MISSENSE,c.283G>A,p.E95K,DCN,decorin,Small leucine rich repeat proteoglycans,ENST00000052754.10,3.0,-,P07585,False,,,,0.3291770573566084,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:1,UV:1,POLE:5",0.978517,0.5868913795721525,0.326,3.0,,,,,,,ACH-001081,1634.0
chr12,132676598,G,C,0.431,28,21,0/1,,SNP,MISSENSE,c.857C>G,p.P286R,POLE,"DNA polymerase epsilon, catalytic subunit",DNA polymerases,ENST00000320574.10,9.0,-,Q07864,False,rs1057519943,,as_specific,0.5062344139650873,,,False,,True,p.P286R(174) p.P286(R^S)(4) p.P286L(2) p.P286(R^S297F)(3) p.P286S(1),cancer;gene_function_loss;dna_repair;,False,False,True,ENST00000320574;ENST00000535270;,,,,7.3,False,True,True,Misc:24,0.884997,0.8045687881348066,0.837,4.0,,,,,,,ACH-001081,5426.0
chr13,21510008,G,A,0.298,162,69,0/1,,SNP,NONSENSE,c.757C>T,p.R253*,MICU2,mitochondrial calcium uptake 2,EF-hand domain containing,ENST00000382374.9,8.0,-,Q8IYU8,False,rs772353232,,as_specific,0.2668329177057356,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:6",0.986608,0.6022871366685337,,3.0,,,,,,,ACH-001081,221154.0
chr15,44715521,G,T,0.543,88,104,0/1,,SNP,NONSENSE,c.166G>T,p.E56*,B2M,beta-2-microglobulin,C1-set domain containing,ENST00000648006.2,2.0,+,P61769,False,,,,0.4189526184538653,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"POLE:2,APOBEC:2",0.971597,0.4301683199221607,,4.0,,,,,,,ACH-001081,567.0
chr15,65756324,C,A,0.434,141,106,0/1,,SNP,NONSENSE,c.127G>T,p.E43*,DENND4A,DENN domain containing 4A,DENN/MADD domain containing,ENST00000431932.6,3.0,-,Q7Z401,False,,,,0.371571072319202,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:5,0.986716,0.5778526739663995,,4.0,,,,,,,ACH-001081,10260.0
chr15,78275702,G,A,0.569,24,29,0/1,,SNP,MISSENSE,c.770G>A,p.R257Q,DNAJA4,DnaJ heat shock protein family (Hsp40) member A4,DNAJ (HSP40) heat shock proteins,ENST00000446172.2,5.0,+,Q8WW22,False,rs751859584,,as_specific,0.3815461346633416,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.955019,0.8791568405664497,0.449,3.0,,,,,,,ACH-001081,55466.0
chr16,20987990,G,A,0.505,43,45,0/1,,SNP,MISSENSE,c.6677C>T,p.S2226L,DNAH3,dynein axonemal heavy chain 3,"Dyneins, axonemal",ENST00000261383.3,45.0,-,Q8TD57,False,,,,0.4613466334164589,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:8,0.743573,,0.266,2.0,,,,,,,ACH-001081,55567.0
chr16,50217581,C,A,0.467,48,46,0/1,,SNP,MISSENSE,c.710C>A,p.S237Y,TENT4B,,,ENST00000561678.6,5.0,+,,False,,,,0.3441396508728179,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.828281,,0.155,3.0,,,,,,,ACH-001081,64282.0
chr16,81017800,C,T,0.453,52,44,0/1,,SNP,MISSENSE,c.320C>T,p.S107L,CENPN,centromere protein N,Constitutive centromere associated network,ENST00000305850.9,5.0,+,Q96H22,False,rs528102999,,as_specific,0.286783042394015,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:1,POLE:6",0.574041,0.8107043631896932,0.054,3.0,,,,,,,ACH-001081,55839.0
chr17,7674894,G,A,0.593,23,35,0/1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-001081,7157.0
chr17,69251855,C,T,0.417,45,33,0/1,,SNP,MISSENSE,c.4427G>A,p.R1476Q,ABCA5,ATP binding cassette subfamily A member 5,ATP binding cassette subfamily A,ENST00000392676.8,35.0,-,Q8WWZ7,False,rs750426352,,as_specific,0.3815461346633416,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:8,0.952719,,0.585,2.0,,,,,,,ACH-001081,23461.0
chr18,36126802,G,T,0.417,76,54,0/1,,SNP,MISSENSE,c.206C>A,p.S69Y,SLC39A6,solute carrier family 39 member 6,Solute carriers,ENST00000590986.5,2.0,-,Q13433,False,rs749354395,,as_specific,0.42643391521197,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"POLE:2,Misc:1",0.516629,0.6270967286706284,0.045,2.0,,,,,,,ACH-001081,25800.0
chr18,53305647,C,T,0.461,93,77,0/1,,SNP,NONSENSE,c.946C>T,p.R316*,DCC,DCC netrin 1 receptor,I-set domain containing Immunoglobulin like domain containing Fibronectin type III domain containing,ENST00000581580.5,10.0,+,P43146,False,,,,0.4114713216957606,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:2,POLE:8",0.991196,0.7570598482907875,,4.0,,,,,,,ACH-001081,1630.0
chr19,12526618,C,A,0.585,54,75,0/1,,SNP,MISSENSE,c.1490G>T,p.R497I,ZNF564,zinc finger protein 564,Zinc fingers C2H2-type,ENST00000339282.12,4.0,-,Q8TBZ8,False,rs763012117,,as_specific,0.3690773067331671,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.477995,0.4566089388895296,0.184,2.0,,,,,,,ACH-001081,163050.0
chr20,64207872,G,A,0.428,15,11,0/1,,SNP,MISSENSE,c.676G>A,p.E226K,MYT1,myelin transcription factor 1,Zinc fingers C2H2C-type,ENST00000650655.1,9.0,+,Q01538,False,,,,0.5935162094763092,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.56817,,0.09,2.0,,,,,,,ACH-001081,4661.0
chr21,28986161,C,A,0.477,22,22,0/1,,SNP,MISSENSE,c.323G>T,p.R108I,LTN1,listerin E3 ubiquitin protein ligase 1,Ring finger proteins,ENST00000389195.7,3.0,-,O94822,False,,,,0.3167082294264339,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.867562,,0.312,2.0,,,,,,,ACH-001081,26046.0
chrX,54811618,G,A,0.517,16,14,0/1,,SNP,MISSENSE,c.955G>A,p.E319K,MAGED2,MAGE family member D2,MAGE family,ENST00000375068.6,6.0,+,Q9UNF1,False,,,,0.5211970074812967,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,,0.8776266808674591,0.253,2.0,,,,,,,ACH-001081,10916.0
chr3,179199690,G,A,0.435,53,45,0/1,,SNP,SPLICE_SITE,c.353G>A,p.G118D,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,3.0,+,P42336,False,rs587777790,,as_specific,0.3092269326683292,"""E, O""",Dom,False,,True,p.G118D(17),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:10,0.895712,0.1837857299103737,0.484,3.0,,,,,,,ACH-002105,5290.0
chr15,83041897,G,C,0.419,48,34,0/1,,SNP,MISSENSE,c.693C>G,p.D231E,BTBD1,BTB domain containing 1,BTB domain containing,ENST00000261721.9,4.0,-,Q9H0C5,False,rs144730017,,as_specific,0.3441396508728179,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.865097,0.9353603641977252,0.607,3.0,,,,,,,ACH-002110,53339.0
chr17,7673803,G,A,0.957,0,21,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-002110,7157.0
chr3,136568813,C,T,0.301,54,24,0/1,,SNP,MISSENSE,c.346G>A,p.A116T,STAG1,stromal antigen 1,Cohesin complex,ENST00000236698.9,5.0,-,Q8WVM7,False,rs757393709,,as_specific,0.314214463840399,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:1,0.796336,0.3712059823763634,0.51,3.0,,,,,,,ACH-002166,10274.0
chr7,140753336,A,T,0.646,50,85,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002166,673.0
chr11,124309847,C,T,0.414,33,25,0/1,,SNP,MISSENSE,c.920G>A,p.G307E,OR8D1,olfactory receptor family 8 subfamily D member 1,"Olfactory receptors, family 8",ENST00000641015.1,3.0,-,Q8WZ84,False,,,,0.3665835411471321,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.397431,0.5996429978944064,0.019,1.0,,,,,,,ACH-002166,283159.0
chr17,7674220,C,T,0.995,0,196,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001750,7157.0
chr17,82832452,C,G,0.985,0,67,1|1,,SNP,START_CODON_SNP,c.3G>C,p.M1I,ZNF750,zinc finger protein 750,,ENST00000269394.4,2.0,-,Q32MQ0,False,,,,0.4887780548628428,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:4,0.915361,,0.294,2.0,,,,,,,ACH-002311,79755.0
chr22,41169525,G,A,0.723,37,95,0/1,,SNP,MISSENSE,c.4195G>A,p.D1399N,EP300,E1A binding protein p300,Zinc fingers ZZ-type Lysine acetyltransferases Bromodomain containing,ENST00000263253.9,26.0,+,Q09472,False,rs1057519889,,as_specific,0.3765586034912718,"""L, E""",Rec,False,"""MLL, RUNXBP2""",True,p.D1399Y(3) p.D1399N(3),cancer;gene_function_loss;structural_relation;,False,False,True,ENST00000263253;,,,,7.3,False,True,True,"CpG:5,POLE:1",0.923848,0.3793505958908378,0.881,4.0,,,,,,,ACH-002311,2033.0
chr12,25245350,C,T,0.367,14,7,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000485,3845.0
chr17,7673806,C,T,0.414,16,11,0/1,,SNP,MISSENSE,c.814G>A,p.V272M,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912657,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.V272M(88) p.0(9) p.F270fs*72(2) p.V272fs*73(2) p.V272A(7) p.V272L(39) p.V272V(4) p.V272E(9) p.G266_E271delGRNSFE(1) p.E271_R273delEVR(1) p.V272G(7) p.E258fs*71(1) p.V272fs*74(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.V272delV(1) p.R267fs*65(1) p.L265_K305del41(1) p.V272fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:1,Misc:10",0.911253,0.5298191979535021,0.907,3.0,,,,,,,ACH-000485,7157.0
chr17,7674220,C,T,0.47,38,32,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-002103,7157.0
chr17,7674220,C,T,0.392,31,19,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000287,7157.0
chr17,7675185,C,T,0.533,21,24,0/1,,SNP,MISSENSE,c.427G>A,p.V143M,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782620,,as_specific,0.5835411471321695,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V143E(9) p.L137_W146del10(1) p.V143A(15) p.K139fs*4(1) p.V143fs*28(2) p.V143V(2) p.V143M(27) p.V143L(4) p.V143fs*4(1) p.V143_P153del(1) p.A138_V143delAKTCPV(1) p.V143G(1) p.C141fs*5(1) p.V143_S149delVQLWVDS(1) p.P142_Q144delPVQ(1) p.V143fs*27(2) p.V143fs*29(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"MSI:1,Misc:1",0.710372,0.3486543740117186,0.659,3.0,,,,,,,ACH-000287,7157.0
chr17,7674233,C,T,0.981,0,54,1|1,,SNP,MISSENSE,c.730G>A,p.G244S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs1057519989,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.96258,,0.936,3.0,,,,,,,ACH-001958,7157.0
chr7,98912179,C,T,0.601,70,108,0/1,,SNP,MISSENSE,c.2162C>T,p.S721F,TRRAP,transformation/transcription domain associated protein,SAGA complex,ENST00000446306.7,17.0,+,Q9Y4A5,False,rs147405090,,as_specific,0.4688279301745636,,,False,,False,p.S722F(3),cancer;,False,False,True,,,,,7.3,False,False,True,"UV:8,POLE_MSI:1",0.926675,,0.603,4.0,,,,,,,ACH-000425,8295.0
chr7,140753336,A,T,0.944,8,160,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000425,673.0
chr11,67418924,G,T,0.586,1,2,0/1,,SNP,MISSENSE,c.164G>T,p.G55V,CARNS1,carnosine synthase 1,,ENST00000307823.7,4.0,+,A5YM72,False,rs780435597,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.300515,,0.112,2.0,,,,,,,ACH-000425,57571.0
chr4,152328232,C,T,0.404,127,84,0/1,,SNP,MISSENSE,c.1154G>A,p.R385H,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs1057519895,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465H(72) p.R465fs*7(9) p.R465L(3) p.R465Y(2) p.R465P(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:15,0.938974,0.1731430175559941,0.557,4.0,,,,,,,ACH-001719,55294.0
chr6,73440307,C,T,0.237,364,119,0/1,,SNP,MISSENSE,c.1016G>A,p.R339H,CGAS,cyclic GMP-AMP synthase,,ENST00000370315.4,3.0,-,Q8N884,False,rs190867294,,as_specific,0.3690773067331671,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:2,0.439248,,0.08,2.0,,,,,,,ACH-001719,115004.0
chr17,7670685,G,A,0.996,0,267,1|1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-001719,7157.0
chr17,7673803,G,A,0.97,0,32,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000365,7157.0
chr3,179234297,A,T,0.716,32,83,0/1,,SNP,MISSENSE,c.3140A>T,p.H1047L,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,1151.0,,12.5,7.3,True,False,True,"APOBEC:1,Misc:27",0.829278,,0.359,3.0,,,,,,,ACH-002251,5290.0
chr10,87957915,C,T,0.991,0,115,1|1,,SNP,NONSENSE,c.697C>T,p.R233*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,7.0,+,P60484,False,rs121909219,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R233*(101) p.0(28) p.G165_K342del(1) p.T232_R233insTQGGAGS(2) p.R233fs*10(14) p.R55fs*1(1) p.R233fs*3(1) p.R234fs*9(1) p.R233fs*24(1) p.R233fs*?(2) p.T232_R233insK*(1) p.N228fs*10(1) p.R233fs*25(2) p.R233fs*13(1) p.R233fs*19(1) p.R233fs*26(1) p.R233fs*20(1) p.R233R(1) p.R233fs*12(1) p.P231fs*2(1) p.K221fs*6(1) p.R233fs*23(1) p.T232_R233insPQGGAGT(1) p.G165_*404del(1) p.R233Q(1),cancer;gene_function_loss;,False,True,True,,110.0,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.",19.0,7.3,False,True,False,,0.971128,0.6883155413500054,,3.0,,,,,,,ACH-000980,5728.0
chr11,118556983,A,G,0.219,66,17,0/1,,SNP,SILENT,c.261T>C,p.D87D,IFT46,intraflagellar transport 46,Intraflagellar transport proteins Cilia and flagella associated,ENST00000264020.6,5.0,-,Q9NQC8,False,,,,0.456359102244389,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"MSI:1,Misc:1",0.162255,,,0.0,,,,,,,ACH-000980,56912.0
chr12,25227341,T,A,0.983,0,56,1|1,,SNP,MISSENSE,c.183A>T,p.Q61H,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs17851045,,as_specific,0.3466334164588528,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"smoking:2,Misc:3",0.812146,0.6464448787056057,0.647,4.0,,,,,,,ACH-000980,3845.0
chr17,7673802,C,T,0.968,0,29,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000980,7157.0
chr19,51034050,T,G,0.5,2,2,0|1,51034050.0,SNP,MISSENSE,c.127A>C,p.T43P,KLK12,kallikrein related peptidase 12,Kallikreins,ENST00000525263.5,2.0,-,Q9UKR0,False,rs747067935,,as_specific,0.5810473815461347,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.566087,,0.318,2.0,,,,,,,ACH-000980,43849.0
chr1,91316145,C,A,0.477,27,27,0/1,,SNP,NONSENSE,c.2938G>T,p.E980*,HFM1,"HFM1, ATP dependent DNA helicase homolog",RNA helicases,ENST00000370425.8,27.0,-,A2PYH4,False,,,,0.2693266832917705,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:5,0.979069,0.8198886278151447,,4.0,,,,,,,ACH-000996,164045.0
chr2,8958590,C,T,0.441,37,32,0/1,,SNP,MISSENSE,c.128G>A,p.R43Q,MBOAT2,membrane bound O-acyltransferase domain containing 2,Membrane bound O-acyltransferases,ENST00000305997.8,2.0,-,Q6ZWT7,False,rs1471364240,,as_specific,0.3192019950124688,,,False,PRKCE,False,,cancer;structural_relation;,False,False,True,,,,,7.3,False,False,True,POLE:8,0.956186,0.6042387472934528,0.534,2.0,,,,,,,ACH-000996,129642.0
chr3,37014545,G,A,0.469,36,32,0/1,,SNP,SPLICE_SITE,c.e10+1G>A,,MLH1,mutL homolog 1,MutL homologs,ENST00000458205.6,,+,P40692,False,rs267607789,,as_specific,0.3690773067331671,"""E, O""",Rec,False,,False,p.?(4),splicing;cancer;gene_function_loss;dna_repair;,False,False,True,,731.0,,2.5,7.3,False,True,False,,0.972304,0.4673546425590275,,1.59129685669006,,,,,,,ACH-000996,4292.0
chr3,179234286,G,T,0.531,84,86,0/1,,SNP,MISSENSE,c.3129G>T,p.M1043I,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913283,,as_specific,0.3890274314214463,"""E, O""",Dom,False,,True,p.M1043I(111) p.M1043L(3) p.M1043V(30) p.M1043T(6),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"POLE:2,APOBEC:1",0.893118,0.4070867429555725,0.372,3.0,,,,,,,ACH-000996,5290.0
chr4,272048,C,A,0.292,13,4,0/1,,SNP,MISSENSE,c.809G>T,p.R270I,ZNF732,zinc finger protein 732,Zinc fingers C2H2-type,ENST00000419098.6,4.0,-,B4DXR9,False,rs782545440,,as_specific,0.3591022443890274,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,POLE:6,0.66429,,0.169,1.0,,,,,,,ACH-000996,654254.0
chr4,13600444,G,A,0.464,34,27,0/1,,SNP,SILENT,c.6456C>T,p.F2152F,BOD1L1,biorientation of chromosomes in cell division 1 like 1,,ENST00000040738.10,10.0,-,Q8NFC6,False,rs139854434,,as_specific,0.5062344139650873,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.556372,,,0.0,,,,,,,ACH-000996,259282.0
chr4,152326214,C,T,0.453,52,45,0/1,,SNP,MISSENSE,c.1196G>A,p.R399Q,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs866987936,,as_specific,0.3665835411471321,"""E, L""",Rec,False,,True,p.R479Q(43) p.R479L(7) p.R479fs*6(3) p.R479P(3) p.D480fs*5(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:1,POLE:1",0.971548,,0.479,4.0,,,,,,,ACH-000996,55294.0
chr5,112842303,C,T,0.616,45,72,0/1,,SNP,NONSENSE,c.6709C>T,p.R2237*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs768922431,,as_specific,0.4214463840399002,"""E, M, O""",Rec,True,,False,p.R2237*(1) p.R2237L(2) p.?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,POLE:7",0.969418,,,5.0,,,,,,,ACH-000996,324.0
chr5,141331561,C,T,0.437,35,30,0/1,,SNP,MISSENSE,c.877C>T,p.R293C,PCDHGA1,"protocadherin gamma subfamily A, 1",Clustered protocadherins,ENST00000517417.2,1.0,+,Q9Y5H4,False,rs898742572,,as_specific,0.4339152119700748,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:8,0.569451,,0.136,2.0,,,,,,,ACH-000996,56114.0
chr5,157651610,C,T,0.5,21,23,0/1,,SNP,MISSENSE,c.469G>A,p.E157K,SOX30,SRY-box 30,SRY-boxes,ENST00000265007.11,1.0,-,O94993,False,rs1490195432,,as_specific,0.6733167082294265,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:1,POLE:4",0.527713,,0.383,4.0,,,,,,,ACH-000996,11063.0
chr6,46140105,G,A,0.448,74,56,0/1,,SNP,SILENT,c.522G>A,p.S174S,ENPP4,ectonucleotide pyrophosphatase/phosphodiesterase 4,,ENST00000321037.5,2.0,+,Q9Y6X5,False,rs751766694,,as_specific,0.4014962593516209,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:3,POLE:5",0.180625,0.848781258809006,,0.0,,,,,,,ACH-000996,22875.0
chr6,98926696,C,T,0.449,57,49,0/1,,SNP,MISSENSE,c.293G>A,p.R98Q,FBXL4,F-box and leucine rich repeat protein 4,F-box and leucine rich repeat proteins,ENST00000369244.7,4.0,-,Q9UKA2,False,rs149860873,,as_specific,0.4364089775561097,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:8,0.939893,,0.31,3.0,,,,,,,ACH-000996,26235.0
chr6,118917601,G,A,0.505,76,75,0/1,,SNP,SILENT,c.864C>T,p.F288F,MCM9,minichromosome maintenance 9 homologous recombination repair factor,MCM family,ENST00000316316.10,5.0,-,Q9NXL9,False,rs564191556,,as_specific,0.4039900249376558,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:3,0.869029,0.6954295520521924,,0.0,,,,,,,ACH-000996,254394.0
chr6,157206493,C,T,0.152,173,29,0/1,,SNP,SILENT,c.5601C>T,p.F1867F,ARID1B,AT-rich interaction domain 1B,AT-rich interaction domain containing,ENST00000346085.10,21.0,+,Q8NFD5,False,rs760729997,,as_specific,0.5336658354114713,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,4.61,False,True,True,"UV:1,POLE:3",0.705638,,,0.0,,,,,,,ACH-000996,57492.0
chr7,95299095,C,T,0.492,75,72,0/1,,SNP,MISSENSE,c.917G>A,p.R306Q,PON1,paraoxonase 1,Paraoxonases,ENST00000222381.8,9.0,-,P27169,False,rs749649413,,as_specific,0.3890274314214463,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:10,0.68897,0.7807916363368471,0.135,2.0,,,,,,,ACH-000996,5444.0
chr7,122320320,G,A,0.176,173,36,0/1,,SNP,NONSENSE,c.3613C>T,p.R1205*,CADPS2,calcium dependent secretion activator 2,Pleckstrin homology domain containing C2 domain containing,ENST00000412584.6,28.0,-,Q86UW7,False,rs1354028382,,as_specific,0.4239401496259352,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:2,POLE:5",0.982409,,,3.0,,,,,,,ACH-000996,93664.0
chr8,144842084,G,T,0.982,1,65,1|1,,SNP,MISSENSE,c.977G>T,p.R326I,ZNF7,zinc finger protein 7,Zinc fingers C2H2-type,ENST00000528372.5,5.0,+,P17097,False,,,,0.5187032418952618,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,,,0.199,2.0,,,,,,,ACH-000996,7553.0
chr9,120980125,G,A,0.421,68,49,0/1,,SNP,MISSENSE,c.3616C>T,p.R1206C,C5,complement C5,"Endogenous ligands Complement system C3 and PZP like, alpha-2-macroglobulin domain containing",ENST00000223642.3,28.0,-,P01031,False,rs1402957355,,as_specific,0.4089775561097257,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:5,POLE:3",0.728459,,0.165,2.0,,,,,,,ACH-000996,727.0
chr10,104072062,G,A,0.5,23,22,0/1,,SNP,NONSENSE,c.433C>T,p.R145*,COL17A1,collagen type XVII alpha 1 chain,Collagens,ENST00000648076.2,8.0,-,Q9UMD9,False,rs121912774,,as_specific,0.4812967581047381,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:6",0.988052,,,4.0,,,,,,,ACH-000996,1308.0
chr10,133168288,C,T,0.442,75,58,0/1,,SNP,SILENT,c.336C>T,p.F112F,KNDC1,kinase non-catalytic C-lobe domain containing 1,,ENST00000304613.8,3.0,+,Q76NI1,False,rs570488032,,as_specific,0.6109725685785536,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"CpG:1,POLE:5",0.777036,0.62828040447614,,0.0,,,,,,,ACH-000996,85442.0
chr11,28023833,G,A,0.395,29,18,0/1,,SNP,MISSENSE,c.2522C>T,p.S841L,KIF18A,kinesin family member 18A,Protein phosphatase 1 regulatory subunits Kinesins,ENST00000263181.7,16.0,-,Q8NI77,False,rs369809315,,as_specific,0.3117206982543641,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,POLE:7,0.590942,0.7966420647636411,0.069,2.0,,,,,,,ACH-000996,81930.0
chr12,22524531,C,T,0.574,31,41,0/1,,SNP,MISSENSE,c.542G>A,p.R181Q,C2CD5,C2 calcium dependent domain containing 5,C2 domain containing,ENST00000536386.5,6.0,-,Q86YS7,False,,,,0.3441396508728179,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.95068,0.7949617100242056,0.295,2.0,,,,,,,ACH-000996,9847.0
chr12,41572467,G,A,0.492,26,26,0/1,,SNP,MISSENSE,c.1688G>A,p.R563Q,PDZRN4,PDZ domain containing ring finger 4,Ring finger proteins PDZ domain containing,ENST00000402685.7,10.0,+,Q6ZMN7,False,rs369918672,,as_specific,0.4314214463840399,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"UV:3,POLE:4",0.915463,0.6904186111245673,0.269,3.0,,,,,,,ACH-000996,29951.0
chr12,132676598,G,C,0.544,27,31,0/1,,SNP,MISSENSE,c.857C>G,p.P286R,POLE,"DNA polymerase epsilon, catalytic subunit",DNA polymerases,ENST00000320574.10,9.0,-,Q07864,False,rs1057519943,,as_specific,0.5062344139650873,,,False,,True,p.P286R(174) p.P286(R^S)(4) p.P286L(2) p.P286(R^S297F)(3) p.P286S(1),cancer;gene_function_loss;dna_repair;,False,False,True,ENST00000320574;ENST00000535270;,,,,7.3,False,True,True,Misc:24,0.884997,0.8045687881348066,0.837,4.0,,,,,,,ACH-000996,5426.0
chr13,48381402,C,T,0.458,37,32,0/1,,SNP,NONSENSE,c.1654C>T,p.R552*,RB1,RB transcriptional corepressor 1,Endogenous ligands,ENST00000267163.5,17.0,+,P06400,False,rs121913303,,as_specific,0.3167082294264339,"""L, E, M, O""",Rec,True,,True,p.0(19) p.R552*(4) p.?(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:2,0.971778,0.6552822183013718,,4.0,,,,,,,ACH-000996,5925.0
chr13,72773778,C,T,0.333,49,25,0/1,,SNP,MISSENSE,c.1055G>A,p.R352Q,DIS3,"DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease",Exosome complex,ENST00000377780.8,8.0,-,Q9Y2L1,False,rs139907646,,as_specific,0.3216957605985037,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,4.31,False,True,True,POLE:6,0.942913,0.6557554282033902,0.215,4.0,,,,,,,ACH-000996,22894.0
chr14,58232220,G,A,0.441,91,65,0/1,,SNP,MISSENSE,c.1025G>A,p.R342Q,ACTR10,actin related protein 10 homolog,Actin related proteins,ENST00000254286.9,12.0,+,Q9NZ32,False,rs554639681,,as_specific,0.3241895261845386,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,POLE:4,0.848485,0.710517920522892,0.347,3.0,,,,,,,ACH-000996,55860.0
chr14,60720206,G,T,0.575,35,50,0/1,,SNP,MISSENSE,c.1103C>A,p.S368Y,SIX4,SIX homeobox 4,SINE class homeoboxes,ENST00000216513.5,2.0,-,Q9UIU6,False,rs369624724,,as_specific,0.4339152119700748,,,False,,False,,cancer;,False,False,True,ENST00000216513;ENST00000556952;,,,,7.3,False,False,True,POLE:4,0.811413,0.7712694842308909,0.814,2.0,,,,,,,ACH-000996,51804.0
chr14,76844864,C,A,0.31,23,9,0/1,,SNP,MISSENSE,c.690C>A,p.F230L,LRRC74A,leucine rich repeat containing 74A,,ENST00000393774.7,7.0,+,Q0VAA2,False,rs779028912,,as_specific,0.42643391521197,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.775307,0.8198315413187115,0.297,3.0,,,,,,,ACH-000996,145497.0
chr16,81017800,C,T,0.333,32,16,0|1,81017800.0,SNP,MISSENSE,c.320C>T,p.S107L,CENPN,centromere protein N,Constitutive centromere associated network,ENST00000305850.9,5.0,+,Q96H22,False,rs528102999,,as_specific,0.286783042394015,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:1,POLE:6",0.574041,0.8107043631896932,0.054,3.0,,,,,,,ACH-000996,55839.0
chr17,7674241,G,T,0.356,53,27,0/1,,SNP,MISSENSE,c.722C>A,p.S241Y,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:5,0.89243,,0.96,3.0,,,,,,,ACH-000996,7157.0
chr17,7674894,G,A,0.474,23,17,0/1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000996,7157.0
chr17,31249093,C,T,0.474,123,104,0/1,,SNP,NONSENSE,c.4084C>T,p.R1362*,NF1,neurofibromin 1,,ENST00000356175.7,30.0,+,P21359,False,rs137854560,,as_specific,0.3366583541147132,O,Rec,True,ASIC2,True,p.R1362*(13) p.R1362fs*18(2) p.0(9),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,"UV:2,POLE:3",0.992775,0.9688736782123002,,5.0,,,,,,,ACH-000996,4763.0
chr17,60066310,G,T,0.466,34,31,0/1,,SNP,MISSENSE,c.1315C>A,p.L439I,HEATR6,HEAT repeat containing 6,,ENST00000184956.11,9.0,-,Q6AI08,False,,,,0.3192019950124688,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.933473,0.7148591497029754,0.18,3.0,,,,,,,ACH-000996,63897.0
chr19,19711558,G,A,0.366,56,33,0/1,,SNP,NONSENSE,c.1723C>T,p.R575*,ZNF14,zinc finger protein 14,Zinc fingers C2H2-type,ENST00000344099.4,4.0,-,P17017,False,rs1473155401,,as_specific,0.4039900249376558,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:7",0.942555,,,3.0,,,,,,,ACH-000996,7561.0
chr19,40626982,C,T,0.333,19,8,0/1,,SNP,SILENT,c.4194C>T,p.F1398F,LTBP4,latent transforming growth factor beta binding protein 4,Latent transforming growth factor beta binding proteins,ENST00000308370.11,31.0,+,Q8N2S1,False,rs371215141,,as_specific,0.6359102244389028,,,False,,False,,cancer;,False,False,True,,,,,3.83,False,False,True,POLE:6,0.715887,0.861900571086519,,0.0,,,,,,,ACH-000996,8425.0
chr19,46921664,C,T,0.294,49,19,0/1,,SNP,NONSENSE,c.2989C>T,p.R997*,ARHGAP35,Rho GTPase activating protein 35,Rho GTPase activating proteins,ENST00000672722.1,2.0,+,Q9NRY4,False,,,,0.4438902743142144,,,True,,False,,cancer;gene_function_gain;gene_function_loss;,False,False,True,,,,,7.3,True,True,True,"UV:1,POLE:10",0.962775,0.5959004308936772,,3.0,,,,,,,ACH-000996,2909.0
chrX,73447385,C,T,0.842,2,16,0/1,,SNP,SILENT,c.132C>T,p.F44F,CDX4,caudal type homeobox 4,HOXL subclass homeoboxes,ENST00000373514.2,1.0,+,O14627,False,,,,0.6084788029925187,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:3,POLE:7",,0.6380293339556065,,0.0,,,,,,,ACH-000996,1046.0
chr12,25245350,C,A,0.673,178,371,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-001999,3845.0
chr12,56085070,G,T,0.489,236,225,0/1,,SNP,MISSENSE,c.310G>T,p.V104L,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,3.0,+,P21860,False,rs1057519893,,as_specific,0.4937655860349127,,,False,,True,p.V104L(1) p.V104M(6),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:4,0.739519,0.7560412700209722,0.466,4.0,,,,,,,ACH-001999,2065.0
chr17,7673803,G,A,0.992,2,409,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001999,7157.0
chr20,58909366,G,A,0.486,484,457,0/1,,SNP,MISSENSE,c.602G>A,p.R201H,GNAS,GNAS complex locus,"G protein subunits alpha, group s Granins",ENST00000371085.7,8.0,+,"O95467, P63092, P84996, Q5JWF2",False,rs121913495,,as_specific,0.4987531172069825,E,Dom,False,,True,p.R201H(703) p.R201C(858) p.R201?(16) p.R201L(4) p.R201S(32) p.R201G(2) p.R201R(1) p.R201P(1),cancer;gene_function_gain;,False,False,True,ENST00000371100;ENST00000371102;ENST00000604005;ENST00000371095;ENST00000371085;ENST00000354359;ENST00000265620;,,,,7.3,True,False,True,CpG:10,0.822809,0.7272591405043412,0.969,4.0,,,,,,,ACH-001999,2778.0
chr17,7675101,C,A,0.967,0,30,1|1,,SNP,NONSENSE,c.511G>T,p.E171*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.571072319201995,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.S149fs*72(1) p.E171K(11) p.Q167fs*2(6) p.E171A(1) p.E171fs*9(1) p.E171*(14) p.H168fs*23(1) p.E171Q(4) p.T170fs*2(1) p.H168_E171del(1) p.E171fs*3(3) p.E171V(2) p.T170fs*8(1) p.E171D(2) p.E171fs*1(1) p.E171fs*10(3) p.H168fs*3(1) p.P151_V173del23(1) p.E171fs*61(1) p.E171G(4) p.K164_P219del(1) p.H168fs*69(1) p.E171_V172delEV(1) p.V157_C176del20(1) p.T170_E171insXX(1) p.V172_E180delVVRRCPHHE(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,APOBEC:1,Misc:2",0.993507,0.446196160933848,,4.0,,,,,,,ACH-000563,7157.0
chr17,7674221,G,A,0.959,0,24,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-002263,7157.0
chr7,140753336,A,T,0.973,2,110,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000269,673.0
chr17,7675095,C,T,0.503,44,39,0/1,,SNP,MISSENSE,c.517G>A,p.V173M,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs876660754,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V173V(8) p.V173L(71) p.S149fs*72(1) p.V173fs*7(2) p.V173G(8) p.V173M(56) p.V173fs*59(2) p.V173E(4) p.V173W(1) p.V173fs*1(4) p.H168fs*23(1) p.V173fs*69(1) p.V173A(13) p.E171fs*1(1) p.P151_V173del23(1) p.E171fs*61(1) p.V173fs*8(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.V173*(1) p.V172_R174delVVR(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:1,0.933723,,0.892,3.0,,,,,,,ACH-000369,7157.0
chr17,7673802,C,T,0.98,0,48,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-002067,7157.0
chr6,55263802,C,T,0.474,77,69,0/1,,SNP,MISSENSE,c.742C>T,p.R248C,HCRTR2,hypocretin receptor 2,Hypocretin receptors,ENST00000370862.3,4.0,+,O43614,False,rs766006062,,as_specific,0.314214463840399,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:7,POLE:1",0.943333,0.6782805152711212,0.186,2.0,,,,,,,ACH-002027,3062.0
chr10,133391346,G,A,0.377,239,147,0/1,,SNP,MISSENSE,c.1427G>A,p.R476H,PAOX,polyamine oxidase,,ENST00000278060.10,7.0,+,Q6QHF9,False,rs1472318687,,as_specific,0.5810473815461347,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.345895,,0.619,2.0,,,,,,,ACH-002027,196743.0
chr12,25245350,C,A,0.46,140,120,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-002027,3845.0
chr17,7674872,T,C,0.909,0,9,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-001680,7157.0
chr12,25245351,C,A,0.44,15,11,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000564,3845.0
chr21,10596079,C,T,0.275,83,29,0/1,,SNP,MISSENSE,c.1268C>T,p.S423L,TPTE,transmembrane phosphatase with tensin homology,PTEN protein phosphatases C2 tensin-type domain containing,ENST00000618007.4,20.0,+,P56180,False,rs570468666,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,3.4,False,False,True,"UV:6,POLE:10",0.988995,0.3421619570457261,,2.0,,,,,,,ACH-000564,7179.0
chr17,7670700,G,A,0.995,0,241,1|1,,SNP,MISSENSE,c.1009C>T,p.R337C,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs587782529,,as_specific,0.4812967581047381,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R337C(43) p.R337H(73) p.R337L(10) p.R337S(1) p.R337P(1) p.R337G(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000504937;ENST00000619186;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000445888;ENST00000619485;ENST00000615910;,,,,7.3,False,True,True,"CpG:3,MSI:1",0.648253,0.5401534229107201,0.715,3.0,,,,,,,ACH-001354,7157.0
chr2,74415153,T,G,0.772,1,7,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002344,388963.0
chr13,101284008,T,G,0.597,125,172,0/1,,SNP,MISSENSE,c.1059A>C,p.E353D,NALCN,"sodium leak channel, non-selective","Sodium leak channels, non selective",ENST00000251127.11,10.0,-,Q8IZF0,False,rs777751467,,as_specific,0.3665835411471321,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:1,0.75954,0.510891761428497,0.484,3.0,,,,,,,ACH-000836,259232.0
chr1,26779863,C,T,0.996,0,270,1|1,,SNP,NONSENSE,c.5314C>T,p.R1772*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,20.0,+,O14497,False,rs879255270,,as_specific,0.5386533665835411,E,Rec,True,1507,True,p.R1989*(19),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:2,POLE:19",0.974353,,,5.0,,,,,,,ACH-001991,8289.0
chr3,41224613,G,A,0.518,152,157,0/1,,SNP,MISSENSE,c.101G>A,p.G34E,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs28931589,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.A5_Q143del(7) p.G34V(103) p.G34R(123) p.G34E(112) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32_S47del(2) p.G34A(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_I35del(1) p.G34D(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.G34I(1) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(2) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.D32fs*9(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.S33_G34insS(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.S33_G34insGTS(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.S33_G34insGI(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_I35del(1) p.A5_T59del(1) p.G34C(1) p.A5_Q72del(1) p.S33_G34del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"MSI:1,UV:1,POLE:1,Misc:2",0.963821,0.7939394540558168,0.593,4.0,,,,,,,ACH-001991,1499.0
chr3,179199088,G,A,0.468,53,47,0/1,,SNP,MISSENSE,c.263G>A,p.R88Q,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs121913287,,as_specific,0.3391521197007481,"""E, O""",Dom,False,,True,p.R88Q(147) p.R88L(1) p.R88?(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,929.0,,0.0,7.3,True,False,True,"CpG:11,MSI:1,POLE:17",0.947755,0.4551598659740948,0.806,3.0,,,,,,,ACH-001991,5290.0
chr3,179234219,A,G,0.467,34,30,0/1,,SNP,MISSENSE,c.3062A>G,p.Y1021C,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913288,,as_specific,0.3790523690773067,"""E, O""",Dom,False,,True,p.Y1021C(44) p.Y1021N(4) p.Y1021F(2) p.Y1021H(3),cancer;gene_function_gain;,False,False,True,ENST00000263967;,,,,7.3,True,False,True,Misc:3,0.821628,0.3872247560214917,0.857,3.0,,,,,,,ACH-001991,5290.0
chr4,174309929,C,T,0.379,91,55,0/1,,SNP,MISSENSE,c.758C>T,p.S253L,CEP44,centrosomal protein 44,,ENST00000503780.6,8.0,+,Q9C0F1,False,rs769157129,,as_specific,0.3117206982543641,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.671898,0.7046283533608756,0.022,1.0,,,,,,,ACH-001991,80817.0
chr5,112842303,C,T,0.5,70,70,0/1,,SNP,NONSENSE,c.6709C>T,p.R2237*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs768922431,,as_specific,0.4214463840399002,"""E, M, O""",Rec,True,,False,p.R2237*(1) p.R2237L(2) p.?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,POLE:7",0.969418,,,5.0,,,,,,,ACH-001991,324.0
chr5,178884161,G,T,0.323,119,57,0/1,,SNP,MISSENSE,c.1709G>T,p.R570I,ZNF354B,zinc finger protein 354B,Zinc fingers C2H2-type,ENST00000322434.8,5.0,+,Q96LW1,False,,,,0.3591022443890274,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"POLE:5,POLE_MSI:2",0.524458,0.647320332471674,0.171,3.0,,,,,,,ACH-001991,117608.0
chr6,56603983,C,A,0.414,100,71,0/1,,SNP,NONSENSE,c.10012G>T,p.E3338*,DST,dystonin,Plakins EF-hand domain containing,ENST00000361203.7,36.0,-,Q03001,False,,,,0.3665835411471321,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:5,0.93955,,,5.0,,,,,,,ACH-001991,667.0
chr6,152376497,G,A,0.493,116,114,0/1,,SNP,NONSENSE,c.9208C>T,p.R3070*,SYNE1,spectrin repeat containing nuclear envelope protein 1,Spectrin repeat containing nuclear envelope family,ENST00000367255.10,58.0,-,Q8NF91,False,rs549779256,,as_specific,0.3615960099750623,,,True,,False,p.R3070*(1),cancer;gene_function_loss;,False,False,True,,,,,4.61,False,True,True,"UV:1,POLE:6",0.990774,0.7745245064613034,,5.0,,,,,,,ACH-001991,23345.0
chr7,112821884,G,A,0.398,65,42,0/1,,SNP,NONSENSE,c.1078C>T,p.R360*,BMT2,base methyltransferase of 25S rRNA 2 homolog,Seven-beta-strand methyltransferase motif containing,ENST00000297145.9,5.0,-,Q1RMZ1,False,,,,0.3865336658354115,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,UV:1,POLE:6",0.989297,0.704523634213334,,3.0,,,,,,,ACH-001991,154743.0
chr9,19346866,G,A,0.493,109,107,0/1,,SNP,MISSENSE,c.3950G>A,p.R1317Q,DENND4C,DENN domain containing 4C,DENN/MADD domain containing,ENST00000602925.5,22.0,+,Q5VZ89,False,rs975704287,,as_specific,0.4538653366583541,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.630801,,0.134,3.0,,,,,,,ACH-001991,55667.0
chr11,118312838,G,A,0.496,137,136,0/1,,SNP,SILENT,c.324G>A,p.A108A,CD3E,CD3e molecule,CD molecules,ENST00000361763.9,6.0,+,P07766,False,rs1313464574,,as_specific,0.4688279301745636,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:2,POLE:5",0.24591,0.7833280852820209,,0.0,,,,,,,ACH-001991,916.0
chr11,124660747,C,T,0.443,190,149,0/1,,SNP,MISSENSE,c.286G>A,p.E96K,SIAE,sialic acid acetylesterase,,ENST00000263593.8,3.0,-,Q9HAT2,False,rs375087861,,as_specific,0.4214463840399002,,,False,,False,,cancer;,False,False,True,,,,,4.01,False,False,True,POLE:8,0.732919,0.2883132437171025,0.445,2.0,,,,,,,ACH-001991,54414.0
chr12,22524531,C,T,0.511,159,159,0/1,,SNP,MISSENSE,c.542G>A,p.R181Q,C2CD5,C2 calcium dependent domain containing 5,C2 domain containing,ENST00000536386.5,6.0,-,Q86YS7,False,,,,0.3441396508728179,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.95068,0.7949617100242056,0.295,2.0,,,,,,,ACH-001991,9847.0
chr12,132673703,C,A,0.453,88,69,0/1,,SNP,MISSENSE,c.1231G>T,p.V411L,POLE,"DNA polymerase epsilon, catalytic subunit",DNA polymerases,ENST00000320574.10,13.0,-,Q07864,False,rs1057519945,,as_specific,0.5810473815461347,,,False,,True,p.V411L(104) p.V411M(1),cancer;gene_function_loss;dna_repair;,False,False,True,,,,,7.3,False,True,True,,0.907765,0.520500289313063,0.457,4.0,,,,,,,ACH-001991,5426.0
chr13,21510008,G,A,0.324,64,29,0/1,,SNP,NONSENSE,c.757C>T,p.R253*,MICU2,mitochondrial calcium uptake 2,EF-hand domain containing,ENST00000382374.9,8.0,-,Q8IYU8,False,rs772353232,,as_specific,0.2668329177057356,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:6",0.986608,0.6022871366685337,,3.0,,,,,,,ACH-001991,221154.0
chr14,90302832,C,T,0.44,71,53,0/1,,SNP,SILENT,c.1299G>A,p.S433S,NRDE2,"NRDE-2, necessary for RNA interference, domain containing",,ENST00000354366.8,6.0,-,Q9H7Z3,False,rs937745011,,as_specific,0.4463840399002494,,,False,,False,,cancer;,False,False,True,,,,,4.13,False,False,True,POLE:6,0.47157,0.6242118313774039,,0.0,,,,,,,ACH-001991,55051.0
chr15,88906664,C,T,0.489,140,135,0/1,,SNP,MISSENSE,c.502G>A,p.E168K,MFGE8,milk fat globule-EGF factor 8 protein,,ENST00000566497.5,4.0,-,Q08431,False,rs769108892,,as_specific,0.5361596009975063,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:6,0.698102,0.8038310304926114,0.403,2.0,,,,,,,ACH-001991,4240.0
chr18,49379743,C,T,0.519,111,113,0/1,,SNP,MISSENSE,c.209G>A,p.R70Q,DYM,dymeclin,,ENST00000269445.10,4.0,-,Q7RTS9,False,rs202085847,,as_specific,0.3067331670822942,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.981267,0.3286323318241979,0.509,3.0,,,,,,,ACH-001991,54808.0
chr20,13782826,G,A,0.52,81,88,0/1,,SNP,SILENT,c.315C>T,p.I105I,ESF1,ESF1 nucleolar pre-rRNA processing protein homolog,,ENST00000202816.5,2.0,-,Q9H501,False,rs374648931,,as_specific,0.3266832917705736,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:4,0.179191,,,0.0,,,,,,,ACH-001991,51575.0
chr22,30958684,C,T,0.356,109,64,0/1,,SNP,MISSENSE,c.79G>A,p.E27K,MORC2,MORC family CW-type zinc finger 2,Zinc fingers CW-type,ENST00000397641.8,2.0,-,Q9Y6X9,False,,,,0.341645885286783,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:3,0.94512,0.4404164540656489,0.392,3.0,,,,,,,ACH-001991,22880.0
chrX,111847345,G,A,0.322,271,126,0/1,,SNP,MISSENSE,c.1469C>T,p.S490L,TRPC5,transient receptor potential cation channel subfamily C member 5,Protein phosphatase 1 regulatory subunits Transient receptor potential cation channels,ENST00000262839.2,6.0,-,Q9UL62,False,rs749102820,,as_specific,0.4389027431421446,,,False,,False,,cancer;,False,False,True,ENST00000262839;,,,,7.3,False,False,True,"UV:2,POLE:6",,,0.861,2.0,,,,,,,ACH-001991,7224.0
chr9,27949444,G,T,0.979,3,135,1|1,,SNP,MISSENSE,c.1228C>A,p.P410T,LINGO2,leucine rich repeat and Ig domain containing 2,I-set domain containing,ENST00000379992.6,6.0,-,Q7L985,False,rs199551773,,as_specific,0.5311720698254364,,,False,,False,,cancer;,False,False,True,ENST00000379992;ENST00000308675;ENST00000613945;,,,,7.3,False,False,True,"smoking:2,Misc:1",0.472618,,0.787,3.0,,,,,,,ACH-001328,158038.0
chr17,7673802,C,T,0.995,0,226,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001328,7157.0
chr12,25245350,C,A,0.968,1,61,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000108,3845.0
chr1,114713909,G,T,0.663,67,131,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000430,4893.0
chr1,114716126,C,T,0.394,98,60,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-000430,4893.0
chr17,7675088,C,T,0.954,1,48,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000430,7157.0
chr21,10596079,C,T,0.282,69,31,0/1,,SNP,MISSENSE,c.1268C>T,p.S423L,TPTE,transmembrane phosphatase with tensin homology,PTEN protein phosphatases C2 tensin-type domain containing,ENST00000618007.4,20.0,+,P56180,False,rs570468666,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,3.4,False,False,True,"UV:6,POLE:10",0.988995,0.3421619570457261,,2.0,,,,,,,ACH-000430,7179.0
chr17,7676059,G,A,0.997,0,287,1|1,,SNP,NONSENSE,c.310C>T,p.Q104*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5561097256857855,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.G59fs*23(3) p.S95_G108del(1) p.W91fs*13(1) p.Q104fs*19(2) p.Y103_G112>C(1) p.Q104*(15) p.Y103_Q104>*(1) p.Y103fs*15(1) p.M1_T125del(1) p.Q104L(1) p.Q104H(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,Misc:1,0.976972,0.3103062833861155,,4.0,,,,,,,ACH-000261,7157.0
chr2,74415153,T,G,0.855,0,5,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002232,388963.0
chr17,7674230,C,T,0.5,28,28,0/1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-002232,7157.0
chr12,25245351,C,T,0.635,78,137,0/1,,SNP,MISSENSE,c.34G>A,p.G12S,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,913.0,,38.0,7.3,True,False,True,"smoking:2,Eso:1,Misc:10",0.902584,,0.79,4.0,,,,,,,ACH-001521,3845.0
chr12,117258434,C,T,0.439,69,51,0/1,,SNP,MISSENSE,c.2494G>A,p.E832K,NOS1,nitric oxide synthase 1,PDZ domain containing,ENST00000338101.8,15.0,-,P29475,False,,,,0.5211970074812967,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.9399,0.5495956213489199,0.224,3.0,,,,,,,ACH-001521,4842.0
chr2,39054637,T,A,0.178,53,10,0/1,,SNP,MISSENSE,c.697A>T,p.N233Y,SOS1,SOS Ras/Rac guanine nucleotide exchange factor 1,Rho guanine nucleotide exchange factors Pleckstrin homology domain containing,ENST00000395038.6,5.0,-,Q07889,False,rs1057519963,,as_specific,0.2967581047381546,,,False,,False,p.N233Y(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"smoking:3,Misc:5",0.884903,,0.58,4.0,,,,,,,ACH-000065,6654.0
chr21,10596079,C,T,0.243,273,88,0/1,,SNP,MISSENSE,c.1268C>T,p.S423L,TPTE,transmembrane phosphatase with tensin homology,PTEN protein phosphatases C2 tensin-type domain containing,ENST00000618007.4,20.0,+,P56180,False,rs570468666,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,3.4,False,False,True,"UV:6,POLE:10",0.988995,0.3421619570457261,,2.0,,,,,,,ACH-000393,7179.0
chr12,25245350,C,A,0.428,15,12,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000107,3845.0
chr17,7675994,C,A,0.979,0,45,1|1,,SNP,SPLICE_SITE,c.375G>T,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:12,MSI:1,Misc:4",0.468898,0.7805428798268306,,0.0,,,,,,,ACH-000107,7157.0
chr6,27807658,G,A,0.97,4,163,1|1,,SNP,SILENT,c.249C>T,p.H83H,H2BC13,,,ENST00000377401.3,1.0,-,,False,rs147149614,,as_specific,0.5785536159600998,,,False,,False,,cancer;,False,False,True,,,,,3.91,False,False,True,Misc:1,0.134151,0.7535661040960056,,0.0,,,,,,,ACH-000461,8340.0
chr17,7673803,G,A,0.969,0,30,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000461,7157.0
chr7,140753336,A,T,0.452,50,45,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000650,673.0
chr19,57135184,G,A,0.342,113,58,0/1,,SNP,MISSENSE,c.1153C>T,p.H385Y,ZIM3,zinc finger imprinted 3,Zinc fingers C2H2-type,ENST00000269834.1,5.0,-,Q96PE6,False,rs150510557,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.419835,0.5507929749384455,0.288,2.0,,,,,,,ACH-000650,114026.0
chr4,152328233,G,A,0.504,63,63,0/1,,SNP,MISSENSE,c.1153C>T,p.R385C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs867384286,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465C(83) p.R465fs*7(13) p.R465S(1) p.R465Y(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:9,0.934034,0.2550529450691629,0.593,4.0,,,,,,,ACH-000222,55294.0
chr12,25245350,C,T,0.913,1,21,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000222,3845.0
chr3,37014545,G,A,0.458,34,26,0/1,,SNP,SPLICE_SITE,c.e10+1G>A,,MLH1,mutL homolog 1,MutL homologs,ENST00000458205.6,,+,P40692,False,rs267607789,,as_specific,0.3690773067331671,"""E, O""",Rec,False,,False,p.?(4),splicing;cancer;gene_function_loss;dna_repair;,False,False,True,,731.0,,2.5,7.3,False,True,False,,0.972304,0.4673546425590275,,1.59129685669006,,,,,,,ACH-001738,4292.0
chr4,152328233,G,A,0.313,133,60,0/1,,SNP,MISSENSE,c.1153C>T,p.R385C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs867384286,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465C(83) p.R465fs*7(13) p.R465S(1) p.R465Y(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:9,0.934034,0.2550529450691629,0.593,4.0,,,,,,,ACH-001738,55294.0
chr12,25245350,C,T,0.424,34,25,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001738,3845.0
chr17,7674220,C,T,0.469,34,32,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001738,7157.0
chr17,7675088,C,T,0.451,35,29,0/1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-001738,7157.0
chr9,21971117,G,A,0.917,0,11,1|1,,SNP,MISSENSE,c.89C>T,p.P30L,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552823,,as_specific,0.7007481296758105,,,False,,True,p.0(1543) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A30fs*18(1) p.P81_A85del(1) p.P81H(2) p.A30P(1) p.A30E(1) p.A76fs*64(2) p.P81L(17) p.R80fs*63(1) p.T79fs*37(1) p.A30V(3) p.A30A(2) p.R29_A34del(2) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;,,,,7.3,False,True,True,UV:3,0.6432,0.998490066843982,0.862,4.0,,,,,,,ACH-001626,1029.0
chr17,7674216,C,A,0.944,0,19,1|1,,SNP,MISSENSE,c.747G>T,p.R249S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934571,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.P250fs*14(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:5,Misc:13",0.776711,,0.769,2.0,,,,,,,ACH-001626,7157.0
chr17,7675208,C,A,0.99,0,109,1|1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-000312,7157.0
chr17,7670685,G,A,0.989,0,97,1|1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-001340,7157.0
chr12,25245350,C,T,0.788,83,305,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001536,3845.0
chr12,25245350,C,A,0.542,12,15,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000721,3845.0
chr7,140753336,A,T,0.709,131,333,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001567,673.0
chr11,66316769,G,T,0.288,10,3,0/1,,SNP,MISSENSE,c.259C>A,p.L87M,CD248,CD248 molecule,CD molecules C-type lectin domain containing,ENST00000311330.4,1.0,-,Q9HCU0,False,rs760481697,,as_specific,0.7406483790523691,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,smoking:1,0.308731,0.5069856782759462,0.283,2.0,,,,,,,ACH-002142,57124.0
chr17,35750138,T,G,0.169,21,4,0/1,,SNP,MISSENSE,c.566A>C,p.D189A,GAS2L2,growth arrest specific 2 like 2,,ENST00000604641.6,2.0,-,Q8NHY3,False,rs1192558412,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.610651,0.5095418527025265,0.061,2.0,,,,,,,ACH-002295,246176.0
chr12,25245350,C,T,0.959,0,22,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001650,3845.0
chr5,112839693,C,T,0.953,3,67,1|1,,SNP,NONSENSE,c.4099C>T,p.Q1367*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913328,,as_specific,0.4638403990024937,"""E, M, O""",Rec,True,,True,p.Q1367*(39) p.Q1367H(2) p.K1363fs*7(1) p.?(1) p.K1192fs*3(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"APOBEC:2,Misc:1",0.963926,0.5902091700563789,,5.0,,,,,,,ACH-000150,324.0
chr17,7674872,T,C,0.909,7,65,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000150,7157.0
chr12,25245350,C,A,0.545,34,38,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000138,3845.0
chr17,7675124,T,C,0.467,33,28,0/1,,SNP,MISSENSE,c.488A>G,p.Y163C,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs148924904,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y163C(136) p.0(9) p.S149fs*72(1) p.Y163fs*1(2) p.Y163H(19) p.Y163N(20) p.A159_Q167delAMAIYKQSQ(1) p.Y163S(5) p.Y163*(8) p.Y163fs*14(1) p.A159_M169del(1) p.Y163_Q165delYKQ(1) p.Y163D(4) p.Y163del(1) p.Y163Y(3) p.P151_V173del23(1) p.I162_Y163delIY(1) p.Y163fs*7(2) p.V157_C176del20(1) p.Y163fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:11,0.897865,0.7273008533507418,0.872,3.0,,,,,,,ACH-002236,7157.0
chr4,152328232,C,T,0.438,161,119,0/1,,SNP,MISSENSE,c.1154G>A,p.R385H,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs1057519895,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465H(72) p.R465fs*7(9) p.R465L(3) p.R465Y(2) p.R465P(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:15,0.938974,0.1731430175559941,0.557,4.0,,,,,,,ACH-000920,55294.0
chr21,10596079,C,T,0.164,134,26,0/1,,SNP,MISSENSE,c.1268C>T,p.S423L,TPTE,transmembrane phosphatase with tensin homology,PTEN protein phosphatases C2 tensin-type domain containing,ENST00000618007.4,20.0,+,P56180,False,rs570468666,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,3.4,False,False,True,"UV:6,POLE:10",0.988995,0.3421619570457261,,2.0,,,,,,,ACH-000920,7179.0
chr7,140753336,A,T,0.995,0,199,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002460,673.0
chr12,117258434,C,T,0.308,193,79,0/1,,SNP,MISSENSE,c.2494G>A,p.E832K,NOS1,nitric oxide synthase 1,PDZ domain containing,ENST00000338101.8,15.0,-,P29475,False,,,,0.5211970074812967,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.9399,0.5495956213489199,0.224,3.0,,,,,,,ACH-002460,4842.0
chr8,144842084,G,T,0.955,4,91,1|1,,SNP,MISSENSE,c.977G>T,p.R326I,ZNF7,zinc finger protein 7,Zinc fingers C2H2-type,ENST00000528372.5,5.0,+,P17097,False,,,,0.5187032418952618,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,,,0.199,2.0,,,,,,,ACH-000831,7553.0
chr12,25245350,C,T,0.97,0,39,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000831,3845.0
chr19,52212729,C,T,0.917,5,68,1|1,,SNP,MISSENSE,c.10C>T,p.R4W,PPP2R1A,protein phosphatase 2 scaffold subunit Aalpha,STRIPAK complex Protein phosphatase 2 scaffold subunits,ENST00000462990.5,5.0,+,P30153,False,rs1057519946,,as_specific,0.5885286783042394,E,Dom?,False,,True,p.R183W(26) p.R183G(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,MSI:1,POLE_MSI:1",0.872264,0.6395465794564451,0.294,4.0,,,,,,,ACH-000831,5518.0
chr1,11130747,C,T,0.267,11,3,0/1,,SNP,MISSENSE,c.5395G>A,p.E1799K,MTOR,mechanistic target of rapamycin kinase,MTOR complex 1 MTOR complex 2,ENST00000361445.9,39.0,-,P42345,False,rs863225264,,as_specific,0.5760598503740648,,,False,,False,,cancer;gene_function_gain;,False,False,True,,544.0,,2.0,7.3,True,False,True,"CpG:5,UV:1,POLE:5",0.978079,0.534376468210211,0.638,4.0,,,,,,,ACH-000994,2475.0
chr3,179198937,C,T,0.559,59,74,0/1,,SNP,MISSENSE,c.112C>T,p.R38C,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs749415085,,as_specific,0.3690773067331671,"""E, O""",Dom,False,,True,p.R38C(12) p.R38H(23) p.R38S(2) p.R38G(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,,,,7.3,True,False,True,"CpG:1,MSI:1,POLE:2",0.635522,0.8092041904693834,0.737,3.0,,,,,,,ACH-000994,5290.0
chr5,68295278,A,G,0.488,74,66,0/1,,SNP,MISSENSE,c.610A>G,p.K204E,PIK3R1,phosphoinositide-3-kinase regulatory subunit 1,SH2 domain containing,ENST00000523872.1,6.0,+,P27986,False,,,,0.3740648379052369,"""E, O""",Rec,False,,False,p.K567E(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,,0.885938,0.6249064453763302,0.468,4.0,,,,,,,ACH-000994,5295.0
chr10,87957915,C,T,0.609,79,119,0/1,,SNP,NONSENSE,c.697C>T,p.R233*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,7.0,+,P60484,False,rs121909219,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R233*(101) p.0(28) p.G165_K342del(1) p.T232_R233insTQGGAGS(2) p.R233fs*10(14) p.R55fs*1(1) p.R233fs*3(1) p.R234fs*9(1) p.R233fs*24(1) p.R233fs*?(2) p.T232_R233insK*(1) p.N228fs*10(1) p.R233fs*25(2) p.R233fs*13(1) p.R233fs*19(1) p.R233fs*26(1) p.R233fs*20(1) p.R233R(1) p.R233fs*12(1) p.P231fs*2(1) p.K221fs*6(1) p.R233fs*23(1) p.T232_R233insPQGGAGT(1) p.G165_*404del(1) p.R233Q(1),cancer;gene_function_loss;,False,True,True,,110.0,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.",19.0,7.3,False,True,False,,0.971128,0.6883155413500054,,3.0,,,,,,,ACH-000994,5728.0
chr11,47326780,C,T,0.231,125,35,0/1,,SNP,NONSENSE,c.4765C>T,p.R1589*,MADD,MAP kinase activating death domain,DENN/MADD domain containing,ENST00000311027.9,34.0,+,Q8WXG6,False,rs267602902,,as_specific,0.516209476309227,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:7,0.985355,0.8462858303024167,,4.0,,,,,,,ACH-000994,8567.0
chr17,7673802,C,T,0.428,24,17,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000994,7157.0
chrX,50607731,C,T,0.268,16,5,0/1,,SNP,SILENT,c.3411G>A,p.E1137E,SHROOM4,shroom family member 4,PDZ domain containing,ENST00000289292.11,6.0,-,Q9ULL8,False,rs781966917,,as_specific,0.5785536159600998,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,,0.8036980905719231,,0.0,,,,,,,ACH-000994,57477.0
chr7,140753336,A,T,0.629,179,306,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001570,673.0
chr9,21971097,C,A,0.995,0,200,1|1,,SNP,NONSENSE,c.109G>T,p.E37*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913384,,as_specific,0.6982543640897756,,,True,,True,p.0(1543) p.E88*(15) p.V82_E88del(1) p.V28_V51del(1) p.E88K(3) p.?(4) p.L32_L37del(6) p.H83fs*2(2) p.E88fs*58(1) p.R87fs*30(1) p.E61_L94del(1) p.L37L(2) p.E87K(2) p.D84_F90del(1) p.A68fs*3(1) p.L37fs*6(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,smoking:2,0.92205,0.9909344162016276,0.584,5.0,,,,,,,ACH-001570,1029.0
chr11,100299243,G,A,0.477,142,133,0/1,,SNP,MISSENSE,c.2467G>A,p.E823K,CNTN5,contactin 5,I-set domain containing Immunoglobulin like domain containing Ig-like cell adhesion molecule family Fibronectin type III domain containing,ENST00000524871.6,20.0,+,O94779,False,rs1385144818,,as_specific,0.341645885286783,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.949314,,0.366,2.0,,,,,,,ACH-001570,53942.0
chr1,114716127,C,T,0.472,61,53,0/1,,SNP,MISSENSE,c.34G>A,p.G12S,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913250,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,,898.0,,7.5,7.3,True,False,False,,0.864195,0.3336378450149014,0.612,4.0,,,,,,,ACH-002241,4893.0
chr17,35750138,T,G,0.275,20,8,0/1,,SNP,MISSENSE,c.566A>C,p.D189A,GAS2L2,growth arrest specific 2 like 2,,ENST00000604641.6,2.0,-,Q8NHY3,False,rs1192558412,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.610651,0.5095418527025265,0.061,2.0,,,,,,,ACH-002241,246176.0
chr4,1801837,C,T,0.967,0,28,1|1,,SNP,MISSENSE,c.742C>T,p.R248C,FGFR3,fibroblast growth factor receptor 3,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000481110.6,7.0,+,P22607,False,rs121913482,,as_specific,0.685785536159601,"""L, E""",Dom,False,"""IGH@, ETV6""",True,p.R248C(423) p.R248H(2) p.R248_S249insC(1) p.R248_S249delRS(1) p.R248_S249insL(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000440486;ENST00000481110;ENST00000340107;ENST00000412135;ENST00000613647;ENST00000352904;ENST00000507588;,2403.0,,0.0,7.3,True,False,False,,0.746396,0.5773203331809318,0.855,3.0,,,,,,,ACH-000973,2261.0
chr4,169400614,G,A,0.991,0,104,1|1,,SNP,SILENT,c.3537C>T,p.C1179C,NEK1,NIMA related kinase 1,,ENST00000439128.6,32.0,-,Q96PY6,False,rs772515579,,as_specific,0.2817955112219451,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:1,0.226292,0.7916286709002321,,0.0,,,,,,,ACH-000973,4750.0
chr9,21971187,G,A,0.572,5,8,0|1,21971187.0,SNP,NONSENSE,c.19C>T,p.R7*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913387,,as_specific,0.6458852867830424,,,True,,True,p.0(1543) p.R58*(112) p.A4_P11del(12) p.V28_V51del(1) p.?(5) p.M54fs*61(2) p.R58fs*61(2) p.P3_P11del(2) p.R58fs*59(2) p.M53_R58del(3) p.A57fs*85(1) p.A57_R58>V*(1) p.G55fs*86(1) p.G55fs*61(1) p.S7_A19del(1) p.R58fs*62(1) p.R58R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:10,UV:4",0.788085,0.9908618465891524,0.22,5.0,,,,,,,ACH-000973,1029.0
chr10,87952142,C,T,0.56,90,117,0/1,,SNP,MISSENSE,c.517C>T,p.R173C,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,6.0,+,P60484,False,rs121913293,,as_specific,0.3266832917705736,"""L, E, M, O""",Rec,False,,True,p.R173C(51) p.0(28) p.R173H(34) p.G165_K342del(1) p.R55fs*1(1) p.V166fs*17(3) p.R173fs*6(1) p.R173fs*10(2) p.Y27_N212>Y(2) p.G165fs*9(3) p.?(1) p.R172fs*5(1) p.R172_Y174>N(1) p.R173S(1) p.R173R(1) p.G165_*404del(1),cancer;gene_function_loss;,False,True,True,ENST00000371953;,838.0,,13.0,7.3,False,True,True,CpG:1,0.941832,0.6442282294657126,0.972,3.0,,,,,,,ACH-000973,5728.0
chr17,7674220,C,T,0.986,0,72,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000973,7157.0
chr12,25245350,C,T,0.995,1,244,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001849,3845.0
chr17,7674238,C,T,0.967,0,30,1|1,,SNP,MISSENSE,c.725G>A,p.C242Y,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912655,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C242fs*20(2) p.C242F(85) p.C242Y(54) p.C242S(35) p.C242*(5) p.H233_C242del10(1) p.N239_C242delNSSC(3) p.C242fs*5(21) p.C242W(6) p.C242G(4) p.C242R(13) p.N239fs*4(1) p.C242C(4) p.C242fs*98(1) p.C242fs*?(3) p.S241_G245delSCMGG(1) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.C242fs*23(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1064.0,,0.0,7.3,False,True,True,Misc:3,0.964036,0.9882502870966408,0.973,3.0,,,,,,,ACH-000318,7157.0
chr10,116476771,A,C,0.375,25,14,0/1,,SNP,MISSENSE,c.1292A>C,p.K431T,PNLIPRP3,pancreatic lipase related protein 3,Lipases,ENST00000369230.4,11.0,+,Q17RR3,False,,,,0.3216957605985037,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:4,0.430379,,0.103,1.0,,,,,,,ACH-001638,119548.0
chr11,67418924,G,T,0.256,8,2,0/1,,SNP,MISSENSE,c.164G>T,p.G55V,CARNS1,carnosine synthase 1,,ENST00000307823.7,4.0,+,A5YM72,False,rs780435597,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.300515,,0.112,2.0,,,,,,,ACH-000189,57571.0
chr17,7675208,C,A,0.305,118,51,0|1,7675208.0,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-001846,7157.0
chr1,114713908,T,C,0.976,3,178,1|1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-000890,4893.0
chr17,7673790,C,A,0.956,1,42,1|1,,SNP,MISSENSE,c.830G>T,p.C277F,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs763098116,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.C277Y(17) p.C275fs*67(1) p.C277*(8) p.C277C(4) p.C277G(9) p.C277W(3) p.C277F(26) p.C277S(2) p.C277fs*68(1) p.V274_P278delVCACP(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.C277fs*?(1) p.C277fs*29(2) p.V272_K292del21(1) p.A276fs*64(1) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.A276_C277delAC(1) p.L265_K305del41(1) p.C277R(2) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:2",0.917615,0.8063810398136229,0.932,3.0,,,,,,,ACH-000890,7157.0
chr2,74415153,T,G,0.6,1,2,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002234,388963.0
chr17,7673803,G,A,0.998,0,559,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001513,7157.0
chr21,10596079,C,T,0.217,112,30,0/1,,SNP,MISSENSE,c.1268C>T,p.S423L,TPTE,transmembrane phosphatase with tensin homology,PTEN protein phosphatases C2 tensin-type domain containing,ENST00000618007.4,20.0,+,P56180,False,rs570468666,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,3.4,False,False,True,"UV:6,POLE:10",0.988995,0.3421619570457261,,2.0,,,,,,,ACH-001513,7179.0
chr17,7674248,T,C,0.509,27,28,0/1,,SNP,MISSENSE,c.715A>G,p.N239D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs876660807,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N239D(42) p.N239fs*22(1) p.H233_C242del10(1) p.N239_C242delNSSC(3) p.N239T(8) p.N239S(26) p.N239fs*25(12) p.C238_N239insX(1) p.N239fs*4(1) p.H233fs*6(1) p.N239K(7) p.M237_N239delMCN(1) p.N239fs*8(3) p.N239I(1) p.N239_S240insN(1) p.N239Y(6) p.V225fs*23(1) p.N239fs*1(2) p.N239_S240insX(2) p.N239N(1) p.C238_M246delCNSSCMGGM(1) p.N239fs*26(1) p.N239_S240delNS(2) p.N239fs*6(1) p.N239fs*?(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.N239*(1) p.N239_S241>T(1) p.N239fs*24(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:8,0.936288,0.9973610804975211,0.948,3.0,,,,,,,ACH-000567,7157.0
chr17,7675139,C,T,0.549,27,34,0/1,,SNP,MISSENSE,c.473G>A,p.R158H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782144,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1695.0,,3.0,7.3,False,True,True,"CpG:6,MSI:1",0.916199,0.785313106525997,0.844,3.0,,,,,,,ACH-000567,7157.0
chr3,179199088,G,A,0.495,48,46,0/1,,SNP,MISSENSE,c.263G>A,p.R88Q,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs121913287,,as_specific,0.3391521197007481,"""E, O""",Dom,False,,True,p.R88Q(147) p.R88L(1) p.R88?(1),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;ENST00000468036;,929.0,,0.0,7.3,True,False,True,"CpG:11,MSI:1,POLE:17",0.947755,0.4551598659740948,0.806,3.0,,,,,,,ACH-001333,5290.0
chr10,62813726,G,T,0.169,74,15,1|0,62813710.0,SNP,SILENT,c.912C>A,p.A304A,EGR2,early growth response 2,Zinc fingers C2H2-type,ENST00000242480.4,2.0,-,P11161,False,rs752399953,,as_specific,0.6608478802992519,,,False,,False,,cancer;,False,False,True,,,,,4.13,False,False,True,"MSI:3,Misc:1",0.081345,0.4941389069847913,,0.0,,,,,,,ACH-001333,1959.0
chr10,87933147,C,T,0.477,141,122,0/1,,SNP,NONSENSE,c.388C>T,p.R130*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,5.0,+,P60484,False,rs121909224,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R130G(140) p.R130Q(108) p.R130fs*4(13) p.R130fs*2(1) p.K128_R130del(4) p.0(28) p.R130L(19) p.R130*(83) p.R130P(7) p.R55fs*1(1) p.R130?(1) p.R130fs*?(5) p.R130R(1) p.R130_T131>P(4) p.R130fs*50(1) p.G129fs*50(1) p.Y27_N212>Y(2) p.G129fs*51(1) p.F56fs*2(1) p.?(1) p.K125fs*46(1) p.A121_F145del(1) p.K128fs*47(1) p.R130Xfs*?(1),cancer;gene_function_loss;,False,False,True,,636.0,,2.0,7.3,False,True,False,,0.97629,0.898071104088428,,4.0,,,,,,,ACH-001333,5728.0
chr10,87957915,C,T,0.467,91,81,0/1,,SNP,NONSENSE,c.697C>T,p.R233*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,7.0,+,P60484,False,rs121909219,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R233*(101) p.0(28) p.G165_K342del(1) p.T232_R233insTQGGAGS(2) p.R233fs*10(14) p.R55fs*1(1) p.R233fs*3(1) p.R234fs*9(1) p.R233fs*24(1) p.R233fs*?(2) p.T232_R233insK*(1) p.N228fs*10(1) p.R233fs*25(2) p.R233fs*13(1) p.R233fs*19(1) p.R233fs*26(1) p.R233fs*20(1) p.R233R(1) p.R233fs*12(1) p.P231fs*2(1) p.K221fs*6(1) p.R233fs*23(1) p.T232_R233insPQGGAGT(1) p.G165_*404del(1) p.R233Q(1),cancer;gene_function_loss;,False,True,True,,110.0,"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.",19.0,7.3,False,True,False,,0.971128,0.6883155413500054,,3.0,,,,,,,ACH-001333,5728.0
chr17,7673803,G,A,0.997,0,404,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001333,7157.0
chr12,25245351,C,T,0.974,0,37,1|1,,SNP,MISSENSE,c.34G>A,p.G12S,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,913.0,,38.0,7.3,True,False,True,"smoking:2,Eso:1,Misc:10",0.902584,,0.79,4.0,,,,,,,ACH-002337,3845.0
chr1,114716126,C,T,0.446,77,65,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-000070,4893.0
chr10,103097350,G,A,0.403,86,56,0/1,,SNP,MISSENSE,c.712C>T,p.R238W,NT5C2,"5'-nucleotidase, cytosolic II",5'-nucleotidases,ENST00000404739.7,9.0,-,P49902,False,,,,0.3366583541147132,,,False,,True,p.R238W(6) p.R238L(1),cancer;gene_function_gain;,False,True,True,,2896.0,,13.0,7.3,True,False,False,,0.878277,,0.413,3.0,,,,,,,ACH-000070,22978.0
chr2,177234216,C,G,0.508,29,34,0/1,,SNP,MISSENSE,c.53G>C,p.R18P,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.3940149625935162,E,Dom,False,,True,p.D16_R34del(1) p.R34Q(8) p.R34P(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,APOBEC:1,0.977862,0.6076315755614368,0.635,3.0,,,,,,,ACH-000946,4780.0
chr3,41224607,A,T,0.425,24,17,0/1,,SNP,MISSENSE,c.95A>T,p.D32V,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913396,,as_specific,0.3940149625935162,"""E, M, O""",Dom,False,PLAG1,True,p.D32H(66) p.D32Y(177) p.A5_A80del(75) p.D32N(123) p.D32V(66) p.D32G(92) p.A5_Q143del(7) p.Q28_D32>H(2) p.D32A(22) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32E(11) p.D32_S47del(2) p.Y30_T40del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_D32del(6) p.W25_I35del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.WQQQSYLD25?(5) p.E9_I140del(1) p.H24_G38del(1) p.S23_S33del(3) p.A20_R151del(1) p.D32_S33insS(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.D32D(1) p.T3_A126del(2) p.D32fs*9(1) p.S23_S33>T(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.W25_S33del(1) p.W25_H36del(2) p.A5_D144>D(1) p.D32F(3) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.V22_S33del(2) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D32del(1) p.D6_A43del(1) p.S23_A39del(1) p.Y30_S33del(2) p.A5_I35del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,Misc:7,0.949258,0.7771428993677211,0.642,4.0,,,,,,,ACH-000946,1499.0
chr11,69651253,C,A,0.5,8,7,0/1,,SNP,MISSENSE,c.859C>A,p.P287T,CCND1,cyclin D1,Cyclins,ENST00000227507.3,5.0,+,P24385,False,,,,0.6433915211970075,"""L, E""",Dom,False,"""IGH@, FSTL3""",False,p.P287L(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,Misc:1,0.667669,0.8583790279105283,0.428,4.0,,,,,,,ACH-000946,595.0
chr17,7673803,G,A,0.973,1,39,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-002112,7157.0
chr12,25225627,G,A,0.249,237,72,0/1,,SNP,MISSENSE,c.437C>T,p.A146V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs1057519725,,as_specific,0.3291770573566084,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1) p.T148fs*6(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,322.0,,8.0,7.3,True,False,False,,0.940928,0.6906510308302181,0.89,4.0,,,,,,,ACH-001634,3845.0
chr1,114713909,G,T,0.532,74,82,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-002247,4893.0
chr2,74415153,T,G,0.691,2,6,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002306,388963.0
chr17,7674221,G,A,0.966,0,35,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000115,7157.0
chr12,25245351,C,A,0.717,17,43,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000861,3845.0
chr7,140753336,A,T,0.647,42,75,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002205,673.0
chr17,7674220,C,T,0.561,17,23,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-002205,7157.0
chr17,7674217,C,A,0.982,0,60,1|1,,SNP,MISSENSE,c.746G>T,p.R249M,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782329,,as_specific,0.5610972568578554,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:4,Misc:1",0.931209,0.9943638226795996,0.911,3.0,,,,,,,ACH-001066,7157.0
chr7,140753336,A,T,0.492,74,66,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000126,673.0
chr12,25079261,C,T,0.263,104,32,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-000126,Unknown
chr7,140753336,A,T,0.572,67,91,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002098,673.0
chr14,19781125,C,T,0.185,152,36,0/1,,SNP,MISSENSE,c.803C>T,p.S268F,OR4M1,olfactory receptor family 4 subfamily M member 1,"Olfactory receptors, family 4",ENST00000641200.1,2.0,+,Q8NGD0,False,,,,0.4039900249376558,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.407885,,0.191,2.0,,,,,,,ACH-002098,441670.0
chr18,61816181,G,A,0.424,15,12,0/1,,SNP,MISSENSE,c.283C>T,p.P95S,RNF152,ring finger protein 152,Ring finger proteins,ENST00000312828.4,2.0,-,Q8N8N0,False,,,,0.6533665835411472,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.937347,,0.603,3.0,,,,,,,ACH-002098,220441.0
chr4,152326137,G,A,0.468,83,75,0/1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-002222,55294.0
chr10,133391346,G,A,0.48,62,57,0/1,,SNP,MISSENSE,c.1427G>A,p.R476H,PAOX,polyamine oxidase,,ENST00000278060.10,7.0,+,Q6QHF9,False,rs1472318687,,as_specific,0.5810473815461347,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.345895,,0.619,2.0,,,,,,,ACH-002222,196743.0
chr1,114716127,C,T,0.506,304,312,0/1,,SNP,MISSENSE,c.34G>A,p.G12S,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913250,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,,898.0,,7.5,7.3,True,False,False,,0.864195,0.3336378450149014,0.612,4.0,,,,,,,ACH-000937,4893.0
chr9,136504970,A,G,0.513,125,132,0/1,,SNP,MISSENSE,c.4721T>C,p.L1574P,NOTCH1,notch 1,Ankyrin repeat domain containing,ENST00000651671.1,26.0,-,P46531,False,,,,0.6932668329177057,L,Dom,False,TRB@,True,p.L1574P(54) p.L1574fs*36(8) p.V1578delV(6) p.?(1) p.V1577_V1578delVV(1) p.L1574Q(2) p.L1574del(1) p.T1573_L1574insSAPR(1),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,ENST00000277541;,1032.0,,0.0,7.3,True,True,False,,0.811351,0.9680881359582952,0.958,3.0,,,,,,,ACH-000937,4851.0
chr11,5678303,C,T,0.415,91,58,0/1,,SNP,SILENT,c.645G>A,p.T215T,TRIM5,tripartite motif containing 5,Tripartite motif containing Ring finger proteins,ENST00000380034.8,4.0,-,Q9C035,False,rs771117948,,as_specific,0.4688279301745636,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,POLE:7,0.410767,0.4623552778383785,,0.0,,,,,,,ACH-000937,85363.0
chr17,7673802,C,T,0.278,539,212,0|1,7673802.0,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000937,7157.0
chr12,25225627,G,A,0.616,69,109,0/1,,SNP,MISSENSE,c.437C>T,p.A146V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs1057519725,,as_specific,0.3291770573566084,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1) p.T148fs*6(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,322.0,,8.0,7.3,True,False,False,,0.940928,0.6906510308302181,0.89,4.0,,,,,,,ACH-000218,3845.0
chr3,10142110,G,A,0.962,9,274,1|1,,SNP,NONSENSE,c.263G>A,p.W88*,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,rs119103277,,as_specific,0.7007481296758105,"""E, M, O""",Rec,True,,True,p.W88R(9) p.W88G(3) p.W88S(2) p.W88*(14) p.V84_E94>E(1) p.W88L(7) p.W88fs*71(3) p.W88C(5) p.W88fs*73(1) p.V87_W88>G(1) p.W88fs*74(1) p.V87_W88del(2) p.W88fs*43(2) p.W88fs*41(1) p.V84fs*69(1) p.R60fs*35(1) p.P86fs*42(1) p.W88fs*44(2) p.W88fs*40(1) p.F76fs*24(1),cancer;gene_function_loss;,False,False,True,,2151.0,,7.5,7.3,False,True,False,,0.96361,0.3692731779548656,,5.0,,,,,,,ACH-000246,7428.0
chr3,41224645,T,C,0.554,36,45,0/1,,SNP,MISSENSE,c.133T>C,p.S45P,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913407,,as_specific,0.3940149625935162,"""E, M, O""",Dom,False,PLAG1,True,p.S45F(831) p.A5_A80del(75) p.S45P(400) p.S45S(1) p.A5_Q143del(7) p.S45T(2) p.S45C(34) p.S45del(114) p.T42_K49>Q(1) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.S45Y(35) p.S45A(21) p.A5_E54del(1) p.M8_L132del(1) p.S45_E54del(1) p.S45N(7) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.S45_S47>C(3) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.T40_L46del(1) p.P44_S45insGATTTAP(1) p.G38_S45del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.A20_R151del(1) p.S45_D58del(1) p.E9_S47del(1) p.P44_S45>AP(1) p.A43_E54del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.I35_K170del(1) p.S45E(1) p.S45_G50del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.S45?(1) p.A43_E53del(2) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.P44_S45insAP(1) p.A5_D144>D(1) p.V22_T102del(1) p.P44_N51del(1) p.P44_S45del(2) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.A5_R90del(1) p.Y30_A97del(1) p.S45_G48del(1) p.T41_N51del(1) p.I35_L46del(1) p.V22_A80del(1) p.S45fs*2(1) p.A21_A152del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.S23_I140del(1) p.A39fs*3(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.T42_G48del(1) p.S45_L46del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1287.0,,35.0,7.3,True,False,True,Misc:18,0.926649,0.7080623709261032,0.338,4.0,,,,,,,ACH-000182,1499.0
chr3,179218304,A,C,0.569,22,31,0/1,,SNP,MISSENSE,c.1634A>C,p.E545A,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913274,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;,,,,7.3,True,False,True,Misc:14,0.929104,0.8384288221013635,0.715,3.0,,,,,,,ACH-000182,5290.0
chr12,25245350,C,T,0.98,0,60,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000182,3845.0
chr18,51065549,G,A,0.947,1,40,1|1,,SNP,MISSENSE,c.794G>A,p.R265H,SMAD4,SMAD family member 4,SMAD family,ENST00000588745.5,5.0,+,Q13485,False,rs377767347,,as_specific,0.3740648379052369,,,False,,True,p.R361H(38) p.0(28) p.T265I(1),cancer;gene_function_loss;,False,False,True,ENST00000398417;ENST00000342988;ENST00000588745;,,,,7.3,False,True,True,"CpG:5,POLE:1",0.950582,,0.955,3.0,,,,,,,ACH-000182,4089.0
chr1,114716127,C,A,0.44,91,74,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913250,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,897.0,,0.0,7.3,True,False,True,"smoking:1,MSI:1,Misc:1",0.849577,,0.773,4.0,,,,,,,ACH-000770,4893.0
chr10,87864488,G,T,0.395,104,63,0/1,,SNP,NONSENSE,c.19G>T,p.E7*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,1.0,+,P60484,False,,,,0.5187032418952618,"""L, E, M, O""",Rec,True,,True,p.E7*(20) p.0(28) p.E7fs*17(3) p.A3fs*14(1) p.E7fs*3(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:11,0.975157,,,4.0,,,,,,,ACH-000770,5728.0
chr12,11885968,C,T,0.501,87,88,0/1,,SNP,MISSENSE,c.1195C>T,p.R399C,ETV6,ETS variant 6,ETS transcription factor family,ENST00000396373.9,7.0,+,P41212,False,rs724159945,,as_specific,0.456359102244389,"""L, E, M""",Dom,False,"""NTRK3, RUNX1, PDGFRB, ABL1, MN1, ABL2, FACL6, CHIC2, ARNT, JAK2, EVI1, CDX2, STL, HLXB9, MDS2, PER1, SYK, TTL, FGFR3, PAX5""",False,p.R399S(1) p.R399P(1),cancer;gene_function_loss;structural_relation;,False,False,True,ENST00000396373;,811.0,,0.0,7.3,False,True,False,,0.788245,0.4701281260891469,0.897,3.0,,,,,,,ACH-000770,2120.0
chr17,7674256,T,C,0.44,27,22,0/1,,SNP,MISSENSE,c.707A>G,p.Y236C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs730882026,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y236delY(4) p.Y236C(58) p.H233_C242del10(1) p.Y236N(21) p.Y236*(13) p.Y236H(13) p.Y236D(6) p.H233fs*6(1) p.Y236_M237>*(1) p.Y236S(4) p.Y236fs*5(1) p.V225fs*23(1) p.Y236Y(2) p.Y236fs*4(2) p.I232_Y236delIHYNY(1) p.?(1) p.Y236_M243delYMCNSSCM(1) p.N235_Y236delNY(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:5,0.844922,0.9351637534056272,0.811,2.0,,,,,,,ACH-000770,7157.0
chr17,7674945,G,A,0.535,21,23,0/1,,SNP,NONSENSE,c.586C>T,p.R196*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516435,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R196*(221) p.R196P(18) p.R196Q(5) p.R196R(6) p.I195fs*12(1) p.R196_R202del(1) p.R196fs*51(4) p.I195_G199delIRVEG(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.R196L(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.R196fs*13(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.986209,0.7393785927987923,,4.0,,,,,,,ACH-000770,7157.0
chr17,7674241,G,C,0.822,4,23,0/1,,SNP,MISSENSE,c.722C>G,p.S241C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"APOBEC:1,Misc:2",0.900614,0.9732631616330862,0.952,3.0,,,,,,,ACH-001136,7157.0
chr3,179218303,G,A,0.382,111,69,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000490,5290.0
chr17,7675208,C,A,0.993,0,140,1|1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-001389,7157.0
chr3,179218294,G,A,0.993,0,165,1|1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-001551,5290.0
chr8,140535501,G,A,0.433,148,112,0/1,,SNP,SILENT,c.2238C>T,p.F746F,AGO2,"argonaute 2, RISC catalytic component",Argonaute/PIWI family,ENST00000220592.10,17.0,-,Q9UKV8,False,rs1012373565,,as_specific,0.6084788029925187,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"CpG:1,UV:1,POLE:6",0.781183,0.4352903356799667,,0.0,,,,,,,ACH-001551,27161.0
chr12,25245350,C,T,0.577,11,14,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001199,3845.0
chr17,7673802,C,T,0.419,17,12,0|1,7673802.0,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001199,7157.0
chr17,7673803,G,A,0.567,12,16,1|0,7673802.0,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001199,7157.0
chr17,39723405,G,A,0.472,33,28,0/1,,SNP,MISSENSE,c.2033G>A,p.R678Q,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,17.0,+,P04626,False,rs1057519862,,as_specific,0.6359102244389028,E,Dom,False,,False,p.R678Q(3) p.R678L(1),cancer;gene_function_gain;,False,False,True,,42.0,"ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.",5.0,7.3,True,False,True,CpG:9,0.905915,0.5881956277268189,0.417,4.0,,,,,,,ACH-001199,2064.0
chr2,178704933,C,T,0.319,94,44,0/1,,SNP,MISSENSE,c.25906G>A,p.E8636K,TTN,titin,Fibronectin type III domain containing I-set domain containing Immunoglobulin like domain containing,ENST00000342992.10,101.0,-,Q8WZ42,False,rs532933900,,as_specific,0.3266832917705736,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"UV:6,POLE:2",0.929445,0.6903741952482925,0.247,3.0,,,,,,,ACH-000765,7273.0
chr7,140753336,A,T,0.59,72,107,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000765,673.0
chr7,140753336,A,T,0.998,0,514,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001838,673.0
chr17,7674962,G,A,0.998,1,443,1|1,,SNP,MISSENSE,c.569C>T,p.P190L,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs876660825,,as_specific,0.5935162094763092,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.P190S(8) p.P190L(30) p.P190F(3) p.P190R(4) p.P190T(5) p.P190P(1) p.?(2) p.P191fs*18(1) p.G187fs*16(2) p.D186_P191delDGLAPP(1) p.P190fs*57(7) p.P190A(2) p.A189_V197delAPPQHLIRV(4) p.P191delP(7) p.A189_P190>X(4) p.A189fs*53(1) p.K164_P219del(1) p.A189_Q192>E(1) p.P190fs*19(1) p.P190H(1) p.P190N(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:4",0.797286,0.4577985545630186,0.824,3.0,,,,,,,ACH-001838,7157.0
chr12,25245350,C,T,0.695,187,420,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001394,3845.0
chr17,7673803,G,A,0.924,33,386,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001394,7157.0
chr17,7673764,C,T,0.998,0,456,1|1,,SNP,MISSENSE,c.856G>A,p.E286K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs786201059,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E286G(17) p.E286K(94) p.E286fs*59(2) p.R283fs*16(2) p.E286*(17) p.E286V(9) p.E286fs*17(2) p.E286Q(7) p.E286D(2) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.R283fs*56(1) p.V272_K292del21(1) p.E286A(2) p.E286E(2) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:3,Misc:1",0.93585,0.6532670016064752,0.949,3.0,,,,,,,ACH-000152,7157.0
chr17,7674230,C,T,0.995,0,204,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-002349,7157.0
chr17,7675124,T,C,0.966,0,32,1|1,,SNP,MISSENSE,c.488A>G,p.Y163C,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs148924904,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y163C(136) p.0(9) p.S149fs*72(1) p.Y163fs*1(2) p.Y163H(19) p.Y163N(20) p.A159_Q167delAMAIYKQSQ(1) p.Y163S(5) p.Y163*(8) p.Y163fs*14(1) p.A159_M169del(1) p.Y163_Q165delYKQ(1) p.Y163D(4) p.Y163del(1) p.Y163Y(3) p.P151_V173del23(1) p.I162_Y163delIY(1) p.Y163fs*7(2) p.V157_C176del20(1) p.Y163fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:11,0.897865,0.7273008533507418,0.872,3.0,,,,,,,ACH-000603,7157.0
chr12,25245351,C,A,0.855,18,111,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000438,3845.0
chr17,7675994,C,A,0.972,1,68,1|1,,SNP,SPLICE_SITE,c.375G>T,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:12,MSI:1,Misc:4",0.468898,0.7805428798268306,,0.0,,,,,,,ACH-000438,7157.0
chr17,7674894,G,A,0.98,0,51,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-002101,7157.0
chr17,7675145,C,G,0.951,2,56,1|1,,SNP,MISSENSE,c.467G>C,p.R156P,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S149fs*72(1) p.R156P(22) p.R156fs*14(12) p.G154fs*22(1) p.R156G(4) p.V157_R158delVR(1) p.R156C(6) p.R156R(3) p.G154_R156delGTR(1) p.R156fs*25(7) p.T155fs*23(2) p.R156L(3) p.R156H(10) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156S(3) p.R156fs*18(1) p.R156fs*12(1) p.T155_V157>I(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.T155_R156delTR(1) p.R156fs*?(1) p.R156delR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:2,Misc:2",0.890792,0.8157253021490875,0.609,3.0,,,,,,,ACH-000613,7157.0
chr1,114713907,T,G,0.508,84,89,0/1,,SNP,MISSENSE,c.183A>C,p.Q61H,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913255,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.E62fs*6(3) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,893.0,,0.0,7.3,True,False,True,"Eso:1,Misc:1",0.749252,0.6040398297406732,0.742,4.0,,,,,,,ACH-002262,4893.0
chr17,7675088,C,T,0.962,0,26,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002262,7157.0
chr17,7673802,C,T,0.996,1,401,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-002046,7157.0
chr1,114713907,T,G,0.471,128,110,0/1,,SNP,MISSENSE,c.183A>C,p.Q61H,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913255,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.E62fs*6(3) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,893.0,,0.0,7.3,True,False,True,"Eso:1,Misc:1",0.749252,0.6040398297406732,0.742,4.0,,,,,,,ACH-002388,4893.0
chr11,5323810,G,A,0.988,0,78,1|1,,SNP,MISSENSE,c.488C>T,p.S163L,OR51B2,olfactory receptor family 51 subfamily B member 2 (gene/pseudogene),"Olfactory receptors, family 51",ENST00000624187.1,1.0,-,Q9Y5P1,False,,,,0.4014962593516209,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.273412,0.3464979020387665,0.034,1.0,,,,,,,ACH-002388,79345.0
chr19,55858466,G,A,0.447,22,16,0/1,,SNP,MISSENSE,c.1073G>A,p.G358E,NLRP4,NLR family pyrin domain containing 4,NLR family Pyrin domain containing,ENST00000301295.11,3.0,+,Q96MN2,False,,,,0.516209476309227,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.382828,0.9027213330001864,0.437,3.0,,,,,,,ACH-002388,147945.0
chr19,58499498,G,A,0.594,12,18,0/1,,SNP,MISSENSE,c.1409C>T,p.T470I,SLC27A5,solute carrier family 27 member 5,Solute carriers Acyl-CoA synthetase family,ENST00000601355.1,7.0,-,Q9Y2P5,False,,,,0.6533665835411472,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:13,0.911109,0.5951441230767975,0.581,2.0,,,,,,,ACH-002388,10998.0
chr2,74415153,T,G,0.57,4,6,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000106,388963.0
chr17,7674953,T,G,0.976,0,40,1|1,,SNP,MISSENSE,c.578A>C,p.H193P,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs786201838,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193L(40) p.H193_I195delHLI(1) p.H193R(78) p.H193Y(29) p.?(2) p.H193D(10) p.H193P(15) p.H193N(7) p.P191fs*53(2) p.A189_V197delAPPQHLIRV(4) p.H193H(2) p.H193fs*16(3) p.A189fs*53(1) p.P191fs*6(1) p.K164_P219del(1) p.H193_I195>AP(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:6",0.936401,0.7616704397151225,0.87,3.0,,,,,,,ACH-000239,7157.0
chr4,1801841,C,G,0.995,0,202,1|1,,SNP,MISSENSE,c.746C>G,p.S249C,FGFR3,fibroblast growth factor receptor 3,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000481110.6,7.0,+,P22607,False,rs121913483,,as_specific,0.685785536159601,"""L, E""",Dom,False,"""IGH@, ETV6""",True,p.S249C(2119) p.R248_S249insC(1) p.R248_S249delRS(1) p.R248_S249insL(1) p.S249T(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000440486;ENST00000481110;ENST00000340107;ENST00000412135;ENST00000613647;ENST00000352904;ENST00000507588;,628.0,,11.0,7.3,True,False,True,"smoking:1,APOBEC:29,Misc:1",0.910414,0.5885492886327983,0.902,3.0,,,,,,,ACH-001408,2261.0
chr17,7673781,C,G,0.997,0,311,1|1,,SNP,MISSENSE,c.839G>C,p.R280T,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912660,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R280T(73) p.R280fs*65(9) p.R280I(15) p.R280K(54) p.R280S(17) p.R280G(33) p.R280_R283>S(1) p.R280*(14) p.D281fs*24(1) p.S269fs*21(1) p.F270_D281del12(1) p.R280fs*?(1) p.V272_K292del21(1) p.D281_R282delDR(2) p.R280R(3) p.A276fs*64(1) p.R280fs*64(1) p.G279_R280delGR(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:19,0.96317,0.7002446792674034,0.94,3.0,,,,,,,ACH-001408,7157.0
chr9,21971187,G,A,0.993,1,297,1|1,,SNP,NONSENSE,c.19C>T,p.R7*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913387,,as_specific,0.6458852867830424,,,True,,True,p.0(1543) p.R58*(112) p.A4_P11del(12) p.V28_V51del(1) p.?(5) p.M54fs*61(2) p.R58fs*61(2) p.P3_P11del(2) p.R58fs*59(2) p.M53_R58del(3) p.A57fs*85(1) p.A57_R58>V*(1) p.G55fs*86(1) p.G55fs*61(1) p.S7_A19del(1) p.R58fs*62(1) p.R58R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:10,UV:4",0.788085,0.9908618465891524,0.22,5.0,,,,,,,ACH-001346,1029.0
chr17,7674233,C,A,0.998,0,469,1|1,,SNP,MISSENSE,c.730G>T,p.G244C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs1057519989,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,MSI:1",0.967868,0.7256135967181565,0.94,3.0,,,,,,,ACH-001346,7157.0
chr6,27807658,G,A,0.681,110,221,0/1,,SNP,SILENT,c.249C>T,p.H83H,H2BC13,,,ENST00000377401.3,1.0,-,,False,rs147149614,,as_specific,0.5785536159600998,,,False,,False,,cancer;,False,False,True,,,,,3.91,False,False,True,Misc:1,0.134151,0.7535661040960056,,0.0,,,,,,,ACH-001573,8340.0
chr17,7674945,G,A,0.989,2,269,1|1,,SNP,NONSENSE,c.586C>T,p.R196*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516435,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R196*(221) p.R196P(18) p.R196Q(5) p.R196R(6) p.I195fs*12(1) p.R196_R202del(1) p.R196fs*51(4) p.I195_G199delIRVEG(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.R196L(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.R196fs*13(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.986209,0.7393785927987923,,4.0,,,,,,,ACH-001573,7157.0
chr12,25245350,C,T,0.696,7,16,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000286,3845.0
chr17,7674962,G,A,0.983,0,60,1|1,,SNP,MISSENSE,c.569C>T,p.P190L,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs876660825,,as_specific,0.5935162094763092,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.P190S(8) p.P190L(30) p.P190F(3) p.P190R(4) p.P190T(5) p.P190P(1) p.?(2) p.P191fs*18(1) p.G187fs*16(2) p.D186_P191delDGLAPP(1) p.P190fs*57(7) p.P190A(2) p.A189_V197delAPPQHLIRV(4) p.P191delP(7) p.A189_P190>X(4) p.A189fs*53(1) p.K164_P219del(1) p.A189_Q192>E(1) p.P190fs*19(1) p.P190H(1) p.P190N(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:4",0.797286,0.4577985545630186,0.824,3.0,,,,,,,ACH-000286,7157.0
chr7,140753336,A,T,0.996,0,253,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002005,673.0
chr9,21971187,G,A,0.995,0,198,1|1,,SNP,NONSENSE,c.19C>T,p.R7*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913387,,as_specific,0.6458852867830424,,,True,,True,p.0(1543) p.R58*(112) p.A4_P11del(12) p.V28_V51del(1) p.?(5) p.M54fs*61(2) p.R58fs*61(2) p.P3_P11del(2) p.R58fs*59(2) p.M53_R58del(3) p.A57fs*85(1) p.A57_R58>V*(1) p.G55fs*86(1) p.G55fs*61(1) p.S7_A19del(1) p.R58fs*62(1) p.R58R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:10,UV:4",0.788085,0.9908618465891524,0.22,5.0,,,,,,,ACH-002005,1029.0
chr9,134728709,G,A,0.228,219,67,0/1,,SNP,MISSENSE,c.826G>A,p.E276K,COL5A1,collagen type V alpha 1 chain,Collagens,ENST00000371817.8,6.0,+,P20908,False,rs776904091,,as_specific,0.6508728179551122,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"CpG:1,UV:5",0.932935,0.685208390871408,0.549,3.0,,,,,,,ACH-002005,1289.0
chr12,25245350,C,T,0.53,31,35,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000949,3845.0
chr17,7673803,G,A,0.639,13,22,0/1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000949,7157.0
chr17,59213312,C,T,0.434,132,101,0/1,,SNP,MISSENSE,c.2489C>T,p.A830V,SMG8,"SMG8, nonsense mediated mRNA decay factor",,ENST00000543872.6,4.0,+,Q8ND04,False,rs765179613,,as_specific,0.4413965087281795,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.786654,,0.093,2.0,,,,,,,ACH-000949,55181.0
chr19,47069155,C,G,0.52,38,40,0/1,,SNP,MISSENSE,c.2335G>C,p.E779Q,ZC3H4,zinc finger CCCH-type containing 4,Zinc fingers CCCH-type,ENST00000253048.10,14.0,-,Q9UPT8,False,rs756950439,,as_specific,0.6783042394014963,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:4,0.890018,0.4849699719102638,0.121,3.0,,,,,,,ACH-000949,23211.0
chr17,7670685,G,A,0.909,4,53,1|1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-000622,7157.0
chr17,7674216,C,A,0.943,1,41,1|1,,SNP,MISSENSE,c.747G>T,p.R249S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934571,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.P250fs*14(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:5,Misc:13",0.776711,,0.769,2.0,,,,,,,ACH-000331,7157.0
chr17,7675088,C,T,0.998,1,568,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000128,7157.0
chr17,7673802,C,T,0.999,0,828,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001172,7157.0
chr3,138655402,T,A,0.717,36,92,0/1,,SNP,MISSENSE,c.3200A>T,p.D1067V,PIK3CB,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit beta,Phosphatidylinositol 3-kinase subunits,ENST00000674063.1,24.0,-,P42338,False,,,,0.3965087281795511,,,False,,False,p.D1067V(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:2,0.877675,0.8684901576871266,0.65,4.0,,,,,,,ACH-000555,5291.0
chr1,114713909,G,T,0.632,73,129,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000801,4893.0
chr6,56069053,C,T,0.563,6,10,0/1,,SNP,MISSENSE,c.2084G>A,p.G695E,COL21A1,collagen type XXI alpha 1 chain,Collagens,ENST00000244728.10,22.0,-,Q96P44,False,rs769722166,,as_specific,0.3491271820448878,,,False,,False,,cancer;,False,False,True,ENST00000244728;ENST00000370819;ENST00000535941;,,,,7.3,False,False,True,UV:6,0.793911,0.8745009108264294,0.955,2.0,,,,,,,ACH-000801,81578.0
chr17,7674218,T,C,0.458,40,31,0/1,,SNP,MISSENSE,c.745A>G,p.R249G,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782082,,as_specific,0.5610972568578554,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.N247_R248delNR(2) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,Misc:3,0.96222,0.7229412758792237,0.888,2.0,,,,,,,ACH-000656,7157.0
chr12,25245350,C,T,0.868,1,13,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000468,3845.0
chr4,55090053,C,T,0.994,0,176,1|1,,SNP,MISSENSE,c.3095G>A,p.R1032Q,KDR,kinase insert domain receptor,I-set domain containing CD molecules V-set domain containing Immunoglobulin like domain containing Receptor Tyrosine Kinases,ENST00000263923.5,23.0,-,P35968,False,rs1190050670,,as_specific,0.4139650872817955,E,Dom,False,,False,p.R1032Q(3) p.R1032*(2),cancer;gene_function_gain;,False,False,True,ENST00000645273;ENST00000263923;,,,,7.3,True,False,True,"UV:7,POLE:2",0.936328,0.7230888046184373,0.844,4.0,,,,,,,ACH-001524,3791.0
chr4,24548907,C,T,0.202,62,16,0/1,,SNP,MISSENSE,c.1196G>A,p.R399H,DHX15,DEAH-box helicase 15,Spliceosomal B complex DEAH-box helicases Spliceosomal A complex U11/U12 di-snRNP,ENST00000336812.5,6.0,-,O43143,False,rs754378482,,as_specific,0.3266832917705736,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:2,POLE_MSI:1",0.932829,0.4610615767862259,0.576,4.0,,,,,,,ACH-002200,1665.0
chr17,7673823,C,A,0.582,10,14,0/1,,SNP,MISSENSE,c.797G>T,p.G266V,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs193920774,,as_specific,0.5236907730673317,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G266V(35) p.G266R(59) p.G266E(59) p.G262_S269delGNLLGRNS(2) p.G266_E271delGRNSFE(2) p.G266fs*79(6) p.G266fs*9(1) p.G266*(14) p.E258fs*71(1) p.G266S(1) p.G266G(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.G266T(1) p.G266A(3) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:8",0.944543,0.742718688783359,0.974,3.0,,,,,,,ACH-002200,7157.0
chr17,7675157,G,A,0.243,32,9,0/1,,SNP,MISSENSE,c.455C>T,p.P152L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782705,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.P152fs*18(21) p.P152P(6) p.0(9) p.P152S(29) p.S149fs*72(1) p.P152L(75) p.P153fs*28(7) p.P152_P153insXXX(1) p.P152T(9) p.P152fs*14(6) p.P152A(2) p.P153fs*16(2) p.P152Q(4) p.P152R(7) p.P152fs*28(3) p.D148fs*23(1) p.T150fs*16(4) p.P152fs*27(1) p.P152fs*29(6) p.V143_P153del(1) p.P151_V173del23(1) p.T150_P153delTPPP(2) p.Q144_G154del11(1) p.P152_P153delPP(1) p.D148_T155delDSTPPPGT(1) p.S149fs*17(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"CpG:2,UV:1",0.952593,0.8618240470838262,0.878,3.0,,,,,,,ACH-002200,7157.0
chr12,25245350,C,A,0.953,0,21,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000467,3845.0
chr17,7674944,C,G,0.963,0,26,1|1,,SNP,MISSENSE,c.587G>C,p.R196P,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs483352697,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R196*(221) p.R196P(18) p.R196Q(5) p.R196R(6) p.R196_R202del(1) p.R196fs*51(4) p.I195_G199delIRVEG(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.R196L(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.R196fs*13(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,APOBEC:2,0.969161,0.7228582979881565,0.941,3.0,,,,,,,ACH-000467,7157.0
chr17,7674872,T,C,0.996,0,297,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-001419,7157.0
chr12,25245347,C,T,0.783,163,571,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-001850,3845.0
chr17,7673776,G,A,0.999,2,1358,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-001850,7157.0
chr2,74415153,T,G,0.6,1,2,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-001383,388963.0
chr6,56069053,C,T,0.43,58,45,0/1,,SNP,MISSENSE,c.2084G>A,p.G695E,COL21A1,collagen type XXI alpha 1 chain,Collagens,ENST00000244728.10,22.0,-,Q96P44,False,rs769722166,,as_specific,0.3491271820448878,,,False,,False,,cancer;,False,False,True,ENST00000244728;ENST00000370819;ENST00000535941;,,,,7.3,False,False,True,UV:6,0.793911,0.8745009108264294,0.955,2.0,,,,,,,ACH-002371,81578.0
chr17,7676040,C,A,0.996,0,257,1|1,,SNP,MISSENSE,c.329G>T,p.R110L,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs11540654,,as_specific,0.5536159600997507,"""L, E, M, O""",Rec,False,NTRK1,True,p.R110P(13) p.0(9) p.R110C(15) p.R110L(25) p.G59fs*23(3) p.R110fs*13(7) p.R110fs*18(1) p.Y103_G112>C(1) p.R110S(1) p.R110H(4) p.F109_R110insXX(1) p.F109_R110delFR(2) p.M1_T125del(1) p.R110fs*?(1) p.G105_T125del21(1) p.Y107fs*38(1) p.R110fs*39(1) p.Y107fs*44(1) p.S33fs*23(1) p.V73fs*9(1) p.S95fs*37(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:4,Misc:2",0.730165,,0.632,2.0,,,,,,,ACH-000366,7157.0
chr17,7675224,G,C,0.724,1,4,0/1,,SNP,MISSENSE,c.388C>G,p.L130V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs863224683,,as_specific,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.L130V(15) p.A129_K132delALNK(1) p.L130P(5) p.L130R(6) p.L130L(4) p.L130fs*19(3) p.L130H(7) p.L130F(6) p.L130Sfs*?(1) p.L130fs*41(1) p.L130_M133delLNKM(1) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.L130fs*40(2) p.S127fs*36(1) p.?(1) p.A129_N131delALN(1) p.L130delL(1) p.P128fs*17(1) p.Y126_N131delYSPALN(3) p.A129_L130insXX(1) p.Y126fs*11(1) p.L130fs*39(1) p.N131fs*27(1) p.V73fs*9(1) p.L130fs*16(1) p.Y126fs*18(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:4,0.87451,0.3245416644848618,0.887,3.0,,,,,,,ACH-001639,7157.0
chr2,208248389,G,C,0.422,29,20,0/1,,SNP,MISSENSE,c.394C>G,p.R132G,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",,ENST00000415913.5,4.0,-,O75874,False,rs121913499,,as_specific,0.3790523690773067,O,Dom,False,,True,p.R132C(1014) p.R132H(6941) p.R132S(229) p.R132?(201) p.R132G(285) p.R132L(126) p.R132P(1) p.R132V(1) p.G131_R132>VL(1),cancer;gene_function_gain;,False,False,True,ENST00000345146;ENST00000446179;ENST00000415913;ENST00000415282;,927.0,,0.0,7.3,True,False,True,"APOBEC:1,Misc:6",0.962673,,0.893,2.0,,,,,,,ACH-002094,3417.0
chr17,7674229,C,T,0.995,1,406,1|1,,SNP,MISSENSE,c.734G>A,p.G245D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912656,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:9,0.965383,0.9964714944038346,0.974,3.0,,,,,,,ACH-001617,7157.0
chr3,179218303,G,A,0.63,21,36,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000028,5290.0
chr12,4518087,C,T,0.393,63,39,0/1,,SNP,MISSENSE,c.1004G>A,p.R335Q,C12orf4,chromosome 12 open reading frame 4,,ENST00000261250.8,8.0,-,Q9NQ89,False,rs532268400,,as_specific,0.3591022443890274,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.977517,0.5996129798173001,0.258,3.0,,,,,,,ACH-000028,57102.0
chr17,7675095,C,T,0.984,0,64,1|1,,SNP,MISSENSE,c.517G>A,p.V173M,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs876660754,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V173V(8) p.V173L(71) p.S149fs*72(1) p.V173fs*7(2) p.V173G(8) p.V173M(56) p.V173fs*59(2) p.V173E(4) p.V173W(1) p.V173fs*1(4) p.H168fs*23(1) p.V173fs*69(1) p.V173A(13) p.E171fs*1(1) p.P151_V173del23(1) p.E171fs*61(1) p.V173fs*8(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.V173*(1) p.V172_R174delVVR(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:1,0.933723,,0.892,3.0,,,,,,,ACH-002280,7157.0
chr1,114716124,C,G,0.423,195,137,0/1,,SNP,MISSENSE,c.37G>C,p.G13R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121434595,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G13D(361) p.G13V(89) p.G13R(150) p.G13G(4) p.G13A(16) p.G13C(39) p.G13Y(1) p.G13S(16) p.G13N(3),cancer;gene_function_gain;,False,False,True,ENST00000369535;,896.0,,2.5,7.3,True,False,True,"smoking:1,Misc:5",0.837442,0.2725070107592524,0.763,4.0,,,,,,,ACH-001563,4893.0
chr2,178719346,G,A,0.404,113,75,0/1,,SNP,MISSENSE,c.20312C>T,p.S6771L,TTN,titin,Fibronectin type III domain containing I-set domain containing Immunoglobulin like domain containing,ENST00000342992.10,80.0,-,Q8WZ42,False,,,,0.486284289276808,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:4,APOBEC:1",0.802671,0.7578309760700238,0.36,3.0,,,,,,,ACH-001563,7273.0
chr2,208248389,G,A,0.344,128,69,0/1,,SNP,MISSENSE,c.394C>T,p.R132C,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",,ENST00000415913.5,4.0,-,O75874,False,rs121913499,,as_specific,0.3790523690773067,O,Dom,False,,True,p.R132C(1014) p.R132H(6941) p.R132S(229) p.R132?(201) p.R132G(285) p.R132L(126) p.R132P(1) p.R132V(1) p.G131_R132>VL(1),splicing;cancer;gene_function_gain;,False,True,True,ENST00000345146;ENST00000446179;ENST00000415913;ENST00000415282;,59.0,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",53.0,7.3,True,False,True,"CpG:19,MSI:1,UV:15",0.961719,0.6398382252727418,0.814,2.0,,,,,,,ACH-001563,3417.0
chr7,140753336,A,T,0.998,0,691,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002001,673.0
chr2,177234076,C,T,0.469,98,93,0/1,,SNP,MISSENSE,c.193G>A,p.G65S,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.4089775561097257,E,Dom,False,,False,p.G81_F83delGEF(2) p.G81S(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:1,0.88056,0.4432380589086047,0.511,3.0,,,,,,,ACH-000026,4780.0
chr3,179218304,A,G,0.211,84,19,0/1,,SNP,MISSENSE,c.1634A>G,p.E545G,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913274,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;,883.0,,2.0,7.3,True,False,True,Misc:2,0.960085,0.8156814306896972,0.737,3.0,,,,,,,ACH-000026,5290.0
chr1,114713908,T,A,0.959,13,307,1|1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000868,4893.0
chr1,160283623,G,A,0.164,214,41,0/1,,SNP,SILENT,c.87C>T,p.F29F,PEX19,peroxisomal biogenesis factor 19,Peroxins,ENST00000368072.9,2.0,-,P40855,False,rs141911166,,as_specific,0.5411471321695761,,,False,,False,,cancer;,False,False,True,,,,,3.53,False,False,True,POLE:5,0.71287,0.5566091566815916,,0.0,,,,,,,ACH-000868,5824.0
chr10,87864518,C,T,0.988,0,90,1|1,,SNP,NONSENSE,c.49C>T,p.Q17*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,1.0,+,P60484,False,rs786204910,,as_specific,0.5037406483790524,"""L, E, M, O""",Rec,True,,True,p.Q17*(12) p.Y16fs*1(1) p.0(28) p.R14fs*26(1) p.Y16fs*21(1) p.R15fs*23(1) p.Q17del(1) p.Q17P(2) p.N12fs*6(1) p.R14_D22del(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,APOBEC:3,0.976608,0.8359760735844961,,4.0,,,,,,,ACH-000707,5728.0
chr17,7673761,C,A,0.531,16,17,0/1,,SNP,NONSENSE,c.859G>T,p.E287*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,,,,0.5311720698254364,"""L, E, M, O""",Rec,True,NTRK1,True,p.E287K(12) p.E287D(11) p.0(9) p.E287G(2) p.E287*(13) p.R283fs*16(2) p.N288fs*13(17) p.E286fs*17(2) p.E285fs*13(1) p.T284fs*57(1) p.E287E(5) p.E287fs*17(1) p.R283fs*56(1) p.V272_K292del21(1) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.E287V(1) p.L265_K305del41(1) p.E285_N288del(1) p.T284_G293del10(1) p.E287fs*53(1) p.E287A(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,smoking:1,0.988925,0.7193251369009958,,4.0,,,,,,,ACH-000707,7157.0
chr17,7675125,A,G,0.381,28,18,0/1,,SNP,MISSENSE,c.487T>C,p.Y163H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786203436,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y163C(136) p.0(9) p.S149fs*72(1) p.Y163fs*1(2) p.Y163H(19) p.Y163N(20) p.A159_Q167delAMAIYKQSQ(1) p.Y163S(5) p.Y163*(8) p.Y163fs*14(1) p.A159_M169del(1) p.Y163_Q165delYKQ(1) p.Y163D(4) p.Y163del(1) p.Y163Y(3) p.P151_V173del23(1) p.I162_Y163delIY(1) p.Y163fs*7(2) p.V157_C176del20(1) p.A161fs*7(1) p.Y163fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:3,0.942416,0.7260651472113124,0.904,3.0,,,,,,,ACH-000707,7157.0
chr3,179234297,A,T,0.694,58,137,0/1,,SNP,MISSENSE,c.3140A>T,p.H1047L,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,1151.0,,12.5,7.3,True,False,True,"APOBEC:1,Misc:27",0.829278,,0.359,3.0,,,,,,,ACH-002169,5290.0
chr17,7674262,T,C,0.97,0,32,1|1,,SNP,MISSENSE,c.701A>G,p.Y234C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587780073,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y234C(87) p.Y234N(13) p.T230_Y234delTTIHY(1) p.H233_C242del10(1) p.Y234S(8) p.Y234fs*6(1) p.Y234D(7) p.Y234fs*4(1) p.D228fs*12(1) p.H233fs*6(1) p.Y234*(15) p.Y234delY(4) p.Y234fs*11(1) p.Y234H(23) p.I232fs*5(1) p.Y234fs*15(1) p.Y234F(1) p.Y234fs*1(1) p.V225fs*23(1) p.Y234fs*5(1) p.I232_Y236delIHYNY(1) p.?(1) p.Y234del(2) p.Y234R(1) p.Y234Y(1) p.Y234_N235insX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1068.0,,0.0,7.3,False,True,True,Misc:7,0.865205,0.7361252184832682,0.945,3.0,,,,,,,ACH-002169,7157.0
chr17,7673803,G,A,0.903,0,9,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000342,7157.0
chr12,25245350,C,T,0.884,4,40,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000517,3845.0
chr17,7675232,G,A,0.813,5,26,0/1,,SNP,MISSENSE,c.380C>T,p.S127F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs730881999,,as_specific,0.5411471321695761,"""L, E, M, O""",Rec,False,NTRK1,True,p.S127Y(9) p.0(9) p.S127fs*43(1) p.S127F(49) p.S127T(7) p.P128fs*42(3) p.P128fs*18(1) p.S127P(10) p.S127fs*22(1) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126_N131delYSPALN(3) p.Y126_S127insQPHH(1) p.S127S(1) p.Y126fs*11(1) p.S127C(1) p.V73fs*9(1) p.S127fs*42(1) p.Y126fs*18(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;ENST00000503591;,,,,7.3,False,True,True,"UV:1,APOBEC:1,Misc:2",0.950312,,0.925,3.0,,,,,,,ACH-000517,7157.0
chr7,140753336,A,T,0.672,64,130,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002206,673.0
chr7,140753336,A,T,0.584,238,344,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001568,673.0
chr7,147132246,G,A,0.402,250,163,0/1,,SNP,SPLICE_SITE,c.1085G>A,p.G362E,CNTNAP2,contactin associated protein like 2,,ENST00000361727.8,8.0,+,Q9UHC6,False,,,,0.4538653366583541,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:10,0.929713,0.8107757256739679,0.664,3.0,,,,,,,ACH-001568,26047.0
chr11,124117765,C,T,0.659,171,328,0/1,,SNP,MISSENSE,c.184C>T,p.P62S,VWA5A,von Willebrand factor A domain containing 5A,,ENST00000392744.4,3.0,+,O00534,False,rs201601409,,as_specific,0.4214463840399002,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.445069,0.5549134685288747,0.183,3.0,,,,,,,ACH-001568,4013.0
chr3,10146518,C,A,0.965,1,56,1|1,,SNP,MISSENSE,c.345C>A,p.H115Q,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,2.0,+,P40337,False,,,,0.4788029925187032,"""E, M, O""",Rec,False,,True,p.?(4) p.H115Y(14) p.H115fs*17(3) p.H115N(9) p.H115del(1) p.L116fs*9(1) p.H115fs*16(1) p.H115fs*15(1) p.H115fs*42(1) p.H115fs*44(3) p.H115Q(2) p.H115R(1) p.L116fs*16(3) p.H115L(1) p.H115D(1) p.H115P(1) p.H115fs*41(1),cancer;gene_function_loss;,False,False,True,ENST00000256474;,1742.0,,5.0,7.3,False,True,False,,0.638593,,0.854,3.0,,,,,,,ACH-000513,7428.0
chr7,140753336,A,T,0.984,1,149,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000661,673.0
chr9,21971121,G,A,0.993,0,150,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-001377,1029.0
chr22,23614162,T,A,0.445,90,73,0/1,,SNP,MISSENSE,c.594A>T,p.E198D,DRICH1,aspartate rich 1,,ENST00000317749.9,9.0,-,Q6PGQ1,False,,,,0.4364089775561097,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.677174,,0.093,1.0,,,,,,,ACH-001377,51233.0
chr12,25227342,T,C,0.53,33,37,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs121913240,,as_specific,0.3491271820448878,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,909.0,,7.5,7.3,True,False,True,Misc:4,0.911063,0.4728932338916854,0.799,4.0,,,,,,,ACH-000031,3845.0
chr17,7673803,G,A,0.955,0,22,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000031,7157.0
chr19,11021837,C,T,0.466,32,26,0/1,,SNP,MISSENSE,c.2729C>T,p.T910M,SMARCA4,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4",Bromodomain containing,ENST00000344626.9,19.0,+,P51532,False,rs1238758086,,as_specific,0.6159600997506235,E,Rec,False,,False,p.T910M(4),cancer;gene_function_loss;,False,False,True,ENST00000344626;ENST00000643549;ENST00000646693;ENST00000642726;ENST00000646484;ENST00000644737;ENST00000642628;ENST00000643296;ENST00000647230;ENST00000646510;ENST00000429416;ENST00000645460;ENST00000541122;ENST00000589677;ENST00000444061;ENST00000590574;ENST00000413806;ENST00000450717;ENST00000643208;ENST00000642350;ENST00000647268;ENST00000646513;,,,,7.3,False,True,True,CpG:5,0.835176,0.70580160552957,0.906,4.0,,,,,,,ACH-000031,6597.0
chr1,114713909,G,T,0.483,49,47,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-002271,4893.0
chr12,25079261,C,T,0.288,113,44,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-002271,Unknown
chr1,34089167,C,T,0.471,18,16,0/1,,SNP,MISSENSE,c.94G>A,p.G32S,CSMD2,CUB and Sushi multiple domains 2,Sushi domain containing,ENST00000373388.6,2.0,-,Q7Z408,False,rs761180145,,as_specific,0.5236907730673317,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:2,0.729538,0.7541215423313146,0.083,3.0,,,,,,,ACH-000798,114784.0
chr5,112838220,C,T,0.441,32,25,0/1,,SNP,NONSENSE,c.2626C>T,p.R876*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913333,,as_specific,0.4239401496259352,"""E, M, O""",Rec,True,,True,p.R876*(88) p.S874_R876>*(1) p.?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:6,0.94274,,,5.0,,,,,,,ACH-000798,324.0
chr12,25245350,C,T,0.625,8,15,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000798,3845.0
chr17,7674220,C,T,0.442,43,33,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000798,7157.0
chr12,25245351,C,A,0.734,15,45,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000860,3845.0
chr3,179234297,A,G,0.546,25,31,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-001388,5290.0
chr20,58909365,C,T,0.659,231,433,0/1,,SNP,MISSENSE,c.601C>T,p.R201C,GNAS,GNAS complex locus,"G protein subunits alpha, group s Granins",ENST00000371085.7,8.0,+,"O95467, P63092, P84996, Q5JWF2",False,rs11554273,,as_specific,0.4987531172069825,E,Dom,False,,True,p.R201H(703) p.R201C(858) p.R201?(16) p.R201L(4) p.R201S(32) p.R201G(2) p.R201R(1) p.R201P(1),cancer;gene_function_gain;,False,False,True,ENST00000371100;ENST00000371102;ENST00000604005;ENST00000371095;ENST00000371085;ENST00000354359;ENST00000265620;,826.0,,5.0,7.3,True,False,True,"CpG:6,UV:1",0.649806,0.7035793687008755,0.943,4.0,,,,,,,ACH-001388,2778.0
chr1,114713908,T,C,0.678,19,43,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-001973,4893.0
chr9,21971029,C,T,0.997,0,454,1|1,,SNP,NONSENSE,c.177G>A,p.W59*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913389,,as_specific,0.6633416458852868,,,True,,True,p.0(1543) p.W110*(37) p.V59fs*61(2) p.?(4) p.W110C(1) p.V59fs*63(1) p.V59fs*60(1) p.V59_G67del(1) p.V59M(1) p.V59fs*58(1) p.V59fs*82(2) p.H83fs*2(2) p.V59fs*45(1) p.D105fs*8(1) p.V59G(1) p.A68fs*3(1),cancer;gene_function_loss;,False,False,True,,1521.0,,0.0,7.3,False,True,False,,0.855169,0.9926462279289228,0.455,5.0,,,,,,,ACH-001973,1029.0
chr14,94289949,C,T,0.476,123,114,0/1,,SNP,SILENT,c.645G>A,p.G215G,SERPINA10,serpin family A member 10,Serpin peptidase inhibitors,ENST00000261994.9,2.0,-,Q9UK55,False,rs367966236,,as_specific,0.4214463840399002,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.250393,0.9200414317847768,,0.0,,,,,,,ACH-001973,51156.0
chr17,7674945,G,A,0.994,0,172,1|1,,SNP,NONSENSE,c.586C>T,p.R196*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516435,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R196*(221) p.R196P(18) p.R196Q(5) p.R196R(6) p.I195fs*12(1) p.R196_R202del(1) p.R196fs*51(4) p.I195_G199delIRVEG(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.R196L(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.R196fs*13(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.986209,0.7393785927987923,,4.0,,,,,,,ACH-001973,7157.0
chr7,140753336,A,T,0.999,1,975,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002003,673.0
chr17,7673802,C,T,0.547,21,25,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000914,7157.0
chr17,7674885,C,T,0.5,26,26,0/1,,SNP,MISSENSE,c.646G>A,p.V216M,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs730882025,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V216M(79) p.V216L(12) p.V216E(5) p.V216fs*6(2) p.V216fs*31(2) p.V216A(4) p.T211fs*28(1) p.S215_V218>M(1) p.V218delV(8) p.H214fs*5(2) p.S215fs*29(1) p.V216G(6) p.S215fs*31(1) p.V216_Y220delVVVPY(1) p.V216fs*33(1) p.S215_V218>RR(1) p.S215_V216insX(1) p.H214Cfs*29(1) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.?(1) p.K164_P219del(1) p.V216fs*5(1) p.V216fs*32(1) p.S215fs*27(1) p.D207_V216del10(1) p.S215_V218>R(1) p.V216fs*28(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:6,0.94216,0.4523770722957338,0.956,3.0,,,,,,,ACH-000914,7157.0
chr1,114713909,G,T,0.497,76,72,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-002253,4893.0
chr3,179230348,G,A,0.472,68,61,0/1,,SNP,MISSENSE,c.2908G>A,p.E970K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,20.0,+,P42336,False,,,,0.3491271820448878,"""E, O""",Dom,False,,False,p.E970K(4),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"POLE:2,APOBEC:1",0.96147,0.727674873757811,0.581,3.0,,,,,,,ACH-000953,5290.0
chr6,161107946,G,A,0.491,29,26,0/1,,SNP,MISSENSE,c.4096G>A,p.G1366R,MAP3K4,mitogen-activated protein kinase kinase kinase 4,Mitogen-activated protein kinase kinase kinases,ENST00000392142.9,21.0,+,Q9Y6R4,False,,,,0.4812967581047381,,,False,,False,p.G1366R(5),cancer;,False,False,True,,,,,7.3,False,False,True,CpG:3,0.903475,,0.564,4.0,,,,,,,ACH-000953,4216.0
chr17,7673802,C,T,0.355,19,10,0/1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000953,7157.0
chr17,7674220,C,T,0.667,13,23,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000953,7157.0
chr17,7673820,C,G,0.871,2,20,0/1,,SNP,MISSENSE,c.800G>C,p.R267P,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs587780075,,as_specific,0.5261845386533666,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R267W(34) p.G262_S269delGNLLGRNS(2) p.R267P(19) p.R267L(4) p.R267Q(11) p.R267R(5) p.G266_E271delGRNSFE(2) p.R267G(2) p.E258fs*71(1) p.N268fs*77(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.R267fs*65(1) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:3,Misc:2",0.917211,,0.927,3.0,,,,,,,ACH-002175,7157.0
chr4,152326137,G,A,0.682,48,103,0/1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-002256,55294.0
chr5,37195921,C,T,0.208,80,22,0/1,,SNP,MISSENSE,c.3748G>A,p.A1250T,CPLANE1,,,ENST00000508244.5,20.0,-,,False,rs752334335,,as_specific,0.3366583541147132,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:1,Misc:1",0.495274,,0.015,1.0,,,,,,,ACH-002256,65250.0
chr9,21971121,G,A,0.951,0,19,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-002256,1029.0
chr17,7673803,G,A,0.527,25,29,0/1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-002256,7157.0
chr17,7675088,C,T,0.486,37,34,0/1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002256,7157.0
chr3,37014545,G,A,0.99,0,107,1|1,,SNP,SPLICE_SITE,c.e10+1G>A,,MLH1,mutL homolog 1,MutL homologs,ENST00000458205.6,,+,P40692,False,rs267607789,,as_specific,0.3690773067331671,"""E, O""",Rec,False,,False,p.?(4),splicing;cancer;gene_function_loss;dna_repair;,False,False,True,,731.0,,2.5,7.3,False,True,False,,0.972304,0.4673546425590275,,1.59129685669006,,,,,,,ACH-001669,4292.0
chr17,41516933,C,T,0.303,46,20,0/1,,SNP,MISSENSE,c.613G>A,p.V205I,KRT15,keratin 15,"Keratins, type I",ENST00000393976.6,5.0,-,P19012,False,rs138271368,,as_specific,0.5910224438902744,,,False,,False,,cancer;,False,False,True,,,,,4.01,False,False,True,"CpG:12,Misc:1",0.364973,0.8570172175887601,0.586,3.0,,,,,,,ACH-000708,3866.0
chr7,82915589,G,A,0.583,96,137,0/1,,SNP,MISSENSE,c.12397C>T,p.R4133C,PCLO,piccolo presynaptic cytomatrix protein,Zinc fingers C2 domain containing PDZ domain containing,ENST00000333891.14,7.0,-,Q9Y6V0,False,rs372497499,,as_specific,0.4139650872817955,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,UV:8,0.864102,,0.415,2.0,,,,,,,ACH-001362,27445.0
chr7,144050613,C,T,0.606,65,101,0/1,,SNP,MISSENSE,c.212C>T,p.S71L,OR2A5,olfactory receptor family 2 subfamily A member 5,"Olfactory receptors, family 2",ENST00000641693.1,2.0,+,Q96R48,False,rs149614119,,as_specific,0.4738154613466334,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,UV:10,0.463594,0.3672976118874545,0.127,2.0,,,,,,,ACH-001362,393046.0
chr12,25245350,C,A,0.997,0,379,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000774,3845.0
chr17,7675136,G,A,0.996,0,226,1|1,,SNP,MISSENSE,c.476C>T,p.A159V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.A159V(42) p.R158fs*8(1) p.A159D(10) p.S149fs*72(1) p.R158_A159insX(4) p.A159fs*11(6) p.A159_Q167delAMAIYKQSQ(1) p.R158_A159delRA(2) p.A159P(25) p.V157fs*19(2) p.A159S(5) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A159A(8) p.R156fs*18(1) p.A159T(9) p.V157_I162delVRAMAI(1) p.A159fs*21(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A159fs*19(1) p.R158_A159insXX(1) p.V157_C176del20(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"UV:1,Misc:3",0.890391,,0.774,3.0,,,,,,,ACH-000774,7157.0
chr17,7673803,G,A,0.983,0,56,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-002294,7157.0
chr17,7673823,C,T,0.556,11,14,0/1,,SNP,MISSENSE,c.797G>A,p.G266E,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs193920774,,as_specific,0.5236907730673317,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G266V(35) p.G266R(59) p.G266E(59) p.G262_S269delGNLLGRNS(2) p.G266_E271delGRNSFE(2) p.G266fs*79(6) p.G266fs*9(1) p.G266*(14) p.E258fs*71(1) p.G266S(1) p.G266G(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.G266T(1) p.G266A(3) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:1,Misc:1",0.961163,0.7111218214186509,0.973,3.0,,,,,,,ACH-000786,7157.0
chr9,77794572,T,A,0.524,38,45,0|1,77794569.0,SNP,MISSENSE,c.626A>T,p.Q209L,GNAQ,G protein subunit alpha q,"G protein subunits alpha, group q",ENST00000286548.9,5.0,-,P50148,False,rs121913492,,as_specific,0.3266832917705736,E,Dom,False,,True,p.Q209L(323) p.Q209P(256) p.Q209R(8) p.Q209H(17) p.Q209?(6) p.Q209Y(1) p.Q209K(1),cancer;gene_function_gain;,False,False,True,ENST00000286548;,,,,7.3,True,False,True,Misc:10,0.923293,,0.936,4.0,,,,,,,ACH-001554,2776.0
chr12,25245350,C,A,0.993,0,160,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000022,3845.0
chr17,7673776,G,A,0.998,0,448,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-000022,7157.0
chr17,7673740,C,A,0.467,311,278,0/1,,SNP,NONSENSE,c.880G>T,p.E294*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1057520607,,as_specific,0.5261845386533666,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E294*(57) p.E294E(4) p.E294K(5) p.K291fs*48(8) p.E294fs*11(1) p.E294fs*51(19) p.E294D(2) p.K291fs*49(1) p.E294fs*12(3) p.R290fs*50(1) p.E294Q(2) p.E294fs*52(2) p.E294fs*?(1) p.E294V(1) p.R290_P295>X(1) p.G293fs*1(1) p.L265_K305del41(1) p.E294G(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:3,APOBEC:1,Misc:5",0.973947,0.4390645778956161,,4.0,,,,,,,ACH-000398,7157.0
chr17,7675217,T,C,0.455,109,87,0/1,,SNP,MISSENSE,c.395A>G,p.K132R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519996,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.N131delN(4) p.K132Q(17) p.K132E(20) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:4,0.930493,0.6899109988020597,0.908,3.0,,,,,,,ACH-000398,7157.0
chr17,7675088,C,T,0.985,1,75,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002237,7157.0
chr3,179218304,A,G,0.461,24,20,0/1,,SNP,MISSENSE,c.1634A>G,p.E545G,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913274,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;,883.0,,2.0,7.3,True,False,True,Misc:2,0.960085,0.8156814306896972,0.737,3.0,,,,,,,ACH-000983,5290.0
chr18,51065549,G,A,0.993,0,142,1|1,,SNP,MISSENSE,c.794G>A,p.R265H,SMAD4,SMAD family member 4,SMAD family,ENST00000588745.5,5.0,+,Q13485,False,rs377767347,,as_specific,0.3740648379052369,,,False,,True,p.R361H(38) p.0(28) p.T265I(1),cancer;gene_function_loss;,False,False,True,ENST00000398417;ENST00000342988;ENST00000588745;,,,,7.3,False,True,True,"CpG:5,POLE:1",0.950582,,0.955,3.0,,,,,,,ACH-001556,4089.0
chr17,7674216,C,G,0.977,0,45,1|1,,SNP,MISSENSE,c.747G>C,p.R249S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934571,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.R249S(391) p.0(9) p.R249fs*15(1) p.R249W(37) p.R249M(35) p.R249G(31) p.R249R(6) p.N247_R249del(1) p.R249fs*96(7) p.R249K(18) p.R249T(19) p.M246_P250delMNRRP(4) p.R249_T256delRPILTIIT(1) p.R249_I251delRPI(1) p.P250fs*14(1) p.R249_P250>SS(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.N247_R249delNRR(1) p.R249fs*14(2) p.R249fs*95(2) p.R249fs*19(1) p.R249_P250delRP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:1",0.815139,0.7005379619944718,0.769,2.0,,,,,,,ACH-000288,7157.0
chr7,17335775,G,C,0.517,32,41,0/1,,SNP,MISSENSE,c.1119G>C,p.Q373H,AC019117.4,,,ENST00000637807.1,9.0,+,,False,,,,0.3192019950124688,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:8,0.652798,0.770686679117409,0.238,3.0,,,,,,,ACH-000862,Unknown
chr17,7673781,C,G,0.92,1,22,1|1,,SNP,MISSENSE,c.839G>C,p.R280T,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121912660,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R280T(73) p.R280fs*65(9) p.R280I(15) p.R280K(54) p.R280S(17) p.R280G(33) p.R280_R283>S(1) p.R280*(14) p.D281fs*24(1) p.S269fs*21(1) p.F270_D281del12(1) p.R280fs*?(1) p.V272_K292del21(1) p.D281_R282delDR(2) p.R280R(3) p.A276fs*64(1) p.R280fs*64(1) p.G279_R280delGR(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:19,0.96317,0.7002446792674034,0.94,3.0,,,,,,,ACH-000862,7157.0
chr20,62857460,C,G,0.448,119,93,0/1,,SNP,MISSENSE,c.1173G>C,p.Q391H,TCFL5,transcription factor like 5,Basic helix-loop-helix proteins,ENST00000335351.8,4.0,-,Q9UL49,False,,,,0.5037406483790524,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:3,0.672052,0.6561264191584172,0.06,2.0,,,,,,,ACH-000862,10732.0
chr1,114713909,G,T,0.625,49,81,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-002153,4893.0
chr17,35750138,T,G,0.153,30,5,0/1,,SNP,MISSENSE,c.566A>C,p.D189A,GAS2L2,growth arrest specific 2 like 2,,ENST00000604641.6,2.0,-,Q8NHY3,False,rs1192558412,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.610651,0.5095418527025265,0.061,2.0,,,,,,,ACH-002153,246176.0
chr1,147908084,C,T,0.535,47,56,0/1,,SNP,SILENT,c.129C>T,p.F43F,GJA8,gap junction protein alpha 8,Gap junction proteins,ENST00000369235.1,1.0,+,P48165,False,rs267598000,,as_specific,0.5860349127182045,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:2,UV:6,POLE:2",0.679718,0.8520121336634799,,0.0,,,,,,,ACH-002309,2703.0
chr2,48709012,C,T,0.208,67,16,0/1,,SNP,MISSENSE,c.616G>A,p.E206K,LHCGR,luteinizing hormone/choriogonadotropin receptor,Glycoprotein hormone receptors,ENST00000294954.12,8.0,-,P22888,False,rs776172758,,as_specific,0.4763092269326683,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.845786,0.5344319733109912,0.369,3.0,,,,,,,ACH-002309,3973.0
chr2,80647798,C,T,0.348,252,134,0/1,,SNP,NONSENSE,c.2788C>T,p.R930*,CTNNA2,catenin alpha 2,Alpha catenins,ENST00000402739.8,18.0,+,P26232,False,rs760139097,,as_specific,0.4339152119700748,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:13,0.988744,0.6456300918102643,,3.0,,,,,,,ACH-002309,1496.0
chr4,125448556,C,T,0.521,44,49,0/1,,SNP,MISSENSE,c.7546C>T,p.H2516Y,FAT4,FAT atypical cadherin 4,Cadherin related,ENST00000394329.8,10.0,+,Q6V0I7,False,rs764574932,,as_specific,0.399002493765586,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.775016,,0.101,3.0,,,,,,,ACH-002309,79633.0
chr5,141246519,C,T,0.59,61,89,0/1,,SNP,MISSENSE,c.941C>T,p.S314L,PCDHB15,protocadherin beta 15,Clustered protocadherins,ENST00000231173.6,1.0,+,Q9Y5E8,False,,,,0.4438902743142144,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:1,POLE:7",0.40327,0.1834821715261767,0.097,2.0,,,,,,,ACH-002309,56121.0
chr12,48526264,C,T,0.63,24,40,0/1,,SNP,SILENT,c.633C>T,p.F211F,OR8S1,olfactory receptor family 8 subfamily S member 1,"Olfactory receptors, family 8",ENST00000641651.1,1.0,+,Q8NH09,False,rs139022158,,as_specific,0.5112219451371571,,,False,,False,,cancer;,False,False,True,,,,,3.43,False,False,True,UV:4,0.278853,0.4253269988742326,,0.0,,,,,,,ACH-002309,341568.0
chr16,9763579,C,T,0.427,100,76,0/1,,SNP,MISSENSE,c.3965G>A,p.G1322E,GRIN2A,glutamate ionotropic receptor NMDA type subunit 2A,Glutamate ionotropic receptor NMDA type subunits,ENST00000330684.4,13.0,-,Q12879,False,,,,0.5336658354114713,,,False,,False,p.G1322E(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,UV:7,,0.7838498453815175,0.075,4.0,,,,,,,ACH-002309,2903.0
chr17,7674894,G,A,0.967,0,29,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-002309,7157.0
chr7,55191822,T,G,0.945,122,2160,1|1,,SNP,MISSENSE,c.2438T>G,p.L813R,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,20.0,+,P00533,False,rs121434568,,as_specific,0.5486284289276808,"""E, O""",Dom,False,,True,p.L858R(2311) p.L858Q(1) p.Y813C(1) p.L858K(1),cancer;gene_function_gain;,False,True,True,ENST00000455089;ENST00000454757;ENST00000275493;,33.0,"EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.",375.0,7.3,True,False,True,"smoking:5,Misc:5",0.914202,0.7052349118740907,0.961,4.0,PA166157527,,,,,,ACH-000109,1956.0
chr3,179234297,A,G,0.435,86,70,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-001611,5290.0
chr9,21971112,G,A,0.996,0,258,1|1,,SNP,MISSENSE,c.94C>T,p.H32Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913385,,as_specific,0.6982543640897756,,,False,,True,p.0(1543) p.P81fs*35(1) p.V82_E88del(1) p.H83Y(39) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.H83N(2) p.P81_A85del(1) p.R80fs*63(1) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1) p.V82fs*62(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;,,,,7.3,False,True,True,Misc:4,0.884844,0.9724149636314106,0.804,4.0,,,,,,,ACH-001611,1029.0
chr3,41224610,C,G,0.254,40,13,0/1,,SNP,MISSENSE,c.98C>G,p.S33C,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913400,,as_specific,0.3940149625935162,"""E, M, O""",Dom,False,PLAG1,True,p.S33C(256) p.A5_A80del(75) p.S33Y(71) p.S33A(24) p.S33P(70) p.S33F(133) p.S33N(3) p.A5_Q143del(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.S33L(4) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.S33T(10) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32_S47del(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_I35del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(2) p.S23_S33del(3) p.A20_R151del(1) p.D32_S33insS(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.S33S(3) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.T3_A126del(2) p.D32fs*9(1) p.S33K(1) p.S23_S33>T(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.S33_G34insS(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_S33del(1) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.S33_G34insGTS(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.S33_G34insGI(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.V22_S33del(2) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.S33del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.Y30_S33del(2) p.A5_I35del(1) p.A5_T59del(1) p.A5_Q72del(1) p.S33_G34del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"APOBEC:2,Misc:9",0.946257,0.6062606386851989,0.453,4.0,,,,,,,ACH-000465,1499.0
chr7,140753336,A,T,0.684,59,129,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000465,673.0
chr2,61492337,C,T,0.184,78,16,0/1,,SNP,MISSENSE,c.1711G>A,p.E571K,XPO1,exportin 1,Exportins,ENST00000401558.7,15.0,-,O14980,False,rs1057520009,,as_specific,0.3067331670822942,L,Dom,False,,True,p.E571K(41) p.E571V(3) p.E571G(5) p.E571I(1) p.E571A(3) p.E571Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"CpG:1,POLE:4",0.979039,0.5942594365771144,0.579,4.0,,,,,,,ACH-000702,7514.0
chr7,140753336,A,T,0.564,34,45,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001039,673.0
chr12,25245351,C,G,0.322,23,9,0/1,,SNP,MISSENSE,c.34G>C,p.G12R,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,530.0,,32.5,7.3,True,False,True,"smoking:1,Misc:32",0.915109,0.6459561688690294,0.821,4.0,,,,,,,ACH-000118,3845.0
chr17,7673776,G,A,0.952,0,20,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-000118,7157.0
chr7,140753336,A,T,0.998,0,501,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002002,673.0
chr12,25245350,C,A,0.985,58,3674,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-001607,3845.0
chr17,7673537,G,A,0.999,0,1012,1|1,,SNP,NONSENSE,c.991C>T,p.Q331*,TP53,tumor protein p53,,ENST00000269305.8,9.0,-,P04637,False,,,,0.4713216957605985,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q331*(36) p.Q331P(3) p.Q331Q(2) p.Q331H(5) p.Q331fs*6(1) p.Q331fs*14(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"UV:2,APOBEC:14",0.991875,0.4912909886354796,,4.0,,,,,,,ACH-001607,7157.0
chr17,7674948,T,A,0.909,4,48,1|1,,SNP,MISSENSE,c.583A>T,p.I195F,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs942158624,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193_I195delHLI(1) p.I195F(27) p.I195T(83) p.I195N(16) p.I195fs*12(1) p.I195L(1) p.I195S(6) p.I195_G199delIRVEG(1) p.I195fs*52(5) p.L194fs*52(1) p.I195fs*50(1) p.A189_V197delAPPQHLIRV(4) p.I195fs*13(1) p.I195fs*14(3) p.P191fs*6(1) p.?(1) p.K164_P219del(1) p.H193_I195>AP(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:5",0.924587,,0.904,3.0,,,,,,,ACH-000256,7157.0
chr2,74415153,T,G,0.483,3,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002300,388963.0
chr11,101051562,C,T,0.464,54,48,0/1,,SNP,MISSENSE,c.2219G>A,p.R740Q,PGR,progesterone receptor,Nuclear hormone receptors,ENST00000325455.10,5.0,-,P06401,False,rs149186732,,as_specific,0.3017456359102244,,,False,,False,,cancer;gene_function_gain;,False,False,True,ENST00000325455;ENST00000534013;ENST00000263463;ENST00000617858;ENST00000619228;,,,,7.3,True,False,True,"CpG:1,POLE:5",0.981043,0.5890141148230612,0.779,3.0,,,,,,,ACH-002300,5241.0
chr1,114713908,T,A,0.992,0,122,1|1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-000336,4893.0
chr1,161509955,A,G,0.388,64,40,0/1,,SNP,MISSENSE,c.497A>G,p.H166R,FCGR2A,Fc fragment of IgG receptor IIa,CD molecules Immunoglobulin like domain containing,ENST00000367972.8,4.0,+,P12318,False,rs1801274,,as_specific,0.5012468827930174,,,False,,False,,expression;cancer;,False,True,True,,456.0,,35.0,0.297,False,False,False,,0.383936,0.6726284498228973,0.053,2.0,PA166153652,,,,,ENSG00000244682.3,ACH-000336,2212.0
chr1,161544752,A,C,0.473,42,36,0/1,,SNP,MISSENSE,c.841T>G,p.F281V,FCGR3A,Fc fragment of IgG receptor IIIa,CD molecules Immunoglobulin like domain containing,ENST00000367969.8,4.0,-,P08637,False,rs396991,,as_specific,0.4962593516209476,,,False,,False,,expression;cancer;,False,True,True,,457.0,,35.0,0.483,False,False,False,,0.456302,0.1488407148928904,0.064,2.0,PA166153571,,,,,ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000162747.5|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000173110.6|ENSG00000244682.3|ENSG00000244682.3|ENSG00000244682.3|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000244682.3|ENSG00000225217.1|ENSG00000224203.2,ACH-000336,2214.0
chr11,67585218,A,G,0.95,0,19,1|1,,SNP,MISSENSE,c.313A>G,p.I105V,GSTP1,glutathione S-transferase pi 1,Soluble glutathione S-transferases,ENST00000398606.10,5.0,+,P09211,False,rs1695,,as_specific,0.6359102244389028,,,False,,False,,expression;cancer;,False,True,True,,259.0,,20.0,0.457,False,False,False,,0.397153,0.2451954443545753,0.013,1.0,PA166154249,,,,,ENSG00000213402.2|ENSG00000084207.11|ENSG00000167792.7|ENSG00000175634.10|ENSG00000213402.2|ENSG00000084207.11|ENSG00000213402.2|ENSG00000084207.11|ENSG00000175634.10|ENSG00000084207.11|ENSG00000255318.1|ENSG00000213402.2|ENSG00000167792.7|ENSG00000175634.10|ENSG00000213402.2|ENSG00000084207.11|ENSG00000167792.7|ENSG00000231793.4|ENSG00000255318.1|ENSG00000167799.5|ENSG00000213402.2|ENSG00000084207.11|ENSG00000231793.4|ENSG00000213402.2|ENSG00000084207.11|ENSG00000167792.7|ENSG00000231793.4|ENSG00000213402.2|ENSG00000084207.11|ENSG00000084207.11|ENSG00000084207.11|ENSG00000084207.11|ENSG00000213402.2|ENSG00000084207.11|ENSG00000213402.2|ENSG00000167792.7|ENSG00000175634.10|ENSG00000231793.4|ENSG00000213402.2|ENSG00000084207.11|ENSG00000231793.4|ENSG00000255318.1|ENSG00000167800.9|ENSG00000213402.2|ENSG00000231793.4|ENSG00000255318.1|ENSG00000175634.10|ENSG00000213402.2|ENSG00000231793.4|ENSG00000175634.10|ENSG00000213402.2|ENSG00000084207.11|ENSG00000167792.7|ENSG00000231793.4|ENSG00000255318.1|ENSG00000167799.5|ENSG00000175634.10|ENSG00000213402.2|ENSG00000084207.11|ENSG00000167799.5|ENSG00000175634.10|ENSG00000213402.2|ENSG00000084207.11|ENSG00000167799.5|ENSG00000167799.5|ENSG00000084207.11|ENSG00000167792.7|ENSG00000167799.5|ENSG00000213402.2|ENSG00000175634.10|ENSG00000213402.2|ENSG00000110711.5|ENSG00000084207.11|ENSG00000231793.4|ENSG00000167799.5|ENSG00000213402.2|ENSG00000167792.7|ENSG00000231793.4|ENSG00000167799.5|ENSG00000110057.3|ENSG00000213402.2|ENSG00000167792.7|ENSG00000213402.2|ENSG00000167792.7|ENSG00000231793.4|ENSG00000213402.2|ENSG00000167792.7|ENSG00000167792.7|ENSG00000213402.2|ENSG00000167792.7|ENSG00000231793.4|ENSG00000175634.10|ENSG00000213402.2|ENSG00000110711.5|ENSG00000167792.7|ENSG00000231793.4|ENSG00000172932.10|ENSG00000213402.2|ENSG00000175634.10|ENSG00000213402.2|ENSG00000110711.5|ENSG00000084207.11|ENSG00000175634.10|ENSG00000213402.2|ENSG00000167792.7|ENSG00000255318.1|ENSG00000231793.4,ACH-000336,2950.0
chr13,28050157,G,A,0.606,27,43,0/1,,SNP,MISSENSE,c.680C>T,p.T227M,FLT3,fms related tyrosine kinase 3,CD molecules Immunoglobulin like domain containing Receptor Tyrosine Kinases,ENST00000241453.12,6.0,-,P36888,False,rs1933437,,as_specific,0.3840399002493765,L,Dom,False,,True,p.T227M(83),expression;cancer;gene_function_gain;,False,True,True,,540.0,"FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.",15.0,0.26,True,False,False,,0.535178,0.3041669824186075,0.264,2.0,PA166154705,,,,,ENSG00000122025.10|ENSG00000122025.10|ENSG00000122025.10|ENSG00000122025.10|ENSG00000122025.10|ENSG00000122025.10,ACH-000336,2322.0
chr13,102845848,A,G,0.75,0,2,0/1,,SNP,INTRON,c.e9+6045A>G,,ERCC5,"ERCC excision repair 5, endonuclease",Xeroderma pigmentosum complementation groups ERCC excision repair associated,ENST00000602836.2,,+,P28715,False,rs751402,,as_specific,0.600997506234414,E,Rec,False,,False,,expression;cancer;gene_function_loss;,False,True,True,,255.0,,15.0,0.115,False,True,False,,0.187898,0.5644404098903105,,1.39175606470083,PA166170004,,,,,,ACH-000336,2073.0
chr14,61747130,T,C,0.984,0,59,1|1,,SNP,THREE_PRIME_UTR,,,HIF1A,hypoxia inducible factor 1 alpha subunit,Basic helix-loop-helix proteins,ENST00000394997.5,15.0,+,Q16665,False,rs2057482,,as_specific,0.3615960099750623,,,False,,False,,cancer;gene_function_gain;,False,True,True,,433.0,,10.0,0.085,True,False,False,,0.682983,0.6381466463380645,,1.54995687704086,,,,,,,ACH-000336,3091.0
chr17,7676154,G,C,0.992,0,113,1|1,,SNP,MISSENSE,c.215C>G,p.P72R,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs1042522,,as_specific,0.6059850374064838,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.P72R(148) p.G59fs*23(3) p.E68_A78del(1) p.E68fs*76(1) p.P72A(13) p.P72S(3) p.R72fs*51(2) p.D48fs*55(1) p.P72H(2) p.M1_T125del(1) p.D57_A76del20(1) p.P72fs*77(1) p.S33fs*23(1) p.R65fs*38(1) p.V73fs*50(1) p.P13fs*18(1),expression;cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,,531.0,"This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.",45.0,0.197,False,True,False,,0.482857,0.1673752190444292,0.368,2.0,PA166155173,,,,,ENSG00000108947.4,ACH-000336,7157.0
chr21,38819714,A,G,0.593,10,16,0/1,,SNP,SILENT,c.1023A>G,p.P341P,ETS2,"ETS proto-oncogene 2, transcription factor",ETS transcription factor family,ENST00000360214.8,9.0,+,P15036,False,rs461155,,as_specific,0.5561097256857855,,,False,,False,,cancer;,False,True,True,,445.0,,10.0,0.121,False,False,False,,0.227594,0.4166348764738978,,0.0,,,,,,,ACH-000336,2114.0
chr7,140781602,C,G,0.992,0,121,1|1,,SNP,MISSENSE,c.1406G>C,p.G469A,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,11.0,-,P15056,False,rs121913355,,as_specific,0.3541147132169576,E,Dom,False,"""AKAP9, KIAA1549""",True,p.G469A(70) p.G469R(28) p.G469V(34) p.G469E(20) p.G469S(7) p.G469del(2) p.G469?(1) p.G469L(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,992.0,,5.0,7.3,True,False,False,,0.908834,,0.9,4.0,,,,,,,ACH-000327,673.0
chr11,108333954,A,G,0.995,0,194,1|1,,SNP,MISSENSE,c.7996A>G,p.T2666A,ATM,ATM serine/threonine kinase,,ENST00000452508.6,55.0,+,Q13315,False,rs745775382,,as_specific,0.3216957605985037,"""L, O""",Rec,False,,False,p.T2666A(1) p.T2666I(1),cancer;gene_function_loss;dna_repair;,False,False,True,ENST00000278616;ENST00000452508;,901.0,,3.0,7.3,False,True,False,,0.915908,0.5561440258583976,0.853,3.0,,,,,,,ACH-000327,472.0
chr17,7675216,C,G,0.969,0,31,1|1,,SNP,MISSENSE,c.396G>C,p.K132N,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs866775781,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.K132Q(17) p.K132E(20) p.M133fs*37(1) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1) p.M133fs*16(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,APOBEC:11,0.933912,,0.895,3.0,,,,,,,ACH-000821,7157.0
chr17,7674894,G,A,0.968,0,33,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000424,7157.0
chr3,41224633,A,G,0.437,207,155,0/1,,SNP,MISSENSE,c.121A>G,p.T41A,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913412,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.T41A(1344) p.A5_A80del(75) p.T41S(7) p.T41I(155) p.A5_Q143del(7) p.T41P(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.T41T(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.T41N(8) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.T40_L46del(1) p.G38_S45del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.A20_R151del(1) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.I35_T41del(1) p.I35_K170del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A39_T42del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.T41_N51del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A39fs*3(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1285.0,,55.0,7.3,True,False,True,Misc:17,0.860853,,0.403,4.0,,,,,,,ACH-001664,1499.0
chr11,118556983,A,G,0.639,36,62,0/1,,SNP,SILENT,c.261T>C,p.D87D,IFT46,intraflagellar transport 46,Intraflagellar transport proteins Cilia and flagella associated,ENST00000264020.6,5.0,-,Q9NQC8,False,,,,0.456359102244389,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"MSI:1,Misc:1",0.162255,,,0.0,,,,,,,ACH-001664,56912.0
chr17,7673776,G,A,0.492,315,307,0|1,7673776.0,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-001664,7157.0
chr7,140753336,A,T,0.643,97,180,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000676,673.0
chr17,7674220,C,T,0.942,1,33,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001162,7157.0
chr3,41224633,A,G,0.989,2,192,1|1,,SNP,MISSENSE,c.121A>G,p.T41A,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913412,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.T41A(1344) p.A5_A80del(75) p.T41S(7) p.T41I(155) p.A5_Q143del(7) p.T41P(7) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.T41T(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.T41N(8) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.T40_L46del(1) p.G38_S45del(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.A20_R151del(1) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.I35_T41del(1) p.I35_K170del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A39_T42del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.T41_N51del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A39fs*3(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1285.0,,55.0,7.3,True,False,True,Misc:17,0.860853,,0.403,4.0,,,,,,,ACH-000757,1499.0
chr12,25245350,C,T,0.527,109,124,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000757,3845.0
chr2,74415153,T,G,0.505,2,2,0|1,74415153.0,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002164,388963.0
chr9,21971121,G,A,0.958,0,22,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-002164,1029.0
chr12,25245350,C,A,0.753,20,62,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-002164,3845.0
chr2,208248388,C,A,0.534,34,41,0/1,,SNP,MISSENSE,c.395G>T,p.R132L,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",,ENST00000415913.5,4.0,-,O75874,False,rs121913500,,as_specific,0.3815461346633416,O,Dom,False,,True,p.R132C(1014) p.R132H(6941) p.R132S(229) p.R132?(201) p.R132G(285) p.R132L(126) p.R132P(1) p.R132V(1) p.G131_R132>VL(1),cancer;gene_function_gain;,False,True,True,ENST00000345146;ENST00000446179;ENST00000415913;ENST00000415282;,880.0,,10.0,7.3,True,False,True,"smoking:1,Misc:2",0.940233,0.5706276054536243,0.835,2.0,,,,,,,ACH-002093,3417.0
chr17,7673803,G,A,0.973,0,36,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-002093,7157.0
chr18,33266925,G,T,0.95,1,37,1|1,33266925.0,SNP,MISSENSE,c.1400C>A,p.T467N,CCDC178,coiled-coil domain containing 178,,ENST00000300227.12,14.0,-,Q5BJE1,False,rs760077046,,as_specific,0.2967581047381546,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,Misc:4,0.575508,,0.042,2.0,,,,,,,ACH-002093,374864.0
chr17,7673767,C,T,0.999,0,809,1|1,,SNP,MISSENSE,c.853G>A,p.E285K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs112431538,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E285K(139) p.E285V(15) p.R283fs*16(2) p.E285Q(5) p.E285G(5) p.E285*(19) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.E285A(2) p.R283fs*56(1) p.V272_K292del21(1) p.E285E(5) p.E285fs*20(1) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285fs*60(2) p.E285fs*21(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:20,0.905537,,0.91,3.0,,,,,,,ACH-001961,7157.0
chr2,177234217,G,C,0.776,19,69,0/1,,SNP,MISSENSE,c.52C>G,p.R18G,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.3940149625935162,E,Dom,False,,True,p.D16_R34del(1) p.R34G(5),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"APOBEC:4,Misc:2",0.908156,,0.543,3.0,,,,,,,ACH-002265,4780.0
chr17,7675076,T,C,0.982,0,50,1|1,,SNP,MISSENSE,c.536A>G,p.H179R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519991,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:27,0.941824,,0.935,3.0,,,,,,,ACH-002265,7157.0
chr17,7674872,T,C,0.963,0,25,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000535,7157.0
chr9,77794572,T,A,0.972,0,34,1|1,,SNP,MISSENSE,c.626A>T,p.Q209L,GNAQ,G protein subunit alpha q,"G protein subunits alpha, group q",ENST00000286548.9,5.0,-,P50148,False,rs121913492,,as_specific,0.3266832917705736,E,Dom,False,,True,p.Q209L(323) p.Q209P(256) p.Q209R(8) p.Q209H(17) p.Q209?(6) p.Q209Y(1) p.Q209K(1),cancer;gene_function_gain;,False,False,True,ENST00000286548;,,,,7.3,True,False,True,Misc:10,0.923293,,0.936,4.0,,,,,,,ACH-002011,2776.0
chr17,7670699,C,A,0.923,0,11,1|1,,SNP,MISSENSE,c.1010G>T,p.R337L,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs121912664,,as_specific,0.4812967581047381,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R337C(43) p.R337H(73) p.R337L(10) p.R337S(1) p.R337P(1) p.R337G(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000504937;ENST00000619186;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000445888;ENST00000619485;ENST00000615910;,,,,7.3,False,True,True,smoking:6,0.670182,0.6003938825683806,0.765,3.0,,,,,,,ACH-000380,7157.0
chr10,8073874,G,A,0.961,2,79,1|1,,SNP,MISSENSE,c.1183G>A,p.A395T,GATA3,GATA binding protein 3,GATA zinc finger domain containing,ENST00000346208.4,6.0,+,P23771,False,rs200935603,,as_specific,0.5261845386533666,E,Rec,False,,False,p.A396T(1) p.A395fs*54(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,,,,,4.31,True,True,True,CpG:1,0.557243,0.5023414627404155,0.556,4.0,,,,,,,ACH-000076,2625.0
chr19,48499143,C,T,0.248,10,3,0/1,,SNP,SILENT,c.1926G>A,p.E642E,LMTK3,lemur tyrosine kinase 3,Protein phosphatase 1 regulatory subunits Receptor Tyrosine Kinases,ENST00000600059.5,11.0,-,Q96Q04,False,rs769591534,,as_specific,0.7381546134663342,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.145211,,,0.0,,,,,,,ACH-000076,114783.0
chr7,140753336,A,T,0.973,1,74,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001307,673.0
chr12,20370109,G,A,0.194,65,15,0/1,,SNP,SILENT,c.825G>A,p.L275L,PDE3A,phosphodiesterase 3A,Phosphodiesterases,ENST00000359062.3,1.0,+,Q14432,False,rs750288734,,as_specific,0.6034912718204489,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,APOBEC:11,0.166036,0.7111934997787612,,0.0,,,,,,,ACH-001307,5139.0
chr3,179199102,C,T,0.407,104,75,0/1,,SNP,MISSENSE,c.277C>T,p.R93W,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,,,,0.3316708229426434,"""E, O""",Dom,False,,True,p.R93W(32) p.R93Q(8) p.R93P(1),cancer;gene_function_gain;,False,False,True,,1178.0,,0.0,7.3,True,False,False,,0.920207,,0.597,3.0,,,,,,,ACH-000570,5290.0
chr21,10596079,C,T,0.248,205,67,0/1,,SNP,MISSENSE,c.1268C>T,p.S423L,TPTE,transmembrane phosphatase with tensin homology,PTEN protein phosphatases C2 tensin-type domain containing,ENST00000618007.4,20.0,+,P56180,False,rs570468666,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,3.4,False,False,True,"UV:6,POLE:10",0.988995,0.3421619570457261,,2.0,,,,,,,ACH-001089,7179.0
chr12,25245350,C,T,0.542,29,33,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001107,3845.0
chr17,7673802,C,T,0.961,0,23,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-001107,7157.0
chr1,33810806,G,A,0.614,87,142,0/1,,SNP,SILENT,c.54C>T,p.F18F,CSMD2,CUB and Sushi multiple domains 2,Sushi domain containing,ENST00000338325.1,3.0,-,Q7Z408,False,rs867435567,,as_specific,0.5112219451371571,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.474609,,,0.0,,,,,,,ACH-000805,114784.0
chr7,140753336,A,T,0.731,352,951,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000805,673.0
chr17,7674872,T,C,0.939,0,14,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-001358,7157.0
chr17,7673764,C,T,0.988,0,78,1|1,,SNP,MISSENSE,c.856G>A,p.E286K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs786201059,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.E286G(17) p.E286K(94) p.E286fs*59(2) p.R283fs*16(2) p.E286*(17) p.E286V(9) p.E286fs*17(2) p.E286Q(7) p.E286D(2) p.E285fs*13(1) p.R283fs*59(1) p.T284fs*57(1) p.R283fs*56(1) p.V272_K292del21(1) p.E286A(2) p.E286E(2) p.R282_E287delRRTEEE(1) p.E285_N288delEEEN(1) p.L265_K305del41(1) p.G279fs*59(1) p.E285_N288del(1) p.T284_G293del10(1) p.E285_L289delEEENL(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:3,Misc:1",0.93585,0.6532670016064752,0.949,3.0,,,,,,,ACH-001118,7157.0
chr4,152326137,G,A,0.996,0,296,1|1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-001332,55294.0
chr17,7675085,C,A,0.473,277,247,0|1,7675082.0,SNP,MISSENSE,c.527G>T,p.C176F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202962,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C176F(140) p.0(9) p.C176S(27) p.C176Y(67) p.C176W(15) p.C176fs*71(7) p.C176R(21) p.C176fs*5(3) p.R174fs*1(2) p.C176*(10) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(7) p.C176G(5) p.H168fs*23(1) p.H178fs*3(1) p.R174_H178>S(1) p.V173fs*69(1) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R174_E180>K(1) p.C176_P177delCP(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.C176delC(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*72(1) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,Misc:11",0.941923,,0.951,3.0,,,,,,,ACH-001332,7157.0
chr17,7676257,G,A,0.476,247,224,0/1,,SNP,NONSENSE,c.112C>T,p.Q38*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,,,,0.5910224438902744,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q38*(5) p.Q38fs*6(2) p.Q38L(1) p.Q38fs*79(1) p.M1_T125del(1) p.S37fs*79(1) p.?(1) p.S33fs*23(1) p.P13fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,,0.968798,,,3.0,,,,,,,ACH-001332,7157.0
chr18,51065548,C,T,0.995,0,186,1|1,,SNP,MISSENSE,c.793C>T,p.R265C,SMAD4,SMAD family member 4,SMAD family,ENST00000588745.5,5.0,+,Q13485,False,rs80338963,,as_specific,0.3765586034912718,,,False,,True,p.R361C(37) p.0(28) p.R361G(6) p.T265I(1) p.R361S(3),cancer;gene_function_loss;,False,False,True,ENST00000398417;ENST00000342988;ENST00000588745;,,,,7.3,False,True,True,"CpG:7,MSI:1",0.953716,,0.945,3.0,,,,,,,ACH-001410,4089.0
chr17,7673802,C,A,0.937,0,14,1|1,,SNP,MISSENSE,c.818G>T,p.R273L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,918.0,,0.0,7.3,False,True,True,"smoking:15,Misc:9",0.887493,0.7009283873752175,0.921,3.0,,,,,,,ACH-000744,7157.0
chr9,21971109,C,A,0.996,0,267,1|1,,SNP,MISSENSE,c.97G>T,p.D33Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552822,,as_specific,0.6957605985037406,,,False,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V82_E88del(1) p.D84H(2) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.D84Y(9) p.P81_A85del(1) p.D84N(4) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.D84fs*63(2) p.E61_L94del(1) p.R80fs*34(1) p.D84_F90del(1) p.E33D(1) p.A68fs*3(1) p.D84fs*1(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;ENST00000579755;ENST00000530628;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.933446,0.9973373924118374,0.803,4.0,,,,,,,ACH-002462,1029.0
chr12,25225628,C,G,0.438,47,33,0/1,,SNP,MISSENSE,c.436G>C,p.A146P,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,905.0,,7.5,7.3,True,False,False,,0.968872,0.6595086461751286,0.935,4.0,,,,,,,ACH-002462,3845.0
chr17,7674954,G,A,0.985,0,69,1|1,,SNP,MISSENSE,c.577C>T,p.H193Y,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs876658468,,as_specific,0.5860349127182045,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H193L(40) p.H193_I195delHLI(1) p.H193R(78) p.H193Y(29) p.?(2) p.H193D(10) p.H193P(15) p.H193N(7) p.P191fs*53(2) p.A189_V197delAPPQHLIRV(4) p.H193H(2) p.H193fs*16(3) p.A189fs*53(1) p.P191fs*6(1) p.K164_P219del(1) p.H193_I195>AP(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:4,0.947843,,0.887,3.0,,,,,,,ACH-000445,7157.0
chr17,7675185,C,T,0.967,0,29,1|1,,SNP,MISSENSE,c.427G>A,p.V143M,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782620,,as_specific,0.5835411471321695,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V143E(9) p.L137_W146del10(1) p.V143A(15) p.K139fs*4(1) p.V143fs*28(2) p.V143V(2) p.V143M(27) p.V143L(4) p.V143fs*4(1) p.V143_P153del(1) p.A138_V143delAKTCPV(1) p.V143G(1) p.C141fs*5(1) p.V143_S149delVQLWVDS(1) p.P142_Q144delPVQ(1) p.V143fs*27(2) p.V143fs*29(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"MSI:1,Misc:1",0.710372,0.3486543740117186,0.659,3.0,,,,,,,ACH-000176,7157.0
chr17,7674241,G,C,0.915,2,27,1|1,,SNP,MISSENSE,c.722C>G,p.S241C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"APOBEC:1,Misc:2",0.900614,0.9732631616330862,0.952,3.0,,,,,,,ACH-002157,7157.0
chr17,7674917,T,C,0.999,0,705,1|1,,SNP,MISSENSE,c.614A>G,p.Y205C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs1057520007,,as_specific,0.5586034912718204,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.Y205D(20) p.Y205S(11) p.Y205C(70) p.L201_H214del(1) p.Y205H(9) p.E204_N210delEYLDDRN(1) p.Y205F(8) p.Y205N(3) p.Y205fs*42(1) p.Y205fs*43(1) p.Y205*(8) p.?(1) p.K164_P219del(1) p.E204fs*39(1) p.Y205fs*?(1) p.L206fs*42(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:11",0.8532,0.8002667275111726,0.873,3.0,,,,,,,ACH-001623,7157.0
chr9,8521481,C,T,0.3,283,123,0/1,,SNP,MISSENSE,c.757G>A,p.V253I,PTPRD,"protein tyrosine phosphatase, receptor type D","Fibronectin type III domain containing I-set domain containing Protein tyrosine phosphatases, receptor type",ENST00000381196.8,17.0,-,P23468,False,rs760428875,,as_specific,0.4214463840399002,,,False,,False,,cancer;gene_function_loss;,False,True,True,,792.0,,10.0,7.3,False,True,False,,0.89,0.9981238076369744,0.096,3.0,,,,,,,ACH-000122,Unknown
chr17,7674894,G,A,0.995,0,223,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000122,7157.0
chr2,74415153,T,G,0.346,6,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000896,388963.0
chr3,65391193,G,T,0.442,29,23,0/1,,SNP,MISSENSE,c.2365C>A,p.P789T,MAGI1,"membrane associated guanylate kinase, WW and PDZ domain containing 1",Trinucleotide repeat containing Membrane associated guanylate kinases PDZ domain containing,ENST00000497477.6,14.0,-,Q96QZ7,False,rs770193154,,as_specific,0.5037406483790524,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:6,0.864519,0.6661910679274031,0.351,4.0,,,,,,,ACH-000896,Unknown
chr17,7670703,C,A,0.522,21,26,0/1,,SNP,NONSENSE,c.1006G>T,p.E336*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,,,,0.4812967581047381,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E336*(8) p.E336fs*12(1) p.E336K(2) p.E336fs*?(1) p.R335_E336insGV(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,APOBEC:3,0.958201,0.6395889856789665,,3.0,,,,,,,ACH-000896,7157.0
chr17,7675085,C,A,0.997,0,319,1|1,,SNP,MISSENSE,c.527G>T,p.C176F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs786202962,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C176F(140) p.0(9) p.C176S(27) p.C176Y(67) p.C176W(15) p.C176fs*71(7) p.C176R(21) p.C176fs*5(3) p.R174fs*1(2) p.C176*(10) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(7) p.C176G(5) p.H168fs*23(1) p.H178fs*3(1) p.R174_H178>S(1) p.V173fs*69(1) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R174_E180>K(1) p.C176_P177delCP(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.C176delC(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2) p.C176fs*72(1) p.C176fs*68(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:3,Misc:11",0.941923,,0.951,3.0,,,,,,,ACH-000087,7157.0
chr17,7675124,T,C,0.996,0,256,1|1,,SNP,MISSENSE,c.488A>G,p.Y163C,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs148924904,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y163C(136) p.0(9) p.S149fs*72(1) p.Y163fs*1(2) p.Y163H(19) p.Y163N(20) p.A159_Q167delAMAIYKQSQ(1) p.Y163S(5) p.Y163*(8) p.Y163fs*14(1) p.A159_M169del(1) p.Y163_Q165delYKQ(1) p.Y163D(4) p.Y163del(1) p.Y163Y(3) p.P151_V173del23(1) p.I162_Y163delIY(1) p.Y163fs*7(2) p.V157_C176del20(1) p.Y163fs*18(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:11,0.897865,0.7273008533507418,0.872,3.0,,,,,,,ACH-000591,7157.0
chr1,114713908,T,C,0.43,66,48,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-001443,4893.0
chr17,7675076,T,C,0.998,2,574,1|1,,SNP,MISSENSE,c.536A>G,p.H179R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519991,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:27,0.941824,,0.935,3.0,,,,,,,ACH-001443,7157.0
chr7,55142382,T,G,0.237,107,33,0/1,,SNP,MISSENSE,c.185T>G,p.L62R,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,2.0,+,P00533,False,,,,0.3890274314214463,"""E, O""",Dom,False,,True,p.L62R(4) p.V30_R297>G(5),cancer;gene_function_gain;,False,False,True,ENST00000455089;ENST00000342916;ENST00000454757;ENST00000344576;ENST00000420316;ENST00000275493;ENST00000450046;,,,,7.3,True,False,True,"MSI:1,Misc:5",0.82106,0.4336040760769216,0.799,4.0,,,,,,,ACH-002268,1956.0
chr10,87952142,C,T,0.954,7,147,1|1,,SNP,MISSENSE,c.517C>T,p.R173C,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,6.0,+,P60484,False,rs121913293,,as_specific,0.3266832917705736,"""L, E, M, O""",Rec,False,,True,p.R173C(51) p.0(28) p.R173H(34) p.G165_K342del(1) p.R55fs*1(1) p.V166fs*17(3) p.R173fs*6(1) p.R173fs*10(2) p.Y27_N212>Y(2) p.G165fs*9(3) p.?(1) p.R172fs*5(1) p.R172_Y174>N(1) p.R173S(1) p.R173R(1) p.G165_*404del(1),cancer;gene_function_loss;,False,True,True,ENST00000371953;,838.0,,13.0,7.3,False,True,True,CpG:1,0.941832,0.6442282294657126,0.972,3.0,,,,,,,ACH-002268,5728.0
chr17,7673776,G,A,0.96,1,46,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-002268,7157.0
chr17,7674957,G,A,0.777,7,33,0/1,,SNP,NONSENSE,c.574C>T,p.Q192*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs866380588,,as_specific,0.5885286783042394,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q192*(84) p.Q192fs*16(1) p.Q192fs*17(1) p.Q192K(2) p.Q192delQ(1) p.Q192Q(2) p.?(2) p.G187fs*16(2) p.Q192H(3) p.P191_Q192del(2) p.Q192fs*30(1) p.P191fs*53(2) p.Q192R(5) p.A189_V197delAPPQHLIRV(4) p.Q192fs*56(1) p.A189fs*53(1) p.P191delP(2) p.P191fs*6(1) p.Q192>XXXXXXXXX(1) p.K164_P219del(1) p.P191_Q192delPQ(1) p.A189_Q192>E(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"APOBEC:11,Misc:2",0.991592,,,4.0,,,,,,,ACH-002292,7157.0
chr1,114716126,C,T,0.421,78,65,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,878.0,,7.5,7.3,True,False,True,"MSI:1,UV:1,Misc:6",0.857833,0.9083791625214868,0.783,4.0,,,,,,,ACH-000972,4893.0
chr3,179210192,T,C,0.481,45,43,0/1,,SNP,MISSENSE,c.1258T>C,p.C420R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,8.0,+,P42336,False,rs121913272,,as_specific,0.2967581047381546,"""E, O""",Dom,False,,True,p.C420R(82) p.H419_C420delHC(1) p.C420fs*?(1) p.C420_L422>*(1) p.C420C(1),cancer;gene_function_gain;,False,True,True,ENST00000263967;ENST00000643187;,931.0,,12.5,7.3,True,False,True,"MSI:1,Misc:13",0.916819,0.6918433106210673,0.788,3.0,,,,,,,ACH-000972,5290.0
chr19,11021837,C,T,0.512,20,20,0/1,,SNP,MISSENSE,c.2729C>T,p.T910M,SMARCA4,"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4",Bromodomain containing,ENST00000344626.9,19.0,+,P51532,False,rs1238758086,,as_specific,0.6159600997506235,E,Rec,False,,False,p.T910M(4),cancer;gene_function_loss;,False,False,True,ENST00000344626;ENST00000643549;ENST00000646693;ENST00000642726;ENST00000646484;ENST00000644737;ENST00000642628;ENST00000643296;ENST00000647230;ENST00000646510;ENST00000429416;ENST00000645460;ENST00000541122;ENST00000589677;ENST00000444061;ENST00000590574;ENST00000413806;ENST00000450717;ENST00000643208;ENST00000642350;ENST00000647268;ENST00000646513;,,,,7.3,False,True,True,CpG:5,0.835176,0.70580160552957,0.906,4.0,,,,,,,ACH-000972,6597.0
chr1,114716126,C,A,0.452,58,52,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121913237,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G12C(154) p.G12D(761) p.G12A(99) p.G12R(32) p.G12S(232) p.G12V(115) p.G12?(2) p.G12Y(1) p.G12G(4) p.G12E(1) p.G12P(1) p.G12N(3) p.G12T(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,1175.0,,0.0,7.3,True,False,False,,0.857368,0.1263021400369732,0.787,4.0,,,,,,,ACH-000274,4893.0
chr16,3738617,G,A,0.625,18,29,0/1,,SNP,MISSENSE,c.4336C>T,p.R1446C,CREBBP,CREB binding protein,Zinc fingers ZZ-type Lysine acetyltransferases Bromodomain containing,ENST00000262367.10,26.0,-,Q92793,False,rs398124146,,as_specific,0.3965087281795511,L,Dom/Rec,False,"""MLL, MORF, RUNXBP2""",True,p.R1446H(4) p.R1446C(5) p.R1446L(2) p.R1446G(1),cancer;gene_function_loss;structural_relation;,False,False,True,ENST00000262367;ENST00000382070;ENST00000570939;,,,,7.3,False,True,True,CpG:3,0.796118,0.3112722326765591,0.952,3.0,,,,,,,ACH-002177,1387.0
chr17,7673704,G,A,0.996,0,281,1|1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-000695,7157.0
chr3,179218303,G,A,0.394,83,54,0|1,179218303.0,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-001061,5290.0
chr8,24914431,C,T,0.51,261,275,0/1,,SNP,MISSENSE,c.638C>T,p.A213V,NEFM,neurofilament medium,Intermediate filaments Type IV,ENST00000518131.5,1.0,+,P07197,False,,,,0.6384039900249376,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.673945,0.3618281763558523,0.587,3.0,,,,,,,ACH-001061,4741.0
chr8,96785205,T,G,0.415,132,95,0/1,,SNP,MISSENSE,c.308T>G,p.V103G,CPQ,carboxypeptidase Q,M14 carboxypeptidases,ENST00000220763.10,2.0,+,Q9Y646,False,,,,0.4413965087281795,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.722579,0.8064408212755596,0.596,2.0,,,,,,,ACH-001061,10404.0
chr12,25245347,C,T,0.498,170,169,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-001061,3845.0
chr13,38688746,T,G,0.53,38,44,0/1,,SNP,MISSENSE,c.1402T>G,p.L468V,FREM2,FRAS1 related extracellular matrix protein 2,,ENST00000280481.9,1.0,+,Q5SZK8,False,,,,0.571072319201995,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.267066,0.3287328725445634,0.222,2.0,,,,,,,ACH-001061,341640.0
chr17,7674241,G,A,0.47,249,216,0/1,,SNP,MISSENSE,c.722C>T,p.S241F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:4,APOBEC:7,Misc:1",0.912713,0.9893558821746748,0.958,3.0,,,,,,,ACH-001061,7157.0
chr1,97515787,A,C,0.341,88,45,0/1,,SNP,MISSENSE,c.1679T>G,p.I560S,DPYD,dihydropyrimidine dehydrogenase,,ENST00000370192.8,13.0,-,Q12882,False,rs55886062,,as_specific,0.341645885286783,,,False,,False,,cancer;,False,True,True,ENST00000370192;,738.0,,50.0,3.65,False,False,False,,0.810433,0.6911970726975902,0.92,2.0,,,,,,,ACH-000169,1806.0
chr1,114713907,T,A,0.626,65,110,0/1,,SNP,MISSENSE,c.183A>T,p.Q61H,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913255,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.E62fs*6(3) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,,,,7.3,True,False,True,UV:1,0.754004,,0.742,4.0,,,,,,,ACH-000169,4893.0
chr17,7674221,G,A,0.974,0,36,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000169,7157.0
chr2,29209798,C,T,0.664,88,177,0/1,,SNP,MISSENSE,c.3824G>A,p.R1275Q,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,25.0,-,Q9UM73,False,rs113994087,,as_specific,0.4763092269326683,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.R1275Q(87) p.R1275?(10) p.R1275L(5) p.R1275*(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000642122;ENST00000389048;ENST00000618119;,9.0,"ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.",23.0,7.3,True,False,False,,0.970662,0.7515153163777522,0.885,4.0,,,,,,,ACH-001674,238.0
chr7,6387261,C,T,0.245,71,22,0/1,,SNP,MISSENSE,c.85C>T,p.P29S,RAC1,Rac family small GTPase 1,Rho family GTPases Endogenous ligands,ENST00000356142.4,2.0,+,P63000,False,rs1057519874,,as_specific,0.3117206982543641,,,False,,True,p.P29S(58) p.P29L(3),cancer;gene_function_gain;,False,False,True,,367.0,,4.0,7.3,True,False,True,"UV:19,APOBEC:1",0.898956,0.7595241052535948,0.585,3.0,,,,,,,ACH-001674,5879.0
chr12,25245350,C,T,0.976,0,42,1|1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000417,3845.0
chr12,25245348,C,A,0.761,26,73,0/1,,SNP,MISSENSE,c.37G>T,p.G13C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913535,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,911.0,,0.0,7.3,True,False,True,"smoking:7,MSI:1,Misc:4",0.929283,,0.868,4.0,,,,,,,ACH-000675,3845.0
chr17,7673802,C,A,0.969,0,32,1|1,,SNP,MISSENSE,c.818G>T,p.R273L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,918.0,,0.0,7.3,False,True,True,"smoking:15,Misc:9",0.887493,0.7009283873752175,0.921,3.0,,,,,,,ACH-000675,7157.0
chr3,41224613,G,T,0.396,37,25,0/1,,SNP,MISSENSE,c.101G>T,p.G34V,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs28931589,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.A5_Q143del(7) p.G34V(103) p.G34R(123) p.G34E(112) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.S23_I35del(1) p.D32_H36>D(1) p.D32_S47del(2) p.G34A(2) p.Y30_T40del(1) p.S33_H36del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.W25_I35del(1) p.G34D(1) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.W25_I140del(4) p.G34I(1) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(2) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.L31_I35del(2) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.D32fs*9(1) p.M1_A87del(1) p.E15_Q143del(1) p.A20_I35del(1) p.Q4_D144del(1) p.S33_G34insS(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.W25_H36del(2) p.A5_D144>D(1) p.V22_T102del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.S29_H36del(1) p.S33_G34insGTS(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.S33_G34insGI(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D32_H36del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_I35del(1) p.A5_T59del(1) p.G34C(1) p.A5_Q72del(1) p.S33_G34del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"smoking:2,Misc:4",0.950078,,0.532,4.0,,,,,,,ACH-000671,1499.0
chr17,7674248,T,C,0.335,49,27,0/1,,SNP,MISSENSE,c.715A>G,p.N239D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs876660807,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N239D(42) p.N239fs*22(1) p.H233_C242del10(1) p.N239_C242delNSSC(3) p.N239T(8) p.N239S(26) p.N239fs*25(12) p.C238_N239insX(1) p.N239fs*4(1) p.H233fs*6(1) p.N239K(7) p.M237_N239delMCN(1) p.N239fs*8(3) p.N239I(1) p.N239_S240insN(1) p.N239Y(6) p.V225fs*23(1) p.N239fs*1(2) p.N239_S240insX(2) p.N239N(1) p.C238_M246delCNSSCMGGM(1) p.N239fs*26(1) p.N239_S240delNS(2) p.N239fs*6(1) p.N239fs*?(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.N239*(1) p.N239_S241>T(1) p.N239fs*24(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:8,0.936288,0.9973610804975211,0.948,3.0,,,,,,,ACH-000671,7157.0
chr6,73077787,G,A,0.605,16,26,0/1,,SNP,MISSENSE,c.818G>A,p.G273E,KCNQ5,potassium voltage-gated channel subfamily Q member 5,Potassium voltage-gated channels,ENST00000370398.5,5.0,+,Q9NR82,False,,,,0.3042394014962593,,,False,,False,,cancer;,False,False,True,ENST00000342056;ENST00000628967;ENST00000403813;ENST00000414165;ENST00000355194;ENST00000402622;ENST00000355635;ENST00000370398;ENST00000370392;ENST00000629977;,,,,7.3,False,False,True,UV:6,0.967505,0.8120468819059478,0.894,2.0,,,,,,,ACH-001550,56479.0
chr7,82915589,G,A,0.54,41,48,0/1,,SNP,MISSENSE,c.12397C>T,p.R4133C,PCLO,piccolo presynaptic cytomatrix protein,Zinc fingers C2 domain containing PDZ domain containing,ENST00000333891.14,7.0,-,Q9Y6V0,False,rs372497499,,as_specific,0.4139650872817955,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,UV:8,0.864102,,0.415,2.0,,,,,,,ACH-001550,27445.0
chr7,134449780,G,A,0.451,181,142,0/1,,SNP,SILENT,c.369C>T,p.F123F,AKR1B1,aldo-keto reductase family 1 member B,Aldo-keto reductases,ENST00000285930.9,4.0,-,P15121,False,,,,0.4413965087281795,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.447737,,,0.0,,,,,,,ACH-001550,231.0
chr9,35826159,C,T,0.46,26,22,0/1,,SNP,START_CODON_SNP,c.3G>A,p.M1I,FAM221B,family with sequence similarity 221 member B,,ENST00000423537.7,2.0,-,A6H8Z2,False,,,,0.5012468827930174,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,UV:7,0.860101,0.988262882365444,0.289,2.0,,,,,,,ACH-001550,392307.0
chr11,533874,T,C,0.723,98,257,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,3.0,-,P01112,False,rs121913233,,as_specific,0.6458852867830424,"""E, L, M""",Dom,False,,True,p.Q61R(289) p.Q61K(113) p.Q61L(184) p.Q61H(24) p.Q61?(16) p.Q61P(3) p.Q61*(1) p.Q61Q(1) p.Q61E(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,,,,7.3,True,True,True,Misc:29,0.796387,0.985128922959183,0.811,4.0,,,,,,,ACH-001550,3265.0
chr14,19921503,G,A,0.527,47,53,0/1,,SNP,SILENT,c.897G>A,p.R299R,OR4K5,olfactory receptor family 4 subfamily K member 5,"Olfactory receptors, family 4",ENST00000315915.4,1.0,+,Q8NGD3,False,rs749816085,,as_specific,0.3615960099750623,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:8,0.212404,0.3686502739396499,,0.0,,,,,,,ACH-001550,79317.0
chr15,24676496,G,A,0.475,57,52,0/1,,SNP,MISSENSE,c.629G>A,p.G210E,NPAP1,nuclear pore associated protein 1,,ENST00000329468.5,1.0,+,Q9NZP6,False,rs868115699,,as_specific,0.6134663341645885,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.43762,0.3660917132507132,0.046,1.0,,,,,,,ACH-001550,23742.0
chr15,40382867,G,A,0.465,133,113,0/1,,SNP,MISSENSE,c.32G>A,p.R11K,KNSTRN,kinetochore localized astrin/SPAG5 binding protein,,ENST00000249776.12,1.0,+,Q9Y448,False,,,,0.5910224438902744,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:3,POLE:1",0.575861,0.7403586690321527,0.004,1.0,,,,,,,ACH-001550,90417.0
chr17,7673788,G,A,0.479,225,220,0/1,,SNP,MISSENSE,c.832C>T,p.P278S,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs17849781,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.P278S(74) p.0(9) p.P278A(20) p.P278T(25) p.C275fs*67(1) p.P278R(29) p.P278F(5) p.P278L(78) p.P278H(12) p.V274_P278delVCACP(1) p.P278P(1) p.S269fs*21(1) p.C277_P278insXXXXXXX(1) p.F270_D281del12(1) p.V272_K292del21(1) p.P278_G279insXXXXX(1) p.A276fs*64(1) p.P278fs*67(5) p.P278_G279>R(1) p.P278fs*28(2) p.R267fs*65(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"UV:2,APOBEC:1,Misc:2",0.949089,0.8832556364693654,0.963,3.0,,,,,,,ACH-001550,7157.0
chr19,55810246,G,A,0.659,71,135,0/1,,SNP,MISSENSE,c.364C>T,p.R122C,NLRP11,NLR family pyrin domain containing 11,NLR family Pyrin domain containing,ENST00000589093.5,3.0,-,P59045,False,rs762382161,,as_specific,0.3790523690773067,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:3,POLE:5",0.789354,0.4940730716066587,0.167,1.0,,,,,,,ACH-001550,204801.0
chr19,56028442,C,T,0.349,187,101,0/1,,SNP,MISSENSE,c.2209C>T,p.R737W,NLRP5,NLR family pyrin domain containing 5,NLR family Pyrin domain containing,ENST00000390649.8,7.0,+,P59047,False,rs537471101,,as_specific,0.513715710723192,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,"CpG:3,UV:4,POLE:1",0.760866,0.9264945167857526,0.514,2.0,,,,,,,ACH-001550,126206.0
chr4,152328232,C,T,0.403,46,29,0/1,,SNP,MISSENSE,c.1154G>A,p.R385H,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs1057519895,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465H(72) p.R465fs*7(9) p.R465L(3) p.R465Y(2) p.R465P(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:15,0.938974,0.1731430175559941,0.557,4.0,,,,,,,ACH-002025,55294.0
chr12,25245351,C,A,0.462,147,127,0/1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-002025,3845.0
chr17,7675190,C,T,0.503,111,114,0/1,,SNP,MISSENSE,c.422G>A,p.C141Y,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781288,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.C141Y(78) p.C141fs*29(2) p.0(9) p.N131fs*27(3) p.L137_W146del10(1) p.K139fs*4(1) p.C141W(12) p.Q136_C141delQLAKTC(1) p.C141G(4) p.C141C(4) p.C141_P142insXX(1) p.C141*(14) p.C141R(17) p.A138_P142delAKTCP(1) p.C141fs*34(1) p.C141fs*30(1) p.C141S(2) p.C141fs*8(2) p.C141F(4) p.A138_V143delAKTCPV(1) p.C141A(1) p.C141fs*5(1) p.A138_C141delAKTC(1) p.K139_C141>N(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,Misc:3,0.931226,0.2411594683277477,0.897,3.0,,,,,,,ACH-002025,7157.0
chr19,11867854,G,T,0.625,35,60,0/1,,SNP,MISSENSE,c.785G>T,p.R262I,ZNF439,zinc finger protein 439,Zinc fingers C2H2-type,ENST00000304030.2,3.0,+,Q8NDP4,False,,,,0.3890274314214463,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.578253,,0.066,1.0,,,,,,,ACH-002025,90594.0
chr19,17838299,C,T,0.608,84,131,0/1,,SNP,MISSENSE,c.1533G>A,p.M511I,JAK3,Janus kinase 3,Jak family tyrosine kinases,ENST00000527670.5,10.0,-,P52333,False,rs752661478,,as_specific,0.5286783042394015,L,Dom,False,,True,p.M511I(37) p.M511fs*9(16) p.T512fs*8(1),cancer;gene_function_gain;,False,False,True,,1288.0,,0.0,7.3,True,False,False,,0.703737,,0.179,4.0,,,,,,,ACH-000406,3718.0
chr3,10142104,C,A,0.994,0,183,1|1,,SNP,MISSENSE,c.257C>A,p.P86H,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,,,,0.7032418952618454,"""E, M, O""",Rec,False,,True,p.V84fs*72(1) p.P86fs*72(2) p.P86L(5) p.S72_V87>L(1) p.V84_E94>E(1) p.L85_V87del(2) p.P86H(8) p.P86S(7) p.P86T(3) p.V84_P86del(1) p.P86R(1) p.L85fs*44(1) p.V84fs*69(1) p.R60fs*35(1) p.P86fs*73(1) p.P86fs*42(1) p.V87fs*45(1) p.P86A(1) p.F76fs*24(1),cancer;gene_function_loss;,False,False,True,ENST00000256474;ENST00000345392;,2307.0,,0.0,7.3,False,True,False,,0.536193,0.4786902170127173,0.871,4.0,,,,,,,ACH-000385,7428.0
chr12,25245350,C,A,0.437,9,6,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000213,3845.0
chr12,25245350,C,A,0.411,33,23,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000638,3845.0
chr17,7675139,C,A,0.97,0,32,1|1,,SNP,MISSENSE,c.473G>T,p.R158L,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1699.0,,4.0,7.3,False,True,True,"smoking:22,Misc:1",0.921338,,0.891,3.0,,,,,,,ACH-000638,7157.0
chr1,114716123,C,T,0.605,88,130,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121434596,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G13D(361) p.G13V(89) p.G13R(150) p.G13G(4) p.G13A(16) p.G13C(39) p.G13Y(1) p.G13S(16) p.G13N(3),cancer;gene_function_gain;,False,False,True,,93.0,"While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.",5.0,7.3,True,False,False,,0.857833,0.4966910708773087,0.699,4.0,,,,,,,ACH-000190,4893.0
chr2,177234076,C,T,0.569,33,41,0/1,,SNP,MISSENSE,c.193G>A,p.G65S,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.4089775561097257,E,Dom,False,,False,p.G81_F83delGEF(2) p.G81S(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:1,0.88056,0.4432380589086047,0.511,3.0,,,,,,,ACH-000011,4780.0
chr3,179218304,A,G,0.263,48,17,0/1,,SNP,MISSENSE,c.1634A>G,p.E545G,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913274,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,False,True,ENST00000263967;ENST00000643187;,883.0,,2.0,7.3,True,False,True,Misc:2,0.960085,0.8156814306896972,0.737,3.0,,,,,,,ACH-000011,5290.0
chr2,74415153,T,G,0.345,6,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000892,388963.0
chr3,179218294,G,A,0.21,224,58,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000892,5290.0
chr17,7675076,T,C,0.975,1,83,1|1,,SNP,MISSENSE,c.536A>G,p.H179R,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1057519991,,as_specific,0.5760598503740648,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.H179R(140) p.H179Y(108) p.H179P(5) p.H179Q(23) p.H179L(39) p.P177_C182delPHHERC(17) p.R174fs*1(2) p.H179D(14) p.H179N(23) p.V173fs*59(2) p.H179H(2) p.H168fs*23(1) p.P177_C182del(2) p.H179fs*68(3) p.H179delH(2) p.E171fs*1(1) p.P177fs*3(2) p.R174fs*24(1) p.P177_H179delPHH(1) p.R174_E180>K(1) p.H179fs*?(1) p.P177_E180delPHHE(1) p.H179fs*2(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.C176fs*65(1) p.K164_P219del(1) p.H178_H179>QY(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:27,0.941824,,0.935,3.0,,,,,,,ACH-000133,7157.0
chr17,7674894,G,A,0.901,4,45,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-002340,7157.0
chr12,25227342,T,C,0.996,0,287,1|1,,SNP,MISSENSE,c.182A>G,p.Q61R,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,3.0,-,P01116,False,rs121913240,,as_specific,0.3491271820448878,"""L, E, M, O""",Dom,False,KRAS,True,p.Q61H(427) p.Q61R(118) p.Q61L(121) p.Q61K(47) p.Q61?(10) p.Q61P(15) p.Q61E(11) p.Q61D(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000256078;,909.0,,7.5,7.3,True,False,True,Misc:4,0.911063,0.4728932338916854,0.799,4.0,,,,,,,ACH-002024,3845.0
chr1,26773456,C,T,0.309,37,16,0/1,,SNP,NONSENSE,c.3826C>T,p.R1276*,ARID1A,AT-rich interaction domain 1A,AT-rich interaction domain containing,ENST00000457599.6,15.0,+,O14497,False,,,,0.57356608478803,E,Rec,True,1507,True,p.R1276*(6) p.M1273fs(1),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:2,0.967435,,,5.0,,,,,,,ACH-000962,8289.0
chr3,179199148,G,A,0.695,22,54,0/1,,SNP,MISSENSE,c.323G>A,p.R108H,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,2.0,+,P42336,False,rs886042002,,as_specific,0.3092269326683292,"""E, O""",Dom,False,,True,p.R108H(27) p.G106_R108del(3) p.R108P(1) p.R108C(2) p.R108L(1) p.V105_R108del(2) p.G106_R108delGNR(1) p.R108del(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,CpG:6,0.929086,,0.466,3.0,,,,,,,ACH-000962,5290.0
chr10,51467729,A,T,0.386,41,24,0/1,,SNP,MISSENSE,c.440A>T,p.K147M,PRKG1,"protein kinase, cGMP-dependent, type I",,ENST00000401604.8,3.0,+,Q13976,False,,,,0.3316708229426434,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.862026,,0.599,3.0,,,,,,,ACH-000962,5592.0
chr12,56085070,G,A,0.699,43,104,0/1,,SNP,MISSENSE,c.310G>A,p.V104M,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,3.0,+,P21860,False,rs1057519893,,as_specific,0.4937655860349127,,,False,,True,p.V104L(1) p.V104M(6),cancer;gene_function_gain;,False,True,True,,701.0,,15.0,7.3,True,False,True,CpG:12,0.711747,,0.584,4.0,,,,,,,ACH-000962,2065.0
chr17,7673802,C,T,0.966,0,27,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000962,7157.0
chr19,47069155,C,G,0.365,43,25,0/1,,SNP,MISSENSE,c.2335G>C,p.E779Q,ZC3H4,zinc finger CCCH-type containing 4,Zinc fingers CCCH-type,ENST00000253048.10,14.0,-,Q9UPT8,False,rs756950439,,as_specific,0.6783042394014963,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:4,0.890018,0.4849699719102638,0.121,3.0,,,,,,,ACH-000962,23211.0
chr17,7675088,C,T,0.997,0,285,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-001497,7157.0
chr17,7674230,C,T,0.981,2,116,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-001192,7157.0
chr12,25245351,C,G,0.758,48,157,0/1,,SNP,MISSENSE,c.34G>C,p.G12R,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,530.0,,32.5,7.3,True,False,True,"smoking:1,Misc:32",0.915109,0.6459561688690294,0.821,4.0,,,,,,,ACH-000320,3845.0
chr17,7670703,C,A,0.961,1,48,1|1,,SNP,NONSENSE,c.1006G>T,p.E336*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,,,,0.4812967581047381,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E336*(8) p.E336fs*12(1) p.E336K(2) p.E336fs*?(1) p.R335_E336insGV(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,APOBEC:3,0.958201,0.6395889856789665,,3.0,,,,,,,ACH-002199,7157.0
chr4,152328232,C,T,0.956,6,164,1|1,,SNP,MISSENSE,c.1154G>A,p.R385H,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,8.0,-,Q969H0,False,rs1057519895,,as_specific,0.3790523690773067,"""E, L""",Rec,False,,True,p.R465H(72) p.R465fs*7(9) p.R465L(3) p.R465Y(2) p.R465P(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:15,0.938974,0.1731430175559941,0.557,4.0,,,,,,,ACH-000636,55294.0
chr4,152326137,G,A,0.498,132,125,0/1,,SNP,MISSENSE,c.1273C>T,p.R425C,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs149680468,,as_specific,0.3915211970074813,"""E, L""",Rec,False,,True,p.R505C(61) p.R505S(4) p.R505fs*19(1) p.R505G(2) p.W425S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:3,0.838776,,0.656,4.0,,,,,,,ACH-001737,55294.0
chr12,25245351,C,A,0.999,0,1747,1|1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000672,3845.0
chr17,7674957,G,A,0.996,1,537,1|1,,SNP,NONSENSE,c.574C>T,p.Q192*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs866380588,,as_specific,0.5885286783042394,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q192*(84) p.Q192fs*16(1) p.Q192fs*17(1) p.Q192K(2) p.Q192delQ(1) p.Q192Q(2) p.?(2) p.G187fs*16(2) p.Q192H(3) p.P191_Q192del(2) p.Q192fs*30(1) p.P191fs*53(2) p.Q192R(5) p.A189_V197delAPPQHLIRV(4) p.Q192fs*56(1) p.A189fs*53(1) p.P191delP(2) p.P191fs*6(1) p.Q192>XXXXXXXXX(1) p.K164_P219del(1) p.P191_Q192delPQ(1) p.A189_Q192>E(1) p.P191fs*15(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"APOBEC:11,Misc:2",0.991592,,,4.0,,,,,,,ACH-000672,7157.0
chr12,25245350,C,T,0.599,14,26,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000813,3845.0
chr17,7675131,C,T,0.924,1,25,1|1,,SNP,MISSENSE,c.481G>A,p.A161T,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs193920817,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R158fs*8(1) p.S149fs*72(1) p.A161T(54) p.A161S(6) p.A159_Q167delAMAIYKQSQ(1) p.A161D(12) p.V157fs*19(2) p.A161fs*19(1) p.A161fs*20(1) p.A161V(10) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A161A(5) p.R156fs*18(1) p.A161P(1) p.V157_I162delVRAMAI(1) p.M160fs*10(2) p.A161fs*9(3) p.A161G(1) p.M160_A161>IS(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.A161F(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A161fs*8(1) p.A161N(1) p.V157_C176del20(1) p.A161fs*7(1) p.A161fs*10(1) p.V157fs*9(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1114.0,,3.0,7.3,False,True,True,"MSI:1,Misc:2",0.858308,,0.79,3.0,,,,,,,ACH-000813,7157.0
chr17,7673779,C,A,0.985,0,63,1|1,,SNP,MISSENSE,c.841G>T,p.D281Y,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs764146326,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.D281Y(11) p.D281N(31) p.D281E(35) p.D281D(8) p.D281H(27) p.R280_R283>S(1) p.D281V(6) p.D281>AGPY(1) p.D281fs*24(1) p.D281_R282>EW(2) p.D281fs*63(2) p.D281G(11) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.A276fs*64(1) p.R280fs*64(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.D281R(1) p.R280fs*62(1) p.D281A(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:1",0.941997,0.7846491142870259,0.957,3.0,,,,,,,ACH-000524,7157.0
chr17,7674230,C,T,0.952,2,60,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-002231,7157.0
chr1,114713907,T,G,0.523,144,159,0/1,,SNP,MISSENSE,c.183A>C,p.Q61H,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913255,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.E62fs*6(3) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,893.0,,0.0,7.3,True,False,True,"Eso:1,Misc:1",0.749252,0.6040398297406732,0.742,4.0,,,,,,,ACH-000981,4893.0
chr3,37014545,G,A,0.987,0,80,1|1,,SNP,SPLICE_SITE,c.e10+1G>A,,MLH1,mutL homolog 1,MutL homologs,ENST00000458205.6,,+,P40692,False,rs267607789,,as_specific,0.3690773067331671,"""E, O""",Rec,False,,False,p.?(4),splicing;cancer;gene_function_loss;dna_repair;,False,False,True,,731.0,,2.5,7.3,False,True,False,,0.972304,0.4673546425590275,,1.59129685669006,,,,,,,ACH-000981,4292.0
chr5,16694504,C,T,0.434,83,63,0/1,,SNP,MISSENSE,c.3667G>A,p.G1223R,MYO10,myosin X,"Myosins, class X Pleckstrin homology domain containing FERM domain containing",ENST00000513610.6,27.0,-,Q9HD67,False,rs1434873123,,as_specific,0.5386533665835411,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,4.61,False,True,True,MSI:2,0.874456,0.9984442399688634,0.448,2.0,,,,,,,ACH-000981,4651.0
chr17,7674220,C,T,0.488,75,68,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000981,7157.0
chr22,36312189,C,T,0.506,50,52,0/1,,SNP,MISSENSE,c.1588G>A,p.E530K,MYH9,myosin heavy chain 9,Deafness associated genes Myosin heavy chains,ENST00000216181.11,14.0,-,P35579,False,,,,0.5910224438902744,L,Dom,False,ALK,False,,cancer;structural_relation;,False,False,True,ENST00000216181;,,,,7.3,False,False,True,APOBEC:1,0.972154,0.4807432056641652,0.945,4.0,,,,,,,ACH-000981,4627.0
chr12,25245350,C,G,0.986,1,146,1|1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-000419,3845.0
chr12,25245351,C,G,0.4,22,15,0/1,,SNP,MISSENSE,c.34G>C,p.G12R,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,530.0,,32.5,7.3,True,False,True,"smoking:1,Misc:32",0.915109,0.6459561688690294,0.821,4.0,,,,,,,ACH-000281,3845.0
chr17,7675130,G,T,0.977,0,48,1|1,,SNP,MISSENSE,c.482C>A,p.A161D,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1064795691,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R158fs*8(1) p.S149fs*72(1) p.A161T(54) p.A161S(6) p.A159_Q167delAMAIYKQSQ(1) p.A161D(12) p.A161fs*19(1) p.A161fs*20(1) p.A161V(10) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A161A(5) p.R156fs*18(1) p.A161P(1) p.V157_I162delVRAMAI(1) p.A161fs*9(3) p.A161G(1) p.M160_A161>IS(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.A161F(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A161fs*8(1) p.I162fs*8(1) p.A161N(1) p.V157_C176del20(1) p.A161fs*7(1) p.A161fs*10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"smoking:2,Misc:1",0.946572,0.7293906543769855,0.908,3.0,,,,,,,ACH-000281,7157.0
chr12,25245350,C,T,0.25,13,3,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000093,3845.0
chr9,21971187,G,A,0.996,0,260,1|1,,SNP,NONSENSE,c.19C>T,p.R7*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913387,,as_specific,0.6458852867830424,,,True,,True,p.0(1543) p.R58*(112) p.A4_P11del(12) p.V28_V51del(1) p.?(5) p.M54fs*61(2) p.R58fs*61(2) p.P3_P11del(2) p.R58fs*59(2) p.M53_R58del(3) p.A57fs*85(1) p.A57_R58>V*(1) p.G55fs*86(1) p.G55fs*61(1) p.S7_A19del(1) p.R58fs*62(1) p.R58R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:10,UV:4",0.788085,0.9908618465891524,0.22,5.0,,,,,,,ACH-001692,1029.0
chr7,55174794,C,T,0.984,0,61,1|1,,SNP,MISSENSE,c.2122C>T,p.P708S,EGFR,epidermal growth factor receptor,Erb-b2 receptor tyrosine kinases,ENST00000455089.5,18.0,+,P00533,False,rs121913231,,as_specific,0.5087281795511222,"""E, O""",Dom,False,,True,p.L747_P753>S(170) p.T751_E758delTSPKANKE(3) p.S752_I759delSPKANKEI(17) p.T751_I759>S(3) p.P753S(6) p.P753_I759delPKANKEI(1) p.A750_I759>PT(1) p.L747_P753>Q(8) p.L747_K754delLREATSPK(2) p.K708M(1) p.K708R(1) p.L747_K754>ANKG(1) p.E746_P753>IS(1) p.E746_P753>VQ(1) p.T751_I759>N(9) p.A750_I759>GS(1) p.A750_K754del(2) p.E746_P753>VS(3) p.T751fs*4(1) p.E746_P753>LS(1) p.A750_E758>P(2) p.A750_E758delATSPKANKE(1) p.L747_A755>SKG(1) p.K708E(2) p.L747_A755>AN(1) p.L747_K754>ST(1) p.T751_I759>REA(1) p.K708N(2) p.L747_P753delLREATSP(1),cancer;gene_function_gain;,False,False,True,,460.0,,7.5,7.3,True,False,False,,0.90907,0.6785535968543643,0.512,4.0,,,,,,,ACH-000615,1956.0
chr7,113879510,C,T,0.987,0,77,1|1,,SNP,MISSENSE,c.1582G>A,p.E528K,PPP1R3A,protein phosphatase 1 regulatory subunit 3A,Protein phosphatase 1 regulatory subunits,ENST00000284601.4,4.0,-,Q16821,False,rs1380388302,,as_specific,0.3840399002493765,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.413804,0.7808996545670526,0.071,2.0,,,,,,,ACH-000615,5506.0
chr7,140753336,A,T,0.983,1,113,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000615,673.0
chr12,57751648,G,A,0.45,21,17,0/1,,SNP,MISSENSE,c.70C>T,p.R24C,CDK4,cyclin dependent kinase 4,Cyclin dependent kinases,ENST00000257904.11,2.0,-,P11802,False,rs11547328,,as_specific,0.5361596009975063,E,Dom,False,,False,,cancer;gene_function_gain;,False,False,True,,556.0,,1.0,7.3,True,False,False,,0.827858,0.9168360121641624,0.576,4.0,,,,,,,ACH-000615,1019.0
chr8,30700128,G,A,0.509,57,60,0/1,,SNP,SILENT,c.648C>T,p.S216S,GSR,glutathione-disulfide reductase,,ENST00000221130.11,6.0,-,P00390,False,,,,0.4139650872817955,,,False,,False,p.S216S(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,Misc:2,0.228928,0.985360814836269,,0.0,,,,,,,ACH-000566,2936.0
chr11,66316769,G,T,0.252,14,4,0/1,,SNP,MISSENSE,c.259C>A,p.L87M,CD248,CD248 molecule,CD molecules C-type lectin domain containing,ENST00000311330.4,1.0,-,Q9HCU0,False,rs760481697,,as_specific,0.7406483790523691,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,smoking:1,0.308731,0.5069856782759462,0.283,2.0,,,,,,,ACH-000566,57124.0
chr17,7673803,G,A,0.91,1,19,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000566,7157.0
chr11,534288,C,T,0.333,27,14,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,2.0,-,P01112,False,rs104894230,,as_specific,0.6783042394014963,"""E, L, M""",Dom,False,,True,p.G12V(255) p.G12C(33) p.G12S(83) p.G12?(1) p.G12A(11) p.G12D(66) p.G12R(15) p.G12_G13insAG(1) p.G12T(2),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,,,,7.3,True,True,True,Misc:2,0.826996,0.9928105567062409,0.781,4.0,,,,,,,ACH-000148,3265.0
chr17,7675143,C,A,0.987,0,79,1|1,,SNP,MISSENSE,c.469G>T,p.V157F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs121912654,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.V157F(176) p.0(9) p.V157A(2) p.V157L(7) p.S149fs*72(1) p.V157D(13) p.V157_R158insV(1) p.V157_R158delVR(3) p.V157I(11) p.G154fs*22(1) p.V157fs*13(3) p.V157fs*24(2) p.V157fs*22(2) p.V157fs*19(2) p.T155fs*23(2) p.V157V(5) p.V157G(12) p.R156_A161delRVRAMA(1) p.D148fs*23(1) p.R156fs*18(1) p.V157fs*23(3) p.R156fs*12(1) p.V157delV(2) p.T155_V157>I(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.P151_V173del23(1) p.R156fs*14(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.V157fs*25(1) p.V157_C176del20(1) p.V157>AL(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1092.0,,4.0,7.3,False,True,True,"smoking:20,Misc:8",0.788392,0.832221967405611,0.708,3.0,,,,,,,ACH-000148,7157.0
chr17,7670685,G,A,0.991,0,123,1|1,,SNP,NONSENSE,c.1024C>T,p.R342*,TP53,tumor protein p53,,ENST00000269305.8,10.0,-,P04637,False,rs730882029,,as_specific,0.486284289276808,"""L, E, M, O""",Rec,True,NTRK1,True,p.R342P(15) p.0(9) p.R342*(110) p.R342fs*3(12) p.R342fs*5(1) p.R342fs*?(2) p.R342_N345delRELN(1) p.M340fs*2(1) p.R342Q(2) p.F341fs*2(1) p.I332fs*5(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"CpG:11,UV:5",0.961533,0.726463714090335,,4.0,,,,,,,ACH-001032,7157.0
chr12,25245350,C,G,0.437,18,13,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-000916,3845.0
chr12,56088753,G,A,0.557,60,73,0/1,,SNP,MISSENSE,c.994G>A,p.E332K,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,9.0,+,P21860,False,,,,0.5236907730673317,,,False,,False,,cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,APOBEC:4,0.962913,0.8964125180129798,0.614,4.0,,,,,,,ACH-000916,2065.0
chr17,7674220,C,A,0.961,0,23,1|1,,SNP,MISSENSE,c.743G>T,p.R248L,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:4,Misc:3",0.932907,0.9843307954424446,0.96,3.0,,,,,,,ACH-000916,7157.0
chr17,7675136,G,A,0.972,0,35,1|1,,SNP,MISSENSE,c.476C>T,p.A159V,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5785536159600998,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.A159V(42) p.R158fs*8(1) p.A159D(10) p.S149fs*72(1) p.R158_A159insX(4) p.A159fs*11(6) p.A159_Q167delAMAIYKQSQ(1) p.R158_A159delRA(2) p.A159P(25) p.V157fs*19(2) p.A159S(5) p.R156_A161delRVRAMA(1) p.A159_M169del(1) p.A159A(8) p.R156fs*18(1) p.A159T(9) p.V157_I162delVRAMAI(1) p.A159fs*21(2) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.A159fs*19(1) p.R158_A159insXX(1) p.V157_C176del20(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,"UV:1,Misc:3",0.890391,,0.774,3.0,,,,,,,ACH-000453,7157.0
chr17,7675088,C,T,0.961,0,23,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002193,7157.0
chr22,41169525,G,A,0.485,40,35,0/1,,SNP,MISSENSE,c.4195G>A,p.D1399N,EP300,E1A binding protein p300,Zinc fingers ZZ-type Lysine acetyltransferases Bromodomain containing,ENST00000263253.9,26.0,+,Q09472,False,rs1057519889,,as_specific,0.3765586034912718,"""L, E""",Rec,False,"""MLL, RUNXBP2""",True,p.D1399Y(3) p.D1399N(3),cancer;gene_function_loss;structural_relation;,False,False,True,ENST00000263253;,,,,7.3,False,True,True,"CpG:5,POLE:1",0.923848,0.3793505958908378,0.881,4.0,,,,,,,ACH-000734,2033.0
chr1,11157173,C,T,0.474,62,54,0/1,,SNP,MISSENSE,c.4448G>A,p.C1483Y,MTOR,mechanistic target of rapamycin kinase,MTOR complex 1 MTOR complex 2,ENST00000361445.9,30.0,-,P42345,False,rs786205165,,as_specific,0.4763092269326683,,,False,,False,,cancer;gene_function_gain;,False,False,True,ENST00000361445;,543.0,,2.0,7.3,True,False,False,,0.885021,0.9521677580142324,0.951,4.0,,,,,,,ACH-000918,2475.0
chr17,7675139,C,T,0.444,19,16,0/1,,SNP,MISSENSE,c.473G>A,p.R158H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587782144,,as_specific,0.5810473815461347,"""L, E, M, O""",Rec,False,NTRK1,True,p.R158L(70) p.0(9) p.R158C(22) p.R158fs*8(1) p.R158H(73) p.S149fs*72(1) p.R158fs*12(9) p.V157_R158insV(1) p.R158_A159insX(4) p.R158G(12) p.V157_R158delVR(3) p.G154fs*22(1) p.R158_A159delRA(2) p.R158P(21) p.V157fs*22(2) p.R158R(7) p.V157fs*19(2) p.R156_A161delRVRAMA(1) p.R156fs*18(1) p.V157_I162delVRAMAI(1) p.R156_R158delRVR(1) p.P153fs*22(2) p.A159fs*21(1) p.R158S(1) p.P151_V173del23(1) p.T155_A161delTRVRAMA(1) p.R156_I162delRVRAMAI(2) p.R158_A161del(1) p.R158_A159insXX(1) p.R158fs*11(2) p.V157_C176del20(1) p.R158F(1) p.V157fs*21(1) p.V157fs*9(1) p.V157_M160delVRAM(1) p.R158fs*24(1) p.V157_R158del(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;,1695.0,,3.0,7.3,False,True,True,"CpG:6,MSI:1",0.916199,0.785313106525997,0.844,3.0,,,,,,,ACH-000918,7157.0
chr7,140753336,A,T,0.543,86,103,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001370,673.0
chr9,21971109,C,A,0.996,0,261,1|1,,SNP,MISSENSE,c.97G>T,p.D33Y,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs11552822,,as_specific,0.6957605985037406,,,False,,True,p.0(1543) p.E33*(3) p.E33fs*8(1) p.V82_E88del(1) p.D84H(2) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.D84Y(9) p.P81_A85del(1) p.D84N(4) p.L32_L37del(6) p.R29_A34del(2) p.H83fs*2(2) p.D84fs*63(2) p.E61_L94del(1) p.R80fs*34(1) p.D84_F90del(1) p.E33D(1) p.A68fs*3(1) p.D84fs*1(1),cancer;gene_function_loss;,False,False,True,ENST00000304494;ENST00000579122;ENST00000578845;ENST00000498124;ENST00000498628;ENST00000494262;ENST00000479692;ENST00000497750;ENST00000579755;ENST00000530628;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.933446,0.9973373924118374,0.803,4.0,,,,,,,ACH-002467,1029.0
chr17,7674872,T,C,0.972,0,35,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000951,7157.0
chr3,10149852,A,T,0.943,2,52,1|1,,SNP,NONSENSE,c.529A>T,p.R177*,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,3.0,+,P40337,False,,,,0.4663341645885286,"""E, M, O""",Rec,True,,True,p.R177fs*>37(3) p.R177*(5) p.R177fs*25(6) p.R177fs*37(2) p.Y175fs*1(1) p.R176fs*24(1) p.R176fs*36(1) p.R177fs*>38(1),cancer;gene_function_loss;,False,False,True,,1827.0,,7.5,7.3,False,True,False,,0.958419,0.5883101740571155,,4.0,,,,,,,ACH-000234,7428.0
chr17,7674220,C,T,0.977,0,43,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000619,7157.0
chr1,114716123,C,T,0.962,2,62,1|1,,SNP,MISSENSE,c.38G>A,p.G13D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121434596,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G13D(361) p.G13V(89) p.G13R(150) p.G13G(4) p.G13A(16) p.G13C(39) p.G13Y(1) p.G13S(16) p.G13N(3),cancer;gene_function_gain;,False,False,True,,93.0,"While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.",5.0,7.3,True,False,False,,0.857833,0.4966910708773087,0.699,4.0,,,,,,,ACH-000889,4893.0
chr17,7674241,G,A,0.392,21,14,0/1,,SNP,MISSENSE,c.722C>T,p.S241F,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"UV:4,APOBEC:7,Misc:1",0.912713,0.9893558821746748,0.958,3.0,,,,,,,ACH-000889,7157.0
chr3,10142178,A,G,0.996,0,294,1|1,,SNP,MISSENSE,c.331A>G,p.S111G,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,1.0,+,P40337,False,,,,0.6533665835411472,"""E, M, O""",Rec,False,,True,p.S111fs*22(2) p.S111fs*47(1) p.S111N(6) p.H110_S111del(1) p.I109_R113del(1) p.S111fs*48(3) p.S111G(3) p.S111R(10) p.S111I(3) p.R107fs*45(1) p.S111S(2) p.S111fs*45(1) p.S111_Y112del(1) p.S111fs*49(1),cancer;gene_function_loss;,False,False,True,,2243.0,,0.0,7.3,False,True,False,,0.797041,0.4960422952149161,0.685,4.0,,,,,,,ACH-001194,7428.0
chr3,179234297,A,G,0.987,0,78,1|1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-001194,5290.0
chr7,140753336,A,T,0.288,117,41,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000640,673.0
chr3,41224621,T,G,0.984,0,60,1|1,,SNP,MISSENSE,c.109T>G,p.S37A,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913228,,as_specific,0.3940149625935162,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.S37F(236) p.S37C(174) p.S37A(70) p.A5_Q143del(7) p.S37P(30) p.S37Y(49) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.S37T(2) p.Y30_T40del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.S37L(2) p.S37S(2) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(4) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.I35_S37>T(1) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.S37_G38>W(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.I35_T41del(1) p.D32fs*9(1) p.I35_K170del(1) p.S37V(1) p.H36_S37del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.S37_A39>S(1) p.I35_G38del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,Misc:5,0.928905,,0.328,4.0,,,,,,,ACH-000048,1499.0
chr17,7675088,C,T,0.977,0,44,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-000048,7157.0
chr12,25079261,C,T,0.587,49,67,0/1,,SNP,SILENT,c.42C>T,p.R14R,LRMP,lymphoid restricted membrane protein,,ENST00000354454.7,6.0,+,Q12912,False,rs114104872,,as_specific,0.3865336658354115,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,CpG:1,0.267392,,,0.0,,,,,,,ACH-002163,Unknown
chr17,7674221,G,A,0.947,0,17,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000202,7157.0
chr3,41224622,C,G,0.563,23,28,0/1,,SNP,MISSENSE,c.110C>G,p.S37C,CTNNB1,catenin beta 1,Armadillo repeat containing Beta catenins,ENST00000645320.1,3.0,+,P35222,False,rs121913403,,as_specific,0.3915211970074813,"""E, M, O""",Dom,False,PLAG1,True,p.A5_A80del(75) p.S37F(236) p.S37C(174) p.S37A(70) p.A5_Q143del(7) p.S37P(30) p.S37Y(49) p.V22_G80>XXXXX(1) p.D17_P128del(1) p.L7_D58del(1) p.?(8) p.H24_Y142del(1) p.A5_E54del(1) p.M8_L132del(1) p.A5fs*7(2) p.L10_N141del(2) p.D17_A126del(1) p.A5_Q143>E(1) p.P16_K133del(2) p.A21_A80del(1) p.H24_S47del(9) p.D32_S47del(2) p.S37T(2) p.Y30_T40del(1) p.H24_M131del(1) p.M14_S45del(1) p.A20_L148del(1) p.Q4_A80del(2) p.S37L(2) p.S37S(2) p.Q28_I140del(1) p.M1_V173del(1) p.V22_L139>V(2) p.S37_G48>C(1) p.W25_I140del(4) p.E9_I140del(1) p.H24_G38del(1) p.I35_G38delIHSG(4) p.A20_R151del(1) p.V22_G38del(3) p.E9_S47del(1) p.D11_Y142>H(1) p.W25_A80del(1) p.Q4_Y142del(1) p.D6_K133del(1) p.M8_A80del(1) p.V22_S71>A(1) p.M5_N141>D(2) p.I35_S37>T(1) p.M8_G50del(1) p.Y30_A80del(1) p.A20_Q143del(1) p.S37_G38>W(1) p.L7_I140del(1) p.G34_S37del(1) p.Q28_H134del(5) p.D11_V137del(2) p.H36_E53>L(1) p.E9_A80del(1) p.T3_A126del(2) p.GIHS34?(1) p.I35_T41del(1) p.D32fs*9(1) p.I35_K170del(1) p.S37V(1) p.H36_S37del(1) p.M1_A87del(1) p.E15_Q143del(1) p.Q4_D144del(1) p.P16_L156del(1) p.A20_A80del(1) p.V22_Y64del(1) p.K19_Y142>V(1) p.S33_S37del(1) p.A5_Y142>D(2) p.A5_D144>D(1) p.V22_T102del(1) p.S37_A39>S(1) p.I35_G38del(1) p.A20_S111del(1) p.M14_Y142del(1) p.A5_G80>(1) p.Q28_A43del(1) p.A5_R90del(1) p.Y30_A97del(1) p.I35_L46del(1) p.A5_T42del(1) p.V22_A80del(1) p.A21_A152del(1) p.M1_T42del(1) p.Q28_Q61del(1) p.A20_N141del(1) p.D6_I140del(1) p.A5_T40del(1) p.S23_I140del(1) p.A13_R151del(1) p.E15_I140>V(1) p.V22_A97del(1) p.A20_Q72del(1) p.D6_A43del(1) p.S23_A39del(1) p.A5_T59del(1) p.A5_Q72del(1),cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,"APOBEC:7,Misc:2",0.939753,0.7262964133289883,0.489,4.0,,,,,,,ACH-000909,1499.0
chr3,179203761,T,G,0.362,40,22,0/1,,SNP,MISSENSE,c.1031T>G,p.V344G,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,5.0,+,P42336,False,rs1057519941,,as_specific,0.341645885286783,"""E, O""",Dom,False,,True,p.V344V(1) p.V344A(2) p.V344M(10) p.V344G(9),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:4,0.956478,0.8993450061871645,0.675,3.0,,,,,,,ACH-000909,5290.0
chr10,121515260,A,G,0.671,54,103,0/1,,SNP,MISSENSE,c.460T>C,p.C154R,FGFR2,fibroblast growth factor receptor 2,I-set domain containing CD molecules Receptor Tyrosine Kinases,ENST00000478859.5,8.0,-,P21802,False,rs121913474,,as_specific,0.4987531172069825,E,Dom,False,,True,p.C382R(5) p.C382G(1),cancer;gene_function_gain;,False,False,True,ENST00000369061;ENST00000357555;ENST00000613048;ENST00000358487;ENST00000478859;ENST00000356226;ENST00000369059;ENST00000346997;ENST00000351936;ENST00000457416;ENST00000360144;ENST00000369056;ENST00000369058;ENST00000336553;,,,,7.3,True,False,True,Misc:2,0.908225,,0.841,4.0,,,,,,,ACH-000909,2263.0
chr1,85706306,G,A,0.177,108,22,0/1,,SNP,NONSENSE,c.772C>T,p.R258*,ZNHIT6,zinc finger HIT-type containing 6,Zinc fingers HIT-type,ENST00000370574.4,3.0,-,Q9NWK9,False,rs374783757,,as_specific,0.3690773067331671,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,4.13,False,True,True,"CpG:1,POLE:9",0.978713,0.6945182557637268,,4.0,,,,,,,ACH-001517,54680.0
chr3,44651139,A,G,0.451,98,81,0/1,,SNP,SILENT,c.72A>G,p.E24E,ZNF35,zinc finger protein 35,Zinc fingers C2H2-type,ENST00000453164.1,2.0,+,P13682,False,rs753622014,,as_specific,0.5261845386533666,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.290013,0.6196210973327331,,0.0,,,,,,,ACH-001517,7584.0
chr3,179234302,G,C,0.654,27,55,0/1,,SNP,MISSENSE,c.3145G>C,p.G1049R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913277,,as_specific,0.3840399002493765,"""E, O""",Dom,False,,True,p.G1049R(78) p.G1049S(34) p.G1049A(6) p.G1049D(3) p.G1049G(9) p.G1049C(1),cancer;gene_function_gain;,False,False,True,,940.0,,0.0,7.3,True,False,True,"APOBEC:1,Misc:7",0.830715,0.3903762856806781,0.391,3.0,,,,,,,ACH-001517,5290.0
chr12,25245350,C,T,0.783,56,200,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001517,3845.0
chr17,7674220,C,T,0.997,0,330,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001517,7157.0
chr17,39724811,C,T,0.449,225,185,0/1,,SNP,MISSENSE,c.2393C>T,p.T798I,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,20.0,+,P04626,False,,,,0.5960099750623441,E,Dom,False,,False,,cancer;gene_function_gain;,False,False,True,ENST00000584601;ENST00000406381;ENST00000541774;ENST00000445658;ENST00000584450;ENST00000269571;,2331.0,,0.0,7.3,True,False,False,,0.908715,0.5110437939199052,0.783,4.0,,,,,,,ACH-001517,2064.0
chr17,39725079,G,A,0.503,136,138,0/1,,SNP,MISSENSE,c.2524G>A,p.V842I,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,21.0,+,P04626,False,rs1057519738,,as_specific,0.5835411471321695,E,Dom,False,,True,p.V842I(18) p.V842E(1),cancer;gene_function_gain;,False,True,True,,45.0,"ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",9.0,7.3,True,False,True,CpG:7,0.925625,0.7707432895054793,0.538,4.0,,,,,,,ACH-001517,2064.0
chr19,47069155,C,G,0.239,278,84,0/1,,SNP,MISSENSE,c.2335G>C,p.E779Q,ZC3H4,zinc finger CCCH-type containing 4,Zinc fingers CCCH-type,ENST00000253048.10,14.0,-,Q9UPT8,False,rs756950439,,as_specific,0.6783042394014963,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:4,0.890018,0.4849699719102638,0.121,3.0,,,,,,,ACH-001517,23211.0
chr17,7673803,G,A,0.967,0,29,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-001606,7157.0
chr22,41169525,G,A,0.989,0,88,1|1,,SNP,MISSENSE,c.4195G>A,p.D1399N,EP300,E1A binding protein p300,Zinc fingers ZZ-type Lysine acetyltransferases Bromodomain containing,ENST00000263253.9,26.0,+,Q09472,False,rs1057519889,,as_specific,0.3765586034912718,"""L, E""",Rec,False,"""MLL, RUNXBP2""",True,p.D1399Y(3) p.D1399N(3),cancer;gene_function_loss;structural_relation;,False,False,True,ENST00000263253;,,,,7.3,False,True,True,"CpG:5,POLE:1",0.923848,0.3793505958908378,0.881,4.0,,,,,,,ACH-001606,2033.0
chr17,7674220,C,T,0.973,0,36,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000373,7157.0
chr7,140753336,A,T,0.347,108,57,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000863,673.0
chr9,21971187,G,A,0.997,0,409,1|1,,SNP,NONSENSE,c.19C>T,p.R7*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913387,,as_specific,0.6458852867830424,,,True,,True,p.0(1543) p.R58*(112) p.A4_P11del(12) p.V28_V51del(1) p.?(5) p.M54fs*61(2) p.R58fs*61(2) p.P3_P11del(2) p.R58fs*59(2) p.M53_R58del(3) p.A57fs*85(1) p.A57_R58>V*(1) p.G55fs*86(1) p.G55fs*61(1) p.S7_A19del(1) p.R58fs*62(1) p.R58R(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:10,UV:4",0.788085,0.9908618465891524,0.22,5.0,,,,,,,ACH-001509,1029.0
chr2,74415153,T,G,0.577,4,6,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-001452,388963.0
chr7,93131432,T,C,0.988,0,76,1|1,,SNP,MISSENSE,c.4540A>G,p.K1514E,SAMD9L,sterile alpha motif domain containing 9 like,Sterile alpha motif domain containing,ENST00000318238.9,5.0,-,Q8IVG5,False,rs773710761,,as_specific,0.4089775561097257,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,Misc:2,0.483061,0.5125889082162628,0.053,1.0,,,,,,,ACH-001802,219285.0
chr17,35750138,T,G,0.172,45,10,0/1,,SNP,MISSENSE,c.566A>C,p.D189A,GAS2L2,growth arrest specific 2 like 2,,ENST00000604641.6,2.0,-,Q8NHY3,False,rs1192558412,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.610651,0.5095418527025265,0.061,2.0,,,,,,,ACH-002092,246176.0
chr9,130872946,C,T,0.989,1,220,1|1,,SNP,MISSENSE,c.1051C>T,p.R351W,ABL1,"ABL proto-oncogene 1, non-receptor tyrosine kinase",SH2 domain containing Abl family tyrosine kinases,ENST00000372348.7,6.0,+,P00519,False,rs779478267,,as_specific,0.571072319201995,L,Dom,False,"""BCR, ETV6, NUP214""",True,p.M351T(103) p.M351K(1) p.R332W(1) p.M351V(1),cancer;gene_function_gain;structural_relation;,False,True,True,,1656.0,,9.0,7.3,True,False,False,,0.586618,,0.511,4.0,,,,,,,ACH-000434,25.0
chr11,533874,T,A,0.766,128,421,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,3.0,-,P01112,False,rs121913233,,as_specific,0.6458852867830424,"""E, L, M""",Dom,False,,True,p.Q61R(289) p.Q61K(113) p.Q61L(184) p.Q61H(24) p.Q61?(16) p.Q61P(3) p.Q61*(1) p.Q61Q(1) p.Q61E(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,854.0,,0.0,7.3,True,True,True,"smoking:2,Misc:4",0.786029,0.9921539220757206,0.839,4.0,,,,,,,ACH-000434,3265.0
chr7,140753336,A,T,0.557,286,352,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001970,673.0
chr2,48709012,C,T,0.458,346,302,0/1,,SNP,MISSENSE,c.616G>A,p.E206K,LHCGR,luteinizing hormone/choriogonadotropin receptor,Glycoprotein hormone receptors,ENST00000294954.12,8.0,-,P22888,False,rs776172758,,as_specific,0.4763092269326683,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.845786,0.5344319733109912,0.369,3.0,,,,,,,ACH-000304,3973.0
chr7,140753335,CA,AT,0.601,284,424,0/1,,DNP,MISSENSE,c.1799_1800TG>AT,p.V600D,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs121913377,,as_specific,0.3358208955223881,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,,11.0,"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.",47.0,7.3,True,False,False,,,,,,,,,,,,ACH-000304,673.0
chr17,7674220,C,T,0.988,0,88,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-002106,7157.0
chr12,25245350,C,A,0.998,0,465,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000596,3845.0
chr9,21971121,G,A,0.997,1,708,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-001616,1029.0
chr2,29220829,G,T,0.567,27,34,0/1,,SNP,MISSENSE,c.3522C>A,p.F1174L,ALK,ALK receptor tyrosine kinase,CD molecules Receptor Tyrosine Kinases,ENST00000389048.8,23.0,-,Q9UM73,False,rs863225281,,as_specific,0.5361596009975063,"""L, E, M""",Dom,False,"""NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17, CARS, EML4, KIF5B, C2orf22""",True,p.F1174L(136) p.F1174S(3) p.F1174V(8) p.F1174?(5) p.F1174C(12) p.F1174I(6),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000642122;ENST00000389048;ENST00000618119;,8.0,"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.",33.5,7.3,True,False,False,,0.936591,0.5618789444624813,0.752,4.0,,,,,,,ACH-002281,238.0
chr2,74415153,T,G,0.56,2,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-002281,388963.0
chr17,7674220,C,T,0.994,0,179,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001041,7157.0
chr17,7675216,C,A,0.917,0,10,1|1,,SNP,MISSENSE,c.396G>T,p.K132N,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs866775781,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.A129_K132delALNK(1) p.K132N(68) p.K132R(46) p.K132M(13) p.K132Q(17) p.K132E(20) p.M133fs*37(1) p.K132K(1) p.K132*(6) p.L130_M133delLNKM(1) p.M133_K139delMFCQLAK(1) p.K132T(5) p.Y126_K132delYSPALNK(6) p.S127_Q136del10(1) p.S127fs*36(1) p.?(1) p.Y126fs*11(1) p.K132fs*38(2) p.K132W(1) p.V73fs*9(1) p.K132_M133del(1) p.M133fs*16(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000514944;ENST00000508793;,,,,7.3,False,True,True,Misc:2,0.935195,0.5705763221732115,0.895,3.0,,,,,,,ACH-000363,7157.0
chr2,208248389,G,T,0.359,190,103,0/1,,SNP,MISSENSE,c.394C>A,p.R132S,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",,ENST00000415913.5,4.0,-,O75874,False,rs121913499,,as_specific,0.3790523690773067,O,Dom,False,,True,p.R132C(1014) p.R132H(6941) p.R132S(229) p.R132?(201) p.R132G(285) p.R132L(126) p.R132P(1) p.R132V(1) p.G131_R132>VL(1),splicing;cancer;gene_function_gain;,False,True,True,ENST00000345146;ENST00000446179;ENST00000415913;ENST00000415282;,928.0,,10.0,7.3,True,False,True,Misc:9,0.936364,0.6444751911220192,0.904,2.0,,,,,,,ACH-001856,3417.0
chr12,25245350,C,A,0.997,0,433,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-001856,3845.0
chr3,179218303,G,A,0.29,51,27,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-000546,5290.0
chr9,21971121,G,A,0.94,2,55,1|1,,SNP,NONSENSE,c.85C>T,p.R29*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913388,,as_specific,0.6957605985037406,,,True,,True,p.0(1543) p.R80*(123) p.P81fs*35(1) p.V28_V51del(1) p.V28_E33del(2) p.?(4) p.A76fs*64(2) p.R80fs*63(1) p.T79fs*37(1) p.R29_A34del(2) p.R29Q(1) p.L65fs*38(1) p.E61_L94del(1) p.R80fs*34(1) p.A21_L32del(1) p.A68fs*3(1),splicing;cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:24,UV:4",0.863989,0.9987764012582928,0.48,5.0,,,,,,,ACH-000546,1029.0
chr17,7674220,C,T,0.943,5,98,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000546,7157.0
chr8,103885868,T,G,0.5,37,39,0/1,,SNP,SILENT,c.603T>G,p.S201S,RIMS2,regulating synaptic membrane exocytosis 2,Regulating synaptic membrane exocytosis family PDZ domain containing,ENST00000436393.6,2.0,+,Q9UQ26,False,,,,0.456359102244389,,,False,,False,p.S231S(1),cancer;,False,False,True,,,,,7.3,False,False,True,"Eso:5,Misc:3",0.098697,0.8196511821522737,,0.0,,,,,,,ACH-000651,9699.0
chr12,25245350,C,A,0.983,1,56,1|1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-000651,3845.0
chr15,54014540,T,G,0.956,1,43,1|1,,SNP,MISSENSE,c.1637T>G,p.L546R,UNC13C,unc-13 homolog C,UNC13 homologs,ENST00000260323.15,1.0,+,Q8NB66,False,rs768743988,,as_specific,0.4114713216957606,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:2,0.578572,0.4991649834086551,0.54,2.0,,,,,,,ACH-000651,440279.0
chr17,7673802,C,T,0.978,0,42,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000651,7157.0
chr15,85723173,C,T,0.472,58,52,0/1,,SNP,MISSENSE,c.6610C>T,p.R2204C,AKAP13,A-kinase anchoring protein 13,A-kinase anchoring proteins Rho guanine nucleotide exchange factors Pleckstrin homology domain containing Minor histocompatibility antigens,ENST00000361243.6,26.0,+,Q12802,False,,,,0.4214463840399002,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.466161,0.7787513582884751,0.64,4.0,,,,,,,ACH-000938,11214.0
chr2,74415153,T,G,0.487,3,3,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-001126,388963.0
chr11,55774129,G,A,0.325,56,27,0/1,,SNP,MISSENSE,c.692G>A,p.R231Q,OR5D13,olfactory receptor family 5 subfamily D member 13 (gene/pseudogene),"Olfactory receptors, family 5",ENST00000623930.1,1.0,+,Q8NGL4,False,rs777852254,,as_specific,0.4089775561097257,,,False,,False,,cancer;,False,False,True,,,,,3.71,False,False,True,"UV:2,POLE:5",0.525827,0.3426717224559398,0.004,1.0,,,,,,,ACH-001126,390142.0
chr17,7673809,C,T,0.462,337,279,0/1,,SNP,MISSENSE,c.811G>A,p.E271K,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1060501191,,as_specific,0.5311720698254364,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.F270fs*72(2) p.E271K(32) p.E271D(3) p.E271*(18) p.G266_E271delGRNSFE(2) p.E271_R273delEVR(1) p.E271V(7) p.E271G(4) p.E271Q(3) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.E271P(1) p.R267fs*65(1) p.E271fs*35(1) p.L265_K305del41(1) p.S269fs*34(1) p.E271delE(1) p.E271E(2) p.E271fs*34(1) p.E271fs*73(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,APOBEC:12,0.963135,,0.935,3.0,,,,,,,ACH-000208,7157.0
chr1,114713907,T,A,0.447,143,114,0/1,,SNP,MISSENSE,c.183A>T,p.Q61H,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913255,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.E62fs*6(3) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,,,,7.3,True,False,True,UV:1,0.754004,,0.742,4.0,,,,,,,ACH-000439,4893.0
chr17,7673776,G,A,0.945,1,33,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-000435,7157.0
chr2,218584683,C,T,0.21,240,62,0/1,,SNP,MISSENSE,c.392C>T,p.P131L,CNOT9,CCR4-NOT transcription complex subunit 9,CCR4-NOT transcription complex,ENST00000295701.9,4.0,+,Q92600,False,rs267599211,,as_specific,0.399002493765586,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:12,0.918335,,0.599,3.0,,,,,,,ACH-000814,9125.0
chr7,140753336,A,T,0.624,58,93,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000814,673.0
chr12,20370109,G,A,0.39,40,24,0/1,,SNP,SILENT,c.825G>A,p.L275L,PDE3A,phosphodiesterase 3A,Phosphodiesterases,ENST00000359062.3,1.0,+,Q14432,False,rs750288734,,as_specific,0.6034912718204489,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,APOBEC:11,0.166036,0.7111934997787612,,0.0,,,,,,,ACH-002145,5139.0
chr17,7673740,C,A,0.973,0,37,1|1,,SNP,NONSENSE,c.880G>T,p.E294*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs1057520607,,as_specific,0.5261845386533666,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.E294*(57) p.E294E(4) p.E294K(5) p.K291fs*48(8) p.E294fs*11(1) p.E294fs*51(19) p.E294D(2) p.K291fs*49(1) p.E294fs*12(3) p.R290fs*50(1) p.E294Q(2) p.E294fs*52(2) p.E294fs*?(1) p.E294V(1) p.R290_P295>X(1) p.G293fs*1(1) p.L265_K305del41(1) p.E294G(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:3,APOBEC:1,Misc:5",0.973947,0.4390645778956161,,4.0,,,,,,,ACH-002145,7157.0
chr12,25245350,C,T,0.383,33,21,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000307,3845.0
chr17,7674252,C,T,0.948,3,62,1|1,,SNP,MISSENSE,c.711G>A,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:9",0.902715,0.9958849948114716,0.923,3.0,,,,,,,ACH-000307,7157.0
chr6,27807658,G,A,0.209,167,44,0/1,,SNP,SILENT,c.249C>T,p.H83H,H2BC13,,,ENST00000377401.3,1.0,-,,False,rs147149614,,as_specific,0.5785536159600998,,,False,,False,,cancer;,False,False,True,,,,,3.91,False,False,True,Misc:1,0.134151,0.7535661040960056,,0.0,,,,,,,ACH-000604,8340.0
chr17,7674220,C,T,0.983,0,62,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000604,7157.0
chr1,114716123,C,T,0.313,104,49,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121434596,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G13D(361) p.G13V(89) p.G13R(150) p.G13G(4) p.G13A(16) p.G13C(39) p.G13Y(1) p.G13S(16) p.G13N(3),cancer;gene_function_gain;,False,False,True,,93.0,"While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.",5.0,7.3,True,False,False,,0.857833,0.4966910708773087,0.699,4.0,,,,,,,ACH-000220,4893.0
chr9,21971097,C,T,0.954,0,22,1|1,,SNP,MISSENSE,c.109G>A,p.E37K,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,,,,0.6982543640897756,,,False,,True,p.0(1543) p.E88*(15) p.V82_E88del(1) p.V28_V51del(1) p.E88K(3) p.?(4) p.L32_L37del(6) p.H83fs*2(2) p.E88fs*58(1) p.R87fs*30(1) p.E61_L94del(1) p.L37L(2) p.E87K(2) p.D84_F90del(1) p.A68fs*3(1) p.L37fs*6(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,UV:3,0.8351,0.9932090571824084,0.547,4.0,,,,,,,ACH-000220,1029.0
chr17,7674252,C,A,0.962,0,25,1|1,,SNP,MISSENSE,c.711G>T,p.M237I,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs587782664,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.M237K(11) p.0(9) p.M237I(142) p.H233_C242del10(1) p.M237_C238insX(1) p.M237R(3) p.H233fs*6(1) p.M237_N239delMCN(1) p.Y236_M237>*(1) p.M237fs*10(4) p.V225fs*23(1) p.C238fs*2(1) p.M237fs*2(1) p.M237V(7) p.M237L(2) p.M237fs*1(1) p.M237T(2) p.?(1) p.Y236_M243delYMCNSSCM(1) p.Y236_M237insXX(1) p.Y236_M237delYM(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,1066.0,,7.0,7.3,False,True,True,"smoking:1,Misc:3",0.91752,0.995844327753855,0.923,3.0,,,,,,,ACH-002156,7157.0
chr7,140753336,A,T,0.996,0,295,1|1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002459,673.0
chr12,117258434,C,T,0.28,246,98,0/1,,SNP,MISSENSE,c.2494G>A,p.E832K,NOS1,nitric oxide synthase 1,PDZ domain containing,ENST00000338101.8,15.0,-,P29475,False,,,,0.5211970074812967,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.9399,0.5495956213489199,0.224,3.0,,,,,,,ACH-002459,4842.0
chr1,240206904,C,T,0.588,122,174,0/1,,SNP,MISSENSE,c.2092C>T,p.P698S,FMN2,formin 2,,ENST00000319653.14,5.0,+,Q9NZ56,False,,,,0.4713216957605985,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:3,POLE_MSI:1",0.724306,,0.172,2.0,,,,,,,ACH-001566,56776.0
chr2,137657119,G,A,0.616,68,118,0/1,,SNP,MISSENSE,c.4334G>A,p.R1445Q,THSD7B,thrombospondin type 1 domain containing 7B,,ENST00000409968.6,24.0,+,Q9C0I4,False,rs267598902,,as_specific,0.399002493765586,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:10,0.972308,0.7928067158014696,0.456,2.0,,,,,,,ACH-001566,80731.0
chr7,140753336,A,T,0.333,427,214,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-001566,673.0
chr12,20883516,G,A,0.458,80,70,0/1,,SNP,SILENT,c.1596G>A,p.R532R,SLCO1B3,solute carrier organic anion transporter family member 1B3,Solute carriers,ENST00000381545.8,13.0,+,Q9NPD5,False,rs914821884,,as_specific,0.3042394014962593,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.285773,,,0.0,,,,,,,ACH-001566,28234.0
chr12,48526150,C,T,0.502,217,222,0/1,,SNP,SILENT,c.519C>T,p.I173I,OR8S1,olfactory receptor family 8 subfamily S member 1,"Olfactory receptors, family 8",ENST00000641651.1,1.0,+,Q8NH09,False,,,,0.5187032418952618,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:5,0.131095,0.7403566452852204,,0.0,,,,,,,ACH-001566,341568.0
chr18,22415595,G,A,0.607,26,41,0/1,,SNP,SILENT,c.2217C>T,p.F739F,CTAGE1,cutaneous T-cell lymphoma-associated antigen 1,CTAGE family,ENST00000391403.4,1.0,-,"Q96RT6, Q9HC47",False,rs766708550,,as_specific,0.4538653366583541,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:7,0.352859,0.6135810493004218,,0.0,,,,,,,ACH-001566,64693.0
chr17,7674220,C,T,0.218,153,40,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001183,7157.0
chr17,7675064,G,C,0.2,174,41,0/1,,SNP,NONSENSE,c.548C>G,p.S183*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,,,,0.5810473815461347,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.S183*(35) p.C182fs*1(1) p.S183L(3) p.?(3) p.V173fs*59(2) p.S183P(3) p.H168fs*23(1) p.E180_S183delERCS(1) p.S183fs*2(1) p.R174fs*24(1) p.E171fs*61(1) p.V173fs*23(1) p.K164_P219del(1) p.S183_D184insPPP*(1) p.S183fs*65(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"APOBEC:7,Misc:1",0.982906,0.1587257172379398,,4.0,,,,,,,ACH-001183,7157.0
chr17,7674221,G,A,0.99,0,104,1|1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-001496,7157.0
chr1,114713909,G,T,0.505,99,103,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000054,4893.0
chr2,208248389,G,A,0.393,51,32,0/1,,SNP,MISSENSE,c.394C>T,p.R132C,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",,ENST00000415913.5,4.0,-,O75874,False,rs121913499,,as_specific,0.3790523690773067,O,Dom,False,,True,p.R132C(1014) p.R132H(6941) p.R132S(229) p.R132?(201) p.R132G(285) p.R132L(126) p.R132P(1) p.R132V(1) p.G131_R132>VL(1),splicing;cancer;gene_function_gain;,False,True,True,ENST00000345146;ENST00000446179;ENST00000415913;ENST00000415282;,59.0,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",53.0,7.3,True,False,True,"CpG:19,MSI:1,UV:15",0.961719,0.6398382252727418,0.814,2.0,,,,,,,ACH-000054,3417.0
chr2,177234076,C,T,0.625,134,226,0/1,,SNP,MISSENSE,c.193G>A,p.G65S,NFE2L2,"nuclear factor, erythroid 2 like 2",Basic leucine zipper proteins,ENST00000446151.6,2.0,-,Q16236,False,,,,0.4089775561097257,E,Dom,False,,False,p.G81_F83delGEF(2) p.G81S(1),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,Misc:1,0.88056,0.4432380589086047,0.511,3.0,,,,,,,ACH-000544,4780.0
chr17,7673776,G,A,0.317,381,177,0/1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-000455,7157.0
chr17,7675095,C,T,0.623,143,237,0/1,,SNP,MISSENSE,c.517G>A,p.V173M,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs876660754,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V173V(8) p.V173L(71) p.S149fs*72(1) p.V173fs*7(2) p.V173G(8) p.V173M(56) p.V173fs*59(2) p.V173E(4) p.V173W(1) p.V173fs*1(4) p.H168fs*23(1) p.V173fs*69(1) p.V173A(13) p.E171fs*1(1) p.P151_V173del23(1) p.E171fs*61(1) p.V173fs*8(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.V173*(1) p.V172_R174delVVR(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:1,0.933723,,0.892,3.0,,,,,,,ACH-000455,7157.0
chr1,114713908,T,A,0.194,151,37,0/1,,SNP,MISSENSE,c.182A>T,p.Q61L,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,95.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",12.5,7.3,True,False,True,"smoking:1,UV:4,Misc:2",0.873923,0.3894953620593414,0.897,4.0,,,,,,,ACH-001716,4893.0
chr12,25245350,C,G,0.993,0,138,1|1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-001375,3845.0
chr17,7674250,C,T,0.993,0,149,1|1,,SNP,MISSENSE,c.713G>A,p.C238Y,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs730882005,,as_specific,0.571072319201995,"""L, E, M, O""",Rec,False,NTRK1,True,p.C238Y(66) p.0(9) p.C238F(41) p.C238fs*?(1) p.C238S(20) p.H233_C242del10(1) p.C238R(16) p.M237_C238insX(1) p.C238_N239insX(1) p.H233fs*6(1) p.M237_N239delMCN(1) p.C238delC(1) p.C238W(4) p.C238*(5) p.V225fs*23(1) p.C238G(2) p.C238fs*2(1) p.C238del(1) p.C238_M246delCNSSCMGGM(1) p.M237fs*1(1) p.C238C(1) p.?(1) p.C238_M243delCNSSCM(1) p.Y236_M243delYMCNSSCM(1) p.C238fs*1(1) p.C238fs*9(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,2648.0,,0.75,7.3,False,True,True,Misc:7,0.960468,0.9929718951229356,0.957,3.0,,,,,,,ACH-001375,7157.0
chr7,6387261,C,T,0.204,176,41,0/1,,SNP,MISSENSE,c.85C>T,p.P29S,RAC1,Rac family small GTPase 1,Rho family GTPases Endogenous ligands,ENST00000356142.4,2.0,+,P63000,False,rs1057519874,,as_specific,0.3117206982543641,,,False,,True,p.P29S(58) p.P29L(3),cancer;gene_function_gain;,False,False,True,,367.0,,4.0,7.3,True,False,True,"UV:19,APOBEC:1",0.898956,0.7595241052535948,0.585,3.0,,,,,,,ACH-000855,5879.0
chr12,56088557,G,T,0.267,166,62,0/1,,SNP,MISSENSE,c.889G>T,p.D297Y,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,8.0,+,P21860,False,rs1057519891,,as_specific,0.5062344139650873,,,False,,False,p.D297Y(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000267101;ENST00000415288;,,,,7.3,True,True,True,Misc:2,0.927937,0.974653447261036,0.883,4.0,,,,,,,ACH-000855,2065.0
chr17,7674220,C,T,0.405,34,22,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000855,7157.0
chr10,87933147,C,T,0.994,0,159,1|1,,SNP,NONSENSE,c.388C>T,p.R130*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,5.0,+,P60484,False,rs121909224,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R130G(140) p.R130Q(108) p.R130fs*4(13) p.R130fs*2(1) p.K128_R130del(4) p.0(28) p.R130L(19) p.R130*(83) p.R130P(7) p.R55fs*1(1) p.R130?(1) p.R130fs*?(5) p.R130R(1) p.R130_T131>P(4) p.R130fs*50(1) p.G129fs*50(1) p.Y27_N212>Y(2) p.G129fs*51(1) p.F56fs*2(1) p.?(1) p.K125fs*46(1) p.A121_F145del(1) p.K128fs*47(1) p.R130Xfs*?(1),cancer;gene_function_loss;,False,False,True,,636.0,,2.0,7.3,False,True,False,,0.97629,0.898071104088428,,4.0,,,,,,,ACH-000903,5728.0
chr12,12477384,G,A,0.599,29,43,0/1,,SNP,NONSENSE,c.1447C>T,p.R483*,DUSP16,dual specificity phosphatase 16,MAP kinase phosphatases,ENST00000298573.9,7.0,-,Q9BY84,False,,,,0.5561097256857855,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,CpG:1,0.881055,0.8116604069191584,,4.0,,,,,,,ACH-000903,80824.0
chr17,7673802,C,T,0.969,0,30,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000903,7157.0
chr12,25245350,C,T,0.346,58,29,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000542,3845.0
chr17,7673823,C,A,0.473,17,15,0/1,,SNP,MISSENSE,c.797G>T,p.G266V,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs193920774,,as_specific,0.5236907730673317,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.G266V(35) p.G266R(59) p.G266E(59) p.G262_S269delGNLLGRNS(2) p.G266_E271delGRNSFE(2) p.G266fs*79(6) p.G266fs*9(1) p.G266*(14) p.E258fs*71(1) p.G266S(1) p.G266G(2) p.G262_F270delGNLLGRNSF(2) p.G262fs*2(1) p.G266T(1) p.G266A(3) p.G266fs*4(1) p.L265_K305del41(1) p.L265_R267delLGR(1) p.G266_N268delGRN(1) p.?(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,"smoking:2,Misc:8",0.944543,0.742718688783359,0.974,3.0,,,,,,,ACH-002100,7157.0
chr5,68295278,A,G,0.419,61,43,0/1,,SNP,MISSENSE,c.610A>G,p.K204E,PIK3R1,phosphoinositide-3-kinase regulatory subunit 1,SH2 domain containing,ENST00000523872.1,6.0,+,P27986,False,,,,0.3740648379052369,"""E, O""",Rec,False,,False,p.K567E(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,,0.885938,0.6249064453763302,0.468,4.0,,,,,,,ACH-000402,5295.0
chr17,7673803,G,A,0.945,1,33,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-000402,7157.0
chr17,7673802,C,A,0.983,0,56,1|1,,SNP,MISSENSE,c.818G>T,p.R273L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,918.0,,0.0,7.3,False,True,True,"smoking:15,Misc:9",0.887493,0.7009283873752175,0.921,3.0,,,,,,,ACH-002133,7157.0
chr12,25225628,C,T,0.686,70,155,0/1,,SNP,MISSENSE,c.436G>A,p.A146T,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,906.0,,21.0,7.3,True,False,True,"MSI:3,Misc:4",0.951882,0.7493523432445548,0.909,4.0,,,,,,,ACH-002273,3845.0
chr17,7674229,C,T,0.955,1,42,1|1,,SNP,MISSENSE,c.734G>A,p.G245D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912656,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:9,0.965383,0.9964714944038346,0.974,3.0,,,,,,,ACH-002099,7157.0
chr17,7673803,G,A,0.97,0,30,1|1,,SNP,MISSENSE,c.817C>T,p.R273C,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913343,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.F270fs*72(2) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,121.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.5,4.61,False,True,True,"CpG:29,MSI:2,POLE_MSI:1,Misc:2",0.760197,0.6031142045610295,0.901,3.0,,,,,,,ACH-002111,7157.0
chr17,7675208,C,A,0.931,1,27,1|1,,SNP,MISSENSE,c.404G>T,p.C135F,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs587781991,,as_specific,0.5561097256857855,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.N131fs*27(3) p.C135F(48) p.C135R(14) p.C135Y(60) p.C135G(8) p.C135fs*35(15) p.Q136_C141delQLAKTC(1) p.C135W(24) p.C135fs*14(2) p.C135C(5) p.C135*(10) p.C135fs*36(2) p.C135S(11) p.Q136fs*13(1) p.M133fs*13(1) p.C135_Q136insX(1) p.M133_K139delMFCQLAK(1) p.S127_Q136del10(1) p.C135fs*15(1) p.F134_T140>S(1) p.Y126fs*11(1) p.V73fs*9(1) p.C135T(1) p.C135_A138delCQLA(1) p.C135_Q136insXXXXXX(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;ENST00000508793;ENST00000604348;,,,,7.3,False,True,True,"smoking:2,Misc:6",0.96053,0.1199176442771419,0.96,3.0,,,,,,,ACH-002109,7157.0
chr5,68295278,A,G,0.494,50,51,0/1,,SNP,MISSENSE,c.610A>G,p.K204E,PIK3R1,phosphoinositide-3-kinase regulatory subunit 1,SH2 domain containing,ENST00000523872.1,6.0,+,P27986,False,,,,0.3740648379052369,"""E, O""",Rec,False,,False,p.K567E(2),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,,0.885938,0.6249064453763302,0.468,4.0,,,,,,,ACH-001064,5295.0
chr11,67418924,G,T,0.232,9,2,0/1,,SNP,MISSENSE,c.164G>T,p.G55V,CARNS1,carnosine synthase 1,,ENST00000307823.7,4.0,+,A5YM72,False,rs780435597,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.300515,,0.112,2.0,,,,,,,ACH-001064,57571.0
chr17,7674232,C,T,0.98,0,50,1|1,,SNP,MISSENSE,c.731G>A,p.G244D,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs985033810,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"MSI:1,Misc:1",0.965383,0.9978215722974868,0.953,3.0,,,,,,,ACH-001064,7157.0
chr4,54733174,T,A,0.993,0,156,1|1,,SNP,MISSENSE,c.2466T>A,p.N822K,KIT,KIT proto-oncogene receptor tyrosine kinase,CD molecules Immunoglobulin like domain containing Receptor Tyrosine Kinases,ENST00000288135.6,17.0,+,P10721,False,rs121913514,,as_specific,0.3341645885286783,"""L, M, O, E""",Dom,False,,True,p.N822K(186) p.N822H(8) p.N822Y(25) p.N822I(3) p.N822S(3) p.N822T(1) p.N822D(1) p.N822N(1) p.S821_N822>GY(1),cancer;gene_function_gain;,False,True,True,,1263.0,,24.5,7.3,True,False,False,,0.726274,,0.682,4.0,,,,,,,ACH-001656,3815.0
chr17,7674220,C,T,0.991,0,123,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-001656,7157.0
chr12,6592417,C,T,0.479,42,37,0/1,,SNP,MISSENSE,c.2924G>A,p.R975H,CHD4,chromodomain helicase DNA binding protein 4,NuRD complex PHD finger proteins,ENST00000544040.7,19.0,-,Q14839,False,,,,0.4763092269326683,,,False,,False,p.R975H(1),cancer;,False,False,True,ENST00000357008;ENST00000544484;ENST00000645022;ENST00000544040;ENST00000643335;ENST00000646806;ENST00000642879;ENST00000645645;ENST00000645095;ENST00000644352;ENST00000645005;ENST00000644289;,,,,7.3,False,False,True,CpG:7,0.952456,0.8896613623901602,0.82,4.0,,,,,,,ACH-000925,1108.0
chr12,25245347,C,T,0.214,24,6,0/1,,SNP,MISSENSE,c.38G>A,p.G13D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs112445441,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,81.0,"While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.",104.5,7.3,True,False,True,"MSI:13,UV:1,Misc:19",0.912095,0.6995771870880665,0.832,4.0,PA166154663,,,,,,ACH-000925,3845.0
chr12,56085070,G,A,0.538,54,59,0/1,,SNP,MISSENSE,c.310G>A,p.V104M,ERBB3,erb-b2 receptor tyrosine kinase 3,Erb-b2 receptor tyrosine kinases,ENST00000267101.8,3.0,+,P21860,False,rs1057519893,,as_specific,0.4937655860349127,,,False,,True,p.V104L(1) p.V104M(6),cancer;gene_function_gain;,False,True,True,,701.0,,15.0,7.3,True,False,True,CpG:12,0.711747,,0.584,4.0,,,,,,,ACH-000925,2065.0
chr17,39725079,G,A,0.565,22,27,0/1,,SNP,MISSENSE,c.2524G>A,p.V842I,ERBB2,erb-b2 receptor tyrosine kinase 2,CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases,ENST00000584450.5,21.0,+,P04626,False,rs1057519738,,as_specific,0.5835411471321695,E,Dom,False,,True,p.V842I(18) p.V842E(1),cancer;gene_function_gain;,False,True,True,,45.0,"ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",9.0,7.3,True,False,True,CpG:7,0.925625,0.7707432895054793,0.538,4.0,,,,,,,ACH-000925,2064.0
chr17,7674220,C,T,0.987,0,83,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000779,7157.0
chr17,7675088,C,T,0.998,0,422,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-001653,7157.0
chr17,17796980,C,T,0.993,0,156,1|1,,SNP,SILENT,c.4032C>T,p.F1344F,RAI1,retinoic acid induced 1,,ENST00000353383.6,3.0,+,Q7Z5J4,False,rs147375487,,as_specific,0.6134663341645885,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.646733,,,0.0,,,,,,,ACH-001653,10743.0
chr17,35750138,T,G,0.166,19,3,0/1,,SNP,MISSENSE,c.566A>C,p.D189A,GAS2L2,growth arrest specific 2 like 2,,ENST00000604641.6,2.0,-,Q8NHY3,False,rs1192558412,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.610651,0.5095418527025265,0.061,2.0,,,,,,,ACH-000181,246176.0
chr1,114713909,G,T,0.161,236,45,0/1,,SNP,MISSENSE,c.181C>A,p.Q61K,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs121913254,,as_specific,0.42643391521197,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,True,True,ENST00000369535;,427.0,,24.5,7.3,True,False,True,"smoking:1,Misc:48",0.931289,0.3713371520368479,0.841,4.0,,,,,,,ACH-000653,4893.0
chr17,7675994,C,T,0.887,5,52,0/1,,SNP,SPLICE_SITE,c.375G>A,p.T125T,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs55863639,,as_specific,0.5461346633416458,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.T125T(28) p.T125M(10) p.T125K(5) p.T125fs*24(2) p.?(1) p.T125R(4) p.T125A(1) p.M1_T125del(1) p.G105_T125del21(1) p.Y126fs*11(1) p.T125fs*45(1) p.V73fs*9(1) p.T125P(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:5,0.392984,0.6099495421221454,,0.0,,,,,,,ACH-002118,7157.0
chr17,7674229,C,A,0.985,0,70,1|1,,SNP,MISSENSE,c.734G>T,p.G245V,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912656,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:9,Misc:5",0.964727,,0.972,3.0,,,,,,,ACH-001049,7157.0
chr3,179218294,G,A,0.48,67,59,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-002148,5290.0
chr7,140753336,A,T,0.438,77,62,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002148,673.0
chr1,114713908,T,C,0.483,82,75,0/1,,SNP,MISSENSE,c.182A>G,p.Q61R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,3.0,-,P01111,False,rs11554290,,as_specific,0.4239401496259352,"""L, E""",Dom,False,,True,p.Q61K(1259) p.Q61R(1687) p.Q61L(367) p.Q61H(239) p.Q61P(34) p.Q61*(2) p.Q61Q(17) p.Q61_E62>HK(1) p.Q61E(12) p.Q61?(13) p.Q61S(1) p.Q61T(1) p.G60_Q61insAS(1),cancer;gene_function_gain;,False,False,True,ENST00000369535;,96.0,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",5.0,7.3,True,False,True,"UV:8,Misc:47",0.879153,0.4868382763114902,0.888,4.0,,,,,,,ACH-000576,4893.0
chr2,74415153,T,G,0.663,2,5,0/1,,SNP,MISSENSE,c.739A>C,p.T247P,C2orf81,chromosome 2 open reading frame 81,,ENST00000640868.1,1.0,-,A6NN90,False,rs753604591,,as_specific,0.683291770573566,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:1,0.627645,0.6251937956036046,0.06,1.0,,,,,,,ACH-000428,388963.0
chr5,37195921,C,T,0.4,77,46,0/1,,SNP,MISSENSE,c.3748G>A,p.A1250T,CPLANE1,,,ENST00000508244.5,20.0,-,,False,rs752334335,,as_specific,0.3366583541147132,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:1,Misc:1",0.495274,,0.015,1.0,,,,,,,ACH-000942,65250.0
chr9,136504970,A,G,0.669,2,5,0/1,,SNP,MISSENSE,c.4721T>C,p.L1574P,NOTCH1,notch 1,Ankyrin repeat domain containing,ENST00000651671.1,26.0,-,P46531,False,,,,0.6932668329177057,L,Dom,False,TRB@,True,p.L1574P(54) p.L1574fs*36(8) p.V1578delV(6) p.?(1) p.V1577_V1578delVV(1) p.L1574Q(2) p.L1574del(1) p.T1573_L1574insSAPR(1),cancer;gene_function_gain;gene_function_loss;structural_relation;,False,False,True,ENST00000277541;,1032.0,,0.0,7.3,True,True,False,,0.811351,0.9680881359582952,0.958,3.0,,,,,,,ACH-000942,4851.0
chr17,7675095,C,T,0.977,0,44,1|1,,SNP,MISSENSE,c.517G>A,p.V173M,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs876660754,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.V173V(8) p.V173L(71) p.S149fs*72(1) p.V173fs*7(2) p.V173G(8) p.V173M(56) p.V173fs*59(2) p.V173E(4) p.V173W(1) p.V173fs*1(4) p.H168fs*23(1) p.V173fs*69(1) p.V173A(13) p.E171fs*1(1) p.P151_V173del23(1) p.E171fs*61(1) p.V173fs*8(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.V173*(1) p.V172_R174delVVR(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,Misc:1,0.933723,,0.892,3.0,,,,,,,ACH-002202,7157.0
chr3,54503539,G,A,0.47,66,55,0/1,,SNP,SILENT,c.429G>A,p.G143G,CACNA2D3,calcium voltage-gated channel auxiliary subunit alpha2delta 3,Calcium voltage-gated channel auxiliary alpha2delta subunits,ENST00000474759.6,5.0,+,Q8IZS8,False,rs267599904,,as_specific,0.4389027431421446,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,UV:6,0.29998,0.3298721411859698,,0.0,,,,,,,ACH-000404,55799.0
chr7,140753336,A,T,0.638,62,113,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000404,673.0
chr1,67093251,C,A,0.449,103,86,0|1,67093249.0,SNP,MISSENSE,c.957G>T,p.Q319H,C1orf141,chromosome 1 open reading frame 141,,ENST00000371007.6,8.0,-,Q5JVX7,False,,,,0.341645885286783,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.324441,,0.032,2.0,,,,,,,ACH-000991,400757.0
chr1,109106637,C,A,0.503,74,76,0/1,,SNP,NONSENSE,c.220G>T,p.E74*,C1orf194,chromosome 1 open reading frame 194,,ENST00000369945.7,3.0,-,Q5T5A4,False,rs763816794,,as_specific,0.4413965087281795,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:4,0.798315,,,3.0,,,,,,,ACH-000991,127003.0
chr1,200603909,C,T,0.56,35,45,0/1,,SNP,MISSENSE,c.1793G>A,p.R598Q,KIF14,kinesin family member 14,Kinesins,ENST00000367350.5,9.0,-,Q15058,False,rs373895990,,as_specific,0.3466334164588528,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.941955,,0.524,4.0,,,,,,,ACH-000991,9928.0
chr1,225411395,C,T,0.473,111,102,0/1,,SNP,MISSENSE,c.1130G>A,p.R377Q,LBR,lamin B receptor,Tudor domain containing,ENST00000272163.9,9.0,-,Q14739,False,rs750036742,,as_specific,0.4214463840399002,,,False,,False,,cancer;,False,False,True,ENST00000272163;ENST00000338179;,,,,7.3,False,False,True,"CpG:1,POLE:6",0.974591,0.4373041680044568,0.921,4.0,,,,,,,ACH-000991,3930.0
chr2,61488232,C,T,0.447,103,81,0/1,,SNP,MISSENSE,c.2246G>A,p.R749Q,XPO1,exportin 1,Exportins,ENST00000401558.7,19.0,-,O14980,False,,,,0.314214463840399,L,Dom,False,,False,p.R749Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,POLE:6,0.957886,0.4542722343535141,0.555,4.0,,,,,,,ACH-000991,7514.0
chr2,61492337,C,T,0.484,52,48,0/1,,SNP,MISSENSE,c.1711G>A,p.E571K,XPO1,exportin 1,Exportins,ENST00000401558.7,15.0,-,O14980,False,rs1057520009,,as_specific,0.3067331670822942,L,Dom,False,,True,p.E571K(41) p.E571V(3) p.E571G(5) p.E571I(1) p.E571A(3) p.E571Q(2),cancer;gene_function_gain;,False,False,True,,,,,7.3,True,False,True,"CpG:1,POLE:4",0.979039,0.5942594365771144,0.579,4.0,,,,,,,ACH-000991,7514.0
chr2,201601766,G,A,0.99,0,106,1|1,,SNP,SILENT,c.489C>T,p.F163F,C2CD6,C2 calcium dependent domain containing 6,C2 domain containing,ENST00000439140.6,4.0,-,Q53TS8,False,rs1204330479,,as_specific,0.2793017456359102,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:4,0.836549,0.62108625280948,,0.0,,,,,,,ACH-000991,151254.0
chr3,51414033,C,T,0.543,41,45,0/1,,SNP,MISSENSE,c.3848G>A,p.R1283Q,DCAF1,DDB1 and CUL4 associated factor 1,DDB1 and CUL4 associated factors,ENST00000423656.5,19.0,-,Q9Y4B6,False,,,,0.3690773067331671,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.981398,0.6764686800887637,0.463,2.0,,,,,,,ACH-000991,9730.0
chr3,160433696,C,T,0.534,49,57,0/1,,SNP,NONSENSE,c.3754C>T,p.R1252*,SMC4,structural maintenance of chromosomes 4,Structural maintenance of chromosomes proteins Condensin I subunits Condensin II subunits,ENST00000344722.5,23.0,+,Q9NTJ3,False,rs753471840,,as_specific,0.2793017456359102,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:6,0.979744,,,5.0,,,,,,,ACH-000991,10051.0
chr3,187725557,C,T,0.604,40,60,0/1,,SNP,MISSENSE,c.1613G>A,p.R538Q,BCL6,B-cell CLL/lymphoma 6,BTB domain containing Zinc fingers C2H2-type,ENST00000450123.6,6.0,-,P41182,False,,,,0.5835411471321695,L,Dom,False,"""IG loci, ZNFN1A1, LCP1, PIM1, TFRC, CIITA, NACA, HSPCB, HSPCA, HIST1H4I, IL21R,  POU2AF1, ARHH, EIF4A2, SFRS3""",False,,cancer;gene_function_gain;structural_relation;,False,False,True,,,,,7.3,True,False,True,POLE:5,0.930621,0.7190456775413793,0.264,4.0,,,,,,,ACH-000991,604.0
chr4,105275342,C,A,0.531,121,138,0/1,,SNP,MISSENSE,c.4832C>A,p.S1611Y,TET2,tet methylcytosine dioxygenase 2,,ENST00000380013.8,11.0,+,Q6N021,False,rs527895107,,as_specific,0.4638403990024937,L,Rec,False,,False,p.L1609fs*45(1) p.S1611fs*?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:4,0.566194,0.4785680586641168,0.145,3.0,,,,,,,ACH-000991,54790.0
chr4,152326214,C,T,0.472,70,58,0/1,,SNP,MISSENSE,c.1196G>A,p.R399Q,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs866987936,,as_specific,0.3665835411471321,"""E, L""",Rec,False,,True,p.R479Q(43) p.R479L(7) p.R479fs*6(3) p.R479P(3) p.D480fs*5(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:1,POLE:1",0.971548,,0.479,4.0,,,,,,,ACH-000991,55294.0
chr5,112839942,C,T,0.469,69,63,0/1,,SNP,NONSENSE,c.4348C>T,p.R1450*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs121913332,,as_specific,0.456359102244389,"""E, M, O""",Rec,True,,True,p.R1450*(222) p.R1450fs*5(1) p.P1424fs*19(1) p.R1450fs*20(1) p.R1450fs*22(1) p.R1435fs*23(1) p.?(1) p.K1192fs*3(1) p.S1436fs*22(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:15,POLE:2",0.916986,0.7909056506666835,,5.0,,,,,,,ACH-000991,324.0
chr5,112842204,C,T,0.498,105,103,0/1,,SNP,NONSENSE,c.6610C>T,p.R2204*,APC,"APC, WNT signaling pathway regulator",Protein phosphatase 1 regulatory subunits Armadillo repeat containing,ENST00000257430.9,16.0,+,P25054,False,rs752654519,,as_specific,0.399002493765586,"""E, M, O""",Rec,True,,False,p.R2204*(1) p.?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:6,0.968212,,,5.0,,,,,,,ACH-000991,324.0
chr5,163518293,G,A,0.507,40,43,0/1,,SNP,MISSENSE,c.935G>A,p.R312Q,MAT2B,methionine adenosyltransferase 2B,Short chain dehydrogenase/reductase superfamily,ENST00000321757.11,7.0,+,Q9NZL9,False,rs768283411,,as_specific,0.3516209476309227,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:6,0.752648,,0.107,3.0,,,,,,,ACH-000991,27430.0
chr6,113943504,G,A,0.4,46,30,0/1,,SNP,NONSENSE,c.1225C>T,p.R409*,HDAC2,histone deacetylase 2,"NuRD complex Histone deacetylases, class I EMSY complex SIN3 histone deacetylase complex",ENST00000519065.6,12.0,-,Q92769,False,rs267600769,,as_specific,0.3167082294264339,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:5,0.992839,0.7103967586921622,,4.0,,,,,,,ACH-000991,3066.0
chr6,118917601,G,A,0.468,87,77,0/1,,SNP,SILENT,c.864C>T,p.F288F,MCM9,minichromosome maintenance 9 homologous recombination repair factor,MCM family,ENST00000316316.10,5.0,-,Q9NXL9,False,rs564191556,,as_specific,0.4039900249376558,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:3,0.869029,0.6954295520521924,,0.0,,,,,,,ACH-000991,254394.0
chr8,140535501,G,A,0.51,50,49,0/1,,SNP,SILENT,c.2238C>T,p.F746F,AGO2,"argonaute 2, RISC catalytic component",Argonaute/PIWI family,ENST00000220592.10,17.0,-,Q9UKV8,False,rs1012373565,,as_specific,0.6084788029925187,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,"CpG:1,UV:1,POLE:6",0.781183,0.4352903356799667,,0.0,,,,,,,ACH-000991,27161.0
chr9,5968511,G,A,0.427,111,84,0/1,,SNP,MISSENSE,c.1720C>T,p.R574C,KIAA2026,KIAA2026,,ENST00000399933.8,3.0,-,Q5HYC2,False,rs1169354787,,as_specific,0.3615960099750623,,,False,,False,,cancer;,False,False,True,,,,,4.61,False,False,True,POLE:7,0.542259,0.8893446736162244,0.265,2.0,,,,,,,ACH-000991,158358.0
chr9,19346108,G,A,0.477,126,117,0/1,,SNP,SILENT,c.3192G>A,p.S1064S,DENND4C,DENN domain containing 4C,DENN/MADD domain containing,ENST00000602925.5,22.0,+,Q5VZ89,False,rs772506615,,as_specific,0.4089775561097257,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.307599,,,0.0,,,,,,,ACH-000991,55667.0
chr11,118312838,G,A,0.541,56,65,0/1,,SNP,SILENT,c.324G>A,p.A108A,CD3E,CD3e molecule,CD molecules,ENST00000361763.9,6.0,+,P07766,False,rs1313464574,,as_specific,0.4688279301745636,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:2,POLE:5",0.24591,0.7833280852820209,,0.0,,,,,,,ACH-000991,916.0
chr12,4518087,C,T,0.493,69,69,0/1,,SNP,MISSENSE,c.1004G>A,p.R335Q,C12orf4,chromosome 12 open reading frame 4,,ENST00000261250.8,8.0,-,Q9NQ89,False,rs532268400,,as_specific,0.3591022443890274,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.977517,0.5996129798173001,0.258,3.0,,,,,,,ACH-000991,57102.0
chr12,25225628,C,T,0.459,63,53,0/1,,SNP,MISSENSE,c.436G>A,p.A146T,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,4.0,-,P01116,False,rs121913527,,as_specific,0.3266832917705736,"""L, E, M, O""",Dom,False,KRAS,True,p.A146V(50) p.A146T(169) p.A146P(7) p.A146S(1) p.A146I(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000256078;,906.0,,21.0,7.3,True,False,True,"MSI:3,Misc:4",0.951882,0.7493523432445548,0.909,4.0,,,,,,,ACH-000991,3845.0
chr12,132676598,G,C,0.388,32,18,0/1,,SNP,MISSENSE,c.857C>G,p.P286R,POLE,"DNA polymerase epsilon, catalytic subunit",DNA polymerases,ENST00000320574.10,9.0,-,Q07864,False,rs1057519943,,as_specific,0.5062344139650873,,,False,,True,p.P286R(174) p.P286(R^S)(4) p.P286L(2) p.P286(R^S297F)(3) p.P286S(1),cancer;gene_function_loss;dna_repair;,False,False,True,ENST00000320574;ENST00000535270;,,,,7.3,False,True,True,Misc:24,0.884997,0.8045687881348066,0.837,4.0,,,,,,,ACH-000991,5426.0
chr13,37104489,G,A,0.457,109,92,0/1,,SNP,SILENT,c.768C>T,p.F256F,CSNK1A1L,casein kinase 1 alpha 1 like,,ENST00000379800.4,1.0,-,Q8N752,False,rs1259640190,,as_specific,0.4613466334164589,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:1,POLE:7",0.702014,0.3957998572715522,,0.0,,,,,,,ACH-000991,122011.0
chr14,58232220,G,A,0.599,123,183,0/1,,SNP,MISSENSE,c.1025G>A,p.R342Q,ACTR10,actin related protein 10 homolog,Actin related proteins,ENST00000254286.9,12.0,+,Q9NZ32,False,rs554639681,,as_specific,0.3241895261845386,,,False,,False,,cancer;,False,False,True,,,,,4.31,False,False,True,POLE:4,0.848485,0.710517920522892,0.347,3.0,,,,,,,ACH-000991,55860.0
chr14,90302832,C,T,0.541,57,69,0|1,90302832.0,SNP,SILENT,c.1299G>A,p.S433S,NRDE2,"NRDE-2, necessary for RNA interference, domain containing",,ENST00000354366.8,6.0,-,Q9H7Z3,False,rs937745011,,as_specific,0.4463840399002494,,,False,,False,,cancer;,False,False,True,,,,,4.13,False,False,True,POLE:6,0.47157,0.6242118313774039,,0.0,,,,,,,ACH-000991,55051.0
chr15,44715521,G,T,0.497,92,89,0/1,,SNP,NONSENSE,c.166G>T,p.E56*,B2M,beta-2-microglobulin,C1-set domain containing,ENST00000648006.2,2.0,+,P61769,False,,,,0.4189526184538653,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"POLE:2,APOBEC:2",0.971597,0.4301683199221607,,4.0,,,,,,,ACH-000991,567.0
chr16,50217581,C,A,0.474,60,53,0/1,,SNP,MISSENSE,c.710C>A,p.S237Y,TENT4B,,,ENST00000561678.6,5.0,+,,False,,,,0.3441396508728179,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:4,0.828281,,0.155,3.0,,,,,,,ACH-000991,64282.0
chr17,7674894,G,A,0.5,27,26,0/1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-000991,7157.0
chr17,31249093,C,T,0.457,120,99,0/1,,SNP,NONSENSE,c.4084C>T,p.R1362*,NF1,neurofibromin 1,,ENST00000356175.7,30.0,+,P21359,False,rs137854560,,as_specific,0.3366583541147132,O,Rec,True,ASIC2,True,p.R1362*(13) p.R1362fs*18(2) p.0(9),cancer;gene_function_loss;structural_relation;,False,False,True,,,,,7.3,False,True,True,"UV:2,POLE:3",0.992775,0.9688736782123002,,5.0,,,,,,,ACH-000991,4763.0
chr17,44741383,C,A,0.45,78,63,0/1,,SNP,MISSENSE,c.761C>A,p.S254Y,DBF4B,DBF4 zinc finger B,Zinc fingers DBF-type,ENST00000315005.8,10.0,+,Q8NFT6,False,rs774436262,,as_specific,0.4912718204488778,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:7,0.730808,,0.123,2.0,,,,,,,ACH-000991,80174.0
chr18,31029545,C,A,0.522,79,86,0/1,,SNP,MISSENSE,c.438G>T,p.E146D,DSC3,desmocollin 3,Desmosomal cadherins,ENST00000360428.9,4.0,-,Q14574,False,,,,0.3516209476309227,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:5,0.751862,0.6114694862317879,0.656,2.0,,,,,,,ACH-000991,1825.0
chr18,74631533,G,T,0.472,203,179,0/1,,SNP,NONSENSE,c.514G>T,p.E172*,ZNF407,zinc finger protein 407,Zinc fingers C2H2-type,ENST00000299687.9,1.0,+,Q9C0G0,False,rs760935640,,as_specific,0.4339152119700748,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,POLE:4,0.955852,,,3.0,,,,,,,ACH-000991,55628.0
chr19,19711558,G,A,0.528,51,56,0/1,,SNP,NONSENSE,c.1723C>T,p.R575*,ZNF14,zinc finger protein 14,Zinc fingers C2H2-type,ENST00000344099.4,4.0,-,P17017,False,rs1473155401,,as_specific,0.4039900249376558,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"UV:1,POLE:7",0.942555,,,3.0,,,,,,,ACH-000991,7561.0
chr19,37669832,C,T,0.426,92,69,0/1,,SNP,MISSENSE,c.317G>A,p.R106Q,ZNF781,zinc finger protein 781,Zinc fingers C2H2-type,ENST00000590008.5,5.0,-,Q8N8C0,False,rs12460961,,as_specific,0.3915211970074813,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"CpG:1,POLE:6",0.617377,0.686534258246389,0.008,1.0,,,,,,,ACH-000991,163115.0
chr20,36431957,C,T,0.558,22,28,0/1,,SNP,SILENT,c.240C>T,p.F80F,DLGAP4,DLG associated protein 4,,ENST00000373913.7,3.0,+,Q9Y2H0,False,rs753759040,,as_specific,0.6608478802992519,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:1,POLE:5",0.794975,0.6162886986813089,,0.0,,,,,,,ACH-000991,22839.0
chr22,41169525,G,A,0.397,80,53,0/1,,SNP,MISSENSE,c.4195G>A,p.D1399N,EP300,E1A binding protein p300,Zinc fingers ZZ-type Lysine acetyltransferases Bromodomain containing,ENST00000263253.9,26.0,+,Q09472,False,rs1057519889,,as_specific,0.3765586034912718,"""L, E""",Rec,False,"""MLL, RUNXBP2""",True,p.D1399Y(3) p.D1399N(3),cancer;gene_function_loss;structural_relation;,False,False,True,ENST00000263253;,,,,7.3,False,True,True,"CpG:5,POLE:1",0.923848,0.3793505958908378,0.881,4.0,,,,,,,ACH-000991,2033.0
chrX,8597081,G,A,0.973,0,34,1|1,,SNP,MISSENSE,c.494C>T,p.S165L,ANOS1,anosmin 1,WAP four-disulfide core domain containing Fibronectin type III domain containing,ENST00000262648.8,4.0,-,P23352,False,rs1404298787,,as_specific,0.4463840399002494,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,"UV:1,POLE:5",,0.8203943356594929,0.48,2.0,,,,,,,ACH-000991,3730.0
chr6,73440307,C,T,0.45,42,32,0/1,,SNP,MISSENSE,c.1016G>A,p.R339H,CGAS,cyclic GMP-AMP synthase,,ENST00000370315.4,3.0,-,Q8N884,False,rs190867294,,as_specific,0.3690773067331671,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,CpG:2,0.439248,,0.08,2.0,,,,,,,ACH-000741,115004.0
chr17,7673537,G,A,0.943,2,60,1|1,,SNP,NONSENSE,c.991C>T,p.Q331*,TP53,tumor protein p53,,ENST00000269305.8,9.0,-,P04637,False,,,,0.4713216957605985,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.Q331*(36) p.Q331P(3) p.Q331Q(2) p.Q331H(5) p.Q331fs*6(1) p.Q331fs*14(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"UV:2,APOBEC:14",0.991875,0.4912909886354796,,4.0,,,,,,,ACH-000741,7157.0
chr1,114716124,C,G,0.538,208,243,0/1,,SNP,MISSENSE,c.37G>C,p.G13R,NRAS,"NRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000369535.5,2.0,-,P01111,False,rs121434595,,as_specific,0.4214463840399002,"""L, E""",Dom,False,,True,p.G13D(361) p.G13V(89) p.G13R(150) p.G13G(4) p.G13A(16) p.G13C(39) p.G13Y(1) p.G13S(16) p.G13N(3),cancer;gene_function_gain;,False,False,True,ENST00000369535;,896.0,,2.5,7.3,True,False,True,"smoking:1,Misc:5",0.837442,0.2725070107592524,0.763,4.0,,,,,,,ACH-001516,4893.0
chr17,7674894,G,A,0.997,0,405,1|1,,SNP,NONSENSE,c.637C>T,p.R213*,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs397516436,,as_specific,0.543640897755611,"""L, E, M, O""",Rec,True,NTRK1,True,p.R213*(293) p.0(9) p.R213fs*34(12) p.R213_S215>X(1) p.R213L(39) p.R213W(3) p.R213Q(38) p.L201_H214del(1) p.R213R(14) p.T211fs*28(1) p.R209fs*6(1) p.R209_R213delRNTFR(1) p.R213P(6) p.R213fs*32(1) p.R213G(3) p.R213fs*?(3) p.D208_V216delDRNTFRHSV(1) p.D208fs*1(1) p.T211_S215delTFRHS(1) p.?(1) p.K164_P219del(1) p.R213*33(1) p.D207_R213delDDRNTFR(1) p.F212_S215del(1) p.R213fs*2(1) p.D207_V216del10(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,2711.0,,0.0,7.3,False,True,True,"CpG:18,UV:6,POLE:8",0.989425,0.7094384842363669,,4.0,,,,,,,ACH-001396,7157.0
chr3,179234297,A,T,0.565,58,79,0/1,,SNP,MISSENSE,c.3140A>T,p.H1047L,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,1151.0,,12.5,7.3,True,False,True,"APOBEC:1,Misc:27",0.829278,,0.359,3.0,,,,,,,ACH-001391,5290.0
chr11,534288,C,T,0.516,105,107,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,HRAS,"HRas proto-oncogene, GTPase",RAS type GTPase family,ENST00000397596.6,2.0,-,P01112,False,rs104894230,,as_specific,0.6783042394014963,"""E, L, M""",Dom,False,,True,p.G12V(255) p.G12C(33) p.G12S(83) p.G12?(1) p.G12A(11) p.G12D(66) p.G12R(15) p.G12_G13insAG(1) p.G12T(2),cancer;gene_function_gain;gene_function_loss;,False,False,True,ENST00000397594;ENST00000397596;ENST00000417302;ENST00000451590;ENST00000311189;,,,,7.3,True,True,True,Misc:2,0.826996,0.9928105567062409,0.781,4.0,,,,,,,ACH-001391,3265.0
chr3,179234297,A,G,0.446,36,28,0/1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-000970,5290.0
chr7,140753336,A,T,0.44,50,39,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-000970,673.0
chr8,81714010,G,A,0.453,37,29,0/1,,SNP,NONSENSE,c.388C>T,p.R130*,ZFAND1,zinc finger AN1-type containing 1,Zinc fingers AN1-type,ENST00000220669.10,6.0,-,Q8TCF1,False,rs1173671877,,as_specific,0.3167082294264339,,,True,,False,,cancer;gene_function_loss;,False,False,True,,,,,4.31,False,True,True,CpG:4,0.980541,,,4.0,,,,,,,ACH-000970,79752.0
chr10,62092489,C,G,0.417,49,35,0/1,,SNP,MISSENSE,c.3026C>G,p.A1009G,ARID5B,AT-rich interaction domain 5B,AT-rich interaction domain containing,ENST00000279873.12,10.0,+,Q14865,False,,,,0.571072319201995,,,False,,False,,cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,Misc:3,0.639587,0.4020160309416056,0.146,3.0,,,,,,,ACH-000970,84159.0
chr17,7674221,G,A,0.342,23,11,0/1,,SNP,MISSENSE,c.742C>T,p.R248W,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs121912651,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,118.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",19.0,7.3,False,True,True,"CpG:42,UV:2",0.877873,0.8163235630115937,0.927,3.0,,,,,,,ACH-000970,7157.0
chr3,179210192,T,C,0.74,107,295,0/1,,SNP,MISSENSE,c.1258T>C,p.C420R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,8.0,+,P42336,False,rs121913272,,as_specific,0.2967581047381546,"""E, O""",Dom,False,,True,p.C420R(82) p.H419_C420delHC(1) p.C420fs*?(1) p.C420_L422>*(1) p.C420C(1),cancer;gene_function_gain;,False,True,True,ENST00000263967;ENST00000643187;,931.0,,12.5,7.3,True,False,True,"MSI:1,Misc:13",0.916819,0.6918433106210673,0.788,3.0,,,,,,,ACH-000527,5290.0
chr19,52212729,C,T,0.499,200,192,0/1,,SNP,MISSENSE,c.10C>T,p.R4W,PPP2R1A,protein phosphatase 2 scaffold subunit Aalpha,STRIPAK complex Protein phosphatase 2 scaffold subunits,ENST00000462990.5,5.0,+,P30153,False,rs1057519946,,as_specific,0.5885286783042394,E,Dom?,False,,True,p.R183W(26) p.R183G(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:1,MSI:1,POLE_MSI:1",0.872264,0.6395465794564451,0.294,4.0,,,,,,,ACH-000527,5518.0
chr17,7674241,G,C,0.957,0,21,1|1,,SNP,MISSENSE,c.722C>G,p.S241C,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934573,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.S241F(107) p.S241C(33) p.N239fs*22(1) p.H233_C242del10(1) p.S241?(2) p.S241Y(15) p.N239_C242delNSSC(3) p.C242fs*5(7) p.N239fs*4(1) p.S241fs*7(1) p.S241S(4) p.S241fs*6(10) p.S241fs*23(1) p.S241A(9) p.S241P(5) p.S241fs*22(2) p.S241delS(5) p.S241_G245delSCMGG(1) p.S241fs*?(1) p.S241T(7) p.S241_C242del(2) p.C238_M246delCNSSCMGGM(1) p.S241del(1) p.?(1) p.C238_M243delCNSSCM(1) p.N239_C242>S(1) p.Y236_M243delYMCNSSCM(1) p.S241_C242delSC(1) p.S241_C242insX(1) p.N239_S241>T(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"APOBEC:1,Misc:2",0.900614,0.9732631616330862,0.952,3.0,,,,,,,ACH-001065,7157.0
chr10,8073874,G,A,0.409,276,198,0/1,,SNP,MISSENSE,c.1183G>A,p.A395T,GATA3,GATA binding protein 3,GATA zinc finger domain containing,ENST00000346208.4,6.0,+,P23771,False,rs200935603,,as_specific,0.5261845386533666,E,Rec,False,,False,p.A396T(1) p.A395fs*54(1),cancer;gene_function_gain;gene_function_loss;,False,False,True,,,,,4.31,True,True,True,CpG:1,0.557243,0.5023414627404155,0.556,4.0,,,,,,,ACH-000605,2625.0
chr17,7674220,C,T,0.998,0,592,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000605,7157.0
chr12,25245348,C,A,0.997,2,1223,1|1,,SNP,MISSENSE,c.37G>T,p.G13C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913535,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G13D(5292) p.G13A(35) p.G13C(344) p.G13R(63) p.G13S(83) p.G13V(42) p.G13_V14insG(6) p.G13M(1) p.G13F(3) p.G13E(7) p.G13G(19) p.G12_G13insG(6) p.G13I(1) p.G13P(3) p.G13_V14>DI(1) p.G13N(5) p.G13K(1) p.G12_G13insA(1) p.G13Y(1) p.G12_G13insAG(1),cancer;gene_function_gain;structural_relation;,False,False,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,911.0,,0.0,7.3,True,False,True,"smoking:7,MSI:1,Misc:4",0.929283,,0.868,4.0,,,,,,,ACH-001538,3845.0
chr18,51065548,C,T,0.998,0,437,1|1,,SNP,MISSENSE,c.793C>T,p.R265C,SMAD4,SMAD family member 4,SMAD family,ENST00000588745.5,5.0,+,Q13485,False,rs80338963,,as_specific,0.3765586034912718,,,False,,True,p.R361C(37) p.0(28) p.R361G(6) p.T265I(1) p.R361S(3),cancer;gene_function_loss;,False,False,True,ENST00000398417;ENST00000342988;ENST00000588745;,,,,7.3,False,True,True,"CpG:7,MSI:1",0.953716,,0.945,3.0,,,,,,,ACH-001538,4089.0
chr17,7675174,C,T,0.951,2,64,1|1,,SNP,NONSENSE,c.438G>A,p.W146*,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs1131691026,,as_specific,0.5785536159600998,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.L137_W146del10(1) p.W146*(77) p.W146C(2) p.W146fs*23(1) p.Q144fs*32(1) p.W146R(5) p.W146fs*1(1) p.W146fs*22(1) p.V143_P153del(1) p.W146_V147insXXXXXXX(1) p.W146S(1) p.V143_S149delVQLWVDS(1) p.Q144_G154del11(1) p.W146fs*25(1) p.W146G(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"smoking:1,Misc:4",0.979855,0.7887579526713587,,4.0,,,,,,,ACH-000503,7157.0
chr17,7674220,C,T,0.955,0,23,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000110,7157.0
chr3,179218303,G,A,0.55,53,61,0/1,,SNP,MISSENSE,c.1633G>A,p.E545K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs104886003,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E545A(231) p.E545G(160) p.E545K(2293) p.E545?(80) p.E545D(31) p.E545Q(49) p.E545L(1) p.E545E(1) p.E545V(7),cancer;gene_function_gain;,False,True,True,,104.0,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",76.5,7.3,True,False,True,"MSI:1,UV:2,Eso:1,APOBEC:175,Misc:11",0.95998,0.7860893377311895,0.654,3.0,,,,,,,ACH-001359,5290.0
chr7,140753336,A,T,0.405,77,53,0/1,,SNP,MISSENSE,c.1799T>A,p.V600E,BRAF,"B-Raf proto-oncogene, serine/threonine kinase",RAF family Mitogen-activated protein kinase kinase kinases,ENST00000646891.1,15.0,-,P15056,False,rs113488022,,as_specific,0.3366583541147132,E,Dom,False,"""AKAP9, KIAA1549""",True,p.V600E(47333) p.V600_K601>E(38) p.V600?(503) p.V600K(1047) p.V600R(154) p.V600(E^K^D)(58) p.T599_V600insT(25) p.V600D(40) p.V600G(14) p.V600A(16) p.V600M(35) p.T599_V600>IK(3) p.T599_K601>TEN(2) p.V600fs*11(1) p.T599_V600insTT(3) p.T599_V600insEAT(1) p.V600L(29) p.V600>YM(9) p.V600_W604>DG(1) p.T599_V600insETT(1) p.V600V(5) p.V600Q(2) p.V600_S602>DT(6) p.T599_V600>IYI(1) p.T599_V600>IAL(2) p.V600_K601>D(2) p.V600T(1) p.T599_R603>I(5) p.V600>DLAT(1) p.V600_W604del(1) p.T599_V600del(1) p.V600_S605>D(1) p.V600_S605>EK(1) p.T599_V600insDFGLAT(1) p.T599_V600insV(1) p.V600_S605>DV(1) p.T599_V600ins2(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000496384;ENST00000644969;ENST00000646891;ENST00000288602;,12.0,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",1353.5,7.3,True,False,True,"smoking:2,UV:2,Misc:345",0.92337,,0.931,4.0,,,,,,,ACH-002310,673.0
chr12,25245350,C,T,0.737,15,44,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000114,3845.0
chr17,7674230,C,T,0.961,0,24,1|1,,SNP,MISSENSE,c.733G>A,p.G245S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs28934575,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.G245V(68) p.G245H(1) p.G245S(374) p.0(9) p.G245R(13) p.G245C(74) p.G244_M246del(1) p.G245D(120) p.G245A(8) p.G245G(3) p.M243fs*18(1) p.G245N(3) p.C242fs*98(1) p.G245delG(2) p.S241_G245delSCMGG(1) p.G245fs*22(1) p.G245fs*2(4) p.G245L(1) p.C238_M246delCNSSCMGGM(1) p.G245fs*17(1) p.G245E(1) p.G245F(1) p.?(1) p.G244fs*17(1) p.G245fs*14(1) p.G245fs*16(1) p.G244_G245insMG(1) p.C242_M246>L(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,879.0,,4.0,4.61,False,True,True,CpG:23,0.959654,0.9979024359347964,0.947,3.0,,,,,,,ACH-000114,7157.0
chr10,87933147,C,T,0.975,1,80,1|1,,SNP,NONSENSE,c.388C>T,p.R130*,PTEN,phosphatase and tensin homolog,PTEN protein phosphatases C2 tensin-type domain containing Phosphoinositide phosphatases,ENST00000371953.8,5.0,+,P60484,False,rs121909224,,as_specific,0.3516209476309227,"""L, E, M, O""",Rec,True,,True,p.R130G(140) p.R130Q(108) p.R130fs*4(13) p.R130fs*2(1) p.K128_R130del(4) p.0(28) p.R130L(19) p.R130*(83) p.R130P(7) p.R55fs*1(1) p.R130?(1) p.R130fs*?(5) p.R130R(1) p.R130_T131>P(4) p.R130fs*50(1) p.G129fs*50(1) p.Y27_N212>Y(2) p.G129fs*51(1) p.F56fs*2(1) p.?(1) p.K125fs*46(1) p.A121_F145del(1) p.K128fs*47(1) p.R130Xfs*?(1),cancer;gene_function_loss;,False,False,True,,636.0,,2.0,7.3,False,True,False,,0.97629,0.898071104088428,,4.0,,,,,,,ACH-000864,5728.0
chr3,10146638,T,C,0.703,21,55,0/1,,SNP,SPLICE_SITE,c.e2+2T>C,,VHL,von Hippel-Lindau tumor suppressor,,ENST00000256474.3,,+,P40337,False,rs5030814,,as_specific,0.4214463840399002,"""E, M, O""",Rec,False,,True,p.?(15),splicing;cancer;gene_function_loss;,False,True,True,,2075.0,,27.5,7.3,False,True,False,,0.973385,0.7186492438924097,,1.76274528115111,,,,,,,ACH-000171,7428.0
chr17,7673802,C,A,0.962,0,23,1|1,,SNP,MISSENSE,c.818G>T,p.R273L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,918.0,,0.0,7.3,False,True,True,"smoking:15,Misc:9",0.887493,0.7009283873752175,0.921,3.0,,,,,,,ACH-000683,7157.0
chr3,192798931,G,C,0.428,15,11,0/1,,SNP,MISSENSE,c.931C>G,p.Q311E,MB21D2,Mab-21 domain containing 2,,ENST00000392452.3,2.0,-,Q8IYB1,False,rs988241015,,as_specific,0.5361596009975063,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,APOBEC:19,0.760565,,0.374,3.0,,,,,,,ACH-000886,151963.0
chr11,67418924,G,T,0.5,3,2,0/1,,SNP,MISSENSE,c.164G>T,p.G55V,CARNS1,carnosine synthase 1,,ENST00000307823.7,4.0,+,A5YM72,False,rs780435597,,as_specific,0.6708229426433915,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Misc:2,0.300515,,0.112,2.0,,,,,,,ACH-000886,57571.0
chr12,25245350,C,G,0.369,32,16,0/1,,SNP,MISSENSE,c.35G>C,p.G12A,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,148.0,"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.",63.0,7.3,True,False,True,"smoking:15,MSI:1,POLE:1,Misc:14",0.91648,0.5024994690236527,0.841,4.0,,,,,,,ACH-000886,3845.0
chr15,44711547,A,G,0.416,21,15,0/1,,SNP,START_CODON_SNP,c.1A>G,p.M1V,B2M,beta-2-microglobulin,C1-set domain containing,ENST00000648006.2,1.0,+,P61769,False,rs1023835002,,as_specific,0.5935162094763092,,,False,,True,p.M1T(1) p.M1L(1) p.M1R(2) p.M1K(2) p.?(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,Misc:2,0.863588,0.8755368419703569,0.287,3.0,,,,,,,ACH-000886,567.0
chr17,7673802,C,A,0.975,0,38,1|1,,SNP,MISSENSE,c.818G>T,p.R273L,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,918.0,,0.0,7.3,False,True,True,"smoking:15,Misc:9",0.887493,0.7009283873752175,0.921,3.0,,,,,,,ACH-000886,7157.0
chr4,152326214,C,T,0.452,24,19,0/1,,SNP,MISSENSE,c.1196G>A,p.R399Q,FBXW7,F-box and WD repeat domain containing 7,F-box and WD repeat domain containing WD repeat domain containing,ENST00000393956.9,9.0,-,Q969H0,False,rs866987936,,as_specific,0.3665835411471321,"""E, L""",Rec,False,,True,p.R479Q(43) p.R479L(7) p.R479fs*6(3) p.R479P(3) p.D480fs*5(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,"CpG:6,UV:1,POLE:1",0.971548,,0.479,4.0,,,,,,,ACH-000470,55294.0
chr11,2929283,G,T,0.272,12,4,0/1,,SNP,MISSENSE,c.82C>A,p.R28S,PHLDA2,pleckstrin homology like domain family A member 2,Pleckstrin homology domain containing,ENST00000314222.5,1.0,-,Q53GA4,False,rs554708054,,as_specific,0.6932668329177057,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,,0.501476,0.7575408281650405,0.132,4.0,,,,,,,ACH-000470,7262.0
chr12,25245351,C,A,0.958,0,24,1|1,,SNP,MISSENSE,c.34G>T,p.G12C,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913530,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,78.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",86.0,7.3,True,False,True,"smoking:57,APOBEC:1,Misc:13",0.93116,0.587367796664097,0.853,4.0,,,,,,,ACH-000470,3845.0
chr15,33562983,T,G,0.938,6,93,1|1,,SNP,SILENT,c.1119T>G,p.T373T,RYR3,ryanodine receptor 3,Ryanodine receptors EF-hand domain containing,ENST00000634891.1,11.0,+,Q15413,False,,,,0.4064837905236907,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,Eso:4,0.212818,0.8365214981231806,,0.0,,,,,,,ACH-000470,6263.0
chr17,7674220,C,T,0.958,0,23,1|1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000470,7157.0
chr12,25245350,C,A,0.787,74,261,0/1,,SNP,MISSENSE,c.35G>T,p.G12V,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,425.0,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,67.5,7.3,True,False,True,"smoking:34,MSI:1,Misc:93",0.922671,0.3869377726948009,0.91,4.0,,,,,,,ACH-001379,3845.0
chr17,7673704,G,A,0.997,0,374,1|1,,SNP,NONSENSE,c.916C>T,p.R306*,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs121913344,,as_specific,0.516209476309227,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.R306*(157) p.?(1) p.R306fs*39(2) p.R306fs*?(1) p.R306R(2) p.R306Q(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,CpG:10,0.98628,0.9835811628784336,,4.0,,,,,,,ACH-001379,7157.0
chr3,52403779,G,A,0.99,0,98,1|1,,SNP,NONSENSE,c.1366C>T,p.Q456*,BAP1,BRCA1 associated protein 1,Ubiquitin C-terminal hydrolases,ENST00000460680.6,13.0,-,Q92560,False,,,,0.5960099750623441,E,Rec,True,,False,p.Q456*(1),cancer;gene_function_loss;,False,False,True,,,,,7.3,False,True,True,Misc:3,0.985034,0.6938849623994391,,3.0,,,,,,,ACH-001673,8314.0
chr17,7676096,C,T,0.991,0,109,1|1,,SNP,NONSENSE,c.273G>A,p.W91*,TP53,tumor protein p53,,ENST00000269305.8,4.0,-,P04637,False,rs876660548,,as_specific,0.57356608478803,"""L, E, M, O""",Rec,True,NTRK1,True,p.0(9) p.G59fs*23(3) p.W91*(29) p.P92fs*57(1) p.W91fs*13(1) p.W91fs*57(1) p.P87fs*54(1) p.A86fs*55(1) p.D48fs*55(1) p.W91fs*?(1) p.M1_T125del(1) p.S33fs*23(1) p.V73fs*9(1) p.W91fs*32(1) p.P13fs*18(1),splicing;cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,,,,,7.3,False,True,True,"MSI:2,Misc:2",0.978778,,,4.0,,,,,,,ACH-001673,7157.0
chr17,7673776,G,A,0.995,3,662,1|1,,SNP,MISSENSE,c.844C>T,p.R282W,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934574,,as_specific,0.5386533665835411,"""L, E, M, O""",Rec,False,NTRK1,True,p.0(9) p.R282W(501) p.R282Q(34) p.R282G(32) p.R282P(18) p.R282R(8) p.R280_R283>S(1) p.R282L(4) p.D281_R282>EW(2) p.D281fs*63(2) p.R282H(1) p.S269fs*21(1) p.V272_K292del21(1) p.D281_R282delDR(3) p.R282fs*63(3) p.R282fs*24(2) p.R282_E287delRRTEEE(1) p.D281_R282insXX(1) p.C275_R283delCACPGRDRR(1) p.L265_K305del41(1) p.G279fs*59(1) p.R280fs*62(1) p.A276_R283delACPGRDRR(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,,,,7.3,False,True,True,CpG:43,0.819804,,0.896,2.0,,,,,,,ACH-001690,7157.0
chr3,179234297,A,G,0.99,0,102,1|1,,SNP,MISSENSE,c.3140A>G,p.H1047R,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,21.0,+,P42336,False,rs121913279,,as_specific,0.3915211970074813,"""E, O""",Dom,False,,True,p.H1047L(442) p.H1047R(3349) p.H1047Y(94) p.H1047?(48) p.H1047Q(11) p.H1047N(1) p.H1047P(2) p.H1047T(1) p.H1047fs*17(1),cancer;gene_function_gain;,False,True,True,,107.0,"PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.",96.5,7.3,True,False,True,"MSI:5,APOBEC:1,Misc:97",0.804314,0.349558388819425,0.455,3.0,,,,,,,ACH-002179,5290.0
chr17,7674233,C,T,0.968,0,31,1|1,,SNP,MISSENSE,c.730G>A,p.G244S,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs1057519989,,as_specific,0.5635910224438903,"""L, E, M, O""",Rec,False,NTRK1,True,p.G244A(8) p.0(9) p.G244_M246del(1) p.G244V(15) p.G244C(45) p.G244G(13) p.G244D(43) p.G244S(42) p.G244fs*3(6) p.M243fs*18(1) p.C242fs*98(1) p.G245delG(1) p.S241_G245delSCMGG(1) p.G244fs*19(1) p.G244fs*4(1) p.C238_M246delCNSSCMGGM(1) p.G244R(4) p.M243_G244>IC(2) p.?(1) p.G244fs*17(1) p.G244_G245insMG(1) p.C242_M246>L(1) p.G244E(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,False,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,,,,7.3,False,True,True,"smoking:1,Misc:2",0.96258,,0.936,3.0,,,,,,,ACH-002179,7157.0
chr3,179218294,G,A,0.3,62,25,0/1,,SNP,MISSENSE,c.1624G>A,p.E542K,PIK3CA,phosphatidylinositol-4%3B5-bisphosphate 3-kinase catalytic subunit alpha,Phosphatidylinositol 3-kinase subunits,ENST00000263967.4,10.0,+,P42336,False,rs121913273,,as_specific,0.2992518703241895,"""E, O""",Dom,False,,True,p.E542K(1405) p.E542Q(18) p.E542V(12) p.E542G(9) p.E542R(1) p.E542A(1),cancer;gene_function_gain;,False,True,True,,103.0,"PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.",74.5,7.3,True,False,True,"POLE:1,APOBEC:116,Misc:6",0.958854,0.8455983021260981,0.439,3.0,,,,,,,ACH-000736,5290.0
chr12,25245350,C,T,0.275,23,7,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-000736,3845.0
chr17,7673802,C,T,0.939,2,45,1|1,,SNP,MISSENSE,c.818G>A,p.R273H,TP53,tumor protein p53,,ENST00000269305.8,8.0,-,P04637,False,rs28934576,,as_specific,0.5361596009975063,"""L, E, M, O""",Rec,False,NTRK1,True,p.R273H(710) p.R273L(151) p.0(9) p.R273C(653) p.R273S(14) p.E271_R273delEVR(1) p.R273P(36) p.R273G(14) p.R273fs*71(1) p.E258fs*71(1) p.S269fs*21(1) p.F270_D281del12(1) p.V272_K292del21(1) p.R273fs*33(2) p.R273_C275delRVC(1) p.R267fs*65(1) p.R273R(1) p.F270fs*72(1) p.L265_K305del41(1) p.R273*(1) p.R273fs*72(3),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;,122.0,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",41.0,7.3,False,True,True,CpG:69,0.876232,,0.868,3.0,,,,,,,ACH-000736,7157.0
chr15,51536240,C,T,0.465,97,83,0/1,,SNP,MISSENSE,c.2240G>A,p.R747Q,DMXL2,Dmx like 2,Deafness associated genes WD repeat domain containing,ENST00000251076.9,12.0,-,Q8TDJ6,False,rs749262883,,as_specific,0.3491271820448878,,,False,,False,,cancer;,False,False,True,,,,,7.3,False,False,True,POLE:6,0.973874,0.2034699033232746,0.475,3.0,,,,,,,ACH-002225,23312.0
chr17,7675088,C,T,0.945,3,69,1|1,,SNP,MISSENSE,c.524G>A,p.R175H,TP53,tumor protein p53,,ENST00000269305.8,5.0,-,P04637,False,rs28934578,,as_specific,0.5685785536159601,"""L, E, M, O""",Rec,False,NTRK1,True,p.R175H(1091) p.0(9) p.R175R(5) p.R175S(8) p.R174fs*1(2) p.R175G(16) p.R175L(21) p.R175C(20) p.R175_H178>X(1) p.V173fs*59(2) p.P177_C182delPHHERC(4) p.H168fs*23(1) p.R175P(7) p.R174_H178>S(1) p.R175fs*72(1) p.V173fs*69(1) p.R175fs*5(2) p.R174_C176delRRC(1) p.E171fs*1(1) p.R174fs*24(1) p.R175fs*6(1) p.R174_E180>K(1) p.E171fs*61(1) p.R174_H179delRRCPHH(1) p.R175_E180del(1) p.V173fs*23(1) p.K164_P219del(1) p.H168fs*69(1) p.R174fs*70(1) p.V157_C176del20(1) p.V172_E180delVVRRCPHHE(2),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,116.0,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).",22.0,7.3,False,True,True,"CpG:42,MSI:3,Misc:2",0.965423,0.3553386237428879,0.922,3.0,,,,,,,ACH-002225,7157.0
chr17,7674220,C,T,0.522,35,38,0/1,,SNP,MISSENSE,c.743G>A,p.R248Q,TP53,tumor protein p53,,ENST00000269305.8,7.0,-,P04637,False,rs11540652,,as_specific,0.5660847880299252,"""L, E, M, O""",Rec,False,NTRK1,True,p.R248Q(737) p.0(9) p.R248W(628) p.R248L(104) p.R248fs*15(1) p.N247_R249del(1) p.R248P(17) p.R248G(20) p.R248R(11) p.R249fs*96(1) p.M246_P250delMNRRP(4) p.N247_R248delNR(3) p.R248C(1) p.R248fs*97(2) p.N247_R248>KW(1) p.R248_P250delRRP(1) p.?(1) p.N247_P250delNRRP(1) p.G245fs*14(1) p.N247_R249delNRR(1) p.R248H(1) p.R248Y(1) p.N247_R248>IP(1) p.R248*(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,117.0,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.",46.0,7.3,False,True,True,CpG:67,0.909876,,0.934,3.0,,,,,,,ACH-000687,7157.0
chr9,21971029,C,T,0.999,0,737,1|1,,SNP,NONSENSE,c.177G>A,p.W59*,CDKN2A,cyclin dependent kinase inhibitor 2A,,ENST00000479692.2,2.0,-,"P42771, Q8N726",False,rs121913389,,as_specific,0.6633416458852868,,,True,,True,p.0(1543) p.W110*(37) p.V59fs*61(2) p.?(4) p.W110C(1) p.V59fs*63(1) p.V59fs*60(1) p.V59_G67del(1) p.V59M(1) p.V59fs*58(1) p.V59fs*82(2) p.H83fs*2(2) p.V59fs*45(1) p.D105fs*8(1) p.V59G(1) p.A68fs*3(1),cancer;gene_function_loss;,False,False,True,,1521.0,,0.0,7.3,False,True,False,,0.855169,0.9926462279289228,0.455,5.0,,,,,,,ACH-001862,1029.0
chr12,25245350,C,T,0.761,54,173,0/1,,SNP,MISSENSE,c.35G>A,p.G12D,KRAS,"KRAS proto-oncogene, GTPase",RAS type GTPase family,ENST00000256078.10,2.0,-,P01116,False,rs121913529,,as_specific,0.3167082294264339,"""L, E, M, O""",Dom,False,KRAS,True,p.G12C(4639) p.G12R(1177) p.G12A(2229) p.G12D(13900) p.G12V(9329) p.G12S(1904) p.G12?(102) p.G12N(7) p.G12F(72) p.G12L(13) p.G12W(5) p.G12T(1) p.G12fs*3(1) p.G12_G13insG(6) p.G12G(10) p.G12E(5) p.A11_G12insV(1) p.A11_G12>VC(1) p.G12I(6) p.G12Y(2) p.A11_G12insGA(3) p.G12fs*22(2) p.G12_G13insA(1) p.G12_G13insAG(1) p.G12K(1),cancer;gene_function_gain;structural_relation;,False,True,True,ENST00000311936;ENST00000557334;ENST00000256078;ENST00000556131;,79.0,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.",162.0,7.3,True,False,True,"smoking:1,MSI:6,UV:1,POLE_MSI:2,Misc:68",0.910278,,0.875,4.0,,,,,,,ACH-001862,3845.0
chr1,162759840,T,G,0.253,65,22,0/1,,SNP,MISSENSE,c.716T>G,p.L239R,DDR2,discoidin domain receptor tyrosine kinase 2,Receptor Tyrosine Kinases,ENST00000367922.7,9.0,+,Q16832,False,rs578015216,,as_specific,0.4713216957605985,,,False,,False,p.L239R(1),cancer;gene_function_gain;,False,False,True,,140.0,"Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.",4.0,7.3,True,False,False,,0.843927,,0.3,4.0,,,,,,,ACH-000840,4921.0
chr17,7674872,T,C,0.973,0,37,1|1,,SNP,MISSENSE,c.659A>G,p.Y220C,TP53,tumor protein p53,,ENST00000269305.8,6.0,-,P04637,False,rs121912666,,as_specific,0.5336658354114713,"""L, E, M, O""",Rec,False,NTRK1,True,p.Y220*(5) p.0(9) p.Y220N(17) p.Y220C(297) p.Y220S(18) p.Y220fs*27(6) p.Y220H(20) p.V218_Y220delVPY(2) p.Y220D(2) p.V218_E221delVPYE(1) p.V216_Y220delVVVPY(1) p.Y220_P223delYEPP(1) p.Y220fs*1(1) p.Y220fs*2(1) p.D208fs*1(1) p.Y220fs*25(1) p.V218fs*26(1) p.?(2) p.Y220L(1) p.P219_V225delPYEPPEV(1),cancer;gene_function_loss;dna_repair;structural_relation;,False,True,True,ENST00000413465;ENST00000359597;ENST00000504290;ENST00000510385;ENST00000504937;ENST00000619186;ENST00000618944;ENST00000610623;ENST00000610292;ENST00000269305;ENST00000620739;ENST00000617185;ENST00000455263;ENST00000420246;ENST00000622645;ENST00000610538;ENST00000445888;ENST00000619485;ENST00000615910;ENST00000509690;ENST00000514944;,922.0,,15.5,7.3,False,True,True,Misc:45,0.916433,,0.936,3.0,,,,,,,ACH-000840,7157.0
